paclitaxel has been researched along with Carcinoma, Non-Small Cell Lung in 2260 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 363 (16.06) | 18.2507 |
| 2000's | 891 (39.42) | 29.6817 |
| 2010's | 797 (35.27) | 24.3611 |
| 2020's | 209 (9.25) | 2.80 |
| Authors | Studies |
|---|---|
| Doshi, JM; Tian, D; Xing, C | 1 |
| Bian, J; Dong, Y; Li, X; Wu, X; You, Q; Zhang, X | 1 |
| Li, X; Li, Z; Wu, X; You, Q; Yu, Y; Zhang, X | 1 |
| Cheng, YS; Chern, JW; Ho, YH; Hung, PY; Lai, HY; Yang, HT; Yu, CW | 1 |
| Chen, Z; Cheng, YY; Duan, HQ; Goto, M; Huang, KY; Lee, KH; Ling, Y; Liu, YL; Morris-Natschke, SL; Tong, XH; Yang, PC; Yang, SL | 1 |
| Du, Y; Wang, C; Yan, H; Zheng, S | 1 |
| Gao, W; Han, W; Liu, Y; Qin, J; Qu, X; Wang, X; Wang, Y; Xia, H | 1 |
| Han, C; Li, H; Li, Z; Liu, Z; Sun, Z; Wu, Y; Zhang, J; Zhang, X | 1 |
| Guo, W; Guo, Y; Wei, L; Yang, L; Zhou, Y | 1 |
| Chiba, Y; Harada, H; Haratani, K; Ito, K; Kenmotsu, H; Kogure, Y; Miyawaki, T; Nakagawa, K; Nishimura, Y; Ohde, Y; Okimoto, T; Sakamoto, T; Sakata, S; Uemura, T; Wakuda, K; Yamamoto, N | 1 |
| Budweiser, S; Chiabudini, M; Dechow, T; Fischer von Weikersthal, L; Hackanson, B; Janssen, J; Nacke, A; Potthoff, K; Riera-Knorrenschild, J; Schulz, H; Taeuscher, D; Welslau, M | 1 |
| Guo, J; Li, W; Li, Y; Ma, Z; Sun, Q; Wang, X; Zhang, C; Zhang, H | 1 |
| Abuhelwa, AY; Badaoui, S; Hopkins, AM; Karapetis, CS; Kichenadasse, G; Logan, JM; McKinnon, RA; Rowland, A; Sorich, MJ | 1 |
| Lakshmikuttyamma, A; Shoyele, SA; Thangavel, C; Thangavel, K | 1 |
| Asai, K; Hirata, K; Kawaguchi, T; Kimura, T; Matsumoto, Y; Mitsuoka, S; Nakai, T; Sawa, K; Yana, T; Yoshimura, N | 1 |
| Cang, S; Cao, P; Chen, G; Chen, J; Cheng, Y; Fang, J; Fang, Y; Geng, Y; Guo, R; Hu, S; Huang, Y; Jiang, T; Li, X; Luo, H; Lv, D; Pan, Y; Ren, S; Shi, J; Shi, W; Wang, D; Wang, Q; Wang, R; Wang, Z; Xing, C; Xu, X; Yang, Z; Yao, W; Yu, J; Zhang, W; Zhang, Y; Zhou, C; Zou, J | 1 |
| Cheng, H; Guo, W; Li, K; Liu, T; Lv, Y; Xu, B; Yu, W; Zeng, X | 1 |
| Dai, S; Fu, SY; Guo, FZ; Hu, HY; Huang, Y; Liu, JW; Luo, F | 1 |
| Calhoun, S; Duan, L; Maki, CG; Perez, RE | 2 |
| Saito, Y; Shinagawa, N; Sugawara, M; Takekuma, Y | 1 |
| Badiyan, SN; Baggstrom, MQ; Bradley, J; Contreras, J; DeWees, T; Govindan, R; Morgensztern, D; Roach, M; Robinson, C; Samson, P; Srivastava, A; Waqar, S | 1 |
| Fukuda, S; Fukumitsu, K; Horiuchi, M; Ito, Y; Kagawa, Y; Kanemitsu, Y; Maeno, K; Niimi, A; Oguri, T; Ohkubo, H; Sone, K; Tajiri, T; Takakuwa, O; Takemura, M; Uemura, T | 1 |
| Adamchuk, GA; Fadeeva, NV; Kalloli, M; Kryukov, F; Matrosova, MP; Nagarkar, R; Roy, B; Shelepen, KG; Shustova, MS; Stroyakovskiy, DL; Voevodin, GD; Zhuravleva, D | 1 |
| Cai, L; Chen, C; Deng, H; Li, S; Lin, X; Liu, M; Qin, Y; Qiu, G; Xie, X; Xie, Z; Yang, Y; Zhou, C | 1 |
| Kataoka, K; Kimura, T; Kondoh, Y; Matsuda, T; Morise, M; Oi, H; Yamano, Y; Yokoyama, T | 1 |
| Abouzgheib, W; Boujaoude, Z; Callahan, K; Hageboutros, A; Khrizman, P; Kubicek, GJ; Patel, A; Squillante, C; Xu, Q | 1 |
| Chen, L; Li, F; Mao, Y; You, H; Zou, A | 1 |
| Avella, DM; Chaudhuri, AA; Kaifi, JT; Kimchi, ET; Li, G; Manjunath, Y; Mitchem, JB; Nussbaum, YI; Pantel, K; Radhakrishnan, V; Shyu, CR; Staveley-O'Carroll, KF; Suvilesh, KN; Warren, WC | 1 |
| Cui, X; Li, B; Li, X; Zhang, B | 1 |
| Fujita, H; Fujitaka, K; Fukuda, H; Harada, H; Imagumbai, T; Kimura, T; Konno, M; Mori, K; Murakami, H; Nakamatsu, K; Nishimura, Y; Omori, S; Tanabe, H; Tatebe, H | 1 |
| Reguart, N; Reyes, R | 1 |
| Arai, R; Ikeda, N; Inoue, T; Kushima, Y; Masawa, M; Nakamura, Y; Niho, S; Okutomi, H; Shimizu, Y; Soda, S; Takemasa, A; Uchida, N | 1 |
| Furusawa, H; Honda, T; Inase, N; Jin, Y; Masuo, M; Mitsumura, T; Miyashita, Y; Miyazaki, Y; Nukui, Y; Ohba, T; Saito, K; Sakakibara, R; Sakashita, H; Shirai, T; Suhara, K; Takagiwa, J; Tsutsui, T; Uchibori, K; Yamashita, T | 1 |
| Ansell, P; Bach, BA; Bar, J; Biesma, B; Dunbar, M; Glasgow, J; Govindan, R; Guclu, S; Hansen, O; He, L; Huang, X; Insa, A; Kato, T; Khan, SA; Kundu, MG; Lee, KH; Lind, M; Nakagawa, K; Sehgal, V; Tafreshi, A; Uskov, D | 1 |
| Li, X; Li, Y; Lin, Q; Qu, W; Wang, Z; Xing, H; Yang, B; Yang, Z; Zhao, Y; Zvyagin, AV | 1 |
| Jin, M; Li, Q; Liu, Y; Xu, R; Zhang, F; Zhang, Y | 1 |
| Ando, M; Atagi, S; Harada, T; Hayashi, H; Horinouchi, H; Ichihara, E; Ichikado, K; Ikeda, S; Kato, T; Kenmotsu, H; Kimura, Y; Kishimoto, J; Kondo, M; Kondoh, Y; Kusumoto, M; Minegishi, Y; Nakagawa, K; Nakanishi, Y; Nakatomi, K; Okamoto, I; Otsubo, K; Takemoto, S; Tamiya, M; Yamamoto, N | 1 |
| Feng, J; Hou, S; Wang, H; Wu, Y; Xie, J | 1 |
| Antunes, C; Branco, H; Oliveira, J; Santos, LL; Vasconcelos, MH; Xavier, CPR | 1 |
| Pu, J; Shen, W; Wang, C; Wang, L; Zuo, Y | 1 |
| Daste, A; Delon, T; Domblides, C; Heraudet, L; Lepetit, H; Ravaud, A; Veillon, R; Vergnenègre, C; Zysman, M | 1 |
| Cui, W; Jia, L; Liu, S; Ren, Y; Tang, X; Wang, J; Wang, L; Wang, W; Wu, C; Yang, J | 1 |
| Abu-Hejleh, T; Allen, BG; Bellizzi, AM; Bodeker, KL; Bossler, AD; Buatti, JM; Buettner, GR; Byrne, MM; Cullen, JJ; Fath, MA; Furqan, M; Hartwig, SM; Henrich, JB; Houtman, JC; Ivanovic, M; Mani, H; Monga, V; Mott, SL; Petronek, M; Pulliam, CF; Smith, BJ; Spitz, DR; Stephens, LM; Varga, SM; Wagner, BA; Zeitler, W; Zhang, J | 1 |
| Jang, HJ; Kwon, H; Lee, HJ; Lee, HY; Min, HY; Moon, HG; Pei, H; Suh, YA; Yun, HJ | 1 |
| Bayliss, R; Choi, J; Fry, AM; Khan, S; Lucken, K; O'Regan, L; Pashley, SL; Sampson, J | 1 |
| Canão, F; Ferreira, H; Neves, NM | 1 |
| Min, S; Zheng, Q; Zhou, Y | 1 |
| Castellano, GM; Garbuzenko, OB; Malhotra, J; Minko, T; Pine, SR; Sabaawy, HE; Zeeshan, S | 1 |
| Fukuda, S; Fukumitsu, K; Horiuchi, M; Ito, Y; Kagawa, Y; Kanemitsu, Y; Maeno, K; Mori, Y; Niimi, A; Oguri, T; Ohkubo, H; Sone, K; Suzuki, Y; Tajiri, T; Takemura, M; Toda, S; Uemura, T; Yamamoto, S | 1 |
| Gu, A; Han, B; Huang, A; Lu, J; Wang, W; Zhong, H | 1 |
| Liu, H; Long, Y; Lyu, X; Ma, D; Qin, Y; Shi, J; Tang, B; Wang, M; Xu, Y | 1 |
| Baker, S; Blanchard, E; Brahmer, JR; Celano, P; Duma, N; Elkins, IB; Ellis, PM; Haddad, RY; Hesketh, PJ; Jain, D; Jaiyesimi, IA; Johnson, DH; Leighl, NB; Mamdani, H; Masters, G; Moffitt, PR; Phillips, T; Riely, GJ; Robinson, AG; Rosell, R; Schiller, JH; Schneider, BJ; Singh, N; Spigel, DR; Temin, S | 1 |
| Du, D; Ji, J; Ma, H; Qiu, Y; Xie, B; Zhang, W; Zhou, J; Zhu, L | 1 |
| Fang, W; He, H; Hong, S; Huang, Y; Lin, Y; Lin, Z; Ma, Y; Salamone, SJ; Wu, Y; Xue, J; Yang, Y; Zhang, L; Zhang, Y; Zhao, H | 1 |
| González-Bakker, A; Padrón, JM; Puerta, A; Santos, G | 1 |
| Hu, R; Huang, Y; Lin, X; Pan, G; Wang, X | 1 |
| Kishimoto, J; Okamoto, I; Shimose, T; Shiraishi, Y; Sugawara, S; Toi, Y | 1 |
| Avagliano, C; Aviello, G; Cimmino, F; Coretti, L; Cristiano, C; Cuozzo, M; Lembo, F; Liguori, FM; Mollica, MP; Russo, R; Turco, L | 1 |
| Cui, X; Li, P; Wang, T; Xu, Z; Zhang, F; Zhang, J; Zhang, W; Zhao, Y | 1 |
| Chen, K; Chen, Q; Ge, D; Lin, X; Liu, L; Liu, YH; Shi, W; Song, L; Wu, YL; Xing, W; Yan, W; Yang, F; Zhang, Q; Zhong, WZ | 1 |
| Hiranuma, O; Iwasaku, M; Katayama, Y; Matsui, Y; Morimoto, K; Morimoto, Y; Shiotsu, S; Takayama, K; Takeda, T; Tamiya, N; Tokuda, S; Yamada, T | 1 |
| Li, Y; Liang, R; Luo, M; Ma, Z | 1 |
| Guo, S; Li, S; Ma, K; Wang, J; Wei, S; Xu, Y; Zhang, F | 1 |
| Cui, H; Gu, X; Li, G; Ma, M; Niu, X; Su, L; Tang, S; Tian, Y; Wu, T; Yang, M; Yin, Q; Zhou, C | 1 |
| Han, B; Qiao, R; Xu, J; Yu, L; Zhong, H; Zhong, R | 1 |
| Fan, XX; Feng, SL; He, F; Leung, EL; Xie, Y; Yan, PY; Yao, XJ; Zhou, H | 1 |
| Borisyuk, BO; Bororov, LV; Ganul, AV; Maliarchuk, K; Shevchenko, AI; Sovenko, VM | 1 |
| Boonsong, T; Chang, A; Khongthong, P; Nakwan, N; Ruklerd, T; Usaha, S | 1 |
| Hou, H; Jiang, M; Li, T; Sun, D; Wang, Y; Zhang, C; Zhang, X; Zhou, N; Zhu, J | 1 |
| Gu, M; Guo, J; Hou, J; Jiang, C; Jiang, Y; Jin, G; Li, H; Li, Q; Li, X; Li, Z; Liu, G; Liu, T; Qian, Y; Ren, B; Shen, J; Shi, Y; Xu, T; Zhang, Z; Zhao, J; Zhao, L; Zhou, T | 1 |
| Wang, Y; Wang, Z; Xuan, X | 1 |
| Du, L; Guo, D; Lin, S; Sun, C; Xu, S; Yan, X | 1 |
| Li, L; Song, C; Sun, Z; Wang, W; Xu, H; Yin, J | 1 |
| Tian, H; Wang, L; Zhang, Z | 1 |
| Ballinger, M; Bruno, R; Friberg, LE; Hoang, T; Jin, JY; Karlsson, MO; Krishnan, SM; Mercier, F; Wu, B; Zhang, R | 1 |
| Fukui, T; Hisashi, M; Hosotani, S; Igawa, S; Kasajima, M; Kusuhara, S; Manabe, H; Manaka, H; Nakahara, Y; Naoki, K; Oguri, A; Sasaki, J; Sato, T; Yamamoto, M | 1 |
| Chen, J; Dong, J; Duan, X; Jiang, S; Li, W; Li, Y; Shi, H; Zou, J | 1 |
| Chu, T; Han, B; Lou, Y; Lu, J; Wang, H; Zhang, W; Zhang, X; Zhang, Y; Zhong, H; Zhong, R | 1 |
| Aoyama, T; Ebi, N; Fujita, M; Harada, T; Hirano, R; Igata, F; Ikeda, T; Ikeuchi, N; Inoue, H; Kawabata, T; Kinoshita, E; Nakao, A; On, R; Osaki, Y; Otsuka, R; Sasaki, T; Tan, I | 1 |
| Naviglio, S; Ragone, A; Salzillo, A; Sapio, L; Spina, A | 1 |
| Budweiser, S; Chiabudini, M; Dechow, T; Hackanson, B; Janssen, J; Nacke, A; Oppermann, U; Potthoff, K; Riera-Knorrenschild, J; Schulz, H; Taeuscher, D; von Weikersthal, LF; Welslau, M | 1 |
| Garg, R; Khan, MA; Khurana, S; Kumar, A; Kumar, S; Malik, PS; Mohan, A; Pathak, N; Pathy, S; Prasad, CP; Pushpam, D; Yadav, M | 1 |
| Frances, N; Geiger, K; Hartung, N; Henrich, A; Holdenrieder, S; Huisinga, W; Joerger, M; Kloft, C; Nassar, YM; Ojara, FW | 1 |
| Bara, I; Cappuzzo, F; Finley, GG; Jotte, RM; Kaul, MD; Mok, TSK; Nishio, M; Paranthaman, N; Reck, M; Socinski, MA; West, HJ; Yu, W | 1 |
| Asahina, H; Hosomi, Y; Kobayashi, K; Maemondo, M; Matsuyama, K; Miyanaga, A; Morita, S; Okano, T; Seike, M; Shukuya, T; Sugawara, S; Tsubata, Y; Watanabe, S | 1 |
| Du, J; Hu, W; Li, J; Tian, Z; Zhao, P; Zhao, Y; Zheng, W | 1 |
| Du, H; Li, J; Li, W; Wu, F; Xiu, W; Zheng, J; Zhou, C; Zhou, F; Zhou, Y | 1 |
| Gao, J; Huang, J; Mu, L; Qi, L; Qu, T; Song, Y; Wang, X; Xin, D; Xu, J; Zhang, B | 1 |
| Guan, Y; He, SQ; Linderoth, B; Raja, SN; Sanchez, KR; Sivanesan, E; Stephens, KE; Zhang, C | 1 |
| Akai, M; Anzai, M; Demura, Y; Honjo, C; Ishizuka, T; Nakashima, K; Ohi, M; Shimada, A; Sonoda, T; Tada, T; Umeda, Y; Waseda, Y; Yamaguchi, M | 1 |
| Qi, Z; Wang, X; Zhao, Y | 1 |
| Kubota, K; Kunitoh, H; Maruyama, R; Matsuda, A; Ohira, T; Okamoto, H; Seto, T; Tsuboi, M; Yamaoka, K | 1 |
| Stinchcombe, TE | 1 |
| Aerts, JGJV; Badrising, SK; de Langen, AJ; Dingemans, AC; Ernst, SM; Paats, MS; Steendam, CMJ | 1 |
| Deng, X; Dong, X; Huang, X; Mao, G; Xing, W | 1 |
| Bowen, SR; Gates, EDH; Hippe, DS; Vesselle, HJ; Zeng, J | 1 |
| Chen, J; Chen, L; Ding, P; Hao, Y; He, X; Hu, W; Ji, QH; Li, L; Liao, T; Lv, X; Wang, X; Xu, Y; Zhang, W; Zhou, D; Zhu, Y | 1 |
| Huang, X; Jiang, G; Li, Z; Tang, L; Zheng, W; Zhu, T | 1 |
| Bhangale, T; Chandler, GS; Crow, M; Hackos, DH; Jung, M; Kaminker, JS; Khan, Z; Maiya, V; McCarthy, MI; Mohindra, R | 1 |
| Adeyemi, SA; Choonara, YE; Marimuthu, T; Ngema, LM; Ngwa, W; Ubanako, PN | 1 |
| Bando, M; Fukuizumi, A; Gemma, A; Homma, S; Isobe, K; Izumi, S; Kishi, K; Koyama, R; Minegishi, Y; Omori, M; Sugiyama, H; Sugiyama, Y; Takahashi, K; Uruga, H | 1 |
| Hu, S; Sun, J; Wang, C; Xue, J; Zhang, Q | 1 |
| Abd-Elmawla, MA; Aborehab, NM; ElSayed, AM; Ezzat, SM; Sabry, O | 1 |
| Ito, S; Kashima, M; Kikuchi, E; Kikuchi, J; Kitai, H; Konno, S; Maeda, M; Morinaga, D; Sakakibara-Konishi, J; Shoji, T; Takahashi, H; Takashima, Y; Tsuji, K | 1 |
| Dadey, DY; Fitzpatrick, J; Hallahan, DE; Kapoor, V; Rau, MJ; Saikia, M; Shah, HK; Singh, AK; Thotala, D; Townsend, R | 1 |
| Akamatsu, H; Hida, T; Inui, N; Kang, JH; Kim, HR; Lee, JS; Lee, KH; Nakagawa, K; Nishio, M; Ohe, Y; Sugawara, S; Takahashi, S; Tamura, T; Tanaka, H; Yamamoto, N; Yang, CT; Yoshida, T; Yu, CJ | 1 |
| Chu, T; Han, B; Hu, M; Liu, H; Lou, Y; Lu, J; Qian, F; Wang, S; Zhang, B; Zhang, Y; Zhong, H; Zhou, C; Zhou, J; Zou, B | 1 |
| Szymaszek, Ż; Twardowska, M; Uram, Ł; Walczak, M; Wołowiec, S; Wróbel, K | 1 |
| Aiba, T; Domeki, Y; Kawana, S; Kawashima, Y; Kimura, Y; Nakamura, A; Sugawara, S; Sugisaka, J; Toi, Y; Yamanda, S | 1 |
| Ballinger, M; Cheng, J; Childress, MA; Gjoerup, O; Gupta, P; Huang, RSP; Krainock, M; Liu, MC; Madison, RW; Miller, ST; Moshkevich, S; Oxnard, GR; Pellini, B; Shames, DS; Socinski, MA; Srivastava, MK; Young, A; Zou, W | 1 |
| Geater, SL; Jirapongsak, J; Raungrut, P; Tanyapattrapong, S; Thongsuksai, P | 1 |
| Wang, C; Xia, S | 1 |
| Ai, X; Hao, X; Lei, S; Li, W; Wang, Y; Xu, H; Yang, G; Yang, Y; Zhang, S | 1 |
| Cremers, S; Martin, JH; Wright, DFB | 1 |
| Er-Bu, A; Tsering, T; Xie, HJ; Zhan-Dui, N; Zhao, J; Zhuo-Ma, D | 1 |
| Cobo, M; Kim, JS; Mavroudis, D; Socinski, MA; Syrigos, K; Villaruz, LC; Zhang, W | 1 |
| Uprety, D | 1 |
| Cappuzzo, F; West, H | 1 |
| de Jong, EEC; Degens, JHRJ; Deist, TM; Dingemans, AC; Jochems, A; Lambin, P; Leijenaar, RTH; Sanders, KJC; Schols, AMWJ; van Elmpt, W; van Timmeren, JE | 1 |
| Diksha, D; Gupta, P; Malik, PS; Mohan, A | 1 |
| Das, M; Diehn, M; Hellyer, JA; Hoang, NT; Jeong, Y; Neal, JW; Niu, X; Padda, SK; Ramchandran, K; Stehr, H; Wakelee, H | 1 |
| Criss, SD; Gainor, JF; Kong, CY; Mooradian, MJ; Reynolds, KL; Watson, TR | 1 |
| Kumagai, T; Kunimasa, K; Nakamura, H; Nakatsuka, SI; Nishino, K | 1 |
| Guan, H; Liu, G; Sheng, Y; Shi, L; Xie, F | 1 |
| Baba, T; Fujiwara, Y; Kato, T; Kenmotsu, H; Ko, R; Mori, K; Ninomiya, T; Ogura, T; Okamoto, H; Ono, A; Yamaguchi, O; Yamamoto, N; Yoh, K | 1 |
| Asahina, H; Dosaka-Akita, H; Fujita, Y; Harada, M; Harada, T; Honda, R; Ikari, T; Isobe, H; Kanazawa, K; Kikuchi, E; Kojima, T; Konno, S; Nishimura, M; Ogi, T; Oizumi, S; Shimizu, K; Sugaya, F; Suzuki, M; Takamura, K; Tanaka, H; Yokouchi, H | 1 |
| Cao, YB; Duan, FG; Fan, XX; Hsiao, WW; Khan, I; Lai, HL; Leung, EL; Li, RZ; Liu, L; Tang, YJ; Wang, MF; Wu, QB; Yao, XJ; Zhang, YZ | 1 |
| Huang, Y; Huang, Z; Li, J; Ma, C; Mo, Z; Pan, X; Wang, W; Wu, C; Yang, Y | 1 |
| Bai, Z; Ding, N; Guan, Q; Liu, X; Ma, L; Tong, B; Wei, Q; Zhang, W; Zhao, M | 1 |
| Furuya, N; Kimura, H; Koji, K; Marushima, H; Miyazawa, T; Nakamura, H; Saji, H; Sakai, H | 1 |
| Dhillon, S; Syed, YY | 1 |
| He, X; Hu, B; Lin, H; Mao, J; Peng, Y; Wang, J; Wang, Y; Zhang, F; Zhang, T; Zheng, J | 1 |
| Dosaka-Akita, H; Iseki, K; Kinoshita, I; Kobayashi, M; Saito, Y; Sakakibara-Konishi, J; Shinagawa, N; Yamada, T | 2 |
| Agresti, B; Garlatti, P; Livi, L; Maragna, V; Mazzini, C; Meacci, F; Perna, M; Pieretti, G; Scotti, V; Vicini, G | 1 |
| Cao, P; Gong, Y; Liang, B; Liu, Y; Lu, Y; Luo, C; Wang, J; Wang, Y; Xu, Y; Xue, J; Yan, T; Zhou, L; Zhou, X; Zhou, Y | 1 |
| Blumenschein, GR; Bogart, JA; Bradley, JD; Choy, H; Curran, WJ; Forster, KM; Hu, C; Iyengar, P; Kavadi, VS; Komaki, RR; Koprowski, CD; Magliocco, AM; Masters, GA; Meng, J; Narayan, S; Olson, MR; Paulus, R; Robinson, CG; Schild, SE; Wynn, RB | 1 |
| Li, L; Li, M; Li, X; Ren, H; Wang, X; Xiao, T; Yang, B; Zhang, L; Zhang, W; Zhou, H | 1 |
| Bao, C; Cai, S; Chen, Q; Kong, J; Liu, D; Lu, H; Luo, J; Wu, C | 1 |
| Dong, Y; Guo, H; Jing, W; Liu, Y; Yu, J; Zhu, H | 1 |
| Aksenov, S; Al-Huniti, N; Dunyak, J; Nagase, M; Yan, H | 1 |
| Bradford, DS; Crane, J; Deal, AM; Irvin, W; Lee, C; Morgensztern, D; Muss, HB; Pecot, C; Pennell, N; Socinski, M; Stevenson, JP; Stinchcombe, T; Villaruz, LC; Weiss, JM; West, HJ | 1 |
| Gundu, N; Jain, D; Kancharla, H; Khurana, S; Kumar, S; Malik, PS; Mohan, A; Pathak, N; Pathy, S; Pushpam, D; Vandidassane, I | 1 |
| Bi, J; Chen, S; Diao, C; Dong, Y; Fan, H; Fan, W; Feng, Q; Geng, D; Han, X; Huang, G; Li, F; Li, G; Li, P; Li, Q; Li, T; Li, W; Li, Y; Liu, B; Meng, M; Meng, Q; Ni, Y; Ren, H; Sheng, L; Sun, D; Sun, L; Sun, W; Sun, Y; Tian, H; Wang, C; Wang, J; Wei, Z; Xu, X; Xu, Y; Xue, G; Yang, X; Ye, X; Yu, G; Zhang, B; Zhang, K; Zhang, L; Zheng, A; Zou, Z | 1 |
| Charles, KA; Clarke, SJ; Galettis, P; Harris, BDW; Martin, JH; McLachlan, AJ; Perera, V; Phan, V; Reuter, SE; Szyc, A; Walpole, E | 1 |
| Aggarwal, C; Aisner, J; Berman, AT; Bradley, JD; Decker, RH; Feigenberg, SJ; Gettinger, SN; Jabbour, SK; Langer, CJ; Lin, Y; Malhotra, J; Simone, CB | 1 |
| Han, J; Liang, Y; Svirskis, D; Tian, B; Wu, Z; Zhang, J | 1 |
| Hattori, Y; Ishii, T; Itoh, S; Kawa, Y; Kono, Y; Satouchi, M; Tanaka, M; Tohnai, R; Urata, Y | 1 |
| Althouse, S; Anouti, B; Durm, G; Hanna, N | 1 |
| Chen, H; Li, J; Liang, X; Pu, X; Shen, T; Song, Z; Wang, L; Wang, W; Xu, C; Yu, Z; Zhang, Y | 1 |
| An, T; Chen, H; Chi, Y; Duan, J; Liang, Q; Wang, J; Wang, S; Wang, Y; Wang, Z; Yang, X; Zhao, J; Zhong, J; Zhuo, M | 1 |
| Li, J; Li, W; Liang, L; Liu, Z; Wang, Y; Xu, F; Xu, H; Yang, G; Yang, L; Ying, J; Zhang, Q; Zhang, S | 1 |
| Jiang, W; Lizaso, A; Mao, X; Mi, J; Song, L; Yang, N; Zeng, L; Zhang, Y; Zhou, Y | 1 |
| Lee, YJ; Oh, SM; Park, HW; Park, JH; Park, SA | 1 |
| Darilay, A; Hansen, RN; Ramsey, SD; Ryan, K; Seal, B; Yong, C; Zhang, Y | 1 |
| Cha, SI; Choi, JE; Choi, SH; Do, SK; Hong, MJ; Jeong, JY; Jin, CC; Kang, HG; Kim, CH; Kim, JH; Lee, J; Lee, JH; Lee, SY; Lee, WK; Lee, YH; Park, JY; Seo, H; Shin, KM; Yoo, SS | 1 |
| Bi, N; Chen, D; Chen, M; Feng, Q; He, J; Hui, Z; Jiang, W; Li, J; Liang, J; Liu, L; Lv, C; Lv, J; Shi, A; Wang, J; Wang, L; Wang, W; Wang, X; Wu, S; Xiao, Z; Xu, Y; Yin, W; Zhang, H; Zhang, T; Zhao, L; Zhou, Z | 1 |
| Jiang, H; Rao, Y; Wu, Z; Zang, F; Zhu, X | 1 |
| Fujiwara, Y; Goto, Y; Horinouchi, H; Kanda, S; Nokihara, H; Ohe, Y; Tamura, T; Yamamoto, N; Yamamoto, T | 1 |
| Abbasnezhad, A; Abd El-Ghafar, OA; Abhilash, L; Abouzid, KAM; Achberger, AM; Ackerman, S; Akhatayeva, Z; Akin, D; Al-Kaysi, RO; Alakhdar, AA; Alame, M; Aleksic Sabo, V; Alinezhadbalalami, N; Allen, JD; Alonso, JM; Alqatani, S; Alsayed, B; Álvarez Larraondo, M; Alvarez, M; Amini, SB; An, Z; Anasir, MI; Anderson, GH; Andremont, A; Andrés, S; Angel, S; Anigboro, AA; Anini, Y; Antonides, CFJ; Arafa, K; Arafa, RK; Aryal, UK; Asbaghi, O; Assefa, MK; Atyah, M; Avwioroko, OJ; Ayora-Talavera, G; Azpilikueta, A; Azyazov, VN; Ba, YF; Bachmann, KF; Badoual, J; Bae, SJ; Baek, SH; Bahrami, B; Bai, J; Baid-Agrawal, S; Bailey, MR; Baillie, JK; Balani, N; Balcar, VJ; Banica, T; Banks, L; Barb, J; Bardeen, CJ; Barrett, HE; Bartnikowski, N; Bashir, R; Battaglia, M; Bautista-Hernández, V; Becker, B; Beekman, FJ; Benidir, M; Benjelloun, M; Bentley, RF; Bergé, J; Berger, D; Bernsen, MR; Berraondo, P; Bhattacharya, R; Bhayani, SB; Bi, W; Bi, X; Bi, YL; Bi, Z; Bian, K; Biesecker, LG; Billadeau, DD; Blaszczyk, R; Blum, JL; Boachie, R; Boelte, K; Bogers, AJJC; Boileau, I; Bonduelle, C; Bonny, O; Bonsu, JM; Boos, LA; Borges-Argáez, R; Bouchard, PA; Boudot, C; Bourgeade-Delmas, S; Boutet-Robinet, E; Boyle, AJ; Branigan, D; Briones, S; Broniowska, KA; Brossas, JY; Brown, WA; Brzezinska, J; Buitron, G; Burnier, M; Bursulaya, B; Burton, PR; Bush, AA; Busuttil, RW; Cabello-Aguilar, S; Cáceres-Farfán, M; Cacheux, V; Caffrey, PJ; Cai, B; Cai, Q; Cai, S; Cai, Y; Calders, P; Cammarota, G; Campbell, DA; Cancelli, C; Cao, Q; Cao, WH; Cao, X; Capet, M; Capoluongo, E; Carey, ME; Carnero, M; Carrasco, LI; Carreno, J; Carrillo-Reyes, J; Casini, I; Cassar, M; Catalan, G; Cattamanchi, A; Cazares-Granillo, M; Celie, B; Cen, YK; Cena, H; Cerbo, RM; Ceron, E; Cetina-Montejo, L; Chaâbane-Banaoues, R; Chabanet, C; Chace-Donahue, F; Chalfun-Júnior, A; Chan-Balan, R; Chang, CS; Chen, CS; Chen, D; Chen, J; Chen, L; Chen, PN; Chen, Q; Chen, S; Chen, W; Chen, WP; Chen, X; Chen, Z; Cheng, H; Cheng, J; Cheng, Q; Cheng, T; Chi, T; Chianelli, D; Chieppa, M; Child, CJ; Cho, JH; Cho, JY; Chogtu, B; Choi, GH; Choi, J; Choi, M; Choi, NG; Cholu, CO; Chow, ES; Chowdhury, AH; Chu, PC; Chu, Q; Chu, S; Chua, H; Chung, T; Chunyan, L; Church, JS; Civardi, E; Cobiella, J; Colinge, J; Collado, CJ; Collins, TJ; Cong, LM; Conkrite, KL; Cope, SJ; Corbett, JA; Cornet, M; Cornillot, E; Corvaisier, S; Costes-Martineau, V; Courtioux, B; Coussens, M; Covino, M; Criado, A; Cui, J; Cui, Y; Cunitz, BW; Curry, AE; Cussó, L; D'Urzo, AD; D'Urzo, KA; Dabbous, S; Dahlgren, RA; Dai, H; Dai, T; Dai, W; Dalinghaus, M; Dang, S; Davalos, RV; Davidson, H; de Andrea, CE; De Angelis, M; de Blois, E; de Carvalho, PA; De Clercq, E; De Giuseppe, R; de Jong, M; De Langhe, S; De Oliveira, L; de Souza Pinto Lemgruber, R; de Souza, LB; de Swart, J; De Wandele, I; de Woestijne, PCV; Delaney, S; Delorme, M; Delvenne, P; Deng, L; Deng, Z; Denkinger, CM; der Meulen, MHV; Deraeve, C; Desco, M; DeSilva, S; Destere, A; Dhali, A; Di Ciano, P; Dias-Santagata, D; Diskin, SJ; Djè, MK; Doddipatla, S; Doerr, AJ; Dokla, EME; Domiciano, D; Domingo, N; Dong, C; Dong, J; Dong, Q; Dong, S; Dong, X; Dong, Z; Douair, I; Douglas, TA; Doyle, SM; Drain, PK; Du, K; Du, L; Du, Q; Du, S; Duan, C; Duan, H; Duan, J; Duan, S; Duan, W; Dueluzeau, R; Dukic, L; Dunmire, BL; Duvauchelle, T; Dymek, B; Dzwonek, K; Earnest, A; Eckardt, KU; El Ghadraoui, L; El Massoudi, S; Elloumi, F; Elnour, IE; Embarak, S; Ende, M; England, K; Enikeev, D; Enyedy, I; Epple, R; Erickson, GE; Eriksson, J; Erndt-Marino, J; Errachidi, F; Etxeberria, I; Evan, AP; Fairlamb, AH; Falahi, E; Fan, CC; Fan, H; Fan, M; Fan, MZ; Fan, S; Fan, Y; Fang, CS; Fang, J; Fang, X; Fang, Z; Farmany, A; Farooqi, A; Farouk, HO; Fazelipour, S; Feng, D; Feng, J; Feng, JX; Feng, YL; Ferraz, SL; Ferreira, CR; Figenshau, RS; Finn, AV; Fiseha, T; Fleischer, AS; Fogleman, AD; Fontaine, O; Ford, CR; Fouladvand, F; Four, M; Fousteri, G; Francis, JR; Fraser, JF; Frazier, RP; Fu, H; Fu, P; Fu, YJ; Fujishima, A; Fuster, V; Gabilan, JC; Gagliani, N; Gai, QY; Galán-Arriola, C; Gale, P; Galimova, GR; Galkin, A; Gallo, A; Gallo, AA; Gang, DD; Ganschow, S; Gao, C; Gao, F; Gao, GP; Gao, H; Gao, K; Gao, M; Gao, MY; Gao, P; Gao, R; Gao, S; Gao, WJ; Gao, Y; Garbacz, P; García Ruiz, L; Garcia, EM; Garofoli, F; Gasbarrini, A; Gattinoni, L; Gaudig, M; Gbureck, U; Ge, X; Genko, N; Gentile, GL; George, MW; Gerety, GF; Gestwicki, JE; Geusens, PP; Ghassemi, M; Giardina, JD; Giebultowicz, JM; Gifford, CA; Gijsen, FJH; Gilfillan, R; Gilson, E; Gingl, K; Giuliano, C; Glybochko, P; Goessler, W; Gofflot, S; Golab, J; Goldstein, A; Golebiowski, A; Gómez, L; Gómez-Carballo, J; Gonçalves, PEO; Gonzales, R; Gonzalez-Cotto, M; González-Fernández, D; Gonzalez-Lopez de Turiso, F; Goodman, JM; Govinda Raju, S; Grimm, J; Gross, AJ; Gruenheid, S; Gu, C; Gu, FF; Gu, S; Gu, Z; Guest, RL; Gui, C; Gui, J; Guillem, A; Guo, G; Guo, L; Guo, Q; Guo, S; Guo, SW; Guo, W; Guo, Y; Guo, YG; Guo, Z; Guretzky, JA; Haenggi, M; Hahn, MS; Hakkola, J; Halim, AA; Hampel, D; Han, B; Han, BH; Han, D; Han, G; Han, J; Han, LZ; Han, R; Han, S; Han, X; Han, Z; Handley, MA; Hanke, I; Hannongbua, S; Hao, P; Happ, JT; Hara, M; Haraux, F; Hare, JL; Harper, JD; Hartley, AM; Harvey, E; Hashimoto, K; Hassan, HM; Hautajärvi, H; Hayton, TW; He, C; He, H; He, HJ; He, WP; He, Y; He, Z; Hedrick, V; Heffernan, JK; Hegrová, J; Heidarimoghadam, R; Helms, K; Hengphasatporn, K; Henry, D; Herrmann, TRW; Hesson, T; Himmelbauer, MK; Hindle, A; Hoffmann, R; Hogg, N; Hong, KB; Hong, SK; Honjol, Y; Hood, C; Hsi, RS; Hsu, JL; Hu, B; Hu, BC; Hu, D; Hu, H; Hu, J; Hu, K; Hu, M; Hu, MK; Hu, T; Hu, W; Hu, Y; Hu, Z; Hua, S; Huang, H; Huang, J; Huang, L; Huang, M; Huang, P; Huang, X; Huang, Y; Huang, Z; Hukkanen, J; Hung, MC; Huo, X; Hyötyläinen, T; Ianiro, G; Ibanez, B; Imran, M; Ireland, S; Irwin, MS; Ishiguro, H; Jackowski, K; Jackson, C; Jacob, SI; Jahromy, MH; Jakob, SM; Jang, J; Javvaji, PK; Jefferson, KK; Jena, P; Ji, H; Jiang, F; Jiang, GH; Jiang, H; Jiang, J; Jiang, X; Jiang, Z; Jiao, J; Jiménez, A; Jin, X; Jincai, W; Jintao, X; Jo, K; Jofra, T; Johari, Y; Johnson, ACM; Jones, JH; Josephine Fauci, A; Juhl, AK; Jun, S; Kaiser, RI; Kajioka, J; Kajiyama, H; Kalliyil, A; Kalthur, SG; Kamalanathan, M; Kamaldinov, T; Kanaani, L; Kang, D; Kang, J; Kang, S; Känsäkoski, P; Kaplan, DL; Karwan, M; Kasibhatla, S; Kaur, A; Kawazoe, Y; Ke, C; Keyser, J; Khalique, A; Khan, IT; Kharshoum, RM; Kher, R; Kherani, J; Ki, KK; Kikkawa, F; Kikkawa, R; Kim, BT; Kim, EH; Kim, GA; Kim, GD; Kim, HB; Kim, HG; Kim, JS; Kim, MJ; Kim, SI; Kim, SJ; Kim, Y; King, K; Kinyamu-Akunda, J; Kirkkala, T; Kjaer-Sorensen, K; Kleppinger, EL; Kloner, RA; Klopfenstein, TJ; Knappe, D; Knezevic, P; Kobos, LM; Kohli, M; Kolano, L; Kolodgie, FD; Kolte, AP; Koneru, B; Kong, D; Kong, F; Kong, X; Konggidinata, MI; Köpke, M; Koski, KG; Kotsis, F; Köttgen, A; Kouakou-Kouamé, CA; Kraemer, US; Krane, V; Krehbiel, CR; Krenning, BJ; Kretzschmar, D; Ku, KB; Kubota, Y; Kulich, P; Kumar, NG; Kupiec-Weglinski, JW; Lalani, SS; Lan, X; Landfeldt, E; Langenberg, E; Lapauw, B; Larkin, J; Lassoued, MA; Laukhtina, E; Laura Martinez, J; Laveillé, A; Lavela, P; Law, AD; Lazraq, A; Le Foll, B; Lee, BK; Lee, C; Lee, CS; Lee, EJ; Lee, EY; Lee, G; Lee, HY; Lee, JH; Lee, JJ; Lee, JO; Lee, JS; Lee, R; Lei, H; Lei, P; Lellouche, F; Lennerz, JK; Leong, W; Leslie, I; Lessem, E; Levin, M; Levinger, I; Li, C; Li, CW; Li, CX; Li, CY; Li, D; Li, H; Li, HM; Li, J; Li, L; Li, LM; Li, N; Li, S; Li, W; Li, X; Li, XX; Li, Y; Li, Z; Li, ZL; Li, ZX; Lian, Q; Liang, C; Liang, GH; Liang, H; Liang, J; Liang, X; Liao, CX; Liao, R; Ličbinský, R; Lim, YS; Lima, HK; Lin, JG; Lin, L; Lin, S; Lin, WP; Lin, Z; Liso, M; Liu, BX; Liu, C; Liu, H; Liu, J; Liu, M; Liu, Q; Liu, S; Liu, SF; Liu, SL; Liu, T; Liu, W; Liu, X; Liu, XB; Liu, Y; Liu, YY; Liu, Z; Liu, ZQ; Lobo, M; Loitzenbauer, M; López, F; Lopez, G; López, GJ; Lou, Z; Lu, IC; Lu, J; Lu, M; Lu, W; Lu, X; Lu, Y; Luhovyy, BL; Luna-Abanto, J; Luo, J; Luo, K; Luo, L; Luo, M; Luo, W; Luo, X; Luo, XM; Lv, Y; Lv, YQ; Lyu, HD; Lyu, J; Ma, C; Ma, G; Ma, L; Ma, Q; Ma, X; Ma, Y; Macha, SJ; MacLean, E; Mahalapbutr, P; Maina, T; Malfait, F; Malfertheiner, MV; Malzert-Fréon, A; Mansouri, E; Mao, C; Marcellin, E; Marchiori, PER; Marcotte, DJ; Maréchal, A; Maric, N; Maris, JM; Maron, L; Marti, CN; Martínez-Milla, J; Mateo, J; Mather, K; Mathison, CJN; Matthay, MA; Maxwell, CL; Mazier, D; Mazumder, D; Mazurkiewicz, M; Mazzucchelli, TG; McAuley, DF; Mccoy, K; McVicar, DW; Mebel, AM; Mech, A; Meester, EJ; Meiselbach, H; Melero, I; Ménard, G; Meng, X; Mengya, Y; Merle, G; Meunier, B; Mfarrej, B; Mi, K; Migueliz, I; Mikuška, P; Miladi, K; Miletich, R; Millar, JE; Mills, MR; Milne, R; Minute, L; Misiak, M; Mo, F; Modi, A; Mok, F; Molina, C; Mollen, CJ; Molteni, V; Montalto, M; Montet, D; Monti, MC; Moor, MB; Moravec, P; Morsiani, C; Murillo, E; Murugan, P; Muslem, R; Myers, RK; N'guessan, FK; Nabil, H; Nadal, J; Nadeem, M; Nafady, MM; Nafie, MS; Nair, HP; Nakano, R; Nance, J; Naren, N; Neil, CJ; Nelson, J; Nery, FC; Netsch, C; Nguyen, TH; Ni, L; Ni, YX; Nie, W; Nielsen, LK; Nigam, K; Nikolayev, AA; Nishiyama, M; Niu, LL; Niu, PP; Nock, BA; Noer, PR; Noll, G; Noll, S; Norenberg, JP; Nowicka, J; Nutho, B; O'Connor, M; Obonyo, NG; Ochiai, T; Ochoa, MC; Oh, BL; Oh, S; Olczak, J; Olivares, X; Ommurugan, B; Oosthuizen, MC; Operario, D; Orešič, M; Oshima, K; Otano, I; Ou, Y; Owen, TW; Oxvig, C; Pacey, V; Pai, M; Paik, H; Paiva, R; Palmieri, EM; Palpant, N; Pan, L; Pan, Q; Panahi, S; Pang, B; Pang, ZC; Pannecouque, C; Paris, L; Park, D; Park, DJ; Park, E; Park, EC; Park, IH; Park, JH; Park, JI; Park, S; Passmore, MR; Pattaranggoon, NC; Paun, M; Pedersen, S; Pedron, J; Peng, M; Peng, X; Penzhorn, BL; Pérez-Camargo, D; Perez-Maldonado, R; Pérez-Vicente, C; Pham, TD; Pickering, L; Pickersgill, NA; Pinault, E; Pinotsis, N; Plan, M; Pocino, K; Poh, CL; Pons, EDC; Popoff, MR; Porri, D; Pourmand, A; Pratviel, G; Prudente, DO; Qi, H; Qi, N; Qian, LY; Qiao, L; Qiao, Q; Qin, QP; Qiu, N; Qiu, SW; Qu, F; Quan, M; Quigg, A; Raee, E; Raibaud, P; Ramanitrahasimbola, D; Rapoport, L; Rasby, RJ; Rasoanirina, BNV; Raspini, B; Ratner, JR; Razafindrakoto, Z; Redd, MA; Ren, H; Ren, N; Rey, J; Reynolds, CP; Rich, PR; Richards, CJ; Rigol, M; Rimoldi, S; Robert, P; Rodrigues, AE; Roe, JH; Rohde, S; Rokita, JL; Roland, J; Rombaut, L; Ronkainen, J; Rothenberg, SM; Roy, SC; Ruan, Z; Rucker, PV; Rueda, D; Ruhwald, M; Rungrotmongkol, T; Rupert, AS; Rusjan, P; Ryabov, AD; Rysä, J; Saad, NES; Sabioni, P; Sadow, PM; Sahai, N; Salem, HF; Salinas, B; Salonurmi, T; Samé Guerra, D; Sánchez, J; Sanchez-González, J; Sanmamed, MF; Sansores-Peraza, P; Santoro, JC; Santschi, PH; Saritas, T; Sarkisova, Y; Savolainen, MJ; Scherberich, JE; Schlom, DG; Schmelz, EM; Schmid, MC; Schneider, MP; Schumacher, S; Schwartz, JC; Schwartzer, JJ; Schwehr, K; Schweitzer, DH; Scott, ME; Sedky, NK; See Hoe, L; Sejian, V; Selvaraju, S; Sen, SK; Seo, G; Šerý, O; Settles, JA; Sfar, S; Shaffer, J; Shan, GL; Shang, Q; Shannahan, JH; Shao, B; Shao, H; Shao, J; Shao, ZH; Shasha, Y; Shaw, K; Sheeba, V; Shekar, K; Shen, G; Shen, H; Shen, XD; Shen, Y; Sherrell, PC; Shete, PB; Shi, AX; Shi, J; Shi, JH; Shi, S; Shi, X; Shigeta, Y; Shimbo, A; Shin, E; Sikka, N; Silhavy, TJ; Simanon, N; Simard, S; Simon, J; Simon, M; Simpson, SD; Simundic, AM; Since, M; Singh, B; Singhroy, DN; Sinisterra, OT; Smith, EH; Sobreira, TJP; Solanes, N; Somasundar, Y; Sommerer, C; Sonei, A; Song, B; Song, E; Song, J; Song, M; Song, Y; Soo Lee, M; Sorensen, MD; Sournia-Saquet, A; Spaepen, E; Spirk, D; Srivastava, S; Stancill, JS; Stanczak, PS; Starenki, D; Starr, F; Step, DL; Steubl, D; Stigliani, JL; Stráská, J; Sträter, N; Su, ZZ; Sudano, I; Suen, JY; Suh, HJ; Sui, ZY; Suico, JG; Suleiman, K; Sumon, K; Sun, HB; Sun, J; Sun, L; Sun, LL; Sun, M; Sun, Q; Sun, W; Sun, X; Sun, XF; Sun, Y; Sun, YB; Sun, YH; Sun, YN; Sun, Z; Sunada, K; Suzuki, S; Sylvan, JB; Takala, J; Talla, D; Tamir, Z; Tan, SJ; Tanda, S; Tang, H; Tang, J; Tang, LF; Tang, SJ; Tang, Y; Tao, FB; Tappel, R; Taratkin, M; Teijeira, Á; Tellew, JE; Thomas, AM; Thomas, SG; Thomson, SR; Tian, J; Tie, Y; Tirado, JL; Tolonen, A; Tosato, G; Tronnet, A; Tsai, S; Turtoi, A; Turtoi, E; Tvrdoňová, M; Tyagi, A; Tzou, DT; Uddin Ahmad, Z; Urias, E; Usawachintachit, M; Ustriyana, P; Utsumi, F; Vacca, M; Vaculovič, T; Vaidya, SS; Valentin, A; Valgepea, K; van den Berg, P; van den Bergh, JP; van der Heiden, K; van Gaalen, K; Van Gemert, W; van Haard, PMM; van Hest, JCM; Vecchiarelli, E; Večeřa, Z; Venkatesh, R; Verhaeghe, P; Verhagen, HJ; Vetter, JM; Vieira, D; Vilchez-Tschischke, JP; Villena-Gutierrez, R; Villoslada Terrones, V; Vital-Jacome, M; Voelkl, J; Vogel, K; Vogrin, S; Volke, D; von Bahr, V; Vysloužil, J; Wade, TL; Wagner-Gillespie, M; Walsh, SW; Wan, LJ; Wan, SP; Wang, AL; Wang, B; Wang, BY; Wang, C; Wang, D; Wang, F; Wang, H; Wang, HR; Wang, HY; Wang, J; Wang, JY; Wang, K; Wang, L; Wang, LF; Wang, P; Wang, Q; Wang, R; Wang, SF; Wang, SP; Wang, SR; Wang, T; Wang, W; Wang, WP; Wang, X; Wang, XJ; Wang, Y; Wang, YL; Wang, YN; Wáng, YXJ; Wang, Z; Wang, ZF; Wang, ZY; Waning, B; Warner, JM; Washington, SL; Watson, AK; Wei, B; Wei, C; Wei, F; Wei, X; Wei, Y; Wemhoff, AP; Wen, Z; Weng, TT; Wesdemiotis, C; Wheeler, DA; Wildner, M; Wilson, BK; Wirth, LJ; Wissler, M; Wu, F; Wu, G; Wu, J; Wu, KH; Wu, MC; Wu, P; Wu, PK; Wu, S; Wu, W; Wu, X; Wu, XP; Wu, Y; Wyatt, E; Wyllie, S; Xia, Y; Xiao, BH; Xiao, SZ; Xiao, W; Xiao, X; Xiao, Z; Xie, D; Xie, K; Xie, X; Xie, Y; Xie, YF; Xin, S; Xin, Z; Xing, Q; Xing, WQ; Xiong, D; Xiong, X; Xu, C; Xu, D; Xu, F; Xu, G; Xu, H; Xu, J; Xu, JY; Xu, L; Xu, N; Xu, W; Xu, X; Xu, Y; Xu, YM; Xue, H; Xue, J; Xue, Z; Yan, R; Yan, SQ; Yan, W; Yan, X; Yan, Z; Yang, C; Yang, D; Yang, F; Yang, FC; Yang, G; Yang, J; Yang, M; Yang, P; Yang, Q; Yang, R; Yang, S; Yang, SJ; Yang, TWW; Yang, X; Yang, Y; Yang, Z; Yao, C; Yao, L; Yao, LP; Yao, M; Yao, T; Yao, W; Yao, Y; Yaseen, T; Yazdani, V; Ye, J; Ye, S; Yerys, BE; Yi, HWL; Yi, JL; Yin, F; Yin, J; Yin, Y; Yin, Z; Yong, ZP; Yongli, S; Yoo, JS; Yoshikawa, N; You, Q; Yu, B; Yu, CQ; Yu, H; Yu, HG; Yu, J; Yu, L; Yu, Q; Yu, X; Yu, Y; Yu, YK; Yu, Z; Yuan, Q; Yuan, R; Yuan, W; Yuan, X; Yuan, Y; Zager, RA; Zagozdzon, A; Zaller, N; Zang, YP; Zappi, ME; Zelikoff, JT; Zeman, T; Zhai, X; Zhan, P; Zhang, B; Zhang, C; Zhang, G; Zhang, H; Zhang, HB; Zhang, J; Zhang, JS; Zhang, L; Zhang, M; Zhang, Q; Zhang, RX; Zhang, S; Zhang, T; Zhang, W; Zhang, WH; Zhang, X; Zhang, XX; Zhang, Y; Zhang, YQ; Zhang, YW; Zhang, Z; Zhang, ZH; Zhao, D; Zhao, FL; Zhao, K; Zhao, L; Zhao, M; Zhao, R; Zhao, S; Zhao, W; Zhao, WG; Zhao, X; Zhao, Y; Zheng, G; Zheng, J; Zheng, S; Zheng, W; Zheng, Y; Zheng, YG; Zhong, Z; Zhou, C; Zhou, D; Zhou, H; Zhou, HY; Zhou, L; Zhou, Q; Zhou, X; Zhou, Y; Zhou, YL; Zhou, Z; Zhu, J; Zhu, L; Zhu, N; Zhu, X; Zhu, XF; Zhu, Y; Zhu, Z | 1 |
| Blasi, M; Bozorgmehr, F; Hommertgen, A; Kieser, M; Krisam, J; Kuon, J; Lasitschka, F; Maenz, M; Schneider, M; Stenzinger, A; Thomas, M | 1 |
| Fan, GH; Huang, J; Zhu, TY | 1 |
| Badanthadka, M; Chokshi, N; Khatri, H; Patel, BM; Patel, MM; Rawal, S | 1 |
| Li, X; Li, Y; Qian, K; Zhang, Y; Zhi, X | 1 |
| Awad, MM; Bacchetta, M; Cheng, SK; Chiuzan, C; D'Ovidio, F; Gainor, JF; Garofano, RF; Grigg, CM; Lanuti, M; Pabani, A; Rizvi, NA; Saqi, A; Shu, CA; Sonett, JR; Stoopler, MB; White, A | 1 |
| Kong, FW; Liu, L; Wang, WM; Wang, X; Wu, WB; Zhang, M | 1 |
| Huang, P; Lai, S; Lin, S; Luo, S; Rao, X; Weng, X; Zeng, D; Zhong, L | 1 |
| Arisawa, T; Hayashi, R; Hayashi, T; Horita, T; Kumagai, M; Nakamura, M; Ota, M; Otsuka, T; Sakurai, N; Takano, H; Yamada, S | 1 |
| Guo, L; Jin, H; Lu, L; Sun, P; Yang, X; Yang, Y; Zhang, N; Zhao, Q; Zhou, L | 1 |
| Fukuda, S; Fukumitsu, K; Ito, Y; Kagawa, Y; Kanemitsu, Y; Maeno, K; Niimi, A; Oguri, T; Ohkubo, H; Sone, K; Tajiri, T; Takakuwa, O; Takemura, M; Takeuchi, A; Uemura, T | 1 |
| Bacon, NA; Larre, I; Lawag, AA; Merritt, C; Rosolen, M; Smith, M; Sollars, VE | 1 |
| Akdeniz, N; Alan, Ö; Bilen, E; Ebinç, S; Ercelep, Ö; Işıkdoğan, A; Kaplan, MA; Karhan, O; Küçüköner, M; Laçin, Ş; Sezgin, Y; Teke, F; Urakçı, Z; Yumuk, PF | 1 |
| Al-Nsour, MA; Carbone, DP; Dakhil, CSR; Das, MS; de Aquino, MTP; Gerber, DE; Horn, L; Johnson, ML; Lee, JW; Liu, JJ; Patel, JD; Ramalingam, S; Schiller, JH; Shanker, A; Wagner, H | 1 |
| Aylon, Y; Azuri, I; Blandino, G; Dassa, B; Di Agostino, S; Mukherjee, S; Oren, M; Ruppin, E; Shreberk-Shaked, M; Sinha, S | 1 |
| Guo, C; Jiang, H; Qiao, L; Wang, H; Wang, X | 1 |
| Cui, W; Li, H; Li, X; Li, Y; Wang, D; Yang, X; Zhao, D | 1 |
| Aoe, K; Atagi, S; Ebiana, V; Fukuhara, T; Han, SR; Hida, T; Horiike, A; Horinouchi, H; Hotta, K; Katakami, N; Kishi, K; Kurata, T; Nakagawa, K; Noguchi, K; Nosaki, K; Ohira, T; Okamoto, H; Okamoto, I; Saka, H; Sakai, H; Satouchi, M; Sekine, A; Sugawara, S; Takahashi, T; Umemura, S; Yamamoto, N | 1 |
| Chen, CG; Jiang, Q; Li, J; Li, XQ; Long, WG; Ren, J; Su, JY; Wang, Y; Zhu, YM | 1 |
| Cheng, P; Gao, H; Li, D; Li, H; Li, Z; Su, X; Wang, G; Xu, H; Yuan, W; Zhang, L; Zhang, T | 1 |
| Cohen, HJ; Dueck, AC; Feliciano, JL; Gao, J; Hurria, A; Jatoi, A; Miaskowski, C; Novotny, PJ; Sloan, JA; Stinchcombe, TE; Thanarajasingam, G; Walter, LC; Wang, X; Wong, ML; Wood, WA | 1 |
| Kamiya, K; Ohtsuki, M; Yamauchi, H | 1 |
| Barneto Aranda, I; Bernabé Caro, R; Calvo, V; Casal-Rubio, J; Casarrubios, M; Cobo, M; Cruz-Bermúdez, A; De Castro Carpeño, J; Del Barco, E; Dómine, M; García-Campelo, MR; Insa, A; Laza-Briviesca, R; López Vivanco, G; Majem, M; Martínez-Martí, A; Massuti, B; Nadal, E; Parra, ER; Pereira, E; Provencio, M; Rodríguez-Abreu, D; Romero, A; Royuela, A; Salas Antón, C; Viñolas, N; Viteri, S; Wistuba, I | 1 |
| Ackermann, CJ; Adderley, H; Califano, R; Khan, A; Ortega-Franco, A; Reck, M | 1 |
| Aydin, C; Esendagli, G; Karpuz, M; Ozer, AY; Ozturk, SC; Silindir-Gunay, M; Tuncel, M; Yanik, H | 1 |
| Aoki, M; Hasegawa, Y; Hatayama, Y; Ishioka, Y; Itoga, M; Makiguchi, T; Okumura, F; Shiratori, T; Tabe, C; Taima, K; Tanaka, H; Tasaka, S; Yokouchi, J | 1 |
| Baltezor, M; Campbell, S; diZerega, G; Dorman, P; Iacobucci, M; Marin, A; Maulhardt, H; Verco, J; Verco, S; Wendt, A; Williams, E | 1 |
| Guevara-Cuellar, CA; Parody-Rúa, E | 1 |
| Ding, L; Han-Zhang, H; Huang, X; Wang, P; Yang, Y | 1 |
| Hu, X; Wang, Z; Yuan, S; Zhao, Y | 1 |
| Arnst, K; Cui, H; Li, W; Miller, DD | 1 |
| Cui, X; Gai, C; Li, W; Wang, S; Wang, Y; Xu, Z; Yu, H; Zhang, W | 1 |
| Cui, ZL; Hess, LM; Li, XI; Molife, C; Oton, AB | 1 |
| Bentsion, D; Bondarenko, I; Chen, CI; Cicin, I; Clingan, P; Gao, B; Gladkov, O; Gogishvili, M; Gullo, G; Gümüş, M; Kilickap, S; Lee, S; Li, S; Lowy, I; Makharadze, T; McGuire, K; Nechaeva, M; Özgüroğlu, M; Paydas, S; Rietschel, P; Rizvi, N; Seebach, F; Sezer, A; Sriuranpong, V; Turk, HM; Weinreich, DM; Yancopoulos, GD | 1 |
| Dai, X; Ni, L; Pan, J; Shen, Z; Shi, A; Su, C; Tao, J; Xu, J; Zhang, Y; Zhao, F | 2 |
| Cui, W; Li, H; Li, XY; Li, YX; Li, YY; Wang, D; Yang, XG; Zhao, DX | 1 |
| Chang, F; Hua, T; Lu, Y; Ni, J; Wu, Y; Xiang, G; Yang, Z; Zhao, J; Zhu, Y | 1 |
| Exner, F; Flentje, M; Höcht, S; Kleine, P; Mantel, F; Müller, E; Polat, B; Richter, A; Ströhle, S; Weick, S; Zimmermann, M | 1 |
| Ando, M; Fukuda, H; Harada, H; Ishikura, S; Kataoka, T; Kenmotsu, H; Mizutani, T; Nomura, S; Ohe, Y; Omori, S; Shimoyama, R; Takahashi, T | 1 |
| Aoki, T; Chiba, Y; Daga, H; Fujimoto, D; Hirashima, T; Iwamoto, Y; Kashiwabara, K; Mori, M; Nakagawa, K; Okuno, M; Omori, S; Saka, H; Satouchi, M; Sawa, K; Sawa, T; Shimizu, J; Tachihara, M; Tsuboi, M; Tsujino, K; Ymamoto, N; Zenke, Y | 1 |
| Bates, V; Boland, A; Chaplin, M; Dundar, Y; Green, JA; Greenhalgh, J; Vecchio, F | 1 |
| Jain, D; Khurana, S; Kumar, L; Malik, PS; Mohan, A; Pathy, S; Vishnubhatla, S; Yadav, A; Yadav, M | 1 |
| Albain, KS; Argiris, A; Byers, LA; Chen, AM; Cristea, MC; Daly, ME; Decker, RH; Faller, BA; Gandara, DR; Garland, LL; Gettinger, SN; Kelly, K; Koczywas, M; Miao, J; Redman, MW; Sands, JM; Wang, D; Yanagihara, RH | 1 |
| Chen, J; Cheng, Z; Luo, J; Meng, Y; Sun, T; Wang, X; Xia, B; Zhang, Z; Zhou, X | 1 |
| Huang, J; Li, L; Liu, H; Lv, Y; Wang, F; Yin, F; Zhao, C; Zheng, Q | 1 |
| Feng, G; Hu, C; Hu, Y; Leaw, SJ; Liang, L; Lin, X; Lu, S; Sun, Y; Wang, J; Wang, Z; Wu, J; Yang, K; Yang, N; Ying, K; Yu, X; Yu, Y; Zhang, J; Zhao, J; Zhou, J; Zhuang, W | 1 |
| Chokchaichamnankit, D; Maneechai, K; Mon, MM; Raungrut, P; Srisomsap, C; Svasti, J; Thongsuksai, P; Watcharatanyatip, K; Weeraphan, C | 1 |
| Cao, R; Guo, YJ; Han, CB; Huang, LT; Jing, W; Ma, J; Song, J; Sun, L; Wang, YR; Zhang, SL; Zhang, XY; Zhao, JZ | 1 |
| Andric, Z; Bellala, RS; Charoentum, C; Costamilan, RC; Del Campo García, A; Florez, A; Fulop, A; Hyder Ali, IA; Katgi, N; Lopez Chuken, YA; Makharadze, T; Millan, S; Paravisini, A; Poddubskaya, E; Reyes-Igama, J; Rumyana, I; Syrigos, K; Trukhin, D; Yañez Ruiz, EP | 1 |
| Dakhlallah, D; Eubank, TD; Gencheva, M; Guo, NL; Hu, G; Ivanov, AV; Kolluri, SK; Marsh, CB; Mohamed, R; Pearce, MC; Ye, Q | 1 |
| Barinova, M; Bratova, M; Cernovska, M; Coupkova, H; Dolezal, D; Fischer, O; Hrnciarik, M; Hurdalkova, K; Koubkova, L; Krejci, D; Krejci, J; Kultan, J; Opalka, P; Pesek, M; Safanda, M; Skrickova, J; Svaton, M; Zemanova, M; Zemanova, P | 1 |
| Cheng, Y; Ji, Y; Kang, W | 1 |
| Baik, C; Chow, L; Cook, K; Eaton, KD; Lee, S; Martins, R; Rodriguez, C; Santana-Davila, R; Wallace, S; Wood, R | 1 |
| Belkaid, W; Blais, N; Florescu, M; Gaudreau, PO; Nassabein, R | 1 |
| Akamatsu, H; Hida, T; Inui, N; Kang, JH; Kim, HR; Lee, JS; Lee, KH; Nakagawa, K; Namba, Y; Nishio, M; Ohe, Y; Sugawara, S; Sumiyoshi, N; Tamura, T; Tanaka, H; Yamamoto, N; Yang, CT; Yoshida, T; Yu, CJ | 1 |
| Li, C; Liu, H; Liu, Y; Wang, J | 1 |
| Amighi, K; Antoine, MH; Chraibi, S; De Prez, E; Gérard, P; Langer, I; Nortier, J; Remmelink, M; Rosière, R; Wauthoz, N | 1 |
| Abe, T; Aoshika, T; Hirai, R; Igari, M; Iino, M; Kagamu, H; Kaira, K; Kato, S; Kumazaki, Y; Miura, Y; Noda, SE; Ohta, T; Ryuno, Y; Saito, S | 1 |
| Abert, I; Andric, Z; Bashir, Z; Bondarenko, IN; Dvorkin, M; Fu, D; Galic, K; Galiulin, R; Jones, S; Kassalow, LM; Kuchava, V; Sriuranpong, V; Syrigos, K; Trukhin, D; Zhavrid, E | 1 |
| Andrasina, I; Bartek, T; Bartunkova, J; Beniak, J; Cernovska, M; Fricke, H; Havel, L; Hraska, M; Jakesova, J; Kadlecova, P; Klepetko, P; Korolkiewicz, RP; Koubkova, L; Kultan, J; Lukesova, S; Pesek, M; Reiterer, P; Salajka, F; Siskova, L; Skrickova, J; Spisek, R; Vanasek, J; Zemanova, M | 1 |
| Makino, T; Matsumoto, T; Nakayama, A; Tsuchiya, K; Xu, L | 1 |
| Bharti, S; Chitikela, S; Jain, D; Khurana, S; Kumar, R; Kumar, S; Madan, K; Malik, PS; Mittal, A; Mohan, A; Pathy, S; Saikia, J; Thulkar, S | 1 |
| Gu, M; Luan, J; Qiu, C; Song, K; Zhang, M; Zhang, X | 1 |
| Liu, S; Pan, Y; Wang, C; Wang, M; Yue, D; Zhang, Y; Zhang, Z; Zhu, J | 1 |
| Feng, N; He, Y; He, Z; Hou, X; Li, Y; Li, Z; Ruan, S; Sun, J; Wang, Z; Wu, T; Xia, Q; Zhang, Y | 1 |
| Ansell, P; Bach, BA; Bar, J; Bentsion, D; Bernabe, R; Byers, LA; Clingan, P; Dunbar, M; Glasgow, J; Govindan, R; Guclu, SZ; He, L; Huang, X; Mazieres, J; Novello, S; Ramalingam, SS; Sehgal, V; Syrigos, K; Szilasi, M; Vokes, EE; Zvirbule, Z | 1 |
| Goto, Y; Hasegawa, Y; Hosomi, Y; Hotta, K; Inoue, A; Kishi, K; Kunitoh, H; Mori, K; Naito, Y; Nishio, M; Ohashi, Y; Tanai, C; Tomizawa, Y; Yamada, K; Yoh, K | 1 |
| André, N; Berges, R; Borge, L; Bourgarel, V; Braguer, D; Buric, D; Carré, M; Carrier, A; Le Grand, M; Montero, MP; Pasquier, E; Vasseur, S | 1 |
| Huang, J; Li, Z; Shen, X; Wang, Y; Zhi, Q; Zhou, J | 1 |
| Feng, J; Hu, W; Luo, Q; Wu, Y | 1 |
| Chao, GY; Depenbrock, H; Khalil, M; Kim, JH; Luft, A; Mayo, C; Natale, R; Obasaju, C; Ramlau, R; Spigel, DR | 1 |
| Liu, L; Lu, X; Lu, Y; Wang, J; Yu, L; Zhao, N; Zhou, X | 1 |
| Akita, T; Kiuchi, Y; Kogo, M; Kurihara, T; Nakajima, H; Nakamura, S; Shikama, Y; Sunaga, T; Tobe, T; Yoneyama, K | 1 |
| Cheng, L; Ju, RJ; Li, CQ; Li, XT; Peng, XM; Wang, X; Xiao, Y | 1 |
| Fan, Z; Han, X; Jin, S; Li, L; Li, W; Li, Y; Liu, Y; Lyu, Z; Ma, Y; Shi, P; Song, Q; Song, Y; Xu, X; Yan, Z; Ye, Q; You, W | 1 |
| Adomako, A; McDaid, HM; Rodriguez-Gabin, A; Samaraweera, L | 1 |
| Fujita, Y; Harada, T; Ichinose, M; Inoue, A; Kato, T; Maemondo, M; Miyauchi, E; Nakagawa, T; Saito, H; Sugawara, S; Suzuki, T; Usui, K; Watanabe, H | 1 |
| Gao, H; He, K; Li, X; Liu, X; Qin, H; Tang, C; Wang, H; Wang, W; Xu, B; Yang, S; Zhao, G | 1 |
| Chen, X; Liao, Y; Lin, X; Long, D; Shen, F; Yu, T | 2 |
| Kimura, H; Kurimoto, N; Marushima, H; Miyazawa, T; Nakamura, H; Saji, H; Sakai, H | 1 |
| Bi, N; Cease, KB; Frey, KA; Gross, M; Hassan, KA; Hayman, J; Kalemkerian, GP; Kong, FM; Lawrence, TS; Matuszak, M; Orringer, M; Ramnath, N; Ritter, T; Schipper, M; Ten Haken, RK; Wang, W | 1 |
| Damhuis, RA; den Bakker, MA; Derks, JL; Dingemans, AC; Groen, HJ; Smit, EF; Speel, EM; Thunnissen, E; van den Broek, EC; van Suylen, RJ | 1 |
| Fenton, M; Martin, MG; Morris, L; Schwartzberg, LS; Stein, MK; Sullivan, JL; VanderWalde, A | 1 |
| Blaydorn, L; Coats, J; Farley, JH; Khemka, V; Lynch, CA; McGahey, K; Niu, J; Sangal, A; Waypa, J; Weiss, GJ | 1 |
| Chen, X; Liao, Y; Lin, X; Long, D; Yu, T | 1 |
| Cardoso, VN; Caro, MSB; Cassali, GD; de Barros, ALB; de Oliveira, MC; Durán, FJ; Lang, KL; Leite, EA; Marostica, LL; Oliveira, J; Salgado, BS; Schenkel, EP; Simões, CMO | 1 |
| Hirata, H; Hosoda, H; Kangawa, K; Kijima, T; Komuta, K; Kuroyama, M; Minami, S; Nakanishi, K; Nojiri, T; Otsuka, T; Yamamoto, S | 1 |
| Ando, M; Atagi, S; Horinouchi, H; Ichihara, E; Ichikado, K; Kato, T; Kenmotsu, H; Kishimoto, J; Kondoh, Y; Kusumoto, M; Minegishi, Y; Nakanishi, Y; Okamoto, I; Otsubo, K; Shiraki, A; Yamamoto, N | 1 |
| Allen, PK; Chang, JY; Cox, JD; Gomez, D; Hahn, S; Heymach, JV; Jeter, M; Komaki, R; Li, H; Li, M; Liao, Z; Lin, SH; Lu, C; Mohan, R; O'Reilly, M; Vaporciyan, AA; Verma, V; Welsh, J; Zhang, W; Zhang, X; Zhu, RX | 1 |
| Miyazaki, K; Satoh, H; Shiozawa, T; Tamura, T | 1 |
| Gong, W; Liu, A; Liu, J; Mu, Z; Sun, P; Yu, C | 1 |
| Du, T; He, F; Jiang, Q; Zhang, Y | 1 |
| Li, Q; Wen, F; Xie, L; Xu, T; Zhan, M; Zheng, H | 1 |
| Chen, X; Deng, Z; Hu, C; Li, X; Liu, Z; Lu, D; Wang, S; Wen, X; Xiao, D; Yin, J; Zhang, W; Zheng, Y; Zhou, H | 1 |
| Baggstrom, MQ; Cosaert, J; Cronier, DM; Dowlati, A; Gerber, DE; Ilaria, R; Lopez-Chavez, A; Pennell, NA; Qin, A; Shahir, A; Swanson, P; Wong, L | 1 |
| Ahn, MJ; Barlesi, F; Fadeeva, N; Ganea, DE; Gonzalez Mella, PF; Govindan, R; Han, B; Jassem, J; Kopit, J; Kurata, T; Lee, KH; Li, M; O'Byrne, K; Postmus, PE; Reck, M; Schneider, CP; Szczesna, A; Tamura, T; Tschaika, M; Vladimirov, V; Von Pawel, J; Zhang, L | 1 |
| Gemma, A; Hirose, T; Kobayashi, Y; Kubota, K; Miya, T; Shimizu, M; Takahashi, A | 1 |
| Gao, L; Lu, W; Nan, L; Peng, T; Sun, J; Sun, L; Wang, H; Wang, J; Wang, Y; Xiao, Y; Yan, Z; Yu, L; Zhang, L; Zhou, J | 1 |
| Chen, S; Chen, Y; Hu, Y; Jiao, S; Li, J; Yan, X; Zhang, G; Zhang, Y | 1 |
| Asato, T; Cho, EK; Hara, K; Hayashi, H; Hida, T; Ichinose, Y; Kaneda, H; Kato, T; Kubota, K; Lee, KH; Lin, CB; Nakagawa, K; Oshita, F; Park, K; Tanaka, H; Yamada, K; Yang, JC; Yoh, K; Yoshioka, H | 1 |
| Eze, C; Manapov, F | 1 |
| Ding, T; Li, ZT; Shi, YT; Zhang, X | 1 |
| Gan, CZ; Li, G; Li, HM; Luo, QS | 1 |
| Argiris, A; Choong, NW; Evans, TL; Hansen, RM; Hugec, V; Lee, JW; Ramalingam, SS; Saltzman, JN; Schiller, JH; Song, W; Stevenson, J; Sulecki, MG | 1 |
| Adjei, AA; Bahleda, R; Besse, B; Dy, GK; Ferte, C; Groen, HJM; Lin, W; Morrissey, K; Planchard, D; Schutzman, JL; Shankar, G; Soria, JC; Ware, J; Zhou, J | 1 |
| Fukuhara, K; Funaki, S; Funakoshi, Y; Inoue, M; Kimura, T; Kusu, T; Kusumoto, H; Maeda, H; Nojiri, T; Okumura, M; Shintani, Y; Takeuchi, Y | 1 |
| Goto, A; Horita, N; Ito, K; Kaneko, T; Nagashima, A; Nakashima, K; Shibata, Y; Yamanaka, T | 1 |
| Hattori, Y; Ito, S; Kawa, Y; Kono, Y; Negoro, S; Nogami, M; Satouchi, M; Takenaka, D; Tohnai, R; Urata, Y; Yasuda, Y | 1 |
| Hayashi, A; Itoga, M; Kumagai, M; Mikuniya, M; Morimoto, T; Nakamura, K; Okudera, K; Taima, K; Takanashi, S; Tanaka, H; Tanaka, Y; Tasaka, S; Yasugahira, H | 1 |
| Bagdas, D; Bigbee, JW; Chen, ZJ; Damaj, MI; Del Fabbro, E; Fang, X; Gewirtz, DA; Kyte, SL; Lichtman, AH; Meade, JA; Schurman, LD; Toma, W | 1 |
| Bi, N; Liang, J; Wang, L | 1 |
| Chen, H; Huang, J; Kong, C; Liu, C; Liu, Z; Qian, F; Yang, K; Zhang, L | 2 |
| Li, SY; Lin, XQ; Liu, YQ; Ouyang, M; Qin, YY; Xie, ZH; Zhang, DH; Zhang, JX; Zhou, CZ | 1 |
| Chen, K; Chen, X; Fu, L; Gai, J; Guan, J; Han, L; Li, Q; Li, W; Liu, S; Shen, F; Sun, X; Xing, J | 1 |
| Danter, WR; Koropatnick, J; Maleki Vareki, S; Salim, KY | 1 |
| Hu, Q; Xie, B; Xu, Z; Zhang, W; Zhang, X; Zheng, J; Zhou, J | 1 |
| Allan, E; Ayan, A; Barney, CL; Bazan, JG; DiCostanzo, D; Grecula, J; Haglund, KE; Otterson, GA; Scoville, N; Williams, T; Xu-Welliver, M | 1 |
| Amano, H; Fujita, T; Hayama, N; Hirano, S; Hiroishi, T; Nakamura, M; Nakamura, S; Shikano, K; Tabeta, H; Yanagisawa, A | 1 |
| Anderson, M; Barlesi, F; Chang, I; Chen, D; Ervin, T; Hegde, P; Juhász, E; Losonczy, G; McCall, B; Reck, M; Rhee, I; Spigel, DR; von Pawel, J; Wakshull, E; Ye, W | 1 |
| Li, Q; Lin, Y; Ma, W; Shao, X; Shi, S; Xie, X; Zhao, D | 1 |
| Dupuis, M; Engel-Riedel, W; Gargano, M; Huhn, RD; Lowe, J; Mattson, P; Patchen, ML; Richard Trout, J; Schneller, F; Trinh, MM; Walsh, R | 1 |
| Brahmer, JR; Coleman, B; Ettinger, DS; Forde, PM; Gabrielson, E; Hann, CL; Kelly, RJ; Marrone, KA; Purtell, M; Rosner, GL; Zhou, X | 1 |
| Grzanka, A; Grzanka, D; Hałas-Wiśniewska, M; Klimaszewska-Wiśniewska, A | 1 |
| An, GJ; Choi, HG; Gautam, M; Gupta, B; Jeong, JH; Kim, JO; Pathak, S; Poudel, BK; Regmi, S; Ruttala, HB; Yong, CS | 1 |
| Chen, H; Cohen, HJ; Edelman, MJ; Feliciano, JL; Gajra, A; Hurria, A; Jatoi, A; Lafky, J; Le-Rademacher, JG; Lilenbaum, R; Maggiore, R; McMurray, RP; Muss, HB; Wong, ML; Zemla, TJ | 1 |
| Fang, Z; Wang, Z; Zheng, Y | 1 |
| Agócs, L; Döme, B; Fábián, K; Fillinger, J; Kajdácsi, Z; Moldvay, J; Pipek, O; Reiniger, L; Rojkó, L; Szállási, Z; Téglási, V; Tímár, J; Vágvölgyi, A | 1 |
| Novello, S; Rossi, A | 1 |
| Bai, W; Xu, F; Yu, J; Zhang, W; Zhou, J | 1 |
| Li, C; Li, X; Liu, S; Liu, Y; Yang, Y; Zhao, X | 1 |
| Dahlberg, SE; Kravets, S | 1 |
| Kimura, B; Shimoyama, T | 1 |
| Hamada, N; Nakanishi, Y; Okamoto, I; Otsubo, K | 1 |
| Fujita, M; Hirano, R; Igata, F; Ikeda, T; Imabayashi, T; Kaneko, Y; Kishimoto, J; Nagata, N; Nakao, A; On, R; Sasaki, T; Takayama, K; Tamiya, N; Tanimura, K; Uchino, J; Watanabe, K; Yamada, T; Yatsugi, H | 1 |
| Chen, H; Cohen, HJ; Edelman, MJ; Feliciano, JL; Gajra, A; Hurria, A; Jatoi, A; Le-Rademacher, JG; Lilenbaum, R; McMurray, R; Muss, H; Zemla, T | 1 |
| Barlesi, F; Cappuzzo, F; Coleman, S; Deng, Y; Finley, G; Jotte, RM; Kelsch, C; Kowanetz, M; Lee, A; Lopez-Chavez, A; Moro-Sibilot, D; Nogami, N; Orlandi, F; Reck, M; Rodríguez-Abreu, D; Sandler, A; Shen, Y; Socinski, MA; Stroyakovskiy, D; Thomas, CA | 1 |
| Ding, XZ; Gao, SG; He, Y; Hu, XC; Kong, DJ; Lam, KS; Li, X; Li, Y; Lin, TY; Wang, XS; Yang, JQ; Zhang, L; Zhao, MQ | 1 |
| Botteman, M; Hirsh, V; Langer, C; Lin, FJ; Margunato-Debay, S; Ong, TJ; Wan, Y | 1 |
| Alshangiti, A; Chandhoke, G; Ellis, PM | 1 |
| Qi, Y; Qian, S; Wu, X; Xing, K; Zhang, L; Zhang, P | 1 |
| Wang, Y; Xu, F; Xu, H; Ying, J; Zhu, W | 1 |
| Arrieta, O; Arroyo-Hernández, M; Bacon-Fonseca, L; Fernández-Plata, R; García-Sancho, C; Gochicoa-Rangel, L; Guzmán-Barragán, A; Lozano-Ruiz, F; Martínez-Briseño, D; Muñoz-Montaño, WR; Pérez-Padilla, R; Torre-Bouscoulet, L; Vergara, E | 1 |
| Chen, G; Du, X; Sheng, L | 1 |
| Crane, S; Gajra, A; Klepin, HD; Miller, AA; Petty, WJ; Ruiz, J; Tooze, JA | 1 |
| Banerjee, S; Banerji, U; Basu, B; Brada, M; Brugger, W; Carreira, S; Dawes, JC; de Bono, JS; de Oliveira, FM; Evans, J; Hall, E; Harrington, EA; Ingles Garces, AH; Jones, R; Krebs, MG; Parmar, M; Purchase, B; Raynaud, FI; Ruddle, R; Spicer, J; Steele, N; Sundar, R; Swales, K; Talbot, DC; Tovey, H; Tunariu, N; Turner, AJ; Wilson, RH | 1 |
| Cheng, L; Fu, M; Ju, RJ; Li, XT; Liu, JJ; Wang, X; Xiao, Y; Xie, HJ | 1 |
| de Bruin-Visser, J; de Langen, AJ; Hashemi, SMS; Jebbink, M; Kuiper, JL; Monkhorst, K; Smit, EF; Thunnissen, E | 1 |
| Min, J; Shen, H; Wang, Q; Wang, ZN; Xi, W; Yang, Q; Yin, L; Yu, Y; Zhang, Y | 1 |
| Cai, P; Chen, G; Li, C; Peng, B; Yu, L; Zhao, B | 1 |
| Bian, X; Chen, S; Jiang, M; Li, W; Ling, C; Liu, Y; Liu, Z; Xu, N | 1 |
| Abe, Y; Atagi, S; Isa, SI; Ishii, S; Suzuki, K; Tamiya, A; Tanaka, T; Taniguchi, Y; Tsuyuguchi, K | 1 |
| Hu, D; Pan, J; Shi, A; Su, C; Tao, J; Xu, J; Zhang, Y; Zhao, F | 1 |
| Itasaka, S; Matsuoka, T; Nakashima, T; Okumura, N; Takahashi, A; Yamanashi, K; Yokoyama, T | 1 |
| Ishimoto, H; Mukae, H; Noguchi, S; Shimabukuro, I; Tanaka, F; Torii, R; Uyama, K; Yatera, K; Yoshii, C | 1 |
| Amadio, AV; Baldotto, CS; Barrios, CH; Castro, G; Coelho, JC; Cordeiro de Lima, VC; Geib, G; Madeira, G; Mathias, C; Nery, RC; Simões, MF; Sobrinho, EM; Zaffaroni, F; Zukin, M | 1 |
| Chen, L; Chen, X; Ding, J; Feng, J; Hu, S; Huang, X; Jiang, Y; Li, N; Li, X; Tang, F; Wang, C; Wang, Y; Xiao, Z; Zhou, M | 1 |
| Çay Şenler, F; Cheng, Y; Csőszi, T; Fülöp, A; Gümüş, M; Halmos, B; Hermes, B; Kato, T; Kowalski, DM; Lee, KH; Li, X; Lubiniecki, GM; Luft, A; Mazières, J; Novello, S; Paz-Ares, L; Piperdi, B; Rodríguez-Cid, J; Sugawara, S; Tafreshi, A; Vicente, D; Wilson, J | 1 |
| Choi, N; Deist, T; Liao, Z; Mohan, R; Paganetti, H; Tucker, SL; Verma, V; Xu, T | 1 |
| Ambudkar, SV; Cai, CY; Chen, ZS; Gupta, P; Ji, N; Kong, D; Lei, ZN; Shukla, S; Wang, JQ; Yang, Y | 1 |
| Chen, B; Du, B; Gong, Q; Ho, HI; Li, Q; Liu, X; Lu, Y; Tan, Y; Wang, K; Wu, W; Xiao, J; Yin, T; Zhan, Y; Zhang, F; Zhang, Y; Zou, Y | 1 |
| Ding, D; Gong, X; Keidar, M; Li, W; Li, X; Wang, S; Wang, Y; Yu, H; Zhang, W | 1 |
| Fujita, Y; Hirano, K; Horiike, A; Hosokawa, S; Inoue, K; Kawano, Y; Kimura, T; Kishimoto, J; Komiya, K; Morinaga, R; Nakanishi, Y; Nishikawa, K; Okamoto, I; Sasaki, T; Satouchi, M; Takahashi, K; Toyozawa, R; Yamaguchi, H | 1 |
| Li, J; Wang, Y; Wu, W; Yan, Y; Zheng, Z; Zhou, Y | 1 |
| Adrianzen Herrera, D; Ashai, N; Cheng, H; Perez-Soler, R | 1 |
| Lv, C; Wang, J; Wu, N; Yan, S; Yang, Y | 1 |
| Zhang, L; Zhang, Y; Zhou, H | 1 |
| Cha, SI; Choi, JE; Do, SK; Hong, MJ; Jeong, JY; Jung, DK; Kang, HG; Kim, CH; Lee, J; Lee, JH; Lee, SY; Lee, WK; Park, JY; Seo, H; Shin, KM; Yoo, SS | 1 |
| Jean-Charles, A; Merle, H; Paul, N | 1 |
| Fukuda, Y; Harada, T; Koga, S; Mukae, H; Ogawara, D; Okuno, D; Soda, H; Taniguchi, H; Tomono, H; Umemura, A; Yamaguchi, H; Yoshida, M | 1 |
| Fukuda, M; Gyoutoku, H; Ikeda, T; Kitazaki, T; Mukae, H; Nagashima, S; Nakamura, Y; Nakano, H; Nakatomi, K; Ogawara, D; Sato, S; Senju, H; Takemoto, S; Tomari, S; Yamaguchi, H | 1 |
| Chen, S; Lin, X; Long, D; Shen, F; Yu, T; Zhao, Y | 1 |
| Chu, HX; Ding, HW; Li, DD; Li, RL; Ma, LX; Qin, XC; Yang, Y; Zhao, QC | 1 |
| Aerts, JGJV; Bezemer, K; de Goeje, PL; Dingemans, AC; Groen, HJM; Hendriks, RW; Kaijen-Lambers, MEH; Kunert, A; Poncin, M; Smit, EF | 1 |
| Austin, AM; Brooks, GA; Dragnev, KH; Schrag, D; Tosteson, ANA; Uno, H | 1 |
| Chu, Y; Ge, D; Gu, J; Liu, R; Liu, Z; Lu, C; Mao, W; Wang, L; Xu, F; Zhu, Q | 1 |
| Blumenschein, GR; Dar, M; Gadgeel, S; Li, X; Takahashi, T; Wheatley-Price, P | 1 |
| Bylin, MV; Dobrodeev, AY; Kostromitsky, DN; Startseva, ZA; Tuzikov, SA; Zaviyalov, AA | 1 |
| Arndorfer, S; Arunachalam, A; Burke, TA; Frederickson, AM; Insinga, R; Lorenzi, M; Simon, GR; Zhang, I | 1 |
| Hirashima, T; Kijima, T; Koba, T; Komuta, K; Minami, S; Mori, M; Morimura, O; Niki, M; Shiroyama, T; Sugimoto, H; Torii, Y; Yokoi, T | 1 |
| Ben, XS; Chen, GY; Chen, HJ; Cheng, Y; Huang, C; Jiang, BY; Song, Y; Wang, BC; Wang, Z; Wu, YL; Xu, CR; Yan, HH; Yang, JJ; Zhou, Q | 1 |
| Akulian, J; Ettinger, D; Feller-Kopman, D; Hales, R; Lee, H; Lin, CT; Mallow, C; Semaan, R; Seward, K; Voong, KR; Wahidi, MM; Yarmus, L | 1 |
| Gu, W; Li, B; Zhu, X | 1 |
| Akiyama, N; Asada, K; Enomoto, N; Fujii, M; Fujisawa, T; Furuhashi, K; Hozumi, H; Inami, N; Inui, N; Kaida, Y; Karayama, M; Matsuda, H; Matsui, T; Matsuura, S; Nakamura, Y; Suda, T; Suzuki, Y; Toyoshima, M; Uto, T; Yasui, H | 1 |
| Chen, X; Chen, Y; Deng, Y; Li, H; Liu, B; Wu, Q; Yang, Y; Yang, Z; Zhang, J; Zhang, L | 1 |
| Imai, K; Matsuzaki, I; Minamiya, Y; Motoyama, S; Nakagawa, T; Nakayama, K; Nomura, K; Orino, K; Saito, H; Sano, M; Sato, K; Sato, Y; Shibata, H | 1 |
| Akamatsu, H; Iwamoto, Y; Masuda, K; Mori, K; Murakami, H; Naito, T; Nakashima, K; Niwa, T; Ozawa, Y; Shoda, H; Takahashi, T; Yamamoto, N; Yokoyama, T; Yoshioka, H | 1 |
| Cao, L; Fan, L; Han, C; Jin, S; Sui, X; Sun, M; Yang, C; Zhou, J; Zhu, W | 1 |
| Chang, Q; Chu, T; Han, B; Qian, J; Qiang, H; Xu, J; Zhang, B; Zhang, Y; Zhong, R | 1 |
| Akimoto, T; Goto, K; Hida, T; Hosomi, Y; Nihei, K; Niho, S; Ohe, Y; Okamoto, H; Tanaka, H; Umemura, S | 1 |
| Barlesi, F; Cappuzzo, F; Coleman, S; Deng, Y; Finley, G; Jotte, RM; Kowanetz, M; Lee, A; Lin, W; Mok, TSK; Moro-Sibilot, D; Nishio, M; Nogami, N; Orlandi, F; Reck, M; Rodríguez-Abreu, D; Shankar, G; Socinski, MA; Stroyakovskiy, D; Thomas, CA | 1 |
| Iyikesici, MS | 1 |
| Bhore, R; Ko, A; Morgensztern, D; O'Brien, M; Ong, TJ; Postmus, PE; Socinski, MA; Waqar, SN | 1 |
| Bessho, A; Fukamatsu, N; Harada, D; Hosokawa, S; Hotta, K; Kiura, K; Kozuki, T; Kubo, T; Kudo, K; Kuyama, S; Nogami, N; Ohashi, K; Oze, I; Sone, N; Takigawa, N; Yasugi, M; Yokoyama, T; Yoshioka, H | 1 |
| Cooper, PA; Cross, SJ; O'Flaherty, L; Pardo, OE; Seckl, MJ; Shnyder, SD; Tavaré, JM; Wakefield, JG | 1 |
| Akın Telli, T; Kılıçkap, S; Kıvrak Salim, D; Tatlı, AM; Yumuk, PF | 1 |
| Hosomi, Y; Kato, Y; Kawai, S; Okamura, T; Okuma, Y; Watanabe, K; Yomota, M | 1 |
| Chen, S; Zhang, J; Zhang, Z | 1 |
| Archer, V; Cappuzzo, F; Conter, HJ; Daniel, D; Hussein, M; Kopp, HG; Kowanetz, M; Lin, W; McCleod, M; McCune, S; Mekhail, T; Morabito, A; Ochi Lohmann, T; Reinmuth, N; Rittmeyer, A; Sadiq, A; Sandler, A; Wang, L; West, H; Zer, A | 1 |
| Li, Y; Wu, YL | 1 |
| Levy, BP; Parisi, M; Patterson-Lomba, O; Signorovitch, JE; Xiang, CQ; Yang, H | 1 |
| Luo, X; Peng, L; Tan, C; Wan, X; Zeng, X; Zhang, Y | 1 |
| Bagdas, D; Bigbee, JW; Cantwell, L; Chen, ZJ; Damaj, MI; Del Fabbro, E; Gewirtz, DA; Jackson, A; Kulkarni, A; Kyte, SL; Meade, JA; Papke, RL; Rahman, F; Thakur, GA; Toma, W | 1 |
| Aoe, M; Date, H; Hotta, K; Morita, S; Nakamura, H; Nakata, M; Okumura, N; Sakamoto, J; Soh, J; Toyooka, S; Yamashita, M | 1 |
| Bertino, EM; Liu, T; Mo, X; Otterson, GA; Owen, DH; Roychowdhury, S; Schweitzer, C; Timmers, CD; Webb, A; Williams, TM | 1 |
| Bao, Y; Cui, Y; Sun, H; Xiong, G; Zhou, H; Zhou, X | 1 |
| Bair, AH; Bondarenko, I; Bryl, M; Hilton, F; Kasahara, K; Liau, K; Reinmuth, N; Syrigos, K; Vladimirov, V; Zereu, M | 1 |
| Atsumi, K; Azuma, A; Fukuizumi, A; Gemma, A; Hisakane, K; Kobayashi, K; Kubota, K; Minegishi, Y; Noro, R; Omori, M; Seike, M; Sugano, T; Takahashi, S; Takano, N; Takeuchi, S | 1 |
| Bingjing, Z; Hu, L; Liang, G; Rufu, X; Xiangdong, Z; Yuliang, W | 1 |
| Cortot, AB; Delourme, J; Dhalluin, X; Habib, S; Lafitte, JJ; Petyt, G; Scherpereel, A; Tacelli, N | 1 |
| Alvarez, PJ; Aranega, A; Caba, O; Gonzalez, B; Luque, R; Melguizo, C; Ortiz, R; Prados, J | 1 |
| Hama, T; Horai, T; Kawakami, K; Kizu, J; Nishio, M; Ohtani, T; Shibata, K; Taguchi, K; Takiguchi, T; Tunoda, T | 1 |
| Axelrod, RS; Bradley, JD; Buyyounouski, MK; Komaki, R; Langer, C; Lawrence, YR; Machtay, M; Movsas, B; Paulus, R; Smith, C; Wasserman, T; Werner-Wasik, M | 1 |
| Xian, L; Xie, Y; Yang, Y | 1 |
| Banna, GL; Basile, A; Fraggetta, F; Ippolito, M; Lipari, H; Marletta, F; Nicolosi, M; Saita, S; Terminella, A; Urso, OE; Vaglica, M | 1 |
| Fang, J; Li, S; Lv, C; Ma, Y; Sun, Y; Wu, N; Yan, S; Yang, Y; Zheng, Q | 1 |
| Cheng, J; Gao, J; Liu, X; Wang, J; Wang, L; Xiong, L | 1 |
| de Lima, MC; Gomes, CP; Gomes-da-Silva, LC; Moreira, JN; Ramalho, JS; Simões, S | 1 |
| Han, JC; Li, HB; Li, XD; Wu, XY; Zhang, YJ | 1 |
| Arrieta, O; Avilés, A; Borbolla-Escoboza, J; Campos-Parra, AD; Cardona, A; Manríquez, ME; Meneses, A; Zuloaga, C | 1 |
| Chu, DT; Fukuoka, M; Mok, TS; Rukazenkov, Y; Saijo, N; Thongprasert, S; Wu, YL; Yang, JC; Yang, JJ | 1 |
| Askamit, I; Bergstrom, K; Tuscher, L; Wang, Z | 1 |
| Ichinose, Y; Kasahara, K; Mitsudomi, T; Negoro, S; Nogami, N; Ohmatsu, H; Okamoto, I; Sakai, H; Satouchi, M; Takeda, K; Yamamoto, N | 1 |
| Chen, AB; Johnson, BE; Schrag, D; Sharma, DB; Weeks, JC; Zhu, J | 1 |
| Borzási, E; Együd, Z; Fodor, E; Furák, J; Hideghéty, K; Kahán, Z; Maráz, A; Pálföldi, R; Tiszlavicz, L; Varga, Z | 1 |
| Abonyi-Tóth, Z; Katona, L; Kovács, G; Moldvay, J; Rokszin, G | 1 |
| Brown, MP; De Leo, JJ; Eberhardt, WE; Gogov, S; Jehl, V; Mills, G; Mitchell, P; Papadimitrakopoulou, V; Schiller, JH; Thomas, M; Urva, SR | 1 |
| Anile, M; Ciccone, AM; D'Andrilli, A; Ibrahim, M; Maurizi, G; Rendina, EA; Venuta, F | 1 |
| Edelman, MJ; Kaleta, R; Kim, HT; Luft, AV; Mukhopadhyay, P; Quoix, E; Reck, M; Schneider, CP; Trifan, OC; Tsai, CM; Whitaker, L | 1 |
| Kashiwabara, K; Tanaka, H; Yamane, H | 1 |
| Dahlberg, SE; Hoang, T; Johnson, DH; Schiller, JH | 1 |
| Chen, B; Cheng, H; Cheng, L; Li, F; Lu, Z; Qin, Q; Sun, N; Sun, X | 1 |
| Bakbak, B; Gedik, S; Kanat, F; Koktekir, BE; Pancar, E; Tulek, B; Yavuzer, K | 1 |
| Aung, T; Chapuy, B; Danner, BC; Güldenzoph, B; Hupfeld, T; Inagaki, N; Krause, D; Overbeck, TR; Schöndube, FA; Truemper, L; Waldmann-Beushausen, R; Wulf, GG | 1 |
| Cho, YJ; Hwang, YS; Jeong, YY; Kim, HC; Kim, IS; Kim, MJ; Kim, SH; Lee, GW; Lee, JD; Lee, S; Ling, H; Oh, SY | 1 |
| Cummings, ND; Moore, DT; Sethi, M; Sukumar, R; Wang, AZ; Wang, EC; Werner, ME | 1 |
| Bigay-Game, L; Braun, D; David, P; Debieuvre, D; Depierre, A; Douillard, JY; Laporte, S; Lavolé, A; Lebeau, B; Lemarié, E; Milleron, B; Molinier, O; Morin, F; Ozenne, G; Poudenx, M; Pujol, JL; Puyraveau, M; Quoix, E; Rivière, A; Westeel, V; Zalcman, G | 1 |
| An, G; Chen, W; Wei, P; Yan, D | 1 |
| Bae, MK; Byun, GE; Chung, KY; Kim, DJ; Kim, J; Lee, CY; Lee, JG; Park, SY | 1 |
| Besrour, H; Cerny, T; Ess, S; Früh, M; Gillessen, S; Hitz, F; Joerger, M; Savidan, A | 1 |
| Dakhil, SR; Hirsh, V; Hon, JK; Okamoto, I; Orsini, J; Page, RD; Renschler, MF; Socinski, MA; Yamamoto, N; Zhang, H | 1 |
| Carter, CA; Chun, G; Figg, W; Giaccone, G; Guha, U; Keating, A; Kelly, RJ; Khozin, S; Lopez-Chavez, A; Poondru, S; Rajan, A; Spencer, S; Steinberg, SM; Szabo, E; Thomas, A; Van Sant, C | 1 |
| Horai, T; Horiike, A; Koizumi, F; Koyama, N; Murakami, H; Nishio, K; Nishio, M; Nokihara, H; Takahashi, T; Tamura, T; Yamamoto, N; Yusa, W | 1 |
| Chansky, K; Edelman, MJ; Franklin, WA; Gandara, DR; Hirsch, FR; Kelly, K; Lara, PN; Mack, PC; Williamson, SK; Wozniak, AJ | 1 |
| Axelrod, R; Campling, B; Cowan, S; Dicker, AP; Evans, N; Fortina, PM; Lu, B; Palmer, J; Solomides, C; Sun, Y; Wang, Z; Werner-Wasik, M; Zaorsky, NG | 1 |
| Che, CL; Dong, FS; Lu, B; Lv, FZ; Sang, YL; Zhang, HH; Zhang, LJ; Zhang, YM | 1 |
| Fang, W; Hua, ZC; Meng, QL; Wang, F; Wang, ZZ; Yan, J; Zheng, YM | 1 |
| Asami, K; Atagi, S; Hirashima, T; Kawaguchi, T; Kawase, I; Morishita, N; Nakao, K; Okamoto, N; Okishio, K; Otsuka, T; Shiroyama, T; Suzuki, H; Tamiya, A; Tamiya, M; Yamadori, T; Yasue, T | 1 |
| Ahn, DH; Brahmer, JR; Dahlberg, SE; Gerber, DE; Johnson, DH; Sandler, AB; Schiller, JH | 1 |
| da Silva, EM; de Castria, TB; Gois, AF; Riera, R | 1 |
| Bildat, S; Eberhardt, WE; Fischer, B; Gauler, TC; Grunenwald, D; Krbek, T; Le Chevalier, T; Lepechoux, C; Poettgen, C; Rodrigo, Hde L; Seeber, S; Stamatis, G; Stuschke, M; Theegarten, D; Welter, S | 1 |
| Kolek, V | 1 |
| Cha, SI; Choi, JE; Choi, YY; Jeon, HS; Kang, HG; Kang, YR; Kim, CH; Kim, KS; Kim, YC; Lee, J; Lee, SY; Lee, WK; Oh, IJ; Park, JY; Shin, KM; Yoo, SS | 1 |
| Bai, CX; Guan, ZZ; Jiang, GL; Shi, YK; Wang, MZ; Wu, YL; Zhang, YP; Zhou, CC; Zhu, YZ | 1 |
| Beckett, L; Chew, HK; Davies, AM; Gandara, DR; Ho, C; Lara, P; Lau, D; Mack, PC; Riess, JW; Sangha, RS | 1 |
| Li, W; Li, Y; Li, Z; Song, L; Wu, S | 1 |
| Alavi, A; Bradley, JD; Cho, KH; DeNittis, A; Duan, F; Gorelick, JJ; Johnson, DW; Kim, SK; Komaki, R; Macapinlac, H; Machtay, M; Munden, R; Neumann, DR; Reddin, JS; Sherwin, N; Siegel, BA; Snyder, BS; Videtic, G; Wilf, LH | 1 |
| Ding, ZY; Liu, YM; Wang, C; Zhou, L | 1 |
| Gao, D; Ibrahim, S; Sinko, PJ | 1 |
| Athanasiadou, K; Kosmas, C; Koufos, N; Michailidou, D; Tomos, P; Tsavaris, N; Xynos, ID | 1 |
| Jamil, K; Naidu Madireddy, UR; Natukula, K; Pingali, UR; Suresh Attili, VS | 1 |
| Ozdemir, O; Ozdemir, P; Ozhan, MH; Uluer, H; Veral, A | 1 |
| Huang, XE; Shen, K; Yan, HA | 1 |
| Ahn, SJ; Ban, HJ; Chung, WK; Kim, KS; Kim, YC; Kim, YI; Kwon, YS; Lim, SC; Nam, TK; Oh, IJ; Song, JY; Yoon, MS | 1 |
| Li, J; Shi, Y; Xing, P | 1 |
| Bruno, R; Claret, L; Gupta, M; Han, K; He, J; Joshi, A; Powell, B; Sarapa, N | 1 |
| Asami, K; Atagi, S; Fujita, Y; Fukuoka, K; Kawahara, M; Kawasaki, M; Komuta, K; Kubota, K; Minato, K; Nogami, N; Ogushi, F; Shibata, K; Tomizawa, Y; Tsuchiya, M; Yamanaka, T; Yonei, T; Yoshioka, H | 1 |
| Beck, T; Bonomi, P; Frimodt-Moller, B; Garon, EB; Govindan, R; Guba, SC; Hermann, RC; John, WJ; Jotte, RM; Liu, J; Obasaju, CK; Olsen, MR; Patel, JD; Pennella, EJ; Reynolds, CH; Richards, DA; Socinski, MA; Spigel, DR | 1 |
| Beckman, RA; Chmielowska, E; Fox, T; Greenberg, J; Hadler, D; Krzakowski, M; Reck, M; Sebastian, M; von Pawel, J; Wang, Q | 1 |
| Chen, JH; Ma, GY; Meng, L; Wang, L; Wang, XW | 1 |
| Altan, B; Azuma, Y; Endoh, H; Kosaka, T; Kuwano, H; Miyazaki, T; Mogi, A; Onozato, R; Tanaka, S; Tomizawa, K; Yajima, T; Yamaki, E; Yokobori, T; Yokoyama, Y | 1 |
| Harada, T; Imanaga, T; Inoue, K; Kawasaki, M; Kuba, M; Matsumoto, T; Nakanishi, Y; Oshima, T; Shioyama, Y; Takayama, K; Takeshita, M; Tokunaga, S | 1 |
| Chen, XF; Han, JH; Ji, FZ; Ji, J; Pu, J; Shen, WY; Su, XL; Tao, GZ; Wang, CS; Xu, YM; Yi, JG; Zhou, XL; Zhu, WG; Zong, CD; Zuo, YS | 1 |
| Dakhil, SR; Gandara, DR; Herbst, RS; Heymach, JV; Hirsch, FR; Kelly, K; Kim, ES; Mack, PC; Moon, J; Redman, MW; Velasco, MR | 1 |
| Bosdet, I; Ho, C; Ionescu, D; Karsan, A; Laskin, JJ; Mariano, C; Melosky, B; Murray, N; Sun, S; Zhai, Y | 1 |
| Alcaro, S; Aqeilan, RI; Croce, CM; Cuda, G; Gaspari, M; Gaudio, E; Hill, GA; Kaou, M; Lovat, F; Ngankeu, A; Ortuso, F; Paduano, F; Rock, J; Spizzo, R; Trapasso, F; Zanesi, N | 1 |
| Aljumaily, R; Gay, HA; Parent, T; Russo, S; Walker, PR; Zhang, J | 1 |
| Dobrodeev, AIu; Musabaeva, LI; Tyzikov, SA; Zav'ialov, AA | 1 |
| Jakobsen, JN; Santoni-Rugiu, E; Sørensen, JB | 2 |
| Besse, B; Bonardel, G; Chargari, C; Farace, F; Gontier, E; Hadoux, J; Helissey, C; Lamand, V; Le Moulec, S; Soria, JC; Tanz, R; Vedrine, L | 1 |
| Hirsh, V; Hon, JK; Okamoto, I; Orsini, J; Page, RD; Renschler, MF; Sakai, H; Socinski, MA; Zhang, H | 1 |
| Bycott, P; Chen, C; Chmielowska, E; de Besi, P; Havel, L; Ingrosso, A; Kim, S; Olszanski, AJ; Popat, S; Sawrycki, P; Schiller, JH; Swieboda-Sadlej, A; Twelves, C; Williams, JA | 1 |
| Arnold, AM; Boyer, MJ; Bradbury, PA; Chen, EX; Clingan, P; Ding, K; Ellis, PM; Fenton, D; Goss, GD; Hirsh, V; Laberge, F; Laurie, SA; Lee, CW; Montenegro, A; Seymour, L; Shepherd, FA; Solomon, BJ; Stockler, MR; Zukin, M | 1 |
| He, D; Li, M; Qian, Z; Wang, J; Wang, R; Xiao, Q; Xiao, X | 1 |
| Chen, W; Feng, J; Gao, S; Miao, H; Tao, X; Yun, Y; Zhang, F; Zhou, J | 1 |
| Li, K; Lu, JQ; Ma, LL; Sun, JW; Zhang, PP | 1 |
| Chang, JY; Fang, B; Gillin, M; Lin, SH; Mohan, R; Zhang, X | 1 |
| Crawford, J; Freeman, DJ; Johnson, CW; Johnson, D; Krishnan, K; Prager, D; Sandler, A; Schwarzenberger, P; Swanson, P; Zhang, K | 1 |
| Enomoto, T; Kobayashi, T; Takeda, A; Yokosuka, T | 1 |
| Dy, GK; Gupta, N; Hatoum, H | 1 |
| Boutros, PC; Feigen, M; Harris, S; John, T; Lambin, P; Liew, MS; Mitchell, P; Sia, J; Starmans, MH; Tafreshi, A; White, S; Zimet, A | 1 |
| Fujita, S; Hata, A; Kaji, R; Katakami, N; Masago, K; Matsumoto, T; Monden, K; Nagata, K; Otsuka, K; Tachikawa, R; Takeshita, J; Tanaka, K; Tomii, K | 1 |
| Kondo, T; Murakami, S; Oshita, F; Saito, H; Yamada, K | 2 |
| Doihara, H; Furutani, T; Fushiki, H; Konagai, S; Kondoh, Y; Kudoh, M; Kuromitsu, S; Mori, K; Mori, M; Saito, R; Sakagami, H; Shimada, I; Shindou, N; Soga, T; Ueno, Y | 1 |
| Hei, YJ; Hsia, TC; Ichinose, Y; Kim, JH; Kim, SW; Kubota, K; Li, RK; Lim, WT; Park, K; Scagliotti, G; Shinkai, T; Spigel, D; Takeda, K; Tiangco, BJ; Yao, B; Yau, S | 1 |
| Gemma, A; Hagiwara, K; Harada, M; Inoue, A; Ishii, Y; Isobe, H; Kobayashi, K; Maemondo, M; Minegishi, Y; Sugawara, S; Watanabe, S; Yoshizawa, H | 1 |
| Hirsh, V | 1 |
| Ando, M; Asami, K; Atagi, S; Ishii, M; Kanazu, M; Kawaguchi, T; Kubo, A; Kusunoki, Y; Maruyama, K; Matsuda, Y; Minomo, S; Ogawa, Y; Takada, M; Uehira, K | 1 |
| Ahn, JS; Ahn, MJ; Chang, WJ; Lee, JY; Park, K; Sun, JM | 1 |
| Chen, X; Gao, G; He, Y; Li, W; Li, X; Ren, S; Zhang, L; Zhou, C; Zhou, F | 1 |
| Camidge, DR; Cebotaru, CL; Dediu, M; Fox, NL; Gribbin, MJ; Harvey, JH; Humphreys, RC; Reck, M; Spigel, DR; von Pawel, J | 1 |
| Cai, L; Li, CH; Li, DD; Liu, MY; Liu, W | 1 |
| Chen, L; Huang, G; Shi, S; Song, H; Tao, L | 1 |
| Bowles, EJ; Carroll, NM; Delate, T; Hornbrook, MC; Kushi, L; Loggers, ET; Menter, A; Ritzwoller, DP | 1 |
| Chen, J; Cui, L; He, XJ; Huang, XE; Jiang, Y; Liu, JJ; Liu, XX; Zhou, XR | 1 |
| Arce-Lara, C; Kelley, MJ; Santana-Davila, R; Szabo, A; Whittle, J; Williams, CD | 1 |
| Cong, B; Hao, Y; Peng, C; Sun, Q; Zhao, X; Zhao, Y | 1 |
| Gemma, A; Harada, T; Inoue, A; Ishimoto, O; Kambe, M; Maemondo, M; Minegishi, Y; Miwa, K; Morikawa, N; Nukiwa, T; Sakakibara, T; Sugawara, S; Ube, K; Usui, K; Watanabe, K | 1 |
| Baba, K; Hirata, Y; Ju-ichi, M; Maeda, R; Matsue, S; Nagaoka, Y; Shibano, M; Taniguchi, M; Uesato, S; Yamamoto, M; Yamashita, H | 1 |
| Akopov, A; Chistyakov, I; Gerasin, A; Kazakov, N; Rusanov, A; Urtenova, M | 1 |
| Chan, WW; Choy, TS; Ho, PP; Khong, PL; Kwong, DL; Lam, KO; Lee, EY; Lee, VH; Leung, DK; Leung, TW | 1 |
| Chang, JY; Hsiao, CJ; Liou, JP; Pai, HC; Pan, SL; Teng, CM; Tsai, AC; Wang, CY; Wang, JC | 1 |
| Cho, J; Choi, NC; Sharp, GC; Shusharina, N | 1 |
| Ambudkar, SV; Ashby, CR; Bates, SE; Chen, ZS; Fu, LW; Kathawala, RJ; Patel, A; Robey, RW; Shukla, S; Talele, TT; Wang, YJ; Zhang, H; Zhang, YK | 1 |
| Cheng, Y; Cun, Y; Li, M; Li, Z; Peng, Y; Qian, C; Ren, T; Wang, D; Xia, L; Xiong, Y; Zhang, S | 1 |
| Bottomley, A; Coens, C; Ediebah, DE; Flechtner, H; Gotay, C; Greimel, E; King, MT; Quinten, C; Reeve, BB; Ringash, J; Schmucker von Koch, J; Smit, EF; Taphoorn, MJ; Weis, J; Zikos, E | 1 |
| Batus, M; Bonomi, P; Dandekar, VK; Fidler, MJ; Kiel, K; Sher, DJ; Young, J | 1 |
| Chu, DJ; Fang, ZR; Hong, Y; Yao, DE; Yu, J; Yu, ZY; Zhu, XC; Zhuang, YF | 1 |
| Barbeiro, AS; Costa, DB; Honma, HN; Leme, MS; Morcillo, AM; Perroud, MW; Saad, BA; Vassallo, J; Zambon, L | 1 |
| Chen, X; Huang, Y; Li, M; Lin, J; Liu, H; Lv, S; Song, W; Tang, Z; Zhang, Y | 1 |
| Bendell, J; Burris, HA; Dowlati, A; Infante, JR; Jones, SF; Kane, MP; Levinson, KT; Stein, MN; Suttle, AB; Tan, AR | 1 |
| Archer, V; Burdaeva, O; Delmar, P; Gorbunova, V; Hilton, M; Juhasz, E; Mok, T; Orlov, S; Pallaud, C; Reck, M; Szima, B; Yu, CJ | 1 |
| Carlson, DM; Horai, T; Horiike, A; Horinouchi, H; Kaneda, H; McKee, MD; Nakagawa, K; Nishio, M; Nokihara, H; Ohyanagi, F; Okabe, T; Tamura, T; Terashima, M; Xiong, H; Yamamoto, N | 1 |
| Akashi, Y; Atagi, S; Ebi, N; Fujii, S; Hirashima, T; Kaneda, H; Kimura, T; Kogure, Y; Maeda, T; Morita, S; Nagase, S; Nakagawa, K; Nakanishi, Y; Nishino, K; Nishio, K; Oizumi, S; Okamoto, I; Okuno, M; Sakai, K; Satouchi, M; Sawa, T; Seto, T; Takahashi, T; Takayama, K; Takeda, K; Tomii, K; Yamamoto, M; Yoshioka, H | 1 |
| Chen, L; Cress, WD; Kurtyka, CA | 1 |
| Wakelee, HA | 1 |
| Cappell, KM; Larson, B; Mytsa, D; Sinnott, R; Taus, P; Whitehurst, AW; Winters, L | 1 |
| Benner, RJ; Jassem, J; Karp, DD; Krzakowski, M; Langer, CJ; Mok, T; Novello, S; Olszanski, AJ; Park, K; Scranton, JR | 1 |
| Ahn, HK; Cho, EK; Jeong, SH; Jung, M; Kang, SM; Kyung, SY; Park, JW; Shin, DB; Sym, SJ | 1 |
| Lin, GN; Liu, DY; Peng, JW; Xia, ZJ; Xiao, JJ | 1 |
| Koyama, N | 1 |
| Elity, MM; Sad, LM; Younis, SG | 1 |
| Dagli, ML; De Carvalho, DD; Fukumasu, H; Mesquita, LG; Pires, PR; Rochetti, AL; Silva, ER; Strefezzi, RF | 1 |
| Chan, EC; Chen, KT; Huang, CY; Lan, CC; Lee, CH; Wu, YK; Yang, MC | 1 |
| Geng, YC; Hu, YX; Li, HQ; Li, QS; Lu, B; Ma, Z; Ouyang, WW; Su, SF | 1 |
| Wang, HY; Zhang, XR | 1 |
| Alama, A; Barletta, G; Biello, F; Boccardo, F; Coco, S; Dal Bello, MG; Genova, C; Grossi, F; Rijavec, E; Truini, A; Vanni, I | 1 |
| Ang, KK; Blumenschein, GR; Choy, H; Curran, WJ; Hirsch, FR; Komaki, R; Paulus, R; Robert, F; Thariat, J; Werner-Wasik, M | 1 |
| Arrieta, O; Dorantes-Gallareta, Y; Flores-Estrada, D; Macedo-Pérez, EO; Mendoza-García, VO; Morales-Oyarvide, V | 1 |
| Gao, XD; Ge, LH; Jin, ZY; Liang, JG; Te, MR; Wang, CL | 1 |
| Bai, C; Chen, H; Gao, Z; Han, B; Jin, L; Li, Q; Li, X; Lu, D; Qian, J; Shao, M; Song, X; Wang, J; Wang, S; Wu, J; Zhao, X | 1 |
| Guan, W; Li, M; Li, Z; Peng, Y; Qing, Y; Wang, D; Xiong, Y; Zhang, S | 1 |
| Benhabbour, SR; Ma, P; Madden, AJ; Mumper, RJ; Peng, L; Schorzman, AN; Zamboni, WC | 1 |
| Guo, Q; Zhuo, Y | 1 |
| Chen, X; Li, W; Li, X; Liu, L; Ren, S; Zhou, C; Zhou, F | 1 |
| Ezer, N; Galsky, MD; Gomez, J; Gu, F; Mhango, G; Smith, CB; Strauss, GM; Wisnivesky, J | 1 |
| Blackhall, F; Hei, YJ; McCoy, S; Novello, S; Scagliotti, GV; Schneider, CP; Spigel, DR; Sydorenko, O; Volovat, C; Vynnychenko, I | 1 |
| Ballas, MS; Berge, EM; Camidge, DR; Doebele, RC; Gao, L; Haigentz, M; Hoffman, D; Jahan, T; Joshi, A; Lee, P; Mita, A; Spicer, J; West, H; Yang, L; Yurasov, S | 1 |
| Gao, X; Guo, S; Liu, X; Zhang, Z | 1 |
| Heigener, D; Reck, M | 1 |
| Blatt, R; Cahal, S; Giladi, M; Itzhaki, A; Kirson, ED; Munster, M; Onn, A; Palti, Y; Porat, Y; Schneiderman, RS; Voloshin, T; Weinberg, U | 1 |
| Fang, Y; Shi, MQ; Wang, L; Xia, GH | 1 |
| Bapsy, PP; Bhattacharyya, GS; Dasappa, L; Digumarti, R; Gerber, DE; Shan, JS; Suresh, AV | 1 |
| Bosc, C; Couraud, S; Moro-Sibilot, D; Souquet, PJ; Toffart, AC; Zarza, V | 1 |
| Fujimoto, D; Katakami, N; Kato, R; Kawamura, T; Matsumoto, T; Nagata, K; Nakagawa, A; Otoshi, T; Otsuka, K; Shimizu, R; Tamai, K; Tomii, K | 1 |
| Simon, GR | 1 |
| Adjei, AA; Aubry, MC; Bearden, JD; Foster, NR; Johnson, DB; Mandrekar, SJ; Mattar, BI; Meyers, JP; Molina, JR; Northfelt, DW; Rowland, KM; Schild, SE; Thomas, SP; Zhao, Y | 1 |
| Bass, MB; Chan, SS; Davis, GJ; Davis, MT; Hei, YJ; Kaesdorf, BA; Patterson, SD; Yao, B; Ye, Y | 1 |
| Fridley, BL; Ghosh, TM; Gupta, P; Lamba, JK; Mehta, G; Yu, Q | 1 |
| Chai, CY; Chang, PC; Cheng, YJ; Chiu, WC; Huang, CJ; Hung, AC; Lee, YC; Su, YH; Tsai, JW; Yuan, SS | 1 |
| Dauth, M; Horwood, K; Lehman, M; Mai, GT; McCaffrey, E; McGrath, M; Pinkham, MB; Trinh, H; Zarate, D | 1 |
| Cui, J; Guo, QQ; Han, LL; Jiang, LL; Jing, L; Liang, X; Liu, Y; Liu, ZY; Ma, JQ; Nan, KJ; Wang, J; Wang, MC; Wu, T; Yang, CC; Yao, Y | 1 |
| Beck, JT; Desaiah, D; Govindan, R; Guba, SC; Hrinczenko, B; Koustenis, AG; Liu, J; Melemed, SA; Modiano, MR; Nikolinakos, PG; Obasaju, CK; Ortuzar, WI; Ross, HJ; Spigel, DR; Treat, JA; Waterhouse, DM; Weaver, RW; Winfree, KB; Zinner, RG | 1 |
| Hao, L; Li, C; Wang, C; Zhang, B; Zhao, X | 1 |
| Bogart, J; Bradley, J; Hodgson, L; Jänne, PA; Katragadda, S; Kong, FM; Lilenbaum, R; Masters, G; Samuels, M; Vokes, E; Wang, X | 1 |
| Arce-Lara, C; Devisetty, K; Gore, EM; Kelley, MJ; Moran, A; Santana-Davila, R; Sparapani, R; Szabo, A; Whittle, J; Williams, CD | 1 |
| Ai, Z; Lu, B; Sun, L; Xu, J; Yan, X | 1 |
| Chakrabarti, G; Chatterjee, A; Chattopadhyay, D | 1 |
| Guerin, A; Hazard, SJ; Ionescu-Ittu, R; Langer, C; Latremouille-Viau, D; Ramalingam, S; Ravelo, A; Wu, EQ | 1 |
| Fujiwara, Y; Furuta, K; Horinouchi, H; Kanda, S; Katsui Taniyama, T; Kitazono, S; Kohno, T; Mizugaki, H; Nakamichi, S; Nokihara, H; Shiraishi, K; Sumi, M; Tamura, T; Tsuta, K; Yagishita, S; Yamamoto, N | 1 |
| Bhora, FY; Latif, MJ; Li, X; Park, K; Razi, SS; Rehmani, S; Schwartz, GS | 1 |
| Maneechawakajorn, J; Suksuperm, J | 1 |
| Bonomi, P; Garon, EB; Govindan, R; Guba, SC; Hermann, RC; Li, S; Liu, J; Obasaju, CK; Olsen, MR; Patel, JD; Pennella, EJ; Reynolds, CH; Socinski, MA; Spigel, DR | 1 |
| Dilling, TJ | 1 |
| Liang, H; Liu, E; Pan, F; Qin, H; Ruan, Z; Zhang, K | 1 |
| Fujita, S; Hata, A; Hattori, Y; Imamura, F; Kaji, R; Kumagai, T; Mori, M; Morita, S; Negoro, S; Nishimura, T; Satouchi, M; Shimada, T; Sunadome, H; Tachihara, M; Urata, Y; Yoneda, T | 1 |
| Axelrod, R; Barrios, CH; Belani, CP; Carlson, DM; Devanarayan, V; Gorbunova, VA; Kolman, P; Makhson, A; McKee, MD; McKeegan, EM; Owonikoko, TK; Pereira, JR; Pittman, KB; Qian, J; Qin, Q; Ramalingam, SS; Ricker, JL; Segalla, JG; Shtivelband, M; Soo, RA; Srkalovic, G | 1 |
| Endo, M; Imai, H; Kenmotsu, H; Ko, R; Mori, K; Murakami, H; Naito, T; Ono, A; Taira, T; Takahashi, T; Wakuda, K | 1 |
| Arai, D; Betsuyaku, T; Ikemura, S; Ishioka, K; Kawada, I; Kuroda, A; Nakachi, I; Nakamura, M; Nakatani, M; Nakayama, S; Naoki, K; Nishino, M; Ohgino, K; Sato, T; Satomi, R; Soejima, K; Tani, T; Terai, H; Watanabe, H; Yasuda, H; Yoda, S | 1 |
| Hirsh, V; Ko, A; Langer, CJ; Renschler, MF; Socinski, MA | 1 |
| Borsellino, N; Catino, A; Cinieri, S; Colucci, G; Di Maio, M; Febbraro, A; Galetta, D; Gebbia, V; Logroscino, A; Maiello, E; Misino, A; Montrone, M; Morabito, A; Pisconti, S; Rizzi, D; Rizzo, P | 1 |
| Kubo, N; Murata, K; Musha, A; Nakano, T; Noda, SE; Ohno, T; Oike, T; Suzuki, Y; Takahashi, A; Takahashi, T; Yoshida, Y | 1 |
| Beitler, J; Blumenschein, G; Bogart, J; Bradley, JD; Choy, H; Curran, W; Forster, K; Garces, YI; Gaur, R; Hu, C; Iyengar, P; Kavadi, V; Komaki, R; Koprowski, C; Magliocco, A; Masters, G; Meng, J; Narayan, S; Paulus, R; Robinson, C; Schild, S; Wynn, RB | 1 |
| Ancukiewicz, M; Duda, DG; Engelman, JA; Fidias, P; Gandhi, L; Heist, RS; Jain, RK; Lynch, TJ; Neal, JW; Pennell, NA; Sahani, DV; Sequist, LV; Shaw, AT; Temel, JS | 1 |
| Bonomi, P; Chen, J; Garon, EB; Govindan, R; Guba, SC; Hermann, RC; Liu, J; Olsen, MR; Patel, JD; Reynolds, CH; Socinski, MA; Spigel, DR; Winfree, KB | 1 |
| Izzo, C | 1 |
| Hazard, SJ; Langer, CJ; Leon, L; Patel, JD; Ramalingam, SS; Sandler, AB; Schiller, JH; Socinski, MA | 1 |
| Arondekar, B; Buck, PO; Miller, PJ; Saverno, KR; Walker, MS | 1 |
| Liu, D; Qian, J; Su, B; Xu, W; Zhang, J; Zhang, ZW; Zheng, H | 1 |
| Zhang, XY; Zhang, YD | 1 |
| Barazzutti, H; Barlesi, F; Boyer, A; Greillier, L; Tomasini, P | 1 |
| Fujita, Y; Fukuhara, T; Gemma, A; Hagiwara, K; Harada, M; Inoue, A; Isobe, H; Kinoshita, I; Kobayashi, K; Maemondo, M; Morita, S; Nukiwa, T; Oizumi, S; Saijo, Y; Sugawara, S; Yoshizawa, H | 1 |
| Aggarwal, C; Dahlberg, SE; Hanna, NH; Hirsch, FR; Kolesar, JM; Ramalingam, SS; Schiller, JH | 1 |
| Choi, CM; Choi, YJ; Chun, YJ; Kim, SY; Lee, JC; Rho, JK; So, KS | 1 |
| Khuri, FR; Li, M; Liu, F; Liu, X; Mao, K; Marcus, AI; Zhou, W | 1 |
| Ho, C; Laskin, J; Ramsden, K | 1 |
| Bai, C; Cao, S; Chen, H; Chen, J; Dai, J; Han, B; Hu, Z; Jin, G; Li, Q; Lu, D; Ma, H; Shen, H; Shu, Y; Song, X; Sun, C; Tang, S; Wang, C; Wang, S; Wu, J; Xu, L; Yin, R | 1 |
| Hiura, K; Iwaki-Egawa, S; Komori, H; Shiraishi, A; Suzuki, C; Takamura, K; Watanabe, Y; Yamamoto, M | 1 |
| Horn, L; Keedy, V; Lammers, PE; Lu, B; Shyr, Y | 1 |
| Gemma, A; Hagiwara, K; Inoue, A; Isobe, H; Kobayashi, K; Maemondo, M; Miyauchi, E; Nukiwa, T; Oizumi, S; Saijo, Y; Sugawara, S; Yoshizawa, H | 1 |
| Ding, C; Lei, G; Liu, J; Liu, Z; Lv, W; Sun, R; Wang, L; Xu, C; Yuan, Y | 1 |
| Fujiwara, Y; Horinouchi, H; Kanda, S; Kitazono, S; Kubota, K; Mizugaki, H; Nokihara, H; Sekine, I; Tamura, T; Tokudome, T; Wakui, H; Yagishita, S; Yamamoto, N | 1 |
| Hu, W; Zhang, Z | 1 |
| Gao, C; Gao, Y; He, W; Qu, W; Yu, Y; Zhang, S; Zhang, Y; Zhu, S | 1 |
| Jamil, K; Jayaraman, A; Subhani, S | 1 |
| Fujimura, M; Hinoue, Y; Hirokami, N; Ishida, Y; Ishiura, Y; Kasahara, K; Saitoh, K; Segawa, M; Shiba, Y; Terasaki, Y | 1 |
| Aoishi, Y; Hirai, Y; Honda, M; Kawago, M; Kiyoi, M; Kokawa, Y; Miyasaka, M; Nishiguchi, H; Ohashi, T; Okamura, Y; Oura, S; Yoshimasu, T | 1 |
| Allen, PK; Blumenschein, GR; Hong, WK; Komaki, R; Lee, JJ; Liu, DD; Tang, X; Wei, X; Welsh, JW; Wistuba, II | 1 |
| Chakraborti, A; Chhetra Lalli, R; Dadsena, S; Ghosh, S; Kaur, K; Srinivasan, R | 1 |
| Hisada, T; Imai, H; Ishihara, S; Kaira, K; Kuwako, T; Masuda, T; Minato, K; Miura, Y; Mogi, A; Saito, R; Shimizu, K; Sunaga, N; Takise, A; Tomizawa, Y; Yamada, M; Yoshino, R | 1 |
| Abesada-Terk, G; Alemany, C; Brown, RH; Cartwright, TH; Faig, D; Fulp, WJ; Jacobsen, PB; Kim, GP; Lee, JH; Levine, RM; Malafa, M; Markham, MJ; Schreiber, F; Sharp, PV; Tanvetyanon, T | 1 |
| Chen, J; He, LJ; Li, Y; Li, YY; Lou, Y; Wang, LR; Wang, Y; Zhang, GB | 1 |
| Chen, G; Cheng, G; Feng, J; Han, B; He, J; Hu, C; Jiang, G; Liu, X; Lu, S; Lu, Y; Pan, H; Song, X; Wang, J; Wu, YL; Yin, AY; Zhang, H; Zheng, W; Zhou, C; Zhu, Y | 1 |
| Bai, C; Gao, Z; Han, B; Li, H; Li, Q; Li, X; Liu, W; Lu, D; Ma, K; Qian, J; Wang, H; Wang, J; Wang, S; Wang, X; Wu, J; Wu, W; Zhao, X | 1 |
| Bartolotti, M; Brandes, AA; Cavallo, G; Di Battista, M; Genestreti, G | 1 |
| Deng, J; Deng, JH; Niu, PG; Ouyang, XN; Shi, DH | 1 |
| Botteman, MF; Hirsh, V; Langer, CJ; Lin, FJ; Okamoto, I; Ong, TJ; Renschler, MF; Wan, Y; Whiting, S | 1 |
| Koivunen, JP; Laurila, N | 1 |
| Aldonza, MB; Bae, SY; Hong, JY; Kim, WK; Lee, SH; Lee, SK; Oh, J; Shin, Y; Song, J | 1 |
| Al-Massarani, G; Alammar, M; Banat, I; Najjar, F | 1 |
| Bertino, EM; Chatterjee, M; Mo, X; Nana-Sinkam, SP; Otterson, GA; Phillips, GS; Rahmani, M; Shilo, K; Villalona-Calero, MA; Williams, TM | 1 |
| Baba, T; Enomoto, Y; Goto, K; Kato, T; Kenmotsu, H; Murakami, H; Ogura, T; Takahashi, T; Watanabe, N; Yoh, K | 1 |
| Han, BH; Jin, B; Lou, YQ; Ren, ZH; Xu, JL; Yang, QZ; Zhou, ZR | 1 |
| Bartoń, S; Biernacka, B; Krawczyk, P; Małecka-Massalska, T; Milanowski, J; Mlak, R; Powrózek, T | 1 |
| Gomez, D; Komaki, R; Lee, MS; Levy, LB; Liao, Z; Lu, C; Tang, C; Zhuang, Y | 1 |
| Fang, P; Gao, F; Hao, L; Hu, Y; Jiao, S; Li, J; Liu, Z; Sun, S; Wei, Z | 1 |
| Chen, WL; Li, JZ; Liu, C; Liu, Y; Yang, SD; Yuan, ZQ; Zhang, CG; Zhang, XN; Zhou, XF; Zhu, WJ | 1 |
| Chen, Y; He, HL; He, LJ; Lin, S; Luo, HQ; Pang, HW; Ren, PR; Shang, CL; Wen, QL; Wu, JB; Xiang, L; Yang, B; Yang, HR; Zhang, JW | 1 |
| Behera, M; Belani, CP; Chen, Z; Khuri, FR; Kim, S; Owonikoko, TK; Pillai, RN; Ramalingam, SS; Saba, NF; Steuer, C | 1 |
| Hanna, N; Jalal, SI; Mamdani, H | 1 |
| Chiba, K; Kurokawa, T; Matsushima, Y; Nakanishi, Y; Narita, Y; Shiroiwa, T; Urushihara, H | 1 |
| Hisada, T; Imai, H; Ishizuka, T; Kaira, K; Kamide, Y; Koga, Y; Kuwako, T; Masuda, T; Ono, A; Sunaga, N; Yamada, M | 1 |
| Bao, Y; Chu, Q; Tan, S; Wu, T; Wu, Y; Zhang, Z; Zhuang, X | 1 |
| Hao, YZ; Lan, WG; Ma, LB; Wang, P; Xu, DH; Zhou, YL | 1 |
| Anaya, P; Arrieta, O; Morales-Oyarvide, V; Polanco, AC; Ramírez-Tirado, LA | 1 |
| Aerts, JG; Bahce, I; Biesma, B; Burgers, JA; Dingemans, AM; Groen, HJ; Herder, GJ; Smit, EF; Stigt, JA; van den Borne, BE; van der Noort, V; Vincent, A | 1 |
| Liang, W; Song, Y; Wu, G; Yang, W; Yin, J; Yuan, D; Zeng, J | 1 |
| Chen, Z; Gao, J; Liu, C; Qian, F; Yang, K; Zhang, L | 1 |
| Ansell, PJ; Bhathena, A; Carlson, DM; Chakravartty, A; Chan, S; Chandran, RK; Davis, G; Devanarayan, V; Dowell, BL; Gawel, SH; McKee, MD; McKeegan, EM; Ramalingam, SS; Ricker, JL | 1 |
| Fujiwara, Y; Giranda, V; Hashiba, H; Horinouchi, H; Kanda, S; Kitazono, S; Mizugaki, H; Nokihara, H; Qian, J; Shepherd, SP; Tamura, T; Xiong, H; Yagishita, S; Yamamoto, N | 1 |
| Futamura, Y; Hasegawa, T; Hayashi, S; Horiba, A; Iida, T; Kaito, D; Kato, T; Ohno, Y; Sawa, T; Suzuki, T; Yoshida, T | 1 |
| Li, FY; Li, J; Xing, XZ; Xing, YJ; Zhang, QL | 1 |
| Araki, N; Fusegawa, H; Hashizume, T; Kaseda, S; Kawai, O; Nemoto, E; Ohkubo, Y; Sugiura, Y | 1 |
| Aggarwal, C; Bauml, J; Brady, AK; Cohen, RB; Evans, TL; Judy, B; Langer, C; McNeill, JD; Vachani, A | 1 |
| Ahn, JH; Choi, CM; Choi, YJ; Kim, SW; Lee, DH; Lee, JS; Lee, SJ | 1 |
| Guo, J; Tang, N; Wang, Y; Wang, Z; Zhang, Q | 1 |
| Abasi, M; Abbasi, MM; Akbarzadeh, A; Jahanban-Esfahlan, R; Sani, HM | 1 |
| He, Z; Huang, C; Huang, J; Sun, W; Teng, Y; Wu, Y; Xu, Y; Zhang, H; Zhang, X | 1 |
| Huang, G; Liu, G; Wang, X; Zang, B; Zhao, J | 1 |
| Belka, C; Budach, W; Cordes, S; De Ruysscher, D; Eberhardt, WE; Fischer, B; Friedel, G; Gauler, TC; Heinrich, V; Hepp, R; Jöckel, KH; Kimmich, M; Lehmann, N; Lütke-Brintrup, D; Pöttgen, C; Schmidberger, H; Schuler, M; Spengler, W; Stamatis, G; Stuschke, M; Veit, S; Welter, S | 1 |
| Bai, Y; Chen, M; Hu, Y; Li, H; Li, J; Li, Q; Li, T; Lu, B; Lu, Y; Ma, Z; Ouyang, W; Su, S; Wang, X; Wang, Y | 1 |
| Atkinson, T; Basch, E; Bennett, A; Kris, MG; Pietanza, MC; Rogak, LJ; Schrag, D; Shaw, M; Shouery, M; Sima, CS; Wood, WA | 1 |
| Brossart, P; Cathomas, R; Klingbiel, D; Mark, M; Mey, U; Volk, V; von Moos, R | 1 |
| Jiang, YH; Li, XM; Peng, CL; Wang, JH; Wang, RM; Ye, L; Yu, XM; Zhang, ZY; Zhao, YP; Zou, W | 1 |
| Chao, TT; Chen, KF; Chen, YL; Chu, PY; Hsiao, YJ; Hung, MH; Shiau, CW; Tai, WT; Wang, CY; Yu, HC | 1 |
| Srinivasan, P; Vanajothi, R | 1 |
| Ahn, SJ; Ban, HJ; Chung, WK; Jeong, JU; Kim, KS; Kim, YC; Kim, YH; Nam, TK; Oh, IJ; Song, JY; Yoon, MS | 1 |
| Ball, DL; Bedő, J; Chabrot, M; Everitt, SJ; Hicks, RJ; Leimgruber, A; MacManus, M; Möller, A; Solomon, B; Wen, SW | 1 |
| Bradley, J; Choy, H; Curran, WJ; Garces, YI; Gaur, R; Gelblum, DY; Hu, C; Johnson, DW; Kavadi, V; Komaki, R; Koprowski, C; MacRae, RM; Masters, G; Michalski, J; Movsas, B; Narayan, S; Paulus, R; Schallenkamp, J; Sloan, J; Wynn, RB | 1 |
| Dai, X; Fan, W; Huang, L; Jiang, Y; Mckinley, D; Shi, L; Tan, C; Tan, W; Wang, Y | 1 |
| Inoue, A; Kobayashi, K; Nukiwa, T; Watanabe, S | 1 |
| Cho, A; Cho, BC; Kim, HR; Kim, JH; Lee, MG; Lim, SM; Park, HS; Shin, HJ; Shin, JG | 1 |
| An, G; Ma, Y; Wang, J; Wang, Q; Xu, F; Yang, L | 1 |
| Bennouna, J; Chand, VK; Chen, YM; Chouaid, C; De Marinis, F; Feng, JF; Grossi, F; Kim, DW; Kim, JH; Liu, X; Lu, S; Park, K; Planchard, D; Schuler, M; Strausz, J; Vinnyk, Y; Wang, B; Wiewrodt, R; Yang, JC; Zhou, C | 1 |
| Ball, M; Davey, P; Graham, C; Hess, LM; Knox, H; Rajan, N; Winfree, K | 1 |
| Bozonnat, MC; Chavaillon, JM; Chouaid, C; Daurès, JP; Fournel, P; Gervais, R; Le Caer, H; Léna, H; Martel-Lafay, I; Robinet, G; Souquet, PJ; Vergnenégre, A | 1 |
| Cho, HJ; Kim, DK; Kim, HR; Kim, YH; Park, SI; Park, YS | 1 |
| Chen, W; He, Z; Huang, J; Ma, J; Shi, Z; Sun, W; Xia, J; Zhang, X | 1 |
| Ahmed, I; Aisner, J; Benenati, B; Chen, T; Deek, MP; Jabbour, SK; Kim, S; Zou, W | 1 |
| Fujiwara, Y; Goto, Y; Horinouchi, H; Kanda, S; Nokihara, H; Ohe, Y; Sumi, M; Tamura, T; Yamamoto, N | 1 |
| Brower, V | 1 |
| Iwata, T; Nakajima, T; Suzuki, H; Tagawa, T; Yoshida, S; Yoshino, I | 1 |
| Anabuki, K; Hatakeyama, N; Kawase, S; Kubota, T; Machida, H; Miyamoto, S; Ogushi, F; Ohnishi, H; Okano, Y; Sakai, M; Takaoka, M; Tsukuda, T; Urata, T; Yamamoto, A; Yokoyama, A | 1 |
| Akerley, WL; Gandara, DR; Hesketh, PJ; Hirsch, FR; Lara, PN; Mack, PC; Moon, J; Redman, MW; Williamson, SK | 1 |
| Adam, J; Bastien, B; Beck, JT; Chouaid, C; Debieuvre, D; Felip, E; Forget, F; Gervais, R; Halluard, C; Kazarnowicz, A; Lacoste, G; Lena, H; Limacher, JM; Losonczy, G; Madroszyk, A; Ottensmeier, C; Palanché, T; Papai, Z; Quoix, E; Szczesna, A; Tavernaro, A; Westeel, V | 1 |
| Gridelli, C; Sacco, PC | 1 |
| Audibert, LF; Cagney, JM; Christos, PJ; Saxena, A; Scheff, RJ; Schneider, BJ | 1 |
| Aliustaoglu, M; Aydin, D; Ercelep, O; Gemici, C; Gumus, M; Isik, D; Korkmaz, T; Mayadagli, A; Mert, AG; Odabas, H; Ozcelik, M; Ozdemir, P; Seker, M; Surmeli, H; Yuksel, S | 1 |
| Hiraoka, M; Nokihara, H; Ohe, Y; Tamura, T; Yamamoto, N | 1 |
| Chen, G; Fang, W; Jia, L; Jiang, X; Li, H; Li, M; Liu, X; Ren, Y; Wang, L; Wu, C; Yang, J; Yuan, X; Zou, S | 1 |
| Lee, HY; Park, SH; Seong, MA | 1 |
| Chen, K; Shi, W | 1 |
| Benepal, T; Cadranel, J; Christoph, DC; Das, M; Fennell, DA; Ferry, D; Lal, R; Maxwell, F; Summers, Y; Visseren-Grul, C | 1 |
| Socinski, MA; Villaruz, LC | 1 |
| Audigier-Valette, C; Auliac, JB; Baize, N; Bérard, H; Bota, S; Chouaïd, C; Corre, R; Dansin, E; Daurès, JP; Decroisette, C; Descourt, R; Dujon, C; Falchero, L; Greillier, L; Lamy, R; Le Caër, H; Léna, H; Marcq, M; Massuti, B; Monnet, I; Pérol, M; Plassot, C; Vergnenègre, A | 1 |
| Baek, SA; Cha, SI; Choi, JE; Hong, MJ; Jeong, JY; Jin, CC; Kang, HJ; Kim, CH; Lee, J; Lee, SY; Lee, WK; Park, JY; Shin, KM; Son, JW; Yoo, SS | 1 |
| Azghari, I; Boukir, A; Boutayeb, S; El Ghissassi, I; El Kabous, M; Errrihani, H; Mrabti, H | 1 |
| Jin, F; Kong, L; Shi, F; Yu, J; Zhu, H | 1 |
| Arrieta, O; De la Torre-Vallejo, M; Juárez-Hernández, E; Luvian-Morales, J; Sánchez-Lara, K; Turcott, JG | 1 |
| Hou, W; Lin, HS; Liu, J; Wang, XQ | 1 |
| Deng, QH; Ji, YL; Jiang, H; Ma, SL; Sun, XJ; Xu, YP; Yu, XM; Zheng, YD | 1 |
| Dobrodeev, AY; Tuzikov, SA; Zav'yalov, AA | 1 |
| Ba, Y; Jiang, RC; Kong, Q; Li, K; Wang, XY | 1 |
| Jiang, Q; Shen, H; Shu, Y; Wang, J | 1 |
| Gao, F; Lan, M; Sun, B; Yuan, H | 1 |
| Chang, JF; Chao, MW; Chung, MC; Lin, CH; Tseng, CY; Wang, JS; Wu, LY | 1 |
| Cai, J; Dong, H; Huang, L; Lin, F; Lin, L; Lin, R; Liu, B; Liu, W; Lu, J; Ma, Y; Tan, J; Wang, J; Wang, Q; Wang, S; Wu, W; Yang, S; Ye, S; Yu, Y; Zeng, Z; Zheng, K; Zhu, L; Zuo, W | 1 |
| Cha, SI; Choi, JE; Do, SK; Hong, MJ; Jeong, JY; Jin, CC; Jung, DK; Kang, HG; Kim, CH; Lee, EB; Lee, J; Lee, SY; Lee, WK; Park, JY; Seok, Y; Shin, KM; Yoo, SS | 1 |
| Bradley, JD; Curran, WJ; Eaton, BR; Johnson, DW; Kavadi, VS; Koprowski, C; Masters, G; Meng, J; Narayan, S; Nedzi, L; Pugh, SL; Robinson, C; Wynn, RB | 1 |
| Asada, K; Enomoto, N; Fujisawa, T; Hayakawa, H; Imokawa, S; Inui, N; Karayama, M; Kuroishi, S; Masuda, M; Nakamura, Y; Suda, T; Suzuki, S; Toyoshima, M; Watanabe, H; Yamada, T; Yokomura, K | 1 |
| Atagi, S; Hamaguchi, M; Hirashima, T; Kawaguchi, T; Morishita, N; Nakao, K; Okamoto, N; Okishio, K; Omachi, N; Shiroyama, T; Suzuki, H; Tamiya, A; Tamiya, M; Tani, E; Yasue, T | 1 |
| Lai, FC; Li, X; Lin, JB; Lin, JW; Lin, M; Liu, B; Luo, RG; Qiu, ML; Tu, YR | 1 |
| Rades, D | 1 |
| Anota, A; Bigay-Game, L; Bonnetain, F; Dansin, E; Dauba, J; Debieuvre, D; Fiteni, F; Milleron, B; Molinier, O; Morin, F; Oster, JP; Pichon, E; Poudenx, M; Quoix, E; Souquet, PJ; Westeel, V; Wislez, M; Zalcman, G | 1 |
| Hosomi, Y; Mikura, S; Nagamata, M; Nakahara, Y; Okuma, Y; Takagi, Y; Takahashi, S; Watanabe, K | 1 |
| Diao, L; Komaki, R; Lin, SH; Liu, H; Potter, A; Proia, DA; Qiao, Y; Tailor, R; Wang, J; Wang, Y; Zhang, J | 1 |
| Belda-Iniesta, C; Boyer, M; Braiteh, F; Cosgriff, T; Gandara, DR; Govindan, R; Hirsch, FR; Isla, D; Phan, S; Rittmeyer, A; Ueda, M; Zvirbule, Z | 1 |
| Chu, T; Han, B; Jiang, L; Ying, W | 1 |
| Copur, MS; DeSpiegelaere, H; Ganti, AK; Huerter, MM; Kessinger, A; Ketcham, M; Kos, ME; Kruse, S; Marr, AS; Meza, JL; Radniecki, SE; Swenson, K; Tolentino, A | 1 |
| Behringer, DM; Eberhardt, W; Fischer, JR; Gauler, TC; Henrich, A; Hilger, RA; Jaehde, U; Joerger, M; Kimmich, M; Kloft, C; Ko, YD; Kopp, HG; Kraff, S; Mayer, F; Miller, MC; Moritz, B; Mueller, L; Reck, M; Reinmuth, N; Roessler, M; Salamone, SJ; von Pawel, J | 1 |
| Chatron, E; Leduc, C; Mennecier, B; Quoix, E; Zapata, E | 1 |
| Aragane, N; Enokizu, A; Fujii, S; Harada, T; Hirosako, S; Iwama, E; Kishi, H; Koga, Y; Kohrogi, H; Komiya, K; Morinaga, R; Nakanishi, Y; Okamoto, I; Otsubo, K; Saeki, S; Sakata, S; Semba, H; Yamaguchi, E; Yoneshima, Y | 1 |
| Ardizzoni, A; Barbera, S; Belani, C; Belvedere, O; Boni, L; Brunsvig, PF; Buffoni, L; Caroti, C; Ceschia, T; Cortinovis, D; D'Alessandro, V; de Marinis, F; Di Maio, M; Favaretto, A; Grimaldi, A; Grossi, F; Huber, RM; Loreggian, L; Morrica, B; Navarria, P; Parisi, S; Ricardi, U; Scagliotti, GV; Scolaro, T; Tiseo, M; Tixi, L | 1 |
| Boellaard, R; de Jong, EE; Dingemans, AC; Groen, HJ; Hoekstra, OS; Lambin, P; Leijenaar, RT; Smit, EF; Troost, EG; van der Noort, V; van Elmpt, W | 1 |
| Gao, L; Li, C; Liu, W; Qian, D; Shi, B; Wang, C; Wang, J; Yin, Y; Zhang, B; Zhang, H; Zhang, L; Zhu, J | 1 |
| Gajbhiye, V; Jain, NK; Kesharwani, P; Nag, M | 1 |
| Carroll, NM; Delate, T; Hornbrook, MC; Jain, RK; Kushi, LH; Menter, AR; Quinn, VP; Ritzwoller, DP; Sakoda, LC | 1 |
| Fang, Y; Sun, L; Xu, X; Ye, J; Zhang, Z; Zhou, G | 1 |
| Chen, Y; Nan, K; Qin, S; Ren, H; Sun, X; Wang, H; Xiao, G; Yang, C; Zhang, B; Zhang, Y | 1 |
| Fujiwara, Y; Goto, K; Horinouchi, H; Hozumi, H; Kanda, S; Kitazono, S; Kubo, E; Mizugaki, H; Nokihara, H; Shiraishi, H; Sunami, K; Tamura, T; Tanaka, A; Utsumi, H; Yamamoto, N | 1 |
| Belani, CP; Chakraborty, BC; Khamar, BM; Modi, RI | 1 |
| Boyer, M; Braiteh, F; Cosgriff, T; De Braud, F; Hsu, J; Kaen, D; Kingsley, CD; Lawler, W; Lena, H; Lowe, T; Mekhail, T; Novello, S; Phan, S; Schütte, W; Wakelee, H; Zvirbule, Z | 1 |
| Hu, K; Huang, X; Si, X; Wang, H; Wang, M; Xu, Y; Zhang, L; Zhang, X; Zhao, J; Zhong, W | 1 |
| Chen, F; Chen, Y; Hu, G; Huang, W; Li, F; Li, J; Xuan, A | 1 |
| Du, N; Kang, H; Li, F; Li, X; Qi, N; Zhao, H | 1 |
| Daly, M; Kelly, K; Tam, K | 1 |
| An, N; Cai, J; Li, Q; Li, Z; Niu, H; Zhang, Y; Zhao, Q | 1 |
| Behera, M; Belani, CP; Curran, WJ; Ernani, V; Higgins, KA; Khuri, FR; Owonikoko, TK; Pakkala, S; Pillai, RN; Ramalingam, SS; Saba, NF; Shin, DM; Steuer, CE | 1 |
| Gajra, A | 1 |
| Ebara, T; Hisada, T; Imai, H; Kaira, K; Kotake, M; Matsuura, M; Minato, K; Ochiai, M; Saito, R; Saitoh, JI; Sakurai, R; Sunaga, N; Tomizawa, Y; Yoshii, A | 1 |
| Augspurger, ME; Bogart, JA; Bosch, W; Bradley, JD; Choy, H; Chun, SG; Dobelbower, MC; Galvin, JM; Hu, C; Iyengar, P; Kavadi, VS; Komaki, RU; MacRae, RM; Narayan, S; Paulus, R; Raben, A; Robinson, CG; Schild, SE; Timmerman, RD; Wynn, RB | 1 |
| Jiang, P; Li, J; Li, T; Sun, R; Yi, W | 1 |
| Chisaki, Y; Nakamura, N; Yano, Y | 1 |
| Diao, T; Feng, F; Hou, R; Huhe, M; Liu, S; Nan, G; Sun, X; Tang, H; Wang, B; Wang, L; Wu, B; Zhang, Y; Zhang, Z; Zhu, Y | 1 |
| Adjei, AA; Garces, YA; Graham, DL; Hillman, SL; Jett, JR; McGinnis, WL; Ross, HJ; Schild, SE; Tan, AD | 1 |
| Al-Khafaji, AS; Davies, MP; Field, JK; Gosney, JR; Koffa, M; Liloglou, T; Marcus, MW; Risk, JM; Shaw, RJ | 1 |
| Faria, C; Force, RW; Margunato-Debay, S; Patel, MB; Peterson, T; Pugmire, BA; Weiss, J | 1 |
| Chang, JT; Hui, RL; Millares, M; Rashid, N; Schottinger, JE; Spence, MM | 1 |
| Bi, N; Chen, D; Chen, M; Chen, W; Du, L; Feng, Q; He, J; Hui, Z; Jiang, W; Li, J; Liang, J; Liu, L; Lv, C; Lv, J; Shi, A; Shyr, Y; Wang, L; Wang, W; Wang, X; Wu, S; Xiao, Z; Xu, Y; Yin, W; Zhang, H; Zhang, T; Zhao, L; Zhou, Z | 1 |
| Jia, X; Song, J; Yan, H; Zhang, Z | 1 |
| Chuang, JC; Das, M; Diehn, M; Huang, J; Liang, Y; Neal, JW; Stehr, H; Wakelee, HA | 1 |
| Arita, KI; Doi, M; Hattori, N; Kitaguchi, S; Kondo, T; Murakami, I; Nakano, K; Sakurai, J; Yamasaki, M | 1 |
| Chewaskulyong, B; Fukuoka, M; Haddad, V; Han, B; Ichinose, Y; Margono, B; Mok, TS; Ohe, Y; Rukazenkov, Y; Saijo, N; Sunpaweravong, P; Thongprasert, S; Wu, YL; Yang, JC; Yang, JJ; Young, H | 1 |
| Brugnara, S; Caffo, O; Caldara, A; Dipasquale, M; Ferro, A; Frisinghelli, M; Maines, F; Murgia, V; Trentin, C; Valduga, F; Veccia, A | 1 |
| Chen, X; Liao, Y; Lin, X; Long, D; Shen, F; Wu, Y; Yu, T | 1 |
| Fang, Q; Gong, H; Hu, Z; Li, H; Ma, Y; Yang, S; Zhao, M | 1 |
| Han, J; Li, K; Liang, Y; Tian, B; Wang, L; Wu, Z; Zhang, J | 1 |
| Apeler, H; Beier, R; Carrigan, PE; Dittmer, F; El Sheikh, S; Golfier, S; Jautelat, R; Kneip, C; Kopitz, C; Kreft, B; Lange, C; Leder, G; Lerchen, HG; Linden, L; Mclean, K; Müller, J; Pena, C; Schuhmacher, J; Stelte-Ludwig, B; Tebbe, J; von Ahsen, O; Willuda, J; Ziegelbauer, K | 1 |
| Belani, CP; Gable, PS; La Rocca, RV; Perry, MC; Ramalingam, S; Rinaldi, D; Tester, WJ | 1 |
| Chen, Y; Hyrien, O; Keng, PC; Pandya, KJ; Zhang, H | 1 |
| Ishida, T; Kataoka, K; Matsuura, M; Miyahara, E; Miyata, Y; Mukaida, H; Okada, M; Okita, R; Okumichi, T; Seno, N; Shimizu, K; Watari, M; Yamashita, Y | 1 |
| Ciuleanu, TE; Dediu, M; Eisenfeld, AJ; Heigener, D; Langer, CJ; Leśniewski-Kmak, K; Mikhailov, SM; O'Byrne, KJ; Oldham, FB; Orlov, SV; Ross, HJ; Sandalic, L; Singer, JW; Smakal, M; Socinski, MA | 1 |
| Agasthian, T; Eng, P; Fong, KW; Foo, KF; Hee, SW; Hsu, AA; Koong, HN; Leong, SS; Lim, WT; Tan, EH; Wee, JTs; Yap, SP | 1 |
| Almendros, P; Blasco, A; Bremnes, RM; Camps, C; Gavilá, J; Iranzo, V; Sirera, R | 1 |
| Cueva, J; Curiel, T; García-González, J; Graña, B; Lamas, MJ; López-López, R | 1 |
| Bandstra, B; Bilynsky, BT; Bondarenko, IN; Eisenfeld, AJ; Ganul, VL; Hotko, YS; Kostinsky, IY; O'Brien, ME; Oldham, FB; Popovich, AY; Sandalic, L; Sandler, AB; Singer, JW; Socinski, MA; Tomova, A | 1 |
| Bukowski, RM; Cogswell, J; Fidias, P; George, S; Kasimis, BS; Schwarzenberger, P; Shapiro, GI | 1 |
| Ahn, JS; Ahn, MJ; Ahn, YC; Han, J; Hwang, IG; Kim, J; Lee, S; Park, BB; Park, K; Shim, YM | 1 |
| Au, JL; Bekaii-Saab, T; Eng, C; Grever, M; Jensen, R; Murgo, AJ; Otterson, GA; Villalona-Calero, MA; Weber, F; Wei, Y; Wientjes, MG; Yeh, TK; Young, D; Zhang, Y | 1 |
| Furuiye, M; Inase, N; Ishiwata, N; Jin, Y; Miyake, S; Miyashita, Y; Takano, S; Yoshizawa, M; Yoshizawa, Y | 1 |
| Buhr, HJ; Loddenkemper, C; Pohlen, U; Schellhaas, E; Schmittel, A | 1 |
| Chen, HQ; He, WZ; Li, ZM; Liao, ML; Lu, S; Wang, JJ; Xiang, JQ; Zhang, J; Zhou, XY; Zhou, Z | 1 |
| Al-Adhami, M; Albert, G; Gravenor, D; Hirsh, V; Krieg, AM; Leichman, CG; Manegold, C; Mezger, J; Readett, D; Woytowitz, D | 1 |
| Algara, M; Fernández-Velilla, E; Foro, P; Lacruz, M; López, JL; Lozano, J; Membrive, I; Quera, J; Reig, A; Rodríguez, N; Sanz, X | 1 |
| Aggarwal, AN; Singh, N | 1 |
| Cai, Y; Chu, Y; Dermawan, K; Jin, M; Liu, R; Xiong, S; Xu, L; Zhang, L; Zhang, Y; Zheng, H | 1 |
| Bobokova, J; Calles Blanco, A; Custodio Carretero, AB; Díaz-Rubio García, E; García Paredes, B; García Sáenz, JA; González Larriba, JL; Hernando Trancho, F; Rodríguez Lajusticia, L | 1 |
| Azim, H; Azim, HA; Elattar, I; Ganti, AK; Loberiza, FR; Mok, T | 1 |
| Besse, B; Le Chevalier, T | 1 |
| Gillenwater, HH; Green, MR; Harpole, DH; Herndon, JE; Johnson, EA; Johnstone, DW; Maddaus, MA; Schilsky, RL; Strauss, GM; Sugarbaker, DJ; Vokes, EE; Watson, DM | 1 |
| Alessandroni, P; Baldelli, AM; Casadei, V; Catalano, G; Catalano, V; Dennetta, D; Fedeli, SL; Giordani, P; Graziano, F; Rossi, D; Ugolini, M | 1 |
| Kunitoh, H; Nokihara, H; Ohe, Y; Sekine, I; Tamura, T; Yamada, K; Yamamoto, H; Yamamoto, N | 1 |
| Bunn, PA; Dziadziuszko, R; Gajapathy, S; Hirsch, FR; Lin, M; O'Neill, V; Skokan, M; Varella-Garcia, M; Xiao, Y | 1 |
| Fujiwara, H; Horiba, A; Ishiguro, T; Minatoguchi, S; Sawa, T; Yoshida, T | 1 |
| Becker, M; Fichtner, I; Hammer, S; Hoffmann, J; Merk, J; Rolff, J; Sommer, A; Soong, R | 1 |
| Brenner, D; Cease, K; Correa, CR; Hayman, J; Kalemkerian, GP; Kong, FM; Lyons, S; Wang, L; Zhao, L | 1 |
| Bonomi, PD; Cohen, G; De Braud, F; Eberhardt, WE; Herbst, RS; Heymach, JV; Johnson, BE; Krebs, AD; Paz-Ares, L; Ranade, AA; Sandler, AB; Sebastian, M; Stewart, DJ; Trigo, JM; Vasselli, J | 1 |
| Kamiyama, Y; Kano, Y; Kobayashi, H; Kodama, T; Mori, K | 1 |
| Aizawa, H; Azuma, K; Hattori, S; Ikeda, J; Itoh, K; Kage, M; Kawahara, A; Kuwano, M; Sasada, T; Takamori, S; Yamada, A | 1 |
| Halle, J; Lee, CB; Limentani, S; Moore, DT; Rivera, MP; Rosenman, JG; Socinski, MA; Stinchcombe, TE | 1 |
| Borghaei, H; Cohen, R; Langer, CJ; Litwin, S; Millenson, M; Mintzer, D; Rovito, M; Ruth, KJ; Seldomridge, JS; Treat, J; Tuttle, H | 1 |
| Green, MR; Herndon, JE; Hodgson, LD; Lynch, TJ; Mauer, AM; Stinchcombe, TE; Vokes, EE | 1 |
| Du, J; Hu, D; Li, L; Liu, Y; Ma, D; Shen, H; Wang, P; Wang, X; Wang, Y; Wei, JM | 1 |
| Fujita, Y; Fukushima, M; Furuse, K; Kawahara, M; Komuta, K; Kubota, K; Minato, K; Nishiwaki, Y; Ogawara, M; Teramukai, S | 1 |
| Ashkenazi, A; Carano, R; Fong, S; Jin, H; Koeppen, H; Lawrence, D; Ross, J; Schwall, R; Stern, H; Totpal, K; Yang, R; Zheng, Z | 1 |
| Gan, PP; Kavallaris, M | 1 |
| Azzoli, CG; Brahmer, JR; Fogle, M; Ginsberg, M; Kris, MG; Miller, VA; Milton, DT; Riely, GJ; Rizvi, NA; Rosen, N; Rudin, CM; Senturk, E; Seshan, VE; Sirotnak, FM; Solit, DB | 1 |
| Arnold, A; Crabb, SJ; Ellis, PM; Goss, G; Laurie, SA; Leighl, NB; Patsios, D; Powers, J; Sauerbrei, E; Seymour, L; Shepherd, FA | 1 |
| Chouaid, C; Freitag, L; Gibbs, D; Jameson, MB; Lafitte, JJ; Mainwaring, PN; McKeage, MJ; Quoix, E; Reck, M; Rosenthal, MA; Serke, M; Sullivan, R; Von Pawel, J | 1 |
| Liu, YG; Shen, HC; Wang, XW | 1 |
| Bergström, S; Friesland, S; Hallqvist, A; Lödén, B; Nyman, J; Sederholm, C; Seke, M; Thaning, L; Wagenius, G | 1 |
| Barnett, J; Cuthbertson, A; Morrison, MS; Ricketts, SA; Tessier, J; Wedge, SR | 1 |
| Halle, J; Hayes, DN; Lee, CB; Moore, DT; Morris, DE; Rivera, MP; Rosenman, JG; Socinski, MA; Stinchcombe, TE | 1 |
| Choy, H; Curran, W; Demas, WF; Ettinger, DS; Jain, AK; Moughan, J; Whipple, G | 1 |
| Ahn, SJ; Cho, KH; Han, JY; Kim, HT; Kim, KS; Kim, YC; Koom, WS; Lee, JS; Moon, SH; Pyo, HR | 1 |
| Barlési, F; Berard, H; Chouaïd, C; Corre, R; Fournel, P; Le Caer, H; Marin, B; Tillon, J; Vergnenègre, A; Vernejoux, JM | 1 |
| Jo, UH; Jung, HY; Kim, YH; Park, KH; Whang, YM | 1 |
| Arao, T; Fujiwara, Y; Fukui, T; Kato, T; Kawaishi, M; Koizumi, F; Kunitoh, H; Nishio, K; Nokihara, H; Ohe, Y; Sekine, I; Shimoda, Y; Tamura, T; Watabe, T; Yamada, K; Yamamoto, N | 1 |
| Colson, YL; Gaffey, A; Grinstaff, MW; Griset, AP; Liu, R; Walpole, J | 1 |
| Bordoni, R; Dobbs, TW; Levine, MA; Saleh, MN; Socinski, MA; Stella, PJ; Trent, DF; Zehngebot, LM | 1 |
| Ansari, RH; Detterbeck, FC; Edelman, MJ; Gralla, RJ; Jahan, TM; Luketich, JD; Monberg, M; Moore, DT; Obasaju, CK; Peng, G; Rivera, MP; Socinski, MA | 1 |
| de Moraes, E; de Moraes, JL; Duarte, ML; Ferreira, CG; Hainaut, P; Pontes, E; Schluckebier, L | 1 |
| Cwiertka, K; Grygarkova, I; Hajduch, M; Klein, J; Kolek, V; Langova, K; Mihal, V; Neoral, C | 1 |
| Brahmer, J; Dimery, I; Gray, R; Johnson, DH; Samant, M; Sandler, AB; Schiller, JH; Wang, LI | 1 |
| Ball, D; Campeau, MP; Drummond, E; Herschtal, A; Hogg, A; Mac Manus, M; Michael, M; Wheeler, G; Wirth, A | 1 |
| Bokemeyer, C; Corless, CL; Harlow, A; Heinrich, MC; Honecker, F; Kanz, L; Kollmannsberger, C; Kurek, R; Morich, J; Oechsle, K; Schittenhelm, MM; Störkel, S; Wong, KK | 1 |
| Carbone, DP; Choy, H; Csiki, I; Johnson, DH; Lu, B; Moretti, L; Morrow, JD; Mutter, R; Sandler, AB; Shyr, Y; Ye, F | 1 |
| Fujimoto, T; Koshiji, M; Nambu, Y; Yamamoto, N | 1 |
| Bao, QL; Chen, P; Dai, CH; Li, J; Li, XQ | 1 |
| Katz, A; Saad, ED | 1 |
| Azim, HA; Peccatori, FA; Scarfone, G | 1 |
| Imada, H; Korogi, Y; Miyaguni, Y; Morioka, T; Nakano, K; Narisada, H; Ohguri, T; Yahara, K | 1 |
| Khuri, FR; Ramalingam, SS | 1 |
| Edelman, MJ | 2 |
| Reck, M | 3 |
| Blakely, LJ; Blumenschein, G; Cardenal, F; Eisenberg, PD; Garland, L; Green, S; Gualberto, A; Haluska, P; Johnson, FM; Karp, DD; Langer, CJ; Novello, S; Paz-Ares, LG | 1 |
| Kunitoh, H; Saijo, N; Takeuchi, M | 1 |
| Hommura, F; Isobe, H; Kojima, T; Konishi, J; Nishimura, M; Oizumi, S; Yamazaki, K; Yokouchi, H | 1 |
| Fukuoka, M; Nakagawa, K; Saijo, N; Sekine, I; Takada, M; Tanigawara, Y; Yamamoto, N | 1 |
| Bral, S; De Grève, J; De Mey, J; Decoster, L; Fontaine, C; Ilsen, B; Meysman, M; Neyns, B; Schallier, D | 1 |
| Freitag, L; Gibbs, D; Jameson, MB; Mainwaring, PN; McKeage, MJ; Reck, M; Rosenthal, MA; Sullivan, R; Von Pawel, J | 1 |
| Manegold, C | 5 |
| Greco, FA; Spigel, DR | 1 |
| Berkovic, K; Eberhardt, WE; Gauler, T; Jawad, JA; Korfee, S; Krbek, T; Pöttgen, C; Stamatis, G; Stuschke, M; Teschler, H | 1 |
| Cao, Y; Chen, B; Cheng, H; Cheng, L; Feng, J; Ji, J; Li, F; Lu, Z; Ma, J; Qin, S; Sun, N; Sun, X; Zhou, Y | 1 |
| Adachi, M; Hirose, T; Kusumoto, S; Nakashima, M; Ogura, K; Ohmori, T; Ohnishi, T; Okuda, K; Shirai, T; Sugiyama, T; Yamaoka, T | 1 |
| Coltman, CA; Crowley, J; Fukuoka, M; Fukushima, M; Furuse, K; Gandara, DR; Gautschi, O; Kawaguchi, T; Kawahara, M; Kubota, K; Lara, PN; Lenz, HJ; Mack, PC; McLeod, HL; Moon, J; Ohe, Y; Saijo, N; Teramukai, S; Williamson, SK | 1 |
| Huwer, H; Leutz, M; Schäfers, HJ; Schlimmer, P; Sybrecht, G; Ukena, D | 1 |
| Bonomi, P; Langer, C; Lilenbaum, R; O'Brien, M; O'Byrne, K; Oldham, FB; Ross, HJ; Sandilac, L; Singer, JW; Socinski, M; Villaflor, VM | 1 |
| Kaji, A; Katayama, K; Kawahara, H; Mitsuhashi, J; Noguchi, K; Sugimoto, Y | 1 |
| Patel, SR; Shord, SS | 1 |
| Fujii, T; Hida, N; Kunikane, H; Naoki, K; Okamoto, H; Tsujimura, S; Watanabe, K | 1 |
| Ji, W; Lü, JM; Ou, GF; Ren, H; Wang, LH; Wang, XZ; Yin, WB; Zhou, ZM | 1 |
| Bedor, M; Burrows, W; Edelman, MJ; Krasna, MJ; Smith, R; Suntharalingam, M | 1 |
| Avallone, A; Chiuri, VE; Cioffi, R; Comella, P; Costanzo, R; De Cataldis, G; Filippelli, G; Franco, L; Greco, E; Maiorino, L; Mancarella, S; Palmeri, L; Putzu, C; Vessia, G | 1 |
| Choi, MK; Kim, JK; Kim, MJ; Lim, SJ | 1 |
| Adema, AD; Honeywell, RJ; Peters, GJ; van der Born, K | 1 |
| Chen, B; Cheng, H; Cheng, L; Feng, J; Lu, Z; Sun, N; Sun, X | 1 |
| Guo, C; Guo, Z; Jin, X; Qiu, L; Zhang, D | 1 |
| Coffey, MC; Mussio, JK; Nagashima, K; Parchment, RE; Sei, S; Shoemaker, RH; Tomaszewski, JE; Yang, QE | 1 |
| Ando, S; Iizasa, T; Ishikawa, A; Itakura, M; Kimura, H; Nakajima, T; Nishimura, H; Shingyoji, M | 1 |
| Endo, M; Igawa, S; Kaira, K; Murakami, H; Naito, T; Nakamura, Y; Ono, A; Shukuya, T; Takahashi, T; Tamiya, A; Tsuya, A; Yamamoto, N | 1 |
| Balius, TE; Belani, CP; Hershberger, PA; Kanterewicz, B; Owonikoko, TK; Ramalingam, SS | 1 |
| Bonomi, P; Girvan, AC; Govindan, R; Guba, SC; Hong, S; Obasaju, C; Patel, JD; Pennella, EJ; Socinski, MA | 1 |
| Bang, YJ; Heo, DS; Im, SA; Kim, DW; Kim, TY; Kim, YW; Lee, JS; Lee, SH; Oh, DY; Sun, JM | 1 |
| Feng, Z; Gough, D; Howell, SB; Yu, L; Zhao, G | 1 |
| Armour, AA; Chewaskulyong, B; Chu, DT; Duffield, EL; Fukuoka, M; Han, B; Ichinose, Y; Jiang, H; Margono, B; Mok, TS; Nishiwaki, Y; Ohe, Y; Saijo, N; Sunpaweravong, P; Thongprasert, S; Watkins, CL; Wu, YL; Yang, CH; Yang, JJ | 1 |
| Bryant, AS; Cerfolio, RJ; Talati, A | 1 |
| Basu, S; Faber, LP; Kim, AW; Liptay, MJ; Miller, C; Milman, S; Warren, WH | 1 |
| Belt, RJ; Boccia, RV; Brown, GL; Burris, HA; Caldwell, DC; Edelman, MJ; Englund, CW; Fidias, PM; Huberman, MS; Jones, M; Keck, JG; Kolevska, T; Lynch, TJ; Melnyk, O; Meng, L; Mills, GM; Rabin, MS; Sequist, LV; Temel, JS | 1 |
| Boral, AL; Eder, JP; Fidias, P; Geary, RS; Johnson, BE; Kwoh, TJ; Lynch, TJ; Pennell, NA; Shapiro, GI; Skarin, AT; Supko, JG | 1 |
| Aikawa, S; Kitada, K; Yamasaki, T | 1 |
| Cardenal, F; Cohen, RB; Demers, L; Eisenberg, PD; Garland, L; Gualberto, A; Haluska, P; Hixon, ML; Karp, DD; Langer, CJ; Leitzel, K; Lipton, A; Paz-Ares, LG; Pollak, MN; Terstappen, LW; Yin, D | 1 |
| Fukino, K; Fukuoka, M; Hasegawa, Y; Kaneda, H; Kawada, A; Miyazaki, M; Morinaga, R; Nakagawa, K; Okamoto, I; Satoh, T; Tanigawa, T; Ueda, S | 1 |
| Che, G; Gong, Y; Hou, M; Huang, M; Li, L; Li, T; Li, W; Liu, L; Liu, Y; Lu, Y; Ren, L; Tang, B; Wang, J; Xu, Y; Zhou, L; Zhu, J; Zou, B | 1 |
| Belani, CP | 12 |
| Bahleda, R; Cadranel, J; Ferte, C; Gomez-Roca, C; Loriot, Y; Moldovan, C; Soria, JC; Wislez, M | 1 |
| Abe, T; Inoue, A; Ishida, T; Kanbe, M; Maemondo, M; Nukiwa, T; Saijo, Y; Sakakibara, T; Sugawara, S; Usui, K; Watanabe, H | 1 |
| Ansari, R; Belani, CP; Catalano, RB; Comis, RL; Edelman, MJ; Gillenwater, HH; Gonin, R; Marinucci, DM; Obasaju, CK; Rowland, KM; Socinski, MA; Treat, JA | 1 |
| Arita, K; Awaya, H; Kajihara, T; Kashiwado, K; Matsuura, K; Mito, A; Nitta, T; Ohashi, N; Yamasaki, M | 1 |
| Fukuyama, C; Hashimoto, J; Kunitoh, H; Nakao, M; Nokihara, H; Ohe, Y; Ohki, E; Sekine, I; Tamura, T; Yamada, K; Yamamoto, N | 1 |
| Akagi, Y; Fujita, K; Ito, A; Ito, K; Kagemoto, M; Kashiwado, K; Kimura, T; Matsuura, K; Monzen, Y; Mori, M; Murakami, Y; Nagata, Y; Wadasaki, K; Yuki, S | 1 |
| Bamberg, M; Budach, W; Eschmann, SM; Friedel, G; Hehr, T; Spengler, W; Steger, V | 1 |
| Amour, E; Beckendorf, V; Bossard, N; Douillard, JY; Girard, N; Grunenwald, D; Milleron, B; Mornex, F; Quoix, E | 1 |
| Cormier, JN; Du, XL; Hardy, D; Liu, CC; Xia, R; Xing, Y | 1 |
| Asmar, L; Barrera, D; Boehm, KA; Jotte, R; Pritchard, S; Reynolds, C; Spira, AI; Weissman, C | 1 |
| Arnold, A; Ciuleanu, TE; Dediu, M; Ding, K; Ellis, PM; Fenton, D; Frymire, E; Gauthier, I; Goss, GD; Ho, C; Laberge, F; Laurie, SA; Lee, CW; Leighl, NB; Noble, J; Seymour, L; Shepherd, FA; Vincent, MD; Walde, D; Zukin, M | 1 |
| Argiris, AE; Belani, CP; Espinoza-Delgado, I; Frankel, P; Gandara, DR; Gitlitz, B; Koczywas, M; Maitland, ML; Ramalingam, SS; Thomas, S; Vokes, EE | 1 |
| Moon, W; Yang, SW | 1 |
| Batist, G; Hu, L; Kandouz, M; Loignon, M; Miao, W | 1 |
| Atoyan, R; Bao, R; Borek, M; Cai, X; DellaRocca, S; Forrester, J; Lai, CJ; Qian, C; Qu, H; Samson, M; Tao, X; Wang, DG; Wang, J; Xu, GX; Yin, L; Zhai, HX; Zifcak, B | 1 |
| Chirieac, LR; Colson, YL; Grinstaff, MW; Liu, R; Southard, E; Walpole, J; Wolinsky, JB | 1 |
| Inoue, F; Momosaki, N; Morizono, G; Takenaka, T; Tanaka, T; Tomisaki, S | 1 |
| Crinò, L; De Marinis, F; Gridelli, C; Liepa, AM; Peterson, P; Ricci, S; Rinaldi, M; Scagliotti, GV; Tonato, M; Zhao, YD | 1 |
| Ikeda, S; Suzuki, K; Takabe, K | 1 |
| Blumenschein, GR; Gladish, G; McGreivy, J; O'Rourke, T; Parson, M; Reckamp, K; Sandler, A; Stephenson, GJ; Sun, YN; Ye, Y | 1 |
| Kolb, MM; Kozloff, MF; Samant, M; Scappaticci, FA; Socinski, MA | 1 |
| Ansari, RH; Belani, CP; Chen, R; Edelman, MJ; Monberg, MJ; Obasaju, CK; Socinski, MA; Treat, J | 1 |
| Fujii, A; Hayashi, A; Hidaka, D; Hiyama, J; Ikeda, K; Koshizuka, H; Misumi, Y; Miyagawa, Y; Nakanishi, K; Nakatsubo, S; Omagari, J; Sanada, H; Sawamoto, R; Tomimitsu, S; Tsuru, M | 1 |
| Favaretto, AG; Magro, C; Pasello, G | 1 |
| Baba, K; Hasegawa, Y; Ichikawa, M; Imaizumi, K; Kataoka, K; Kondo, M; Kume, H; Matsumoto, S; Noda, Y; Shindo, Y; Shindoh, J; Suzuki, K; Suzuki, R; Takagi, K; Taniguchi, H; Tanikawa, Y | 1 |
| Harada, R; Isobe, K; Ito, H; Kobayashi, H; Takiguchi, Y; Tatsumi, K; Ueno, N; Uno, T; Watanabe, M | 1 |
| Brahmer, JR; Dahlberg, SE; Johnson, DH; Sandler, AB; Schiller, JH | 1 |
| Neal, JW | 1 |
| Hayase, K; Kimura, M; Morihata, K; Nakao, T; Okada, K; Usami, E; Yasuda, T; Yoshimura, T | 1 |
| Blumenschein, GR; Herbst, RS; Kim, ES; Lu, C; Lum, BL; Malik, M; Oh, YW; Papadimitrakopoulou, VA; Tran, HT; Zinner, RG | 1 |
| Awad, M; Dakhil, S; Harbison, CT; Hart, LL; Hermann, RC; Horak, CE; Khambata-Ford, S; Lynch, TJ; Weber, MR; Xu, LA | 1 |
| Dakhil, S; Dreisbach, L; Gorton, S; Heim, WJ; Hermann, RC; Iannotti, NO; Lynch, TJ; McCleod, M; Paschold, E; Patel, T; Pautret, V; Weber, MR; Woytowitz, D | 1 |
| Aebert, H; Al-Kamash, F; Bamberg, M; Budach, W; Dippon, J; Eschmann, SM; Friedel, G; Hehr, T; Kimmich, M; Kohlhaeufl, M; Kyriss, T; Pfannenberg, C; Spengler, W; Steger, V; Veit, S; Walles, T | 1 |
| Minami, H; Mukohara, T; Tamura, T; Yamada, K; Yamada, Y; Yamamoto, N | 1 |
| Besse, B; Blackhall, F; Hsu, CP; Khayat, D; Reese, D; Smit, E; Soria, JC; Wiezorek, J; Yang, X | 1 |
| Arrieta, O; Diaz-Romero, C; Flores-Estrada, D; Martínez, L; Michel Ortega, RM; Rodríguez, CM; Sánchez-Lara, K; Serna-Thomé, MG; Villanueva-Rodríguez, G | 1 |
| Imamura, F; Kawase, I; Komuta, K; Matsui, K; Mori, M; Osaki, T; Tanio, Y; Yokota, S | 1 |
| Huang, XE; Jiang, W; Li, C; Lin, Y; Shi, MQ; Shu, YQ; Sunh, WL; Ye, Z; Zhang, Q; Zhou, JN | 1 |
| Cai, YP; Lin, SJ; Xu, S | 1 |
| Abrão Miziara, JE; Albert, I; Arén, O; Balint, B; Barrios, CH; Cihon, F; Csollak, M; Cupit, L; De Marinis, F; Dimatteo, S; Grossi, F; Hanna, N; Keller, A; Krzakowski, M; Novello, S; Pereira, JR; Reck, M; Scagliotti, G; Thomas, M; von Pawel, J | 1 |
| Bunn, PA; Chansky, K; Crowley, JJ; Franklin, WA; Gandara, D; Ginsberg, RJ; Pisters, KM; Putnam, JB; Vallières, E | 1 |
| Santoni-Rugiu, E; Sørensen, JB; Vilmar, AC | 2 |
| Baas, P; Lee, SM; Wakelee, H | 1 |
| Belani, CP; Chen, R; Edelman, MJ; Monberg, MJ; Obasaju, CK; Socinski, MA; Treat, J | 1 |
| Bae, K; Bradley, JD; Byhardt, R; Choy, H; Fowler, J; Gore, E; Govindan, R; Graham, MV; Michalski, JM; Purdy, JA | 1 |
| Santoni-Rugiu, E; Sørensen, JB; Vilmar, A | 1 |
| Ansari, RH; Belani, CP; Catalano, RB; Chen, R; Comis, RL; Edelman, MJ; Gonin, R; Marinucci, DM; Monberg, MJ; Obasaju, CK; Socinski, MA; Treat, J | 1 |
| Arnold, A; Ciuleanu, T; Dediu, M; Ding, K; Ellis, PM; Fenton, D; Goodwin, R; Laberge, F; Laurie, SA; LeMaître, A; Seymour, L; Shepherd, FA; Vincent, M; Walde, D; Zukin, M | 1 |
| Antoniou, D; Bastas, A; Dimitroulis, J; Georgatou, N; Lolis, N; Marosis, K; Michalopoulou, P; Pappas, C; Provata, A; Stathopoulos, GP; Stathopoulos, J; Toubis, M; Tsoukalas, G; Veldekis, D; Yiamboudakis, P | 1 |
| Chen, Y; Fang, X; Hao, J; Luo, J; Sha, X; Shi, Y; Yu, S; Zhang, W | 1 |
| Bradley, JD; Byhardt, R; Choy, H; Fowler, J; Gore, E; Govindan, R; Graham, MV; Michalski, JM; Moughan, J; Purdy, JA | 1 |
| Fukuoka, M; Hausheer, F; Kudoh, S; Masuda, N; Matsui, K; Nakagawa, K; Negoro, S; Ohashi, Y; Takeda, K; Yamamoto, N; Yoshimura, N | 1 |
| Azuma, A; Gemma, A; Kudoh, S; Kuribayasi, H; Minegishi, Y; Mizutani, H; Seike, M; Sudoh, J; Yoshimura, A | 1 |
| An, SJ; Chen, HJ; Chen, ZH; Cheng, H; Dong, S; Guo, AL; Lin, QX; Wu, YL; Zhang, XC; Zhang, YF | 1 |
| Fang, Q; Li, P; Ou, W; Sun, HB; Wang, SY; Yang, H; Ye, X; Zhang, BB | 1 |
| Lv, M; Ren, S; Xu, J; Zhang, J; Zhang, L; Zhou, C; Zhou, S | 1 |
| Aguiló, R; Alberola, V; Alonso, G; Astudillo, J; Borro, JM; Camps, C; Felip, E; González-Larriba, JL; Guijarro, R; Hermosilla, E; Isla, D; Maestre, JA; Massuti, B; Morán, T; Padilla, J; Rodríguez-Paniagua, JM; Rosell, R; Sánchez, JJ; Sánchez-Palencia, A; Torres, A | 1 |
| Bhar, P; Cheporov, SV; Iglesias, J; Makhson, AN; Manikhas, GM; Orlov, SV; Socinski, MA; Stroyakovsky, DL; Yablonsky, PK | 1 |
| Ganti, AK; Kessinger, A; Loberiza, FR | 1 |
| Alvarez-Avitia, MA; Aréchaga-Ocampo, E; Arrieta, O; Cerón-Lizárraga, TL; De la Garza, J; González-De la Rosa, CH; Hernández-Pedro, N; Martínez-Barrera, L; Ríos-Trejo, MA; Rojas-Marín, C; Vázquez-Manríquez, ME; Villanueva-Rodríguez, G | 1 |
| Ando, M; Fujita, Y; Gemma, A; Hagiwara, K; Harada, M; Harada, T; Hirano, H; Inoue, A; Isobe, H; Kinoshita, I; Kobayashi, K; Maemondo, M; Miyazawa, H; Morita, S; Nukiwa, T; Ogura, T; Oizumi, S; Okinaga, S; Saijo, Y; Sugawara, S; Tanaka, T; Yoshimori, K; Yoshizawa, H | 1 |
| Gao, ZW; Guo, CB; Zhang, DL | 1 |
| Ansari, RH; Catalano, RB; Chen, R; Comis, RL; Liles, DK; Marinucci, DM; Monberg, MJ; Obasaju, CK; Ribeiro, MJ; Socinski, MA; Treat, J | 1 |
| Chang, HW; Chen, BH; Chen, JY; Chen, WY; Chiu, CC; Chu, YC; Fang, K; Fu, TF; Huang, YL; Hwang, CC; Lee, JC; Lin, JC; Tsai, WH | 1 |
| Chiba, Y; Fukuoka, M; Hida, T; Imamura, F; Iwamoto, Y; Katakami, N; Kawahara, M; Kudo, S; Nakagawa, K; Nishimura, Y; Saka, H; Satouchi, M; Sawa, T; Semba, H; Seto, T; Takeda, K; Tsujino, K; Uejima, H; Yamamoto, N; Yokota, S | 1 |
| Leaw, SJ; Luo, J; Xu, Y; Zheng, D | 1 |
| Socinski, MA; Stinchcombe, TE | 1 |
| Li, P; Ma, Z; Wang, H; Wang, Q | 1 |
| Wang, Y; Yang, M; Zhao, J | 1 |
| Ball, DL; Binns, D; Ding, Z; Herschtal, A; Hicks, RJ; Hogg, A; Mac Manus, MP | 1 |
| Hanagiri, T; Nagashima, A; Nakanishi, K; Nakanishi, R; Sakata, H; Sugaya, M; Uchiyama, A; Uramoto, H; Yasumoto, K | 1 |
| Bogart, J; Dipetrillo, T; Garst, J; Graziano, S; Green, MR; Gu, L; Jänne, PA; Ready, N; Vokes, EE; Wang, X | 1 |
| Dahlberg, S; Hambleton, J; Johnson, DH; Kolb, MM; Sandler, A; Schiller, J; Wang, L; Yi, J | 1 |
| Chen, H; Li, C; Pan, Y; Sun, Y; Wang, Q; Yang, S | 1 |
| Bischoff, HG; Chouaid, C; de Castro Carpeño, J; Heigener, DF; Mueller, E; Schmidt, E; Stanisic, S; Vergnenègre, A; Walzer, S | 1 |
| DeCamp, MM; Flickinger, JC; Medford-Davis, LN; Recht, A; Schaefer, E; Varlotto, JM | 1 |
| Cappell, KM; Larson, B; Sciaky, N; Whitehurst, AW | 1 |
| Bradley, JD; Chang, AJ | 1 |
| Monberg, MJ; Ortuzar, WI; Peng, G; Saxman, SB; Zinner, RG | 1 |
| Arita, K; Awaya, H; Ikegami, Y; Kajihara, T; Mito, A; Nitta, T; Ohashi, N; Yamasaki, M | 1 |
| Chen, L; Wang, X; Wei, Y; Zheng, H; Zhu, Z | 1 |
| Koga, T; Maehara, Y; Nakanishi, Y; Sueishi, K; Takayama, K; Takeshita, M; Yano, T | 1 |
| Argiris, A; Belani, CP; Championsmith, T; Epperly, MW; Gooding, W; Greenberger, JS; Kane, K; Liggitt, D; Luketich, JD; Pennathur, A; Petro, D; Ramalingam, SS; Tarhini, AA; Zhang, X | 1 |
| Bafaloukos, D; Bakogiannis, C; Boukovinas, J; Dimopoulos, MA; Eleftheraki, AG; Fountzilas, G; Kalofonos, HP; Katirtzoglou, N; Kosmidis, PA; Lambaki, S; Pectasides, D; Pentheroudakis, G; Samantas, E; Skarlos, D; Syrigos, KN | 1 |
| Der, CJ; Roberts, PJ; Socinski, MA; Stinchcombe, TE | 1 |
| Albain, KS; Atkins, JN; Chansky, K; Crowley, JJ; Dakhil, SR; Franklin, WA; Gandara, DR; Herbst, RS; Hirsch, FR; Kelly, K; Kim, ES; Mack, PC; Redman, M | 1 |
| Aita, M; Cappuzzo, F; de Marinis, F; Douillard, JY; Gridelli, C; Grossi, F; Kubota, K | 1 |
| Dhand, R; Guntur, VP; Guo, JJ; Selting, K; Waldrep, JC | 1 |
| Albain, K; Bae, K; Curran, WJ; Gore, EM; Komaki, R; Machtay, M; Movsas, B; Paulus, R; Sause, WT | 1 |
| Agelaki, S; Androulakis, N; Bozionelou, V; Georgoulias, V; Hatzidaki, D; Kalbakis, K; Kalykaki, A; Kotsakis, A; Saridaki, Z; Vamvakas, L; Vardakis, N | 1 |
| Hara, M; Ishiwata, T; Koyama, R; Muraki, K; Shibayama, R; Shukuya, T; Takahashi, K | 1 |
| Bagust, A; Boland, A; Brown, T; Dickson, R; Dundar, Y; Hockenhull, J; Oyee, J; Proudlove, C; Ramani, VS | 1 |
| Erson-Bensan, AE; Keller, JA; Petty, EM | 1 |
| Ando, M; Asami, K; Fukuoka, M; Hirashima, T; Ikeda, N; Iwamoto, Y; Kudoh, S; Kurata, T; Miyazaki, M; Morita, S; Nakagawa, K; Okamoto, I; Saka, H; Satouchi, M; Sawa, T; Seto, T; Takeda, K; Tamura, K; Yamamoto, N; Yoshioka, H | 1 |
| Katori, N; Kunitoh, H; Laird, NM; Minami, H; Ohe, Y; Ohnami, S; Saijo, N; Saito, Y; Sakamoto, H; Sato, Y; Sawada, J; Tamura, T; Yamamoto, N; Yoshida, T | 1 |
| Brahmer, JR; Dahlberg, SE; Gray, RJ; Johnson, DH; Perry, MC; Sandler, A; Schiller, JH | 1 |
| Gemma, A; Inage, S; Ise, Y; Katayama, S; Obayashi, M | 1 |
| Chen, L; Jiao, SC; Li, J; Lv, YL; Shi, Y; Sun, Q; Wang, LX | 1 |
| Patlak, M | 1 |
| Blakely, J; Dolled-Filhart, M; Green, S; Gualberto, A; Hixon, ML; Karp, DD; Langer, CJ; Li, D; Novello, S; Paz-Ares, LG; Pollak, MN | 1 |
| Azzoli, C; Fang, L; Faoro, L; Hainsworth, JD; Huang, JE; Karlin, D; Russell, K | 1 |
| Hirabayashi, N; Kitano, M; Nakagawa, K; Okamoto, I; Takeda, M | 1 |
| Fujita, S; Fukuhara, A; Hata, A; Hatachi, Y; Kaji, R; Katakami, N; Kim, YH; Masago, K; Mio, T; Mishima, M | 1 |
| Inoue, M; Nagashima, A; Nakanishi, K; Nakanishi, R; Osaki, T; Sakata, H; Uchiyama, A; Uramoto, H; Yasumoto, K; Yoshimatsu, T | 1 |
| Feng, R; Ma, L; Meng, X; Yu, JM; Yue, JB; Zhang, HQ | 1 |
| Al-Khater, AM; Rasul, KI | 1 |
| Airoldi, M; Amoroso, D; Ardizzoia, A; Aurilio, G; Bajetta, E; Ballardini, P; Balzelloni, ML; Banna, GL; Barbieri, F; Barletta, E; Basso, U; Bernardini, I; Boni, C; Bordin, V; Bretti, S; Bria, E; Bronte, G; Brunetti, C; Buti, S; Capanna, L; Collovà, E; Colombo, A; Condemi, G; Cortinovis, D; Dambrosio, M; Di Fonzo, C; Di Lucca, G; Di Maio, M; Dima, G; Falzetta, A; Favaretto, A; Ferraù, F; Follador, A; Garetto, L; Gebbia, V; Genestreti, G; Gentile, AL; Giovanardi, F; Labianca, R; Lorusso, V; Mantovani, G; Martelli, O; Massari, F; Mazzoli, M; Menis, J; Michetti, G; Mordenti, P; Mucciarini, C; Munao, S; Nacci, A; Novello, S; Pogliani, C; Procopio, G; Riccardi, F; Rizzato, S; Rossi, A; Rosti, G; Russo, P; Saladino, T; Salesi, N; Santangelo, D; Sava, T; Savarino, A; Spinnato, F; Tiseo, M; Tomassi, O; Tondulli, L; Tonini, G; Turano, S; Valerio, MR; Verderame, F; Zanelli, F; Zanon, E | 1 |
| Agustí, C; Campayo, M; Casas, F; Ferrer, F; Jeremic, B; Lomeña, F; Maria Gimferrer, J; Sanchez, M; Viñolas, N | 1 |
| Fukuda, M; Kasai, T; Kinoshita, A; Kohno, S; Masuda, N; Nagashima, S; Nakamura, Y; Nakatomi, K; Oka, M; Soda, H; Soejima, Y; Takatani, H; Tsukamoto, K | 1 |
| Ahn, YC; Choi, JY; Choi, YS; Kim, HK; Kim, J; Kim, K; Lee, KS; Park, K; Shim, YM | 1 |
| Agelaki, S; Georgoulias, V; Markomanolaki, H; Mavroudis, D; Mela, M; Spiliotaki, M | 1 |
| Hida, T; Hirashima, T; Horai, T; Horio, Y; Kobayashi, K; Nishio, M; Shi, MM; Tamiya, M; Tanii, H; Yamamoto, N | 1 |
| Asmar, L; Kobina, S; Neubauer, MA; Pritchard, S; Reynolds, CH; Weissman, CH | 1 |
| Belmont, LD; Berry, L; Fairbrother, WJ; Kassees, R; Malek, M; Sampath, D; Tan, N; Yue, P; Zha, J | 1 |
| Wang, XY; Zhao, YL | 1 |
| Biesma, B; Dalesio, O; Groen, HJM; Slaets, JPJ; Smit, EF; Smit, HJM; Stigt, JA; van Felius, CL; van Putten, JWG; Vincent, A; Wymenga, ANM | 1 |
| An, SJ; Chen, ZH; Cheng, H; Dong, S; Wu, YL; Zhang, XC; Zhang, YF | 1 |
| Bertino, E; Grever, M; Otterson, GA; Ross, P; Villalona-Calero, MA | 1 |
| Chang, KT; Chen, JT; Chen, YM; Chiu, CH; Hsiao, SY; Lai, CL; Stewart, DJ; Tsai, CM | 1 |
| Allen, PK; Chang, JY; Cox, JD; Gillin, M; Komaki, R; Liao, Z; Lu, C; Sejpal, S; Tsao, A; Wei, X | 1 |
| Jahnke, K; Keilholz, U; Lüftner, D; Schmittel, A; Thiel, E | 1 |
| Bepler, G; Chen, DT; Chiappori, A; Dilling, TJ; Greenberg, H; Haura, E; Hazelton, T; Simon, G; Stevens, C; Tanvetyanon, T; Wagner, H; Walsh, F; Williams, C | 1 |
| Ando, M; Fukuoka, M; Iwamoto, Y; Katakami, N; Kurata, T; Maeda, M; Nakagawa, K; Nakano, T; Saito, H; Takeda, K | 1 |
| Antoniou, D; Dimitroulis, J; Marosis, K; Michalopoulou, P; Stathopoulos, GP; Stathopoulos, J | 1 |
| Corona, M; Falbo, T; Lanzetta, G; Nardoni, C; Restuccia, MR; Rozzi, A | 1 |
| Beck, JT; Blumenschein, GR; Hei, YJ; Kabbinavar, F; Kracht, K; Lakshmaiah, K; Menon, H; Mok, TSK; Reckamp, K; Schwartzberg, L; Sikorski, R; Stephenson, J; Sun, YN | 1 |
| Dai, Y; Jiang, W; Wei, R; Yuan, J | 1 |
| Behrens, RJ; Cannon, MW; Friedman, EL; Gross, GG; Hillman, SL; Jatoi, A; Mc Kean, H; Rowland, KM; Sborov, MD; Stella, PJ | 1 |
| Ducoloné, A; Fraisse, P; Mennecier, B; Quoix, E | 1 |
| Dosaka-Akita, H; Inoue, T; Kato, M; Katoh, N; Kikuchi, J; Kinoshita, I; Nishimura, M; Oizumi, S; Onimaru, R; Sakakibara-Konishi, J; Shinagawa, N; Shirato, H | 1 |
| Hotta, K; Kiura, K; Matsuo, K; Nagio, T | 1 |
| Shi, A; Wang, Y; Xia, T; Yu, R; Zhu, G | 1 |
| Colson, YL; Grinstaff, MW; Griset, AP; Khullar, OV; Liu, R; Wade, JE; Zubris, KA | 1 |
| Azzoli, CG; Heelan, RT; James, LP; Kris, MG; Miller, VA; Moore, E; Ng, KK; Paik, PK; Riely, GJ; Rizvi, NA; Sima, CS | 1 |
| Blackstock, AW; Bogart, JA; Crawford, JC; Gu, L; Morano, K; Salama, JK; Socinski, MA; Stinchcombe, TE; Vokes, EE; Wang, X | 1 |
| Bai, H; Han, B; Qian, J; Shen, J | 1 |
| Eller, J; Furák, J; Hideghéty, K; Kahán, Z; Maráz, A; Molnár, J; Pálföldi, R; Szántó, E; Thurzó, L; Tiszlavicz, L | 1 |
| Au, JS; Chang, GC; Cheng, AC; Tsai, CM; Wu, YL; Zhou, C | 1 |
| Green, M; Hodgson, L; Masters, GA; Shea, T; Vokes, E; Wang, X | 1 |
| Abrams, RA; Basu, S; Batus, M; Bonomi, P; Faber, LP; Fidler, MJ; Gielda, BT; Liptay, M; Marsh, JC; Warren, WH; Zusag, TW | 1 |
| Adjei, AA; Dy, GK; Hylander, B; Repasky, E; Salavaggione, OE; Shao, H; Tan, W; Tang, H; Yu, C | 1 |
| Bai, C; Gu, A; Guo, S; Han, B; Jiang, L; Jin, X; Liu, W; Luo, Y; Shen, J; Wang, H; Xiu, Q; Zhang, Y; Zhao, Y; Zhou, J; Zhuang, Z | 1 |
| Advani, SH; Bapna, A; Digumarti, R; Doval, DC; Julka, PK; Madhavan, J; Malik, R; Nag, S; Parikh, PM; Patil, S; Raman, G; Ranade, AA; Varadhachary, A; Wang, Y | 1 |
| Kubota, K; Murakami, H; Nakagawa, K; Nogami, N; Ohe, Y; Okamoto, I; Ono, K; Yamamoto, N; Yamaya, H | 1 |
| Agelaki, S; Ardavanis, A; Chandrinos, V; Christophyllakis, C; Georgoulias, V; Giassas, S; Karachaliou, N; Kotsakis, A; Pallis, AG; Polyzos, A; Samonis, G; Saridaki, Z; Syrigos, K; Vamvakas, L; Vardakis, N; Varthalitis, I | 1 |
| Chung, I; Duan, Z; Holleman, A; Kwak, B; Mizokami, A; Olsen, RR; Parissenti, A; Saijo, N; Voest, EE; Zetter, BR | 1 |
| Eschenbrenner, J; Hammer, S; Hoffmann, J; Klar, U; Mittelstaedt, K; Sommer, A; Winsel, S | 1 |
| Liu, T; Zhang, JQ; Zhang, L | 1 |
| Banković, D; Baskić, D; Ilić, N; Petrović, M | 1 |
| Chalfant, CE; Goehe, RW; Hawkins, AJ; Massiello, A; Mayton, EK; Mukerjee, P; Murudkar, CS; Park, MA; Pinkerman, RL; Shultz, JC; Wijesinghe, DS | 1 |
| Huang, XE; Jin, GF; Li, Y; Shen, HB; Xu, L | 1 |
| Arrieta, O; Bajetta, E; Benner, RJ; Boyer, M; Eberhardt, WE; Fowst, C; Hirsh, V; Meech, SJ; Middleton, G; Paz-Ares, L; Raats, J; Readett, D; Reiterer, P; Rosell, R; Saleh, M; Schiller, JH; Szczesna, A; Webb, RT | 1 |
| Jeremić, B; Miličić, B; Milisavljevic, S | 2 |
| Shepherd, FA | 3 |
| Armour, AA; Chao, TY; Chu, DT; Duffield, EL; Fukuoka, M; Jiang, H; Leong, SS; Mok, TS; Nakagawa, K; Rukazenkov, Y; Saijo, N; Speake, G; Sriuranpong, V; Sunpaweravong, P; Thongprasert, S; To, KF; Wu, YL; Yang, JC | 1 |
| Albain, KS; Besse, B; Blais, N; Chao, RC; Gervais, R; Hainsworth, JD; Hamm, JT; Kim, ST; Laskin, J; Lipton, A; Masters, GA; Natale, RB; Page, RD; Selaru, P | 1 |
| Blasco, A; Cabrera, A; Camps, C; Carrato, A; Gil, M; Gómez-Aldaraví, L; González-Larriba, JL; Guijarro, R; Iranzo, V; Jantus, E; Massuti, B; Provencio, M; Rossell, R; Sanmartín, E; Sirera, R; Velasco, A | 1 |
| Albert, I; Douillard, JY; Fan, X; Fandi, A; Heo, DS; Lara, PN; Losonczy, G; McKeage, MJ; Nakagawa, K; Reck, M; Scagliotti, G; von Pawel, J | 1 |
| Fujimoto, S; Fukuda, T; Furihata, T; Hase, I; Ishii, Y; Kikkawa, Y; Miyoshi, M; Okazaki, K; Takizawa, H; Yamada, I | 1 |
| Zekri, JM | 1 |
| Deng, AM; Liang, AB; Qu, YQ; Wang, H; Xiu, B; Zeng, HZ; Zhang, WJ | 1 |
| Asahina, H; Goto, Y; Kikkawa, H; Kunitoh, H; Nokihara, H; Ohe, Y; Ohki, E; Sekine, I; Shibata, T; Tamura, T; Tanai, C; Tanioka, M; Yamamoto, N | 1 |
| Bunn, PA; Camidge, DR; Camidge, R; Dziadziuszko, R; Eisen, T; Franklin, WA; Hirsch, FR; Kabbinavar, F; Martins, R; Richardson, F; Richardson, K; Rusk, J; Schnell, FM; Sternberg, DW; Varella-Garcia, M; Wacker, B | 1 |
| Reckamp, KL | 1 |
| Baudrin, L; Bennouna, J; Bigay-Game, L; Dansin, E; Dauba, J; Debieuvre, D; Ducoloné, A; Herman, D; Laporte, S; Lavolé, A; Lebitasy, MP; Milleron, B; Molinier, O; Moro-Sibilot, D; Oster, JP; Pichon, E; Poudenx, M; Quoix, E; Souquet, PJ; Tredaniel, J; Vaylet, F; Westeel, V; Zalcman, G | 1 |
| Borsellino, N; Cinieri, S; Colucci, G; Febbraro, A; Galetta, D; Gebbia, V; Maiello, E; Marzano, N; Montrone, M; Pappagallo, GL; Pisconti, S; Rinaldi, A; Rizzo, P; Sasso, N | 1 |
| Ando, M; Hasegawa, Y; Isa, S; Kawaguchi, T; Kubo, A; Nakagawa, K; Ou, SH; Shiraishi, J; Takada, M; Tsuji, T; Tsujino, K | 1 |
| Ahmed, S; Aswad, BI; Birnbaum, AE; Dipetrillo, TA; Ng, T; Ready, NE; Safran, HP | 1 |
| Fukushima, M; Furuse, K; Kawahara, M; Kubota, K; Origasa, H; Shinkai, T; Tada, H; Teramukai, S; Tokoro, A | 1 |
| Brown, KC; Gray, BP; Li, S; McGuire, MJ | 1 |
| Bai, J; Chen, F; Fu, S; Hou, J; Jin, Y; Liu, P; Meng, X; Sun, W; Wang, G; Yu, Y | 1 |
| Duffield, E; Fukuoka, M; Goto, K; Ichinose, Y; Itoh, Y; Jiang, H; McCormack, R; Mok, T; Negoro, S; Nishio, K; Ohe, Y; Saijo, N; Yamamoto, N | 1 |
| Chen, CP; Jablons, DM; Jahan, TM; Weinberg, VK; Yom, SS | 1 |
| Aultman, R; Carpeño, Jde C; Chouaid, C; Nuijten, MJ; Siebert, U; Vergnenègre, A; Walzer, S | 1 |
| Aljančić, IS; Banković, J; Jadranin, M; Marković, ID; Momčilović, M; Pešić, M; Ruždijić, S; Tanić, N; Tešević, VV; Todorović, NM; Vajs, VE; Vučković, I | 1 |
| Albert, I; Amler, L; Ashkenazi, A; Baker, N; Blackhall, F; Hei, YJ; Juhász, E; Kozielski, J; Márk, Z; Pan, Y; Pujol, JL; Smethurst, D; Soria, JC; Stern, H; Szima, B; Zatloukal, P | 1 |
| Armour, A; Chen, YM; Chu, DT; Duffield, E; Fukuoka, M; Kuo, HP; Lam, KC; Liao, M; Magill, P; Negoro, S; Saijo, N; Thongprasert, S; Wu, YL; Yang, JC | 1 |
| Berger, DP; Chen, Y; Krzakowski, MJ; Lizambri, R; Massuti, B; Otterson, GA; Schuette, W; Wei, H | 1 |
| Feenstra, K; Huang, Y; Jiang, W; Qian, CN; Resau, JH; Xue, C; Zhang, L; Zhao, HY; Zhao, YY | 1 |
| Exarchou, A; Georgakopoulos, CD; Makri, OE; Vasilakis, P | 1 |
| Fujioka, S; Haruki, T; Miwa, K; Nakamura, H; Takagi, Y; Taniguchi, Y; Yurugi, Y | 1 |
| Lv, PP; Ma, GH; Wang, LY; Wei, W; Yang, TY; Yue, H | 1 |
| Brekken, RA; Gazdar, AF; Girard, L; Greer, RM; Harran, P; Larsen, JE; Minna, JD; Peyton, M; Wang, L; Wang, X; Xie, Y | 1 |
| Colson, YL; Grinstaff, MW; Zubris, KA | 1 |
| Chu, Q; Jacobs, CD; Lopez-Anaya, A; Rodon, J; Rowinsky, EK; Takimoto, CH; Wakelee, HA | 1 |
| Hokoda, N; Kasahara, K; Kitamura, R; Miyazaki, M; Nakagawa, K; Nakayama, H; Ohyama, A; Okamoto, I; Satouchi, M; Seto, T; Takeda, K; Yamamoto, N; Yoshihara, E; Yoshioka, H | 1 |
| Chiba, Y; Fukuda, H; Fukuoka, M; Kokubo, M; Kudoh, S; Nakagawa, K; Nakanishi, Y; Negoro, S; Nishimura, Y; Tada, T; Tsujino, K | 1 |
| Cohen, EE; Faoro, L; Gao, F; Govindan, R; Karrison, T; Kozloff, M; Salgia, R; Subramanian, J; Szeto, L; Vokes, EE | 1 |
| Chen, J; Cheng, J; Ha, M; Sun, J; Tong, C; Wang, Y | 1 |
| Chen, F; Liu, Y; Sun, Y; Wu, X | 1 |
| Arrieta, O; Blake-Cerda, M; de la Garza, J; de la Mata, MD; Muñiz-Hernández, S; Villarreal-Garza, C; Zamora, J; Zavala, DG | 1 |
| Asmar, L; Boehm, KA; Carter, DL; Garfield, D; Hathorn, J; Ilegbodu, D; Mundis, R; Reynolds, C | 1 |
| Charoentum, C; Chewaskulyong, B; Permsuwan, U; Ruengorn, C; Thongprasert, S | 1 |
| Fushiki, S; Itoh, K; Kato, D; Shimada, J; Shimomura, M; Terauchi, K; Yaoi, T | 1 |
| Cheng, J; Cong, X; Ha, MW; Sun, J; Tong, CY; Wang, YD; Zhang, WL | 1 |
| Jiang, G; Li, J; Li, X; Li, Y; Liu, J; Wang, J; Yang, F; Zhao, H | 1 |
| Cai, JZ; Chai, XS; Deng, H; He, WF; Liao, GY; Long, SQ; Wang, B; Wu, WY; Zhang, HB | 1 |
| Bacoyiannis, C; Bafaloukos, D; Boukovinas, I; Dimopoulos, MA; Fountzilas, G; Kalofonos, HP; Kosmidis, PA; Pavlidis, N; Pectasides, D; Skarlos, D; Syrigos, K | 1 |
| Chu, H; Gao, G; Gui, T; Shi, J; Xu, Q; Zhao, L | 1 |
| Blackman, RK; Foley, KP; He, S; Koya, K; Liu, Y; Proia, DA; Sang, J; Sequeira, M; Smith, DL; Wada, Y; Ye, S; Zhang, C; Zhou, D | 1 |
| Li, L; Wang, M; Zhang, L; Zhao, X; Zhong, W | 1 |
| Fukuoka, M; Hida, T; Horai, T; Ichinose, Y; Kawahara, M; Kiura, K; Kudoh, S; Kunitoh, H; Matsui, K; Mori, K; Nakagawa, K; Negoro, S; Niho, S; Nokihara, H; Okamoto, H; Saijo, N; Sakai, H; Shinkai, T; Takeda, K; Yamamoto, N; Yokota, S; Yokoyama, A | 1 |
| Belinsky, SA; Dahlberg, SE; Fitzgerald, TJ; Hoang, T; Johnson, DH; Mehta, MP; Schiller, JH | 1 |
| Bekele, BN; Biernacka, A; Erez, B; Herbst, RS; Hosho, K; Jacoby, JJ; Jürgensmeier, JM; Komaki, R; Korshunova, MV; O'Reilly, MS; Ryan, A; Smith, PD; Takahashi, O; Wistuba, II | 1 |
| Ruan, L; Tzeng, CM; Whyte, D; Zhang, HL; Zheng, LM; Zhou, XW | 1 |
| Boulmay, BC; Jahangir, KS; Simpson, CE; Varughese, S | 1 |
| Bai, CX; Gu, AQ; Guo, SL; Han, BH; Jiang, LY; Jin, B; Jin, XQ; Liu, WC; Luo, Y; Shen, J; Shi, CL; Wang, HM; Xiu, QY; Zhang, Y; Zhao, YZ; Zhou, JY; Zhuang, ZX | 1 |
| Gao, Q; Wang, FY; Yu, H | 1 |
| Hou, M; Li, Z; Zeng, X | 1 |
| Jin, ZL; Li, K; Li, N; Liu, ZJ; Wang, J | 1 |
| Camidge, DR; Conkling, P; Doebele, RC; Kaiser, R; Otterson, GA; Stopfer, P; Traynor, AM; Wind, S; Zhao, Y | 1 |
| Gill, KK; Kaddoumi, A; Nazzal, S | 1 |
| Cho, JH; Choi, YS; Kim, HK; Kim, J; Kim, K; Shim, YM | 1 |
| Bi, N; Cao, J; Li, J; Li, W; Liang, J; Lv, J; Ou, G; Ren, H; Wang, L; Wu, S; Zhang, X; Zhou, Z | 1 |
| Jung, CK; Kang, JH; Kim, JO; Oh, JE; Shin, JY; Yoon, SA; Zhang, XH | 1 |
| Antoine, M; Beau-Faller, M; Bergot, E; Brambilla, E; Braun, D; Creveuil, C; de Fraipont, F; Debieuvre, D; Favrot, MC; Hainaut, P; Levallet, G; Milleron, B; Morin, F; Moro-Sibilot, D; Mounawar, M; Quoix, E; Richard, N; Rouquette, I; Westeel, V; Zalcman, G | 1 |
| Jin, W; Lou, LG; Xie, CY; Xu, YP | 1 |
| Iyoda, A; Jiang, SX; Kageyama, T; Masuda, N; Matsumoto, T; Nagashio, R; Ryuge, S; Saegusa, M; Sato, Y; Satoh, Y | 1 |
| Behrens, C; Correa, AM; Erasmus, JJ; Kalhor, N; Kim, ES; Lee, JJ; Pataer, A; Raso, MG; Roth, JA; Stewart, DJ; Swisher, SG; Vaporciyan, AA; Wistuba, II | 1 |
| Breitenbuecher, F; Guyot, M; Hoffarth, S; Höhn, Y; Meiler, J; Schuler, M; Wesarg, E | 1 |
| Chen, Y; Deng, X; Li, G; Liang, J; Peng, X; Zhao, J | 1 |
| Gao, Y; Li, X; Nong, J; Wang, J; Wang, Q; Yang, X; Zhang, H; Zhang, Q; Zhang, S | 1 |
| Chen, AB; Gray, SW; Schrag, D; Sharma, DB; Weeks, JC; Zhu, J | 1 |
| Bai, H; Chivukula, P; Clamme, JP; Co, E; Jiang, X; Jin, Y; Liu, X; Liu, Y; Taylor, WD; Tsang, KY; Wang, H; Wang, Y; Yang, D; Ying, W; Yu, L | 1 |
| Fang, WS; Tao, JY; Wang, SR; Zhang, SE; Zhao, Y; Zhou, D | 1 |
| Burrows, W; Choy, H; Edelman, MJ; Gore, E; Krasna, M; Paulus, R; Suntharalingam, M; Wilson, LD | 1 |
| Chang, JY; Cox, JD; Koay, EJ; Komaki, R; Lege, D; Mohan, R | 1 |
| Juergens, R; Levine, MN | 1 |
| Bhar, P; Bondarenko, I; Hirsh, V; Hon, JK; Iglesias, JL; Karaseva, NA; Makhson, AM; Okamoto, I; Renschler, MF; Socinski, MA; Vynnychenko, I; Zhang, H | 1 |
| Barlesi, F; Bondarenko, I; Chacko, R; Cuillerot, JM; Lu, H; Luft, A; Lynch, TJ; Neal, J; Reck, M; Sebastian, M; Serwatowski, P | 1 |
| Funai, K; Sekihara, K; Shiiya, N; Shimizu, K; Suzuki, K | 1 |
| Gemma, A; Hagiwara, K; Harada, M; Harada, T; Inoue, A; Isobe, H; Kato, T; Kinoshita, I; Kobayashi, K; Maemondo, M; Morita, S; Nukiwa, T; Oizumi, S; Okinaga, S; Saijo, Y; Sugawara, S; Yokomizo, Y; Yoshizawa, H | 1 |
| Mason, DP | 1 |
| Chang, KT; Chen, JT; Chen, YM; Chiu, CH; Hsiao, SY; Lai, CL; Tsai, CM | 1 |
| Barriger, RB; Bradley, JD; De Petris, L; Kim, TH; Marks, LB; Moreno, M; Palma, DA; Ramella, S; Rengan, R; Rodrigues, G; Senan, S; Stitt, L; Tsujino, K | 1 |
| Baker, M; Borkowski, R; DeSevo, C; Du, L; Gazdar, AF; Greer, R; Minna, JD; Pertsemlidis, A; Schageman, JJ; Subauste, MC; Suraokar, M; Wistuba, II; Yang, CR; Zhao, Z | 1 |
| Gődény, M; Láng, I; Nagy, T; Rubovszky, G; Szász, A | 1 |
| Banaclocha, NM; Blackhall, F; Ciuleanu, TE; Dediu, M; Galimi, F; Galiulin, R; Hei, YJ; Ichinose, Y; Kubota, K; McCoy, S; Papai-Szekely, Z; Park, K; Pirker, R; Scagliotti, GV; Spigel, DR; Sydorenko, O; Vynnychenko, I; Yao, B | 1 |
| Chang, WC; Chang, WT; Chen, JY; Chen, RF; Chiu, CC; Chou, HL; Chu, YC; Fong, Y; Lin, CL; Wang, HM; Wu, CY | 1 |
| Chen, J; He, J; Jiang, L; Li, B; Sun, G; Wang, L; Xiu, Q; Yu, H; Zhao, L | 1 |
| Baudrin, L; Cadranel, J; Coëtmeur, D; Duruisseaux, M; Monnet, I; Morère, JF; Morin, F; Moro-Sibilot, D; Mourlanette, P; Quoix, E; Soria, JC; Westeel, V; Wislez, M | 1 |
| Cui, Y; Huang, CB; Li, Y; Qi, DL; Wang, HQ; Wang, QS; Xin, L; Xu, L; Yang, YZ | 1 |
| Choi, EK; Chung, HK; Jeong, SY; Jung, J; Kang, HW; Lee, SW; Park, HJ; Park, SJ; Seo, MH; Song, SY | 1 |
| Bokemeyer, C; Cascorbi, I; Hartmann, JT; Heeger, S; Kollmannsberger, C; Mayer, F; Schittenhelm, MM | 1 |
| Brahmer, JR; Dahlberg, SE; Hoang, T; Johnson, DH; Sandler, AB; Schiller, JH | 1 |
| Asami, K; Atagi, S; Hirashima, T; Kawaguchi, T; Kawase, I; Kobayashi, M; Morishita, N; Nakao, K; Okamoto, N; Okishio, K; Sasada, S; Satomu, M; Shiroyama, T; Suzuki, H; Tamiya, A; Tamiya, M | 1 |
| Chu, Z; Huang, R; Jiang, J; Liang, X; Zhan, Q; Zhou, X | 2 |
| Cappell, KM; Maxfield, K; Scarbrough, M; Sinnott, R; Taus, P; Whitehurst, AW | 1 |
| Inal, A; Isikdogan, A; Kaplan, MA; Karakus, A; Kucukoner, M; Urakci, Z | 1 |
| Chen, LK; Liang, Y; Liu, GZ; Wei, WD; Xu, F; Xu, GC; Yang, QY; Zhou, NN | 1 |
| Hu, LM; Hu, ZB; Huang, MD; Shen, HB; Shu, YQ; Wang, ZW; Xu, JL; Yin, ZQ | 1 |
| Cao, N; Li, Z; Ma, B; Mi, D; Tian, J; Yang, K | 1 |
| Almokadem, S; Belani, CP; Besse, B; Chao, DT; Fang, Y; Soria, JC; Tsao, LC | 1 |
| Bruno, R; Claret, L; Hei, YJ; Hsu, CP; Lu, JF; Sun, YN | 1 |
| Abraham, M; Beider, K; Eizenberg, O; Fahham, D; Hanna, W; Izhar, U; Peled, A; Shapira, OM; Shlomai, Z; Wald, O; Weiss, ID; Zamir, G | 1 |
| Bando, T; Chen, F; Date, H; Kim, YH; Matsuo, Y; Okubo, K; Shibuya, K; Sonobe, M; Yanagihara, K | 1 |
| Chen, XC; Jiang, N; Zhao, Y | 1 |
| Fujita, Y; Gemma, A; Hagiwara, K; Harada, M; Harada, T; Hirano, H; Inoue, A; Isobe, H; Kinoshita, I; Kobayashi, K; Maemondo, M; Morita, S; Nukiwa, T; Oizumi, S; Okinaga, S; Saijo, Y; Sugawara, S; Yoshimori, K; Yoshizawa, H | 1 |
| Arriola, E; Cohen, RB; De Castro Carpeño, J; Herbst, RS; Kim, S; Kozloff, MF; Krzakowski, M; Martin, LP; Olszanski, AJ; Rado, TA; Rosbrook, B; Samuel, TA; Tarazi, J; Tortorici, M | 1 |
| Bussink, J; Soetekouw, PM; Timmer-Bonte, JN; Tjan-Heijnen, VC; van der Drift, MA; van Die, L; van Leeuwen, F; Wagenaar, M | 1 |
| Fujikawa, A; Furugen, A; Iseki, K; Ito, H; Kobayashi, M; Mano, N; Miyamori, K; Ogura, J; Takahashi, N; Tanaka, N; Yamada, T; Yamaguchi, H | 1 |
| Arias-Pulido, H; Bauman, JE; Carr, LL; Cerilli, LA; Eaton, KD; Jones, DV; Lee, SJ; Martins, RG; Wallace, SG | 1 |
| Santoni-Rugiu, E; Sorensen, JB; Vilmar, AC | 1 |
| Brahmer, JR; Dowlati, A; Fages, S; Johnson, DH; Leon, L; Lopez-Chavez, A; Sandler, A; Schiller, JH; Young, T | 1 |
| Fujishima, S; Imai, K; Kawaharada, Y; Konno, H; Minamiya, Y; Ogawa, J; Saito, H | 1 |
| Boudria, A; Brambilla, E; Drissi, R; Eymin, B; Gazzeri, S; Gout, S; Lantuejoul, S | 1 |
| Endo, T; Furukawa, K; Hashimoto, T; Hayashihara, K; Hizawa, N; Ichimura, H; Inagaki, M; Ishikawa, H; Kaburagi, T; Kagohashi, K; Kamiyama, K; Kishi, K; Kurishima, K; Matsumura, T; Nakamura, H; Nawa, T; Nishimura, Y; Saito, T; Sakai, M; Sato, Y; Satoh, H; Shinohara, Y; Unoura, K | 1 |
| Dakhil, SR; Hirsh, V; Hon, JK; Langer, CJ; Okamoto, I; Orsini, J; Page, RD; Renschler, MF; Socinski, MA; Zhang, H | 1 |
| Amler, LC; Brachmann, RK; Fridlyand, J; Friedman, LS; Hampton, GM; Haverty, PM; Huw, L; Koeppen, H; Lackner, MR; Mohan, S; O'Brien, C; Pandita, A; Ross, L; Sampath, D; Shames, DS; Spoerke, JM | 1 |
| Antoine, M; Belmont, L; Cadranel, J; Duruisseaux, M; Giroux Leprieur, E; Gounant, V; Lacave, R; Lavolé, A; Milleron, B; Poulot, V; Rabbe, N; Vieira, T; Wislez, M | 1 |
| Chu, TQ; Ding, H; Du, WD; Garfield, DH; Gu, AQ; Han, BH; Pei, J | 1 |
| Dong, HX; Ke, HG; Li, J; Liu, JH; Shen, Y; Shen, ZY; Yan, Y; You, QS | 1 |
| Davis, KR; Jung, M; Jung, Y; Kim, J; Lee, G; Lee, MA; Lee, S; Park, J; Park, JH; Yeom, CH; Yi, SY | 1 |
| Gagliato, Dde M; Jardim, DL; Katz, A; Ribeiro, KB; Shimada, AK | 1 |
| Chen, HJ; Chiu, HC; Huang, YC; Huang, YJ; Lin, YW; Tseng, SC; Weng, SH; Wo, TY | 1 |
| Hiyoshi, Y; Igawa, S; Ishihara, M; Kasajima, M; Katono, K; Kimura, M; Kubota, M; Maki, S; Masuda, N; Nagashima, Y; Otani, S; Takakura, A | 1 |
| Levent, E; Orki, A; Sarıman, N; Saygı, A; Yener, NA | 1 |
| Hamada, A; Hamaguchi, S; Honda, T; Isobe, T; Iwamoto, S; Karino, F; Kuraki, T; Miura, K; Ohe, M; Okimoto, T; Sutani, A; Tada, M; Tsubata, Y | 1 |
| Levra, MG; Novello, S; Pelosi, E; Scagliotti, GV; Solitro, F; Vavalà, T; Veltri, A | 1 |
| Ando, M; Atagi, S; Hirashima, T; Ikeda, N; Iwamoto, Y; Kudoh, S; Morita, S; Nakagawa, K; Nakanishi, Y; Okamoto, I; Saka, H; Satouchi, M; Sawa, T; Seto, T; Takeda, K; Yamamoto, N; Yoshioka, H | 1 |
| Hirashima, T; Imamura, F; Kawase, I; Kijima, T; Komuta, K; Minami, S; Nakatani, T; Namba, Y; Ogata, Y; Okafuji, K; Osaki, T; Otsuka, T; Shiroyama, T; Tachibana, I; Uchida, J; Yamamoto, S | 1 |
| Jang, TW; Jeon, YJ; Kim, HJ; Kim, KS; Kim, SY; Kim, YC; Lee, KH; Lee, KY; Lee, SY; Oh, IJ; Park, HS | 1 |
| Ishigatsubo, Y; Kaneko, T; Klinman, DM; Sato, T; Shimosato, T; Takahashi, R | 1 |
| Bálint, B; Cottrell, S; de Boer, RH; De Souza, P; Galimi, F; Haddad, V; Hei, YJ; Hsu, CP; Pan, Y; Paz-Ares, L; RamLau, R; Sabin, T; van Meerbeeck, JP; Wierzbicki, R | 1 |
| Bonomi, PD; Katz, TL; Lee, HJ; Mace, J; Mandanas, RA; Min, M; Olsen, M; Sheth, G; Youssoufian, H | 1 |
| Akazawa, Y; Aono, N; Imamura, F; Ito, Y; Kumagai, T; Nishino, K; Okuyama, T; Uchida, J; Yoshinami, T | 1 |
| Khuri, FR | 1 |
| Fossella, FV | 4 |
| Hong, WK | 1 |
| Khuri, FR; Kim, ES | 1 |
| Cheewakriangkrai, R; Euathrongchit, J; Thaikla, K; Thongprasert, S | 1 |
| Diepolder, H; Heinemann, V; Kenngotte, S; Stemmler, HJ | 1 |
| Sierra, A; Torre, W | 1 |
| Carey, D; Childs, HA; Hawkins, MH; Meredith, RF; Robert, F; Spencer, SA; Wheeler, RH; Zhang, R | 1 |
| Abad, A; Barnadas, A; Font, A; Guillot, M; Manzano, JL; Margeli, M; Martinez, E; Rosell, R; Sanchez, JM; Taron, M | 1 |
| Amato, S; Bologna, F; Domínguez, ME; Fasce, H; Flores Acosta, L; Lacava, JA; Langhi, MJ; Leone, BA; Machiavelli, MR; Marrone, N; Ortiz, EH; Pérez, JE; Romero Acuña, JM; Romero Acuña, LA; Romero, AO; Vallejo, CT | 1 |
| Malayeri, R | 1 |
| Hortobagyi, GN; Kris, MG | 1 |
| Green, MR | 3 |
| Casado, E; De Castro, J; Feliu, J; González Barón, M; Ordoñez, A | 1 |
| Kobayashi, H; Kubo, K; Okubo, Y; Takashi, S; Tsukadaira, A | 1 |
| Bahlitzanakis, N; Froudarakis, M; Koukourakis, GV; Koukourakis, MI; Kyrgias, G; Retalis, G; Romanidis, K | 1 |
| Castro Kreder, N; Franken, NA; Haveman, J; Loves, WJ; Peters, GJ; van Bree, C | 1 |
| O'Brien, ME; Waters, JS | 1 |
| Bunn, PA | 6 |
| Bacoyiannis, C; Boukovinas, J; Dimopoulos, M; Economopoulos, T; Fountzilas, G; Kalophonos, C; Kosmidis, P; Mylonakis, N; Nicolaides, C; Papakostas, P; Samantas, E; Skarlos, D; Tsavdaridis, D | 1 |
| Fukuda, M; Kasai, T; Kawabata, S; Kinoshita, A; Kohno, S; Nagashima, S; Nakamura, Y; Nakatomi, K; Oka, M; Soda, H; Takatani, H; Tsurutani, J | 1 |
| Choy, H; Johnson, D; MacRae, R; Shyr, Y | 1 |
| Aizawa, H; Gohara, R; Hoashi, S; Ichiki, M; Kamimura, T; Koga, T; Oshita, Y; Rikimaru, T | 1 |
| Bakri, K; Hudgens, S; Kies, MS; Lee, JH; Peterman, A; Schell, MJ; Socinski, MA; Unger, P; Yates, S | 1 |
| Barton, JH; Burris, HA; Butts, JA; Erland, JB; Gray, JR; Greco, FA; Hainsworth, JD; Houston, GA; Litchy, S; Scott, C; Thompson, DS; Webb, C | 1 |
| Antonellini, A; Elfring, GL; Gillenwater, HH; Israel, VK; Locker, PK; Miller, LL; Natale, RB; Sandler, AB; Socinski, MA | 1 |
| Hsu, NY; Hsu, WH; Kao, CH; Lee, CC; Lin, CC; Shiun, SC; Yen, RF | 1 |
| Deschesne, K; Fraser, R; Halle, JS; Johnson, H; Moore, DT; Morris, DE; Rosenman, JG; Socinski, MA | 1 |
| Ichinose, Y | 1 |
| Adachi, S; Fung, MC; Ishiguro, H; Sakata, T | 1 |
| Popa, IE; Rizvi, NA; Smith, FP; Stewart, K | 1 |
| Ansari, R; Bhatia, S; Einhorn, L; Hanna, N; Ng, E; Pletcher, W; Sandler, A | 1 |
| Ansari, R; Bhatia, S; Einhorn, L; Hanna, N; Sandler, A | 1 |
| Borsellino, N; Cazzato, C; Colucci, G; Durini, E; Galetta, D; Gebbia, V; Giotta, F; Pezzella, G; Romito, S | 1 |
| Chang, WC; Chao, TY; Chen, CH; Hsu, JW; Lin, MC; Tsao, TC | 1 |
| Cosaert, J; Quoix, E | 1 |
| Le Chevalier, T; Soria, JC | 1 |
| Ardizzoni, A; Berthet, P; Betticher, DC; Bogaerts, J; Breau, JL; Chemaissani, A; Gallant, G; Gatzemeier, U; Keppler, U; Lianes, P; Macha, HN; Nicholson, M; Pirker, R; Rosell, R | 1 |
| Crawford, J; Green, MR; Herndon, JE; Leopold, KA; Miller, AA; Perry, MC; Vokes, EE | 1 |
| Chen, YM; Lin, WC; Perng, RP; Tsai, CM; Whang-Peng, J; Wu, HW | 1 |
| Barsoum, J; Brickelmaier, M; Carmillo, A; Goelz, S; Qin, XQ | 1 |
| Christias, H; Ginopoulos, P; Karana, A; Kardamakis, D; Kontomanolis, E; Mandellos, G; Rathosis, S; Sougleri, M | 1 |
| Fukuoka, M; Inoue, A; Kunitoh, H; Mori, K; Nukiwa, T; Saijo, N | 1 |
| Adamo, V; Altavilla, G; Boni, C; Ceribelli, A; Clerici, M; Crinò, L; De Marinis, F; Di Costanzo, F; Failla, G; Frontini, L; Gridelli, C; Marangolo, M; Matano, E; Ricci, S; Rinaldi, M; Scagliotti, GV; Tonato, M | 1 |
| Harper, P; Marx, G | 1 |
| Allgood, V; Blumenschein, GR; Crane, EA; Dordal, M; Fossella, FV; Fritsche, HA; Goodin, T; Herbst, RS; Hinton, L; Hong, WK; Khuri, FR; Madden, TL; Meyers, CA; Newman, RA; Puduvalli, VK; Seabrooke, LF; Tran, HT | 1 |
| Balañá, C; Font, A; Guillot, M; Manzano, JL; Margelí, M; Richardet, M; Rosell, R; Sánchez, JJ; Sánchez, JM | 1 |
| Gerinière, L; Souquet, PJ | 2 |
| Depierre, A; Jacoulet, P; Westeel, V | 1 |
| Choma, D; Jacot, W; Pujol, JL; Quantin, X | 1 |
| Ash-Bernal, R; Browner, I; Erlich, R | 1 |
| Chen, XB; Li, DX | 1 |
| Carpagnano, F; Crucitta, E; De Lena, M; Guida, M; Lorusso, V; Mancarella, S; Panza, N; Sambiasi, D; Silvestris, N | 1 |
| Baas, P; Beijnen, JH; Keilholz, U; Kruijtzer, CM; Marcus, S; Mathôt, RA; Mezger, J; Rosing, H; Schellens, JH; Scheulen, ME; van Tinteren, H | 1 |
| Aramendia, JM; Aristu, JJ; Bosch, A; Brugarolas, A; Calvo, E; Claver, A; Cortes, J; Garcia-Foncillas, J; Gurpide, A; Lopez-Picazo, JM; Martin-Algarra, S; Rodriguez, J; Salgado, E | 1 |
| Terao, I | 1 |
| Duran, GE; Fojo, T; Kim, JH; Oefner, PJ; Sale, S; Shen, P; Sikic, BI; Sung, R; Wang, Y; Yu, K | 1 |
| Crinò, L | 1 |
| Belani, CP; Ramalingam, S | 3 |
| Chada, S; Gomyo, Y; Mukhopadhyay, T; Ramesh, R; Roth, JA; Sasaki, J | 1 |
| Fossella, FV; Lynch, T; Shepherd, FA | 1 |
| Belani, CP; Langer, C | 1 |
| Choy, H; Gandara, D; Mattson, K; Vokes, EE | 1 |
| Douillard, JY; Eckardt, J; Scagliotti, GV | 1 |
| Gridelli, C; Hainsworth, J | 1 |
| Abratt, RP; Krofta, K; Mattson, KV; ten Velde, G | 1 |
| Andre, F; Fandi, A; Fossella, F; Herbst, RS; Le Chevalier, T; Lee, JJ; Liu, DD; Massarelli, E; Ochs, J; Wolf, M | 1 |
| Ceciarini, F; Correale, P; Fiaschi, AI; Francini, G; Gotti, G; Marsili, S; Messinese, S; Petrioli, R; Pozzessere, D; Sabatino, M; Voltolini, L | 1 |
| Bang, YJ; Choi, IS; Heo, DS; Kim, BS; Kim, DY; Kim, JH; Kim, NK; Kim, TY; Lee, SH; Lee, SY; Park, SR | 1 |
| Alberola, V; Albert, A; Campos, JM; Carañana, V; Casany, R; Juan, O; Ordoño, F | 1 |
| Alberola, V; Cortesi, E; Juan, O | 1 |
| Esik, O; Homel, P; Keller, S; Moskovitz, T; Pisch, J | 1 |
| Du, CW; Li, DR; Lin, W; Lin, Y; Lin, YC; Wu, MY | 1 |
| Wang, SM; Zhang, J; Zhao, Y | 1 |
| Dicker, AP; Grant, DS; Williams, TL; Zahaczewsky, M | 1 |
| Morère, JF | 2 |
| Postmus, P | 1 |
| Fournel, P | 1 |
| Fukushima, M; Furuse, K; Harada, H; Hosoe, S; Iwamoto, Y; Kawahara, M; Komuta, K; Morioka, T; Ohsaki, Y; Origasa, H; Shibata, K | 1 |
| Ardizzoni, A; Ariganello, O; Boni, C; Cafferata, MA; De Marinis, F; Meriggi, F; Neumaier, CE; Portalone, L; Rosso, R; Torri, V; Zaniboni, A | 1 |
| Senzer, N | 1 |
| Fujimura, M; Iwasa, K; Kasahara, K; Kimura, H; Myo, S; Nakao, S; Nishi, K; Shibata, K; Shintani, H; Shirasaki, H; Yasuda, U | 1 |
| Filippa, DA; Kris, MG; Krug, LM; Miller, VA; Ng, KK; Venkatraman, E | 1 |
| Curiel, TJ; Hartz, R; Kovitz, K; Mudad, R; Nedzi, LL; Ramsey, M; Weiner, RS; Zakris, EL | 1 |
| Gajewski, TF; Hoffman, PC; Krauss, S; Mauer, AM; Rudin, CM; Vokes, EE; Winegarden, JD | 1 |
| Chen, MC; Chen, YM; Lee, CS; Lin, WC; Perng, RP; Shih, JF; Tsai, CM | 1 |
| Castro, M | 1 |
| Hirai, I; Honda, K; Kokawa, Y; Okamura, Y; Oura, S; Sakurai, T; Sasaki, R; Tanino, H; Yoshimasu, T | 1 |
| Bunn, PA; Lilenbaum, R | 1 |
| Cüneyt Ulutin, H; Pak, Y | 1 |
| Berille, J; Bruno, R; Chaikin, P; Hammershaimb, L; Olivares, R; Rhodes, GR; Rigas, JR; Vivier, N | 1 |
| Bunn, PA; Simon, GR | 1 |
| Beitler, JJ | 1 |
| Fujiwara, K; Hamasaki, S; Kiura, K; Tabata, M; Tanimoto, M; Ueoka, H | 1 |
| Araki, T; Ishihara, H; Komiyama, T; Kuriyama, K; Nishikawa, K; Onishi, H; Tanaka, S; Yamaguchi, M | 1 |
| Burioka, N; Endo, M; Hitsuda, Y; Igishi, T; Matsumoto, S; Miyata, M; Nakamoto, M; Nakanishi, H; Sako, T; Shigeoka, Y; Shimizu, E; Suyama, H; Yasuda, K | 1 |
| Aoki, Y; Furukawa, T; Haruta, Y; Hayashi, S; Iwanaga, K; Kato, O; Koyanagi, K; Kuroki, S; Nagata, M; Naitoh, K; Soejima, Y; Takahashi, K | 1 |
| Kleiman, NS; Nguyen-Ho, P; Verani, MS | 1 |
| Cheewakriangkrai, R; Napapan, S; Thongprasert, S | 1 |
| Bonomi, P; Cella, D; Eton, DT; Fairclough, DL; Johnson, DH; Yount, SE | 1 |
| Ansari, RH; Cotter, T; Gabrys, GT; Hoffman, PC; Krauss, SA; Mauer, AM; Schumm, LP; Szeto, L; Taber, D; Tembe, SA; Vokes, EE | 1 |
| Goto, K; Kakinuma, R; Kubota, K; Matsumoto, T; Niho, S; Nishiwaki, Y; Ohmatsu, H | 1 |
| Ayoub, J; Charpentier, D; Desjardins, P; Hirsh, V; Langleben, A; Ofiara, L; Pintos, J; Small, D; Whittom, R | 1 |
| Abdah-Bortnyak, R; Anacak, Y; Best, L; Billan, S; Chetver, L; Daoud, K; Kuten, A; Nijem, R; Zen Al Deen, I | 1 |
| Betticher, DC; Cerny, T; Egli, F; Furrer, M; Habicht, J; Hansen, E; Honegger, H; Hsu Schmitz, SF; Joss, C; Pless, M; Ris, HB; Roth, AD; Schmid, RA; Spiliopoulos, A; Stahel, R; Stupp, R; Tötsch, M; von Briel, C; Weder, W; Wernli, M | 1 |
| Ang, P; Ang, PT; Chew, L; Fong, KW; Foo, KF; Lee, KM; Leong, SS; Lim, SH; Ong, YK; Tai, BC; Tan, EH; Wee, J; Wilder-Smith, E | 1 |
| Faucette, SR; Gillenwater, HH; Hawke, RL; Lindley, C; Pescatore, SL; Shord, SS; Socinski, MA | 1 |
| Akerley, W; Egorin, MJ; Green, MR; Herndon, JE; Hollis, D; Kindler, HL; Lyss, AP; Ratain, MJ; Rosen, DM; Savarese, DM; Sherman, CA | 1 |
| Albain, KS; Bearden, JD; Burris, H; Chansky, K; Crowley, J; Gandara, DR; Gaspar, LE; Gumerlock, P; Kuebler, JP; Lara, PN; Leigh, BR; Livingston, R | 1 |
| Aizawa, H; Fujiki, R; Gohara, R; Hoashi, S; Ichiki, M; Rikimaru, T | 1 |
| Breathnach, OS; Fujishita, T; Gentler, M; Johnson, BE; Kashii, T; Loda, M; Turner, RE | 1 |
| Benoit, L; Chauffert, B; Collin, F; Cuisenier, J; Favoulet, P; Feutray, S; Fraisse, J | 1 |
| Carbone, D; Heelan, RT; Johnson, DH; Kris, MG; Krozely, P; Krug, LM; Miller, VA; Ochs, J; Perez, W; Pizzo, B; Sandler, A; Smith, R; Tyson, L | 1 |
| Bepler, G; Boni, C; Cooc, J; Crinò, L; Danenberg, KD; De Marinis, F; Di Costanzo, F; Gozzelino, F; Lord, RV; Marangolo, M; Novello, S; Rinaldi, M; Rosell, R; Salonga, D; Sánchez, JJ; Scagliotti, G; Stephens, C; Taron, M; Tonato, M | 1 |
| Chen, Q; Li, L; Li, LQ; Liu, J; Wang, YJ; Zhang, QZ; Zhao, WH; Zhou, QH | 1 |
| Aglione, S; Bajetta, E; Bedini, VA; Bidoli, P; De Candis, D; Navarria, P; Potepan, P; Stani, SC | 1 |
| Biesma, B; Debruyne, C; Giaccone, G; Krzakowski, M; Legrand, C; O'Brien, ME; Smid-Geirnaerdt, MJ; Smit, EF; Splinter, T; Stigt, J; Tjan-Heijnen, VC; Van Bochove, A | 1 |
| Belda-Iniesta, C; Casado, E; Cejas, P; de Castro, J; Feliu, J; Fresno Vara, JA; González-Barón, M; Hardisson, D; Nistal, M; Ordóñez, A; Sánchez, JJ | 1 |
| Belani, CP; Fidias, P; Fossella, F; Gorbounova, V; Kaukel, E; Mattson, KV; Millward, M; Pereira, JR; Pluzanska, A; Ramlau, R; Szczesna, A; von Pawel, J | 1 |
| Bando, T; Hasegawa, S; Inui, K; Kambayashi, T; Miyahara, R; Ri, M; Wada, H; Yanagihara, K | 1 |
| Chan, V; Guan, Z; Handoyo, P; Ho, JC; Huang, JS; Jusuf, A; Lam, WK; Leong, SS; Li, R; Liao, M; Luna, G; Sun, Y; Tan, EH; Tsang, KW; Wahid, MI; Wang, CH | 1 |
| Altorki, NK; Dannenberg, AJ; Ferrara, CA; Flieder, DB; Keresztes, RS; Korst, RJ; Libby, DM; Pasmantier, MW; Port, JL; Subbaramaiah, K; Yankelevitz, DF | 1 |
| Fujiwara, Y; Hasegawa, S; Miyoshi, Y; Monden, M; Noguchi, S; Takiguchi, S; Urano, N; Yano, M; Yasuda, T | 1 |
| Kim, DS; Kim, SW; Kim, WD; Kim, WS; Lee, JS; Lee, SD; Suh, C | 1 |
| Adelstein, DJ; Blackstone, EH; Chidel, MA; DeCamp, MM; Murthy, SC; Rice, TW; Rybicki, LA | 1 |
| Bally, M; Dragowska, WH; Hu, Y; Mayer, L | 1 |
| Barstis, J; Belani, CP; Clark, R; La Rocca, RV; Mills, GM; Nattam, SR; Perry, MC; Rinaldi, D | 1 |
| Hensing, TA; Lee, JH; Peterman, AH; Schell, MJ; Socinski, MA | 1 |
| Cella, D; Hudgens, S; Peterman, A; Socinski, MA; Webster, K | 1 |
| Ball, DL; MacManus, M; Michael, M; Millward, M; Muceniekas, L; O'Kane, C; Richardson, G; Rischin, D; Ryan, G; Smith, JG; Solomon, B; Wirth, A | 1 |
| Alberola, V; Albert, A; Campos, JM; Caranana, V; Casan, R; Juan, O; Sánchez, R; Villarroya, T | 1 |
| Bessho, A; Eguchi, K; Harada, M; Harita, S; Hiraki, S; Hiraki, Y; Kamei, H; Kiura, K; Okimoto, N; Segawa, Y; Tabata, M; Takemoto, M; Takigawa, N; Tanimoto, M; Ueoka, H; Watanabe, Y | 1 |
| Ho, ST; Kao, A; Shiau, YC; Shih, CM; Wang, JJ | 1 |
| Antonadou, D; Bolanos, N; Petridis, A; Sagriotis, A; Synodinou, M; Throuvalas, N | 1 |
| Au, JL; Chen, D; DeHoff, C; Fischer, B; Grever, M; Kanter, S; Murgo, AJ; Otterson, GA; Song, S; Villalona-Calero, MA; Wientjes, MG; Yeh, TK; Young, D | 1 |
| Ho, ST; Hsu, WH; Huang, WT; Kao, A; Shih, CM; Wang, JJ | 1 |
| Ahrendt, SA; Chen, Y; Okunieff, P | 1 |
| Baier, K; Flentje, M; Jost, A; Willner, J | 1 |
| Baran, I; Coskun, H; Demiray, M; Evrensel, T; Gonullu, G; Kanat, O; Kurt, E; Manavoglu, O; Turan, OF; Zarifoglu, M | 1 |
| Allgood, V; Bekele, BN; Carbone, DP; Desai, A; Hait, H; Hammond, LA; Herbst, RS; Holroyd, KJ; Schiller, JH; Solomon, S; Tran, HT; Williams, JI | 1 |
| Cannon, MW; Geyer, S; Hillman, S; Jatoi, A; Jett, JR; Mailliard, JA; Perez, EA; Stella, PJ; Vanone, S; Wiesenfeld, M | 1 |
| Estephan, FF; Jones, DV; Lin, JT; Spell, DW | 1 |
| Brancaccio, L; Cortesi, E; Crispino, C; De Marinis, F; Gridelli, C; Martelli, O; Migliorino, MR; Nelli, F; Portalone, L; Treggiari, S | 1 |
| Dowlati, A; Levitan, N | 1 |
| Corral, N; Esteban, E; Estrada, E; Fernández, JL; Fernández, Y; Fra, J; González de Sande, L; Lacave, AJ; Muñiz, I; Palacio, I; Vieitez, JM | 1 |
| Ball, ED; Chen, J; Mokotoff, M; Shultz, LD; Zhong, R; Zhou, J | 1 |
| Biesma, B; Debruyne, C; Gaafar, R; Giaccone, G; Legrand, C; Lianes, P; Manegold, C; Neymark, N; Schramel, F; Smit, EF; Smit, H; van Meerbeeck, JP | 1 |
| Clements, CM; Hod, Y; Lich, JD; MacKeigan, JP; Pope, RM; Ting, JP | 1 |
| Chun, JH; Han, JY; Hong, EK; Kim, HY; Lee, DH; Lee, HG; Lee, JS; Lee, SY; Shin, EH; Yoon, SM | 1 |
| Boni, C; Zanelli, F | 1 |
| Cammer, M; Chen, JG; Horwitz, SB; Yang, CP | 1 |
| Andruccetti, M; Bartolini, S; Benedetti, G; Calandri, C; Cappuzzo, F; Cortesi, E; Crinò, L; De Marinis, F; Maestri, A; Martelli, O; Migliorino, MR; Nelli, F; Rastelli, F | 1 |
| Furukawa, K; Kataba, H; Kato, H; Miura, T; Saito, M | 1 |
| Fidler, IJ; Herbst, RS; Isobe, T; Itasaka, S; Ki Hong, W; O'Reilly, MS; Onn, A; Wu, W | 1 |
| Bellucci, A; Calvani, M; Camerini, B; Carminati, P; Castorina, M; Cavaletti, G; Cicuzza, S; Galbiati, S; Laccabue, D; Lo Giudice, P; Marmiroli, P; Nicolini, G; Pacifici, L; Pisano, C; Pratesi, G; Tredici, G; Vesci, L; Zunino, F | 1 |
| Histuda, Y; Igishi, T; Kato, K; Kawasaki, Y; Kotani, M; Matsumoto, S; Sako, T; Shigeoka, Y; Shimizu, E; Sugitani, A; Yamamoto, M; Yasuda, K | 1 |
| Sandler, A | 2 |
| Chiou, JF; Ho, ST; Hsu, WH; Kao, A; Liang, JA; Wang, JJ | 1 |
| Comella, G; Comella, P; De Cataldis, G; De Rosa, V; Fiore, F; Frasci, G; Lapenta, L; Licenziato, M; Maiorino, L | 1 |
| Antonadou, D; Bolanos, N; Petridis, A; Sagriotis, A; Synodinou, M; Throuvalas, N; Veslemes, M | 1 |
| Bröker, LE; Giaccone, G; Huisman, C; Kruyt, FA; Rodriguez, JA; Span, SW | 1 |
| Braunschweiger, P; De Young, LR; Hamilton, K; Lampidis, TJ; Maschek, G; Priebe, W; Savaraj, N; Tidmarsh, GF | 1 |
| Chen, YM; Lee, CS; Lee, YC; Perng, RP; Shih, JF; Tsai, CM; Whang-Peng, J | 2 |
| Chen, GA; Cole, G; Nguyen, DM; Reddy, R; Schrump, DS; Schrump, WD; Tsai, W | 1 |
| Akiyama, Y; Hotta, K; Inoue, A; Kodama, T; Kunitoh, H; Kusaba, H; Nokihara, H; Ohe, Y; Saijo, N; Sawada, M; Sekine, I; Shimoyama, T; Tamura, T; Watanabe, H; Yamamoto, N | 1 |
| den Bakker, MA; Gelderblom, H; Kloover, JS; van Meerbeeck, JP | 1 |
| Johnson, DH; Langer, CJ; Stephenson, P; Thor, A; Vangel, M | 1 |
| Averbuch, SD; Fandi, A; Giaccone, G; Grous, J; Herbst, RS; Johnson, DH; Krebs, AD; Manegold, C; Miller, V; Natale, RB; Ochs, JS; Oliff, I; Reeves, JA; Rosell, R; Scagliotti, G; Schiller, JH; Wolf, MK | 1 |
| Horiike, A; Kodama, T; Kunitoh, H; Nokihara, H; Ohe, Y; Saijo, N; Sekine, I; Tamura, T; Yamamoto, N | 1 |
| Hirata, K; Kawaguchi, T; Kudoh, S; Mukohara, T; Nakaoka, Y; Yamada, M; Yamauchi, S; Yoshikawa, J; Yoshimura, N | 1 |
| Barutcu, I; Esen, AM; Gullu, H; Ozdemir, R; Sezgin, AT | 1 |
| Shimizu, E | 1 |
| Burioka, N; Chikumi, H; Fukuoka, Y; Kurai, J; Miyata, M; Sako, T; Shimizu, E; Suyama, H; Tomita, K; Ueda, Y; Watanabe, M; Yasuda, K | 1 |
| Asai, M; Iwahori, K; Koga, K; Komuta, K; Kondo, J; Minami, S; Mukouchi, C; Nobuyama, S | 1 |
| Baas, P; Beijnen, JH; de Jonge, ME; Huitema, AD; Mathôt, RA; Rosing, H; Schellens, JH; van den Bongard, HJ; van Zandwijk, N | 1 |
| Bencardino, KB; Bordonaro, R; Ceresoli, GL; Cordio, S; Cozzarini, C; Gregorc, V; Schipani, S; Villa, E | 1 |
| MacLeod, P; Maziak, DE; Shamji, FM; Stewart, DJ; Tomiak, E | 1 |
| Christodoulou, C; Deliyiannis, F; Malamos, NA; Rigatos, SK; Skarlos, DV; Stathopoulos, GP; Stathopoulos, JG | 1 |
| Ikehara, M; Noda, K; Nomura, I; Oshita, F; Tanaka, G; Yamada, K | 1 |
| Daga, H; Fujitaka, K; Isobe, T; Kohno, N; Kondo, K; Miyazaki, M | 1 |
| Endoh, K; Fukuda, K; Hirabayashi, M; Kagioka, H; Nakade, M; Nakai, N; Okuda, M; Teramachi, M; Tokuhisa, H; Yamaguchi, K | 1 |
| Barduagni, M; Ceribelli, A; Cognetti, F; Cortesi, E; De Marco, S; De Marinis, F; Fabi, A; Facciolo, F; Ferraresi, V; Gabriele, A; Gamucci, T; Pellicciotta, M; Saltarelli, R | 1 |
| Hoffman, PC; Kasza, K; Lanzotti, VJ; Mauer, AM; Otterson, GA; Rudin, CM; Szeto, L; Villalona-Calero, MA; Vokes, EE; Winegarden, JD | 1 |
| Rigas, JR | 4 |
| Damico, LA; DeVore, RF; Fehrenbacher, L; Gaudreault, J; Herbst, RS; Holmgren, E; Jablons, DM; Johnson, DH; Kabbinavar, F; Langer, CJ; Nemunaitis, JJ; Novotny, WF | 1 |
| Aramendia, JM; Aristu, JJ; Brugarolas, A; Calvo, E; Cortes, J; Garcia-Foncillas, J; Gurpide, A; Hernandez, B; Hidalgo, R; Lopez-Picazo, JM; Martin-Algarra, S; Rodriguez, J; Salgado, E | 1 |
| Fujiwara, K; Hisamoto, A; Hosokawa, S; Hotta, K; Kiura, K; Kozuki, T; Kuyama, S; Satoh, K; Tabata, M; Tanimoto, M; Ueoka, H | 1 |
| Antoniou, D; Bastani, S; Charalambatou, M; Dimitroulis, I; Georgatou, N; Gerogianni, A; Giamboudakis, P; Grigoratou, T; Kalatzi, E; Katis, K; Loukides, S; Marossis, K; Michalopoulou, P; Paspalli, A; Rigatos, SK; Stathopoulos, GP; Stoka, M; Tsavdaridis, D; Vergos, K; Veslemes, M | 1 |
| Socinski, MA | 2 |
| Kim, CH; Kim, HT; Lee, JC; Park, YH; Ryoo, BY | 1 |
| Buccheri, G; Ferrigno, D | 2 |
| Argiris, A; Kies, MS; LaCombe, M; Liptay, M; Marymont, M; Masters, G; Sundaresan, S | 1 |
| Braguer, D; Briand, C; Honore, S; Horwitz, SB; Jordan, MA; Kamath, K; Wilson, L | 1 |
| Langer, CJ | 6 |
| Buzzi, F; Carnicelli, P; Cioffi, R; Comella, P; Filippelli, G; Frasci, G; Guida, M; Maiorino, L; Mancarella, S; Massidda, B; Panza, N | 1 |
| Albain, K; Bhoopalam, N; Chansky, K; Clark, JI; Crowley, J; Edelman, MJ; Gandara, DR; Giguere, JK; Kelly, K; Weiss, GR | 1 |
| Hatayama, O; Hayasaka, M; Inou, H; Koizumi, T; Kubo, K; Sasabayashi, M; Tsushima, K; Yamamoto, H; Yoshiike, F | 1 |
| Lin, DX; Miao, XP; Tan, W; Wang, ZH; Xu, BH; Zhang, XR | 1 |
| Wu, SX; Xie, CY; Zhang, P | 1 |
| Bearden, JD; Gray, JR; Greco, FA; Hainsworth, JD; Houston, GA; Litchy, S; Shaffer, DW | 1 |
| Hitsuda, Y; Igishi, T; Katayama, S; Kato, K; Kawasaki, Y; Matsumoto, S; Sako, T; Shigeoka, Y; Shimizu, E; Sugitani, A; Suyama, H; Yamamoto, M; Yasuda, K | 1 |
| Barbone, F; Belvedere, O; Ceschia, T; Fasola, G; Follador, A; Grossi, F; Guglielmi, A; Morelli, A; Puglisi, F; Recchia, L; Rizzato, S; Sibau, A; Sobrero, AF; Talmassons, G; Vigevani, E | 1 |
| Ahn, JJ; Cha, HJ; Jeong, AK; Jung, JP; Lee, KM; Min, YJ; Noh, YJ; Park, CR; Park, JH; Suh, JH | 1 |
| Ab, O; Baloglu, E; Chari, RV; Goldmacher, VS; Leece, BA; Miller, ML; Roller, EE; Zhao, RY | 1 |
| D'Haene, N; Darro, F; Gaussin, JF; Kiss, R; Mathieu, A; Penant, S; Remmelink, M; Salmon, I; Van Ginckel, R | 1 |
| Chohnabayashi, N; Nasu, H; Nishimura, N; Uchiyama, N | 1 |
| Doyle, A; Edelman, MJ; Gamliel, Z; Hausner, P; Krasna, M; Patel, AB; Sonett, JR; Suntharalingam, M | 1 |
| Asahina, H; Dosaka-Akita, H; Imura, M; Kikuchi, E; Kikuchi, J; Kinoshita, I; Konishi, J; Nishimura, M; Oki, H; Shinagawa, N; Yamazaki, K | 1 |
| Anscher, M; Blackstock, AW; Clough, R; Crawford, J; Garst, J; Herndon, JE; Marks, LB; Rosenman, J; Shafman, T; Sibley, G; Socinski, MA; Tisch, A; Turrisi, A; Yu, X; Zhou, S | 1 |
| Detterbeck, FC; Fraser, R; Halle, JS; Hensing, TA; Limentani, SA; Mears, A; Moore, DT; Morris, DE; Rivera, MP; Rosenman, JG; Socinski, MA; Tynan, M | 1 |
| Ang, P; Fong, KW; Foo, KF; Lee, KM; Leong, SS; Ong, YK; Tan, EH; Wee, J | 1 |
| Lilenbaum, RC | 1 |
| Farquhar, D; Fu, H; Ghosh, S; Klostergaard, J; Zou, Y | 1 |
| Breton, JL; Gervais, R; Jacot, W; Pujol, JL; Quantin, X; Rebattu, P | 1 |
| Arnold, A; Davis, M; Douillard, JY; Humphrey, J; Ottaway, J; Paz-Ares, L; Peschel, C; Seymour, L; Shepherd, F; Smylie, M; Tonato, M; Tu, D; Voi, M; Vreckem, AV; Young, K | 1 |
| Cohen, EE; Haraf, DJ; Hellman, S; Mauer, AM; Mehta, N; Vokes, EE; Weichselbaum, RR | 1 |
| Guan, ZZ; Hawkins, M; Liu, DG; Luo, HY; Soon-Shiong, P; Teng, XY; Yao, ZW; Zhou, NN | 1 |
| Chen, LK; Liang, Y; Liu, JL; Xu, GC; Yang, QY; Zhang, LN | 1 |
| Akedo, I; Kubo, M; Mori, M; Nakagawa, C; Nishida, Y; Ono, H; Sakai, K; Takeda, E; Tamura, K; Tsugawa, M; Yanagi, K | 1 |
| Altýnbas, M; Bilgin, M; Canoz, O; Er, O; Eroglu, C; Gulec, M; Gulmez, I; Kaplan, B; Karahacioglu, E; Ozkan, M | 1 |
| Casas, F; Jeremic, B | 1 |
| Aguiar, D; Aguiar, J; Bohn, U | 1 |
| Chen, CS; Chidiac, T; Lane, SR; Lilenbaum, RC; Schwarzenberger, PO; Thant, M; Versola, M | 1 |
| Asmar, L; Boehm, KA; Garfield, DH; Khan, MM; Look, RM; Marsland, TA | 1 |
| Abe, Y; Aoki, M; Basaki, K; Hasegawa, Y; Kondo, H; Okudera, K; Okumura, K; Takahata, T; Takanashi, S; Tateishi, T; Yasui-Furukori, N | 1 |
| Fidler, IJ; Herbst, RS; Isobe, T; Itasaka, S; Kenji, Y; O'reilly, MS; Onn, A; Shibuya, K; Shintani, T; Wu, W | 1 |
| Bissonnette, RP; Cooke, TA; Corpuz, MR; Lamph, WW; Negro-Vilar, A; Prudente, RY; Yen, WC | 1 |
| Chahinian, P; Desch, C; Graziano, SL; Green, MR; Herndon, JE; Holland, JC; Lilenbaum, RC; List, MA; Miller, AA; Perry, MC; Saville, W; Watson, DM; Weeks, JC | 1 |
| Ando, K; Aritomi, T; Ichinose, I; Kumagawa, M; Shirahama, S; Takeo, S; Tamura, K; Wakamatsu, S | 1 |
| Hua, XM; Li, ZJ; Liu, FL; Liu, JY; Liu, Y; Liu, YG; Ren, XW; Xu, L; Zhang, CJ | 1 |
| Hensing, TA; Lee, JH; Schell, MJ; Socinski, MA | 1 |
| Addeo, A; Barone, C; Berruti, A; Bertetto, O; Buffoni, L; Dongiovanni, D; Dongiovanni, V; Fissore, C; Ottaviani, D; Polimeni, MA | 1 |
| Argyriou, AA; Chroni, E; Ellul, J; Iconomou, G; Kalofonos, HP; Katsoulas, G; Koutras, A; Papapetropoulos, S | 1 |
| Ahiskali, R; Aliustaoglu, M; Gumus, M; Hatabay, NF; Ozkan, A; Salepci, T; Turhal, NS; Turken, O; Yumuk, PF | 1 |
| Hennequin, C | 1 |
| Bak, JY; Bang, YJ; Choi, IS; Heo, DS; Kim, DW; Kim, JH; Kim, NK; Kim, SI; Kim, TY; Kim, YT; Kim, YW; Kwon, JH; Oh, DY; Park, CI; Park, SR; Sung, SW; You, CK | 1 |
| Ardizzoni, A; Bacigalupo, A; Cafferata, MA; Mereu, C; Monetti, F; Rosso, R; Scolaro, T; Tiseo, M; Tixi, L | 1 |
| Belani, CP; Eckardt, J | 1 |
| Baker, B; Bernareggi, A; Besman, M; Nienstedt, D; Shaffer, S; Singer, JW; Stromatt, S | 1 |
| Hu, HM; Li, R; Moudgil, T; Ross, HJ | 1 |
| Gillenwater, HH; Hensing, TA; Qaqish, BF; Socinski, MA; Stinchcombe, TE; Tyann, M | 1 |
| Acimovic, L; Jeremic, B; Milicic, B; Milisavljevic, S | 2 |
| Dumontet, C; Sève, P | 1 |
| Axelrod, R; Byhardt, R; Komaki, R; Langer, C; Machtay, M; Movsas, B; Nicolaou, N; Sarna, L; Scott, C; Smith, C; Wasserman, T; Werner-Wasik, M | 1 |
| Baum, RP; Bonnet, R; Junker, K; Müller, KM; Schmücking, M | 1 |
| Chen, SY; Kussick, SJ; Roberson, RS; Vallieres, E; Wu, DY | 1 |
| Grossman, A; Horwitz, SB; Keller, S; Lia, M; Lopez-Barcons, L; McDaid, HM; Pérez-Soler, R | 1 |
| Belani, CP; Johnson, DH; Mehta, M; Schiller, J; Veeder, M; Wagner, H; Wang, W | 1 |
| Arnold, A; Betticher, DC; Bezjak, A; Crawford, J; Depierre, A; Douillard, JY; Galbraith, S; Gatzemeier, U; Hann, K; Humphrey, JS; Jassem, J; Leighl, NB; Paz-Ares, L; Peschel, C; Santoro, A; Seymour, L; Shepherd, FA; Tu, D; Voi, M | 1 |
| Tyagi, P | 2 |
| Fujii, S; Goto, E; Imamura, F; Kishi, H; Kiyofuji, C; Matsumoto, M; Mori, T; Moriyama, E; Nomura, M; Okamoto, I | 1 |
| Ayral-Kaloustian, S; Cai, P; Chaudhary, I; Fawzi, M; Frost, P; Gaydos, C; Gibbons, J; Gu, J; Li, F; Lotvin, J; Lucas, J; Mansour, T; Petersen, R; Ruppen, M; Skotnicki, J; Toral-Barza, L; Yu, K; Zask, A; Zhu, T | 1 |
| Ahn, SD; Choi, EK; Kim, DS; Kim, JH; Kim, SW; Kim, WS; Kim, YS; Lee, JS; Lee, SW; Park, CI; Park, HJ; Shin, SS; Suh, C; Yi, BY; Yoon, SM | 1 |
| Furukawa, T; Hirai, I; Kokawa, Y; Okamura, Y; Oura, S; Yoshimasu, T | 1 |
| Ansari, R; Belani, CP; Lee, JS; Lilenbaum, R; Natale, RB; Robert, F; Rowland, K; Socinski, MA; Waterhouse, D | 1 |
| Anderson, IC; Eder, JP; Goffin, JR; Johnson, BE; Lynch, TJ; Shapiro, GI; Shipp, M; Skarin, AT; Supko, JG | 1 |
| El-Naggar, A; Giannakakou, P; Hamel, E; Khuri, FR; Marcus, AI; Nivens, M; O'Brate, A; Wong, J; Yao, TP; Zhou, J | 1 |
| Crinò, L; De Marinis, F; Foggi, P; Kielhorn, A; Maestri, A; Migliorino, AM; Novello, S; Rinaldi, M; Scagliotti, GV; Selvaggi, G; Stynes, G; Tilden, D; Tonato, M | 1 |
| Guillou, L; Krueger, T; Pezzetta, E; Ris, HB; Stupp, R; Taffé, P; von Briel, C; Zouhair, A | 1 |
| Atkins, J; Bradley, JD; Curran, WJ; Ettinger, DS; Graham, MV; Johnstone, DW; Komaki, R; Machtay, M; Paulus, R; Pilepich, MV | 1 |
| Barlési, F; Pujol, JL | 1 |
| Akerley, W; Chen, H; Choy, H; Johnson, DH; Kim, DW; Shyr, Y | 1 |
| De Marinis, F; De Petris, L; Gebbia, V | 1 |
| Harman, EM; Keene, KS; Knauf, DG; McCarley, D; Zlotecki, RA | 1 |
| Athanasiadis, A; Athanasiadou, DC; Papakostoulis, T; Roussos, G; Stathopoulos, GP | 1 |
| Bang, YJ; Heo, DS; Kim, DW; Kim, DY; Kim, NK; Kim, TY; Lee, KW; Yun, T | 1 |
| Besse, B; Le Chevalier, T; Soria, JC | 1 |
| Dainer, PM; Jillella, AP; Kallab, AM; Nalamolu, Y | 1 |
| Ichinose, Y; Okamoto, T | 1 |
| Ueoka, H | 2 |
| Alberola, V; Juan, O; Rocher, A; Sánchez, A; Sánchez, JJ | 1 |
| Achiwa, H; Bessho, Y; Maeda, H; Muramatsu, H; Niimi, T; Oguri, T; Sato, S; Ueda, R | 1 |
| Bissonnette, RP; Fan, B; Hermann, TW; Lamph, WW; Negro-Vilar, A; Roegner, K; Tooker, P; Yen, WC | 1 |
| Chen, YM; Perng, RP; Shih, JF; Tsai, CM; Whang-Peng, J | 2 |
| Devine, P; Machtay, M; Washam, C | 1 |
| Ardizzoni, A; Bosquee, L; de Bruin, HG; Dussenne, S; Eberhardt, W; Giaccone, G; Legrand, C; O'Brien, M; Scagliotti, GV; Smid-Geirnaerdt, M; Smit, E; Zatloukal, P | 1 |
| Chen, MC; Cheng, AL; Hsu, CH; Whang-Peng, J; Yang, CH; Yang, PC; Yeh, KH; Yu, YC | 1 |
| Au, JL; Lu, Z; Wientjes, TS | 1 |
| Fossella, FV; Glisson, BS; Khuri, FR; Kies, MS; Kim, ES; Munden, RF; Papadimitrakopoulou, V; Pisters, KM; Rogatko, A; Statkevich, P; Summey, C; Tighiouart, M; Zaknoen, S | 1 |
| Akerley, W; Choy, H; Johnson, DH; Kim, DW; Shaktour, B; Shyr, Y | 1 |
| Amler, LC; Eberhard, DA; Goddard, AD; Heldens, SL; Herbst, RS; Hillan, KJ; Ince, WL; Jänne, PA; Januario, T; Johnson, BE; Johnson, DH; Klein, P; Miller, VA; Ostland, MA; Ramies, DA; Sebisanovic, D; Seshagiri, S; Stinson, JA; Zhang, YR | 1 |
| Fehrenbacher, L; Herbst, RS; Hermann, R; Johnson, BE; Johnson, DH; Klein, P; Kris, MG; Li, X; Miller, VA; Prager, D; Ramies, D; Sandler, A; Tran, HT | 1 |
| Furukawa, T; Hata, K; Hirai, I; Kawago, M; Kokawa, Y; Okamura, Y; Oura, S; Tanino, H; Yoshimasu, T | 1 |
| Belani, CP; Bonomi, P; Choy, H; Curran, WJ; Haluschak, J; Scott, C; Travis, P | 1 |
| Reddy, GK | 1 |
| Akerley, W; Choy, H; Graziano, S; Green, MR; Herndon, JE; Lyss, AP; Turrisi, A; Vokes, EE; Williams, T; Zhang, C | 1 |
| Oral, EN | 1 |
| Bartolini, S; Cappuzzo, F; Crinò, L; Finocchiaro, G; Metro, G; Toschi, L; Trisolini, R | 1 |
| Ayoub, J; Boyd, AP; Cagnoni, PJ; Choy, H; Curran, WJ; Hamburg, S; Kleinberg, L; Kreisman, H; Nabid, A; Roa, W; Scott, C; Smith, C; Souhami, L; Spanos, W; Stea, B | 1 |
| Chu, Q; Evans, WK; Logan, D; Mackay, JA; Vincent, M | 1 |
| Busby, EM; Carey, D; Divers, SG; Hyatt, MD; Robert, F; Spencer, SA | 1 |
| Belani, CP; Bhatnagar, A; Flickinger, JC; Greenberger, JS; Ramalingam, S; Wolski, MJ | 1 |
| Dugan, MC; Greenblatt, MS; Grunberg, SM; Ospina, DJ; Valentine, JW | 1 |
| Chang, JW; Chen, CH; Lee, CH; Tsao, TC | 1 |
| Azzoli, CG; Crapanzano, J; Gomez, J; Heelan, RT; Kris, MG; Krug, LM; Miller, VA; Patel, J; Pizzo, B; Ross, JS; Sheehan, C; Tyson, L; Venkatraman, E | 1 |
| Brown, ER; Shepherd, FA | 1 |
| Han, SK; Kim, CH; Kim, YW; Lee, CT; Shim, YS; Yoo, CG; Yoo, JS | 1 |
| Hikosaka, Y; Nakashima, Y; Niwa, H; Tanahashi, M; Yamada, T; Yoshitomi, H | 1 |
| Kaneda, T; Narita, Y; Suzuki, A; Takahashi, N; Tsunematsu, K | 1 |
| Bunn, PA; Gustafson, DL; Hanna, N; Kelly, K; Long, ME; Needle, MN; Rosenberg, A; Thienelt, CD | 1 |
| Busby, E; Carey, D; Forero, A; Grizzle, WE; Khazaeli, MB; LoBuglio, AF; Meredith, RF; Robert, F; Shen, S | 1 |
| Baggstrom, MQ; Bakri, K; Beaumont, J; Hensing, TA; Ivanova, A; Mears, A; Niell, HB; Peterman, AH; Socinski, MA; Tynan, M; Wall, J | 1 |
| Antoniou, D; Armenaki, O; Dimitroulis, J; Grigoratou, T; Katis, C; Marosis, C; Michalopoulou, P; Stathopoulos, GP; Stathopoulos, J; Tsavdaridis, D | 1 |
| Andersen, N; Brandt, D; Davies, MJ; Murren, JR; Nadkarni, R; Parisot, N; Pizzorno, G; Psyrri, D; Rose, M; Rosenfield, AT; Zelterman, D | 1 |
| Aydiner, A; Eralp, Y; Oral, EN; Topuz, E | 1 |
| De Petris, L; Friesland, S; Lax, I; Sirzén, F | 1 |
| Basso, B; Bujor, L; Franchin, G; Gigante, M; Gobitti, C; Minatel, E; Trovò, MG | 1 |
| Lianes, P; Neymark, N; Smit, EF; van Meerbeeck, JP | 1 |
| Dobrolecki, L; Estes, D; Hanna, N; Hickey, R; Kurup, A; Lin, C-; Mariano, L; Murry, DJ; Sidor, C; Yiannoutsos, CT | 1 |
| Bordonaro, R; Castorina, S; Giannitto, GC; Giuffrida, D; La Venia, G; Marletta, F; Pappalardo, A; Potenza, E; Russo, A; Saita, S; Vincenzi, B | 1 |
| Horio, Y; Mitsudomi, T; Shimizu, J | 1 |
| Abou El Hassan, MA; Braam, SR; Kruyt, FA | 1 |
| Fujimoto, K; Hatayama, O; Kitaguchi, Y; Koizumi, T; Kubo, K; Sasabayashi, M; Wakamatsu, H; Yasuo, M; Yoshiike, F | 1 |
| Endo, M; Kado, T; Kotani, Y; Obayashi, K; Satouchi, M; Sugimura, K; Takada, Y | 1 |
| Bodkin, D; Neubauer, MA; Oldham, F; Richards, DA; Richards, P | 1 |
| Crowley, JJ; Gandara, DR; Lara, PN; Lau, DH; McCoy, J; Mills, GM; Tucker, RW; Williamson, SK | 1 |
| Dumontet, C; Isaac, S; Lai, R; Mackey, J; Pérol, M; Sève, P; Souquet, PJ; Trédan, O; Voloch, A | 1 |
| Aizawa, H; Ichiki, M; Iwami, F; Kawasaki, M; Kuba, M; Miyazaki, N; Nakanishi, Y; Ninomiya, K; Oishi, K; Takayama, K; Takeo, S | 1 |
| Fujimura, M; Inoue, K; Isobe, K; Komagata, H; Sakai, H; Shirai, T; Tabei, T; Yoneda, S | 1 |
| Bordonaro, R; Castorina, S; Failla, G; Giorgio, CG; Giuffrida, D; Nunzio, R; Pappalardo, A; Petralia, G; Russo, A; Santini, D | 1 |
| Eremenco, S; Kim, H; Kim, S; Suh, C; Yoo, H | 1 |
| Laskin, JJ; Sandler, AB | 1 |
| Ballas, MS; Dennis, PA | 1 |
| Barbieri, F; Bearz, A; Belloni, P; Biason, R; Ceresoli, G; Chella, A; Clerici, M; Favaretto, A; Ghi, MG; Nicoletto, MO; Oniga, F; Paccagnella, A; Riccardi, A; Ridolfi, R; Tirelli, U; Tumolo, S; Veglia, F | 1 |
| Lilenbaum, R; Raez, LE | 1 |
| Barlesi, F; Daurès, JP; Pujol, JL | 1 |
| Gomi, K; Inoue, A; Ishimoto, O; Kanbe, M; Koinumaru, S; Matsubara, N; Nukiwa, T; Saijo, Y; Tanaka, M; Usui, K | 1 |
| Dimitroulis, J; Dimou, E; Karaindros, D; Katis, C; Stathopoulos, GP; Stathopoulos, J; Tsavdaridis, D | 1 |
| Beijnen, JH; Giaccone, G; Kroep, JR; Peters, GJ; Pinedo, HM; Postmus, PE; Smit, EF; Van der Born, K; Van der Vijgh, WJ; Van Groeningen, CJ | 1 |
| Bokemeyer, C; Honecker, F; Kanz, L; Kollmannsberger, C; Oechsle, K; Schittenhelm, M; Tillner, J; Weber, D | 1 |
| Jankovic, D; Kanazir, S; Markovic, ID; Markovic, JZ; Pesic, M; Rakic, L; Ruzdijic, S | 1 |
| Eberhardt, W; Pöttgen, C; Stuschke, M | 1 |
| Chellappan, S; Dasgupta, P; Decook, C; Haura, E; Joshi, B; Kinkade, R | 1 |
| Hashizume, T; Hayashi, M; Kozawa, S; Miyazawa, N; Nakamura, M; Ogura, T; Takahashi, H; Watanuki, Y; Yamaguchi, N | 1 |
| Tominaga, T | 1 |
| Ai, B; Han, XH; He, XH; Huang, DZ; Li, B; Liu, P; Qin, Y; Shi, YK; Sun, Y; Yang, S; Zhang, CG | 1 |
| Appel, T; Blankenburg, T; Chemaissani, A; Dickgreber, N; Dittrich, I; Guschall, W; Schroeder, M; Schuette, W; Schumann, C; Schweisfurth, H; Ukena, D | 1 |
| Bhalla, S; Guerreiro, M; Laranjeira, L; Pimentel, FL | 1 |
| Kobayashi, K; Sutani, A | 1 |
| Fanucchi, M; Khuri, FR | 1 |
| Au, JL; Chen, D; Grever, M; Jensen, R; Murgo, AJ; Otterson, GA; Song, SH; Villalona-Calero, M; Wientjes, MG; Yeh, TK; Zhao, L | 1 |
| Depierre, A | 1 |
| Krazkowski, M | 1 |
| Soria, JC | 1 |
| Adjei, A; Fitch, TR; Garces, YI; Graham, D; Hillman, S; Jett, J; McGinnis, WL; Northfelt, D; Schaefer, PL; Schild, SE; Shahidi, H; Tschetter, LK | 1 |
| Johnston, PG; Karaiskou-McCaul, A; Kelly, DM; Kyula, J; Longley, DB; Stokesberry, SA; Van Cutsem, E; Van Schaeybroeck, S | 1 |
| Afanasyev, B; Bhar, P; Green, MR; Hawkins, MJ; Makhson, AM; Manikhas, GM; Orlov, S | 1 |
| Lin, DX; Miao, XP; Sun, Y; Tan, W; Wang, ZH; Xu, BH; Yuan, P; Zhang, XM; Zhang, XR | 2 |
| Babbar, N; Casero, RA; Hacker, A; Huang, Y | 1 |
| Antoniou, D; Chaimala, D; Chondrou, E; Dariotaki, F; Karydis, I; Papageorgiou, C; Pavlakou, G; Stathopoulos, GP; Veslemes, M | 1 |
| Doi, M; Fukuhara, K; Kuwabara, M; Maeda, H; Miyamoto, S; Sumiyoshi, H; Yamasaki, M | 1 |
| Bemis, L; Cappuzzo, F; Varella-Garcia, M | 1 |
| Breau, JL; Brechot, JM; Chouahnia, K; Des-Guetz, G; Morere, JF; Saintigny, P | 1 |
| Aisner, J; Guensch, L; Joyce, M; Lutzker, S; Schwartz, S; Sovak, MA; Wu, Y; Zheng, L | 1 |
| Daly, BD; Dipetrillo, TA; Fernando, HC; Kachnic, LA; Ketchedjian, A; Morelli, DM; Shemin, RJ | 1 |
| Davies, AM; Gandara, DR; Gumerlock, PH; Ho, C; Lara, PN; Mack, P | 1 |
| Albain, KS; Belani, CP; Bonomi, P; O'Byrne, KJ; Schiller, JH; Socinski, M | 1 |
| Favaretto, AG | 1 |
| Bang, YJ; Chung, DH; Han, SW; Heo, DS; Hwang, PG; Im, SA; Kim, DW; Kim, TY; Lee, KH; Oh, DY | 1 |
| AbouEl Hassan, MA; Braam, SR; Kruyt, FA | 1 |
| Baribaud, F; Caudler, E; Fridman, JS; Friedman, SM; Gazdar, AF; Girard, L; He, B; Jablons, DM; Li, Y; Liu, C; Lo, Y; Mikami, I; Minna, JD; Newton, RC; Peyton, M; Reguart, N; Scherle, PA; Vaddi, K; Yang, G; Yao, W; Zhou, BB | 1 |
| Ahn, JS; Ahn, YC; Choi, YS; Kim, H; Kim, J; Kim, K; Park, BB; Park, JO; Park, K; Shim, YM | 1 |
| Crawford, K; Fischer, SA; Perry, DJ; Randolph, P; Soberman, M | 1 |
| Akerley, W; Kennedy, T; Mega, T; Ready, N; Safran, H; Zaner, K | 1 |
| Cai, YM; Chen, ZM; Han, XH; He, XH; Liu, P; Shi, YK; Yang, S | 1 |
| Dickson, J; Lyn, BE; Rojas, AM; Saunders, MI; Shah, N; Williams, FJ; Wilson, EM | 1 |
| Katakami, N | 1 |
| Buccheri, G; Ferrigno, D; Giordano, MC | 1 |
| Ambrosch, G; Eckersberger, F; Klepetko, W; Krajnik, G; Maier, A; Malayeri, R; Minar, W; Müller, RM; Pirker, R; Pohl, G; Pokrajac, B; Schäfer-Prokop, C; Schmeikal, S; Woltsche, M | 1 |
| Mountzios, G; Soria, JC | 1 |
| Li, L; Liu, L; Wang, XW; Yu, XJ; Zhang, WD; Zhang, X | 1 |
| Flentje, M; Gosse, H; Huber, RM; Pöllinger, B; Schmidt, M; Ulm, K; Willner, J | 1 |
| Bonassi, S; Cellini, F; Cesario, A; Ciresa, M; Corbo, GM; Cortesi, E; D'Angelillo, RM; De Marinis, F; Granone, P; Margaritora, S; Migliorino, MR; Nelli, F; Porziella, V; Ramella, S; Russo, P; Trodella, L; Valente, S | 1 |
| Ashiku, S; Bergman, M; Berman, S; Boyd-Sirard, C; Coute, D; DeCamp, M; Goldstein, M; Halmos, B; Huberman, M; Karp, D; Lam, P; Muzikansky, A; Ou, SH; Schumer, S; Thurer, R; Woodard, C | 1 |
| Boselli, S; Catania, C; Curigliano, G; de Braud, F; De Pas, T; Milani, A; Noberasco, C; Orlando, L; Putzu, C; Sabrina, B; Spaggiari, L | 1 |
| Cohen, RB; Cosgriff, TM; Eisenberg, PD; Hainsworth, JD; Healey, D; Langer, CJ; Liau, K; Madajewicz, S; Pierce, K; Simon, GR; Xu, H | 1 |
| Belani, CP; Clark, RH; Dakhil, S; Desch, CE; Monberg, MJ; Obasaju, CK; Rooney, DK; Waterhouse, DM; Ye, Z | 1 |
| Bao, Y; Chen, M; Cui, NJ; Deng, XW; Li, KX; Lu, TX; Wang, WH; Xu, GC; Zhang, L | 1 |
| Gu, YH; Huang, PW; Lu, KH; Shu, YQ | 1 |
| Bianco, M; Buzzi, F; Cioffi, R; Comella, P; De Cataldis, G; Filippelli, G; Frasci, G; Gambardella, A; Ghiani, M; Maiorino, L; Mancarella, S; Massidda, B; Masullo, P; Milia, V; Natale, D; Palmeri, S; Putzu, C; Roselli, M | 1 |
| Ariyoshi, Y; Fukuoka, M; Kubota, K; Nakagawa, K; Negoro, S; Nishiwaki, Y; Ohashi, Y; Ohe, Y; Saijo, N; Tamura, T | 1 |
| Kamiyama, Y; Kano, Y; Kodama, T; Kondo, T; Mori, K | 1 |
| Socinski, M | 1 |
| Nelson, R | 1 |
| Chansky, K; Crowley, JJ; Davies, AM; Gandara, DR; Gaspar, LE; Lau, DH; Leigh, BR; Weiss, GR; Wozniak, AJ | 1 |
| Bares, R; Budach, W; Dittmann, H; Eschmann, SM; Friedel, G; Hehr, T; Langen, HJ; Paulsen, F; Reimold, M | 1 |
| Herbst, R; Sandler, A; Vokes, E | 1 |
| Hashimoto, K; Igishi, T; Kodani, M; Morita, M; Shigeoka, Y; Shimizu, E; Sumikawa, T; Suyama, H; Takeda, K | 1 |
| Brahmer, J; Dowlati, A; Gray, R; Johnson, DH; Lilenbaum, R; Perry, MC; Sandler, A; Schiller, JH | 1 |
| Miyagi, Y; Noda, K; Oshita, F; Saito, H; Sekiyama, A; Yamada, K | 1 |
| Chen, SJ; Feng, FY; Gao, YN; Hu, Y; Liu, YN; Xiao, T | 1 |
| El-Geneidy, MM; Eldeeb, NA; Elkerm, YM; Gouda, YS; Kohail, HM; Omar, AM | 1 |
| Johnson, DH; Langer, C; Li, S; Rapoport, BL; Schiller, J; Tester, W | 1 |
| Banerjee, S; Chiritescu, G; Dahrouge, S; Stewart, DJ; Tomiak, EM | 1 |
| Avallone, A; Barbato, E; Comella, P; Condemi, G; De Cataldis, G; Franco, L; Gambardella, A; Massidda, B; Putzu, C | 1 |
| Bonner, JA; Green, MR; Gu, L; Kohman, LJ; Perry, MC; Vokes, EE; Wang, X | 1 |
| Bando, M; Kobayashi, A; Oono, S; Sugiyama, Y; Tsujita, A; Yamasawa, H | 1 |
| De Grève, J; De Mey, J; Fontaine, C; Meysman, M; Neyns, B; Schallier, D; Steene, JV | 1 |
| Golemis, EA; Khazak, V; Menon, S; Skobeleva, N; Weber, L | 1 |
| Cheng, SJ; Feng, FY; Gao, YN; Hu, Y; Liu, YN; Xiao, T | 1 |
| Dimitroulis, J; Karaindros, D; Katis, C; Koutandos, J; Stathopoulos, GP; Stathopoulos, J; Toubis, M | 1 |
| Garassino, MC; Hollander, L; Torri, V | 1 |
| Oxnard, GR | 1 |
| Sonpavde, G | 1 |
| Meert, AP; Paesmans, M; Sculier, JP | 1 |
| Alexopoulos, CG; Berchier, MC; Berghmans, T; Collon, T; Efremidis, A; Giner, V; Lafitte, JJ; Lecomte, J; Meert, AP; Ninane, V; Paesmans, M; Scherpereel, A; Sculier, JP; Van Cutsem, O | 1 |
| Akerley, W; Atkins, JN; Cicchetti, MG; Green, MR; Herndon, JE; Kelley, MJ; Neill, H; Ramnath, N; Vokes, EE; Watson, DM | 1 |
| Coia, LR; Feigenberg, SJ; Goldberg, M; Hanlon, AL; Lanciano, R; Langer, C; Millenson, M; Movsas, B; Nicolaou, N | 1 |
| Algazy, KM; Carbone, DP; Fuller, CD; Kaiser, LR; Loiacano, ME; Machtay, M; Meyer, DM; Rosenthal, DI; Yardley, DA | 1 |
| Abratt, RP; Boyer, M; Brnabic, AJ; Han, JY; Kim, SW; Lee, JS; Lehnert, M; Mok, T; Reece, WH; Tsai, CM | 1 |
| Chen, YM; Perng, RP; Tsai, CM; Whang-Peng, J | 1 |
| Barstis, J; Belani, CP; Clark, R; La Rocca, RV; Mills, GM; Nattam, SR; Perry, MC; Ramalingam, S; Rinaldi, D | 1 |
| Breton, JL; Debieuvre, D; Depierre, A; Gervais, R; Hominal, S; Milleron, B; Molinier, O; Namouni, F; Pujol, JL; Quoix, E; Tonelli, D | 1 |
| Danson, S; Dunlop, D; Ellis, P; Payne, M; Ranson, M; Schacter, L; Talbot, D | 1 |
| Bitran, JD; Burnett, D; Chiappori, AA; Eiseman, I; Ellis, PM; Hamm, JT; Lenehan, P; Lovalvo, J; Olson, S; Zinner, RG | 1 |
| Davies, A; Fukuoka, M; Garfield, DH; Giaccone, G; Jassem, J; Kris, MG; Quoix, EA; Sandler, AB; Scagliotti, GV; Van Meerbeeck, JP; West, H | 1 |
| Bonomi, P | 2 |
| Bodemann, BO; Cardenas, J; Ferguson, D; Girard, L; Hao, W; Michnoff, C; Minna, JD; Peyton, M; Roth, MG; White, MA; Whitehurst, AW; Xie, XJ | 1 |
| Hosomi, Y; Shibuya, M | 1 |
| Yoneda, S | 1 |
| Alberola, V; Albert, A; Campos, JM; Caranyana, V; Juan, O; Muñoz, J | 1 |
| Fujisaka, Y; Ito, Y; Kato, T; Kunitoh, H; Nokihara, H; Ohe, Y; Sekine, I; Sumi, M; Tamura, T; Yamamoto, N | 1 |
| Bareschino, MA; Ciardiello, F; Morgillo, F | 1 |
| Bartolini, S; Cancellieri, A; Cappuzzo, F; Crino, L; Finocchiaro, G; Hirsch, FR; Ligorio, C; Magrini, E; Paioli, D; Rossi, E; Toschi, L; Trisolini, R; Varella-Garcia, M | 1 |
| Alexopoulos, CG; Berchier, MC; Berghmans, T; Collon, T; Efremidis, A; Giner, V; Lafitte, JJ; Leclercq, N; Lecomte, J; Meert, AP; Ninane, V; Paesmans, M; Scherpereel, A; Sculier, JP; Van Cutsem, O | 1 |
| Kajiwara, N; Kato, H; Miyajima, K; Ohira, T; Saji, H; Tsuboi, M; Uchida, O; Usuda, J | 1 |
| Ariyoshi, Y; Fukuoka, M; Fuwa, N; Hida, T; Hirokawa, K; Katakami, N; Kawahara, M; Nakagawa, K; Negoro, S; Nishimura, Y; Segawa, Y; Takeda, K; Tanaka, M; Tsujino, K; Yamamoto, N | 1 |
| An, T; Liu, X; Shi, A; Xu, B; Xu, G; Yu, R; Zhu, G | 1 |
| Beckett, LA; Gandara, DR; Shelton, DK; Yoneda, KY | 1 |
| Goto, K; Kakinuma, R; Kubota, K; Niho, S; Nishiwaki, Y; Ohmatsu, H; Saijo, N; Yoh, K | 1 |
| Feng, L; Garcia, GE; Jing, N; Mao, L; Weerasinghe, P; Yuan, P; Zhu, Q | 1 |
| Belzer, K; Gadgeel, S; Heilbrun, LK; Kalemkerian, GP; Kraut, MJ; Kucuk, O; Venkatramanamoorthy, R; Wozniak, AJ | 1 |
| Okamoto, H; Watanabe, K | 2 |
| Adachi, M; Ando, K; Hirose, T; Horichi, N; Ishida, H; Kusumoto, S; Ohmori, T; Ohnishi, T; Okuda, K; Shirai, T; Sugiyama, T | 1 |
| Cohen, MH; Gootenberg, J; Keegan, P; Pazdur, R | 1 |
| Ramaswamy, S | 1 |
| Bianco, A; Campbell, S; Caputo, F; D'Agostino, D; Gilli, M; Marsico, SA; Mazzarella, G; Piantedosi, FV; Pontillo, A | 1 |
| Barnadas, A; Basterrechea, L; Capdevila, J; Ciria, JP; Farré, N; Gomez-Segura, G; Membrive, I; Pallarés, C; Paredes, A | 1 |
| Buncher, R; Howington, J; Jazieh, AR; Redmond, K; Safa, M; Younas, A | 1 |
| Bauman, JE; Eaton, KD; Martins, RG | 1 |
| Biesterfeld, S; Hoffarth, S; Huber, C; Kröll, M; Schuler, M; Wesarg, E; Wiewrodt, R | 1 |
| Argnani, M; Ciucci, G; De Giorgi, U; Kopf, B; Marangolo, M; Minzi, C; Rosti, G | 1 |
| Furukawa, M; Hirashima, T; Kawase, I; Kobayashi, M; Matsui, K; Nakamura, Y; Nitta, T; Sasada, S; Takimoto, T | 1 |
| Avallone, A; Comella, P; Costanzo, R; Frasci, G; Gambardella, A | 1 |
| Bréchot, JM; Morère, JF; Pailler, M | 1 |
| Noda, K; Oshita, F; Saito, H; Yamada, K | 1 |
| Heo, DS; Kim, DW; Kim, HK; Kim, JS; Kim, SW; Kim, SY; Lee, MY; Park, K; Shin, SW | 1 |
| Baggstrom, MQ; Fried, DB; Hensing, TA; Poole, C; Socinski, MA; Stinchcombe, TE | 1 |
| Bradley, J; Gilstrap, E; Govindan, R; Velcheti, V | 1 |
| Girard, N; Mornex, F | 1 |
| Seto, T | 1 |
| Jett, JR; Keith, RL; Kesler, KA; Schild, SE | 1 |
| Hirose, T; Hirose, Y; Kajikawa, A; Kenzaki, K; Nagao, T; Sugimoto, T; Sumi, T; Yoshida, M | 1 |
| Fan, KW; Fang, W; Ji, SD; Li, Y; Meng, QL; Wang, F; Wang, ZZ | 1 |
| Gan, PP; Kavallaris, M; Pasquier, E | 1 |
| Ayoub, JP; Charpentier, D; Del Vecchio, P; Duclos, M; Faria, S; Gruber, J; Hirsh, V; Ofiara, L; Portelance, L; Souhami, L; Soulieres, D | 1 |
| Hino, M; Kamizuru, R; Kudoh, S; Omata, M; Ono, Y; Soma, T; Tanaka, Y; Ueda, Y; Uehara, T | 1 |
| Kaira, K; Mori, M; Nomura, S; Saito, R; Sakai, S; Sato, K; Sunaga, N; Tsuchiya, S; Tsuchiya, Y; Watanabe, S; Yanagitani, N | 1 |
| Miletzki, A | 1 |
| Burris, HA; Gandhi, JG; Gray, JR; Greco, FA; Hainsworth, JD; Kuzur, ME; Pati, A; Shipley, D; Spigel, DR; Thompson, DS; Webb, CD; Yardley, DA | 1 |
| Bafaloukos, D; Bakogiannis, C; Bamias, A; Boukovinas, I; Christodoulou, C; Dimopoulos, MA; Fountzilas, G; Kalofonos, HP; Kosmidis, PA; Makatsoris, T; Nicolaides, C; Samantas, E; Skarlos, D; Syrigos, K; Xiros, N | 1 |
| Charoentum, C; Chewasakulyong, B; Thongprasert, S | 1 |
| Kitada, K; Yamasaki, T | 1 |
| Chen, LK; Guan, ZZ; Hang, Y; Xu, GC; Yang, QY | 1 |
| Li, L; Li, M; Sun, ML; Wang, P; Wang, XW; Wei, JM; Yi, CH | 1 |
| Beijnen, JH; Bussink, J; Huitema, AD; Punt, CJ; Timmer-Bonte, JN; Tjan-Heijnen, VC; van Die, CE; vd Heijden, HF | 1 |
| Chang, YC; Cheng, AL; Hsu, C; Hsu, CH; Lin, CC; Lin, ZZ; Yang, CH; Yang, PC; Yu, CJ | 1 |
| Ceribelli, A; Cognetti, F; Fariello, AM; Gamucci, T; Giampaolo, MA; Mansueto, G; Narducci, F; Pino, MS; Sperduti, I; Trapasso, T | 1 |
| Hede, K | 1 |
| Gong, LQ; Gu, F; Su, YJ; Wang, CL; Wang, M; You, J | 1 |
| Chang, J; Cho, BC; Choi, HJ; Chung, KY; Kim, DJ; Kim, JH; Kim, SH; Kim, SK; Park, MS; Shin, SJ; Sohn, JH | 1 |
| Chen, Y; Feins, R; Johnstone, DW; Keng, PC; Pandya, KJ; Smudzin, T; Watson, T | 1 |
| Asmis, TR; Ding, K; Goss, GD; Graham, BC; Leighl, NB; Seymour, L; Shepherd, FA; Spaans, JN; Whitehead, M; Winton, TL | 1 |
| Belani, CP; Brahmer, JR; Dahlberg, SE; Gray, R; Johnson, DH; Langer, CJ; Ramalingam, SS; Sandler, AB; Schiller, JH | 1 |
| Detterbeck, FC; Edelman, MJ; Govindan, R; Gralla, RJ; Jahan, TM; Limentani, SA; Loesch, DM; Monberg, MJ; Obasaju, CK; Socinski, MA; Ye, Z; Zaman, MB | 1 |
| Choong, NW; Ferguson, MK; Haraf, DJ; Hoffman, PC; Kasza, K; Krauss, SA; Mauer, AM; Rudin, CM; Szeto, L; Tothy, PK; Vokes, EE | 1 |
| Bria, E; Di Maio, M; Perrone, F; Rossi, A | 1 |
| Davies, AM; Gandara, DR; Sangha, R | 1 |
| Arteaga, CL; Chandarlapaty, S; Gonen, M; Greulich, H; Rosen, N; Sawai, A; Sellers, W; Solit, DB; Ye, Q | 1 |
| Bedor, M; Brahmer, J; Bridges, BB; Doyle, LA; Edelman, MJ; Hausner, PF; Smith, R; Thomas, L | 1 |
| Belani, CP; Gable, PS; LaRocca, RV; Perry, MC; Ramalingam, S; Rinaldi, D; Tester, WJ | 1 |
| Azzoli, CG; Brower, M; Chia, G; Fiore, J; Hawkins, MJ; Heelan, R; Kris, MG; Miller, VA; Ng, KK; Riely, GJ; Rizvi, NA | 1 |
| Klein, F | 1 |
| Albert, D; Axelrod, R; Botkin, D; Dowlati, A; Lilenbaum, R; Seigel, L; Thomas, S; Witt, K | 1 |
| Ichinose, Y; Kato, M; Maruyama, R; Nakanishi, Y; Ohta, M; Tokunaga, S; Yamazaki, K; Yoshimine, H; Yoshino, I | 1 |
| Chung, HT; Han, DH; Hyun Kim, J; Jung, HW; Kim, DG; Lee, SH; Paek, SH; Yang, SY | 1 |
| Dowlati, A; Gray, R; Johnson, DH; Sandler, AB; Schiller, JH | 1 |
| Antonia, S; Bepler, G; Boulware, D; Burton, M; Chiappori, AA; Haura, E; Kapoor, R; Lush, R; Neuger, AM; Padilla, B; Rodriguez, FA; Simon, G; Sullivan, DM; Williams, C | 1 |
| Halle, JS; Hayes, DN; Lee, CB; Moore, DT; Morris, DE; Rivera, MP; Rosenman, JG; Socinski, MA; Stinchcombe, TE | 1 |
| Fang, W; Ji, S; Li, Y; Wang, F; Wang, Z; Zhao, M; Zheng, Y | 1 |
| Adelstein, DJ; Mekhail, TM; Murthy, S; Rice, TW; Saxton, JP; Suh, JH; Videtic, GM | 1 |
| Goto, Y; Kunitoh, H; Nokihara, H; Ohe, Y; Sekine, I; Tamura, T; Yamada, K; Yamamoto, N | 1 |
| Christakis, NA; Henderson, IC; Herndon, JE; Lamont, EB; Lilenbaum, R; Schilsky, RL; Weeks, JC | 1 |
| De Grève, J; De Mey, J; Decoster, L; Everaert, H; Meysman, M; Neyns, B; Nieboer, K; Schallier, D | 1 |
| Chen, DF; Feng, QF; Ou, GF; Wang, LH; Wang, M; Xiao, ZF; Yin, WB; Zhang, HX; Zhou, ZM; Zhu, XZ | 1 |
| Pang, QS; Wang, J; Wang, P; Wang, W | 1 |
| Arnold, A; Chen, E; Ellis, PM; Gauthier, I; Goss, G; Laurie, SA; Powers, J; Puchalski, TA; Robertson, J; Seymour, L; Shepherd, FA; Tu, D; Walsh, W | 1 |
| Blumenschein, GR; Dziewanowska, ZE; Gatzemeier, U; Jotte, RM; Khuri, FR; Le Treut, J; Miller, WH; Negro-Vilar, A; Sun, SL; von Pawel, J; Zhang, JK | 1 |
| Demol, H; Gevaert, K; Impens, F; Van Damme, J; Van Damme, P; Vandekerckhove, J | 1 |
| Atkins, CD | 1 |
| Goel, S | 1 |
| Bessho, Y; Maeda, H; Maeno, K; Miyazaki, M; Oguri, T; Ozasa, H; Sato, S; Ueda, R; Uemura, T | 1 |
| Dees, EC; Goldberg, RM; Hayes, DN; Lee, CB; Moore, DT; Socinski, MA; Stinchcombe, TE | 1 |
| Bandstra, B; Bischoff, H; Bonomi, P; Bover, I; Digel, W; Eisenfeld, AJ; Freitag, L; García-Campelo, R; Gatzemeier, U; Iannotti, N; Kaukel, E; O'Brien, M; Oldham, FB; Paz-Ares, L; Prendiville, J; Reiterer, P; Riviere, A; Ross, H; Singer, JW; Von Pawel, J | 1 |
| Li, DR; Lin, HS | 1 |
| Blackstock, AW; Bogart, JA; Green, M; Gu, L; Masters, GA; Miller, AA; Munley, M; Rosenman, J; Sleeper, A; Socinski, MA; Ungaro, P; Vokes, EE; Wang, X | 1 |
| Bartling, B; Hofmann, HS; Silber, RE; Simm, A | 1 |
| Benekli, M; Buyukberber, S; Coskun, U; Dikilitas, M; Kaya, AO; Ozkan, S; Ozturk, B; Uner, A; Yamac, D; Yaman, E; Yildiz, R | 1 |
| Gonda, H; Hasegawa, Y; Imaizumi, K; Nomura, F; Saka, H; Shimokata, K; Shindoh, J; Suzuki, R; Taniguchi, H; Tanikawa, Y; Yamamoto, M | 1 |
| Langer, CJ; Sherman, E; Somer, RA | 1 |
| Byhardt, R; Komaki, R; Langer, C; Machtay, M; Movsas, B; Nicolaou, N; Sarna, L; Swann, S; Wasserman, T; Werner-Wasik, M | 1 |
| Aisner, J; Belani, CP; Engstrom, C; Erkmen, K; Hiponia, D; Kearns, CM; Ramanathan, R; Trenn, MR; Zacharski, D; Zuhowski, M | 1 |
| Aisner, J; Belani, CP; Conley, B; Egorin, MJ; Engstrom, C; Hiponia, D; Kearns, C; Zuhowski, E | 1 |
| Comis, R; Langer, CJ; Leighton, J; McAleer, C; O'Dwyer, P; Ozols, R | 1 |
| Bonjo, CA; Comis, RL; Engstrom, PF; Langer, CJ; Leighton, JC; Litwin, S; McAleer, CA; O'Dwyer, PJ; Ozols, RF | 1 |
| Bitran, JD; Drinkard, LC; Golomb, HM; Hoffman, PC; Krauss, SA; Masters, GA; Samuels, BL; Vokes, EE; Watson, S | 1 |
| Bonjo, CA; Comis, RL; Engstrom, PF; Johnson, S; Langer, CJ; Leighton, JC; Litwin, S; McAleer, CA; O'Dwyer, PJ; Ozols, RF | 1 |
| Georgiadis, MS; Johnson, BE; Schuler, B | 1 |
| Aisner, J; Belani, CP; Engstrom, C; Hiponia, D | 1 |
| Carey, RW; Elias, AD; Grossbard, ML; Jacobs, C; Jauss, S; Kwiatkowski, DJ; Lynch, TJ; Shulman, LN; Strauss, GM; Sugarbaker, DJ | 1 |
| Beijnen, JH; Dalesio, O; Giaccone, G; Huizing, M; Koolen, M; Pinedo, HM; Postmus, PE; ten Bokkel Huinink, WW; van Zandwijk, N; Vermorken, JB | 1 |
| Giaccone, G | 3 |
| Dreps, A; Gatzemeier, U; Heckmayr, M; Neuhauss, R; Pawel, JV; Schlüter, I; Wagner, H | 1 |
| Akerley, W; Choy, H | 2 |
| Klastersky, J; Sculier, JP | 2 |
| Comis, RL; Friedland, DM | 1 |
| Johnson, DH | 1 |
| Hillner, BE | 1 |
| Bunn, PA; Kelly, K | 3 |
| Browne, MJ; Choy, H | 1 |
| Greco, FA; Hainsworth, JD; Thompson, DS | 1 |
| Einhorn, LH; Johnson, DH | 1 |
| Close, LG; Fathallah-Skaykh, H; Gazdar, AF; Griener, J; Kamen, B; Lucci, JA; Rosenthal, DI; Schold, SC; Truelson, J; Vuitch, FM | 1 |
| DeVore, RF; Hande, KR; Johnson, DH; Paul, DM | 1 |
| Alberts, M; Antonia, SJ; Hilstro, J; Hubbell, D; Robinson, L; Ruckdeschel, JC; Wagner, H; Williams, C | 1 |
| Bowling, MK; Ettinger, DS; Flood, WA; Rowinsky, EK; Sartorius, SE; Wagner, J | 1 |
| Choy, H; Safran, H | 1 |
| Bonomi, P; Faber, LP; Lincoln, S; Recine, D | 1 |
| Greco, FA; Hainsworth, JD; Stroup, SL | 1 |
| Israel, V; Jeffers, S; McRae, A; Muggia, FM; Natale, R; Rogers, M; Vafai, D; Zaretsky, S | 1 |
| Berghmans, T; Klastersky, J | 1 |
| Cheson, B; Christian, M; Feigal, EG; Friedman, MA; Grever, M | 1 |
| Grant, SC; Kris, MG | 1 |
| Klastersky, J | 1 |
| Niitani, H | 1 |
| Berille, J; Fossella, FV; Hong, WK; Lee, JS | 1 |
| Grant, SC; Kris, MG; Miller, VA; Pisters, KM; Rigas, JR | 1 |
| Fukuoka, M; Yoshikawa, A | 1 |
| Abe, S; Fujii, M; Furuse, K; Inoue, Y; Kurita, Y; Oizumi, K; Onoshi, T; Sato, K; Sugiura, T; Watanabe, K | 1 |
| Francis, PA; Grant, SC; Heelan, RT; Kris, MG; Miller, VA; Pisters, KM; Rigas, JR; Venkatraman, ES; Woolley, K | 1 |
| Chang, AY; Ettinger, DS; Johnson, DH | 1 |
| Benner, S; Calayag, M; Fossella, FV; Glisson, B; Huber, M; Lee, JS; Lippman, S; Murphy, WK; Perez-Soler, R; Shin, DM | 1 |
| Martin, V | 1 |
| Nightingale, SL | 1 |
| Francis, PA; Heelan, RT; Kris, MG; Orazem, JP; Pisters, KM; Rigas, JR; Woolley, KJ | 1 |
| Benner, S; Calayag, M; Chasen, M; Fossella, FV; Glisson, B; Lee, JS; Lippman, SM; Murphy, WK; Pang, A; Shin, DM | 1 |
| Ettinger, DS | 2 |
| Cerny, T; Epelbaum, R; Franklin, HR; Kaplan, S; Kaye, S; Pavlidis, N; Schöffski, P; van Meerbeek, J; Wanders, J | 1 |
| Greco, FA; Hainsworth, JD | 7 |
| Rowinsky, EK | 1 |
| Ariyoshi, Y; Fukuoka, M; Furue, H; Furuse, K; Hasegawa, K; Ishitani, K; Kanamaru, R; Niitani, H; Noda, K; Taguchi, T | 1 |
| Beijnen, J; Dalesio, O; Giaccone, G; Huizing, M; Koolen, M; Postmus, P; ten Bokkel Huinink, W; van Kralingen, K; van Zandwijk, N; Vermorken, J | 1 |
| Kurita, Y; Minoda, S; Nakano, M; Negoro, S; Niitani, H; Ogura, T; Taguchi, T; Watanabe, K; Yokoyama, A | 1 |
| Arita, K; Fujita, A; Hino, M; Igarashi, T; Kudo, S; Niitani, H; Taguchi, T | 1 |
| Akerley, W; Choy, H; Clark, J; Glantz, M; Leone, L; Papa, A; Puthawala, Y; Rege, V; Safran, H; Soderberg, C | 1 |
| Hisakatsu, S; Niitani, H | 1 |
| Eisenhauer, EA | 1 |
| Davilla, E; Dhingra, H; Fossella, FV; Gross, HM; Hynes, HE; Leimert, J; Murphy, WK; Raber, MN; Shin, DM; Winn, RJ | 1 |
| Anderson, T; Chang, AY; Glick, J; Johnson, D; Karp, D; Kim, K | 1 |
| Reed, E; Sarosy, G | 1 |
| Eisenhauer, E | 1 |
| Alberola, V; Benito, D; de Anta, JM; González-Larriba, JL; Molina, F; Monzó, M; Pérez, JM; Rosell, R | 1 |
| Diergarten, K; Faoro, C; Goerg, C; Havemann, K; Pfab, R; Wolf, M | 1 |
| Bell, DR; Bishop, JF; Friedlander, M; Goldstein, D; Levi, JA; Millward, MJ; Olver, IN; Rischin, D; Smith, JG; Toner, GC | 1 |
| Huber, H; Kneussl, M; Krajnik, G; Malayeri, R; Pirker, R; Zöchbauer, S | 1 |
| Punt, CJ; van Herpen, CM; van Hoesel, QG | 1 |
| Edelman, MJ; Gandara, DR | 1 |
| Crinis, NA; Millward, MJ; Morton, CG; Webster, LK | 1 |
| Chang, AY; DeVore, R; Johnson, D | 1 |
| Alberola, V; Ayala, F; Benito, D; García-Conde, J; González-Larriba, JL; Molina, F; Pérez, JM; Rosell, R | 1 |
| Gray, JR; Greco, FA; Hainsworth, JD; Stroup, SL | 1 |
| Furuse, K; Kunitoh, H; Niitani, H; Onoshi, T; Taguchi, T; Watanabe, K | 1 |
| Diergarten, K; Faoro, C; Görg, C; Havemann, K; Merte, H; Pfab, R; Wolf, M | 1 |
| Goes-Schmieder, R; Kettner, H; Kober, B; Kolotas, C; Martin, T; Mitrou, PS; Schneider, LV; Vogt, HG; Zamboglou, N | 1 |
| Dreps, A; Gatzemeier, U; Heckmayer, M; Neuhauss, R; Schlüter, I; von Pawel, J; Wagner, H | 1 |
| Adams, D; Belli, L; Gottfried, M; LeCesne, A; LeChevalier, T; Pellae-Cosset, B; Ruffie, P; Tete, L | 1 |
| Natale, RB | 5 |
| Choy, H; Cole, BF; Yee, L | 1 |
| Ariyoshi, Y; Fukuoka, M; Furuse, K; Hara, N; Ikegami, H; Kimura, I; Kurita, Y; Niitani, H; Nishiwaki, Y; Saijo, N; Yoneda, S | 1 |
| Havemann, K; Merte, H; Pfab, R; Pflüger, KH; Reckzeh, B; Wolf, M | 1 |
| Drinkard, LC; Golomb, HM; Hoffman, PC; Krauss, SA; Masters, GA; Samuels, BL; Vokes, EE | 2 |
| Blanke, C; De Vore, RF; Hande, KR; Johnson, DH; Lewis, M; Murphy, B; Paul, DM; Shyr, Y | 1 |
| Dunlop, DJ; Steward, WP | 1 |
| Drinkard, LC; Golomb, HM; Hoffman, PC; Krauss, SA; Masters, GA; Vokes, EE | 1 |
| Crump, M; Eisenhauer, E; Fisher, B; Latreille, J; Shepherd, FA; Stewart, D; Tomiak, E | 1 |
| Le Chevalier, T | 1 |
| Bernacki, RJ; Ojima, I; Sharma, A; Straubinger, RM | 1 |
| Baughman, TM; Bumol, TF; Cao, J; Dantzig, AH; Ehlhardt, WJ; Law, KL; Shepard, RL; Starling, JJ | 1 |
| Choy, H; Cole, B; Gollerkeri, A; King, T; Kwakwa, H; Lopez, F; Myers, J; Rosmarin, A; Safran, H; Tarpey, J | 1 |
| Markman, M | 1 |
| Trudeau, ME | 1 |
| Gallant, G; Tsao, MS; Viallet, J | 1 |
| Dulude, H; Evans, WK; Gertler, SZ; Goss, G; Huan, S; Logan, D; Stewart, DJ; Tomiak, EM; Yau, J | 1 |
| Debruyne, C; Giaccone, G; Postmus, PE; Sahmoud, T; Splinter, TA; van Zandwijk, N | 1 |
| Gromotka, E; Hanske, M; Heider, A; Koschel, G; Niederle, N; von Pawel, J; Wagner, H | 1 |
| Akerley, W; Choy, H; Glantz, M | 1 |
| Aisner, J; Belani, CP; Hiponia, D; Ramanathan, R | 1 |
| Boyer, R; Halme, M; Jekunen, A; Mattson, K; Pyrhönen, S; Roubille, N; Saarinen, A; Tamminen, K | 1 |
| Bakker, PJ; Beijnen, JH; Bierhorst, FJ; Dalesio, O; Giaccone, G; Huizing, MT; Koolen, MG; Lai, A; Pinedo, HM; Postmus, PE; Rosing, H; ten Bokkel Huinink, WW; van der Vijgh, WJ; van Warmerdam, LJ; van Zandwijk, N; Veenhof, CH; Vermorken, JB | 1 |
| Athanasiadis, A; Fountzilas, G; Kosmidis, P; Mylonakis, N; Samantas, E; Skarlos, D | 2 |
| Diergarten, K; Dornoff, W; Kolotas, C; Martin, T; Mitrou, PS; Neeb, A; Schneider, LV; Vogt, HG; Zamboglou, N | 1 |
| Emiliani, E; Giannini, M; Marangolo, M; Rosti, G; Vertogen, B; Zumaglini, F | 2 |
| Alexander, R; Bonjo, CA; Kosierowski, R; Langer, CJ; Litwin, S; McAleer, CA; Millenson, M; O'Dwyer, P; Ozols, R | 1 |
| DeVore, R; Hande, KR; Johnson, DH; Paul, DM | 1 |
| Hanske, M; Hecker, D; Heider, A; Koschel, G; Niederle, N; von Pawel, J; Wagner, H | 1 |
| Akerley, W | 2 |
| Splinter, TA | 1 |
| Ruckdeschel, JC | 1 |
| Carney, DN | 2 |
| Favaretto, A; Oniga, F; Ossana, L; Paccagnella, A | 1 |
| Corgna, E; Crinó, L; Gentile, A; Masiero, P; Palladino, M; Pozzi, E; Salsano, V; Scagliotti, GV; Tonato, M | 1 |
| Eisenhauer, E; Latreille, J; Paul, K; Shepherd, FA | 1 |
| Diergarten, K; Gatzemeier, U; Neuhauss, R; Schluter, I; von Pawel, J; Wagner, H | 1 |
| Bonomi, P; Faber, LP; Lincoln, S; Recine, D; Sharma, M; Siddiqui, S; Warren, W | 1 |
| Faoro, C; Goerg, C; Havemann, K; Kettner, H; Pfab, R; Wolf, M | 1 |
| Aisner, J; Bahri, S; Belani, CP; Capazolli, MJ; Day, R; Engstrom, C; Hiponia, D; Jett, J | 1 |
| Akerley, W; Choy, H; Chung, C; Graziano, S; Safran, H | 1 |
| Diergarten, K; Goes-Schmieder, R; Kober, B; Kolotas, C; Martin, T; Mitrou, PS; Schneider, LV; Vogt, HG; Zamboglou, N | 1 |
| Akerley, W; Choy, H; Cole, BF; Egorin, MJ; Glantz, MJ; Kearns, CM; Rhodes, CH | 1 |
| Crawford, J; Fanucchi, M; Figlin, R; Garst, J; Glaspy, J; Harker, L; Menchaca, D; Ozer, H; Sheridan, W; Tomita, D | 1 |
| Cohen, MH; Cohn, JB; Jin, PY; Reardon, DH; Tester, WJ | 1 |
| Palackdharry, CS | 1 |
| Carbone, DP; Fathallah-Shaykh, H; Gazdar, AF; Griener, J; Hamilton, L; Landay, M; McWhorter, J; Mendelsohn, D; Okani, O; Orr, KY; Rosenthal, DI; Tourville, J; Truelson, JM; Vuitch, FM | 1 |
| Beijnen, JH; Giaccone, G; Helmerhorst, TJ; Huizing, MT; Koolen, MG; Postmus, PE; ten Bokkel Huinink, WW; van der Vijgh, WJ; van Warmerdam, LJ; van Zandwijk, N; Veenhof, CH | 1 |
| Brown, JE; Georgiadis, MS; Johnson, BE; Kelley, MJ; Kieffer, LV; Schuler, BS; Steinberg, SM; Takimoto, CH; Wilson, WH | 1 |
| Bishop, JF; Blanc, C; Bruno, R; Cosolo, W; James, R; Laird, J; Loret, C; Millward, MJ; Rischin, D; Toner, GC; Urch, M; Webster, LK; Zalcberg, J; Zimet, A | 1 |
| Fossella, FV; Hong, WK; Huber, MH; Lee, JS; Lippman, SM; Newman, RA; Wester, M | 1 |
| Gatzemeier, U | 2 |
| Leutz, M; Schlimmer, P; Sybrecht, G; Ukena, D; Zell, L | 1 |
| Bonomi, P; Johnson, D; Kim, K; Kusler, J | 1 |
| Ardizzoni, A; Debruyne, C; Diaz-Puente, M; Giaccone, G; Postmus, PE; Scagliotti, G; Splinter, TA; Van Meerbeeck, J; Van Zandwijk, N | 1 |
| Casaretti, R; Comella, G; Comella, P; Daponte, A; Fiore, F; Frasci, G; Gravina, A; Guida, C; Parziale, A; Scoppa, G | 1 |
| Pedersen, AG | 1 |
| Boyer, MJ; Clarke, SJ | 1 |
| Bowling, KM; Ettinger, DS; Flood, WA; Rowinsky, EK; Sartorius, SE | 1 |
| Giannikos, L; Gogas, J; Kosmas, C; Polyzos, A; Tsavaris, N | 1 |
| Boyer, MJ; McKeage, MJ; Millward, MJ; Olver, IN; Richardson, G; Zalcberg, J | 1 |
| Tsukagoshi, S | 1 |
| Dahrouge, S; Dulude, H; Earle, CC; Evans, WK; Gertler, SZ; Goel, R; Goss, G; Logan, D; Stewart, DJ; Tomiak, E | 1 |
| Bible, KC; Kaufmann, SH | 1 |
| Shea, TC | 1 |
| Belani, CP; Ramanathan, RK | 1 |
| Fossella, FV; Hong, WK; Lee, JS | 1 |
| Andreopoulou, E; Athanasiadis, A; Fountzilas, G; Kosmidis, PA; Mylonakis, N; Pavlidis, N; Samantas, E; Skarlos, D | 1 |
| Anderson, H; Jayson, G; Perkins, S; Ranson, MR; Thatcher, N | 1 |
| Akerley, W; Choy, H; Rege, V; Safran, H; Sambandam, S; Sikov, W; Wittels, E | 1 |
| Dombernowsky, P; Sørensen, JB; Wedervang, K | 1 |
| Choy, H; DeVore, RF; Hande, KR; Johnson, DH; LaPorte, K; Porter, LL; Rosenblatt, P; Schlabach, L; Shyr, Y; Smith, C; Yunus, F | 1 |
| DeVore, RF; Jagasia, M; Johnson, DH | 1 |
| Athanassiadis, A; Fountzilas, G; Kosmidis, P; Mylonakis, N; Pavlidis, N; Samantas, E; Skarlos, D | 1 |
| Durham, SJ; Durzinsky, DS; Palackdharry, CS; Veltri, S | 1 |
| Desai, P; Roychowdhury, DF; Zhu, YW | 1 |
| Bunn, PA; Crowley, JJ; Ginsberg, RJ; Johnson, DH; Kris, MG; Pisters, KM; Ruckdeschel, JC | 1 |
| Shea, TC; Socinski, MA | 1 |
| Fossella, FV; Glisson, BS; Khuri, FR; Komaki, R; Lee, JS; Pisters, KM; Schea, R | 1 |
| Androulakis, N; Dimopoulos, MA; Georgoulias, V; Hatzidaki, D; Kakolyris, S; Kalbakis, K; Kotsakis, T; Kourousis, C; Merambeliotakis, N; Papadakis, E; Vardakis, N | 1 |
| Benito, D; Camps, C; Felip, E; González-Larriba, JL; López-Cabrerizo, MP; Massuti, B; Puerto-Pica, J; Rosell, R; Salamanca, O | 1 |
| Golomb, HM; Hoffman, PC; Masters, G; Mauer, AM; Vokes, EE; Watson, S | 1 |
| Alghisi, A; Bozzola, G; Marini, G; Meriggi, F; Mutti, S; Pascarella, A; Rizzi, A; Zaniboni, A | 1 |
| Carey, RW; Elias, AD; Grossbard, ML; Herbst, R; Jacobs, C; Kwiatkowski, DJ; Leong, T; Lynch, C; Lynch, TJ; Skarin, AT; Strauss, GM | 1 |
| Bonjo, CA; Langer, CJ; Litwin, S; McAleer, CA; Millenson, M; Ozols, R; Rosvold, E | 1 |
| Curran, W; Hudes, R; Keenan, E; Kilpatrick, D; Langer, CJ; Movsas, B; Schol, J; Yeung, C | 1 |
| Carbone, DP; Corak, J; Frenkel, EF; Gazdar, AF; Greiner, J; Kamen, B; Kavanaugh, D; Okani, O; Rosenthal, DI; Vuitch, FM | 1 |
| Kolotas, C; Martin, T; Schneider, L; Strassmann, G; Vogt, HG; Zamboglou, N | 1 |
| Doroshow, J; Gandara, DR; Lau, DH; Leigh, B; Morgan, R; Ryu, JK; Wilder, R | 1 |
| Casaretti, R; Comella, G; Comella, P; Daponte, A; Fiore, F; Frasci, G; Gravina, A; Guida, C; Ruffolo, P; Scoppa, G | 1 |
| Clark, JA; Halle, J; Kaluzny, B; Rosenman, JG; Socinski, MA; Steagall, A | 1 |
| Clamon, GH; Crawford, J; Green, MR; Miller, AA; Neill, HB; Perry, MC | 1 |
| Grant, SC; Kris, MG; Miller, VA; Ng, KK | 1 |
| Jekunen, A; Mattson, K; Saarinen, A | 1 |
| Agelidou, M; Androulakis, N; Apostolopoulou, F; Bouros, D; Georgopoulou, T; Georgoulias, V; Halkiadakis, G; Hatzidaki, D; Kakolyris, S; Kourousis, C; Papadakis, E; Souglakos, J | 1 |
| Miller, VA | 2 |
| Crown, JP; Donnellan, PP | 1 |
| Androulakis, N; Bouros, D; Dimopoulos, MA; Georgoulias, V; Hatzakis, K; Hatzidaki, D; Heras, P; Kakolyris, S; Kalbakis, K; Kotsakis, T; Kourousis, C; Meramveliotakis, N; Papadimitriou, C; Vardakis, N | 1 |
| Golomb, HM; Haraf, DJ; Hoffman, PC; Masters, GA; Mauer, AM; Vokes, EE | 1 |
| Harper, P | 1 |
| Auff, E; Berger, T; Doppelbauer, A; Huber, H; Krajnik, G; Malayeri, R; Pirker, R | 1 |
| Furuse, K | 1 |
| Aapro, MS | 1 |
| Masuda, N | 1 |
| Asbury, R; Boros, L; Chang, AY; Hui, L; Rubins, J | 1 |
| Furuse, K; Kawahara, M; Ogawara, M | 1 |
| Capizzi, RL; Fernandes, D; Johnson, CS; List, AF; Paine-Murrieta, GD; Taylor, CW; Wang, LM | 1 |
| Dulude, H; Eisenhauer, E; Fisher, B; Gelmon, K; Kirkbride, P | 1 |
| Bishop, JF; Macarounas-Kirchman, K | 1 |
| Boyer, MJ | 1 |
| Saijo, N | 1 |
| Akerley, W; Choy, H; Glantz, M; Joseph, P; Leone, L; Rege, V; Rodrigues, B; Sambandam, S; Wingate, P; Yee, L | 1 |
| Golomb, HM; Haraf, DJ; Hoffman, PC; Masters, GA; Mauer, AM; Vokes, EE; Watson, SM | 1 |
| Bruno, R; Burris, HA; Chevallier, B; Fossella, FV; Fumoleau, P; Hille, D; Kaye, SB; Ravdin, PM; Rigas, JR; Riva, A; Seidman, AD; Sheiner, LB; ten Bokkel Huinnink, WW; Valero, V; van Oosterom, AT; Verweij, J; Vivier, N | 1 |
| Klastersky, J; Sotiriou, C; van Houtte, P | 1 |
| Cook, J; Goldspiel, B; Hahn, SM; Herscher, LL; Kroog, G; Liebmann, J; Mitchell, JB; Pass, H; Temeck, B | 1 |
| Kudoh, S; Yamada, M | 1 |
| Berg, M; Leutz, M; Schlimmer, P; Sybrecht, GW; Ukena, D; Zell, L | 1 |
| Bonomi, P; Chang, AY; Ettinger, DS; Johnson, DH; Kim, KM | 1 |
| Akerley, W; Choy, H; Devore, R | 1 |
| Eisenhauer, E; Shepherd, FA | 1 |
| Golomb, HM; Hoffman, PC; Masters, GA; Mauer, AM; Vokes, EE; Watson, S | 1 |
| Büchholz, E; Drings, P; Manegold, C | 1 |
| Engstrom, C; Green, M; Lilenbaum, RC; MacManus, D | 1 |
| Barter, C; Berille, J; Bishop, J; Bougan, N; Friedlander, M; James, R; Loret, C; McKeage, M; Millward, M; Rischin, D; Toner, G; Zalcberg, J; Zimet, A | 1 |
| Agelidou, M; Androulakis, N; Apostolopoulou, F; Dimopoulos, AM; Georgoulias, V; Hatzidaki, D; Heras, P; Kakolyris, S; Kourousis, C; Mavromanolakis, E; Papadakis, E; Papadimitriou, C; Tzannes, S; Vlachonicolis, J; Vossos, A | 1 |
| Etienne, B; Guérin, JC; Nesme, P; Pérol, M; Robinet, G; Vuillermoz, S | 1 |
| Curran, D; Debruyne, C; Giaccone, G; Kho, GS; Lianes, P; Pennucci, MC; Postmus, PE; Sahmoud, T; Scagliotti, G; Splinter, TA; van Hoesel, Q; van Meerbeeck, J; van Zandwijk, N | 1 |
| Thongprasert, S | 1 |
| Conner, A; Mitchell, RB; Roa, V | 1 |
| Golomb, H; Hoffman, PC; Krauss, SA; Masters, GA; Mauer, AM; Samuels, BL; Vokes, EE; Watson, S; Wyka, D | 1 |
| Chen, YM; Chou, KC; Lin, WC; Liu, JM; Perng, RP; Whang-Peng, J; Wu, MF | 1 |
| Armstrong, J; Crown, J; Donnellan, P; Fennelly, D; Lynch, V; McDonnell, T; McNicholas, W; Rowan, S | 1 |
| Haraf, DJ; Hoffman, PC; Mauer, AM; Vokes, EE | 1 |
| Halme, M; Isokangas, OP; Jekunen, A; Joensuu, H; Mattson, K | 1 |
| Greco, FA; Hainsworth, JD; Hon, JK; Hopkins, LG; Stagg, MP; Thomas, M; Thompson, KA; Urba, WJ | 1 |
| Anderson, N; Bern, M; Coco, F; Dow, E; Gotthardt, S; Lokich, J; Oliynyk, P | 1 |
| Loddenkemper, R; Schönfeld, N; Serke, M | 1 |
| Akerley, W; Bogart, JA; Choy, H; Cole, BF; Graziano, SL; Safran, H | 1 |
| Dombernowsky, P; Giaccone, G; Sandler, A; Schwartsmann, G | 1 |
| Benson, LT; Einzig, AI; Kaplan, J; Tan, V; Tentoramano, L; Wadler, S; Wiernik, PH | 1 |
| Earle, CC; Evans, WK | 2 |
| Bernard, S; Brouwer, KL; Gonzalez, P; Lawrence, P; Letrent, SP; Mudd, PN; Radomski, KM; Socinski, MA; Steagall, A | 1 |
| Schiller, JH | 1 |
| Akerley, W; Choy, H; Chung, C; Cole, B; Graziano, S; Kennedy, T; Safran, H; Williams, T | 1 |
| Aamdal, S; Oian, P; Semb, KA | 1 |
| Chiang, CD; Hsu, JW; Hsu, JY | 1 |
| Kosmas, C; Tsavaris, NB | 1 |
| Androulakis, N; Bahlitzanakis, N; Georgoulias, V; Giatromanolaki, A; Kakolyris, S; Kamilaki, M; Kotsakis, A; Koukouraki, S; Koukourakis, MI; Kourousis, C | 1 |
| Bagnell, RD; Estes, L; Kelner, MJ; McMorris, TC; Samson, KM; Taetle, R | 1 |
| Euaree, A; Jirajarus, M; Ratanatharathorn, V; Sirachainan, E; Sirilerttrakul, S; Supatchaipisit, P | 1 |
| Curiel, DT; D'Amico, A; Frizelle, S; Grim, J; Kratzke, RA; Zhou, J | 1 |
| Gazdar, AF; Georgiadis, MS; Johnson, BE; Russell, EK | 1 |
| Bunn, PA; Huffman, DH; Kelly, K; Murphy, J; Pan, Z | 1 |
| Baille, P; Bruno, R; Millward, M; Montay, G; Schellens, JH; Verweij, J; Webster, LK | 1 |
| Nishiwaki, Y; Saijo, N; Sekine, I; Watanabe, K; Yoneda, S | 1 |
| Androulakis, N; Chalkiadakis, G; Georgoulias, V; Kakolyris, S; Kourousis, C; Maltezakis, G; Metaxaris, G; Samonis, G; Souglakos, J; Vlachonikolis, J | 1 |
| Baselga, J; Benito, D; Camps, C; Felip, E; González-Larriba, JL; Isla, D; López-Cabrerizo, MP; Massuti, B; Moyano, A; Puerto-Pica, J; Rosell, R; Salamanca, O | 1 |
| Androulakis, N; Dimopoulou, I; Georgopoulou, T; Georgoulias, V; Geroyianni, A; Hatzidaki, D; Kakolyris, S; Kotsakis, A; Kouroussis, C; Papadakis, E; Papadimitriou, C; Souglakos, J; Tzannes, S; Vardakis, N | 1 |
| Jones, J; Laufman, LR; Nicol, S; Rhodes, VA; Spiridonidis, CH; Wallace, K | 1 |
| Androulakis, N; Apostopoloulou, F; Bouros, D; Chatzakis, K; Georgopoulou, T; Georgoulias, V; Hatzidaki, D; Kotsakis, T; Kouroussis, C; Panagos, G; Papadakis, M; Souklakos, J; Vlachonikolis, J | 1 |
| Chu, JJ; Lai, YK; Liu, RS; Rao, CS | 1 |
| Criée, CP; Dalichau, H; Griesinger, F; Hannemann, P; Hemmerlein, B; Herse, B; Hess, CF; Hiddemann, W; Schmidberger, H; Wörmann, B | 1 |
| Creaven, P; Kindler, H; Meropol, N; Pendyala, L; Perez, R; Raghavan, D; Schwartz, GN | 1 |
| Alexopoulos, K; Androulakis, N; Georgoulias, V; Kakolyris, S; Kouroussis, C; Papadakis, E; Patila, E; Samantas, E; Samelis, G; Vaslamatzis, M; Vossos, A | 1 |
| Orel, NF | 1 |
| Adelstein, DJ; Becker, ME; Blackstone, EH; Ciezki, JP; Farver, CF; Larto, MA; Rice, TW; Rybicki, LA | 1 |
| Armand, JP; Couteau, C | 1 |
| Georgoulias, V; Giatromanolaki, A; Kakolyris, S; Koukourakis, MI; Schiza, S | 1 |
| Anderson, N; Bern, M; Coco, F; Dow, E; Lokich, JJ | 1 |
| Belli, L; Bérille, J; Bougon, N; Douillard, JY; Ibrahim, N; Le Chevalier, T; Monnier, A; Ruffie, P; Sun, XS | 1 |
| Agelidou, A; Androulakis, N; Apostolopoulou, F; Bouros, D; Dimopoulos, MA; Georgoulias, V; Hatzakis, K; Kakolyris, S; Kalbakis, K; Kotsakis, A; Kouroussis, C; Papadakis, E; Papadimitriou, C; Vardakis, N; Vlachonicolis, J | 1 |
| Aisner, J; Belani, CP; Capozzoli, MJ; Egorin, MJ; Engstrom, C; Erkmen, K; Hiponia, D; Kearns, CM; Ramanathan, RK; Zacharski, D; Zuhowski, EG | 1 |
| MacDonald, N | 1 |
| Gillenwater, H; Socinski, MA; Steagall, A | 1 |
| Beijnen, JH; Huizing, MT; Panday, VR; Rodenhuis, S; Schellens, JH; van Warmerdam, LJ | 1 |
| Burris, HA; Erland, JB; Greco, FA; Hainsworth, JD; Hon, JK; Kalman, LA; Meluch, AA; Morrissey, LH; Scullin, DC; Smith, SW | 1 |
| Akerley, W; Choy, H; DeVore, RF | 1 |
| Estalilla, OC; King, TC; Safran, H | 1 |
| Choy, H; Knill-Selby, E; LaPorte, K; Mohr, P; Shyr, Y | 1 |
| Aviles, V; Carbone, DP; Chalian, AA; Dowell, JE; Machtay, M; Rosenthal, DI; Sinard, R; Weber, RS; Weinstein, GS; Yardley, DA | 1 |
| Eisenhauer, E; Gelmon, K; Kirkbride, P | 1 |
| Doroshow, J; Gandara, D; Lau, D; Leigh, B; Morgan, R; Ryu, J; Wilder, R | 1 |
| Fox, NT; Hittelman, WN; Hong, WK; Kalapurakal, SK; Komaki, R; Lee, JS; Morice, RC; Murphy, WK; Ro, JY; Schea, R; Shin, DM; Walsh, GL | 1 |
| Leopold, KA; Rathmann, J; Rigas, JR | 1 |
| Childs, HA; Hawkins, MM; Redden, DT; Robert, F; Spencer, SA | 1 |
| Baker, SD; Bonomi, P; Jiroutek, M; Johnson, D; Rowinsky, EK | 1 |
| Belani, CP; Selvaggi, G | 1 |
| Apicella, A; Cartení, G; Comella, G; Comella, P; Frasci, G; Gravina, A; Guida, T; Lapenta, L; Lombardi, R; Natale, M; Nicolella, GP; Pacilio, C; Panza, N | 1 |
| Burkhart, CA; Horwitz, SB; Kavallaris, M | 1 |
| Kuroda, M; Mizuno, A; Noguchi, S; Ohishi, A; Sakuma, F; Takagi, T; Terashima, K | 1 |
| Appelt, K; Bloom, LA; Brekken, J; McDermott, CD; Shalinsky, DR; Varki, NM; Zook, S; Zou, H | 1 |
| Kris, MG; Millward, M | 1 |
| Edelman, MJ; Gandara, DR; Lau, D | 1 |
| van Oosterom, AT | 1 |
| Miller, V | 1 |
| Mattson, K | 3 |
| Andersson, L; Anjedani, D; Ek, L; Helsing, M; Hero, U; Lamberg, K; Månsson, T; Martinsson, JE; Sederholm, C; Svennson, G; Thaning, L | 1 |
| Rosell, R | 2 |
| Fossella, FV; Rigas, J | 1 |
| Bérille, J; Bizzari, JP; Bougon, N; Douillard, JY; James, R; Le Chevalier, T; Loret, C; McKeage, MJ; Millward, MJ; Monnier, A; Soulas, F; Zalcberg, JR | 1 |
| Rizvi, NA | 1 |
| Corgna, E; Crinó, L; Gentile, A; Marracolo, F; Novello, S; Palladino, M; Pozzi, E; Salsano, G; Scagliotti, GV; Selvaggi, G; Tonato, M | 1 |
| Bahlitzanakis, N; Beroukas, K; Christodoulou, M; Froudarakis, M; Georgoulias, V; Giatromanolaki, A; Kostantelos, J; Koukourakis, MI; Koumiotaki, S; Kyrias, G; Skarlatos, J | 1 |
| Ardizzoni, A; de Cupis, A; Favoni, RE; Grossi, F; Loprevite, M; Merlo, F; Pirani, P | 1 |
| Akutsu, M; Kano, Y; Mori, K; Suzuki, K; Tsunoda, S; Yazawa, Y | 1 |
| Bavbek, S; Kaytan, E; Kizir, A; Oral, EN; Tenececi, N; Topuz, E; Yöney, A | 1 |
| Chen, A; Mixon, A; Nguyen, DM; Schrump, DS | 1 |
| Beijnen, JH; Huizing, MT; Nannan Panday, VR; Schellens, JH; Ten Bokkel Huinink, WW; van Warmerdam, LJ | 1 |
| Chakravarthy, A; Choy, H; Johnson, D | 1 |
| Comella, G; Frasci, G; Pacilio, G; Panza, N | 1 |
| Flentje, M; Willner, J | 1 |
| Alberola, V; González-Larriba, JL; Lee, JS; Lorenzo, JC; Martín, C; Monzó, M; Núñez, L; O'Brate, A; Ro, JY; Rosell, R; Sánchez, JJ | 1 |
| Beijnen, JH; Giaccone, G; Kroep, JR; Peters, GJ; Pinedo, HM; Postmus, PE; Rosing, H; Smit, EF; van Groeningen, CJ; van Moorsel, CJ; Voorn, DA | 1 |
| Belli, M; Bilancia, D; Carpagnano, F; Cioffi, R; Comella, G; Comella, P; Contu, A; De Cataldis, G; De Lena, M; Frasci, G; Lorusso, V; Maiorino, L; Manzione, L; Mascia, V; Massidda, B; Micillo, E; Natale, M; Nicolella, GP; Panza, N; Pusceddu, G | 1 |
| Dombernowsky, P; Hansen, HH; Stenbygaard, LE; Sørensen, JB | 1 |
| Amadori, D; Bacci, F; Barzanti, F; Dal Susino, M; Folli, S; Frassineti, GL; Ricotti, L; Tesei, A; Zoli, W | 1 |
| Antoniou, F; Aspropotamitis, A; Athanassiou, A; Batzios, S; Halikia, A; Kalantaridou, A; Karvounis, N; Pectasides, D; Visvikis, A | 1 |
| Balaña, C; Martin, C; Rosell, R | 1 |
| Nervi, AM; Ornstein, DL; Rigas, JR | 1 |
| Bengtson, EM; Rigas, JR | 1 |
| Krug, LM; Miller, VA | 1 |
| Bhargava, P; Dahut, W; Davis, TH; Figuera, M; Hawkins, MJ; Marshall, JL; Rizvi, NA; Spiridonidis, CH | 1 |
| Adjei, AA; Argiris, A; Murren, JR | 1 |
| Langer, CJ; Socinski, MA | 1 |
| Arpornvivat, W; Cheirsilpa, A; Jaisathaporn, K; Laohavinij, S; Maneechavakajorn, J; Maoleekoonpairoj, S; Ratanatharathorn, V; Sirachainant, E | 1 |
| Friedberg, JS | 1 |
| Belani, C; Bonomi, P; Carbone, D; Comis, R; Devore, R; Gandara, DR; Green, M; Karp, D; Vokes, E | 1 |
| Belani, CP; Fossella, F; Rigas, JR | 1 |
| Dang, W; Garver, RI; Harper, E; Lapidus, RG | 1 |
| Amorino, GP; Choy, H; Hamilton, VM | 1 |
| Bonomi, P; Cella, D; Fairclough, D; Jiroutek, M; Johnson, D; Kim, K; Kugler, J; Rowinsky, E | 1 |
| Ferreira, CG; Giaccone, G; Kummer, AJ; Peters, GJ; Pinedo, HM; Span, SW; Tolis, C; van Lopik, T | 1 |
| Atassi, G; Guilbaud, N; Jan, M; Kraus-Berthier, L; Naze, M; Pierré, A | 1 |
| Goldberg, M; Langer, CJ; Millenson, MM; Movsas, B; Rogatko, A; Rogers, B; Schilder, RJ | 1 |
| Goto, K; Hojo, F; Hosomi, Y; Kakinuma, R; Kodama, K; Matsumoto, T; Mito, K; Moriyama, E; Niho, S; Nishiwaki, Y; Ohe, Y; Ohmatsu, H; Tanaka, K; Uramoto, H | 1 |
| Giaccone, G; Golding, RP; Laan, D; Pinedo, HM; Postmus, PE; Smit, EF; Splinter, T; van Meerbeeck, JP; van Tinteren, H | 1 |
| Bunn, PA; Crowley, JJ; Ginsberg, RJ; Giroux, DJ; Johnson, DH; Kris, MG; Mault, J; Pisters, KM; Putnam, JB; Roberts, JR | 1 |
| Dimitriadis, K; Dimopoulos, A; Fountzilas, G; Kalophonos, C; Kosmidis, P; Mylonakis, N; Pavlidis, N; Samantas, E; Skarlos, D; Tsavdaridis, D | 1 |
| Burris, HA; Erland, JB; Greco, FA; Hainsworth, JD; Hon, JK; Kalman, LA; Morrissey, LH; Scullin, DC; Smith, SW | 1 |
| Aasebo, U; Berille, J; Krzakowski, M; Olivares, R; Parisi, A; Pham Tran, N; Pluzanska, A; Roszkowski, K; Saigi, E; Smith, AP | 1 |
| Heelan, RT; Kris, MG; Krug, LM; Miller, VA; Ng, KK; Perez, W; Pizzo, B | 2 |
| Atkins, JN; Green, MR; Grethein, SJ; Grossbard, ML; Herndon, JE; Ihde, DC; Perry, MC; Vokes, EE | 1 |
| Cheirsilpa, A; Kraipiboon, P; Lertsanguansinchai, P; Lorvidhaya, V; Maoleekoonpairoj, S; Pattaranutaporn, P; Phromratanapongse, P; Ratanatharathorn, V; Sirachainan, E; Srimuninnimit, V; Tangkaratt, S | 1 |
| Choy, H; Cmelak, AJ; Johnson, DH; Mohr, PJ; Shyr, Y | 1 |
| Amoscato, AA; Kim, PK; Lotze, MT; Luketich, JD; Odoux, C; Weigel, TL | 1 |
| Alexander, R; Blankstein, K; Bonjo, CA; Kosierowski, R; Langer, CJ; Litwin, S; McAleer, CA; Millenson, M; Ozols, RF | 1 |
| Ho, YJ; Hsieh, JF; Kao, CH; Lee, JK; Tsai, SC | 1 |
| Amsrud, T; Chen, V; Forler, PA; Menon, K; Phares, VG; Shih, C; Teicher, BA | 1 |
| Bessa, EH; Lena, H; Paillotin, D; Pérol, M; Robinet, G; Schuller-Lebeau, MP; Taytard, A; Thomas, P; Vergnenègre, A | 2 |
| Bargetzi, M; Bérille, J; Fillet, G; Gatzemeier, U; Jekunen, A; Mattson, K; Olivares, R; Saarinen, A; Soussan-Lazard, K; Stupp, R; Teixeira, M; Vansteenkiste, J | 1 |
| Agelaki, S; Androulakis, N; Dimou, T; Georgoulias, V; Giannakakis, T; Hatzidaki, D; Kakolyris, S; Mavroudis, D; Parashos, M; Sarra, E; Vlachonikolis, J; Ziras, N | 1 |
| Crown, J; O'Leary, M | 1 |
| Burris, HA | 1 |
| Kris, MG; Miller, VA | 1 |
| Berille, J; Burkes, R; Coughlin, S; Dancey, J; Gralla, R; Gressot, L; Kim, Y; Levitan, N; Mattson, K; O'Rourke, M; Ramlau, R; Shepherd, FA; Vincent, M | 1 |
| Collins, TS; Lee, LF; Ting, JP | 1 |
| Fukuoka, M | 1 |
| Kamiya, Y; Kunitoh, H; Saijo, N; Sekine, I; Tamura, T; Yamamoto, N | 1 |
| Bishop, J; Boyer, M; Davison, J; Emmett, E; McClure, B; Michael, M; Millward, M; Rischin, D; Smith, J; Zalcberg, J | 1 |
| Bennouna, J; Berille, J; Douillard, JY; Lemarie, E; Milleron, B; Monnier, A; Rivière, A; Soussan-Lazard, K; Trillet-Lenoir, V | 1 |
| Crawford, J; DeVore, R; Dunphy, F; Fossella, FV; Gamza, F; Gandara, D; Hammershaimb, L; Kalman, L; Karp, D; Kerr, RN; Kim, Y; Kris, M; Lee, JS; Miller, V; Moore, M; Natale, RR; Vokes, E | 1 |
| Chan, CC; Chua, ET; Goh, BC; Kong, HL; Lee, SC; Lehnert, M; Lim, HL; Ng, AW; Wee, J; Wong, JE | 1 |
| Choy, H; Devore, RF; Hande, KR; Johnson, DH; Porter, LL; Rosenblatt, P; Schlabach, L; Shyr, Y; Smith, C; Yunus, F | 1 |
| Anderson, H; Carmichael, J; Davidson, N; Falk, S; Gallant, G; Gustafson, N; Jeynes, A; Lopez, P; Nicolson, M; Ranson, M; Thatcher, N; Washington, T | 1 |
| Annemans, L; Giaccone, G; Vergnenègre, A | 1 |
| Armand, JP | 1 |
| Hukom, R; Jayusman, AM; Jusuf, A; Mariono, SA; Reksodiputro, AH; Soetandyo, N; Suratman, E; Tambunan, KL | 1 |
| Ceresoli, GL; Dell'Oro, S; Passoni, P; Villa, E | 1 |
| Breathnach, OS; Georgiadis, MS; Johnson, BE; Kasturi, V; Llorens, V; O'Neil, K; Pizzella, P; Schuler, BS; Steinberg, SM; Takimoto, CH | 1 |
| Barton, JH; Bradof, JE; Burris, HA; Greco, FA; Hainsworth, JD; Litchy, S; Morrissey, LH | 1 |
| Guan, Z; Lin, T; Wu, H | 1 |
| Fiebiger, WC; Greul, R; Hejna, M; Kornek, GV; Marosi, L; Raderer, M; Scheithauer, W; Schneeweiss, B; Ulrich-Pur, H | 1 |
| Clark, J; Detterbeck, FC; Fraser, R; Halle, J; Limentani, S; Mitchell, W; Rivera, MP; Rosenman, JG; Russo, S; Schell, MJ; Socinski, MA | 1 |
| Comer, AM; Goa, KL | 1 |
| Belani, CP; Bonomi, P; Capozzoli, MJ; Cohen, LJ; Dobbs, T; Earhart, R; Einzig, A; Luketich, JD | 1 |
| Georgoulias, V; Kakolyris, S; Kalbakis, K; Kouroussis, C; Kremos, S; Mavroudis, D; Souglakos, J | 1 |
| Fukuoka, M; Kudoh, S; Masuda, N; Nakagawa, K; Negoro, S; Niitani, H; Saka, H; Sugiura, T; Takada, M | 1 |
| Kubota, K | 1 |
| Akerley, W; Fan, AC; Hsiu Chen, M; King, TC; Mangray, S; Moore, T; Safran, H | 1 |
| Antonopoulos, MJ; Dosios, T; Kalofonos, HP; Kosmas, C; Malamos, NA; Polyzos, A; Sepsas, E; Tsavaris, NB; Vadiaka, M | 1 |
| Bhupalam, L; Fleming, DR; Glisson, SD; Goldsmith, GH; LaRocca, RV; Michelson, GD | 1 |
| Cappuzzo, F; Green, MR; Rocha Lima, CM; Sherman, CA | 1 |
| Burris, HA; Greco, FA; Hainsworth, JD | 2 |
| Comella, P | 2 |
| Kosmidis, P | 1 |
| Furuse, K; Nakamura, Y; Saijo, N; Sekine, I | 1 |
| Israel, VP; Miller, L; Natale, RB; Sandler, A; Socinski, M | 1 |
| Giaccone, G; Groeningen, CJ; Kroep, JR; Loves, WJ; Peters, GJ; Pinedo, HM; Tolis, C; Voorn, DA | 1 |
| Berille, J; Bosquee, L; Brägas, B; Dabouis, G; Douillard, JY; Le Chevalier, T; Le Groumellec, A; Marien, S; Mattson, K; Olivares, R; Pujol, JL; Stupp, R | 1 |
| Dimopoulos, M; Fountzilas, G; Kalophonos, C; Kosmidis, P; Mylonakis, N; Nikolaidis, C; Papaconstantinou, C; Papadimitriou, C; Pavlidis, N; Samantas, E; Skarlos, D | 1 |
| Catania, C; Cinieri, S; Curigliano, G; Danesi, R; de Braud, F; De Pas, T; del Tacca, M; Fogli, S; Goldhirsch, A; Marrocco, E; Milani, A; Rocca, A; Sbanotto, A; Sessa, C; Zampino, G | 1 |
| Bunn, PA; Kelly, K; Mikhaeel-Kamel, N; Murphy, J; Pan, Z; Prindiville, S | 1 |
| Bogaerts, J; de Marinis, F; Gallant, G; Gatzemeier, U; Gottfried, M; Harper, P; Lucenti, A; Mattson, K; Robinet, G; Salvati, F; ten Velde, GP; von Pawel, J | 1 |
| Breau, JL; Brunet, A; Coulon, MA; L'Her, P; Morère, JF; Piperno-Neumann, S; Quinaux, E; Vaylet, F | 1 |
| Ascherman, JA; Attkiss, K; Knowles, SL | 1 |
| Ballatori, E; Del Favero, A; Roila, F | 1 |
| Jirajarus, M; Ratanatharathorn, V; Sirachainan, E | 1 |
| Cox, G; Jeyapalan, K; Muller, S; O'Byrne, KJ; Sharma, RA; Shields, F; Steward, WP; Thomas, AL | 1 |
| Bukowski, RM; Ganapathi, MK; Ganapathi, R; Grabowski, DR; Tabata, M; Tabata, R | 1 |
| Beijnen, JH; Boschma, MU; Giaccone, G; Huizing, MT; Meerum Terwogt, J; Nannan Panday, VR; Schellens, JH; ten Bokkel Huinink, WW; van Tellingen, O; Veenhof, CH | 1 |
| Kosmas, C; Koufos, C; Malamos, NA; Tsavaris, NB; Vadiaka, M | 1 |
| Azinovic, I; Brugarolas, A; Calvo, E; Cortes, J; de Irala, J; Fernandez-Hildago, O; Garzon, C; Martinez-Aguillo, M; Martinez-Monge, R; Ramon Y Cajal, T; Rodriguez, J | 1 |
| Agelaki, S; Georgoulias, V; Kakolyris, S; Kourousis, CH; Malliotakis, P; Mavroudis, D; Sarra, E; Souglakos, J | 1 |
| Barbarisi, A; De Marino, V; Elia, S; Facchini, G; Fraioli, G; Frattolillo, A; Gentile, M; Gravina, A; Griffo, S; Iaffaioli, RV; Illiano, A; Libutti, M; Muto, P; Tortoriello, A; Turitto, G | 1 |
| Beijnen, JH; Jewell, RC; Koopman, FJ; Malingré, MM; Paul, EM; Rosing, H; Schellens, JH; Ten Bokkel Huinink, WW | 1 |
| Barbieri, F; Bearz, A; Ceresoli, GL; Favaretto, A; Frustaci, S; Ghiotto, C; Oniga, F; Paccagnella, A; Schiavon, S; Villa, E | 1 |
| Fujita, A; Sekine, K; Tagaki, S; Takabatake, H | 1 |
| Pitoniak, RF; Takita, H | 1 |
| Gomez, J; Jagirdar, J; Kemp, B; Lee, JS; Ling, YH; Mao, L; Perez-Soler, R; Wu, QP; Yee, H; Zeleniuch-Jacquotte, A | 1 |
| Charnsangavej, C; Chow, D; Hung, MC; Li, C; Tansey, W; Wallace, S; Wu, QP; Zou, Y | 1 |
| Bruno, R; Chaikin, P; Olivares, R; Rhodes, GR; Veyrat-Follet, C | 1 |
| Alberola, V; Artal, A; Azagra, P; Camps, C; Carrato, A; Felip, E; González-Larriba, JL; Isla, D; Martin, C; Massutí, B; Rosell, R; Sánchez, JJ | 1 |
| Elfring, GL; Hanover, CK; Israel, VK; Locker, PK; Miller, LL; Natale, RB; Pirotta, N; Sandler, AB; Socinski, MA | 1 |
| Anscher, M; Blackstock, W; Crawford, J; Garst, J; Herndon, J; Marks, LB; Rosenman, J; Shafman, T; Sibley, GS; Socinski, MA; Turrisi, A; Zhou, S | 1 |
| Vokes, EE | 1 |
| Chen, YM; Chou, KC; Lee, YC; Perng, RP; Shih, JF; Tsai, CM | 1 |
| Changlai, SP; Ho, YJ; Hsieh, JF; Kao, CH; Lee, JK; Tsai, SC | 1 |
| Wang, H | 1 |
| Doroshow, J; Edelman, M; Gandara, D; Israel, V; Lara, P; Lau, D; Leigh, B; Morgan, R; Ryu, J; Wilder, R | 1 |
| Gaspar, LE | 1 |
| Bonomi, P; Shirazi, W | 1 |
| Belani, CP; Calvo, AR | 1 |
| Capuano, G; D'Alessandro, V; Lelli, G; Morelli, F; Nanni, L; Palomba, G; Piano, A; Rinaldi, B; Simeon, A; Sirotovà, Z | 1 |
| Blair, S; Carman, L; Colborn, D; George, C; Jones, J; Kuebler, JP; Laufman, LR; Moore, T; Patel, T; Roach, R; Rupert, R; Spiridonidis, CH; Zangmeister, J | 1 |
| Buhl, R; De Greve, JL; Fritz, MA; Gatzemeier, U; Gralla, R; Herrmann, R; Heussel, CP; Horowitz, JA; Huber, C; Kommoss, F; Kuball, J; Laufman, L; Perruchoud, AP; Rochlitz, C; Schuler, M; Shepherd, FA; Stewart, AK; Stewart, DJ | 1 |
| Shin, KH; Takita, H | 1 |
| Boyer, MJ; Clarke, SJ; Davis, I; Goldstein, D; Millward, MJ; Mitchell, P; Olver, IN; Richardson, G | 1 |
| Kris, MG; Manegold, C | 1 |
| Belani, C; Lynch, T | 1 |
| Douillard, JY; Eckardt, J; Georgoulias, V; Manegold, C; Miller, V; Scagliotti, G | 1 |
| Hainsworth, JD; Vokes, EE | 1 |
| Green, M; Gumerlock, P; Rosell, R | 1 |
| Armand, JP; Fossella, FV; Kris, MG; Lynch, T; Rigas, JR; Shepherd, FA | 1 |
| Dingemans, AC; Giaccone, G; Postmus, PE; Scagliotti, GV; Span, S; van Ark-Otte, J; van der Valk, P | 1 |
| Dirkx, M; Senan, S; van Meerbeeck, J; van Sörnsen de Koste, J; Voet, P | 1 |
| Borgmeier, A; Flentje, M; Huber, RM; Kirschner, J; Lang, S; Schmidt, M; Willner, J | 1 |
| Agelaki, S; Androulakis, N; Bania, E; Chainis, K; Georgoulias, V; Kakolyris, S; Kalofonos, C; Kouroussis, C; Papadakis, E; Rapti, A; Sarra, E; Toubis, M; Tsiafaki, X; Vardakis, N | 1 |
| Antonopoulos, M; Kalofonos, HP; Kosmas, C; Kourelis, T; Malamos, N; Panopoulos, C; Stavroyianni, N; Tsavaris, N; Vadiaka, M | 1 |
| Genvresse, I; Harder, H; Lange, C; Possinger, K; Schanz, J; Schweigert, M; Späth-Schwalbe, E | 1 |
| Goto, K; Kakinuma, R; Kubota, K; Kunitoh, H; Matsumoto, T; Niho, S; Nishiwaki, Y; Ohe, Y; Ohmatsu, H; Saijo, N | 1 |
| Kakinuma, R; Kodama, T; Kubota, K; Kunitoh, H; Kurata, T; Matsumoto, T; Nishiwaki, Y; Ohe, Y; Omatsu, H; Saijo, N; Shinkai, T; Tamura, T | 1 |
| Assouline, D; Bennouna, J; Douillard, JY; Grau, B; Haller, AM; Lerouge, D; Monnier, A; Rivière, A; Sun, XS | 1 |
| Gandara, DR; Goldberg, Z; Lara, PN; Lau, DH; Roberts, P | 1 |
| Alexopoulos, A; Georgoulias, V; Palamidas, P; Papadakis, E; Rapti, A; Tsiafaki, X; Veslemes, M; Vlachonikolis, I | 1 |
| Athanasiadis, A; Constantinidis, TC; Delis, D; Fachantidou, E; Goutsikas, J; Hatziapostolou, P; Kontakiotis, T; Patakas, D; Zarogoulidis, K | 1 |
| Burtness, BA; Gollerkeri, A; Harrold, L; Jain, D; Rose, M | 1 |
| Bruno, R; Montay, G; Rhodes, GR; Veyrat-Follet, C; Vivier, N | 1 |
| Minato, K; Mori, M; Saitoh, R; Sato, K; Takei, Y; Tsuchiya, S; Watanabe, S | 1 |
| Bunn, PA; Crowley, J; Gandara, DR; Grevstad, PK; Israel, VK; Kelly, K; Livingston, RB; Moinpour, CM; Moore, DF; Presant, CA; Ramsey, SD; Weiss, GR; Wozniak, AJ | 1 |
| Green, M; Kawahara, M; Kris, MG; Kunitoh, H | 1 |
| Belani, C | 1 |
| Gandara, DR; Goldberg, Z; Lara, PN; Lau, DH | 1 |
| Edelman, MJ; Gandara, DR; Lara, P; Lau, DH; Lauder, IJ; Tracy, D | 1 |
| Lynch, TJ | 1 |
| Bando, H; Miyata, J; Sano, T; Sumitomo, M | 1 |
| Guillen Grima, F; Ruiz Echeverría, J; Sánchez de la Rosa, R | 1 |
| Alberts, DS; Dorr, RT; Waltmire, CN | 1 |
| Murren, JR | 1 |
| Chen, GA; Lorang, D; Nguyen, DM; Schrump, DS; Stewart, JH; Tabibi, E | 1 |
| Rixe, O | 1 |
| Kim, KM; Larson, M; Leu, KM; Schiller, JH | 1 |
| Fujimoto, K; Hirai, K; Koizumi, T; Koyama, S; Kubo, K; Nomura, H; Okada, K; Tsunoda, T | 1 |
| Edelman, MJ; Mullins, B; Quam, H | 1 |
| Braguer, D; Briand, C; Gonçalves, A; Horwitz, S; Jordan, MA; Kamath, K; Martello, L; Wilson, L | 1 |
| Carbone, D; Choy, H; Devore, R; Eustis, C; Johnson, D; Roberts, JR | 1 |
| Abe, M; Endo, M; Hirota, S; Hishikawa, Y; Kado, T; Kono, M; Kotani, Y; Obayashi, K; Satouchi, M; Takada, Y; Tsujino, K | 1 |
| Clark, J; Detterbeck, FC; Fraser, R; Halle, J; Limentani, S; Lin, Y; Mitchell, W; Rivera, MP; Rosenman, JG; Russo, S; Schell, MJ; Socinski, MA | 1 |
| Hitsuda, Y; Kato, K; Kawasaki, Y; Mikami, M; Miyata, M; Shimizu, E; Yano, S; Yasuda, K | 1 |
| Choy, H; Kim, JS; MacRae, R; Pyo, H | 1 |
| Chen, Y; Feins, R; Keng, PP; Okunieff, P; Pandya, K; Raubertas, R; Rosenblatt, J; Smudzin, T | 1 |
| Baron, A; Bunn, PA; Chan, DC; Franklin, WA; Helfrich, B; Hirsch, FR; Soriano, AF; Varella-Garcia, M; Zeng, C | 1 |
| Burris, HA; Dobbs, C; Erland, JB; Gray, JR; Greco, FA; Hainsworth, JD; Litchy, S; Morrissey, LH; Raefsky, EL; Rinaldi, D; Smith, S | 1 |
| Belette, F; Blaustein, A; Davila, E; Lilenbaum, RC; Schwartz, MA; Seigel, L; Wittlin, FN | 1 |
| Eckardt, JR | 1 |
| Le Chevalier, T; Novello, S | 1 |
| Asbury, R; Boros, L; Chang, AY; Hui, LF; Rubins, J | 1 |
| Choy, H; MacRae, R | 1 |
| Felip, E; Rosell, R | 1 |
| Satoh, H; Sekizawa, K | 1 |
| Antonuzzo, A; Crinó, L; Darwish, S; Galli, L; Marrocolo, F; Novello, S; Pozzi, E; Ricci, S; Scagliotti, GV; Selvaggi, G; Sorbolini, S; Tonato, M | 1 |
| Albain, KS; Clark, JI; Fisher, S; Hantel, A; Kancharla, K; Millbrandt, L; Panganiban, J; Qamar, R | 1 |
| Bonfill, X; Losa, F; Montesinos, J; Nogué, M; Sacristán, M; Serra, C | 2 |
| Akiyama, Y; Inoue, A; Kodama, T; Kunitoh, H; Kusaba, H; Ohe, Y; Saijo, N; Sawada, M; Sekine, I; Tamura, T; Yamamoto, N | 1 |
| Horowitz, J | 1 |
| Choy, H; DeVore, RF; Hande, KR; Johnson, DH; Laporte, K; Porter, LL; Rosenblatt, PA; Shyr, Y; Slovis, B | 1 |
| Perng, RP; Wang, GS; Yang, KY | 1 |
| Hurst, M; Plosker, GL | 1 |
| Astudillo, J; Felip, E; Maestre, J; Manzano, JL; Monzo, M; Rosell, R; Sanchez, JJ; Sanchez, JM; Taron, M | 1 |
| Abratt, R; Avril, I; Krofta, K; Mattson, K; Ten, GV; Tonelli, D | 1 |
| Agosta, G; Armata, MG; Bajardi, E; Cicero, G; Gebbia, N; Grassi, N; Gulotta, G; Latteri, MA; Modica, G; Pantuso, G; Russo, A; Valerio, MR | 1 |
| Boccieri, MG; Bruschi, G; Lo Re, G; Saracchini, S; Toffoli, G; Tumolo, S | 1 |
| Greco, FA | 1 |
| Alexopoulos, A; Georgoulias, V; Giannakakis, T; Grigoratou, T; Kakolyris, S; Kouroussis, C; Mavroudis, D; Palamidas, P; Papadakis, E; Rapti, A; Samonis, G; Tsiafaki, X; Veslemes, M; Vlachonikolis, J | 1 |
| Caffo, O | 1 |
| Belani, CP; Harrington, D; Johnson, DH; Krook, J; Langer, C; Sandler, AB; Schiller, J; Sweeney, CJ; Zhu, J | 1 |
| Baker, M; Billings, FT; Bradof, JE; Burris, HA; Greco, FA; Hainsworth, JD | 1 |
| Kobina, S; Moyano, A; Rubio-Terrés, C; Tisaire, JL | 1 |
| Boral, A; Carey, R; Fidias, P; Grossbard, M; Johnson, BE; Lucca, J; Lynch, TJ; Martins, R; Ostler, P; Shapiro, G; Skarin, A; Supko, JG | 1 |
| Harpole, DH; Kelley, MJ; Li, S | 1 |
| Kalofonos, HP; Kosmas, C; Koutras, A; Malamos, N; Onyenadum, A; Polyzos, A; Rokana, S; Stavroyianni, N; Tsavaris, N; Vadiaka, M | 1 |
| Miyazaki, M; Mukohara, T; Negoro, S; Takeda, K; Takifuji, N; Terakawa, K | 1 |
| Chacón, JI; de Castro, J; Dorta, J; Espinosa, E; Feliu, J; González Barón, M; Lizón, J; Martin, G; Rodríguez, A; Sánchez Heras, B; Torrego, JC | 1 |
| Guan, X; Li, L; Zou, Y | 1 |
| Ahn, YC; Bang, YJ; Choi, EK; Kim, YW; Lim, TH; Park, CI; Park, K; Suh, C; Wu, HG | 1 |
| Ahn, JG; Choi, BG; Han, JY; Lee, KS; Song, DH; Yoon, JS | 1 |
| Belani, CP; Harrington, D; Johnson, DH; Krook, J; Langer, C; Sandler, A; Schiller, JH; Zhu, J | 1 |
| Doi, S; Fukuda, M; Kanda, T; Kawabata, S; Kinoshita, A; Kohno, S; Nagashima, S; Nakamura, Y; Narasaki, F; Oka, M; Soda, H; Suenaga, M; Takatani, H; Tsurutani, J | 1 |
| Nishiwaki, Y; Saijo, N; Sakai, H; Tamura, T; Watanabe, K; Yokoyama, A; Yoneda, S | 1 |
| Albers, A; Amoscato, AA; Lotze, MT; Odoux, C; Wong, MK | 1 |
| Goto, K; Kakinuma, R; Kubota, K; Matsumoto, T; Niho, S; Nishiwaki, Y; Ohe, Y; Ohmatsu, H | 1 |
| Clegg, A; Hewitson, P; Scott, DA; Sidhu, M; Waugh, N | 2 |
| Curigliano, G; Danesi, R; De Braud, F; De Pas, T; Del Tacca, M; Fogli, S; Giovannetti, G | 1 |
| Bernardo, P; Bonomi, P; Cella, D; Johnson, DH; Kugler, JW; Langer, CJ; Manola, J | 1 |
| Bröker, LE; Ferreira, CG; Giaccone, G; Huisman, C; Kruyt, FA; Postmus, PE; Rodriguez, JA; Smit, EF | 1 |
| Barbounis, V; Dahabre, J; Demiri, M; Efremidis, AP; Gontikakis, E; Koumakis, G; Pamouksoglou, P; Vassilomanolakis, M | 1 |
| Baba, H; Hoffmeier, A; Kamanabrou, D; Roos, N; Rothenburger, M; Scheld, HH; Schmidt, C; Semik, M | 1 |
| Crowley, JJ; Gandara, DR; Grevstad, P; Kelly, K; Lovato, LC; Moinpour, CM; Presant, CA; Ramsey, SD; Rivkin, SE | 1 |
| Dimitropoulos, D; Kalofonos, HP; Kosmas, C; Makatsoris, T; Onyenadum, A; Rokana, S; Sepsas, E; Stavroyianni, N; Tsavaris, NB; Vadiaka, M | 1 |
| Bakri, K; Gitten, R; Kies, MS; Lee, J; Lee, JH; Moore, M; Peterman, A; Schell, MJ; Socinski, MA; Tynan, M; Unger, P; Yates, S | 1 |
| Burkes, RL; Feld, R; Goodwin, PJ; Kwong, R; Leighl, NB; Shepherd, FA | 1 |
| Ho, ST; Ho, YJ; Kao, CH; Shiau, YC; Tsai, SC; Wang, JJ | 1 |
| Alila, H; Bunn, PA; Chan, DC; Earle, K; Helfrich, B; Kelly, K; Pamukcu, R; Piazza, G; Thompson, W; Whitehead, CM; Zhao, TL | 1 |
| Alila, H; Baron, A; Bunn, PA; Chan, DC; Earle, KA; Helfrich, B; Nelson, P; Pamukcu, R; Piazza, G; Thompson, WJ; Whitehead, CM; Zeng, C; Zhao, TL | 1 |
| Kato, Y; Saijo, N | 1 |
| Burke, P; Gandour-Edwards, R; Guo, L; Lau, D; Lo, SH | 1 |
| Axelrod, RS; Chapman, AE; Curran, WJ; Deshields, M; Friedland, DP; Grubbs, S; Hauck, W; Rose, LJ; Werner-Wasik, M | 1 |
| Douillard, JY | 1 |
| Mavroudis, D | 1 |
| Chen, JG; Horwitz, SB | 1 |
| Atagi, S; Haryu, H; Hosoe, S; Inoue, K; Kawaguchi, T; Kawahara, M; Mitsuoka, S; Naka, N; Ogawara, M; Okishio, K; Origasa, H; Sunami, T; Yoneda, T | 1 |
| Adelstein, DJ; Carroll, MA; Ciezki, JP; DeCamp, MM; Greskovich, JF; Rice, TW; Rybicki, LA | 1 |
| Georgoulias, V | 1 |
| Bunn, PA; Chan, DC; Chan, KK; Covey, JM; Feng, WY; Gera, L; Helfrich, B; Stewart, JM; Zhao, TL | 1 |
| Dierlamm, T; Dürk, H; Fiedler, W; Knuffmann, C; Kurt Hossfeld, D; Laack, E; Popp, J; Schmied, B; Verpoort, K; Wacker-Backerhaus, G; Zeller, W | 1 |
| Choi, YH; Hong, DS; In, KH; Jeong, TJ; Kim, HK; Kim, JS; Kim, YH; Lee, KS; Lee, SN; Lee, YY; Nam, E; Park, HS | 1 |
| Buckner, ZM; Crowley, J; Czaplicki, K; Gandara, DR; Ganz, PA; Grevstad, PK; Kelly, K; Lovato, LC; Lyons, B; Moinpour, CM | 1 |
| Breathnach, OS; Edison, M; Georgiadis, MS; Herscher, L; Johnson, BE; Kasturi, V; Kaye, F; O'Neil, K; Pizzella, P; Schuler, BS; Steinberg, SM | 1 |
| Kato, H; Tsuboi, M | 1 |
| Athanassiou, A; Bountouroglou, N; Glotsos, J; Karvounis, N; Kouloubinis, A; Pectasides, D; Visvikis, A; Ziras, N | 1 |
| Fujita, A; Hoshino, H; Ohkubo, T; Sekine, K; Tagaki, S; Takabatake, H | 1 |
| Berghmans, T; Klastersky, J; Lafitte, JJ; Mommen, P; Ninane, V; Paesmans, M; Recloux, P; Richez, M; Sculier, JP; Van Cutsem, O | 1 |
| Kalofonos, HP; Kosmas, C; Tsavaris, N | 1 |
| Belleguic, C; Blanchon, F; Coste, E; Fournel, P; Le Caer, H; Léna, H; Pérol, M; Pham, E; Robinet, G; Schuller-Lebeau, MP; Thomas, P; Vergnenègre, A; Vernejoux, JM | 1 |
| Cortés-Funes, H | 1 |
| Gray, JR; Greco, FA; Hainsworth, JD; Hon, JK; Kalman, LA; Morrissey, LH | 1 |
| Hino, M; Kudo, S | 1 |
| Takigawa, N | 1 |
| Takeda, K | 1 |
| Watanabe, H | 1 |
| Arbea, L; Calvo, E; Cambeiro, M; Cortes, J; Diaz-Gonzalez, JA; Garcia-Foncillas, J; Garzon, C; Gil-Bazo, I; Gurpide, A; Martin-Algarra, S; Navarro, V; Nicolas, AI; Rodriguez, J | 1 |
| Cheson, BD | 1 |
| Furuse, K; Kawahara, M | 1 |
| Pautier, P | 1 |
| Chen, S; Dai, S; Liu, Y; Shao, T; Shou, L; Shu, Q; Wang, H; Xu, Z; Zhang, GC; Zhao, F | 1 |
| Wang, J; Zhang, H; Zhang, S | 1 |
| Cai, X; Chen, S; Chen, T; Chen, Y; Dai, S; Shou, L; Shu, Q; Wang, H; Zhang, G | 1 |
| An, SH; Guo, QM; Jiang, YQ; Liu, QY; Su, F; Tai, JB; Xu, JL; Xu, XC; Xu, XP | 1 |
295 review(s) available for paclitaxel and Carcinoma, Non-Small Cell Lung
| Article | Year |
|---|---|
Efficacy and safety of apatinib alone or apatinib plus paclitaxel/docetaxel versus paclitaxel/docetaxel in the treatment of advanced non-small cell lung cancer: A meta-analysis.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Docetaxel; Humans; Lung Neoplasms; Paclitaxel; Protein Kinase Inhibitors; Pyridines | 2021 |
Liposomal formulations for lung cancer treatment in the last two decades: a systematic review.
Topics: Carcinoma, Non-Small-Cell Lung; Cisplatin; Humans; Liposomes; Lung Neoplasms; Paclitaxel | 2022 |
A network meta-analysis for efficacies and toxicities of different concurrent chemoradiotherapy regimens in the treatment of locally advanced non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Cisplatin; Docetaxel; Etoposide; Humans; Irinotecan; Lung Neoplasms; Network Meta-Analysis; Paclitaxel; Pemetrexed; Vinorelbine | 2022 |
Efficacy and safety of anlotinib combined with PD-1/PD-L1 inhibitors as second-line and subsequent therapy in advanced small-cell lung cancer.
Topics: Antineoplastic Agents, Immunological; B7-H1 Antigen; Carcinoma, Non-Small-Cell Lung; China; Humans; Immune Checkpoint Inhibitors; Lung Neoplasms; Paclitaxel; Programmed Cell Death 1 Receptor; Small Cell Lung Carcinoma | 2023 |
Sarcopenia as a Determinant of the Efficacy of Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer: A Meta-Analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Body Composition; Carcinoma, Non-Small-Cell Lung; Humans; Immune Checkpoint Inhibitors; Lung Neoplasms; Neoplasms; Odds Ratio; Paclitaxel; Prospective Studies; Sarcopenia | 2023 |
Atezolizumab First-Line Combination Therapy: A Review in Metastatic Nonsquamous NSCLC.
Topics: Albumins; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Non-Small-Cell Lung; Humans; Lung Neoplasms; Neoplasm Metastasis; Paclitaxel; Prognosis; Randomized Controlled Trials as Topic; Survival Rate | 2019 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor Proteins, Signal Transducing; Adenine; Adenocarcinoma; Adipogenesis; Administration, Cutaneous; Administration, Ophthalmic; Adolescent; Adsorption; Adult; Aeromonas hydrophila; Aerosols; Aged; Aged, 80 and over; Aging; Agriculture; Air Pollutants; Air Pollution; Airway Remodeling; Alanine Transaminase; Albuminuria; Aldehyde Dehydrogenase 1 Family; Algorithms; AlkB Homolog 2, Alpha-Ketoglutarate-Dependent Dioxygenase; Alzheimer Disease; Amino Acid Sequence; Ammonia; Ammonium Compounds; Anaerobiosis; Anesthetics, Dissociative; Anesthetics, Inhalation; Animals; Anti-Bacterial Agents; Anti-HIV Agents; Anti-Infective Agents; Anti-Inflammatory Agents; Antibiotics, Antineoplastic; Antibodies, Antineutrophil Cytoplasmic; Antibodies, Monoclonal, Humanized; Antifungal Agents; Antigens, Bacterial; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Antitubercular Agents; Antiviral Agents; Apolipoproteins E; Apoptosis; Arabidopsis; Arabidopsis Proteins; Arsenic; Arthritis, Rheumatoid; Asthma; Atherosclerosis; ATP-Dependent Proteases; Attitude of Health Personnel; Australia; Austria; Autophagy; Axitinib; Bacteria; Bacterial Outer Membrane Proteins; Bacterial Proteins; Bacterial Toxins; Bacterial Typing Techniques; Bariatric Surgery; Base Composition; Bayes Theorem; Benzoxazoles; Benzylamines; beta Catenin; Betacoronavirus; Betula; Binding Sites; Biological Availability; Biological Oxygen Demand Analysis; Biomarkers; Biomarkers, Tumor; Biopsy; Bioreactors; Biosensing Techniques; Birth Weight; Blindness; Blood Chemical Analysis; Blood Gas Analysis; Blood Glucose; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Blood-Brain Barrier; Blotting, Western; Body Mass Index; Body Weight; Bone and Bones; Bone Density; Bone Resorption; Borates; Brain; Brain Infarction; Brain Injuries, Traumatic; Brain Neoplasms; Breakfast; Breast Milk Expression; Breast Neoplasms; Bronchi; Bronchoalveolar Lavage Fluid; Buffaloes; Cadherins; Calcification, Physiologic; Calcium Compounds; Calcium, Dietary; Cannula; Caprolactam; Carbon; Carbon Dioxide; Carboplatin; Carcinogenesis; Carcinoma, Ductal; Carcinoma, Ehrlich Tumor; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Pancreatic Ductal; Carcinoma, Renal Cell; Cardiovascular Diseases; Carps; Carrageenan; Case-Control Studies; Catalysis; Catalytic Domain; Cattle; CD8-Positive T-Lymphocytes; Cell Adhesion; Cell Cycle Proteins; Cell Death; Cell Differentiation; Cell Line; Cell Line, Tumor; Cell Movement; Cell Nucleus; Cell Phone Use; Cell Proliferation; Cell Survival; Cell Transformation, Neoplastic; Cell Transformation, Viral; Cells, Cultured; Cellulose; Chemical Phenomena; Chemoradiotherapy; Child; Child Development; Child, Preschool; China; Chitosan; Chlorocebus aethiops; Cholecalciferol; Chromatography, Liquid; Circadian Clocks; Circadian Rhythm; Circular Dichroism; Cisplatin; Citric Acid; Clinical Competence; Clinical Laboratory Techniques; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clostridioides difficile; Clostridium Infections; Coculture Techniques; Cohort Studies; Cold Temperature; Colitis; Collagen Type I; Collagen Type I, alpha 1 Chain; Collagen Type XI; Color; Connective Tissue Diseases; Copper; Coronary Angiography; Coronavirus 3C Proteases; Coronavirus Infections; Cost of Illness; Counselors; COVID-19; COVID-19 Testing; Creatine Kinase; Creatinine; Cross-Over Studies; Cross-Sectional Studies; Cryoelectron Microscopy; Cryosurgery; Crystallography, X-Ray; Cues; Cultural Competency; Cultural Diversity; Curriculum; Cyclic AMP Response Element-Binding Protein; Cyclin-Dependent Kinase Inhibitor p21; Cycloparaffins; Cysteine Endopeptidases; Cytokines; Cytoplasm; Cytoprotection; Databases, Factual; Denitrification; Deoxycytidine; Diabetes Complications; Diabetes Mellitus; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diagnosis, Differential; Diatoms; Diet; Diet, High-Fat; Dietary Exposure; Diffusion Magnetic Resonance Imaging; Diketopiperazines; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Disease Models, Animal; Disease Progression; Disease-Free Survival; DNA; DNA Damage; DNA Glycosylases; DNA Repair; DNA-Binding Proteins; DNA, Bacterial; DNA, Viral; Docetaxel; Dose Fractionation, Radiation; Dose-Response Relationship, Drug; Down-Regulation; Doxorubicin; Drosophila; Drosophila melanogaster; Drug Carriers; Drug Delivery Systems; Drug Liberation; Drug Repositioning; Drug Resistance, Bacterial; Drug Resistance, Multiple, Bacterial; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; Drug Therapy, Combination; Edema; Edible Grain; Education, Graduate; Education, Medical, Graduate; Education, Pharmacy; Ehlers-Danlos Syndrome; Electron Transport Complex III; Electron Transport Complex IV; Electronic Nicotine Delivery Systems; Emergency Service, Hospital; Empathy; Emulsions; Endothelial Cells; Endurance Training; Energy Intake; Enterovirus A, Human; Environment; Environmental Monitoring; Enzyme Assays; Enzyme Inhibitors; Epithelial Cells; Epithelial-Mesenchymal Transition; Epoxide Hydrolases; Epoxy Compounds; Erythrocyte Count; Erythrocytes; Escherichia coli; Escherichia coli Infections; Escherichia coli Proteins; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Esophagectomy; Estrogens; Etanercept; Ethiopia; Ethnicity; Ethylenes; Exanthema; Exercise; Exercise Test; Exercise Tolerance; Extracellular Matrix; Extracorporeal Membrane Oxygenation; Eye Infections, Fungal; False Negative Reactions; Fatty Acids; Fecal Microbiota Transplantation; Feces; Female; Femur Neck; Fermentation; Ferritins; Fetal Development; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Fibroblasts; Fibroins; Fish Proteins; Flavanones; Flavonoids; Focus Groups; Follow-Up Studies; Food Handling; Food Supply; Food, Formulated; Forced Expiratory Volume; Forests; Fractures, Bone; Fruit and Vegetable Juices; Fusobacteria; G1 Phase Cell Cycle Checkpoints; G2 Phase Cell Cycle Checkpoints; Gamma Rays; Gastrectomy; Gastrointestinal Microbiome; Gastrointestinal Stromal Tumors; Gefitinib; Gels; Gemcitabine; Gene Amplification; Gene Expression; Gene Expression Regulation; Gene Expression Regulation, Bacterial; Gene Expression Regulation, Neoplastic; Gene Expression Regulation, Plant; Gene Knockdown Techniques; Gene-Environment Interaction; Genotype; Germany; Glioma; Glomerular Filtration Rate; Glucagon; Glucocorticoids; Glycemic Control; Glycerol; Glycogen Synthase Kinase 3 beta; Glycolipids; Glycolysis; Goblet Cells; Gram-Negative Bacterial Infections; Granulocyte Colony-Stimulating Factor; Graphite; Greenhouse Effect; Guanidines; Haemophilus influenzae; HCT116 Cells; Health Knowledge, Attitudes, Practice; Health Personnel; Health Services Accessibility; Health Services Needs and Demand; Health Status Disparities; Healthy Volunteers; Heart Failure; Heart Rate; Heart Transplantation; Heart-Assist Devices; HEK293 Cells; Heme; Heme Oxygenase-1; Hemolysis; Hemorrhage; Hepatitis B; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Hepatocytes; Hexoses; High-Throughput Nucleotide Sequencing; Hippo Signaling Pathway; Histamine; Histamine Agonists; Histidine; Histone Deacetylase 2; HIV Infections; HIV Reverse Transcriptase; HIV-1; Homebound Persons; Homeodomain Proteins; Homosexuality, Male; Hospice and Palliative Care Nursing; HSP70 Heat-Shock Proteins; Humans; Hyaluronan Receptors; Hydrogen; Hydrogen Peroxide; Hydrogen-Ion Concentration; Hydrolysis; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemia; Hypoglycemic Agents; Hypoxia; Idiopathic Interstitial Pneumonias; Imaging, Three-Dimensional; Imatinib Mesylate; Immunotherapy; Implementation Science; Incidence; INDEL Mutation; Induced Pluripotent Stem Cells; Industrial Waste; Infant; Infant, Newborn; Inflammation; Inflammation Mediators; Infliximab; Infusions, Intravenous; Inhibitory Concentration 50; Injections; Insecticides; Insulin-Like Growth Factor Binding Protein 5; Insulin-Secreting Cells; Interleukin-1; Interleukin-17; Interleukin-8; Internship and Residency; Intestines; Intracellular Signaling Peptides and Proteins; Ion Transport; Iridaceae; Iridoid Glucosides; Islets of Langerhans Transplantation; Isodon; Isoflurane; Isotopes; Italy; Joint Instability; Ketamine; Kidney; Kidney Failure, Chronic; Kidney Function Tests; Kidney Neoplasms; Kinetics; Klebsiella pneumoniae; Knee Joint; Kruppel-Like Factor 4; Kruppel-Like Transcription Factors; Lactate Dehydrogenase 5; Laparoscopy; Laser Therapy; Lasers, Semiconductor; Lasers, Solid-State; Laurates; Lead; Leukocyte L1 Antigen Complex; Leukocytes, Mononuclear; Light; Lipid Peroxidation; Lipopolysaccharides; Liposomes; Liver; Liver Cirrhosis; Liver Neoplasms; Liver Transplantation; Locomotion; Longitudinal Studies; Lopinavir; Lower Urinary Tract Symptoms; Lubricants; Lung; Lung Diseases, Interstitial; Lung Neoplasms; Lymphocyte Activation; Lymphocytes, Tumor-Infiltrating; Lymphoma, Mantle-Cell; Lysosomes; Macrophages; Male; Manganese Compounds; MAP Kinase Kinase 4; Mass Screening; Maternal Health; Medicine, Chinese Traditional; Melanoma, Experimental; Memantine; Membrane Glycoproteins; Membrane Proteins; Mesenchymal Stem Cell Transplantation; Metal Nanoparticles; Metalloendopeptidases; Metalloporphyrins; Methadone; Methane; Methicillin-Resistant Staphylococcus aureus; Mexico; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Inbred ICR; Mice, Knockout; Mice, Nude; Mice, SCID; Mice, Transgenic; Microarray Analysis; Microbial Sensitivity Tests; Microbiota; Micronutrients; MicroRNAs; Microscopy, Confocal; Microsomes, Liver; Middle Aged; Milk; Milk, Human; Minority Groups; Mitochondria; Mitochondrial Membranes; Mitochondrial Proteins; Models, Animal; Models, Molecular; Molecular Conformation; Molecular Docking Simulation; Molecular Dynamics Simulation; Molecular Epidemiology; Molecular Structure; Molecular Weight; Multilocus Sequence Typing; Multimodal Imaging; Muscle Strength; Muscle, Skeletal; Muscular Diseases; Mutation; Mycobacterium tuberculosis; Myocardial Stunning; Myristates; NAD(P)H Dehydrogenase (Quinone); Nanocomposites; Nanogels; Nanoparticles; Nanotechnology; Naphthalenes; Nasal Cavity; National Health Programs; Necrosis; Needs Assessment; Neoadjuvant Therapy; Neonicotinoids; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Proteins; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasm Transplantation; Neoplasms; Neoplastic Stem Cells; Netherlands; Neuroblastoma; Neuroprotective Agents; Neutrophils; NF-kappa B; NFATC Transcription Factors; Nicotiana; Nicotine; Nitrates; Nitrification; Nitrites; Nitro Compounds; Nitrogen; Nitrogen Dioxide; North Carolina; Nuclear Magnetic Resonance, Biomolecular; Nuclear Proteins; Nucleic Acid Hybridization; Nucleosomes; Nutrients; Obesity; Obesity, Morbid; Oceans and Seas; Oncogene Protein v-akt; Oncogenes; Oocytes; Open Reading Frames; Osteoclasts; Osteogenesis; Osteoporosis; Osteoporosis, Postmenopausal; Outpatients; Ovarian Neoplasms; Ovariectomy; Overweight; Oxazines; Oxidants; Oxidation-Reduction; Oxidative Stress; Oxides; Oxidoreductases; Oxygen; Oxygen Inhalation Therapy; Oxygenators, Membrane; Ozone; Paclitaxel; Paenibacillus; Pain Measurement; Palliative Care; Pancreatic Neoplasms; Pandemics; Parasympathetic Nervous System; Particulate Matter; Pasteurization; Patient Preference; Patient Satisfaction; Pediatric Obesity; Permeability; Peroxiredoxins; Peroxynitrous Acid; Pharmaceutical Services; Pharmacists; Pharmacy; Phaseolus; Phenotype; Phoeniceae; Phosphates; Phosphatidylinositol 3-Kinases; Phospholipid Transfer Proteins; Phospholipids; Phosphorus; Phosphorylation; Photoperiod; Photosynthesis; Phylogeny; Physical Endurance; Physicians; Pilot Projects; Piperidines; Pituitary Adenylate Cyclase-Activating Polypeptide; Plant Extracts; Plant Leaves; Plant Proteins; Plant Roots; Plaque, Atherosclerotic; Pneumonia; Pneumonia, Viral; Point-of-Care Testing; Polyethylene Glycols; Polymers; Polysorbates; Pore Forming Cytotoxic Proteins; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Postprandial Period; Poverty; Pre-Exposure Prophylaxis; Prediabetic State; Predictive Value of Tests; Pregnancy; Pregnancy Trimester, First; Pregnancy, High-Risk; Prenatal Exposure Delayed Effects; Pressure; Prevalence; Primary Graft Dysfunction; Primary Health Care; Professional Role; Professionalism; Prognosis; Progression-Free Survival; Prolactin; Promoter Regions, Genetic; Proof of Concept Study; Proportional Hazards Models; Propylene Glycol; Prospective Studies; Prostate; Protein Binding; Protein Biosynthesis; Protein Isoforms; Protein Kinase Inhibitors; Protein Phosphatase 2; Protein Processing, Post-Translational; Protein Serine-Threonine Kinases; Protein Structure, Tertiary; Protein Transport; Proteoglycans; Proteome; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-myc; Proto-Oncogene Proteins c-ret; Proto-Oncogene Proteins p21(ras); Proton Pumps; Protons; Protoporphyrins; Pseudomonas aeruginosa; Pseudomonas fluorescens; Pulmonary Artery; Pulmonary Disease, Chronic Obstructive; Pulmonary Gas Exchange; Pulmonary Veins; Pyrazoles; Pyridines; Pyrimidines; Qualitative Research; Quinoxalines; Rabbits; Random Allocation; Rats; Rats, Sprague-Dawley; Rats, Wistar; Receptors, Histamine H3; Receptors, Immunologic; Receptors, Transferrin; Recombinant Proteins; Recurrence; Reference Values; Referral and Consultation; Regional Blood Flow; Registries; Regulon; Renal Insufficiency, Chronic; Reperfusion Injury; Repressor Proteins; Reproducibility of Results; Republic of Korea; Research Design; Resistance Training; Respiration, Artificial; Respiratory Distress Syndrome; Respiratory Insufficiency; Resuscitation; Retinal Dehydrogenase; Retreatment; Retrospective Studies; Reverse Transcriptase Inhibitors; Rhinitis, Allergic; Ribosomal Proteins; Ribosomes; Risk Assessment; Risk Factors; Ritonavir; Rivers; RNA Interference; RNA-Seq; RNA, Messenger; RNA, Ribosomal, 16S; RNA, Small Interfering; Rosuvastatin Calcium; Rural Population; Saccharomyces cerevisiae; Saccharomyces cerevisiae Proteins; Salivary Ducts; Salivary Gland Neoplasms; San Francisco; SARS-CoV-2; Satiation; Satiety Response; Schools; Schools, Pharmacy; Seasons; Seawater; Selection, Genetic; Sequence Analysis, DNA; Serine-Threonine Kinase 3; Sewage; Sheep; Sheep, Domestic; Shock, Hemorrhagic; Signal Transduction; Silver; Silymarin; Single Photon Emission Computed Tomography Computed Tomography; Sirolimus; Sirtuin 1; Skin; Skin Neoplasms; Skin Physiological Phenomena; Sleep Initiation and Maintenance Disorders; Social Class; Social Participation; Social Support; Soil; Soil Microbiology; Solutions; Somatomedins; Soot; Specimen Handling; Spectrophotometry, Ultraviolet; Spectroscopy, Fourier Transform Infrared; Spectrum Analysis; Spinal Fractures; Spirometry; Staphylococcus aureus; STAT1 Transcription Factor; STAT3 Transcription Factor; Streptomyces coelicolor; Stress, Psychological; Stroke; Stroke Volume; Structure-Activity Relationship; Students, Medical; Students, Pharmacy; Substance Abuse Treatment Centers; Sulfur Dioxide; Surface Properties; Surface-Active Agents; Surveys and Questionnaires; Survival Analysis; Survival Rate; Survivin; Sweden; Swine; Swine, Miniature; Sympathetic Nervous System; T-Lymphocytes, Regulatory; Talaromyces; Tandem Mass Spectrometry; tau Proteins; Telemedicine; Telomerase; Telomere; Telomere Homeostasis; Temperature; Terminally Ill; Th1 Cells; Thiamethoxam; Thiazoles; Thiophenes; Thioredoxin Reductase 1; Thrombosis; Thulium; Thyroid Cancer, Papillary; Thyroid Carcinoma, Anaplastic; Thyroid Neoplasms; Time Factors; Titanium; Tomography, Emission-Computed, Single-Photon; Tomography, X-Ray Computed; TOR Serine-Threonine Kinases; Transcription Factor AP-1; Transcription Factors; Transcription, Genetic; Transcriptional Activation; Transcriptome; Transforming Growth Factor beta1; Transistors, Electronic; Translational Research, Biomedical; Transplantation Tolerance; Transplantation, Homologous; Transportation; Treatment Outcome; Tretinoin; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary; Tubulin Modulators; Tumor Microenvironment; Tumor Necrosis Factor Inhibitors; Tumor Necrosis Factor-alpha; Twins; Ultrasonic Therapy; Ultrasonography; Ultraviolet Rays; United States; Up-Regulation; Uranium; Urethra; Urinary Bladder; Urodynamics; Uromodulin; Uveitis; Vasoconstrictor Agents; Ventricular Function, Left; Vero Cells; Vesicular Transport Proteins; Viral Nonstructural Proteins; Visual Acuity; Vital Capacity; Vitamin D; Vitamin D Deficiency; Vitamin K 2; Vitamins; Volatilization; Voriconazole; Waiting Lists; Waste Disposal, Fluid; Wastewater; Water Pollutants, Chemical; Whole Genome Sequencing; Wine; Wnt Signaling Pathway; Wound Healing; Wounds and Injuries; WW Domains; X-linked Nuclear Protein; X-Ray Diffraction; Xanthines; Xenograft Model Antitumor Assays; YAP-Signaling Proteins; Yogurt; Young Adult; Zebrafish; Zebrafish Proteins; Ziziphus | 2016 |
First-line albumin-bound paclitaxel/carboplatin plus apatinib in advanced pulmonary sarcomatoid carcinoma: A case series and review of the literature.
Topics: Aged; Albumins; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Carboplatin; Carcinoma, Non-Small-Cell Lung; Humans; Lung Neoplasms; Male; Middle Aged; Non-Smokers; Paclitaxel; Pyridines; Smokers; Tomography, X-Ray Computed | 2020 |
First-Line Immune Checkpoint Inhibition for Advanced Non-Small-Cell Lung Cancer: State of the Art and Future Directions.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; B7-H1 Antigen; Carboplatin; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; CTLA-4 Antigen; Humans; Immune Checkpoint Inhibitors; Ipilimumab; Lung; Lung Neoplasms; Neoplasm Recurrence, Local; Nivolumab; Paclitaxel; Pemetrexed; Programmed Cell Death 1 Receptor; Progression-Free Survival; Quality of Life; Review Literature as Topic | 2020 |
Local administration of submicron particle paclitaxel to solid carcinomas induces direct cytotoxicity and immune-mediated tumoricidal effects without local or systemic toxicity: preclinical and clinical studies.
Topics: Carcinoma; Carcinoma, Non-Small-Cell Lung; Humans; Immunotherapy; Lung Neoplasms; Male; Paclitaxel | 2021 |
Recent Advances in Elucidating Paclitaxel Resistance Mechanisms in Non-small Cell Lung Cancer and Strategies to Overcome Drug Resistance.
Topics: Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; Humans; Lung Neoplasms; Paclitaxel | 2020 |
First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
Topics: Afatinib; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bias; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cetuximab; Crown Ethers; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Paclitaxel; Pemetrexed; Progression-Free Survival; Protein Kinase Inhibitors; Quality of Life; Quinazolines; Randomized Controlled Trials as Topic | 2021 |
The impacts of race and regimens on the efficacy and safety of paclitaxel and platinum combination treatment for patients with advanced non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Asian People; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; Lung Neoplasms; Monte Carlo Method; Neoplasm Staging; Paclitaxel; Platinum; Survival Analysis | 2021 |
Clinical option of pemetrexed-based versus paclitaxel-based first-line chemotherapeutic regimens in combination with bevacizumab for advanced non-squamous non-small-cell lung cancer and optimal maintenance therapy: evidence from a meta-analysis of randomi
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Female; Humans; Induction Chemotherapy; Lung Neoplasms; Maintenance Chemotherapy; Male; Neoplasm Metastasis; Neoplasm Staging; Paclitaxel; Pemetrexed; Publication Bias; Randomized Controlled Trials as Topic; Treatment Outcome | 2021 |
The best platinum regimens for chemo-naive incurable non-small cell lung cancer: network meta-analysis.
Topics: Antineoplastic Agents; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Lung Neoplasms; Network Meta-Analysis; Paclitaxel; Platinum | 2017 |
Anticancer drug treatment for advanced lung cancer with interstitial lung disease.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease Progression; Etoposide; Follow-Up Studies; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Paclitaxel; Platinum; Retrospective Studies; Risk Assessment; Risk Factors | 2018 |
Antiangiogenic therapies in non-small-cell lung cancer.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Humans; Lung Neoplasms; Neovascularization, Pathologic; Paclitaxel | 2018 |
Clinical efficacy and safety of Aidi injection plus paclitaxel-based chemotherapy for advanced non-small cell lung cancer: A meta-analysis of 31 randomized controlled trials following the PRISMA guidelines.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Drugs, Chinese Herbal; Humans; Lung Neoplasms; Paclitaxel; Phytotherapy; Randomized Controlled Trials as Topic; Treatment Outcome | 2019 |
Nanoparticle albumin bound-paclitaxel for treatment of advanced non-small cell lung cancer: an evaluation of the clinical evidence.
Topics: Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Humans; Lung Neoplasms; Paclitaxel | 2019 |
Pembrolizumab plus chemotherapy for first-line treatment of metastatic nonsquamous non-small-cell lung cancer: a network meta-analysis.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Humans; Lung Neoplasms; Neoplasm Metastasis; Paclitaxel; Pemetrexed; Survival Rate | 2019 |
Breast cancer susceptibility gene 1 (BRCA1) predict clinical outcome in platinum- and toxal-based chemotherapy in non-small-cell lung cancer (NSCLC) patients: a system review and meta-analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Female; Genes, BRCA1; Humans; Lung Neoplasms; Organoplatinum Compounds; Paclitaxel; Randomized Controlled Trials as Topic; Treatment Outcome | 2013 |
Cisplatin versus carboplatin in combination with third-generation drugs for advanced non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Lung Neoplasms; Paclitaxel; Randomized Controlled Trials as Topic | 2013 |
[Contemporary trends of the adjutant chemotherapy in non-small cell lung cancer].
Topics: Age Factors; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Cisplatin; Deoxycytidine; Docetaxel; Evidence-Based Medicine; Gemcitabine; Humans; Lung Neoplasms; Neoplasm Staging; Paclitaxel; Prognosis; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2013 |
First line treatment of advanced non-small-cell lung cancer - specific focus on albumin bound paclitaxel.
Topics: Albumins; Animals; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Humans; Lung Neoplasms; Nanocapsules; Paclitaxel; Particle Size; Treatment Outcome | 2014 |
nab-paclitaxel for the management of patients with advanced non-small-cell lung cancer.
Topics: Albumins; Animals; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Drug Approval; Humans; Lung Neoplasms; Paclitaxel; Survival; Treatment Outcome; United States; United States Food and Drug Administration | 2014 |
Efficacy of motesanib diphosphate in non-small-cell lung cancer.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Humans; Indoles; Lung; Lung Neoplasms; Neovascularization, Pathologic; Niacinamide; Oligonucleotides; Paclitaxel; Protein Kinase Inhibitors; Protein-Tyrosine Kinases | 2014 |
Exploring the potential of immuno-oncology-based treatment for patients with non-small cell lung cancer.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Humans; Immunotherapy; Lung Neoplasms; Paclitaxel | 2015 |
nab-Paclitaxel for the treatment of advanced squamous non-small-cell lung cancer: a comprehensive update.
Topics: Albumins; Animals; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Clinical Trials, Phase III as Topic; Drug Therapy, Combination; Humans; Lung Neoplasms; Neoplasm Staging; Paclitaxel | 2014 |
Radiation dose in non-small cell lung cancer: too much of a good thing?
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cetuximab; Clinical Trials, Phase I as Topic; Clinical Trials, Phase III as Topic; Dose Fractionation, Radiation; Hospitals, High-Volume; Humans; Incidence; Lung Neoplasms; Paclitaxel; Quality of Life; Radiation Injuries; Radiotherapy Dosage; Retreatment; Retrospective Studies; Treatment Outcome | 2014 |
Maintenance therapy in non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Gemcitabine; Humans; Lung Neoplasms; Paclitaxel | 2015 |
Chemotherapy plus Erlotinib versus Chemotherapy Alone for Treating Advanced Non-Small Cell Lung Cancer: A Meta-Analysis.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Multicenter Studies as Topic; Neoplasm Proteins; Paclitaxel; Pemetrexed; Protein Kinase Inhibitors; Publication Bias; Randomized Controlled Trials as Topic; Smoking; Treatment Outcome; Young Adult | 2015 |
Bevacizumab in Combination with Taxane versus Non-Taxane Containing Regimens for Advanced/Metastatic Nonsquamous Non-Small-Cell Lung Cancer: A Systematic Review.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Disease-Free Survival; Docetaxel; Humans; Lung Neoplasms; Neoplasm Staging; Paclitaxel; Survival Rate; Taxoids | 2015 |
Locally Advanced Non-Small Cell Lung Cancer: Optimal Chemotherapeutic Agents and Duration.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Cisplatin; Etoposide; Humans; Lung Neoplasms; Paclitaxel; Patient Selection; Precision Medicine; Radiotherapy, Adjuvant; Risk Factors | 2015 |
Prognostic value of survivin expression in stage III non-small cell lung cancer patients treated with platinum-based therapy.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Adenosquamous; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Combined Modality Therapy; Female; Follow-Up Studies; Humans; Immunoenzyme Techniques; Inhibitor of Apoptosis Proteins; Lung Neoplasms; Lymph Node Excision; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Prognosis; Retrospective Studies; Survival Rate; Survivin | 2015 |
Novel cytotoxic drugs in advanced nonsmall cell lung cancer.
Topics: Albumins; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Docetaxel; Humans; Lung Neoplasms; Organoplatinum Compounds; Paclitaxel; Taxoids; Treatment Outcome | 2016 |
Cisplatin in the modern era: The backbone of first-line chemotherapy for non-small cell lung cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Docetaxel; Drug Discovery; Gemcitabine; History, 19th Century; History, 20th Century; History, 21st Century; Humans; Lung Neoplasms; Paclitaxel; Taxoids | 2016 |
Is there a role of nab-paclitaxel in the treatment of advanced non-small cell lung cancer? The data suggest yes.
Topics: Albumins; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemistry, Pharmaceutical; Humans; Lung Neoplasms; Paclitaxel; Patient Selection; Risk Factors; Treatment Outcome | 2016 |
Treatment of Locally Advanced Non-Small Cell Lung Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Etoposide; Humans; Lung Neoplasms; Paclitaxel; Radiotherapy Dosage | 2017 |
EGFR-TKIs versus taxanes agents in therapy for nonsmall-cell lung cancer patients: A PRISMA-compliant systematic review with meta-analysis and meta-regression.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Docetaxel; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Paclitaxel; Quinazolines; Survival Analysis; Taxoids | 2016 |
Comparison of Concurrent Use of Thoracic Radiation With Either Carboplatin-Paclitaxel or Cisplatin-Etoposide for Patients With Stage III Non-Small-Cell Lung Cancer: A Systematic Review.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Cisplatin; Etoposide; Humans; Lung Neoplasms; Paclitaxel; Thorax | 2017 |
Third generation triplet cytotoxic chemotherapy in advanced non-small cell lung cancer: a systematic overview.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials, Phase III as Topic; Deoxycytidine; Gemcitabine; Humans; Ifosfamide; Lung Neoplasms; Paclitaxel; Randomized Controlled Trials as Topic; Vinblastine; Vinorelbine | 2009 |
The role of the taxanes in the treatment of older patients with advanced stage non-small cell lung cancer.
Topics: Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Docetaxel; Evidence-Based Medicine; Humans; Lung Neoplasms; Meta-Analysis as Topic; Neoplasm Staging; Paclitaxel; Palliative Care; Quality of Life; Randomized Controlled Trials as Topic; Severity of Illness Index; Taxoids; Treatment Outcome | 2009 |
Novel taxane formulations and microtubule-binding agents in non-small-cell lung cancer.
Topics: Antineoplastic Agents; Bibenzyls; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Drug Resistance, Neoplasm; Epothilones; Humans; Lung Neoplasms; Paclitaxel; Polyglutamic Acid; Tubulin Modulators; Vinblastine; Vinorelbine | 2009 |
Gefitinib in the treatment of advanced non-small-cell lung cancer.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Docetaxel; Double-Blind Method; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Multicenter Studies as Topic; Neoplasm Proteins; Paclitaxel; Protein Kinase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic; Research Design; Survival Analysis; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2009 |
Reasons for response differences seen in the V15-32, INTEREST and IPASS trials.
Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Asia; Asian People; Carboplatin; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; Disease Progression; Disease-Free Survival; Docetaxel; ErbB Receptors; Europe; Female; Gefitinib; Humans; Lung Neoplasms; Male; Multicenter Studies as Topic; Neoplasm Metastasis; Neoplasm Staging; North America; Paclitaxel; Platinum Compounds; Protein Kinase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic; Recurrence; South America; Survival Analysis; Taxoids; Tumor Burden | 2009 |
New options for integrating antiangiogenic therapy and platinum-based first-line chemotherapy for advanced non-small-cell lung cancer.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease Progression; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Paclitaxel; Platinum Compounds; Protein Kinase Inhibitors; Quinazolines; Vascular Endothelial Growth Factor A | 2008 |
What is the role of novel taxanes in non-small-cell lung cancer?
Topics: Antineoplastic Agents, Phytogenic; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cross-Linking Reagents; Docetaxel; Humans; Lung Neoplasms; Paclitaxel; Taxoids | 2008 |
Challenges in advanced NSCLC: optimizing platinum-based chemotherapy and treating special populations.
Topics: Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Carboplatin; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; Evidence-Based Medicine; Humans; Lung Neoplasms; Organoplatinum Compounds; Paclitaxel; Severity of Illness Index; Treatment Outcome | 2004 |
[Research progresses of albumin-bound paclitaxel in the treatment of non-small cell lung cancer].
Topics: Albumin-Bound Paclitaxel; Albumins; Carcinoma, Non-Small-Cell Lung; Humans; Lung Neoplasms; Neoplasm Staging; Paclitaxel; Survival Analysis; Treatment Outcome | 2010 |
Gemcitabine plus paclitaxel versus carboplatin plus either gemcitabine or paclitaxel in advanced non-small-cell lung cancer: a literature-based meta-analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Deoxycytidine; Gemcitabine; Humans; Lung Neoplasms; Paclitaxel; Randomized Controlled Trials as Topic | 2010 |
Personalized medicine in non-small-cell lung cancer: is KRAS a useful marker in selecting patients for epidermal growth factor receptor-targeted therapy?
Topics: Anaplastic Lymphoma Kinase; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Biomarkers, Tumor; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cell Cycle Proteins; Cetuximab; Cisplatin; Clinical Trials as Topic; Deoxycytidine; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gemcitabine; Humans; Lung Neoplasms; Microtubule-Associated Proteins; Mutation; Paclitaxel; Patient Selection; Precision Medicine; Predictive Value of Tests; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Receptor Protein-Tyrosine Kinases; Serine Endopeptidases; Signal Transduction; Survival Analysis; Translocation, Genetic | 2010 |
Future scenarios for the treatment of advanced non-small cell lung cancer: focus on taxane-containing regimens.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Docetaxel; Female; Humans; Lung Neoplasms; Male; Meta-Analysis as Topic; Paclitaxel; Randomized Controlled Trials as Topic; Retrospective Studies; Taxoids | 2010 |
Gefitinib for the first-line treatment of locally advanced or metastatic non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; Cost-Benefit Analysis; Gefitinib; Humans; Lung Neoplasms; Multicenter Studies as Topic; Paclitaxel; Quinazolines; Randomized Controlled Trials as Topic | 2010 |
[Metastatic non-small cell lung cancer: Systemic treatment of patients aged 70 and over].
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Deoxycytidine; Disease Progression; Drug Administration Schedule; Gemcitabine; Humans; Long-Term Care; Lung Neoplasms; Neoplasm Staging; Paclitaxel; Palliative Care; Prognosis; Vinblastine; Vinorelbine | 2011 |
Case report and review of literature: temporary asymptomatic sinus bradycardia with carboplatin, paclitaxel and bevacizumab: under-reported in clinical trials and under-disclosed in practice.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Bradycardia; Carboplatin; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Humans; Lung Neoplasms; Male; Paclitaxel | 2011 |
An indirect comparison of the efficacy of bevacizumab plus carboplatin and paclitaxel versus pemetrexed with cisplatin in patients with advanced or recurrent non-squamous adenocarcinoma non-small cell lung cancer.
Topics: Adenocarcinoma; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Disease-Free Survival; Glutamates; Guanine; Humans; Markov Chains; Paclitaxel; Pemetrexed; Treatment Outcome | 2011 |
A meta-analysis of paclitaxel-based chemotherapies administered once every week compared with once every 3 weeks first-line treatment of advanced non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Drug Administration Schedule; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Treatment Outcome | 2012 |
Association between class III β-tubulin expression and response to paclitaxel/vinorebine-based chemotherapy for non-small cell lung cancer: a meta-analysis.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Gene Expression; Humans; Lung Neoplasms; Paclitaxel; Survival Analysis; Treatment Outcome; Tubulin; Vinblastine; Vinorelbine | 2012 |
A paradigm shift in the treatment of advanced non-small cell lung cancer.
Topics: Antineoplastic Agents; Brain Neoplasms; Carboplatin; Carcinoma, Non-Small-Cell Lung; Female; Humans; Lung Neoplasms; Maintenance Chemotherapy; Middle Aged; Paclitaxel | 2012 |
The role of surgery for locally advanced non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Erlotinib Hydrochloride; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Lymphatic Metastasis; Multimodal Imaging; Neoplasm Staging; Paclitaxel; Positron-Emission Tomography; Prognosis; Protein Kinase Inhibitors; Quinazolines; Survival Rate; Tomography, X-Ray Computed | 2012 |
Predicting radiation pneumonitis after chemoradiation therapy for lung cancer: an international individual patient data meta-analysis.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Asia; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Cisplatin; Decision Trees; Etoposide; Europe; Female; Humans; Logistic Models; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; North America; Paclitaxel; Radiation Pneumonitis; Radiotherapy Dosage | 2013 |
Non-platinum doublets were as effective as platinum-based doublets for chemotherapy-naïve advanced non-small-cell lung cancer in the era of third-generation agents.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials as Topic; Deoxycytidine; Disease-Free Survival; Docetaxel; Gemcitabine; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Odds Ratio; Paclitaxel; Platinum Compounds; Publication Bias; Research Report; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2013 |
[Thermo-chemotherapy of GP or TP for advanced non-small cell lung cancer: a systematic review].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Hyperthermia, Induced; Lung Neoplasms; Paclitaxel; Safety; Taxoids | 2012 |
What future opportunities may immuno-oncology provide for improving the treatment of patients with lung cancer?
Topics: Antibodies, Monoclonal; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Cancer Vaccines; Carboplatin; Carcinoma, Non-Small-Cell Lung; CTLA-4 Antigen; Disease-Free Survival; Humans; Immunotherapy; Ipilimumab; Lactoferrin; Lung Neoplasms; Membrane Glycoproteins; Neoplasm Proteins; Nivolumab; Paclitaxel | 2012 |
Docetaxel for locally advanced or metastatic non-small-cell lung cancer. Current data and future directions as front-line therapy.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Docetaxel; Humans; Lung Neoplasms; Neoplasm Staging; Paclitaxel; Quality of Life; Taxoids | 2002 |
Docetaxel for previously treated non-small-cell lung cancer.
Topics: Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; Docetaxel; Humans; Lung Neoplasms; Paclitaxel; Quality of Life; Randomized Controlled Trials as Topic; Taxoids | 2002 |
Docetaxel and radiation as combined-modality therapy.
Topics: Antineoplastic Agents, Phytogenic; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Combined Modality Therapy; Docetaxel; Humans; Lung Neoplasms; Paclitaxel; Radiation-Sensitizing Agents; Taxoids | 2002 |
Phase I study of weekly CPT-11 (irinotecan)/docetaxel in patients with advanced solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Carcinoma, Squamous Cell; Docetaxel; Dose-Response Relationship, Drug; Female; Head and Neck Neoplasms; Humans; Irinotecan; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Paclitaxel; Taxoids; Treatment Outcome | 2002 |
Expanding horizons: an update on the use of docetaxel in non-small cell lung, ovarian, and breast cancers.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Docetaxel; Female; Humans; Lung Neoplasms; Male; Ovarian Neoplasms; Paclitaxel; Randomized Controlled Trials as Topic; Taxoids | 2002 |
Docetaxel in combination with platinums (cisplatin or carboplatin) in advanced and metastatic non-small cell lung cancer.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Docetaxel; Drug Administration Schedule; Humans; Lung Neoplasms; Paclitaxel; Randomized Controlled Trials as Topic; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2002 |
Perspectives and opportunities: Docetaxel in the current and future treatment of non-small cell lung cancer.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials, Phase II as Topic; Deoxycytidine; Docetaxel; Drug Administration Schedule; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Neoplasm Staging; Paclitaxel; Randomized Controlled Trials as Topic; Taxoids; Treatment Outcome | 2002 |
Concurrent administration of Docetaxel and Stealth liposomal doxorubicin with radiotherapy in non-small cell lung cancer : excellent tolerance using subcutaneous amifostine for cytoprotection.
Topics: Amifostine; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Docetaxel; Doxorubicin; Drug Administration Schedule; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Radiation-Protective Agents; Radiotherapy; Radiotherapy Dosage; Taxoids; Time Factors; Treatment Outcome | 2002 |
The case for the introduction of new chemotherapy agents in the treatment of advanced non small cell lung cancer in the wake of the findings of The National Institute of Clinical Excellence (NICE).
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Cisplatin; Clinical Trials as Topic; Deoxycytidine; Docetaxel; Drug Administration Schedule; Europe; Gemcitabine; Hematologic Diseases; Humans; Lung Neoplasms; Middle Aged; Paclitaxel; Palliative Care; Quality of Life; Randomized Controlled Trials as Topic; Survival Analysis; Taxoids; Treatment Outcome; United Kingdom; Vinblastine; Vinorelbine | 2002 |
[Randomized controlled trials in Japan--lung cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cisplatin; Clinical Trials, Phase III as Topic; Docetaxel; Humans; Irinotecan; Lung Neoplasms; Meta-Analysis as Topic; Paclitaxel; Randomized Controlled Trials as Topic; Survival Rate; Taxoids | 2002 |
[Gemcitabine-based chemotherapy for non-small cell lung cancer (NSCLC)--a review of 30 randomized trials].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Randomized Controlled Trials as Topic; Vinblastine; Vinorelbine | 2002 |
Platinum drugs in the treatment of non-small-cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials as Topic; Combined Modality Therapy; Etoposide; Humans; Lung Neoplasms; Paclitaxel | 2002 |
Non-platinum gemcitabine combinations in non-small cell lung cancer.
Topics: Aged; Aging; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Paclitaxel; Survival; Taxoids; Treatment Outcome | 2002 |
[Combinations of platinum salts and gemcitabine in the treatment of non-small-cell lung cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Deoxycytidine; Docetaxel; Etoposide; Gastrointestinal Diseases; Gemcitabine; Hematologic Diseases; Humans; Lung Neoplasms; Neoadjuvant Therapy; Paclitaxel; Pneumonectomy; Randomized Controlled Trials as Topic; Remission Induction; Reproducibility of Results; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2002 |
[New neoadjuvant approaches using gemcitabine in non-small-cell lung cancer].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials, Phase II as Topic; Combined Modality Therapy; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Lung Neoplasms; Neoadjuvant Therapy; Paclitaxel; Pneumonectomy; Randomized Controlled Trials as Topic; Remission Induction; Taxoids; Treatment Outcome | 2002 |
[Platinum-free gemcitabine-based combinations: an alternative to conventional chemotherapy of non-small-cell lung cancers?].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Deoxycytidine; Docetaxel; Gastrointestinal Diseases; Gemcitabine; Hematologic Diseases; Humans; Life Tables; Lung Neoplasms; Neoadjuvant Therapy; Paclitaxel; Pneumonectomy; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Remission Induction; Survival Analysis; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2002 |
Taxanes for advanced non-small cell lung cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials as Topic; Docetaxel; Drug Administration Schedule; Drug Resistance, Neoplasm; Humans; Lung Neoplasms; Paclitaxel; Taxoids | 2002 |
Second line chemotherapy for NSCLC: establishing a gold standard.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Docetaxel; Humans; Lung Neoplasms; Neoplasm Recurrence, Local; Paclitaxel; Prognosis; Quality of Life; Taxoids; Treatment Outcome | 2002 |
First-line chemotherapy for NSCLC: an overview of relevant trials.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials as Topic; Disease Progression; Docetaxel; Humans; Lung Neoplasms; Paclitaxel; Quality of Life; Survival; Taxoids; Treatment Outcome | 2002 |
Adjuvant and neoadjuvant treatments for NSCLC.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Cisplatin; Docetaxel; Dose Fractionation, Radiation; Etoposide; Humans; Lung Neoplasms; Neoadjuvant Therapy; Paclitaxel; Radiotherapy, Adjuvant; Survival; Taxoids | 2002 |
Challenging the platinum combinations in the chemotherapy of NSCLC.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials as Topic; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Neutropenia; Paclitaxel; Taxoids | 2002 |
Meeting the chemotherapy needs of elderly and poor performance status patients with NSCLC.
Topics: Aged; Aged, 80 and over; Aging; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Deoxycytidine; Docetaxel; Drug Administration Schedule; Gemcitabine; Health Status; Humans; Lung Neoplasms; Paclitaxel; Palliative Care; Survival; Taxoids; Vinblastine; Vinorelbine | 2002 |
Weekly paclitaxel in the treatment of metastatic and/or recurrent non-small cell lung cancer.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Drug Administration Schedule; Humans; Lung Neoplasms; Paclitaxel | 2002 |
Chemotherapy for elderly patients with advanced non-small-cell lung cancer.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Gemcitabine; Humans; Lung Neoplasms; Meta-Analysis as Topic; Paclitaxel; Randomized Controlled Trials as Topic; SEER Program; Survival Analysis; Treatment Outcome; Vinblastine; Vinorelbine | 2003 |
Taxanes in the treatment of advanced (stage III and IV) non-small cell lung cancer (NSCLC): recent developments.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Combined Modality Therapy; Deoxycytidine; Docetaxel; Etoposide; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Microtubules; Multicenter Studies as Topic; Neoadjuvant Therapy; Organoplatinum Compounds; Paclitaxel; Palliative Care; Podophyllotoxin; Randomized Controlled Trials as Topic; Salvage Therapy; Survival Analysis; Taxoids; Teniposide; Treatment Outcome; Vinblastine; Vinorelbine | 2003 |
[A case of endobronchial squamous cell lung cancer successfully treated with weekly chemotherapy of carboplatin and paclitaxel].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bronchial Neoplasms; Carboplatin; Carcinoma, Non-Small-Cell Lung; Drug Administration Schedule; Humans; Lung Neoplasms; Lymphatic Metastasis; Neoplasms, Multiple Primary; Paclitaxel | 2003 |
Translational research in lung cancer.
Topics: Antineoplastic Agents, Phytogenic; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Cytokines; Genetic Predisposition to Disease; Genetic Testing; Humans; Lung Neoplasms; Paclitaxel; Prognosis; Radiation Pneumonitis | 2003 |
Ifosfamide in non-small cell lung cancer.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Ifosfamide; Lung Neoplasms; Paclitaxel; Vinblastine; Vinorelbine | 2003 |
Clinical experience with the HER1/EGFR tyrosine kinase inhibitor erlotinib.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Bevacizumab; Carboplatin; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Paclitaxel; Quinazolines; Survival Analysis; Treatment Outcome | 2003 |
[Molecular pathogenesis of lung cancers and the preservative therapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cell Cycle Proteins; Cisplatin; Enzyme Inhibitors; Etoposide; Gefitinib; Gene Targeting; Genes, bcl-2; Genes, p53; Genetic Therapy; Humans; Lung Neoplasms; Mass Screening; Mutation; Paclitaxel; Protein-Tyrosine Kinases; Quinazolines; Radiotherapy, Adjuvant | 2004 |
Taxane-platinum combinations in advanced non-small cell lung cancer: a review.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials, Phase III as Topic; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Neoplasm Invasiveness; Neoplasm Staging; Paclitaxel; Prognosis; Risk Assessment; Survival Analysis; Taxoids; Treatment Outcome | 2004 |
Current data and ongoing trials in patients with recurrent non-small-cell lung cancer.
Topics: Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Cytotoxins; Docetaxel; ErbB Receptors; Erlotinib Hydrochloride; Glutamates; Glutathione; Guanine; Humans; Lung Neoplasms; Neoplasm Recurrence, Local; Paclitaxel; Pemetrexed; Prodrugs; Prognosis; Quinazolines; Taxoids | 2004 |
Cytotoxic chemotherapy in advanced non-small cell lung cancer: a review of standard treatment paradigms.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Humans; Lung Neoplasms; Paclitaxel; Prognosis; Randomized Controlled Trials as Topic | 2004 |
Paclitaxel for non-small cell lung cancer.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials as Topic; Combined Modality Therapy; Drug Administration Schedule; Humans; Lung Neoplasms; Neoadjuvant Therapy; Paclitaxel; Pharmaceutical Vehicles; Polyethylene Glycols | 2004 |
Dilemmas in management: the controversial role of chemotherapy in PS 2 advanced NSCLC and the potential role of CT-2103 (Xyotax).
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Humans; Lung Neoplasms; Paclitaxel; Polyglutamic Acid; Taxoids | 2004 |
Pulmonary resection after curative intent radiotherapy (>59 Gy) and concurrent chemotherapy in non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Disease-Free Survival; Etoposide; Female; Follow-Up Studies; Humans; Length of Stay; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Pancoast Syndrome; Pneumonectomy; Postoperative Complications; Radiotherapy Dosage; Radiotherapy, Conformal; Radiotherapy, High-Energy; Retrospective Studies; Salvage Therapy; Survival Analysis; Survival Rate; Treatment Outcome; Vinblastine; Vinorelbine | 2004 |
CT-2103: emerging utility and therapy for solid tumours.
Topics: Animals; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Colorectal Neoplasms; Female; Humans; Neoplasms; Ovarian Neoplasms; Paclitaxel; Polyglutamic Acid; Taxoids | 2004 |
[Do combinations without cisplatin represent an alternative to conventional chemotherapy in non-small cell lung cancers?].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Lung Neoplasms; Neoplasm Staging; Paclitaxel; Taxoids; Vinblastine; Vinorelbine | 2004 |
CT-2103: a novel macromolecular taxane with potential advantages compared with conventional taxanes.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Humans; Lung Neoplasms; Molecular Structure; Paclitaxel; Polyglutamic Acid; Taxoids | 2004 |
[Association of taxanes and radiotherapy: preclinical and clinical studies].
Topics: Animals; Antineoplastic Agents, Phytogenic; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Cells, Cultured; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Disease-Free Survival; Docetaxel; Esophageal Neoplasms; Female; Head and Neck Neoplasms; Humans; Lung Neoplasms; Male; Neoplasms; Paclitaxel; Radiation-Sensitizing Agents; Radiotherapy Dosage; Taxoids; Time Factors; Tumor Cells, Cultured | 2004 |
Development of docetaxel in advanced non-small-cell lung cancer.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials as Topic; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Lung Neoplasms; Paclitaxel; Taxoids; Vinblastine; Vinorelbine | 2004 |
Paclitaxel poliglumex (XYOTAX; CT-2103): an intracellularly targeted taxane.
Topics: Animals; Antineoplastic Agents; Area Under Curve; Carcinoma, Non-Small-Cell Lung; Drug Synergism; Female; Half-Life; Humans; Lung Neoplasms; Mice; Ovarian Neoplasms; Paclitaxel; Polyglutamic Acid; Randomized Controlled Trials as Topic; Taxoids | 2005 |
Chemoresistance in non-small cell lung cancer.
Topics: Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Docetaxel; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Paclitaxel; Taxoids; Tubulin; Vinblastine; Vinorelbine | 2005 |
Phase III study of the Eastern Cooperative Oncology Group (ECOG 2597): induction chemotherapy followed by either standard thoracic radiotherapy or hyperfractionated accelerated radiotherapy for patients with unresectable stage IIIA and B non-small-cell lu
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Dose Fractionation, Radiation; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Radiotherapy Dosage; Remission Induction; Survival Rate; Treatment Outcome | 2005 |
Phase II study of carboplatin-paclitaxel combination chemotherapy in elderly patients with advanced non-small cell lung cancer.
Topics: Age Factors; Aged; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Drug Administration Schedule; Endpoint Determination; Humans; Leukopenia; Lung Neoplasms; Neoplasm Staging; Neutropenia; Paclitaxel; Prospective Studies; Survival Rate | 2005 |
Combination of chemotherapy without platinum compounds in the treatment of advanced non-small cell lung cancer: a systematic review of phase III trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Clinical Trials, Phase III as Topic; Databases, Bibliographic; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Lung Neoplasms; Paclitaxel; Platinum Compounds; Quality Control; Randomized Controlled Trials as Topic; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2005 |
Neoadjuvant chemotherapy for stage IIIA-N2 non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Cisplatin; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Lung Neoplasms; Neoplasm Staging; Paclitaxel; Radiotherapy, Adjuvant; Taxoids | 2005 |
[Postoperative adjuvant chemotherapy for non-small cell lung cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Cisplatin; Drug Administration Schedule; Drug Combinations; Humans; Lung Neoplasms; Meta-Analysis as Topic; Mitomycin; Paclitaxel; Pneumonectomy; Postoperative Care; Randomized Controlled Trials as Topic; Tegafur; Uracil; Vinblastine; Vindesine; Vinorelbine | 2005 |
[Chemotherapy for advanced non-small cell lung cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Docetaxel; Drug Administration Schedule; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Paclitaxel; Survival Rate; Taxoids; Vinblastine; Vinorelbine | 2005 |
Perspectives on salvage therapy for non-small-cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gefitinib; Gemcitabine; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Paclitaxel; Pemetrexed; Prognosis; Quinazolines; Salvage Therapy; Survival Analysis; Taxoids; Treatment Outcome | 2005 |
Taxanes as first-line therapy for advanced non-small cell lung cancer: a systematic review and practice guideline.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials, Phase III as Topic; Docetaxel; Humans; Lung Neoplasms; Meta-Analysis as Topic; Paclitaxel; Randomized Controlled Trials as Topic; Taxoids | 2005 |
Erlotinib in the treatment of non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Deoxycytidine; ErbB Receptors; Erlotinib Hydrochloride; Gemcitabine; Humans; Lung Neoplasms; Paclitaxel; Protein Kinase Inhibitors; Quinazolines | 2005 |
[Molecular targeted therapy--non-small-cell lung cancer and gefitinib].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Deoxycytidine; ErbB Receptors; Female; Gefitinib; Gemcitabine; Genes, erbB-1; Humans; Lung Neoplasms; Male; Mutation; Paclitaxel; Quinazolines; Survival Rate | 2005 |
First-line treatment for advanced non-small-cell lung cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; Enzyme Inhibitors; ErbB Receptors; Humans; Lung Neoplasms; Paclitaxel; Survival Rate; Time Factors | 2005 |
New developments in chemotherapy for advanced non-small cell lung cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Epothilones; Glutamates; Glutathione; Guanine; Humans; Lung Neoplasms; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Pemetrexed; Pyrazines | 2006 |
Should chemotherapy combinations for advanced non-small cell lung cancer be platinum-based? A meta-analysis of phase III randomized trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials, Phase III as Topic; Deoxycytidine; Epirubicin; Gemcitabine; Humans; Ifosfamide; Lung Neoplasms; Paclitaxel; Randomized Controlled Trials as Topic; Survival Rate; Taxoids; Vinblastine; Vinorelbine | 2006 |
Optimizing chemotherapy for advanced non-small cell lung cancer: focus on docetaxel.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Lung Neoplasms; Middle Aged; Paclitaxel; Survival Rate; Taxoids | 2005 |
Chemoradiation paradigm for the treatment of lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Etoposide; Humans; Lung Neoplasms; Multicenter Studies as Topic; Paclitaxel; Randomized Controlled Trials as Topic | 2006 |
[Clinical trials of vnorelbine in breast cancer--its scientific usefulness and development history until regulatory approval].
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Bridged-Ring Compounds; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Cyclophosphamide; Dose-Response Relationship, Drug; Doxorubicin; Drug Approval; Female; Fluorouracil; Humans; Japan; Lung Neoplasms; Male; Paclitaxel; Taxoids; Vinblastine; Vinorelbine | 2006 |
[Lung carcinoma].
Topics: Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Drug Administration Schedule; Humans; Irinotecan; Lung Neoplasms; Paclitaxel; Quality of Life; Vinblastine; Vinorelbine | 2006 |
Pharmacodynamic separation of epidermal growth factor receptor tyrosine kinase inhibitors and chemotherapy in non-small-cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Drug Administration Schedule; ErbB Receptors; Erlotinib Hydrochloride; Gemcitabine; Humans; Lung Neoplasms; Paclitaxel; Protein Kinase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic; Survival Analysis; Taxoids | 2006 |
Non-platinum combination of gemcitabine in NSCLC.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Lung Neoplasms; Paclitaxel; Platinum Compounds; Taxoids; Vinblastine; Vinorelbine | 2006 |
Update on nanoparticle albumin-bound paclitaxel.
Topics: Albumin-Bound Paclitaxel; Albumins; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Dose-Response Relationship, Drug; Humans; Lung Neoplasms; Nanoparticles; Paclitaxel; Serum Albumin | 2006 |
Angiogenesis inhibition in the treatment of lung cancer.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; Disease-Free Survival; Erlotinib Hydrochloride; Hemorrhage; Humans; Lung Neoplasms; Neovascularization, Pathologic; Paclitaxel; Protein Kinase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic; Risk Factors; Survival Rate; Vascular Endothelial Growth Factor A | 2006 |
Chemotherapy dose--response relationships in non-small cell lung cancer and implied resistance mechanisms.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Etoposide; Gemcitabine; Humans; Lung Neoplasms; Paclitaxel; Survival Rate; Vinblastine; Vinorelbine | 2007 |
Paclitaxel poliglumex (PPX, CT-2103): macromolecular medicine for advanced non-small-cell lung cancer.
Topics: Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Humans; Lung Neoplasms; Macromolecular Substances; Paclitaxel; Polyglutamic Acid; Taxoids | 2007 |
[Non-cisplatin based chemotherapy in advanced non-small cell lung cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Paclitaxel; Survival Rate; Taxoids; Vinblastine; Vinorelbine | 2007 |
Combination of standard chemotherapy and targeted agents.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Humans; Lung Neoplasms; Paclitaxel; Receptors, Vascular Endothelial Growth Factor; Treatment Outcome | 2007 |
The present status of postoperative adjuvant chemotherapy for completely resected non-small cell lung cancer.
Topics: Adenocarcinoma; Antineoplastic Agents, Phytogenic; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Clinical Trials, Phase III as Topic; Humans; Lung Neoplasms; Paclitaxel; Survival Analysis | 2007 |
Antagonism of platelet-derived growth factor receptor in non small cell lung cancer: rationale and investigations.
Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Humans; Imatinib Mesylate; Lung Neoplasms; Paclitaxel; Pericytes; Piperazines; Pyrimidines; Receptors, Platelet-Derived Growth Factor | 2007 |
Third-generation chemotherapy agents in the treatment of advanced non-small cell lung cancer: a meta-analysis.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Immunosuppressive Agents; Irinotecan; Lung Neoplasms; Neoplasm Staging; Paclitaxel; Radiation-Sensitizing Agents; Randomized Controlled Trials as Topic; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2007 |
[Gemcitabine and radiotherapy in non-small cell lung cancer: dolce vita at last!].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials as Topic; Combined Modality Therapy; Deoxycytidine; Gemcitabine; Humans; Lung Neoplasms; Paclitaxel; Radiation-Sensitizing Agents; Remission Induction | 2007 |
[Chemotherapy in lung cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Etoposide; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Paclitaxel; Survival Rate | 2007 |
New drugs in non-small cell lung cancer. An overview.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Docetaxel; Drug Design; Humans; Lung Neoplasms; Paclitaxel; Taxoids; Topoisomerase I Inhibitors; Vinblastine; Vinorelbine | 1995 |
New chemotherapy agents in the treatment of advanced non-small cell lung cancer: an update including data from the Seventh World Conference on Lung Cancer.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Drug Design; Growth Substances; Humans; Interferons; Interleukins; Lung Neoplasms; Paclitaxel; Tumor Cells, Cultured | 1995 |
New treatment agents for advanced small cell and non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Combined Modality Therapy; Humans; Lung Neoplasms; Paclitaxel; Randomized Controlled Trials as Topic | 1995 |
New chemotherapeutic agents in non-small-cell lung cancer.
Topics: Aminopterin; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Drug Design; Humans; Interferons; Irinotecan; Lung Neoplasms; Paclitaxel; Topotecan; Vinblastine; Vinorelbine | 1993 |
New antineoplastic agents in lung cancer 1988-1993.
Topics: Aminopterin; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Clinical Trials as Topic; Humans; Irinotecan; Lung Neoplasms; Nitrosourea Compounds; Organophosphorus Compounds; Paclitaxel; Teniposide; Vinblastine; Vinorelbine | 1995 |
New drug for therapy of non-small cell lung cancer.
Topics: Aminopterin; Antineoplastic Agents; Camptothecin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Paclitaxel; Taxoids; Vinblastine; Vinorelbine | 1994 |
[Phase II study].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase II as Topic; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Lung Neoplasms; Paclitaxel; Practice Guidelines as Topic; Taxoids | 1995 |
Summary of phase II data of docetaxel (Taxotere), an active agent in the first- and second-line treatment of advanced non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials, Phase II as Topic; Docetaxel; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Survival Analysis; Taxoids; Treatment Failure | 1995 |
New chemotherapeutic agents for non-small cell lung cancer.
Topics: Aminopterin; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Paclitaxel; Quinoxalines; Sulfanilamides; Taxoids; Topotecan; Vinblastine; Vinorelbine | 1995 |
[Therapeutic strategy for advanced non-small cell lung cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Combined Modality Therapy; Deoxycytidine; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Paclitaxel; Vinblastine; Vinorelbine | 1995 |
Taxol (paclitaxel) in the treatment of lung cancer: the Eastern Cooperative Oncology Group experience.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cisplatin; Clinical Trials, Phase II as Topic; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Randomized Controlled Trials as Topic; Salvage Therapy | 1994 |
Overview of paclitaxel (TAXOL).
Topics: Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Female; Humans; Lung Neoplasms; Microtubules; Ovarian Neoplasms; Paclitaxel | 1993 |
Update on the antitumor activity of paclitaxel in clinical trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Female; Head and Neck Neoplasms; Humans; Lung Neoplasms; Neoplasms; Ovarian Neoplasms; Paclitaxel | 1994 |
[Antimicrotubule agents].
Topics: Aminophenols; Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Docetaxel; Humans; Leukemia, Experimental; Lung Neoplasms; Mice; Microtubules; Paclitaxel; Sulfonamides; Taxoids; Vinblastine; Vinorelbine | 1993 |
New directions for chemotherapy in non-small-cell lung cancer.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma, Non-Small-Cell Lung; Humans; Irinotecan; Lung Neoplasms; Paclitaxel; Topotecan; Vinblastine; Vinorelbine | 1993 |
Overview of paclitaxel (Taxol) in advanced lung cancer.
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Clinical Trials as Topic; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel | 1993 |
Taxol dose intensification and its clinical implications.
Topics: Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; Female; Humans; Lung Neoplasms; Ovarian Neoplasms; Paclitaxel | 1993 |
Promising new agents in the treatment of non-small cell lung cancer.
Topics: Aminopterin; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Lung Neoplasms; Paclitaxel; Taxoids; Vinblastine; Vinorelbine | 1996 |
Combined-modality therapy for advanced non-small cell lung cancer: paclitaxel and thoracic irradiation.
Topics: Ambulatory Care; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Cohort Studies; Combined Modality Therapy; Dose-Response Relationship, Drug; Drug Hypersensitivity; Esophagitis; Follow-Up Studies; Humans; Infusions, Intravenous; Lung Neoplasms; Neutropenia; Paclitaxel; Premedication; Radiation Pneumonitis; Radiation-Sensitizing Agents; Radiotherapy Dosage; Radiotherapy, High-Energy; Remission Induction | 1995 |
New drugs in the treatment of non-small cell lung cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma, Non-Small-Cell Lung; Humans; Lung Neoplasms; Paclitaxel; Vinblastine; Vinorelbine | 1995 |
Docetaxel: meeting the challenge of non-small cell lung cancer management.
Topics: Animals; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase II as Topic; Cricetinae; Docetaxel; Humans; Lung Neoplasms; Neoplasm Staging; Paclitaxel; Survival Rate; Taxoids | 1995 |
Docetaxel: a review of its pharmacology and clinical activity.
Topics: Anthracyclines; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Carcinoma, Non-Small-Cell Lung; Cell Division; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Docetaxel; Drug Eruptions; Drug Resistance, Neoplasm; Female; Head and Neck Neoplasms; Humans; Lung Neoplasms; Microtubules; Neutropenia; Ovarian Neoplasms; Paclitaxel; Pancreatic Neoplasms; Taxoids; Tubulin | 1996 |
Combination paclitaxel and platinum in the treatment of lung cancer: US experience.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cisplatin; Clinical Trials as Topic; Humans; Lung Neoplasms; Paclitaxel | 1996 |
The North American experience with paclitaxel combined with cisplatin or carboplatin in lung cancer.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cisplatin; Etoposide; Humans; Lung Neoplasms; Neutropenia; Paclitaxel; Thrombocytopenia; Treatment Outcome | 1996 |
Preoperative paclitaxel plus carboplatin for patients with intermediate-risk non-small cell lung cancer.
Topics: Antineoplastic Agents, Phytogenic; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Combined Modality Therapy; Humans; Lung Neoplasms; Paclitaxel; Research Design | 1996 |
Chemotherapy in the management of patients with inoperable non-small cell lung cancer.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Humans; Lung Neoplasms; Meta-Analysis as Topic; Paclitaxel; Treatment Outcome | 1996 |
Paclitaxel via 1-hour infusion: clinical experience.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Humans; Infusions, Parenteral; Lung Neoplasms; Neoplasms; Paclitaxel | 1996 |
[Taxol in bronchial carcinoma].
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Bronchogenic; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Clinical Trials as Topic; Humans; Lung Neoplasms; Neoplasm Staging; Paclitaxel; Survival Rate; Treatment Outcome | 1996 |
Overview of current and future chemotherapeutic agents in non-small cell lung cancer.
Topics: Antineoplastic Agents; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Forecasting; Gemcitabine; Humans; Lung Neoplasms; Paclitaxel; Randomized Controlled Trials as Topic | 1997 |
[Development of a new tubulin-interacting agent, docetaxel (taxotere) in Japan].
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Docetaxel; Drug Synergism; Humans; Lung Neoplasms; Paclitaxel; Taxoids; Tubulin | 1997 |
Chemotherapy for advanced non-small cell lung cancer: past, present, and future.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Docetaxel; Humans; Irinotecan; Lung Neoplasms; Paclitaxel; Taxoids; Vinblastine; Vinorelbine | 1997 |
Management strategies for recurrent non-small cell lung cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Docetaxel; Humans; Lung Neoplasms; Neoplasm Recurrence, Local; Paclitaxel; Survival Rate; Taxoids; Treatment Failure | 1997 |
High-dose therapy with carboplatin and paclitaxel in non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Combined Modality Therapy; Drug Administration Schedule; Filgrastim; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Lung Neoplasms; Paclitaxel; Recombinant Proteins | 1997 |
Simultaneous paclitaxel and radiotherapy: initial clinical experience in lung cancer and other malignancies.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Combined Modality Therapy; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Radiation-Sensitizing Agents; Survival Analysis; Urinary Bladder Neoplasms; Uterine Cervical Neoplasms | 1997 |
Defining the role of paclitaxel in lung cancer: summary of recent studies and implications for future directions.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cisplatin; Clinical Trials as Topic; Combined Modality Therapy; Humans; Lung Neoplasms; Paclitaxel; Radiation-Sensitizing Agents | 1997 |
The Fox Chase Cancer Center and Free University Hospital Investigators' Workshop and Consensus Conference on Paclitaxel. Part 1: Lung Cancer. Puerto Rico, March 12-16, 1997.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Combined Modality Therapy; Humans; Lung Neoplasms; Paclitaxel; Radiation-Sensitizing Agents | 1997 |
[Lung cancer].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase II as Topic; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Paclitaxel; Taxoids; Topotecan; Vinblastine; Vinorelbine | 1997 |
Docetaxel in combination with platinums in patients with advanced non-small-cell lung cancer.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Docetaxel; Granulocyte Colony-Stimulating Factor; Humans; Infusions, Intravenous; Lung Neoplasms; Multicenter Studies as Topic; Paclitaxel; Randomized Controlled Trials as Topic; Remission Induction; Survival Rate; Taxoids | 1997 |
Combination docetaxel/vinorelbine for metastatic breast cancer and non-small-cell lung cancer.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Docetaxel; Drug Synergism; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Neoplasm Metastasis; Nervous System Diseases; Paclitaxel; Remission Induction; Survival Rate; Taxoids; Vinblastine; Vinorelbine | 1997 |
[Combination chemotherapy in the treatment of inoperable non-small cell lung cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Meta-Analysis as Topic; Mitomycin; Paclitaxel; Survival Rate; Vinblastine; Vindesine; Vinorelbine | 1997 |
[The recent progress in chemoradiotherapy of lung cancer].
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cisplatin; Combined Modality Therapy; Humans; Lung Neoplasms; Meta-Analysis as Topic; Paclitaxel; Radiation-Sensitizing Agents; Radiotherapy Dosage; Randomized Controlled Trials as Topic; Survival Rate | 1997 |
The pharmacoeconomics of cancer therapies.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Female; Humans; Lung Neoplasms; Neoplasms; Ovarian Neoplasms; Paclitaxel; Quality of Life | 1997 |
New chemotherapeutic agents in the treatment of non-small cell lung cancer: the Australian experience.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Australia; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Lung Neoplasms; Paclitaxel; Taxoids; Treatment Outcome | 1998 |
New chemotherapeutic agents for the treatment of non-small cell lung cancer: the Japanese experience.
Topics: Alkaloids; Animals; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carbazoles; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Docetaxel; Glucosides; Humans; Irinotecan; Japan; Lung Neoplasms; Mitomycin; Mitomycins; Neoplasms, Experimental; Paclitaxel; Purine Nucleosides; Staurosporine; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 1998 |
Experience with new chemotherapeutic agents in non-small cell lung cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Paclitaxel; Randomized Controlled Trials as Topic; Treatment Outcome | 1998 |
[Docetaxel (taxotere) in non-small-cell bronchial carcinoma].
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Docetaxel; Humans; Lung Neoplasms; Neoplasm Staging; Paclitaxel; Survival Rate; Taxoids; Treatment Outcome | 1997 |
[Cytokine in cancer chemotherapy--clinical trials of IL-3, IL-11 and thrombopoietin against thrombocytopenia].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Clinical Trials, Phase II as Topic; Drug Administration Schedule; Granulocyte Colony-Stimulating Factor; Humans; Interleukin-11; Interleukin-3; Lung Neoplasms; Paclitaxel; Platelet Count; Randomized Controlled Trials as Topic; Thrombocytopenia; Thrombopoietin; United States | 1998 |
Recent advances with chemotherapy for NSCLC: the ECOG experience. Eastern Cooperative Oncology Group.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Forecasting; Humans; Lung Neoplasms; Paclitaxel | 1998 |
Paclitaxel/carboplatin in the treatment of non-small-cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Combined Modality Therapy; Forecasting; Humans; Lung Neoplasms; Paclitaxel | 1998 |
Paclitaxel, carboplatin and radiation therapy for non-small-cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Combined Modality Therapy; Humans; Lung Neoplasms; Paclitaxel | 1998 |
Ifosfamide and paclitaxel combinations for the treatment of advanced non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Etoposide; Humans; Ifosfamide; Lung Neoplasms; Paclitaxel; Platinum Compounds | 1998 |
Ifosfamide and docetaxel in non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Docetaxel; Humans; Ifosfamide; Lung Neoplasms; Paclitaxel; Taxoids | 1998 |
New chemotherapeutic agents prolong survival and improve quality of life in non-small cell lung cancer: a review of the literature and future directions.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Neoplasm Staging; Paclitaxel; Quality of Life; Randomized Controlled Trials as Topic; Taxoids; Topotecan; Vinblastine; Vinorelbine | 1998 |
Do newer chemotherapeutic agents improve survival in non-small cell lung cancer?
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials as Topic; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Lung Neoplasms; Paclitaxel; Survival Analysis; Taxoids; Vinblastine; Vinorelbine | 1998 |
Docetaxel in the management of advanced non-small cell lung cancer.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials as Topic; Docetaxel; Humans; Lung Neoplasms; Paclitaxel; Taxoids; Vinblastine; Vinorelbine | 1998 |
Single agents in the second-line treatment of non-small cell lung cancer.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma, Non-Small-Cell Lung; Docetaxel; Humans; Lung Neoplasms; Paclitaxel; Taxoids; Treatment Failure; Vinblastine; Vinorelbine | 1998 |
Gemcitabine and paclitaxel combinations in non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials as Topic; Deoxycytidine; Gemcitabine; Humans; Lung Neoplasms; Paclitaxel | 1998 |
New agents in the management of advanced non-small cell lung cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Lung Neoplasms; Paclitaxel; Taxoids; Topotecan; Vinblastine; Vinorelbine | 1998 |
Role of taxanes in lung-cancer chemotherapy.
Topics: Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Clinical Trials as Topic; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Docetaxel; Drug Administration Schedule; Humans; Lung Neoplasms; Paclitaxel; Taxoids | 1998 |
[Docetaxel (taxotere): current status of clinical development in non-small-cell bronchial carcinoma (NSCLC)].
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Bronchogenic; Carcinoma, Non-Small-Cell Lung; Docetaxel; Humans; Lung Neoplasms; Paclitaxel; Randomized Controlled Trials as Topic; Taxoids; Treatment Outcome | 1998 |
The clinical development of paclitaxel and the paclitaxel/carboplatin combination.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase I as Topic; Dose-Response Relationship, Drug; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel | 1998 |
[Taxotere in various solid tumors].
Topics: Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Clinical Trials as Topic; Clinical Trials, Phase II as Topic; Docetaxel; Female; Head and Neck Neoplasms; Humans; Lung Neoplasms; Male; Melanoma; Ovarian Neoplasms; Paclitaxel; Pancreatic Neoplasms; Prostatic Neoplasms; Sarcoma; Skin Neoplasms; Soft Tissue Neoplasms; Taxoids; Urinary Bladder Neoplasms; Uterine Cervical Neoplasms | 1998 |
[Irinotecan-containing combinations in solid tumors, except colonic carcinomas].
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cisplatin; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Diarrhea; Docetaxel; Enzyme Inhibitors; Etoposide; Female; Genital Neoplasms, Female; Humans; Irinotecan; Lung Neoplasms; Lymphoma, Non-Hodgkin; Male; Neoplasm Proteins; Neoplasms; Neutropenia; Paclitaxel; Stomach Neoplasms; Taxoids; Topoisomerase I Inhibitors; Treatment Outcome | 1998 |
Concurrent paclitaxel, carboplatin, and radiation therapy for locally advanced non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Combined Modality Therapy; Humans; Lung Neoplasms; Paclitaxel | 1999 |
Incorporation of paclitaxel and carboplatin in combined-modality therapy for locally advanced non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Combined Modality Therapy; Humans; Lung Neoplasms; Paclitaxel | 1999 |
Review of paclitaxel/carboplatin in advanced non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Humans; Lung Neoplasms; Paclitaxel | 1999 |
Chemotherapy for non-small cell lung cancer: have we reached a new plateau?
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Enzyme Inhibitors; Gemcitabine; Humans; Lung Neoplasms; Paclitaxel; Palliative Care; Randomized Controlled Trials as Topic; Tirapazamine; Triazines; Vinblastine; Vinorelbine | 1999 |
Gemcitabine plus taxane combinations in non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Deoxycytidine; Gemcitabine; Humans; Lung Neoplasms; Paclitaxel; Platinum Compounds | 1999 |
Triplet chemotherapy with gemcitabine, a platinum, and a third agent in the treatment of advanced non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials as Topic; Deoxycytidine; Gemcitabine; Humans; Ifosfamide; Lung Neoplasms; Paclitaxel; Vinblastine; Vinorelbine | 1999 |
Role of p53 and p16 gene alterations in determining response to concurrent paclitaxel and radiation in solid tumor.
Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Combined Modality Therapy; Genes, cdc; Genes, p16; Genes, p53; Humans; Lung Neoplasms; Mutation; Paclitaxel; Pancreatic Neoplasms; Radiation-Sensitizing Agents; Stomach Neoplasms | 1999 |
Carboplatin and paclitaxel in non-small cell lung cancer: the role of amifostine.
Topics: Amifostine; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Cytoprotection; Humans; Lung Neoplasms; Nervous System Diseases; Paclitaxel; Protective Agents; Randomized Controlled Trials as Topic | 1999 |
[Paclitaxel and new concepts. Advances in the management of bronchial carcinoma].
Topics: Bronchial Neoplasms; Carcinoma, Non-Small-Cell Lung; Humans; Lung Neoplasms; Paclitaxel | 1999 |
Emerging role of docetaxel (Taxotere) in advanced non-small cell lung cancer.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials as Topic; Docetaxel; Humans; Lung Neoplasms; Paclitaxel; Taxoids; Treatment Failure | 1999 |
Docetaxel (Taxotere) and gemcitabine phase I and early phase II studies: results to date and an overview of ongoing studies.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Lung Neoplasms; Paclitaxel; Taxoids | 1999 |
Docetaxel (Taxotere) in combination with platinum-based regimens in non-small cell lung cancer: results and future developments.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials as Topic; Docetaxel; Humans; Lung Neoplasms; Paclitaxel; Taxoids | 1999 |
Docetaxel (Taxotere) and neoadjuvant chemotherapy for non-small cell lung cancer.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Docetaxel; Humans; Lung Neoplasms; Paclitaxel; Taxoids | 1999 |
Overview of docetaxel (Taxotere) in the treatment of non-small cell lung cancer.
Topics: Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase II as Topic; Docetaxel; Humans; Lung Neoplasms; Paclitaxel; Taxoids | 1999 |
Docetaxel (Taxotere) and gemcitabine in combination therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Lung Neoplasms; Paclitaxel; Taxoids | 1999 |
Docetaxel (Taxotere) in non-small cell lung cancer: ongoing studies in Heidelberg and future plans.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Ifosfamide; Lung Neoplasms; Paclitaxel; Palliative Care; Radiotherapy, Adjuvant; Taxoids | 1999 |
New approaches in the adjuvant and neoadjuvant therapy of non-small cell lung cancer, including docetaxel (Taxotere) combinations.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Combined Modality Therapy; Docetaxel; Humans; Lung Neoplasms; Paclitaxel; Taxoids | 1999 |
The role of radiation, with or without chemotherapy, in the management of NSCLC.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Combined Modality Therapy; Deoxycytidine; Drug Synergism; Gemcitabine; Humans; Lung Neoplasms; Paclitaxel; Radiation-Sensitizing Agents; Topotecan; Vinblastine; Vinorelbine | 1999 |
Single-agent paclitaxel in the treatment of advanced non-small cell lung cancer.
Topics: Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Humans; Lung Neoplasms; Paclitaxel; Survival Rate | 1999 |
[Combined radiochemotherapy of non-small-cell bronchial carcinoma with taxol].
Topics: Carcinoma, Bronchogenic; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Dose Fractionation, Radiation; Humans; Lung Neoplasms; Paclitaxel; Radiation-Sensitizing Agents; Radiotherapy Planning, Computer-Assisted | 1999 |
Ifosfamide in non-small-cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Etoposide; Gemcitabine; Humans; Ifosfamide; Lung Neoplasms; Paclitaxel | 1999 |
Docetaxel (Taxotere) in combination chemotherapy and in association with thoracic radiotherapy for the treatment of non-small-cell lung cancer. Thoracic Oncology Program.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Combined Modality Therapy; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Lung Neoplasms; Paclitaxel; Survival Analysis; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 1999 |
Paclitaxel-based therapy in non-small-cell lung cancer: improved third generation chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Humans; Infusions, Intravenous; Lung Neoplasms; Neoplasm Staging; Paclitaxel; Survival Analysis; Treatment Outcome | 1999 |
Docetaxel in the treatment of non-small cell lung cancer: review of single-agent trials.
Topics: Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Docetaxel; Humans; Lung Neoplasms; Paclitaxel; Radiation-Sensitizing Agents; Radiotherapy, Adjuvant; Taxoids | 1999 |
Phase II trials of vinorelbine and docetaxel in the treatment of advanced non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase II as Topic; Docetaxel; Humans; Lung Neoplasms; Paclitaxel; Survival Analysis; Taxoids; Vinblastine; Vinorelbine | 1999 |
Docetaxel and gemcitabine combinations in non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Lung Neoplasms; Paclitaxel; Taxoids | 1999 |
Docetaxel and irinotecan, alone and in combination, in the treatment of non-small cell lung cancer.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Docetaxel; Humans; Irinotecan; Lung Neoplasms; Paclitaxel; Taxoids | 1999 |
Single-agent paclitaxel and paclitaxel/non-platinum combination therapy in advanced non-small cell lung cancer.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Deoxycytidine; Enzyme Inhibitors; Etoposide; Gemcitabine; Humans; Ifosfamide; Lung Neoplasms; Paclitaxel; Topoisomerase I Inhibitors; Vinblastine; Vinorelbine | 1999 |
New options in the treatment of non-small cell lung cancer.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials, Phase III as Topic; Docetaxel; Humans; Ifosfamide; Lung Neoplasms; Multicenter Studies as Topic; Paclitaxel; Randomized Controlled Trials as Topic; Taxoids; Vinblastine; Vinorelbine | 1999 |
[Treatment of unresectable non-small-cell lung cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials, Phase II as Topic; Combined Modality Therapy; Humans; Lung Neoplasms; Paclitaxel; Survival Analysis; Vinblastine; Vinorelbine | 2000 |
Combined modality therapy for unresectable stage III non-small cell lung cancer: new chemotherapy combinations.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Humans; Lung Neoplasms; Paclitaxel; Radiotherapy Dosage; Randomized Controlled Trials as Topic; Survival Rate | 2000 |
Paclitaxel and docetaxel combinations in non-small cell lung cancer.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Docetaxel; Dose-Response Relationship, Drug; Humans; Lung Neoplasms; Paclitaxel; Randomized Controlled Trials as Topic; Taxoids | 2000 |
The taxanes: an update.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Docetaxel; Female; Humans; Lung Neoplasms; Male; Ovarian Neoplasms; Paclitaxel; Randomized Controlled Trials as Topic; Taxoids | 2000 |
Docetaxel (Taxotere) in the treatment of cancer.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Docetaxel; Female; Humans; Lung Neoplasms; Male; Paclitaxel; Prognosis; Prostatic Neoplasms; Taxoids | 2000 |
Docetaxel (Taxotere) as a single agent and in combination chemotherapy for the treatment of patients with advanced non-small cell lung cancer.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Docetaxel; Drug Administration Schedule; Humans; Lung Neoplasms; Neutropenia; Paclitaxel; Taxoids; Treatment Outcome | 2000 |
[Current perspectives of new agents in lung cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials as Topic; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Paclitaxel; Taxoids; Vinblastine; Vinorelbine | 2000 |
Advanced non-small cell lung carcinoma: the emerging role of docetaxel.
Topics: Animals; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Docetaxel; Humans; Lung Neoplasms; Paclitaxel; Salvage Therapy; Taxoids | 2000 |
Docetaxel (Taxotere) in the treatment of non-small cell lung cancer (NSCLC)--is there a role for a new chemotherapy programme?
Topics: Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase II as Topic; Docetaxel; Humans; Lung Neoplasms; Paclitaxel; Randomized Controlled Trials as Topic; Survival Analysis; Taxoids | 2000 |
Experience of treatment of lung cancer patients using paclitaxel and carboplatin.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Drug Administration Schedule; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neutropenia; Paclitaxel; Survival Rate; Thrombocytopenia | 2000 |
Docetaxel: a review of its use in non-small cell lung cancer.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Docetaxel; Drug Resistance, Neoplasm; Humans; Lung Neoplasms; Paclitaxel; Quality of Life; Taxoids | 2000 |
[Vinorelbine in the treatment of non-small-cell lung cancer and breast cancer].
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Docetaxel; Doxorubicin; Evidence-Based Medicine; Female; Humans; Lung Neoplasms; Male; Paclitaxel; Survival Analysis; Taxoids; Vinblastine; Vinorelbine | 2000 |
Advances in treatment of inoperable NSCLC: gemcitabine doublets--a promising alternative.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Deoxycytidine; Disease-Free Survival; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Gemcitabine; Humans; Lung Neoplasms; Paclitaxel; Randomized Controlled Trials as Topic; Remission Induction; Taxoids; Vinblastine; Vinorelbine | 2000 |
Second-line chemotherapy for recurrent non-small cell lung cancer: do new agents make a difference?
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Drugs, Investigational; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Neoplasm Recurrence, Local; Paclitaxel; Randomized Controlled Trials as Topic; Salvage Therapy; Taxoids; Vinblastine; Vinorelbine | 2000 |
Chemotherapy in metastatic non-small-cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials as Topic; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Ifosfamide; Irinotecan; Lung Neoplasms; Mitomycin; Paclitaxel; Taxoids; Tirapazamine; Triazines; Vinblastine; Vinorelbine | 2000 |
Second-line chemotherapy for non-small-cell lung cancer.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Disease Progression; Docetaxel; Drug Resistance, Neoplasm; Health Status; Humans; Ifosfamide; Lung Neoplasms; Paclitaxel; Randomized Controlled Trials as Topic; Survival Analysis; Taxoids; Vinblastine; Vinorelbine | 2000 |
[Chemotherapy of stage IV non-small-cell lung cancer: contribution of gemcitabine].
Topics: Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Deoxycytidine; Gemcitabine; Humans; Ifosfamide; Lung Neoplasms; Mitomycin; Paclitaxel; Prognosis; Randomized Controlled Trials as Topic; Vinblastine; Vinorelbine | 2000 |
Optimizing chemoradiation therapy approaches to unresectable stage III non--small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials as Topic; Humans; Lung Neoplasms; Neoplasm Staging; Paclitaxel; Radiotherapy Dosage; Survival Rate | 2001 |
Chemoradiation in locally advanced non-small cell lung cancer.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Deoxycytidine; Docetaxel; Drug Administration Schedule; Etoposide; Forecasting; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Multicenter Studies as Topic; Paclitaxel; Radiotherapy, Adjuvant; Randomized Controlled Trials as Topic; Survival Rate; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2001 |
Lung cancer: therapeutic options for stage IV and recurrent NSCLC.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Deoxycytidine; Docetaxel; Etoposide; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Multicenter Studies as Topic; Neoplasm Recurrence, Local; Paclitaxel; Prognosis; Randomized Controlled Trials as Topic; Risk Factors; Survival Rate; Taxoids; Teniposide; Treatment Outcome; Vinblastine; Vinorelbine | 2001 |
Docetaxel (Taxotere) in combination with platinums in patients with non-small cell lung cancer: trial data and implications for clinical management.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials as Topic; Docetaxel; Humans; Lung Neoplasms; Neoadjuvant Therapy; Paclitaxel; Radiation-Sensitizing Agents; Taxoids | 2001 |
Challenging the platinum combinations: docetaxel (Taxotere) combined with gemcitabine or vinorelbine in non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Lung Neoplasms; Paclitaxel; Taxoids; Vinblastine; Vinorelbine | 2001 |
Docetaxel (Taxotere) in combination with radiation therapy and the potential of weekly administration in elderly and/or poor performance status patients with advanced non-small cell lung cancer.
Topics: Aged; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Docetaxel; Drug Administration Schedule; Humans; Lung Neoplasms; Middle Aged; Paclitaxel; Radiation-Sensitizing Agents; Taxoids | 2001 |
Advances in the treatment of non-small cell lung cancer: molecular markers take the stage.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Cell Cycle Proteins; Clinical Trials as Topic; Combined Modality Therapy; Docetaxel; Humans; Lung Neoplasms; Neoplasm Proteins; Neoplasm Staging; Nuclear Proteins; Paclitaxel; Proto-Oncogene Proteins; Taxoids | 2001 |
Docetaxel (Taxotere) shows survival and quality-of-life benefits in the second-line treatment of non-small cell lung cancer: a review of two phase III trials.
Topics: Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase II as Topic; Docetaxel; Humans; Lung Neoplasms; Paclitaxel; Quality of Life; Radiation-Sensitizing Agents; Randomized Controlled Trials as Topic; Survival Analysis; Taxoids | 2001 |
Sequential chemo- and radiochemotherapy with weekly paclitaxel (Taxol) and 3D-conformal radiotherapy of stage III inoperable non-small cell lung cancer. Results of a dose escalation study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Cohort Studies; Combined Modality Therapy; Disease-Free Survival; Drug Hypersensitivity; Esophagitis; Humans; Leukopenia; Life Tables; Lung Neoplasms; Maximum Tolerated Dose; Nausea; Neoplasm Staging; Paclitaxel; Prospective Studies; Radiation Injuries; Radiation Pneumonitis; Radiotherapy, Conformal; Remission Induction; Survival Analysis; Survival Rate; Treatment Outcome; Vomiting | 2001 |
The current status of docetaxel for advanced non-small cell lung cancer.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Docetaxel; Humans; Lung Neoplasms; Neoplasm Staging; Paclitaxel; Randomized Controlled Trials as Topic; Taxoids | 2001 |
Neoadjuvant therapy for non-small cell lung cancer.
Topics: Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Docetaxel; Humans; Lung Neoplasms; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Randomized Controlled Trials as Topic; Taxoids | 2001 |
Population pharmacokinetics and pharmacokinetic-pharmacodynamic relationships for docetaxel.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Computer Simulation; Docetaxel; Humans; Lung Neoplasms; Models, Statistical; Neoplasms; Nonlinear Dynamics; Paclitaxel; Prospective Studies; Research Design; Taxoids | 2001 |
New drug and multimodality combinations in the treatment of advanced non--small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Docetaxel; Humans; Lung Neoplasms; Neoadjuvant Therapy; Paclitaxel; Survival Rate; Taxoids | 2001 |
Phase III randomized trial of docetaxel in combination with cisplatin or carboplatin or vinorelbine plus cisplatin in advanced non--small cell lung cancer: interim analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials, Phase III as Topic; Docetaxel; Humans; Lung Neoplasms; Paclitaxel; Quality of Life; Randomized Controlled Trials as Topic; Survival Rate; Taxoids; Vinblastine; Vinorelbine | 2001 |
Integration of new chemotherapeutic agents into chemoradiotherapy for stage III non--small cell lung cancer: focus on docetaxel.
Topics: Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Docetaxel; Drug Administration Schedule; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Radiation-Sensitizing Agents; Survival Rate; Taxoids | 2001 |
Non-platinum based combination chemotherapy: phase I and II trials of docetaxel plus gemcitabine, vinorelbine, or irinotecan.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Taxoids; Vinblastine; Vinorelbine | 2001 |
Weekly docetaxel as a single agent and in combination with gemcitabine in elderly and poor performance status patients with advanced non--small cell lung cancer.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Drug Administration Schedule; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Radiation-Sensitizing Agents; Survival Rate; Taxoids | 2001 |
Review of two phase III randomized trials of single-agent docetaxel in previously treated advanced non--small cell lung cancer.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; Docetaxel; Humans; Ifosfamide; Lung Neoplasms; Paclitaxel; Quality of Life; Radiation-Sensitizing Agents; Randomized Controlled Trials as Topic; Survival Rate; Taxoids; Vinblastine; Vinorelbine | 2001 |
[Assessment of paclitaxel treatment of non-small-cell lung cancer].
Topics: Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Humans; Lung Neoplasms; Paclitaxel | 2001 |
The emerging world role of irinotecan in lung cancer.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials as Topic; Drug Synergism; Humans; Irinotecan; Japan; Lung Neoplasms; Paclitaxel; Radiotherapy, Adjuvant; Survival Analysis; Treatment Outcome; United States | 2001 |
Rationale for non-platinum chemotherapy in advanced NSCLC.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Paclitaxel; Randomized Controlled Trials as Topic; Taxoids; Vinblastine; Vinorelbine | 2001 |
Indications for chemotherapy in stage IV non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Lung Neoplasms; Neoplasm Staging; Paclitaxel; Prognosis; Survival Rate; Taxoids; Tirapazamine; Triazines; Vinblastine; Vinorelbine | 2001 |
Role of taxanes in the combined modality treatment of patients with locally advanced non-small cell lung cancer.
Topics: Antineoplastic Agents, Phytogenic; Bridged-Ring Compounds; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Combined Modality Therapy; Docetaxel; Guidelines as Topic; Lung Neoplasms; Multicenter Studies as Topic; Neoplasm Staging; Paclitaxel; Taxoids; Treatment Outcome | 2001 |
European perspectives on paclitaxel/platinum-based therapy for advanced non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials as Topic; Combined Modality Therapy; Drug Evaluation, Preclinical; Etoposide; Europe; Humans; Lung Neoplasms; Paclitaxel; Radiation-Sensitizing Agents | 2001 |
The current state of paclitaxel and radiation in the combined-modality therapy of non-small cell lung cancer.
Topics: Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Combined Modality Therapy; Drug Evaluation, Preclinical; Humans; Lung Neoplasms; Paclitaxel; Radiation-Sensitizing Agents | 2001 |
Predicting response to paclitaxel/carboplatin-based therapy in non-small cell lung cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; DNA, Neoplasm; Drug Evaluation, Preclinical; Drug Resistance, Neoplasm; Humans; Lung Neoplasms; Paclitaxel; Tubulin | 2001 |
Second-line chemotherapy for non-small cell lung cancer.
Topics: Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Docetaxel; Humans; Lung Neoplasms; Paclitaxel; Randomized Controlled Trials as Topic; Taxoids | 2001 |
Adenovirus-mediated p53 gene therapy: overview of preclinical studies and potential clinical applications.
Topics: Adenoviridae; Animals; Antineoplastic Agents; Apoptosis; Carcinoma; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Colorectal Neoplasms; Combined Modality Therapy; Drug Resistance, Neoplasm; Female; Genes, p53; Genetic Therapy; Genetic Vectors; Glioblastoma; Head and Neck Neoplasms; Humans; Injections; Interleukin-2; Liver Neoplasms; Lung Neoplasms; Multicenter Studies as Topic; Neoplasm Recurrence, Local; Neoplasms; Ovarian Neoplasms; Paclitaxel; Radiotherapy, Adjuvant; Recombinant Fusion Proteins; Salvage Therapy; Signal Transduction; Treatment Outcome; Tumor Suppressor Protein p53; Xenograft Model Antitumor Assays | 1999 |
Chemotherapy for advanced non-small cell lung cancer: standards.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Decision Making; Docetaxel; Humans; Lung Neoplasms; Paclitaxel; Palliative Care; Patient Selection; Practice Guidelines as Topic; Prognosis; Quality of Life; Randomized Controlled Trials as Topic; Survival Analysis; Taxoids | 2001 |
Paclitaxel: a pharmacoeconomic review of its use in non-small cell lung cancer.
Topics: Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Costs and Cost Analysis; Economics, Pharmaceutical; Humans; Lung Neoplasms; Paclitaxel; Quality of Life; Randomized Controlled Trials as Topic | 2001 |
The role of chemotherapy in early non-small-cell lung cancer management.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; DNA, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Neoadjuvant Therapy; Neoplasm Metastasis; Neoplasm Staging; Paclitaxel; Prognosis; Survival Analysis | 2001 |
Topoisomerase I inhibitors combination chemotherapy in non-small cell lung cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials as Topic; Combined Modality Therapy; Deoxycytidine; Docetaxel; Doxorubicin; Enzyme Inhibitors; Etoposide; Gemcitabine; Humans; Ifosfamide; Irinotecan; Lung Neoplasms; Paclitaxel; Taxoids; Topoisomerase I Inhibitors; Topotecan; Vinblastine; Vinorelbine | 2001 |
Paclitaxel-based combination chemotherapy in advanced non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Humans; Lung Neoplasms; Paclitaxel | 2001 |
Radiosensitization with chemotherapeutic agents.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials as Topic; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Paclitaxel; Platinum Compounds; Radiation-Sensitizing Agents; Taxoids; Vinblastine; Vinorelbine | 2001 |
Clinical and cost effectiveness of paclitaxel, docetaxel, gemcitabine, and vinorelbine in non-small cell lung cancer: a systematic review.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cost of Illness; Cost-Benefit Analysis; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Lung Neoplasms; Paclitaxel; Quality of Life; Randomized Controlled Trials as Topic; Sensitivity and Specificity; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2002 |
Preclinical and clinical studies of docetaxel and exisulind in the treatment of human lung cancer.
Topics: Administration, Oral; Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Disease Models, Animal; Docetaxel; Humans; Immunohistochemistry; Lung Neoplasms; Mice; Paclitaxel; Rats; Sulindac; Survival Analysis; Taxoids; Treatment Outcome; Tumor Cells, Cultured | 2002 |
[Developed new agents for lung cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cisplatin; Clinical Trials as Topic; Deoxycytidine; Docetaxel; Enzyme Inhibitors; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Paclitaxel; Taxoids; Topoisomerase I Inhibitors; Topotecan; Vinblastine; Vinorelbine | 2002 |
[New prospects in the treatment of non-small-cell lung carcinoma (NSCLC): new biological factors].
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Epidermal Growth Factor; ErbB Receptors; Female; Humans; Lung Neoplasms; Metalloendopeptidases; Neovascularization, Pathologic; Organic Chemicals; Paclitaxel; Prognosis; Randomized Controlled Trials as Topic; Research; Time Factors | 2001 |
[New therapeutic approaches in non-small-cell lung carcinoma (NSCLC), stages IV].
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials as Topic; Clinical Trials, Phase III as Topic; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Irinotecan; Lung; Lung Neoplasms; Neoplasm Staging; Paclitaxel; Taxoids; Time Factors; Vinblastine; Vinorelbine | 2001 |
[Current status of the chemotherapy for lung cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cisplatin; Docetaxel; Drug Administration Schedule; Humans; Irinotecan; Lung Neoplasms; Paclitaxel; Survival Rate; Taxoids | 2002 |
A rapid and systematic review of the clinical effectiveness and cost-effectiveness of paclitaxel, docetaxel, gemcitabine and vinorelbine in non-small-cell lung cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cost-Benefit Analysis; Deoxycytidine; Docetaxel; England; Gemcitabine; Humans; Lung Neoplasms; Paclitaxel; Quality of Life; Survival Rate; Taxoids; Vinblastine; Vinorelbine; Wales | 2001 |
Second-line chemotherapy for non-small cell lung cancer.
Topics: Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Humans; Lung Neoplasms; Paclitaxel; Randomized Controlled Trials as Topic | 2002 |
New treatment approaches for lung cancer and impact on survival.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Incidence; Lung Neoplasms; Paclitaxel; Survival Rate | 2002 |
[Paclitaxel].
Topics: Antibodies, Monoclonal; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Chemotherapy, Adjuvant; Clinical Trials as Topic; Endothelial Growth Factors; Humans; Intercellular Signaling Peptides and Proteins; Lung Neoplasms; Lymphokines; Paclitaxel; Pneumonectomy; Radiotherapy, Adjuvant; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors | 2002 |
[Docetaxel].
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials as Topic; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Lung Neoplasms; Paclitaxel; Radiotherapy, Adjuvant; Taxoids | 2002 |
[Gemcitabine].
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Docetaxel; Etoposide; Gemcitabine; Humans; Lung Neoplasms; Paclitaxel; Randomized Controlled Trials as Topic; Taxoids; Vinblastine; Vinorelbine | 2002 |
[Carboplatin].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Docetaxel; Etoposide; Gemcitabine; Humans; Lung Neoplasms; Paclitaxel; Randomized Controlled Trials as Topic; Taxoids; Treatment Outcome | 2002 |
[Chemotherapy for elderly patients with lung cancer].
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cisplatin; Clinical Trials as Topic; Deoxycytidine; Docetaxel; Doxorubicin; Etoposide; Gemcitabine; Humans; Lung Neoplasms; Paclitaxel; Taxoids; Vinblastine; Vincristine; Vinorelbine | 2002 |
[Recent results of anticancer drugs acting on microtubules--navelbine, taxol and taxotere for the treatment of lung cancer].
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Docetaxel; Drug Administration Schedule; Female; Humans; Lung Neoplasms; Male; Microtubules; Paclitaxel; Taxoids; Vinblastine; Vinorelbine | 1992 |
1053 trial(s) available for paclitaxel and Carcinoma, Non-Small Cell Lung
| Article | Year |
|---|---|
Phase II study of multidisciplinary therapy combined with pembrolizumab for patients with synchronous oligometastatic non-small cell lung cancer TRAP OLIGO study (WJOG11118L).
Topics: Adult; Aged; Albumins; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Drug Administration Schedule; Humans; Immune Checkpoint Inhibitors; Induction Chemotherapy; Japan; Lung Neoplasms; Maintenance Chemotherapy; Middle Aged; Paclitaxel; Pemetrexed; Progression-Free Survival | 2021 |
Efficacy of first-line atezolizumab combination therapy in patients with non-small cell lung cancer receiving proton pump inhibitors: post hoc analysis of IMpower150.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Non-Small-Cell Lung; Female; Humans; Immune Checkpoint Inhibitors; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Proton Pump Inhibitors; Survival Rate; Treatment Outcome | 2022 |
Phase II Study of the Modified Weekly Nab-paclitaxel Regimen in Previously Treated Patients With Advanced Non-Small Cell Lung Cancer.
Topics: Aged; Aged, 80 and over; Albumins; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Drug Administration Schedule; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Progression-Free Survival; Treatment Outcome | 2021 |
Camrelizumab Plus Carboplatin and Paclitaxel as First-Line Treatment for Advanced Squamous NSCLC (CameL-Sq): A Phase 3 Trial.
Topics: Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camelus; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Humans; Lung Neoplasms; Paclitaxel | 2022 |
Phase I Study of Accelerated Hypofractionated Proton Therapy and Chemotherapy for Locally Advanced Non-Small Cell Lung Cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Female; Humans; Lung Neoplasms; Male; Paclitaxel; Proton Therapy | 2022 |
Randomized double-blind clinical trial comparing safety and efficacy of the biosimilar BCD-021 with reference bevacizumab.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biosimilar Pharmaceuticals; Carboplatin; Carcinoma, Non-Small-Cell Lung; Double-Blind Method; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Russia; Therapeutic Equivalency; Treatment Outcome; Ukraine; Young Adult | 2022 |
Stereotactic Body Radiotherapy and Systemic Dose Chemotherapy for Locally Advanced Lung Cancer: Single Arm Phase 2 Study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Humans; Lung Neoplasms; Neoplasm Staging; Paclitaxel; Quality of Life; Radiosurgery | 2022 |
Carboplatin plus nab-paclitaxel for recurrent small cell lung cancer: A phase II study.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Neoplasm Recurrence, Local; Paclitaxel; Small Cell Lung Carcinoma | 2022 |
A phase II feasibility study of carboplatin and nab-paclitaxel for advanced non-small cell lung cancer patients with interstitial lung disease (YLOG0114).
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Feasibility Studies; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Paclitaxel | 2022 |
Veliparib Plus Carboplatin and Paclitaxel Versus Investigator's Choice of Standard Chemotherapy in Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Carboplatin; Carcinoma, Non-Small-Cell Lung; Humans; Lung Neoplasms; Paclitaxel | 2022 |
Nintedanib plus chemotherapy for nonsmall cell lung cancer with idiopathic pulmonary fibrosis: a randomised phase 3 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Female; Humans; Idiopathic Pulmonary Fibrosis; Lung Neoplasms; Male; Paclitaxel | 2022 |
Pharmacological ascorbate improves the response to platinum-based chemotherapy in advanced stage non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Humans; Leukocytes, Mononuclear; Lung Neoplasms; Paclitaxel; Platinum | 2022 |
Polymeric micellar paclitaxel (Pm-Pac) prolonged overall survival for NSCLC patients without pleural metastasis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Disease-Free Survival; Humans; Lung Neoplasms; Paclitaxel; Polymers; Treatment Outcome | 2022 |
Paclitaxel exposure-toxicity analysis reveals a pharmacokinetic determinant for dose-limiting neutropenia in East-Asian solid tumor patients: results from two prospective, phase II studies.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Humans; Lung Neoplasms; Nasopharyngeal Neoplasms; Neutropenia; Paclitaxel; Prospective Studies | 2022 |
Phase II study of carboplatin/nab-paclitaxel/atezolizumab combination therapy for advanced nonsquamous non-small cell lung cancer patients with impaired renal function: RESTART trial.
Topics: Albumins; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Humans; Kidney; Lung Neoplasms; Paclitaxel; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Renal Insufficiency | 2022 |
Adebrelimab (SHR-1316) in Combination With Chemotherapy as Perioperative Treatment in Patients With Resectable Stage II to III NSCLCs: An Open-Label, Multicenter, Phase 1b Trial.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Humans; Lung Neoplasms; Neoadjuvant Therapy; Paclitaxel; Progression-Free Survival | 2023 |
Neoadjuvant toripalimab plus platinum-paclitaxel chemotherapy in stage II-III non-small cell lung cancer: a single-center, single-arm, phase I study in China.
Topics: Antineoplastic Combined Chemotherapy Protocols; B7-H1 Antigen; Carcinoma, Non-Small-Cell Lung; Humans; Lung Neoplasms; Neoadjuvant Therapy; Paclitaxel; Platinum | 2023 |
Sarcopenia as a Determinant of the Efficacy of Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer: A Meta-Analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Body Composition; Carcinoma, Non-Small-Cell Lung; Humans; Immune Checkpoint Inhibitors; Lung Neoplasms; Neoplasms; Odds Ratio; Paclitaxel; Prospective Studies; Sarcopenia | 2023 |
Improving the performance status in advanced non-small cell lung cancer patients with chemotherapy (ImPACt trial): a phase 2 study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Humans; Lung Neoplasms; Middle Aged; Paclitaxel; Progression-Free Survival; Quality of Life | 2023 |
A Phase I/II Study of Necitumumab Plus Pembrolizumab, Nab-Paclitaxel, and Carboplatin for Previously Untreated Advanced Squamous Non-Small Cell Lung Cancer Study: (NEJ048A/NEXUS).
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Humans; Lung Neoplasms; Paclitaxel | 2023 |
The efficacy and safety of nanoparticle albumin bound-paclitaxel-based regimen as second- or third-line treatment in patients with advanced esophageal squamous cell carcinoma.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Humans; Lung Neoplasms; Nanoparticles; Paclitaxel; Retrospective Studies | 2023 |
Efficacy and safety of nanoparticle albumin-bound paclitaxel monotherapy after immune checkpoint inhibitor administration for advanced non-small cell lung cancer: A multicenter Phase 2 clinical trial.
Topics: Albumin-Bound Paclitaxel; Albumins; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Humans; Immune Checkpoint Inhibitors; Lung Neoplasms; Nanoparticles; Neutropenia; Paclitaxel | 2023 |
Quality of life with docetaxel plus cisplatin versus paclitaxel plus carboplatin in patients with completely resected non-small cell lung cancer: quality of life analysis of TORG 0503.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Docetaxel; Humans; Lung Neoplasms; Paclitaxel; Quality of Life; Taxoids | 2023 |
Independent association of metabolic tumor response on FDG-PET with pulmonary toxicity following risk-adaptive chemoradiation for unresectable non-small cell lung cancer: Inherent radiosensitivity or immune response?
Topics: Carboplatin; Carcinoma, Non-Small-Cell Lung; Fluorodeoxyglucose F18; Humans; Immunity; Lung Neoplasms; Paclitaxel; Pneumonia; Positron Emission Tomography Computed Tomography; Radiation Pneumonitis; Radiation Tolerance | 2023 |
Carboplatin and weekly paclitaxel in combination with bevacizumab for the treatment of advanced non-small cell lung cancer complicated by idiopathic interstitial pneumonias: A feasibility study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Non-Small-Cell Lung; Feasibility Studies; Humans; Idiopathic Interstitial Pneumonias; Lung Neoplasms; Neoplasm Recurrence, Local; Paclitaxel; Prospective Studies | 2023 |
First-line nivolumab, paclitaxel, carboplatin, and bevacizumab for advanced non-squamous non-small cell lung cancer: Updated survival analysis of the ONO-4538-52/TASUKI-52 randomized controlled trial.
Topics: Bevacizumab; Carboplatin; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Humans; Lung Neoplasms; Neoplasm Recurrence, Local; Nivolumab; Paclitaxel; Platinum; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Receptor Protein-Tyrosine Kinases; Survival Analysis | 2023 |
A phase II study of nab-paclitaxel and carboplatin chemotherapy plus necitumumab in the first-line treatment of patients with stage IV squamous non-small cell lung cancer.
Topics: Aged; Aged, 80 and over; Albumins; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Prognosis; Retreatment; Treatment Outcome | 2019 |
Can radiomics help to predict skeletal muscle response to chemotherapy in stage IV non-small cell lung cancer?
Topics: Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Bevacizumab; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cohort Studies; Cross-Sectional Studies; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Muscle, Skeletal; Neoplasm Staging; Nitroglycerin; Paclitaxel; Survival Rate; Tomography, X-Ray Computed | 2019 |
Phase II study of nab-paclitaxel + carboplatin for patients with non-small-cell lung cancer and interstitial lung disease.
Topics: Aged; Aged, 80 and over; Albumins; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Female; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Prospective Studies | 2019 |
A prospective phase II study of carboplatin and nab-paclitaxel in patients with advanced non-small cell lung cancer and concomitant interstitial lung disease (HOT1302).
Topics: Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Female; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Prospective Studies; Survival Rate | 2019 |
Long-Term Results of NRG Oncology RTOG 0617: Standard- Versus High-Dose Chemoradiotherapy With or Without Cetuximab for Unresectable Stage III Non-Small-Cell Lung Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cetuximab; Chemoradiotherapy; Dose Fractionation, Radiation; Dose-Response Relationship, Radiation; Humans; Lung Neoplasms; Neoplasm Staging; Paclitaxel; Progression-Free Survival; Survival Rate | 2020 |
Modeling Tumor Growth and Treatment Resistance Dynamics Characterizes Different Response to Gefitinib or Chemotherapy in Non-Small Cell Lung Cancer.
Topics: Algorithms; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Asia; Bayes Theorem; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Drug Discovery; Drug Resistance; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Paclitaxel; Protein Kinase Inhibitors; Tumor Burden | 2020 |
Nab-paclitaxel in older patients with non-small cell lung cancer who have developed disease progression after platinum-based doublet chemotherapy.
Topics: Adenocarcinoma of Lung; Aged; Aged, 80 and over; Albumins; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Paclitaxel; Platinum; Prognosis; Retrospective Studies; Salvage Therapy; Survival Rate | 2020 |
Microwave ablation plus chemotherapy versus chemotherapy in advanced non-small cell lung cancer: a multicenter, randomized, controlled, phase III clinical trial.
Topics: Adenocarcinoma of Lung; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Deoxycytidine; Disease-Free Survival; Docetaxel; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Microwaves; Middle Aged; Neoplasm Recurrence, Local; Organoplatinum Compounds; Paclitaxel; Pemetrexed; Progression-Free Survival; Prospective Studies; Radiofrequency Ablation; Treatment Outcome; Vinorelbine | 2020 |
Phase 1 Trial of Pembrolizumab Administered Concurrently With Chemoradiotherapy for Locally Advanced Non-Small Cell Lung Cancer: A Nonrandomized Controlled Trial.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Female; Humans; Immune Checkpoint Inhibitors; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Programmed Cell Death 1 Receptor; Treatment Outcome | 2020 |
Five-year safety and efficacy data from a phase Ib study of nivolumab and chemotherapy in advanced non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Nivolumab; Paclitaxel; Pemetrexed; Progression-Free Survival; Treatment Outcome | 2020 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor Proteins, Signal Transducing; Adenine; Adenocarcinoma; Adipogenesis; Administration, Cutaneous; Administration, Ophthalmic; Adolescent; Adsorption; Adult; Aeromonas hydrophila; Aerosols; Aged; Aged, 80 and over; Aging; Agriculture; Air Pollutants; Air Pollution; Airway Remodeling; Alanine Transaminase; Albuminuria; Aldehyde Dehydrogenase 1 Family; Algorithms; AlkB Homolog 2, Alpha-Ketoglutarate-Dependent Dioxygenase; Alzheimer Disease; Amino Acid Sequence; Ammonia; Ammonium Compounds; Anaerobiosis; Anesthetics, Dissociative; Anesthetics, Inhalation; Animals; Anti-Bacterial Agents; Anti-HIV Agents; Anti-Infective Agents; Anti-Inflammatory Agents; Antibiotics, Antineoplastic; Antibodies, Antineutrophil Cytoplasmic; Antibodies, Monoclonal, Humanized; Antifungal Agents; Antigens, Bacterial; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Antitubercular Agents; Antiviral Agents; Apolipoproteins E; Apoptosis; Arabidopsis; Arabidopsis Proteins; Arsenic; Arthritis, Rheumatoid; Asthma; Atherosclerosis; ATP-Dependent Proteases; Attitude of Health Personnel; Australia; Austria; Autophagy; Axitinib; Bacteria; Bacterial Outer Membrane Proteins; Bacterial Proteins; Bacterial Toxins; Bacterial Typing Techniques; Bariatric Surgery; Base Composition; Bayes Theorem; Benzoxazoles; Benzylamines; beta Catenin; Betacoronavirus; Betula; Binding Sites; Biological Availability; Biological Oxygen Demand Analysis; Biomarkers; Biomarkers, Tumor; Biopsy; Bioreactors; Biosensing Techniques; Birth Weight; Blindness; Blood Chemical Analysis; Blood Gas Analysis; Blood Glucose; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Blood-Brain Barrier; Blotting, Western; Body Mass Index; Body Weight; Bone and Bones; Bone Density; Bone Resorption; Borates; Brain; Brain Infarction; Brain Injuries, Traumatic; Brain Neoplasms; Breakfast; Breast Milk Expression; Breast Neoplasms; Bronchi; Bronchoalveolar Lavage Fluid; Buffaloes; Cadherins; Calcification, Physiologic; Calcium Compounds; Calcium, Dietary; Cannula; Caprolactam; Carbon; Carbon Dioxide; Carboplatin; Carcinogenesis; Carcinoma, Ductal; Carcinoma, Ehrlich Tumor; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Pancreatic Ductal; Carcinoma, Renal Cell; Cardiovascular Diseases; Carps; Carrageenan; Case-Control Studies; Catalysis; Catalytic Domain; Cattle; CD8-Positive T-Lymphocytes; Cell Adhesion; Cell Cycle Proteins; Cell Death; Cell Differentiation; Cell Line; Cell Line, Tumor; Cell Movement; Cell Nucleus; Cell Phone Use; Cell Proliferation; Cell Survival; Cell Transformation, Neoplastic; Cell Transformation, Viral; Cells, Cultured; Cellulose; Chemical Phenomena; Chemoradiotherapy; Child; Child Development; Child, Preschool; China; Chitosan; Chlorocebus aethiops; Cholecalciferol; Chromatography, Liquid; Circadian Clocks; Circadian Rhythm; Circular Dichroism; Cisplatin; Citric Acid; Clinical Competence; Clinical Laboratory Techniques; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clostridioides difficile; Clostridium Infections; Coculture Techniques; Cohort Studies; Cold Temperature; Colitis; Collagen Type I; Collagen Type I, alpha 1 Chain; Collagen Type XI; Color; Connective Tissue Diseases; Copper; Coronary Angiography; Coronavirus 3C Proteases; Coronavirus Infections; Cost of Illness; Counselors; COVID-19; COVID-19 Testing; Creatine Kinase; Creatinine; Cross-Over Studies; Cross-Sectional Studies; Cryoelectron Microscopy; Cryosurgery; Crystallography, X-Ray; Cues; Cultural Competency; Cultural Diversity; Curriculum; Cyclic AMP Response Element-Binding Protein; Cyclin-Dependent Kinase Inhibitor p21; Cycloparaffins; Cysteine Endopeptidases; Cytokines; Cytoplasm; Cytoprotection; Databases, Factual; Denitrification; Deoxycytidine; Diabetes Complications; Diabetes Mellitus; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diagnosis, Differential; Diatoms; Diet; Diet, High-Fat; Dietary Exposure; Diffusion Magnetic Resonance Imaging; Diketopiperazines; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Disease Models, Animal; Disease Progression; Disease-Free Survival; DNA; DNA Damage; DNA Glycosylases; DNA Repair; DNA-Binding Proteins; DNA, Bacterial; DNA, Viral; Docetaxel; Dose Fractionation, Radiation; Dose-Response Relationship, Drug; Down-Regulation; Doxorubicin; Drosophila; Drosophila melanogaster; Drug Carriers; Drug Delivery Systems; Drug Liberation; Drug Repositioning; Drug Resistance, Bacterial; Drug Resistance, Multiple, Bacterial; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; Drug Therapy, Combination; Edema; Edible Grain; Education, Graduate; Education, Medical, Graduate; Education, Pharmacy; Ehlers-Danlos Syndrome; Electron Transport Complex III; Electron Transport Complex IV; Electronic Nicotine Delivery Systems; Emergency Service, Hospital; Empathy; Emulsions; Endothelial Cells; Endurance Training; Energy Intake; Enterovirus A, Human; Environment; Environmental Monitoring; Enzyme Assays; Enzyme Inhibitors; Epithelial Cells; Epithelial-Mesenchymal Transition; Epoxide Hydrolases; Epoxy Compounds; Erythrocyte Count; Erythrocytes; Escherichia coli; Escherichia coli Infections; Escherichia coli Proteins; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Esophagectomy; Estrogens; Etanercept; Ethiopia; Ethnicity; Ethylenes; Exanthema; Exercise; Exercise Test; Exercise Tolerance; Extracellular Matrix; Extracorporeal Membrane Oxygenation; Eye Infections, Fungal; False Negative Reactions; Fatty Acids; Fecal Microbiota Transplantation; Feces; Female; Femur Neck; Fermentation; Ferritins; Fetal Development; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Fibroblasts; Fibroins; Fish Proteins; Flavanones; Flavonoids; Focus Groups; Follow-Up Studies; Food Handling; Food Supply; Food, Formulated; Forced Expiratory Volume; Forests; Fractures, Bone; Fruit and Vegetable Juices; Fusobacteria; G1 Phase Cell Cycle Checkpoints; G2 Phase Cell Cycle Checkpoints; Gamma Rays; Gastrectomy; Gastrointestinal Microbiome; Gastrointestinal Stromal Tumors; Gefitinib; Gels; Gemcitabine; Gene Amplification; Gene Expression; Gene Expression Regulation; Gene Expression Regulation, Bacterial; Gene Expression Regulation, Neoplastic; Gene Expression Regulation, Plant; Gene Knockdown Techniques; Gene-Environment Interaction; Genotype; Germany; Glioma; Glomerular Filtration Rate; Glucagon; Glucocorticoids; Glycemic Control; Glycerol; Glycogen Synthase Kinase 3 beta; Glycolipids; Glycolysis; Goblet Cells; Gram-Negative Bacterial Infections; Granulocyte Colony-Stimulating Factor; Graphite; Greenhouse Effect; Guanidines; Haemophilus influenzae; HCT116 Cells; Health Knowledge, Attitudes, Practice; Health Personnel; Health Services Accessibility; Health Services Needs and Demand; Health Status Disparities; Healthy Volunteers; Heart Failure; Heart Rate; Heart Transplantation; Heart-Assist Devices; HEK293 Cells; Heme; Heme Oxygenase-1; Hemolysis; Hemorrhage; Hepatitis B; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Hepatocytes; Hexoses; High-Throughput Nucleotide Sequencing; Hippo Signaling Pathway; Histamine; Histamine Agonists; Histidine; Histone Deacetylase 2; HIV Infections; HIV Reverse Transcriptase; HIV-1; Homebound Persons; Homeodomain Proteins; Homosexuality, Male; Hospice and Palliative Care Nursing; HSP70 Heat-Shock Proteins; Humans; Hyaluronan Receptors; Hydrogen; Hydrogen Peroxide; Hydrogen-Ion Concentration; Hydrolysis; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemia; Hypoglycemic Agents; Hypoxia; Idiopathic Interstitial Pneumonias; Imaging, Three-Dimensional; Imatinib Mesylate; Immunotherapy; Implementation Science; Incidence; INDEL Mutation; Induced Pluripotent Stem Cells; Industrial Waste; Infant; Infant, Newborn; Inflammation; Inflammation Mediators; Infliximab; Infusions, Intravenous; Inhibitory Concentration 50; Injections; Insecticides; Insulin-Like Growth Factor Binding Protein 5; Insulin-Secreting Cells; Interleukin-1; Interleukin-17; Interleukin-8; Internship and Residency; Intestines; Intracellular Signaling Peptides and Proteins; Ion Transport; Iridaceae; Iridoid Glucosides; Islets of Langerhans Transplantation; Isodon; Isoflurane; Isotopes; Italy; Joint Instability; Ketamine; Kidney; Kidney Failure, Chronic; Kidney Function Tests; Kidney Neoplasms; Kinetics; Klebsiella pneumoniae; Knee Joint; Kruppel-Like Factor 4; Kruppel-Like Transcription Factors; Lactate Dehydrogenase 5; Laparoscopy; Laser Therapy; Lasers, Semiconductor; Lasers, Solid-State; Laurates; Lead; Leukocyte L1 Antigen Complex; Leukocytes, Mononuclear; Light; Lipid Peroxidation; Lipopolysaccharides; Liposomes; Liver; Liver Cirrhosis; Liver Neoplasms; Liver Transplantation; Locomotion; Longitudinal Studies; Lopinavir; Lower Urinary Tract Symptoms; Lubricants; Lung; Lung Diseases, Interstitial; Lung Neoplasms; Lymphocyte Activation; Lymphocytes, Tumor-Infiltrating; Lymphoma, Mantle-Cell; Lysosomes; Macrophages; Male; Manganese Compounds; MAP Kinase Kinase 4; Mass Screening; Maternal Health; Medicine, Chinese Traditional; Melanoma, Experimental; Memantine; Membrane Glycoproteins; Membrane Proteins; Mesenchymal Stem Cell Transplantation; Metal Nanoparticles; Metalloendopeptidases; Metalloporphyrins; Methadone; Methane; Methicillin-Resistant Staphylococcus aureus; Mexico; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Inbred ICR; Mice, Knockout; Mice, Nude; Mice, SCID; Mice, Transgenic; Microarray Analysis; Microbial Sensitivity Tests; Microbiota; Micronutrients; MicroRNAs; Microscopy, Confocal; Microsomes, Liver; Middle Aged; Milk; Milk, Human; Minority Groups; Mitochondria; Mitochondrial Membranes; Mitochondrial Proteins; Models, Animal; Models, Molecular; Molecular Conformation; Molecular Docking Simulation; Molecular Dynamics Simulation; Molecular Epidemiology; Molecular Structure; Molecular Weight; Multilocus Sequence Typing; Multimodal Imaging; Muscle Strength; Muscle, Skeletal; Muscular Diseases; Mutation; Mycobacterium tuberculosis; Myocardial Stunning; Myristates; NAD(P)H Dehydrogenase (Quinone); Nanocomposites; Nanogels; Nanoparticles; Nanotechnology; Naphthalenes; Nasal Cavity; National Health Programs; Necrosis; Needs Assessment; Neoadjuvant Therapy; Neonicotinoids; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Proteins; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasm Transplantation; Neoplasms; Neoplastic Stem Cells; Netherlands; Neuroblastoma; Neuroprotective Agents; Neutrophils; NF-kappa B; NFATC Transcription Factors; Nicotiana; Nicotine; Nitrates; Nitrification; Nitrites; Nitro Compounds; Nitrogen; Nitrogen Dioxide; North Carolina; Nuclear Magnetic Resonance, Biomolecular; Nuclear Proteins; Nucleic Acid Hybridization; Nucleosomes; Nutrients; Obesity; Obesity, Morbid; Oceans and Seas; Oncogene Protein v-akt; Oncogenes; Oocytes; Open Reading Frames; Osteoclasts; Osteogenesis; Osteoporosis; Osteoporosis, Postmenopausal; Outpatients; Ovarian Neoplasms; Ovariectomy; Overweight; Oxazines; Oxidants; Oxidation-Reduction; Oxidative Stress; Oxides; Oxidoreductases; Oxygen; Oxygen Inhalation Therapy; Oxygenators, Membrane; Ozone; Paclitaxel; Paenibacillus; Pain Measurement; Palliative Care; Pancreatic Neoplasms; Pandemics; Parasympathetic Nervous System; Particulate Matter; Pasteurization; Patient Preference; Patient Satisfaction; Pediatric Obesity; Permeability; Peroxiredoxins; Peroxynitrous Acid; Pharmaceutical Services; Pharmacists; Pharmacy; Phaseolus; Phenotype; Phoeniceae; Phosphates; Phosphatidylinositol 3-Kinases; Phospholipid Transfer Proteins; Phospholipids; Phosphorus; Phosphorylation; Photoperiod; Photosynthesis; Phylogeny; Physical Endurance; Physicians; Pilot Projects; Piperidines; Pituitary Adenylate Cyclase-Activating Polypeptide; Plant Extracts; Plant Leaves; Plant Proteins; Plant Roots; Plaque, Atherosclerotic; Pneumonia; Pneumonia, Viral; Point-of-Care Testing; Polyethylene Glycols; Polymers; Polysorbates; Pore Forming Cytotoxic Proteins; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Postprandial Period; Poverty; Pre-Exposure Prophylaxis; Prediabetic State; Predictive Value of Tests; Pregnancy; Pregnancy Trimester, First; Pregnancy, High-Risk; Prenatal Exposure Delayed Effects; Pressure; Prevalence; Primary Graft Dysfunction; Primary Health Care; Professional Role; Professionalism; Prognosis; Progression-Free Survival; Prolactin; Promoter Regions, Genetic; Proof of Concept Study; Proportional Hazards Models; Propylene Glycol; Prospective Studies; Prostate; Protein Binding; Protein Biosynthesis; Protein Isoforms; Protein Kinase Inhibitors; Protein Phosphatase 2; Protein Processing, Post-Translational; Protein Serine-Threonine Kinases; Protein Structure, Tertiary; Protein Transport; Proteoglycans; Proteome; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-myc; Proto-Oncogene Proteins c-ret; Proto-Oncogene Proteins p21(ras); Proton Pumps; Protons; Protoporphyrins; Pseudomonas aeruginosa; Pseudomonas fluorescens; Pulmonary Artery; Pulmonary Disease, Chronic Obstructive; Pulmonary Gas Exchange; Pulmonary Veins; Pyrazoles; Pyridines; Pyrimidines; Qualitative Research; Quinoxalines; Rabbits; Random Allocation; Rats; Rats, Sprague-Dawley; Rats, Wistar; Receptors, Histamine H3; Receptors, Immunologic; Receptors, Transferrin; Recombinant Proteins; Recurrence; Reference Values; Referral and Consultation; Regional Blood Flow; Registries; Regulon; Renal Insufficiency, Chronic; Reperfusion Injury; Repressor Proteins; Reproducibility of Results; Republic of Korea; Research Design; Resistance Training; Respiration, Artificial; Respiratory Distress Syndrome; Respiratory Insufficiency; Resuscitation; Retinal Dehydrogenase; Retreatment; Retrospective Studies; Reverse Transcriptase Inhibitors; Rhinitis, Allergic; Ribosomal Proteins; Ribosomes; Risk Assessment; Risk Factors; Ritonavir; Rivers; RNA Interference; RNA-Seq; RNA, Messenger; RNA, Ribosomal, 16S; RNA, Small Interfering; Rosuvastatin Calcium; Rural Population; Saccharomyces cerevisiae; Saccharomyces cerevisiae Proteins; Salivary Ducts; Salivary Gland Neoplasms; San Francisco; SARS-CoV-2; Satiation; Satiety Response; Schools; Schools, Pharmacy; Seasons; Seawater; Selection, Genetic; Sequence Analysis, DNA; Serine-Threonine Kinase 3; Sewage; Sheep; Sheep, Domestic; Shock, Hemorrhagic; Signal Transduction; Silver; Silymarin; Single Photon Emission Computed Tomography Computed Tomography; Sirolimus; Sirtuin 1; Skin; Skin Neoplasms; Skin Physiological Phenomena; Sleep Initiation and Maintenance Disorders; Social Class; Social Participation; Social Support; Soil; Soil Microbiology; Solutions; Somatomedins; Soot; Specimen Handling; Spectrophotometry, Ultraviolet; Spectroscopy, Fourier Transform Infrared; Spectrum Analysis; Spinal Fractures; Spirometry; Staphylococcus aureus; STAT1 Transcription Factor; STAT3 Transcription Factor; Streptomyces coelicolor; Stress, Psychological; Stroke; Stroke Volume; Structure-Activity Relationship; Students, Medical; Students, Pharmacy; Substance Abuse Treatment Centers; Sulfur Dioxide; Surface Properties; Surface-Active Agents; Surveys and Questionnaires; Survival Analysis; Survival Rate; Survivin; Sweden; Swine; Swine, Miniature; Sympathetic Nervous System; T-Lymphocytes, Regulatory; Talaromyces; Tandem Mass Spectrometry; tau Proteins; Telemedicine; Telomerase; Telomere; Telomere Homeostasis; Temperature; Terminally Ill; Th1 Cells; Thiamethoxam; Thiazoles; Thiophenes; Thioredoxin Reductase 1; Thrombosis; Thulium; Thyroid Cancer, Papillary; Thyroid Carcinoma, Anaplastic; Thyroid Neoplasms; Time Factors; Titanium; Tomography, Emission-Computed, Single-Photon; Tomography, X-Ray Computed; TOR Serine-Threonine Kinases; Transcription Factor AP-1; Transcription Factors; Transcription, Genetic; Transcriptional Activation; Transcriptome; Transforming Growth Factor beta1; Transistors, Electronic; Translational Research, Biomedical; Transplantation Tolerance; Transplantation, Homologous; Transportation; Treatment Outcome; Tretinoin; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary; Tubulin Modulators; Tumor Microenvironment; Tumor Necrosis Factor Inhibitors; Tumor Necrosis Factor-alpha; Twins; Ultrasonic Therapy; Ultrasonography; Ultraviolet Rays; United States; Up-Regulation; Uranium; Urethra; Urinary Bladder; Urodynamics; Uromodulin; Uveitis; Vasoconstrictor Agents; Ventricular Function, Left; Vero Cells; Vesicular Transport Proteins; Viral Nonstructural Proteins; Visual Acuity; Vital Capacity; Vitamin D; Vitamin D Deficiency; Vitamin K 2; Vitamins; Volatilization; Voriconazole; Waiting Lists; Waste Disposal, Fluid; Wastewater; Water Pollutants, Chemical; Whole Genome Sequencing; Wine; Wnt Signaling Pathway; Wound Healing; Wounds and Injuries; WW Domains; X-linked Nuclear Protein; X-Ray Diffraction; Xanthines; Xenograft Model Antitumor Assays; YAP-Signaling Proteins; Yogurt; Young Adult; Zebrafish; Zebrafish Proteins; Ziziphus | 2016 |
Durvalumab in frail and elderly patients with stage four non-small cell lung cancer: Study protocol of the randomized phase II DURATION trial.
Topics: Aged; Aged, 80 and over; Albumins; Antibodies, Monoclonal; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase II as Topic; Deoxycytidine; Female; Frail Elderly; Gemcitabine; Germany; Humans; Immunotherapy; Lung Neoplasms; Male; Multicenter Studies as Topic; Neoplasm Staging; Paclitaxel; Progression-Free Survival; Prospective Studies; Randomized Controlled Trials as Topic; Vinorelbine | 2020 |
Analysis of Clinical Efficacy of Nano-Albumin Paclitaxel Treatment for Advanced Cell Lung Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Humans; Lung Neoplasms; Paclitaxel; Treatment Outcome | 2020 |
Neoadjuvant atezolizumab and chemotherapy in patients with resectable non-small-cell lung cancer: an open-label, multicentre, single-arm, phase 2 trial.
Topics: Aged; Albumins; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Boston; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; New York City; Paclitaxel; Pneumonectomy; Programmed Cell Death 1 Receptor; Time Factors; Treatment Outcome | 2020 |
Cost-effectiveness of atezolizumab plus chemotherapy for advanced non-small-cell lung cancer.
Topics: Albumins; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cost-Benefit Analysis; Humans; Lung Neoplasms; Markov Chains; Paclitaxel; Quality-Adjusted Life Years | 2020 |
Phase II Study of Immunotherapy With Tecemotide and Bevacizumab After Chemoradiation in Patients With Unresectable Stage III Non-Squamous Non-Small-Cell Lung Cancer (NS-NSCLC): A Trial of the ECOG-ACRIN Cancer Research Group (E6508).
Topics: Adenocarcinoma of Lung; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Cancer Vaccines; Carboplatin; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Female; Follow-Up Studies; Humans; Immunotherapy; Lung Neoplasms; Male; Membrane Glycoproteins; Middle Aged; Paclitaxel; Prognosis; Survival Rate | 2020 |
First-line pembrolizumab vs chemotherapy in metastatic non-small-cell lung cancer: KEYNOTE-024 Japan subset.
Topics: Adult; Aged; Aged, 80 and over; Anaplastic Lymphoma Kinase; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; B7-H1 Antigen; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Confidence Intervals; Cross-Over Studies; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Genes, erbB-1; Humans; Japan; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Pemetrexed; Programmed Cell Death 1 Receptor; Progression-Free Survival; Treatment Outcome | 2020 |
Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM): an open-label, multicentre, single-arm, phase 2 trial.
Topics: Aged; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; B7-H1 Antigen; Carboplatin; Carcinoma, Non-Small-Cell Lung; Female; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Nivolumab; Paclitaxel; Programmed Cell Death 1 Receptor; Progression-Free Survival; Spain; Treatment Outcome | 2020 |
A Phase I/II Study of Biweekly Carboplatin and Nab-paclitaxel With Concurrent Radiotherapy for Patients With Locally Advanced Unresectable Stage III Non-small-cell Lung Cancer.
Topics: Adenocarcinoma of Lung; Adult; Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Chemoradiotherapy; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Paclitaxel; Prognosis; Retrospective Studies; Survival Rate; Young Adult | 2021 |
Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; B7-H1 Antigen; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Immune Checkpoint Inhibitors; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Pemetrexed; Progression-Free Survival; Survival Rate | 2021 |
A multi-institutional randomized phase III study comparing weekly carboplatin plus nab-paclitaxel and daily low-dose carboplatin as regimens for concurrent chemoradiotherapy in elderly patients with unresectable locally advanced non-small cell lung cancer
Topics: Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Female; Humans; Japan; Lung Neoplasms; Male; Paclitaxel | 2021 |
Effect of Second-generation vs Third-generation Chemotherapy Regimens With Thoracic Radiotherapy on Unresectable Stage III Non-Small-Cell Lung Cancer: 10-Year Follow-up of a WJTOG0105 Phase 3 Randomized Clinical Trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Female; Follow-Up Studies; Humans; Lung Neoplasms; Neoplasm Staging; Paclitaxel | 2021 |
An Open-Label Randomized Controlled Trial Comparing the Efficacy and Safety of Pemetrexed-Carboplatin versus (Weekly) Paclitaxel-Carboplatin as First-Line Chemotherapy in Advanced Non-Squamous Non-Small Cell Lung Cancer.
Topics: Academic Medical Centers; Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Drug Administration Schedule; Female; Humans; India; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Pemetrexed; Survival Analysis; Tertiary Care Centers; Treatment Outcome | 2021 |
A Dose-finding Study Followed by a Phase II Randomized, Placebo-controlled Trial of Chemoradiotherapy With or Without Veliparib in Stage III Non-small-cell Lung Cancer: SWOG 1206 (8811).
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Dose-Response Relationship, Drug; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Progression-Free Survival; Survival Rate | 2021 |
Tislelizumab Plus Chemotherapy vs Chemotherapy Alone as First-line Treatment for Advanced Squamous Non-Small-Cell Lung Cancer: A Phase 3 Randomized Clinical Trial.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Humans; Lung Neoplasms; Paclitaxel | 2021 |
Efficacy, Safety and Immunogenicity of MB02 (Bevacizumab Biosimilar) versus Reference Bevacizumab in Advanced Non-Small Cell Lung Cancer: A Randomized, Double-Blind, Phase III Study (STELLA).
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biosimilar Pharmaceuticals; Carboplatin; Carcinoma, Non-Small-Cell Lung; Humans; Lung Neoplasms; Paclitaxel; Treatment Outcome | 2021 |
A Phase II study of nab-Paclitaxel (nab-P) in patients with advanced non-small cell lung cancer with EGFR mutations after frontline tyrosine kinase inhibitor therapy.
Topics: Aged; Aged, 80 and over; Albumins; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Humans; Lung Neoplasms; Middle Aged; Mutation; Paclitaxel; Protein Kinase Inhibitors | 2021 |
A phase I/II study of pembrolizumab in combination with nab-paclitaxel in patients with unresectable stage III or stage IV non small-cell lung carcinoma (NSCLC).
Topics: Aged; Albumins; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel | 2021 |
Nivolumab with carboplatin, paclitaxel, and bevacizumab for first-line treatment of advanced nonsquamous non-small-cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Non-Small-Cell Lung; Double-Blind Method; Humans; Lung Neoplasms; Neoplasm Recurrence, Local; Nivolumab; Paclitaxel; Protein-Tyrosine Kinases; Proto-Oncogene Proteins | 2021 |
Efficacy and Safety of Bevacizumab Biosimilar FKB238 Versus Originator Bevacizumab: Results from AVANA, a Phase III Trial in Patients with Non-Squamous Non-Small-Cell Lung Cancer (non-sq-NSCLC).
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biosimilar Pharmaceuticals; Carboplatin; Carcinoma, Non-Small-Cell Lung; Humans; Lung Neoplasms; Neoplasm Recurrence, Local; Paclitaxel; Treatment Outcome | 2021 |
Autologous dendritic cell-based immunotherapy (DCVAC/LuCa) and carboplatin/paclitaxel in advanced non-small cell lung cancer: A randomized, open-label, phase I/II trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Dendritic Cells; Female; Humans; Immunotherapy; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Young Adult | 2021 |
Dose-dense Paclitaxel and Carboplatin as Neoadjuvant Chemotherapy for Stage IIB/IIIA Non-small Cell Lung Cancer - A Phase II trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Humans; Lung Neoplasms; Middle Aged; Neoadjuvant Therapy; Paclitaxel | 2021 |
Outcomes in 36 Patients with Stage IIIA-N2 Squamous Cell Carcinoma of the Lung Treated with Nab-Paclitaxel Plus Carboplatin as Neoadjuvant Therapy: A Prospective Study from a Single Center.
Topics: Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Humans; Lung Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Pneumonectomy; Progression-Free Survival; Prospective Studies | 2021 |
Veliparib in Combination With Platinum-Based Chemotherapy for First-Line Treatment of Advanced Squamous Cell Lung Cancer: A Randomized, Multicenter Phase III Study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Biomarkers, Tumor; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Clinical Decision-Making; Female; Gene Expression Profiling; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Patient Selection; Progression-Free Survival; Smokers; Time Factors; Transcriptome | 2021 |
A randomized placebo-controlled clinical study of
Topics: Adult; Aged; Albumins; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Survival Rate | 2017 |
An Open-Label, Randomized, Controlled Phase II Study of Paclitaxel-Carboplatin Chemotherapy With Necitumumab Versus Paclitaxel-Carboplatin Alone in First-Line Treatment of Patients With Stage IV Squamous Non-Small-Cell Lung Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Disease-Free Survival; Drug Eruptions; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Response Evaluation Criteria in Solid Tumors; Survival Rate | 2017 |
Phase II Study of Modified Carboplatin Plus Weekly Nab-Paclitaxel in Elderly Patients with Non-Small Cell Lung Cancer: North Japan Lung Cancer Study Group Trial 1301.
Topics: Aged; Aged, 80 and over; Albumins; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Japan; Male; Paclitaxel; Treatment Outcome | 2017 |
[Detection of Serum Peptides in Patients with Lung Squamous Cell Carcinoma by MALDI-TOF-MS and Analysis of Their Correlation with Chemotherapy Efficacy].
Topics: Adult; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Drug Monitoring; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Peptides; Platinum; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Treatment Outcome; Young Adult | 2017 |
Feasibility study of adjuvant chemotherapy with modified weekly nab-paclitaxel and carboplatin for completely resected non-small-cell lung cancer: FAST-nab.
Topics: Adult; Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Drug Administration Schedule; Feasibility Studies; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel | 2017 |
Effect of Midtreatment PET/CT-Adapted Radiation Therapy With Concurrent Chemotherapy in Patients With Locally Advanced Non-Small-Cell Lung Cancer: A Phase 2 Clinical Trial.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Dose Fractionation, Radiation; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Positron Emission Tomography Computed Tomography; Precision Medicine; Radiotherapy, Conformal; Survival Analysis; Treatment Outcome | 2017 |
A phase Ib study of pembrolizumab plus chemotherapy in patients with advanced cancer (PembroPlus).
Topics: Adenocarcinoma; Adult; Aged; Albumins; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Camptothecin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Diarrhea; Docetaxel; Doxorubicin; Drug Eruptions; Fatigue; Female; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Nausea; Neoplasms; Ovarian Neoplasms; Paclitaxel; Pancreatic Neoplasms; Polyethylene Glycols; Sarcoma; Small Cell Lung Carcinoma; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine; Vomiting | 2017 |
Treatment Rationale and Design for J-SONIC: A Randomized Study of Carboplatin Plus Nab-paclitaxel With or Without Nintedanib for Advanced Non-Small-cell Lung Cancer With Idiopathic Pulmonary Fibrosis.
Topics: Adult; Aged; Aged, 80 and over; Albumins; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease Progression; Female; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Survival Analysis; Young Adult | 2018 |
Proton Beam Radiotherapy and Concurrent Chemotherapy for Unresectable Stage III Non-Small Cell Lung Cancer: Final Results of a Phase 2 Study.
Topics: Adult; Aged; Antineoplastic Agents; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Disease-Free Survival; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Proton Therapy; Protons | 2017 |
Cost-effectiveness analysis of the addition of bevacizumab to chemotherapy as induction and maintenance therapy for metastatic non-squamous non-small-cell lung cancer.
Topics: Adenocarcinoma; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; China; Cost-Benefit Analysis; Humans; Induction Chemotherapy; Lung Neoplasms; Maintenance Chemotherapy; Paclitaxel | 2018 |
Phase II study of olaratumab with paclitaxel/carboplatin (P/C) or P/C alone in previously untreated advanced NSCLC.
Topics: Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Drug Administration Schedule; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Remission Induction; Survival Analysis; Treatment Outcome | 2017 |
Phase III Trial of Ipilimumab Combined With Paclitaxel and Carboplatin in Advanced Squamous Non-Small-Cell Lung Cancer.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Diarrhea; Double-Blind Method; Female; Humans; Ipilimumab; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neutropenia; Outcome Assessment, Health Care; Paclitaxel; Proportional Hazards Models | 2017 |
Phase III, Randomized, Placebo-Controlled, Double-Blind Trial of Motesanib (AMG-706) in Combination With Paclitaxel and Carboplatin in East Asian Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Double-Blind Method; Female; Hong Kong; Humans; Indoles; Japan; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Niacinamide; Oligonucleotides; Paclitaxel; Republic of Korea; Survival Rate; Treatment Outcome | 2017 |
Phase II randomized trial of carboplatin, paclitaxel, bevacizumab with or without cixutumumab (IMC-A12) in patients with advanced non-squamous, non-small-cell lung cancer: a trial of the ECOG-ACRIN Cancer Research Group (E3508).
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Lung Neoplasms; Male; Paclitaxel; Survival Rate | 2017 |
A phase IB dose-escalation study of the safety and pharmacokinetics of pictilisib in combination with either paclitaxel and carboplatin (with or without bevacizumab) or pemetrexed and cisplatin (with or without bevacizumab) in patients with advanced non-s
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Drug Administration Schedule; Drug Dosage Calculations; Female; Humans; Indazoles; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Pemetrexed; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Sulfonamides; Treatment Outcome | 2017 |
Collagen gel droplet-embedded culture drug sensitivity test for adjuvant chemotherapy after complete resection of non-small-cell lung cancer.
Topics: Adult; Aged; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Collagen; Culture Media; Culture Techniques; Drug Screening Assays, Antitumor; Drug Therapy, Combination; Female; Gels; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Pneumonectomy; Precision Medicine; Prospective Studies; Survival Rate; Treatment Outcome | 2018 |
A single-arm phase II study of nab-paclitaxel for patients with chemorefractory non-small cell lung cancer.
Topics: Aged; Aged, 80 and over; Albumins; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Paclitaxel | 2017 |
Randomized Phase II Trial of Parsatuzumab (Anti-EGFL7) or Placebo in Combination with Carboplatin, Paclitaxel, and Bevacizumab for First-Line Nonsquamous Non-Small Cell Lung Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Non-Small-Cell Lung; Double-Blind Method; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Progression-Free Survival | 2018 |
A randomized, controlled trial evaluating the efficacy and safety of BTH1677 in combination with bevacizumab, carboplatin, and paclitaxel in first-line treatment of advanced non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Non-Small-Cell Lung; Female; Glucans; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Treatment Outcome | 2018 |
A Randomized Phase II Study of Metformin plus Paclitaxel/Carboplatin/Bevacizumab in Patients with Chemotherapy-Naïve Advanced or Metastatic Nonsquamous Non-Small Cell Lung Cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Non-Small-Cell Lung; Female; Humans; Hypoglycemic Agents; Lung Neoplasms; Male; Metformin; Middle Aged; Neoplasm Metastasis; Paclitaxel | 2018 |
Time-to-Treatment-Failure and Related Outcomes Among 1000+ Advanced Non-Small Cell Lung Cancer Patients: Comparisons Between Older Versus Younger Patients (Alliance A151711).
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Male; Paclitaxel; Pemetrexed; Prospective Studies; Survival Rate; Time-to-Treatment; Treatment Failure | 2018 |
Nab-paclitaxel maintenance therapy following carboplatin + nab-paclitaxel combination therapy in chemotherapy naïve patients with advanced non-small cell lung cancer: multicenter, open-label, single-arm phase II trial.
Topics: Aged; Aged, 80 and over; Albumins; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neutropenia; Paclitaxel | 2018 |
Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC.
Topics: Aged; Anaplastic Lymphoma Kinase; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; B7-H1 Antigen; Bevacizumab; Carboplatin; Carcinoma, Non-Small-Cell Lung; Female; Genes, erbB-1; Humans; Immunotherapy; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Metastasis; Paclitaxel; Receptor Protein-Tyrosine Kinases; Survival Analysis; Vascular Endothelial Growth Factor A | 2018 |
Efficacy and safety of liposome-paclitaxel and carboplatin based concurrent chemoradiotherapy for locally advanced lung squamous cell carcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Chemoradiotherapy; Female; Humans; Liposomes; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Prognosis; Progression-Free Survival; Radiotherapy, Intensity-Modulated | 2018 |
Vistusertib (dual m-TORC1/2 inhibitor) in combination with paclitaxel in patients with high-grade serous ovarian and squamous non-small-cell lung cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Carcinoma, Non-Small-Cell Lung; Drug Administration Schedule; Female; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Mechanistic Target of Rapamycin Complex 1; Mechanistic Target of Rapamycin Complex 2; Middle Aged; Morpholines; Ovarian Neoplasms; Paclitaxel; Phosphorylation; Protein Kinase Inhibitors; Pyrimidines; Response Evaluation Criteria in Solid Tumors; Ribosomal Protein S6 Kinases | 2018 |
Trastuzumab and paclitaxel in patients with EGFR mutated NSCLC that express HER2 after progression on EGFR TKI treatment.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Female; Gene Dosage; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Paclitaxel; Protein Kinase Inhibitors; Receptor, ErbB-2; Survival Analysis; Trastuzumab; Treatment Outcome | 2018 |
Stage III Non-Small-Cell Lung Cancer Treated With Concurrent Chemoradiation Followed or Not by Consolidation Chemotherapy: A Survival Analysis From a Brazilian Multicentric Cohort.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Brazil; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Cisplatin; Combined Modality Therapy; Consolidation Chemotherapy; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Paclitaxel; Progression-Free Survival; Treatment Outcome | 2018 |
Pembrolizumab plus Chemotherapy for Squamous Non-Small-Cell Lung Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Double-Blind Method; Female; Humans; Intention to Treat Analysis; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Programmed Cell Death 1 Receptor; Progression-Free Survival; Survival Analysis | 2018 |
Validation of Effective Dose as a Better Predictor of Radiation Pneumonitis Risk Than Mean Lung Dose: Secondary Analysis of a Randomized Trial.
Topics: Adult; Aged; Aged, 80 and over; Bayes Theorem; Carboplatin; Carcinoma, Non-Small-Cell Lung; Data Interpretation, Statistical; Female; Humans; Incidence; Lung; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Photons; Proton Therapy; Protons; Radiation Pneumonitis; Radiometry; Radiotherapy; Radiotherapy, Intensity-Modulated; Reproducibility of Results; Risk; Scattering, Radiation; Smoking; Young Adult | 2019 |
Phase I/II study of carboplatin plus nab-paclitaxel and concurrent radiotherapy for patients with locally advanced non-small cell lung cancer.
Topics: Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Female; Humans; Leukopenia; Lung Neoplasms; Male; Middle Aged; Paclitaxel | 2018 |
Which is the optimal immunotherapy for advanced squamous non-small-cell lung cancer in combination with chemotherapy: anti-PD-1 or anti-PD-L1?
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; B7-H1 Antigen; Carboplatin; Carcinoma, Non-Small-Cell Lung; Female; Humans; Immunotherapy; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Programmed Cell Death 1 Receptor; Young Adult | 2018 |
Dynamics of blood neutrophil-related indices during nivolumab treatment may be associated with response to salvage chemotherapy for non-small cell lung cancer: A hypothesis-generating study.
Topics: Adenocarcinoma; Aged; Albumins; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Case-Control Studies; Docetaxel; Drug Combinations; Female; Follow-Up Studies; Humans; Lung Neoplasms; Lymphocytes; Male; Middle Aged; Neutrophils; Nivolumab; Oxonic Acid; Paclitaxel; Prognosis; Ramucirumab; Retrospective Studies; Salvage Therapy; Survival Rate; Tegafur | 2019 |
Phase II trial of a non-platinum triplet for patients with advanced non-small cell lung carcinoma (NSCLC) overexpressing ERCC1 messenger RNA.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; DNA-Binding Proteins; Endonucleases; Female; Humans; Irinotecan; Male; Middle Aged; Neoplasm Staging; Paclitaxel; RNA, Messenger; Treatment Outcome; Ultrasonography | 2019 |
Induction of Peripheral Effector CD8 T-cell Proliferation by Combination of Paclitaxel, Carboplatin, and Bevacizumab in Non-small Cell Lung Cancer Patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Carboplatin; Carcinoma, Non-Small-Cell Lung; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Cell Proliferation; Female; Gene Expression; Humans; Immunophenotyping; Lung Neoplasms; Lymphocyte Activation; Lymphocyte Count; Male; Paclitaxel; Prognosis; Treatment Outcome | 2019 |
Phase 1b/2 Randomized Study of MEDI-575 in Combination With Carboplatin Plus Paclitaxel Versus Carboplatin Plus Paclitaxel Alone in Adult Patients With Previously Untreated Advanced Non-Small-Cell Lung Cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Female; Humans; Lung Neoplasms; Male; Neoplasm Staging; Paclitaxel; Survival Analysis; Treatment Outcome | 2019 |
A randomised phase II clinical trial of nab-paclitaxel and carboplatin compared with gemcitabine and carboplatin as first-line therapy in advanced squamous cell lung carcinoma (C-TONG1002).
Topics: Adult; Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Prognosis; Quality of Life; Survival Rate | 2019 |
Prospective Multicentered Safety and Feasibility Pilot for Endobronchial Intratumoral Chemotherapy.
Topics: Aged; Airway Obstruction; Antineoplastic Agents, Phytogenic; Bronchoscopy; Carcinoma, Non-Small-Cell Lung; Feasibility Studies; Female; Humans; Injections, Intralesional; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Prospective Studies; Quality of Life; Stents; Treatment Outcome | 2019 |
Switch maintenance therapy with S-1 after induction therapy with carboplatin and nanoparticle albumin-bound paclitaxel in advanced lung squamous cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Albumins; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Brain Neoplasms; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Drug Combinations; Female; Follow-Up Studies; Humans; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Maintenance Chemotherapy; Male; Middle Aged; Nanoparticles; Oxonic Acid; Paclitaxel; Prognosis; Survival Rate; Tegafur | 2019 |
Phase II trial of induction chemotherapy with carboplatin and paclitaxel plus bevacizumab in patients with stage IIIA to IV nonsquamous non-small cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Female; Humans; Induction Chemotherapy; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Survival Rate; Treatment Outcome | 2019 |
Carboplatin Plus Nab-paclitaxel in Performance Status 2 Patients With Advanced Non-small-cell Lung Cancer.
Topics: Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Treatment Outcome | 2019 |
Carboplatin, S-1 and concurrent thoracic radiotherapy for elderly patients with locally advanced non-small cell lung cancer: a multicenter Phase I/II study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Drug Combinations; Female; Humans; Leukopenia; Lung Neoplasms; Male; Neoplasm Staging; Oxonic Acid; Paclitaxel; Progression-Free Survival; Radiation Pneumonitis; Tegafur; Treatment Outcome | 2019 |
Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Humans; Liver Neoplasms; Lung Neoplasms; Middle Aged; Mutation; Paclitaxel; Treatment Outcome | 2019 |
Association between depth of response and survival in patients with advanced-stage non-small cell lung cancer treated with first-line chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Albumins; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Female; Humans; Lung Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Paclitaxel; Progression-Free Survival; Response Evaluation Criteria in Solid Tumors; Retrospective Studies; Tumor Burden; Young Adult | 2019 |
A phase I/II trial of weekly nab-paclitaxel for pretreated non-small-cell lung cancer patients without epidermal growth factor receptor mutations and anaplastic lymphoma kinase rearrangement.
Topics: Aged; Albumins; Anaplastic Lymphoma Kinase; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Humans; Lung Neoplasms; Male; Mutation; Paclitaxel | 2019 |
A single-arm phase II trial of weekly nanoparticle albumin-bound paclitaxel (nab-paclitaxel) monotherapy after standard of chemotherapy for previously treated advanced non-small cell lung cancer.
Topics: Adult; Aged; Albumins; Carcinoma, Non-Small-Cell Lung; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel | 2019 |
Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 tria
Topics: Aged; Aged, 80 and over; Albumins; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Female; Humans; Lung Neoplasms; Male; Paclitaxel | 2019 |
Impact of pathological stage and histological subtype on clinical outcome of adjuvant chemotherapy of paclitaxel plus carboplatin versus oral uracil-tegafur for non-small cell lung cancer: subanalysis of SLCG0401 trial.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Tegafur; Treatment Outcome; Uracil | 2019 |
PF-06439535 (a Bevacizumab Biosimilar) Compared with Reference Bevacizumab (Avastin
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biosimilar Pharmaceuticals; Carboplatin; Carcinoma, Non-Small-Cell Lung; Double-Blind Method; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Treatment Outcome; Young Adult | 2019 |
Weekly paclitaxel in combination with carboplatin for advanced non-small-cell lung cancer complicated by idiopathic interstitial pneumonias: a single-arm phase II study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Female; Humans; Idiopathic Interstitial Pneumonias; Japan; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Pilot Projects; Prospective Studies; Survival Analysis; Treatment Outcome | 2019 |
Assessing the effectiveness and safety of liposomal paclitaxel in combination with cisplatin as first-line chemotherapy for patients with advanced NSCLC with regional lymph-node metastasis: study protocol for a randomized controlled trial (PLC-GC trial).
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemistry, Pharmaceutical; China; Cisplatin; Clinical Protocols; Deoxycytidine; Disease Progression; Disease-Free Survival; Gemcitabine; Humans; Kaplan-Meier Estimate; Liposomes; Lung Neoplasms; Lymphatic Metastasis; Neoplasm Staging; Paclitaxel; Prospective Studies; Research Design; Time Factors; Treatment Outcome | 2013 |
The addition of amifostine to carboplatin and paclitaxel based chemoradiation in locally advanced non-small cell lung cancer: long-term follow-up of Radiation Therapy Oncology Group (RTOG) randomized trial 9801.
Topics: Adult; Aged; Aged, 80 and over; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Disease-Free Survival; Drug-Related Side Effects and Adverse Reactions; Female; Follow-Up Studies; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel | 2013 |
Tumor response and health-related quality of life in clinically selected patients from Asia with advanced non-small-cell lung cancer treated with first-line gefitinib: post hoc analyses from the IPASS study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Asia; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; ErbB Receptors; Exanthema; Female; Gefitinib; Humans; Lung Neoplasms; Male; Paclitaxel; Quality of Life; Quinazolines | 2013 |
Efficacy and safety of weekly nab-paclitaxel plus carboplatin in patients with advanced non-small cell lung cancer.
Topics: Aged; Albumins; Anemia; Antineoplastic Combined Chemotherapy Protocols; Asian People; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Female; Humans; Lung Neoplasms; Male; Paclitaxel; Thrombocytopenia; Treatment Outcome | 2013 |
Randomized phase II study of ixabepilone or paclitaxel plus carboplatin in patients with non-small-cell lung cancer prospectively stratified by beta-3 tubulin status.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Biomarkers, Tumor; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Drug Administration Schedule; Epothilones; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Predictive Value of Tests; Prospective Studies; Treatment Outcome; Tubulin; Tubulin Modulators | 2013 |
Does histology predict survival of advanced non-small cell lung cancer patients treated with platin-based chemotherapy? An analysis of the Eastern Cooperative Oncology Group Study E1594.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carboplatin; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Lung Neoplasms; Middle Aged; Neoplasms, Squamous Cell; Paclitaxel; Retrospective Studies; Taxoids; Treatment Outcome | 2013 |
Assessment of ocular neurotoxicity in patients treated with systemic cancer chemotherapeutics.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Female; Humans; Injections, Intravenous; Lung Neoplasms; Male; Middle Aged; Nerve Fibers; Optic Nerve; Paclitaxel; Prospective Studies; Visual Fields | 2014 |
A randomised trial comparing preoperative to perioperative chemotherapy in early-stage non-small-cell lung cancer (IFCT 0002 trial).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Nausea; Neoplasm Staging; Neutropenia; Paclitaxel; Perioperative Care; Preoperative Care; Quality of Life; Treatment Outcome; Vomiting | 2013 |
Safety and efficacy analysis by histology of weekly nab-paclitaxel in combination with carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Albumins; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neoplasms, Squamous Cell; Organoplatinum Compounds; Paclitaxel; Survival; Survival Rate; Treatment Outcome | 2013 |
A phase I/II study of sepantronium bromide (YM155, survivin suppressor) with paclitaxel and carboplatin in patients with advanced non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Female; Humans; Imidazoles; Inhibitor of Apoptosis Proteins; Lung Neoplasms; Male; Middle Aged; Naphthoquinones; Paclitaxel; Survival; Survivin; Treatment Outcome | 2013 |
Phase 1 study of lenvatinib combined with carboplatin and paclitaxel in patients with non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Phenylurea Compounds; Quinolines | 2013 |
Phase2 study of bevacizumab with carboplatin-paclitaxel for non-small cell lung cancer with malignant pleural effusion.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease Progression; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Pleural Effusion, Malignant; Survival Rate; Treatment Outcome; Vascular Endothelial Growth Factor A | 2013 |
Baseline tumour measurements predict survival in advanced non-small cell lung cancer.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Non-Small-Cell Lung; Female; Humans; Lung Neoplasms; Male; Neoplasm Invasiveness; Neoplasm Staging; Paclitaxel; Predictive Value of Tests; Prognosis; Proportional Hazards Models; Survival Analysis; Treatment Outcome | 2013 |
10-year long-term survival (LTS) of induction chemotherapy with three cycles cisplatin/paclitaxel followed by concurrent chemoradiation cisplatin/etoposide/45 Gy (1.5 Gy bid) plus surgery in locally advanced non-small-cell lung cancer (NSCLC)-a multicente
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Cisplatin; Etoposide; Female; Follow-Up Studies; Humans; Induction Chemotherapy; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Prospective Studies; Survivors; Treatment Outcome | 2013 |
Safety and efficacy of first-line bevacizumab combination therapy in Chinese population with advanced non-squamous NSCLC: data of subgroup analyses from MO19390 (SAiL) study.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Asian People; Bevacizumab; Carboplatin; Carcinoma, Non-Small-Cell Lung; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Treatment Outcome | 2014 |
Phase I/II trial of pemetrexed plus nab-paclitaxel in advanced solid tumor patients with emphasis on non-small cell lung cancer.
Topics: Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Drug Administration Schedule; Female; Glutamates; Guanine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Paclitaxel; Pemetrexed | 2013 |
Prediction of survival by [18F]fluorodeoxyglucose positron emission tomography in patients with locally advanced non-small-cell lung cancer undergoing definitive chemoradiation therapy: results of the ACRIN 6668/RTOG 0235 trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Cisplatin; Etoposide; Female; Fluorodeoxyglucose F18; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Positron-Emission Tomography; Predictive Value of Tests; Proportional Hazards Models; Prospective Studies; Radiopharmaceuticals; Radiotherapy Dosage; Treatment Outcome | 2013 |
Modulation of peripheral immune responses by paclitaxel-ifosfamide-cisplatin chemotherapy in advanced non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Female; Humans; Ifosfamide; Immunity, Innate; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Survival Analysis | 2013 |
A phase III concurrent chemoradiotherapy trial with cisplatin and paclitaxel or docetaxel or gemcitabine in unresectable non-small cell lung cancer: KASLC 0401.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Cisplatin; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Prospective Studies; Radiation Injuries; Radiotherapy, Conformal; Survival Rate; Taxoids; Treatment Outcome | 2013 |
Prediction of overall survival or progression free survival by disease control rate at week 8 is independent of ethnicity: Western versus Chinese patients with first-line non-small cell lung cancer treated with chemotherapy with or without bevacizumab.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Humans; Lung Neoplasms; Models, Biological; Paclitaxel; Racial Groups; Serum Albumin; Treatment Outcome | 2014 |
Carboplatin plus either docetaxel or paclitaxel for Japanese patients with advanced non-small cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Docetaxel; Female; Humans; Japan; Kaplan-Meier Estimate; Lung Neoplasms; Male; Paclitaxel; Taxoids; Treatment Outcome | 2013 |
PointBreak: a randomized phase III study of pemetrexed plus carboplatin and bevacizumab followed by maintenance pemetrexed and bevacizumab versus paclitaxel plus carboplatin and bevacizumab followed by maintenance bevacizumab in patients with stage IIIB o
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Non-Small-Cell Lung; Drug Administration Schedule; Female; Glutamates; Guanine; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Pemetrexed; Proportional Hazards Models; Time Factors; Treatment Outcome; United States | 2013 |
A randomized, double-blind, placebo-controlled phase 2 study of tigatuzumab (CS-1008) in combination with carboplatin/paclitaxel in patients with chemotherapy-naïve metastatic/unresectable non-small cell lung cancer.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Double-Blind Method; Europe; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Neutropenia; Paclitaxel; Placebos; Receptors, TNF-Related Apoptosis-Inducing Ligand | 2013 |
Phase II study of concurrent thoracic radiotherapy in combination with weekly paclitaxel plus carboplatin in locally advanced non-small cell lung cancer: LOGIK0401.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Chemoradiotherapy; Disease-Free Survival; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Survival Rate; Treatment Outcome; Vinblastine; Vinorelbine | 2013 |
Comparison of efficacy for postoperative chemotherapy and concurrent radiochemotherapy in patients with IIIA-pN2 non-small cell lung cancer: an early closed randomized controlled trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Chemotherapy, Adjuvant; Cisplatin; Disease-Free Survival; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Pneumonectomy; Postoperative Care; Survival Rate; Treatment Outcome | 2014 |
Phase II trial of carboplatin, paclitaxel, cetuximab, and bevacizumab followed by cetuximab and bevacizumab in advanced nonsquamous non-small-cell lung cancer: SWOG S0536.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cetuximab; Feasibility Studies; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Prognosis; Survival Rate | 2013 |
A population-based review of the feasibility of platinum-based combination chemotherapy after tyrosine kinase inhibition in EGFR mutation positive non-small cell lung cancer patients with advanced disease.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Feasibility Studies; Female; Gefitinib; Humans; Lung Neoplasms; Male; Mutation; Paclitaxel; Platinum Compounds; Population Groups; Quinazolines | 2014 |
Phase II study of low-dose paclitaxel with timed thoracic radiotherapy followed by adjuvant gemcitabine and carboplatin in unresectable stage III non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Radiotherapy; Thorax | 2014 |
[The results of combined treatment for stage III lung cancer including the use of intraoperative radiotherapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Female; Humans; Intraoperative Care; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Radiotherapy, Adjuvant; Time Factors; Treatment Outcome | 2013 |
Patient-reported neuropathy and taxane-associated symptoms in a phase 3 trial of nab-paclitaxel plus carboplatin versus solvent-based paclitaxel plus carboplatin for advanced non-small-cell lung cancer.
Topics: Adult; Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Carboplatin; Carcinoma, Non-Small-Cell Lung; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Paraneoplastic Polyneuropathy; Quality of Life; Taxoids | 2014 |
Randomised phase II study of axitinib or bevacizumab combined with paclitaxel/carboplatin as first-line therapy for patients with advanced non-small-cell lung cancer.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Bevacizumab; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Female; Humans; Imidazoles; Indazoles; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Neutropenia; Paclitaxel; Proportional Hazards Models; Treatment Outcome | 2014 |
Randomised, double-blind trial of carboplatin and paclitaxel with daily oral cediranib or placebo in patients with advanced non-small cell lung cancer: NCIC Clinical Trials Group study BR29.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease Progression; Double-Blind Method; Drug Administration Schedule; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Placebos; Quinazolines; Survival Analysis; Young Adult | 2014 |
A phase 2 randomized trial of paclitaxel and carboplatin with or without panitumumab for first-line treatment of advanced non-small-cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Paclitaxel; Panitumumab; Prognosis; Survival Rate | 2013 |
Prospective study of paclitaxel and irinotecan for elderly patients with unresectable non-small cell lung cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Female; Humans; Irinotecan; Lung Neoplasms; Male; Neoplasm Staging; Paclitaxel; Prospective Studies; Survival Rate | 2013 |
Phase III study (MONET1) of motesanib plus carboplatin/paclitaxel in patients with advanced nonsquamous nonsmall-cell lung cancer (NSCLC): Asian subgroup analysis.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Asian People; Carboplatin; Carcinoma, Non-Small-Cell Lung; Diarrhea; Disease-Free Survival; Double-Blind Method; Female; Humans; Indoles; Lung Neoplasms; Male; Middle Aged; Niacinamide; Oligonucleotides; Paclitaxel; Proportional Hazards Models; Treatment Outcome; Young Adult | 2014 |
Effectiveness of gefitinib against non-small-cell lung cancer with the uncommon EGFR mutations G719X and L861Q.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Follow-Up Studies; Gefitinib; Genotype; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Paclitaxel; Polymerase Chain Reaction; Prognosis; Quinazolines; Retrospective Studies; Sequence Deletion; Survival Rate | 2014 |
Early pharmacodynamic assessment using ¹⁸F-fluorodeoxyglucose positron-emission tomography on molecular targeted therapy and cytotoxic chemotherapy for clinical outcome prediction.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Female; Fluorodeoxyglucose F18; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Paclitaxel; Positron-Emission Tomography; Quinazolines; Radiopharmaceuticals; Treatment Outcome | 2014 |
Phase II trial of mapatumumab, a fully human agonist monoclonal antibody to tumor necrosis factor-related apoptosis-inducing ligand receptor 1 (TRAIL-R1), in combination with paclitaxel and carboplatin in patients with advanced non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Receptors, TNF-Related Apoptosis-Inducing Ligand; Survival Rate; Treatment Outcome | 2014 |
Randomized control study of nedaplatin or cisplatin concomitant with other chemotherapy in the treatment of advanced non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Case-Control Studies; Cisplatin; Deoxycytidine; Docetaxel; Female; Follow-Up Studies; Gemcitabine; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Paclitaxel; Pemetrexed; Prognosis; Retrospective Studies; Survival Rate; Taxoids; Vinblastine; Vinorelbine; Young Adult | 2014 |
Phase II study on dose escalating schedule of paclitaxel concurrent with radiotherapy in treating patients with locally advanced non-small cell lung cancer.
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Combined Modality Therapy; Disease-Free Survival; Dose Fractionation, Radiation; Drug Administration Schedule; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Radiotherapy, Conformal; Survival Rate | 2014 |
Randomized phase II trial comparing carboplatin plus weekly paclitaxel and docetaxel alone in elderly patients with advanced non-small cell lung cancer: north japan lung cancer group trial 0801.
Topics: Aged; Aged, 80 and over; Aging; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Humans; Japan; Lung Neoplasms; Paclitaxel; Taxoids; Treatment Outcome | 2014 |
Preoperative endobronchial photodynamic therapy improves resectability in initially irresectable (inoperable) locally advanced non small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Drug Combinations; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Photochemotherapy; Photosensitizing Agents; Pneumonectomy; Porphyrins; Thoracotomy; Treatment Failure; Treatment Outcome | 2014 |
Azithromycin enhances the favorable results of paclitaxel and cisplatin in patients with advanced non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Azithromycin; Carcinoma, Non-Small-Cell Lung; Chlamydia Infections; Chlamydophila pneumoniae; Cisplatin; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Quality of Life | 2014 |
Phase I study of weekly paclitaxel in combination with pazopanib and lapatinib in advanced solid malignancies.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Carcinoma, Non-Small-Cell Lung; Drug Administration Schedule; Female; Humans; Indazoles; Lapatinib; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Paclitaxel; Pyrimidines; Quinazolines; Salivary Gland Neoplasms; Sulfonamides; Treatment Outcome | 2014 |
A correlative biomarker analysis of the combination of bevacizumab and carboplatin-based chemotherapy for advanced nonsquamous non-small-cell lung cancer: results of the phase II randomized ABIGAIL study (BO21015).
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease-Free Survival; E-Selectin; Female; Fibroblast Growth Factor 2; Gemcitabine; Humans; Intercellular Adhesion Molecule-1; Lung Neoplasms; Male; Neuropilins; Paclitaxel; Placenta Growth Factor; Platelet Endothelial Cell Adhesion Molecule-1; Pregnancy Proteins; Prospective Studies; Survival Rate; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-1; Vascular Endothelial Growth Factor Receptor-2 | 2014 |
A phase 1 study of linifanib in combination with carboplatin/paclitaxel as first-line treatment of Japanese patients with advanced or metastatic non-small cell lung cancer (NSCLC).
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Carcinoma, Non-Small-Cell Lung; Chemotherapy-Induced Febrile Neutropenia; Cohort Studies; Dose-Response Relationship, Drug; Female; Humans; Indazoles; Japan; Leukopenia; Lung; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Phenylurea Compounds; Protein Kinase Inhibitors; Receptors, Platelet-Derived Growth Factor; Receptors, Vascular Endothelial Growth Factor; Severity of Illness Index; Thrombocytopenia; Tumor Burden | 2014 |
Multiplex genomic profiling of non-small cell lung cancers from the LETS phase III trial of first-line S-1/carboplatin versus paclitaxel/carboplatin: results of a West Japan Oncology Group study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; DNA Mutational Analysis; Drug Combinations; Female; Gene Expression Profiling; Humans; In Situ Hybridization, Fluorescence; Kaplan-Meier Estimate; Lung Neoplasms; Male; Mass Spectrometry; Middle Aged; Multiplex Polymerase Chain Reaction; Mutation; Oxonic Acid; Paclitaxel; Tegafur | 2014 |
PL03.05 An intergroup randomized phase III comparison of standard-dose (60 Gy) vs high-dose (74 Gy) chemoradiotherapy (CRT) +/- cetuximab (cetux) for stage III non-small cell lung cancer (NSCLC): results on cetux from RTOG 0617.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cetuximab; Chemoradiotherapy; Consolidation Chemotherapy; Disease-Free Survival; ErbB Receptors; Esophagitis; Female; Humans; Lung Neoplasms; Male; Neoplasm Proteins; Paclitaxel; Protein Kinase Inhibitors; Radiation Injuries; Radiotherapy Dosage; Survival Analysis | 2014 |
O02.03 Value of adding erlotinib to thoracic radiation therapy with chemotherapy for stage III non-small cell lung cancer: a prospective phase II study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Consolidation Chemotherapy; Disease-Free Survival; DNA Mutational Analysis; DNA, Neoplasm; Docetaxel; Erlotinib Hydrochloride; Esophagitis; Genes, erbB-1; Humans; Lung Neoplasms; Paclitaxel; Prospective Studies; Quinazolines; Radiation Injuries; Radiation Pneumonitis; Radiation-Sensitizing Agents; Radiotherapy Dosage; Survival Analysis; Taxoids | 2014 |
Randomized, phase III trial of first-line figitumumab in combination with paclitaxel and carboplatin versus paclitaxel and carboplatin alone in patients with advanced non-small-cell lung cancer.
Topics: Adult; Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Drug Administration Schedule; Female; Glycated Hemoglobin; Humans; Insulin-Like Growth Factor I; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Treatment Outcome | 2014 |
A phase II trial of Cremorphor EL-free paclitaxel (Genexol-PM) and gemcitabine in patients with advanced non-small cell lung cancer.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Liposomes; Lung Neoplasms; Male; Middle Aged; Nanoparticles; Neoplasm Staging; Paclitaxel; Prognosis; Prospective Studies; Survival Rate; Young Adult | 2014 |
Prognostic impact of circulating monocytes and lymphocyte-to-monocyte ratio on previously untreated metastatic non-small cell lung cancer patients receiving platinum-based doublet.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Disease-Free Survival; Docetaxel; Female; Glutamates; Guanine; Humans; Lung Neoplasms; Lymphocyte Count; Lymphocytes; Male; Middle Aged; Monocytes; Paclitaxel; Pemetrexed; Prognosis; Proportional Hazards Models; Taxoids; Treatment Outcome | 2014 |
Prognostic and predictive role of ERCC1 protein expression in locally advanced stage III non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease-Free Survival; DNA-Binding Proteins; Endonucleases; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Prognosis; Survival Rate; Treatment Outcome | 2014 |
Nuclear survivin expression: a prognostic factor for the response to taxane-platinum chemotherapy in patients with advanced non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Cell Nucleus; Cell Proliferation; Cisplatin; Docetaxel; Female; Humans; Inhibitor of Apoptosis Proteins; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Predictive Value of Tests; Prognosis; Survivin; Taxoids; Treatment Outcome | 2014 |
Comparison of efficacy and safety between liposome-paclitaxel injection plus carboplatin and paclitaxel plus carboplatin as first line treatment in advanced non-small cell lung cancer.
Topics: Adult; Aged; Carboplatin; Carcinoma, Non-Small-Cell Lung; Female; Humans; Liposomes; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Treatment Outcome | 2014 |
EGFR expression and survival in patients given cetuximab and chemoradiation for stage III non-small cell lung cancer: a secondary analysis of RTOG 0324.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cetuximab; Chemoradiotherapy; Disease-Free Survival; ErbB Receptors; Female; Humans; Immunohistochemistry; In Situ Hybridization, Fluorescence; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Prognosis; Treatment Outcome | 2014 |
Motesanib plus carboplatin/paclitaxel in patients with advanced squamous non-small-cell lung cancer: results from the randomized controlled MONET1 study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Disease-Free Survival; Double-Blind Method; Early Termination of Clinical Trials; Female; Hemoptysis; Humans; Indoles; Lung Neoplasms; Male; Middle Aged; Niacinamide; Oligonucleotides; Paclitaxel; Survival Rate | 2014 |
A phase II, open-label study of ramucirumab in combination with paclitaxel and carboplatin as first-line therapy in patients with stage IIIB/IV non-small-cell lung cancer.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Ramucirumab | 2014 |
Bavituximab plus paclitaxel and carboplatin for the treatment of advanced non-small-cell lung cancer.
Topics: Adult; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Risk Factors; Treatment Outcome | 2014 |
A phase I/II study of bortezomib in combination with paclitaxel, carboplatin, and concurrent thoracic radiation therapy for non-small-cell lung cancer: North Central Cancer Treatment Group (NCCTG)-N0321.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Pyrazines; Survival Analysis | 2015 |
Challenges in developing a validated biomarker for angiogenesis inhibitors: the motesanib experience.
Topics: Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Biomarkers, Tumor; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Double-Blind Method; Drug Administration Schedule; Female; Humans; Indoles; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Oligonucleotides; Paclitaxel; Placebo Effect; Placenta Growth Factor; Pregnancy Proteins; Proportional Hazards Models; ROC Curve; Survival Rate | 2014 |
PRONOUNCE: randomized, open-label, phase III study of first-line pemetrexed + carboplatin followed by maintenance pemetrexed versus paclitaxel + carboplatin + bevacizumab followed by maintenance bevacizumab in patients ith advanced nonsquamous non-small-c
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Drug Administration Schedule; Female; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Pemetrexed | 2015 |
A phase II study of induction chemotherapy followed by thoracic radiotherapy and erlotinib in poor-risk stage III non-small-cell lung cancer: results of CALGB 30605 (Alliance)/RTOG 0972 (NRG).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Humans; Induction Chemotherapy; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Quinazolines; Radiotherapy Dosage; Radiotherapy, Adjuvant | 2015 |
Intratumoral chemotherapy with paclitaxel liposome combined with systemic chemotherapy: a new method of neoadjuvant chemotherapy for stage III unresectable non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Gemcitabine; Humans; Injections, Intralesional; Kaplan-Meier Estimate; Liposomes; Lung Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel | 2015 |
Exploratory Subset Analysis of African Americans From the PointBreak Study: Pemetrexed-Carboplatin-Bevacizumab Followed by Maintenance Pemetrexed-Bevacizumab Versus Paclitaxel-Carboplatin-Bevacizumab Followed by Maintenance Bevacizumab in Patients With St
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Black or African American; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Pemetrexed; Retrospective Studies; Survival Analysis; Treatment Outcome | 2015 |
A phase 2 study of bevacizumab in combination with carboplatin and paclitaxel in patients with non-squamous non-small-cell lung cancer harboring mutations of epidermal growth factor receptor (EGFR) after failing first-line EGFR-tyrosine kinase inhibitors
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease Progression; ErbB Receptors; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Paclitaxel; Recurrence; Retreatment; Risk Factors; Treatment Failure; Treatment Outcome | 2015 |
Randomized phase II study of carboplatin and paclitaxel with either linifanib or placebo for advanced nonsquamous non-small-cell lung cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Indazoles; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Phenylurea Compounds; Receptors, Platelet-Derived Growth Factor; Treatment Outcome; Vascular Endothelial Growth Factor A | 2015 |
A phase II study of biweekly paclitaxel and carboplatin in elderly patients with advanced non-small cell lung cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Disease-Free Survival; Female; Humans; Lung Neoplasms; Male; Neoplasm Staging; Paclitaxel; Survival Rate; Treatment Outcome | 2015 |
Weekly nab-paclitaxel in combination with carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer: analysis of safety and efficacy in patients with renal impairment.
Topics: Adult; Aged; Aged, 80 and over; Albumins; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Renal Insufficiency; Survival Rate; Treatment Outcome; Young Adult | 2015 |
Cisplatin/Pemetrexed Followed by Maintenance Pemetrexed Versus Carboplatin/Paclitaxel/Bevacizumab Followed by Maintenance Bevacizumab in Advanced Nonsquamous Lung Cancer: The GOIM (Gruppo Oncologico Italia Meridionale) ERACLE Phase III Randomized Trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Pemetrexed; Quality of Life; Treatment Outcome | 2015 |
Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial p
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cetuximab; Chemoradiotherapy; Combined Modality Therapy; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Paclitaxel; Prognosis; Radiotherapy Dosage; Radiotherapy, Conformal; Radiotherapy, Image-Guided; Survival Rate | 2015 |
Improved tumor vascularization after anti-VEGF therapy with carboplatin and nab-paclitaxel associates with survival in lung cancer.
Topics: Albumins; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Carboplatin; Carcinoma, Non-Small-Cell Lung; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neovascularization, Pathologic; Paclitaxel; Vascular Endothelial Growth Factor A | 2015 |
Quality of life analyses from the randomized, open-label, phase III PointBreak study of pemetrexed-carboplatin-bevacizumab followed by maintenance pemetrexed-bevacizumab versus paclitaxel-carboplatin-bevacizumab followed by maintenance bevacizumab in pati
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Non-Small-Cell Lung; Drug Administration Schedule; Female; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Neoplasm Staging; Paclitaxel; Pemetrexed; Quality of Life; Treatment Outcome | 2015 |
Isolating the Role of Bevacizumab in Elderly Patients With Previously Untreated Nonsquamous Non-Small Cell Lung Cancer: Secondary Analyses of the ECOG 4599 and PointBreak Trials.
Topics: Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Non-Small-Cell Lung; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Survival Rate | 2016 |
Three-arm, randomized, phase 2 study of carboplatin and paclitaxel in combination with cetuximab, cixutumumab, or both for advanced non-small cell lung cancer (NSCLC) patients who will not receive bevacizumab-based therapy: An Eastern Cooperative Oncology
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cetuximab; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel | 2015 |
nab-Paclitaxel in Combination With Weekly Carboplatin With Concurrent Radiotherapy in Stage III Non-Small Cell Lung Cancer.
Topics: Adult; Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Combined Modality Therapy; Female; Humans; Male; Middle Aged; Neoplasm Staging; Paclitaxel | 2015 |
Efficacy of chemotherapy after first-line gefitinib therapy in EGFR mutation-positive advanced non-small cell lung cancer-data from a randomized Phase III study comparing gefitinib with carboplatin plus paclitaxel (NEJ002).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease Progression; Drug Administration Schedule; ErbB Receptors; Exons; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Quinazolines; Sequence Deletion; Tomography, X-Ray Computed; Treatment Outcome | 2015 |
Phase I study of ipilimumab in phased combination with paclitaxel and carboplatin in Japanese patients with non-small-cell lung cancer.
Topics: Adult; Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Asian People; Carboplatin; Carcinoma, Non-Small-Cell Lung; Female; Humans; Ipilimumab; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Treatment Outcome | 2015 |
A phase II clinical study of using nab-paclitaxel as second-line chemotherapy for Chinese patients with advanced non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Albumins; Antineoplastic Agents; Asian People; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Treatment Outcome | 2015 |
A randomized phase II study of erlotinib plus nab-paclitaxel versus erlotinib alone as second-line therapy for Chinese patients with advanced EGFR wild-type non-small-cell lung cancer.
Topics: Adult; Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Asian People; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Erlotinib Hydrochloride; Female; Genes, erbB-1; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Quinazolines | 2015 |
Adding Erlotinib to Chemoradiation Improves Overall Survival but Not Progression-Free Survival in Stage III Non-Small Cell Lung Cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Brain Neoplasms; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Chemoradiotherapy; Disease Progression; Disease-Free Survival; Dose Fractionation, Radiation; Drug Administration Schedule; ErbB Receptors; Erlotinib Hydrochloride; Feasibility Studies; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Paclitaxel; Prospective Studies; Protein Kinase Inhibitors; Quinazolines; Radiotherapy, Intensity-Modulated; Time Factors | 2015 |
BEYOND: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase III Study of First-Line Carboplatin/Paclitaxel Plus Bevacizumab or Placebo in Chinese Patients With Advanced or Recurrent Nonsquamous Non-Small-Cell Lung Cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Carboplatin; Carcinoma, Non-Small-Cell Lung; China; Double-Blind Method; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Placebos; Survival Analysis; Treatment Outcome | 2015 |
Survival, quality-adjusted survival, and other clinical end points in older advanced non-small-cell lung cancer patients treated with albumin-bound paclitaxel.
Topics: Aged; Aged, 80 and over; Albumin-Bound Paclitaxel; Albumins; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Quality of Life; Survival Analysis; Treatment Outcome | 2015 |
Stromal Caveolin-1 Is Associated With Response and Survival in a Phase II Trial of nab-Paclitaxel With Carboplatin for Advanced NSCLC Patients.
Topics: Adult; Aged; Aged, 80 and over; Albumins; Bevacizumab; Biomarkers, Pharmacological; Carboplatin; Carcinoma, Non-Small-Cell Lung; Caveolin 1; Contraindications; Drug Therapy, Combination; Fatigue; Female; Humans; Lung Neoplasms; Male; Middle Aged; Nanoparticles; Neoplasm Staging; Nervous System Diseases; Paclitaxel; Stromal Cells; Survival Analysis | 2015 |
A phase II open-label clinical study of comparing nab-paclitaxel with pemetrexed as second-line chemotherapy for patients with stage IIIB/IV non-small-cell lung cancer.
Topics: Adult; Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Pemetrexed; Survival Analysis; Treatment Outcome | 2015 |
Computed Tomography-Guided Interstitial High-Dose-Rate Brachytherapy in Combination With Regional Positive Lymph Node Intensity-Modulated Radiation Therapy in Locally Advanced Peripheral Non-Small Cell Lung Cancer: A Phase 1 Clinical Trial.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Etoposide; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Pneumothorax; Prospective Studies; Radiotherapy Dosage; Radiotherapy, Image-Guided; Radiotherapy, Intensity-Modulated; Remission Induction; Safety; Survival Rate; Time Factors | 2015 |
Phase I dose escalation study of amrubicin plus paclitaxel in previously treated advanced non-small cell lung cancer.
Topics: Adenocarcinoma; Administration, Intravenous; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Prognosis; Salvage Therapy; Survival Rate | 2016 |
A randomized phase II study comparing paclitaxel-carboplatin-bevacizumab with or without nitroglycerin patches in patients with stage IV nonsquamous nonsmall-cell lung cancer: NVALT12 (NCT01171170)†.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Non-Small-Cell Lung; Female; Humans; Hypoxia-Inducible Factor 1; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Nitroglycerin; Paclitaxel | 2015 |
A phase 1 study evaluating the pharmacokinetics and preliminary efficacy of veliparib (ABT-888) in combination with carboplatin/paclitaxel in Japanese subjects with non-small cell lung cancer (NSCLC).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Benzimidazoles; Carboplatin; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Dose-Response Relationship, Drug; Drug Eruptions; Drug Synergism; Female; Hematologic Diseases; Humans; Japan; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Poly(ADP-ribose) Polymerase Inhibitors; Radiography; Salvage Therapy; Tumor Burden | 2015 |
A phase II study of nab-paclitaxel plus carboplatin in combination with thoracic radiation in patients with locally advanced non-small-cell lung cancer.
Topics: Aged; Aged, 80 and over; Albumins; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Grading; Paclitaxel; Radiation; Survival Analysis; Thorax; Treatment Outcome | 2016 |
Pretreatment Pokemon Level as a Predictor of Response to Cisplatin and Paclitaxel in Patients with Unresectable Non-Small Cell Lung Cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; China; Cisplatin; DNA-Binding Proteins; Female; Humans; Incidence; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Pneumonectomy; Prognosis; Reproducibility of Results; Risk Factors; Sensitivity and Specificity; Survival Rate; Transcription Factors; Treatment Outcome | 2015 |
Randomized phase II study of paclitaxel/carboplatin intercalated with gefitinib compared to paclitaxel/carboplatin alone for chemotherapy-naïve non-small cell lung cancer in a clinically selected population excluding patients with non-smoking adenocarcino
Topics: Adult; Aged; Antineoplastic Agents; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; DNA Mutational Analysis; DNA, Neoplasm; Drug Administration Schedule; Drug Therapy, Combination; ErbB Receptors; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Paclitaxel; Prospective Studies; Quinazolines | 2015 |
Phase III Study of Surgery Versus Definitive Concurrent Chemoradiotherapy Boost in Patients With Resectable Stage IIIA(N2) and Selected IIIB Non-Small-Cell Lung Cancer After Induction Chemotherapy and Concurrent Chemoradiotherapy (ESPATUE).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Cisplatin; Dose Fractionation, Radiation; Drug Administration Schedule; Female; Humans; Induction Chemotherapy; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Pneumonectomy; Survival Analysis; Treatment Outcome; Vinblastine; Vinorelbine | 2015 |
Three-Dimensional Radiation Therapy to the Primary Tumor With Concurrent Chemotherapy in Patients With Stage IV Non-Small Cell Lung Cancer: Results of a Multicenter Phase 2 Study From PPRA-RTOG, China.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; China; Cisplatin; Confidence Intervals; Disease-Free Survival; Docetaxel; Esophagitis; Female; Humans; Karnofsky Performance Status; Leukopenia; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Neoplasm Staging; Paclitaxel; Pemetrexed; Prospective Studies; Radiation Pneumonitis; Radiotherapy; Survival Rate; Taxoids; Thrombocytopenia; Treatment Outcome; Vinblastine; Vinorelbine; Young Adult | 2015 |
Spleen Volume Variation in Patients with Locally Advanced Non-Small Cell Lung Cancer Receiving Platinum-Based Chemo-Radiotherapy.
Topics: Aged; Carboplatin; Carcinoma, Non-Small-Cell Lung; Etoposide; Female; Humans; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Positron-Emission Tomography; Prognosis; Radiography; Spleen | 2015 |
Quality of Life Analysis of a Radiation Dose-Escalation Study of Patients With Non-Small-Cell Lung Cancer: A Secondary Analysis of the Radiation Therapy Oncology Group 0617 Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Canada; Carboplatin; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Radiation; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Quality of Life; Radiotherapy Dosage; Radiotherapy, Conformal; Radiotherapy, Intensity-Modulated; Surveys and Questionnaires; Treatment Outcome; United States | 2016 |
Comparison of Gefitinib Versus Chemotherapy in Patients with Non-small Cell Lung Cancer with Exon 19 Deletion.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Exons; Gefitinib; Lung Neoplasms; Mutation; Paclitaxel; Quinazolines; Retrospective Studies; Sequence Deletion | 2015 |
Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib: phase III randomized LUX-Lung 5 trial.
Topics: Afatinib; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Prospective Studies; Protein Kinase Inhibitors; Quinazolines | 2016 |
Cost Analyses in the US and Japan: A Cross-Country Comparative Analysis Applied to the PRONOUNCE Trial in Non-Squamous Non-Small Cell Lung Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Non-Small-Cell Lung; Costs and Cost Analysis; Cross-Cultural Comparison; Humans; Japan; Lung Neoplasms; Models, Econometric; Paclitaxel; Pemetrexed; United States | 2015 |
Induction or consolidation chemotherapy for unresectable stage III non-small-cell lung cancer patients treated with concurrent chemoradiation: a randomised phase II trial GFPC - IFCT 02-01.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Cisplatin; Consolidation Chemotherapy; Disease-Free Survival; Female; Humans; Induction Chemotherapy; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Radiotherapy Dosage; Risk Factors; Survival Analysis; Time Factors; Treatment Outcome; Vinblastine; Vinorelbine | 2016 |
Carboplatin plus Weekly Paclitaxel with Bevacizumab for First-line Treatment of Non-small Cell Lung Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Non-Small-Cell Lung; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Prospective Studies | 2016 |
SWOG S0709: Randomized Phase II Trial of Erlotinib versus Erlotinib Plus Carboplatin/Paclitaxel in Patients with Advanced Non-Small Cell Lung Cancer and Impaired Performance Status as Selected by a Serum Proteomics Assay.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cohort Studies; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Proteomics | 2016 |
TG4010 immunotherapy and first-line chemotherapy for advanced non-small-cell lung cancer (TIME): results from the phase 2b part of a randomised, double-blind, placebo-controlled, phase 2b/3 trial.
Topics: Aged; Anemia; Antigens, CD; Antigens, Differentiation, T-Lymphocyte; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Cancer Vaccines; Carboplatin; Carcinoma, Non-Small-Cell Lung; CD56 Antigen; Cisplatin; Deoxycytidine; Disease-Free Survival; Double-Blind Method; Erlotinib Hydrochloride; Fatigue; Female; Gemcitabine; Humans; Immunotherapy; Lectins, C-Type; Lung Neoplasms; Lymphocyte Activation; Lymphocytes; Male; Membrane Glycoproteins; Middle Aged; Mucin-1; Neutropenia; Paclitaxel; Pemetrexed; Predictive Value of Tests; Receptors, IgG | 2016 |
Treatment of recurrent and platinum-refractory stage IV non-small cell lung cancer with nanoparticle albumin-bound paclitaxel (nab-paclitaxel) as a single agent.
Topics: Aged; Aged, 80 and over; Albumins; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Treatment Outcome | 2016 |
Pharmacokinetics of Weekly Paclitaxel and Feasibility of Dexamethasone Taper in Japanese Patients with Advanced Non-small Cell Lung Cancer.
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Dexamethasone; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Peripheral Nervous System Diseases | 2016 |
Use of a Comprehensive Geriatric Assessment for the Management of Elderly Patients With Advanced Non-Small-Cell Lung Cancer: The Phase III Randomized ESOGIA-GFPC-GECP 08-02 Study.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Deoxycytidine; Docetaxel; Female; Follow-Up Studies; Gemcitabine; Geriatric Assessment; Humans; Lung Neoplasms; Male; Neoplasm Staging; Paclitaxel; Pemetrexed; Prognosis; Quality of Life; Survival Rate; Taxoids | 2016 |
A multicenter randomized controlled open-label trial to assess the efficacy of compound kushen injection in combination with single-agent chemotherapy in treatment of elderly patients with advanced non-small cell lung cancer: study protocol for a randomiz
Topics: Age Factors; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Protocols; Deoxycytidine; Disease-Free Survival; Docetaxel; Drugs, Chinese Herbal; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Karnofsky Performance Status; Lung Neoplasms; Male; Paclitaxel; Proportional Hazards Models; Quality of Life; Research Design; Taxoids; Time Factors; Treatment Outcome | 2016 |
A phase II study of Endostatin in combination with paclitaxel, carboplatin, and radiotherapy in patients with unresectable locally advanced non-small cell lung cancer.
Topics: Adult; Aged; Carboplatin; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Disease-Free Survival; Endostatins; Female; Humans; Male; Middle Aged; Paclitaxel; Remission Induction | 2016 |
Institutional Enrollment and Survival Among NSCLC Patients Receiving Chemoradiation: NRG Oncology Radiation Therapy Oncology Group (RTOG) 0617.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cetuximab; Disease-Free Survival; Esophagus; Female; Heart; Hospitals, High-Volume; Hospitals, Low-Volume; Humans; Lung Neoplasms; Male; Middle Aged; Organs at Risk; Paclitaxel; Patient Selection; Radiotherapy Dosage; Radiotherapy, Intensity-Modulated; Survival Rate | 2016 |
Sequential addition of aprepitant in patients receiving carboplatin-based chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Agents; Aprepitant; Bevacizumab; Carboplatin; Carcinoma, Non-Small-Cell Lung; Dexamethasone; Female; Granisetron; Humans; Lung Neoplasms; Male; Middle Aged; Morpholines; Nausea; Ondansetron; Paclitaxel; Pemetrexed; Vomiting | 2016 |
Sequential treatment strategy for malignant pleural effusion in non-small cell lung cancer with the activated epithelial grow factor receptor mutation.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carboplatin; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Gefitinib; Humans; Male; Middle Aged; Mutation; Paclitaxel; Pleural Effusion, Malignant; Quinazolines | 2017 |
[The role of surgery for the management of resectable stage III non-small cell lung cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Cisplatin; Combined Modality Therapy; Dose Fractionation, Radiation; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Pneumonectomy; Treatment Outcome | 2016 |
Health-related quality of life in elderly patients with advanced non-small cell lung cancer comparing carboplatin and weekly paclitaxel doublet chemotherapy with monotherapy.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Decision Making; Deoxycytidine; Europe; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Quality of Life; Surveys and Questionnaires; Time Factors; Vinblastine; Vinorelbine | 2016 |
A phase II study of nanoparticle albumin-bound paclitaxel plus carboplatin as the first-line therapy in elderly patients with previously untreated advanced non-small cell lung cancer.
Topics: Aged; Aged, 80 and over; Albumins; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Asian People; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Humans; Lung Neoplasms; Paclitaxel; Survival Rate | 2016 |
Efficacy and Safety Results From a Phase II, Placebo-Controlled Study of Onartuzumab Plus First-Line Platinum-Doublet Chemotherapy for Advanced Squamous Cell Non-Small-Cell Lung Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Double-Blind Method; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Prognosis; Safety; Survival Rate | 2017 |
Weekly vinorelbine and paclitaxel in older patients with advanced non-small cell lung cancer: A phase II Fred and Pamela Buffet Cancer Center Clinical Trials Network study.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy Protocols; Brain Ischemia; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Chemotherapy-Induced Febrile Neutropenia; Disease-Free Survival; Early Termination of Clinical Trials; Female; Heart Arrest; Humans; Hypoxia; Lung Neoplasms; Lymphopenia; Male; Neutropenia; Paclitaxel; Pneumonia; Quality of Life; Respiratory Insufficiency; Survival Rate; Tomography, X-Ray Computed; Vinblastine; Vinorelbine | 2017 |
Open-label, randomized study of individualized, pharmacokinetically (PK)-guided dosing of paclitaxel combined with carboplatin or cisplatin in patients with advanced non-small-cell lung cancer (NSCLC).
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Disease-Free Survival; Dose-Response Relationship, Drug; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Male; Middle Aged; Neoplasm Staging; Paclitaxel | 2016 |
Phase II trial of weekly nab-paclitaxel for previously treated advanced non-small cell lung cancer: Kumamoto thoracic oncology study group (KTOSG) trial 1301.
Topics: Adult; Aged; Albumins; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Administration Schedule; Female; Genes, erbB-1; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Paclitaxel; Retreatment; Treatment Outcome | 2016 |
Randomized phase III PITCAP trial and meta-analysis of induction chemotherapy followed by thoracic irradiation with or without concurrent taxane-based chemotherapy in locally advanced NSCLC.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Carboplatin; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Female; Humans; Induction Chemotherapy; Male; Meta-Analysis as Topic; Middle Aged; Neoplasm Staging; Paclitaxel; Survival Rate; Taxoids; Treatment Outcome | 2016 |
[18F]FDG PET/CT-based response assessment of stage IV non-small cell lung cancer treated with paclitaxel-carboplatin-bevacizumab with or without nitroglycerin patches.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Non-Small-Cell Lung; Feasibility Studies; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Netherlands; Nitroglycerin; Paclitaxel; Positron Emission Tomography Computed Tomography; Radiopharmaceuticals; Reproducibility of Results; Sensitivity and Specificity; Survival Rate; Treatment Outcome; Vasodilator Agents | 2017 |
Safety and efficacy of nivolumab and standard chemotherapy drug combination in patients with advanced non-small-cell lung cancer: a four arms phase Ib study.
Topics: Adult; Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease-Free Survival; Docetaxel; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Nivolumab; Paclitaxel; Pemetrexed; Taxoids | 2016 |
A randomized trial of TLR-2 agonist CADI-05 targeting desmocollin-3 for advanced non-small-cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bacterial Vaccines; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Desmocollins; Disease-Free Survival; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Proportional Hazards Models; Toll-Like Receptor 2; Treatment Outcome | 2017 |
Efficacy and Safety of Onartuzumab in Combination With First-Line Bevacizumab- or Pemetrexed-Based Chemotherapy Regimens in Advanced Non-Squamous Non-Small-Cell Lung Cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Double-Blind Method; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Pemetrexed; Prognosis; Safety; Survival Rate | 2017 |
Phase I study of nab-paclitaxel plus carboplatin and concurrent thoracic radiotherapy in patients with locally advanced non-small cell lung cancer.
Topics: Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Prospective Studies; Thorax | 2017 |
Impact of Intensity-Modulated Radiation Therapy Technique for Locally Advanced Non-Small-Cell Lung Cancer: A Secondary Analysis of the NRG Oncology RTOG 0617 Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cetuximab; Chemoradiotherapy; Disease-Free Survival; Female; Follow-Up Studies; Heart; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Organs at Risk; Paclitaxel; Prospective Studies; Radiation Dosage; Radiation Pneumonitis; Radiotherapy Dosage; Radiotherapy, Conformal; Radiotherapy, Intensity-Modulated; Survival Rate | 2017 |
Long-Term Results of a Trial of Concurrent Chemotherapy and Escalating Doses of Radiation for Unresectable Non-Small Cell Lung Cancer: NCCTG N0028 (Alliance).
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Chemoradiotherapy; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Paclitaxel; Prognosis; Radiotherapy Dosage; Radiotherapy, Conformal; Survival Rate | 2017 |
Etoposide and cisplatin versus paclitaxel and carboplatin with concurrent thoracic radiotherapy in unresectable stage III non-small cell lung cancer: a multicenter randomized phase III trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Cisplatin; Etoposide; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Proportional Hazards Models | 2017 |
Carboplatin plus Weekly Paclitaxel Combined with Bevacizumab as First-line Treatment for Non-small Cell Lung Cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Non-Small-Cell Lung; Diarrhea; Disease-Free Survival; Drug Administration Schedule; Febrile Neutropenia; Female; Humans; Infections; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Treatment Outcome; Vomiting | 2017 |
Efficacy according to blind independent central review: Post-hoc analyses from the phase III, randomized, multicenter, IPASS study of first-line gefitinib versus carboplatin/paclitaxel in Asian patients with EGFR mutation-positive advanced NSCLC.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Asian People; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Paclitaxel; Protein Kinase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic; Smoking | 2017 |
Comparison of outcomes for elderly patients treated with weekly paclitaxel in combination with carboplatin versus the standard 3-weekly paclitaxel and carboplatin for advanced nonsmall cell lung cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Drug Administration Schedule; Female; Humans; Lung Neoplasms; Male; Neoplasm Staging; Paclitaxel; Survival Analysis; Treatment Outcome | 2008 |
Tumor response kinetics after schedule-dependent paclitaxel chemoradiation treatment for inoperable non-small cell lung cancer: a model for low-dose chemotherapy radiosensitization.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Contraindications; Dose-Response Relationship, Radiation; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Pneumonectomy; Retrospective Studies; Severity of Illness Index; Tomography, X-Ray Computed; Treatment Outcome | 2008 |
A feasibility study of postoperative adjuvant therapy of carboplatin and weekly paclitaxel for completely resected non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Agents; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Administration Schedule; Drug Therapy, Combination; Feasibility Studies; Female; Follow-Up Studies; Humans; Japan; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Pneumonectomy; Postoperative Care; Prospective Studies; Survival Rate; Time Factors; Treatment Outcome | 2008 |
Phase III trial comparing paclitaxel poliglumex (CT-2103, PPX) in combination with carboplatin versus standard paclitaxel and carboplatin in the treatment of PS 2 patients with chemotherapy-naïve advanced non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Polyglutamic Acid; Quality of Life; Retrospective Studies; Survival Rate; Treatment Outcome; United States | 2008 |
Induction chemotherapy followed by concurrent chemoradiation for patients with non-operable stage III non-small-cell lung cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Disease Progression; Female; Humans; Lung Neoplasms; Male; Medical Oncology; Middle Aged; Paclitaxel; Retrospective Studies | 2009 |
Randomized phase III trial comparing single-agent paclitaxel Poliglumex (CT-2103, PPX) with single-agent gemcitabine or vinorelbine for the treatment of PS 2 patients with chemotherapy-naïve advanced non-small cell lung cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Polyglutamic Acid; Survival Rate | 2008 |
Phase I study of flavopiridol in combination with Paclitaxel and Carboplatin in patients with non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; Female; Flavonoids; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Paclitaxel; Piperidines | 2008 |
Noncytotoxic suramin as a chemosensitizer in patients with advanced non-small-cell lung cancer: a phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; Drug Synergism; Female; Fibroblast Growth Factor 1; Fibroblast Growth Factor 2; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Suramin | 2008 |
[Randomized phase II study of carboplatin/paclitaxel followed by gemcitabine versus carboplatin/gemcitabine followed by docetaxel in patients with advanced nonsmall cell lung cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease Progression; Docetaxel; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Survival Rate; Taxoids | 2008 |
Randomized phase II trial of a toll-like receptor 9 agonist oligodeoxynucleotide, PF-3512676, in combination with first-line taxane plus platinum chemotherapy for advanced-stage non-small-cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Docetaxel; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Oligodeoxyribonucleotides; Paclitaxel; Taxoids; Toll-Like Receptor 9 | 2008 |
Adjuvant chemotherapy for early-stage non-small-cell lung cancer. Single-centre experience and literature review.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Cisplatin; Docetaxel; Feasibility Studies; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Prognosis; Retrospective Studies; Survival Rate; Taxoids | 2008 |
Adjuvant paclitaxel plus carboplatin compared with observation in stage IB non-small-cell lung cancer: CALGB 9633 with the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Groups.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Disease-Free Survival; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Observation; Paclitaxel; Patient Selection; Pneumonectomy; Risk Assessment; Survival Analysis; Time Factors; Treatment Outcome; United States | 2008 |
Weekly paclitaxel in elderly patients (aged > or = 70 years) with advanced non-small-cell lung cancer: an alternative choice? Results of a phase II study.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Bone Neoplasms; Brain Neoplasms; Carcinoma; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Female; Humans; Liver Neoplasms; Lung Neoplasms; Male; Paclitaxel; Prognosis; Salvage Therapy; Survival Rate | 2008 |
Fluorescence in situ hybridization subgroup analysis of TRIBUTE, a phase III trial of erlotinib plus carboplatin and paclitaxel in non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Gene Expression Regulation, Neoplastic; Humans; In Situ Hybridization, Fluorescence; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Quinazolines | 2008 |
Randomized phase II study of vandetanib alone or with paclitaxel and carboplatin as first-line treatment for advanced non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease Progression; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Piperidines; Quinazolines; Vascular Endothelial Growth Factor A | 2008 |
A phase II trial of weekly chemotherapy with paclitaxel plus gemcitabine as a first-line treatment in advanced non-small-cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Neutropenia; Paclitaxel; Survival Rate; Thrombocytopenia; Treatment Outcome | 2009 |
Long-term follow-up of a phase I/II trial of dose escalating three-dimensional conformal thoracic radiation therapy with induction and concurrent carboplatin and paclitaxel in unresectable stage IIIA/B non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Feasibility Studies; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Paclitaxel; Prognosis; Radiotherapy, Conformal; Remission Induction; Survival Rate; Time Factors | 2008 |
Phase II study of paclitaxel, carboplatin, and cetuximab as first line treatment, for patients with advanced non-small cell lung cancer (NSCLC): results of OPN-017.
Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cetuximab; ErbB Receptors; Female; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Paclitaxel; Prognosis; Survival Rate | 2008 |
Phase II trial of paclitaxel and cisplatin in patients with extensive stage small cell lung cancer: Cancer and Leukemia Group B Trial 9430.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Female; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Paclitaxel; Prognosis; Survival Rate | 2008 |
Vinorelbine plus gemcitabine followed by docetaxel versus carboplatin plus paclitaxel in patients with advanced non-small-cell lung cancer: a randomised, open-label, phase III study.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease-Free Survival; Docetaxel; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Smoking; Taxoids; Vinblastine; Vinorelbine | 2008 |
Randomized phase II study of pulse erlotinib before or after carboplatin and paclitaxel in current or former smokers with advanced non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Drug Administration Schedule; ErbB Receptors; Erlotinib Hydrochloride; Female; Genes, ras; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Quinazolines; Smoking; Treatment Outcome | 2009 |
Randomised phase II study of ASA404 combined with carboplatin and paclitaxel in previously untreated advanced non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease Progression; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Survival Rate; Treatment Outcome; Xanthones | 2008 |
How to improve loco-regional control in stages IIIa-b NSCLC? Results of a three-armed randomized trial from the Swedish Lung Cancer Study Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Prognosis; Quality of Life; Survival Rate | 2009 |
Late complications of high-dose (>/=66 Gy) thoracic conformal radiation therapy in combined modality trials in unresectable stage III non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Feasibility Studies; Female; Follow-Up Studies; Forced Expiratory Volume; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasms, Second Primary; Paclitaxel; Prognosis; Radiotherapy Dosage; Radiotherapy, Conformal; Remission Induction; Retrospective Studies; Risk Factors; Survival Rate; Treatment Outcome | 2009 |
RTOG 0017: a phase I trial of concurrent gemcitabine/carboplatin or gemcitabine/paclitaxel and radiation therapy ("ping-pong trial") followed by adjuvant chemotherapy for patients with favorable prognosis inoperable stage IIIA/B non-small cell lung cancer
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cohort Studies; Combined Modality Therapy; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Paclitaxel; Prognosis; Radiotherapy Dosage; Remission Induction; Survival Rate; Treatment Outcome | 2009 |
A Phase II study of synchronous three-dimensional conformal boost to the gross tumor volume for patients with unresectable Stage III non-small-cell lung cancer: results of Korean Radiation Oncology Group 0301 study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Dose Fractionation, Radiation; Female; Follow-Up Studies; Humans; Korea; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Radiotherapy, Conformal; Survival Analysis; Treatment Failure; Tumor Burden | 2009 |
A randomized phase II trial assessing in advanced non-small cell lung cancer patients with stable disease after two courses of cisplatin-gemcitabine an early modification of chemotherapy doublet with paclitaxel-gemcitabine versus continuation of cisplatin
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Paclitaxel; Probability; Prognosis; Quality of Life; Statistics, Nonparametric; Survival Analysis; Treatment Outcome | 2009 |
A randomized, phase II trial of two dose schedules of carboplatin/paclitaxel/cetuximab in stage IIIB/IV non-small-cell lung cancer (NSCLC).
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cetuximab; Dose-Response Relationship, Drug; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel | 2009 |
Impact of preoperative chemotherapy on pulmonary function tests in resectable early-stage non-small cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Cisplatin; Confidence Intervals; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Pneumonectomy; Preoperative Care; Probability; Respiratory Function Tests; Risk Assessment; Survival Analysis | 2009 |
Long term follow-up of neoadjuvant-adjuvant combination treatment of IIIA stage non-small-cell-lung cancer: results of neoadjuvant carboplatin/vinorelbine and carboplatin/paclitaxel regimens combined with selective adjuvant chemotherapy according to in-vi
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Drug Resistance, Neoplasm; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Survival Rate; Vinblastine; Vinorelbine | 2008 |
Retrospective evaluation of the clinical and radiographic risk factors associated with severe pulmonary hemorrhage in first-line advanced, unresectable non-small-cell lung cancer treated with Carboplatin and Paclitaxel plus bevacizumab.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Non-Small-Cell Lung; Case-Control Studies; Cohort Studies; Hemorrhage; Humans; Lung Diseases; Lung Neoplasms; Paclitaxel; Radiography; Retrospective Studies; Risk Factors | 2009 |
A phase II study of celecoxib in combination with paclitaxel, carboplatin, and radiotherapy for patients with inoperable stage IIIA/B non-small cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Celecoxib; Combined Modality Therapy; Cyclooxygenase 2 Inhibitors; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Prostaglandins; Pyrazoles; Sulfonamides; Vascular Endothelial Growth Factor A | 2009 |
A landmark point analysis with cytotoxic agents for advanced NSCLC.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Drug Screening Assays, Antitumor; Female; Gemcitabine; Glutamates; Guanine; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Pemetrexed; Prognosis; Survival Rate; Treatment Outcome; Vinblastine; Vinorelbine; Young Adult | 2009 |
Phase II study of the anti-insulin-like growth factor type 1 receptor antibody CP-751,871 in combination with paclitaxel and carboplatin in previously untreated, locally advanced, or metastatic non-small-cell lung cancer.
Topics: Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Female; Humans; Immunoglobulins, Intravenous; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Paclitaxel | 2009 |
Phase I study of amrubicin and vinorelbine in non-small cell lung cancer previously treated with platinum-based chemotherapy.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Vinblastine; Vinorelbine | 2009 |
Phase II study of ASA404 (vadimezan, 5,6-dimethylxanthenone-4-acetic acid/DMXAA) 1800mg/m(2) combined with carboplatin and paclitaxel in previously untreated advanced non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Xanthones | 2009 |
Intensified high-dose chemoradiotherapy with induction chemotherapy in patients with locally advanced non-small-cell lung cancer-safety and toxicity results within a prospective trial.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Esophagitis; Female; Humans; Leukopenia; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Pneumonia; Prospective Studies; Remission Induction; Survival Analysis; Vinblastine; Vinorelbine | 2010 |
Phase II study of the combination of nedaplatin and weekly paclitaxel in patients with advanced non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Female; Humans; Lung Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Paclitaxel | 2009 |
[Non-small cell lung cancer (NSCLC) stage IIIA/IIIB. A pilot study of neoadjuvant chemotherapy with paclitaxel and carboplatin].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Dose Fractionation, Radiation; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Lymph Node Excision; Lymphatic Metastasis; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Pilot Projects; Pneumonectomy; Prospective Studies; Radiotherapy, Adjuvant | 1997 |
Dose-escalating and pharmacokinetic study of a weekly combination of paclitaxel and carboplatin for inoperable non-small cell lung cancer: JCOG 9910-DI.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; Female; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Paclitaxel; Prognosis; Prospective Studies; Survival Rate; Tissue Distribution; Treatment Outcome | 2009 |
Phase I trial of carboplatin/paclitaxel/bortezomib and concurrent radiotherapy followed by surgical resection in Stage III non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Carboplatin; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Early Termination of Clinical Trials; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Pneumonectomy; Postoperative Complications; Protease Inhibitors; Pyrazines; Radiotherapy; Respiratory Insufficiency | 2010 |
Gemcitabine combined with either pemetrexed or paclitaxel in the treatment of advanced non-small cell lung cancer: a randomized phase II SICOG trial.
Topics: Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease Progression; Disease-Free Survival; Female; Follow-Up Studies; Gemcitabine; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Neutropenia; Paclitaxel; Pemetrexed; Peripheral Nervous System Diseases; Survival Analysis | 2010 |
MRP2 and GSTP1 polymorphisms and chemotherapy response in advanced non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Electrophoresis, Polyacrylamide Gel; Female; Gene Frequency; Genotype; Glutathione S-Transferase pi; Humans; Male; Microfilament Proteins; Middle Aged; Multidrug Resistance-Associated Protein 2; Oligonucleotide Array Sequence Analysis; Paclitaxel; Polymorphism, Single Nucleotide; Treatment Outcome | 2010 |
VEGF in patients with non-small cell lung cancer during combination chemotherapy of carboplatin and paclitaxel.
Topics: Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Carcinoma, Non-Small-Cell Lung; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; RNA, Messenger; Survival Analysis; Vascular Endothelial Growth Factor A | 2009 |
Treatment rationale and study design for the pointbreak study: a randomized, open-label phase III study of pemetrexed/carboplatin/bevacizumab followed by maintenance pemetrexed/bevacizumab versus paclitaxel/carboplatin/bevacizumab followed by maintenance
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Glutamates; Guanine; Humans; Lung Neoplasms; Paclitaxel; Pemetrexed; Prognosis; Treatment Outcome | 2009 |
Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Paclitaxel; Proportional Hazards Models; Protein Kinase Inhibitors; Quinazolines | 2009 |
Phase 1-2a multicenter dose-ranging study of canfosfamide in combination with carboplatin and paclitaxel as first-line therapy for patients with advanced non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cytotoxins; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Follow-Up Studies; Glutathione; Humans; Injections, Intravenous; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Treatment Outcome | 2009 |
Phase I study of the c-raf-1 antisense oligonucleotide ISIS 5132 in combination with carboplatin and paclitaxel in patients with previously untreated, advanced non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Female; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Paclitaxel; Proto-Oncogene Proteins c-raf; Thionucleotides | 2009 |
Safety, pharmacokinetics, and pharmacodynamics of the insulin-like growth factor type 1 receptor inhibitor figitumumab (CP-751,871) in combination with paclitaxel and carboplatin.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Agents; Carboplatin; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Immunoglobulins, Intravenous; Injections, Intravenous; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Receptor, IGF Type 1; Retrospective Studies; Treatment Outcome | 2009 |
Phase I clinical and pharmacokinetic study of sorafenib in combination with carboplatin and paclitaxel in patients with advanced non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carboplatin; Carcinoma, Non-Small-Cell Lung; Demography; Dose-Response Relationship, Drug; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Paclitaxel; Phenylurea Compounds; Pyridines; Radiography; Sorafenib; Treatment Outcome | 2010 |
Phase II study of paclitaxel and irinotecan with intercalated gefitinib in patients with advanced non-small-cell lung cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Female; Gefitinib; Humans; Irinotecan; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Paclitaxel; Prognosis; Quinazolines; Survival Rate; Treatment Outcome | 2010 |
Randomized phase II trial of weekly paclitaxel combined with carboplatin versus standard paclitaxel combined with carboplatin for elderly patients with advanced non-small-cell lung cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease Progression; Dosage Forms; Drug Administration Schedule; Female; Humans; Lung Neoplasms; Male; Paclitaxel; Survival Analysis; Treatment Outcome | 2010 |
A randomized, phase III multicenter trial of gemcitabine in combination with carboplatin or paclitaxel versus paclitaxel plus carboplatin in patients with advanced or metastatic non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Prospective Studies; Survival Rate; Treatment Outcome | 2010 |
Phase I study of TLR9 agonist PF-3512676 in combination with carboplatin and paclitaxel in patients with advanced non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Female; Humans; Lung Neoplasms; Male; Middle Aged; Oligodeoxyribonucleotides; Paclitaxel; Toll-Like Receptor 9 | 2010 |
Results of a preliminary study using hypofractionated involved-field radiation therapy and concurrent carboplatin/paclitaxel in the treatment of locally advanced non-small-cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Disease-Free Survival; Dose Fractionation, Radiation; Feasibility Studies; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Pilot Projects; Radiotherapy, Adjuvant; Radiotherapy, Conformal; Time Factors; Treatment Outcome | 2009 |
Neoadjuvant chemoradiation with paclitaxel/carboplatin for selected Stage III non-small-cell lung cancer: long-term results of a trimodality Phase II protocol.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Dose Fractionation, Radiation; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Remission Induction; Survival Analysis | 2010 |
Is neoadjuvant chemoradiotherapy a feasible strategy for stage IIIA-N2 non-small cell lung cancer? Mature results of the randomized IFCT-0101 phase II trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Feasibility Studies; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Survival Analysis; Vinblastine; Vinorelbine | 2010 |
Phase II trial of nanoparticle albumin-bound paclitaxel, carboplatin, and bevacizumab in first-line patients with advanced nonsquamous non-small cell lung cancer.
Topics: Adenocarcinoma, Bronchiolo-Alveolar; Adult; Aged; Aged, 80 and over; Albumin-Bound Paclitaxel; Albumins; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Nanoparticles; Neoplasm Staging; Paclitaxel; Prognosis; Quality of Life; Survival Rate; Treatment Outcome | 2009 |
Randomized, double-blind trial of carboplatin and paclitaxel with either daily oral cediranib or placebo in advanced non-small-cell lung cancer: NCIC clinical trials group BR24 study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Double-Blind Method; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Placebos; Quinazolines | 2010 |
Carboplatin and Paclitaxel in combination with either vorinostat or placebo for first-line therapy of advanced non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Double-Blind Method; Female; Humans; Hydroxamic Acids; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Placebos; Vorinostat | 2010 |
The role of histology with common first-line regimens for advanced non-small cell lung cancer: a brief report of the retrospective analysis of a three-arm randomized trial.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Male; Paclitaxel; Prognosis; Retrospective Studies; Survival Rate; Time Factors; Treatment Outcome; Vinblastine; Vinorelbine | 2009 |
Phase 1b study of motesanib, an oral angiogenesis inhibitor, in combination with carboplatin/paclitaxel and/or panitumumab for the treatment of advanced non-small cell lung cancer.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Female; Humans; Indoles; Lung Neoplasms; Male; Middle Aged; Niacinamide; Oligonucleotides; Paclitaxel; Panitumumab; Receptors, Vascular Endothelial Growth Factor | 2010 |
Safety and efficacy of combining sunitinib with bevacizumab + paclitaxel/carboplatin in non-small cell lung cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cohort Studies; Female; Humans; Indoles; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Paclitaxel; Prognosis; Pyrroles; Safety; Sunitinib; Survival Rate | 2010 |
Outcomes associated with brain metastases in a three-arm phase III trial of gemcitabine-containing regimens versus paclitaxel plus carboplatin for advanced non-small cell lung cancer.
Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carboplatin; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Male; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Prognosis; Retrospective Studies; Survival Rate; Treatment Outcome | 2010 |
Second-line weekly paclitaxel in resistant or relapsed non-small cell lung cancer treated with docetaxel and carboplatin: a multi-center phase II study.
Topics: Adult; Aged; Anemia; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease Progression; Docetaxel; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Leukopenia; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Survival Analysis; Taxoids | 2010 |
Clinical course of advanced non-small-cell lung cancer patients experiencing hypertension during treatment with bevacizumab in combination with carboplatin and paclitaxel on ECOG 4599.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Blood Pressure; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Female; Humans; Hypertension; Lung Neoplasms; Male; Neoplasm Staging; Paclitaxel; Prognosis; Survival Rate; Treatment Outcome | 2010 |
Pharmacokinetic study of the phase III, randomized, double-blind, multicenter trial (TRIBUTE) of paclitaxel and carboplatin combined with erlotinib or placebo in patients with advanced Non-small Cell Lung Cancer (NSCLC).
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Double-Blind Method; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Placebos; Quinazolines; Time Factors | 2011 |
Analysis of potential predictive markers of cetuximab benefit in BMS099, a phase III study of cetuximab and first-line taxane/carboplatin in advanced non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cetuximab; Docetaxel; ErbB Receptors; Female; Gene Dosage; Humans; In Situ Hybridization, Fluorescence; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Paclitaxel; Prognosis; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins; Retrospective Studies; Survival Rate; Taxoids; Treatment Outcome | 2010 |
Cetuximab and first-line taxane/carboplatin chemotherapy in advanced non-small-cell lung cancer: results of the randomized multicenter phase III trial BMS099.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cetuximab; Docetaxel; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Prognosis; Survival Rate; Taxoids; Treatment Outcome | 2010 |
Phase II trial of a trimodality regimen for stage III non-small-cell lung cancer using chemotherapy as induction treatment with concurrent hyperfractionated chemoradiation with carboplatin and paclitaxel followed by subsequent resection: a single-center s
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Dose Fractionation, Radiation; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Prognosis; Remission Induction; Survival Rate; Thoracotomy; Treatment Outcome; Young Adult | 2010 |
Phase I and pharmacokinetic study of ABI-007, albumin-bound paclitaxel, administered every 3 weeks in Japanese patients with solid tumors.
Topics: Adult; Aged; Albumin-Bound Paclitaxel; Albumins; Antineoplastic Agents, Phytogenic; Asian People; Carcinoma, Non-Small-Cell Lung; Drug Administration Schedule; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Japan; Linear Models; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Nanoparticles; Neoplasms; Neurotoxicity Syndromes; Paclitaxel | 2010 |
Phase 1b study of dulanermin (recombinant human Apo2L/TRAIL) in combination with paclitaxel, carboplatin, and bevacizumab in patients with advanced non-squamous non-small-cell lung cancer.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Non-Small-Cell Lung; Female; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Paclitaxel; Recombinant Proteins; TNF-Related Apoptosis-Inducing Ligand | 2010 |
A phase II study directed by a clinical pathway for carboplatin and weekly paclitaxel in previously untreated patients with unresectable non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Drug Administration Schedule; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Survival Rate | 2010 |
Phase III study of carboplatin and paclitaxel alone or with sorafenib in advanced non-small-cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carboplatin; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Paclitaxel; Phenylurea Compounds; Placebos; Pyridines; Sorafenib; Survival Rate; Treatment Outcome | 2010 |
Surgery with or without preoperative paclitaxel and carboplatin in early-stage non-small-cell lung cancer: Southwest Oncology Group Trial S9900, an intergroup, randomized, phase III trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Combined Modality Therapy; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Survival Rate; Thoracic Surgery; Treatment Outcome | 2010 |
ERCC1 and histopathology in advanced NSCLC patients randomized in a large multicenter phase III trial.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; DNA-Binding Proteins; Endonucleases; Female; Gemcitabine; Humans; Immunoenzyme Techniques; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Prognosis; Survival Rate; Vinblastine; Vinorelbine; Young Adult | 2010 |
A retrospective analysis of outcomes across histological subgroups in a three-arm phase III trial of gemcitabine in combination with carboplatin or paclitaxel versus paclitaxel plus carboplatin for advanced non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease Progression; Disease-Free Survival; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Retrospective Studies; Survival Analysis | 2010 |
Primary analysis of the phase II component of a phase I/II dose intensification study using three-dimensional conformal radiation therapy and concurrent chemotherapy for patients with inoperable non-small-cell lung cancer: RTOG 0117.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Chi-Square Distribution; Disease-Free Survival; Dose Fractionation, Radiation; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Radiotherapy, Adjuvant; Radiotherapy, Conformal; Time Factors; Treatment Outcome | 2010 |
ERCC1, toxicity and quality of life in advanced NSCLC patients randomized in a large multicentre phase III trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; DNA-Binding Proteins; Endonucleases; Female; Gemcitabine; Humans; Immunohistochemistry; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Quality of Life; Young Adult | 2010 |
Treatment-emergent hypertension and outcomes in patients with advanced non-small-cell lung cancer receiving chemotherapy with or without the vascular endothelial growth factor receptor inhibitor cediranib: NCIC Clinical Trials Group Study BR24.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Hypertension; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Placebos; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Retrospective Studies; Survival Rate; Treatment Outcome | 2010 |
Liposomal cisplatin combined with paclitaxel versus cisplatin and paclitaxel in non-small-cell lung cancer: a randomized phase III multicenter trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Disease Progression; Female; Humans; Liposomes; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Survival Rate; Time Factors; Treatment Outcome | 2010 |
A phase I/II radiation dose escalation study with concurrent chemotherapy for patients with inoperable stages I to III non-small-cell lung cancer: phase I results of RTOG 0117.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Carcinoma, Non-Small-Cell Lung; Clinical Protocols; Combined Modality Therapy; Dose Fractionation, Radiation; Esophagitis; Female; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Paclitaxel; Radiation Pneumonitis; Radiotherapy, Conformal | 2010 |
Phase I and pharmacologic study of BNP7787, a novel chemoprotector in patients with advanced non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carcinoma, Non-Small-Cell Lung; Cisplatin; Dose-Response Relationship, Drug; Female; Humans; Lung Neoplasms; Male; Mesna; Middle Aged; Neoplasm Staging; Paclitaxel; Treatment Outcome | 2011 |
The safety and efficacy of weekly paclitaxel in combination with carboplatin for advanced non-small cell lung cancer with idiopathic interstitial pneumonias.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Idiopathic Interstitial Pneumonias; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Retrospective Studies | 2011 |
Adjuvant carboplatin-based chemotherapy in resected stage IIIA-N2 non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Female; Follow-Up Studies; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Squamous Cell; Paclitaxel; Survival Rate; Treatment Outcome; Vinblastine; Vinorelbine | 2010 |
High-level mRNA of excision repair cross-complementation group 1 gene is associated with poor outcome of platinum-based doublet chemotherapy of advanced nonsmall cell lung cancer patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease-Free Survival; DNA-Binding Proteins; Docetaxel; Drug Resistance, Neoplasm; Endonucleases; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Prognosis; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2010 |
Preoperative chemotherapy plus surgery versus surgery plus adjuvant chemotherapy versus surgery alone in early-stage non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Combined Modality Therapy; Drug Administration Schedule; Fatigue; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Neutropenia; Paclitaxel; Preoperative Care; Treatment Outcome | 2010 |
A dose finding study of weekly and every-3-week nab-Paclitaxel followed by carboplatin as first-line therapy in patients with advanced non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Albumin-Bound Paclitaxel; Albumins; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Drug Administration Schedule; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Retrospective Studies | 2010 |
Randomized phase II trial of All-trans-retinoic acid with chemotherapy based on paclitaxel and cisplatin as first-line treatment in patients with advanced non-small-cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Double-Blind Method; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Receptors, Retinoic Acid; Tretinoin | 2010 |
Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Gefitinib; Genes, erbB-1; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Paclitaxel; Protein Kinase Inhibitors; Quinazolines; Survival Analysis | 2010 |
A Comparison of white and African American outcomes from a three-arm, randomized, phase III multicenter trial of advanced or metastatic non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Black or African American; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Survival Rate; Treatment Outcome; White People | 2010 |
Phase III study comparing second- and third-generation regimens with concurrent thoracic radiotherapy in patients with unresectable stage III non-small-cell lung cancer: West Japan Thoracic Oncology Group WJTOG0105.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Mitomycin; Paclitaxel; Radiotherapy, Adjuvant; Vindesine | 2010 |
Targeted therapies: Biomarkers in NSCLC for selecting cetuximab therapy.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Biomarkers, Tumor; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cetuximab; Disease Progression; Docetaxel; Drug Therapy, Combination; ErbB Receptors; Humans; Lung Neoplasms; Paclitaxel; Retrospective Studies; Taxoids; United States | 2010 |
[BSD2000 deep hyperthermia combined with chemotherapy of PT regimen in patients with non-small cell lung cancer].
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Female; Humans; Hyperthermia, Induced; Lung Neoplasms; Male; Paclitaxel; Treatment Outcome | 2010 |
Phase II trial of adjuvant chemotherapy with bi-weekly carboplatin plus paclitaxel in patients with completely resected non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Prospective Studies; Survival Rate | 2010 |
Chemoradiotherapy and gefitinib in stage III non-small cell lung cancer with epidermal growth factor receptor and KRAS mutation analysis: cancer and leukemia group B (CALEB) 30106, a CALGB-stratified phase II trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Combined Modality Therapy; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Paclitaxel; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; Radiotherapy; ras Proteins; Survival Rate; Treatment Outcome | 2010 |
Treatment outcomes by tumor histology in Eastern Cooperative Group Study E4599 of bevacizumab with paclitaxel/carboplatin for advanced non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Non-Small-Cell Lung; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Retrospective Studies; Survival Rate; Treatment Outcome | 2010 |
Treatment rationale and study design for a randomized trial of pemetrexed/carboplatin followed by maintenance pemetrexed versus paclitaxel/carboplatin/bevacizumab followed by maintenance bevacizumab in patients with advanced non-small-cell lung cancer of
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Non-Small-Cell Lung; Clinical Protocols; Drug Administration Schedule; Female; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Neoplasm Staging; Paclitaxel; Patient Selection; Pemetrexed; Research Design | 2010 |
A phase I study of concurrent chemotherapy (paclitaxel and carboplatin) and thoracic radiotherapy with swallowed manganese superoxide dismutase plasmid liposome protection in patients with locally advanced stage III non-small-cell lung cancer.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Esophagus; Female; Genetic Therapy; Humans; Liposomes; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Plasmids; Polymerase Chain Reaction; Superoxide Dismutase; Transgenes; Treatment Outcome | 2011 |
Paclitaxel and gemcitabine versus paclitaxel and vinorelbine in patients with advanced non-small-cell lung cancer. A phase III study of the Hellenic Cooperative Oncology Group (HeCOG).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Gemcitabine; Greece; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Vinblastine; Vinorelbine | 2011 |
Phase II selection design trial of concurrent chemotherapy and cetuximab versus chemotherapy followed by cetuximab in advanced-stage non-small-cell lung cancer: Southwest Oncology Group study S0342.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cetuximab; Disease-Free Survival; Drug Administration Schedule; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Paclitaxel; Patient Selection; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Research Design; Southwestern United States; Treatment Outcome | 2010 |
Higher biologically effective dose of radiotherapy is associated with improved outcomes for locally advanced non-small cell lung carcinoma treated with chemoradiation: an analysis of the Radiation Therapy Oncology Group.
Topics: Adult; Aged; Aged, 80 and over; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Cisplatin; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Proportional Hazards Models; Radiotherapy Dosage; Relative Biological Effectiveness; Retrospective Studies; Survival Analysis; Treatment Failure; Vinblastine | 2012 |
Phase III trial comparing oral S-1 plus carboplatin with paclitaxel plus carboplatin in chemotherapy-naïve patients with advanced non-small-cell lung cancer: results of a west Japan oncology group study.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Drug Combinations; Female; Humans; Lung Neoplasms; Male; Middle Aged; Oxonic Acid; Paclitaxel; Survival Analysis; Tegafur | 2010 |
Sex differences in outcome with bevacizumab therapy: analysis of patients with advanced-stage non-small cell lung cancer treated with or without bevacizumab in combination with paclitaxel and carboplatin in the Eastern Cooperative Oncology Group Trial 459
Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Non-Small-Cell Lung; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Neoplasm Staging; Paclitaxel; Retrospective Studies; Sex Factors; Survival Rate; Treatment Outcome | 2011 |
BRIDGE: an open-label phase II trial evaluating the safety of bevacizumab + carboplatin/paclitaxel as first-line treatment for patients with advanced, previously untreated, squamous non-small cell lung cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Bone Neoplasms; Brain Neoplasms; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Female; Follow-Up Studies; Hemorrhage; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Pilot Projects; Risk Factors; Survival Rate; Treatment Outcome | 2011 |
A randomized phase II trial of adjuvant chemotherapy with bi-weekly carboplatin plus paclitaxel versus carboplatin plus gemcitabine in patients with completely resected non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Prospective Studies; Survival Rate; Treatment Outcome | 2010 |
Long-term results of a phase II trial of induction paclitaxel-carboplatin followed by concurrent radiation therapy and weekly paclitaxel and consolidation paclitaxel-carboplatin in stage III non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Combined Modality Therapy; Disease Progression; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Radiotherapy Dosage; Remission Induction; Survival Rate; Time Factors; Treatment Outcome | 2011 |
Randomized phase II trial of irinotecan with paclitaxel or gemcitabine for non-small cell lung cancer: association of UGT1A1*6 and UGT1A1*27 with severe neutropenia.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Glucuronosyltransferase; Humans; Irinotecan; Lung Neoplasms; Male; Neoplasm Staging; Neutropenia; Paclitaxel; Polymorphism, Genetic; Risk Factors; Survival Rate; Treatment Outcome | 2011 |
Outcomes of mediastinoscopy and surgery with or without neoadjuvant therapy in patients with non-small cell lung cancer who are N2 negative on positron emission tomography and computed tomography.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Female; Follow-Up Studies; Humans; Lung Neoplasms; Lymph Node Excision; Male; Mediastinoscopy; Mediastinum; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Positron-Emission Tomography; Radiotherapy Dosage; Retrospective Studies; Survival Rate; Tomography, X-Ray Computed; Treatment Outcome; Young Adult | 2011 |
Phase I study of intravenous ASA404 (vadimezan) administered in combination with paclitaxel and carboplatin in Japanese patients with non-small cell lung cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Asian People; Biomarkers, Tumor; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Female; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Paclitaxel; Remission Induction; Survival Rate; Tissue Distribution; Treatment Outcome; Xanthones | 2011 |
A phase III randomized trial of gemcitabine-oxaliplatin versus carboplatin-paclitaxel as first-line therapy in patients with advanced non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Survival Rate; Treatment Outcome | 2011 |
[Clinical efficacy and adverse effects of taxol plus carboplatin or gemcitabine plus carboplatin in patients with advanced non-small-cell lung carcinoma].
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel | 2010 |
Quality of life, geriatric assessment and survival in elderly patients with non-small-cell lung cancer treated with carboplatin-gemcitabine or carboplatin-paclitaxel: NVALT-3 a phase III study.
Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Geriatric Assessment; Humans; Lung Neoplasms; Male; Paclitaxel; Quality of Life; Survival Rate; Treatment Outcome | 2011 |
Randomized phase II study of paclitaxel and carboplatin or vinorelbine in advanced non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Remission Induction; Survival Rate; Treatment Outcome; Vinblastine; Vinorelbine | 2011 |
Phase II trial of induction gemcitabine and carboplatin followed by conformal thoracic radiation to 74 Gy with weekly paclitaxel and carboplatin in unresectable stage III non-small cell lung cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Combined Modality Therapy; Deoxycytidine; Female; Follow-Up Studies; Gamma Rays; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Prospective Studies; Radiography, Thoracic; Radiotherapy Dosage; Standard of Care; Survival Rate; Treatment Outcome | 2011 |
Randomized phase II study of carboplatin-paclitaxel or gemcitabine-vinorelbine in patients with advanced nonsmall cell lung cancer and a performance status of 2: West Japan Thoracic Oncology Group 0004.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Infections; Japan; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Neutropenia; Paclitaxel; Survival Analysis; Treatment Outcome; Vinblastine; Vinorelbine | 2012 |
Comparison of liposomal cisplatin versus cisplatin in non-squamous cell non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Female; Humans; Liposomes; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Survival Rate; Treatment Outcome | 2011 |
Weekly regimen of paclitaxel and carboplatin as first-line chemotherapy in elderly patients with stage IIIB-IV non small cell lung cancer (NSCLC): results of a phase II study.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease Progression; Drug Administration Schedule; Female; Humans; Lung Neoplasms; Male; Neoplasm Staging; Paclitaxel; Survival Rate; Treatment Outcome | 2010 |
A phase II, multicenter, open-label randomized study of motesanib or bevacizumab in combination with paclitaxel and carboplatin for advanced nonsquamous non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Drug Administration Schedule; Humans; Indoles; Lung Neoplasms; Male; Middle Aged; Niacinamide; Oligonucleotides; Paclitaxel; Survival Rate | 2011 |
[A randomized study on the effects of paclitaxel liposme and cisplatin induction chemotherapy followed concurrent chemoradiotherapy and sequential radiotherapy on locally advanced non-small cell lung cancer patients].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Radiotherapy | 2011 |
Exploring therapeutic decisions in elderly patients with non-small cell lung cancer: results and conclusions from North Central Cancer Treatment Group Study N0222.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Female; Gefitinib; Humans; Lung Neoplasms; Male; Paclitaxel; Patient Selection; Practice Patterns, Physicians'; Quinazolines; Surveys and Questionnaires; Survival Analysis; Time Factors; Treatment Outcome; United States | 2011 |
Phase I study of concurrent real-time tumor-tracking thoracic radiation therapy with paclitaxel and carboplatin in locally advanced non-small cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Drug Dosage Calculations; Female; Humans; Japan; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Paclitaxel | 2011 |
[A randomized phase I/II trial to compare weekly usage with triple weekly usage of paclitaxel in concurrent radiochemotherapy for patients with locally advanced non-small cell lung cancer].
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Drug Administration Schedule; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Young Adult | 2011 |
A phase 2 study of weekly albumin-bound paclitaxel (Abraxane®) given as a two-hour infusion.
Topics: Aged; Aged, 80 and over; Albumin-Bound Paclitaxel; Albumins; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Survival Analysis | 2011 |
Pulmonary toxicity in Stage III non-small cell lung cancer patients treated with high-dose (74 Gy) 3-dimensional conformal thoracic radiotherapy and concurrent chemotherapy following induction chemotherapy: a secondary analysis of Cancer and Leukemia Grou
Topics: Adult; Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Deoxycytidine; Female; Gemcitabine; Humans; Induction Chemotherapy; Lung; Lung Neoplasms; Male; Middle Aged; Organs at Risk; Paclitaxel; Radiotherapy Dosage; Radiotherapy Planning, Computer-Assisted; Radiotherapy, Conformal | 2011 |
[The clinical analysis of paclitaxel at two dose levels plus carboplatin as the first-line treatment in advanced non-small cell lung cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease Progression; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Survival Rate; Treatment Outcome | 2011 |
Safety and efficacy of first-line bevacizumab with chemotherapy in Asian patients with advanced nonsquamous NSCLC: results from the phase IV MO19390 (SAiL) study.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Asian People; Bevacizumab; Carboplatin; Carcinoma, Non-Small-Cell Lung; China; Clinical Trials, Phase IV as Topic; Disease Progression; Drug Therapy, Combination; Female; Follow-Up Studies; Hong Kong; Humans; Lung Neoplasms; Male; Middle Aged; Multicenter Studies as Topic; Paclitaxel; Survival Analysis; Taiwan; Time Factors; Treatment Outcome | 2011 |
A phase II trial of high dose carboplatin and paclitaxel with G-CSF and peripheral blood stem cell support followed by surgery and/or chest radiation in patients with stage III non-small cell lung cancer: CALGB 9531.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Drug Dosage Calculations; Female; Follow-Up Studies; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cells; Humans; Lung Neoplasms; Lymphopenia; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Pneumonectomy; Survival Analysis; Thorax | 2011 |
A multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy of paclitaxel-carboplatin alone or with endostar for advanced non-small cell lung cancer.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Double-Blind Method; Endostatins; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neovascularization, Pathologic; Paclitaxel; Recombinant Proteins; Treatment Outcome | 2011 |
A randomized, double-blind, placebo-controlled, phase II study of oral talactoferrin in combination with carboplatin and paclitaxel in previously untreated locally advanced or metastatic non-small cell lung cancer.
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Double-Blind Method; Female; Humans; Lactoferrin; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Prospective Studies; Survival Analysis; Treatment Outcome | 2011 |
Safety and pharmacokinetic study of nab-paclitaxel plus carboplatin in chemotherapy-naïve patients with advanced non-small cell lung cancer.
Topics: Adult; Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Asian People; Carboplatin; Carcinoma, Non-Small-Cell Lung; Female; Humans; Male; Middle Aged; Paclitaxel | 2012 |
Second-line paclitaxel/carboplatin versus vinorelbine/carboplatin in patients who have advanced non-small-cell lung cancer pretreated with non-platinum-based chemotherapy: a multicenter randomized phase II study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease Progression; Docetaxel; Drug Administration Schedule; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Survival Rate; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2011 |
Randomized phase III trial of paclitaxel/carboplatin with or without PF-3512676 (Toll-like receptor 9 agonist) as first-line treatment for advanced non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease Progression; Female; Humans; Lung Neoplasms; Male; Middle Aged; Oligodeoxyribonucleotides; Paclitaxel; Toll-Like Receptor 9; Treatment Outcome | 2011 |
Concurrent hyperfractionated radiation therapy and chemotherapy in locally advanced (Stage III) non-small-cell lung cancer: single institution experience with 600 patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Disease-Free Survival; Dose Fractionation, Radiation; Drug Administration Schedule; Esophagitis; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Pneumonia; Retrospective Studies; Treatment Outcome | 2012 |
Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS).
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Asia; Biomarkers, Tumor; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Female; Gefitinib; Gene Dosage; Humans; Immunohistochemistry; In Situ Hybridization, Fluorescence; Kaplan-Meier Estimate; Logistic Models; Lung Neoplasms; Male; Middle Aged; Mutation; Odds Ratio; Paclitaxel; Patient Selection; Precision Medicine; Predictive Value of Tests; Proportional Hazards Models; Protein Kinase Inhibitors; Quinazolines; Risk Assessment; Risk Factors; Survival Rate; Time Factors; Treatment Outcome | 2011 |
Phase II study of sunitinib as maintenance therapy in patients with locally advanced or metastatic non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease Progression; Female; Follow-Up Studies; Humans; Indoles; Lung Neoplasms; Maintenance Chemotherapy; Male; Middle Aged; Neoplasm Metastasis; Paclitaxel; Pyrroles; Sunitinib; Survival Analysis | 2011 |
Phase II clinical trial with gemcitabine and paclitaxel sequential monotherapy as first-line treatment for advanced non-small-cell lung cancer (SLCG 01-04).
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Survival Rate; Treatment Outcome | 2011 |
Class III β-tubulin in advanced NSCLC of adenocarcinoma subtype predicts superior outcome in a randomized trial.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Prognosis; Survival Rate; Treatment Outcome; Tubulin; Vinblastine; Vinorelbine | 2011 |
Clinical prognostic factors in patients with locally advanced (stage III) nonsmall cell lung cancer treated with hyperfractionated radiation therapy with and without concurrent chemotherapy: single-Institution Experience in 600 Patients.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Disease-Free Survival; Dose Fractionation, Radiation; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Paclitaxel; Prognosis; Proportional Hazards Models; Treatment Outcome | 2011 |
Randomized phase III placebo-controlled trial of carboplatin and paclitaxel with or without the vascular disrupting agent vadimezan (ASA404) in advanced non-small-cell lung cancer.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Double-Blind Method; Drug Administration Schedule; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Odds Ratio; Paclitaxel; Quality of Life; Surveys and Questionnaires; Treatment Failure; Xanthones | 2011 |
Fractionated administration of carboplatin/paclitaxel reduces neurotoxicity in patients with advanced non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Dose Fractionation, Radiation; Drug Administration Schedule; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neurotoxicity Syndromes; Paclitaxel; Peripheral Nervous System Diseases; Survival Analysis | 2011 |
Figitumumab combined with carboplatin and paclitaxel in treatment-naïve Japanese patients with advanced non-small cell lung cancer.
Topics: Adult; Aged; Antibodies, Monoclonal; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Asian People; Biomarkers, Tumor; Carboplatin; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; Female; Humans; Immunoglobulins, Intravenous; Japan; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Time Factors; Treatment Outcome; Young Adult | 2012 |
A randomized, phase II, biomarker-selected study comparing erlotinib to erlotinib intercalated with chemotherapy in first-line therapy for advanced non-small-cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Pharmacological; Cadherins; Carboplatin; Carcinoma, Non-Small-Cell Lung; Drug Administration Schedule; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Paclitaxel; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Survival Analysis; Vimentin | 2011 |
Carboplatin and weekly paclitaxel doublet chemotherapy compared with monotherapy in elderly patients with advanced non-small-cell lung cancer: IFCT-0501 randomised, phase 3 trial.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Paclitaxel; Survival Rate; Vinblastine; Vinorelbine | 2011 |
Induction pemetrexed and cisplatin followed by maintenance pemetrexed versus carboplatin plus paclitaxel plus bevacizumab followed by maintenance bevacizumab: a quality of life-oriented randomized phase III study in patients with advanced non-squamous non
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Female; Follow-Up Studies; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Pemetrexed; Quality of Life; Remission Induction; Survival Rate; Treatment Outcome; Young Adult | 2011 |
Pathologic response after neoadjuvant carboplatin and weekly paclitaxel for early-stage lung cancer: a Brown University oncology group phase II study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Remission Induction; Survival Rate; Treatment Outcome | 2011 |
Quality-of-life evaluation for advanced non-small-cell lung cancer: a comparison between vinorelbine plus gemcitabine followed by docetaxel versus paclitaxel plus carboplatin regimens in a randomized trial: Japan Multinational Trial Organization LC00-03 (
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Japan; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Quality of Life; Self-Assessment; Surveys and Questionnaires; Taxoids; Vinblastine; Vinorelbine | 2011 |
Epidermal growth factor receptor mutation status in circulating free DNA in serum: from IPASS, a phase III study of gefitinib or carboplatin/paclitaxel in non-small cell lung cancer.
Topics: Acrylic Resins; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; DNA Mutational Analysis; ErbB Receptors; False Negative Reactions; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Paclitaxel; Polyvinyls; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2012 |
Randomized phase II study of dulanermin in combination with paclitaxel, carboplatin, and bevacizumab in advanced non-small-cell lung cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Non-Small-Cell Lung; Female; Humans; Keratin-18; Lung Neoplasms; Male; Middle Aged; N-Acetylgalactosaminyltransferases; Paclitaxel; Polypeptide N-acetylgalactosaminyltransferase; TNF-Related Apoptosis-Inducing Ligand | 2011 |
Health-related quality-of-life in a randomized phase III first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients from Asia with advanced NSCLC (IPASS).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Asia; Carboplatin; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Mutation; Neoplasm Staging; Paclitaxel; Patient Selection; Prognosis; Protein Kinase Inhibitors; Quality of Life; Quinazolines; Treatment Outcome | 2011 |
Randomized phase II study of palifermin for reducing dysphagia in patients receiving concurrent chemoradiotherapy for locally advanced unresectable non-small cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Deglutition Disorders; Disease Progression; Disease-Free Survival; Double-Blind Method; Female; Fibroblast Growth Factor 7; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Severity of Illness Index; Treatment Outcome | 2012 |
A phase I pharmacokinetic study of bexarotene with paclitaxel and carboplatin in patients with advanced non-small cell lung cancer (NSCLC).
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Bexarotene; Carboplatin; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Interactions; Female; Humans; Hypolipidemic Agents; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Retinoid X Receptors; Tetrahydronaphthalenes | 2012 |
Phase I clinical study of the angiogenesis inhibitor TSU-68 combined with carboplatin and paclitaxel in chemotherapy-naive patients with advanced non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Feasibility Studies; Female; Follow-Up Studies; Humans; Indoles; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Oxindoles; Paclitaxel; Propionates; Pyrroles; Tissue Distribution; Treatment Outcome; Young Adult | 2012 |
A Phase I study of chemoradiotherapy with use of involved-field conformal radiotherapy and accelerated hyperfractionation for Stage III non-small cell lung cancer: WJTOG 3305.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Chemoradiotherapy; Dose Fractionation, Radiation; Drug Administration Schedule; Esophagitis; Female; Fever; Humans; Injections, Intravenous; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neutropenia; Paclitaxel; Radiotherapy, Conformal; Tumor Burden | 2012 |
Targeted and cytotoxic therapy in coordinated sequence (TACTICS): erlotinib, bevacizumab, and standard chemotherapy for non-small-cell lung cancer, a phase II trial.
Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Prognosis; Quinazolines; Survival Rate | 2012 |
A randomized phase III trial of combined paclitaxel, carboplatin, and radiation therapy followed by weekly paclitaxel or observation for patients with locally advanced inoperable non-small-cell lung cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Female; Follow-Up Studies; Humans; Lung Neoplasms; Maintenance Chemotherapy; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Survival Analysis; Treatment Outcome | 2012 |
Cost-effectiveness analysis of cisplatin plus etoposide and carboplatin plus paclitaxel in a phase III randomized trial for non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Cost-Benefit Analysis; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel | 2011 |
[Influence of Shenfu Injection on the quality of life of lung cancer patients receiving chemotherapy].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Drugs, Chinese Herbal; Female; Humans; Lung Neoplasms; Male; Middle Aged; Nausea; Paclitaxel; Phytotherapy; Quality of Life; Surveys and Questionnaires; Vinblastine; Vinorelbine; Vomiting | 2011 |
Vinorelbine versus paclitaxel for patients with advanced non-small cell lung cancer (NSCLC) and a performance status of 2.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Brain Neoplasms; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Disease Progression; Female; Follow-Up Studies; Humans; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Small Cell Lung Carcinoma; Survival Rate; Treatment Outcome; Vinblastine; Vinorelbine | 2012 |
[Evaluation of efficacy and safety of bevacizumab combined with chemotherapy for Chinese patients with advanced non-small cell lung cancer].
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Non-Small-Cell Lung; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel | 2012 |
Randomized phase II study of first-line carboplatin-paclitaxel with or without bevacizumab in Japanese patients with advanced non-squamous non-small-cell lung cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Asian People; Bevacizumab; Carboplatin; Carcinoma, Non-Small-Cell Lung; Female; Humans; Japan; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Survival Analysis; Treatment Outcome | 2012 |
Randomized phase III study of thoracic radiation in combination with paclitaxel and carboplatin with or without thalidomide in patients with stage III non-small-cell lung cancer: the ECOG 3598 study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Disease-Free Survival; Drug Administration Schedule; Fatigue; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Micrometastasis; Neoplasm Staging; Paclitaxel; Survival Rate; Thalidomide; Thromboembolism | 2012 |
[A multicenter, randomized, double-blind, placebo-controlled safety study to evaluate the clinical effects and quality of life of paclitaxel-carboplatin (PC) alone or combined with endostar for advanced non-small cell lung cancer (NSCLC)].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; Double-Blind Method; Endostatins; Follow-Up Studies; Humans; Leukopenia; Lung Neoplasms; Nausea; Neoplasm Staging; Paclitaxel; Prospective Studies; Quality of Life; Recombinant Proteins; Remission Induction | 2011 |
[A randomized controlled trial of the efficacy of combination of gemcitabine and carboplatin or paclitaxel and combination of paclitaxel and carboplatin in the treatment for advanced non-small cell lung cancer].
Topics: Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Leukopenia; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Remission Induction; Survival Rate; Thrombocytopenia | 2011 |
[A randomized clinical trial on the clinical efficacy and toxicities of single-agent paclitaxel liposome versus paclitaxel liposome plus oxaliplatin as first-line chemotherapy for advanced non-small cell lung cancer in elderly patients].
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Administration Schedule; Female; Humans; Liposomes; Male; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Treatment Outcome | 2012 |
[Efficacy of endostar combined with chemotherapy in multi-cycle treatment of patients with advanced non-small cell lung cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Disease Progression; Endostatins; Endothelial Cells; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Neutropenia; Paclitaxel; Quality of Life; Recombinant Proteins; Remission Induction; Vinblastine; Vinorelbine; Vomiting | 2011 |
A phase I, open-label dose-escalation study of continuous treatment with BIBF 1120 in combination with paclitaxel and carboplatin as first-line treatment in patients with advanced non-small-cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cohort Studies; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Indoles; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel | 2012 |
Randomized phase II study of concurrent cisplatin/etoposide or paclitaxel/carboplatin and thoracic radiotherapy in patients with stage III non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Cisplatin; Disease-Free Survival; Esophagitis; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Neoplasm Staging; Neutropenia; Paclitaxel; Radiation Pneumonitis; Treatment Outcome | 2012 |
An apoptosis methylation prognostic signature for early lung cancer in the IFCT-0002 trial.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Biomarkers, Tumor; Calcium-Calmodulin-Dependent Protein Kinases; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Cytoskeleton; Death-Associated Protein Kinases; Deoxycytidine; Disease-Free Survival; DNA Methylation; ErbB Receptors; Female; Gemcitabine; Genes, p53; Genes, ras; Humans; Lung Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Prognosis; Promoter Regions, Genetic; RNA Interference; RNA, Small Interfering; Tumor Suppressor Protein p53; Tumor Suppressor Proteins | 2012 |
[A randomized trial of liposomal paclitaxel plus cisplatin as first-line therapy for advanced non-small cell lung cancer].
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Cisplatin; Drug Carriers; Drug Therapy, Combination; Female; Humans; Liposomes; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Treatment Outcome | 2012 |
Radiation therapy oncology group protocol 02-29: a phase II trial of neoadjuvant therapy with concurrent chemotherapy and full-dose radiation therapy followed by surgical resection and consolidative therapy for locally advanced non-small cell carcinoma of
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Consolidation Chemotherapy; Disease-Free Survival; Female; Humans; Lung Neoplasms; Lymph Nodes; Lymphatic Metastasis; Male; Mediastinum; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Pneumonectomy; Preoperative Care; Prospective Studies; Radiotherapy Dosage | 2012 |
Adaptive/nonadaptive proton radiation planning and outcomes in a phase II trial for locally advanced non-small cell lung cancer.
Topics: Aged; Antineoplastic Agents; Carboplatin; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Esophagus; Female; Humans; Lung Neoplasms; Male; Organs at Risk; Paclitaxel; Prospective Studies; Proton Therapy; Protons; Radiation Injuries; Radiography; Radiotherapy Dosage; Radiotherapy Planning, Computer-Assisted; Spinal Cord; Treatment Outcome; Tumor Burden | 2012 |
Weekly nab-paclitaxel in combination with carboplatin versus solvent-based paclitaxel plus carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer: final results of a phase III trial.
Topics: Adult; Aged; Aged, 80 and over; Albumins; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Carcinoma, Non-Small-Cell Lung; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Solvents; Treatment Outcome | 2012 |
Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Double-Blind Method; Female; Humans; Ipilimumab; Lung Neoplasms; Male; Melanoma; Middle Aged; Paclitaxel; Placebos; Proportional Hazards Models; Treatment Outcome | 2012 |
Quality of life with gefitinib in patients with EGFR-mutated non-small cell lung cancer: quality of life analysis of North East Japan Study Group 002 Trial.
Topics: Adult; Aged; Antineoplastic Agents; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Endpoint Determination; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Paclitaxel; Prospective Studies; Quality of Life; Quinazolines; Treatment Outcome | 2012 |
International, randomized, placebo-controlled, double-blind phase III study of motesanib plus carboplatin/paclitaxel in patients with advanced nonsquamous non-small-cell lung cancer: MONET1.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Double-Blind Method; Female; Humans; Indoles; Lung Neoplasms; Male; Middle Aged; Niacinamide; Oligonucleotides; Paclitaxel; Receptors, Vascular Endothelial Growth Factor; Young Adult | 2012 |
Chemotherapy effectiveness after first-line gefitinib treatment for advanced lepidic predominant adenocarcinoma (formerly advanced bronchioloalveolar carcinoma): exploratory analysis of the IFCT-0401 trial.
Topics: Adenocarcinoma, Bronchiolo-Alveolar; Adenocarcinoma, Mucinous; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Follow-Up Studies; Gefitinib; Gemcitabine; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Neoplasm Staging; Paclitaxel; Pemetrexed; Prognosis; Prospective Studies; Quinazolines; Salvage Therapy; Survival Rate | 2012 |
[Efficacy and adverse effets of nimotuzumab plus palitaxel liposome and carboplatin in the treatment for advanced non-small cell lung cancer].
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoembryonic Antigen; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Exanthema; Female; Humans; Keratin-19; Liposomes; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Phosphopyruvate Hydratase; Remission Induction | 2012 |
A phase I pharmacokinetic study of matuzumab in combination with paclitaxel in patients with EGFR-expressing advanced non-small cell lung cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Paclitaxel | 2013 |
Prognostic models to predict survival in non-small-cell lung cancer patients treated with first-line paclitaxel and carboplatin with or without bevacizumab.
Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Case-Control Studies; Female; Humans; Lung Neoplasms; Male; Neoplasm Metastasis; Neoplasm Staging; Nomograms; Paclitaxel; Prognosis; Retrospective Studies; Survival Rate | 2012 |
Cisplatin-based therapy for the treatment of elderly patients with non-small-cell lung cancer: a retrospective analysis of a single institution.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Neoplasm Staging; Paclitaxel; Prognosis; Retrospective Studies; Survival Rate; Taxoids | 2012 |
Phase Ib safety and pharmacokinetic study of volociximab, an anti-α5β1 integrin antibody, in combination with carboplatin and paclitaxel in advanced non-small-cell lung cancer.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cohort Studies; Humans; Integrin alpha5beta1; Lung Neoplasms; Maximum Tolerated Dose; Paclitaxel | 2013 |
Simulations using a drug-disease modeling framework and phase II data predict phase III survival outcome in first-line non-small-cell lung cancer.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Non-Small-Cell Lung; Computer Simulation; Humans; Indoles; Lung Neoplasms; Models, Biological; Niacinamide; Oligonucleotides; Paclitaxel; Proportional Hazards Models; Survival Rate | 2012 |
Hyperfractionated irradiation with 3 cycles of induction chemotherapy in stage IIIA-N2 lung cancer.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy, Adjuvant; Dose Fractionation, Radiation; Feasibility Studies; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Pneumonectomy; Prospective Studies; Radiotherapy, Conformal; Survival Analysis; Treatment Outcome | 2012 |
Updated overall survival results from a randomized phase III trial comparing gefitinib with carboplatin-paclitaxel for chemo-naïve non-small cell lung cancer with sensitive EGFR gene mutations (NEJ002).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Mutation; Paclitaxel; Quinazolines; Survival Analysis | 2013 |
Phase I trial of axitinib combined with platinum doublets in patients with advanced non-small cell lung cancer and other solid tumours.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Female; Humans; Imidazoles; Indazoles; Lung Neoplasms; Male; Middle Aged; Neoplasms; Paclitaxel; Protein Kinase Inhibitors; Treatment Outcome | 2012 |
Safety and efficacy of sequential chemotherapy with carboplatin plus gemcitabine followed by weekly paclitaxel in advanced non-small cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Drug-Related Side Effects and Adverse Reactions; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Treatment Outcome | 2013 |
A Phase II study of pulse dose imatinib mesylate and weekly paclitaxel in patients aged 70 and over with advanced non-small cell lung cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; Drug Administration Schedule; Fatigue; Female; Frail Elderly; Humans; Imatinib Mesylate; Lung; Lung Neoplasms; Male; Neoplasm Staging; Neutropenia; Paclitaxel; Piperazines; Proto-Oncogene Proteins c-sis; Pyrimidines; Receptors, Platelet-Derived Growth Factor; Remission Induction; Signal Transduction; Survival Analysis; Treatment Outcome | 2012 |
Predictive impact of RRM1 protein expression on vinorelbine efficacy in NSCLC patients randomly assigned in a chemotherapy phase III trial.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Prognosis; Radiation-Sensitizing Agents; Ribonucleoside Diphosphate Reductase; Survival Rate; Tumor Suppressor Proteins; Vinblastine; Vinorelbine; Young Adult | 2013 |
Bevacizumab maintenance in patients with advanced non-small-cell lung cancer, clinical patterns, and outcomes in the Eastern Cooperative Oncology Group 4599 Study: results of an exploratory analysis.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease Management; Disease Progression; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Neoplasm Staging; Paclitaxel; Prognosis; Remission Induction; Retrospective Studies; Survival Rate | 2012 |
Safety and efficacy of weekly nab®-paclitaxel in combination with carboplatin as first-line therapy in elderly patients with advanced non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Aging; Albumins; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neutropenia; Paclitaxel; Survival Rate; Treatment Outcome | 2013 |
Can determination of circulating endothelial cells and serum caspase-cleaved CK18 predict for response and survival in patients with advanced non-small-cell lung cancer receiving endostatin and paclitaxel-carboplatin chemotherapy? a retrospective study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Case-Control Studies; Caspases; Double-Blind Method; Endostatins; Endothelium, Vascular; Female; Humans; Keratin-18; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplastic Cells, Circulating; Paclitaxel; Prognosis; Retrospective Studies; Survival Rate | 2012 |
Phase I clinical and pharmacokinetic study of bi-weekly carboplatin/paclitaxel chemotherapy in elderly patients with advanced non-small cell lung cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Female; Humans; Male; Maximum Tolerated Dose; Neoplasm Staging; Paclitaxel; Quality of Life | 2013 |
Early response to chemotherapy in patients with non-small-cell lung cancer assessed by [18F]-fluoro-deoxy-D-glucose positron emission tomography and computed tomography.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Multimodal Imaging; Niacinamide; Paclitaxel; Phenylurea Compounds; Positron-Emission Tomography; Prognosis; Radiopharmaceuticals; Sorafenib; Tomography, X-Ray Computed | 2013 |
Efficacy and safety analysis according to histology for S-1 in combination with carboplatin as first-line chemotherapy in patients with advanced non-small-cell lung cancer: updated results of the West Japan Oncology Group LETS study.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cross-Linking Reagents; Disease-Free Survival; Drug Combinations; Female; Humans; Japan; Lung Neoplasms; Male; Middle Aged; Oxonic Acid; Paclitaxel; Tegafur; Treatment Outcome; Young Adult | 2013 |
Randomized Phase II trial of paclitaxel and carboplatin followed by gemcitabine switch-maintenance therapy versus gemcitabine and carboplatin followed by gemcitabine continuation-maintenance therapy in previously untreated advanced non-small cell lung can
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel | 2013 |
Paclitaxel-loaded polymeric micelle (230 mg/m(2)) and cisplatin (60 mg/m(2)) vs. paclitaxel (175 mg/m(2)) and cisplatin (60 mg/m(2)) in advanced non-small-cell lung cancer: a multicenter randomized phase IIB trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Disease-Free Survival; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Micelles; Middle Aged; Paclitaxel; Proportional Hazards Models | 2013 |
A randomized phase 2 study of paclitaxel and carboplatin with or without conatumumab for first-line treatment of advanced non-small-cell lung cancer.
Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Prognosis; Survival Rate | 2013 |
Randomized phase II study of cetuximab and bevacizumab in combination with two regimens of paclitaxel and carboplatin in chemonaive patients with stage IIIB/IV non-small-cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cetuximab; Clinical Trials, Phase III as Topic; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Prognosis; Survival Rate | 2013 |
Study shows 2-year survival advantage for docetaxel.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Docetaxel; Humans; Lung Neoplasms; Paclitaxel; Survival Analysis; Taxoids | 2001 |
Concurrent chemoradiation therapy with cisplatin and paclitaxel for locally advanced non-small cell lung cancer: long-term follow-up of a phase I trial.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Feasibility Studies; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Respiratory Function Tests; Survival Rate | 2002 |
Phase I study of weekly CPT-11 (irinotecan)/docetaxel in patients with advanced solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Carcinoma, Squamous Cell; Docetaxel; Dose-Response Relationship, Drug; Female; Head and Neck Neoplasms; Humans; Irinotecan; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Paclitaxel; Taxoids; Treatment Outcome | 2002 |
Vinorelbine and paclitaxel for locoregional advanced or metastatic non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Prospective Studies; Survival Analysis; Vinblastine; Vinorelbine | 2002 |
Concurrent administration of Docetaxel and Stealth liposomal doxorubicin with radiotherapy in non-small cell lung cancer : excellent tolerance using subcutaneous amifostine for cytoprotection.
Topics: Amifostine; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Docetaxel; Doxorubicin; Drug Administration Schedule; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Radiation-Protective Agents; Radiotherapy; Radiotherapy Dosage; Taxoids; Time Factors; Treatment Outcome | 2002 |
Paclitaxel plus carboplatin versus gemcitabine plus paclitaxel in advanced non-small-cell lung cancer: a phase III randomized trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Greece; Health Care Costs; Humans; Logistic Models; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Paclitaxel; Retrospective Studies; Survival Rate | 2002 |
Phase I and pharmacokinetic study of paclitaxel and irinotecan for patients with advanced non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; Female; Hematologic Diseases; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Paclitaxel | 2002 |
[Phase I study of biweekly paclitaxel and carboplatin administration in patients with advanced non-small cell lung cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Taxoids | 2002 |
Second-line, low-dose, weekly paclitaxel in patients with stage IIIB/IV nonsmall cell lung carcinoma who fail first-line chemotherapy with carboplatin plus paclitaxel.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease Progression; Drug Administration Schedule; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Peripheral Nervous System Diseases; Survival Rate; Treatment Outcome | 2002 |
Prospective randomized study of four novel chemotherapy regimens in patients with advanced nonsmall cell lung carcinoma: a minnie pearl cancer research network trial.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Prospective Studies; Survival Rate; Treatment Outcome; Vinblastine; Vinorelbine | 2002 |
Phase II trial of irinotecan, paclitaxel and carboplatin in patients with previously untreated Stage IIIB/IV nonsmall cell lung carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Diarrhea; Disease Progression; Female; Humans; Infusions, Intravenous; Irinotecan; Lung Neoplasms; Male; Middle Aged; Nausea; Neutropenia; Paclitaxel; Survival Analysis; Vomiting | 2002 |
High-dose conformal radiotherapy for treatment of stage IIIA/IIIB non-small-cell lung cancer: technical issues and results of a phase I/II trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Esophagitis; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Prognosis; Radiation Injuries; Radiotherapy Dosage; Remission Induction; Survival Analysis; Treatment Failure | 2002 |
A phase II trial of gemcitabine and docetaxel in patients with chemotherapy-naive, advanced nonsmall cell lung carcinoma.
Topics: Aged; Aged, 80 and over; Anemia; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Survival Analysis; Taxoids; Thrombocytopenia; Treatment Outcome | 2002 |
A phase II study of weekly gemcitabine and paclitaxel in patients with previously untreated stage IIIb and IV non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease Progression; Disease-Free Survival; Female; Gemcitabine; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Neutropenia; Paclitaxel; Pneumonia; Thrombocytopenia; Treatment Outcome | 2002 |
Carboplatin plus paclitaxel and sequential radiation followed by consolidation carboplatin and paclitaxel in patients with previously untreated locally advanced NSCLC. A Hoosier Oncology Group (HOG) phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Neutropenia; Paclitaxel; Survival; Treatment Outcome | 2002 |
Gemcitabine and docetaxel every 2 weeks in advanced non-small cell lung cancer: a phase II study of the Gruppo Oncologico Italia Meridionale.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cost Control; Deoxycytidine; Disease Progression; Docetaxel; Drug Costs; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neutropenia; Paclitaxel; Survival; Taxoids; Treatment Outcome | 2002 |
Phase II study of paclitaxel (Genaxol) and cisplatin combination in treating Chinese patients with advanced non-small cell lung cancer (NSCLC).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Asthenia; Carcinoma, Non-Small-Cell Lung; China; Cisplatin; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Nausea; Neutropenia; Paclitaxel; Quality of Life; Survival; Vomiting | 2002 |
Phase III randomised trial comparing paclitaxel/carboplatin with paclitaxel/cisplatin in patients with advanced non-small-cell lung cancer: a cooperative multinational trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Quality of Life; Survival | 2002 |
Randomized phase II study of cisplatin with gemcitabine or paclitaxel or vinorelbine as induction chemotherapy followed by concomitant chemoradiotherapy for stage IIIB non-small-cell lung cancer: cancer and leukemia group B study 9431.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Radiotherapy Dosage; Survival Analysis; Vinblastine; Vinorelbine | 2002 |
Phase II study of docetaxel and gemcitabine combination chemotherapy in non-small-cell lung cancer patients failing previous chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Middle Aged; Paclitaxel; Quality of Life; Salvage Therapy; Survival Analysis; Taxoids | 2002 |
A phase II study of non-platinum based chemotherapy with paclitaxel and vinorelbine in non-small cell lung cancer.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Erythropoietin; Female; Granulocyte Colony-Stimulating Factor; Humans; Infusions, Intravenous; Leukopenia; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Treatment Outcome; Vinblastine; Vinorelbine | 2002 |
Phase I trial of weekly docetaxel in elderly patients with non-small cell lung cancer.
Topics: Age Factors; Aged; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Diarrhea; Docetaxel; Drug Administration Schedule; Female; Humans; Infections; Lung Neoplasms; Male; Neutropenia; Paclitaxel; Taxoids | 2002 |
Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Neutropenia; Paclitaxel; Survival Analysis; Thrombocytopenia; Treatment Outcome; Vinblastine; Vinorelbine | 2002 |
Safety and pharmacokinetic effects of TNP-470, an angiogenesis inhibitor, combined with paclitaxel in patients with solid tumors: evidence for activity in non-small-cell lung cancer.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cyclohexanes; Drug Administration Schedule; Female; Humans; Lung Neoplasms; Male; Middle Aged; O-(Chloroacetylcarbamoyl)fumagillol; Paclitaxel; Sesquiterpenes; Treatment Outcome | 2002 |
Phase II non-randomized study of three different sequences of docetaxel and vinorelbine in patients with advanced non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Docetaxel; Drug Administration Schedule; Drug Synergism; Female; Granulocyte Colony-Stimulating Factor; Humans; Lung Neoplasms; Male; Middle Aged; Neutropenia; Paclitaxel; Survival Rate; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2002 |
[Comparison of paclitaxel and carboplatin versus ifosfamide, etoposide, and carboplatin regimen for treatment of patients with advanced non-small cell lung cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Etoposide; Female; Humans; Ifosfamide; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Survival Rate; Treatment Outcome | 2002 |
Phase I/II study of paclitaxel, gemcitabine and vinorelbine as first-line chemotherapy of non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Gemcitabine; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Paclitaxel; Risk Assessment; Survival Analysis; Treatment Outcome; Vinblastine; Vinorelbine | 2002 |
Phase II and pharmacologic study of weekly oral paclitaxel plus cyclosporine in patients with advanced non-small-cell lung cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cyclosporine; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Immunosuppressive Agents; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Survival Analysis; Treatment Outcome | 2002 |
[Phase I study of gemcitabine (GEM) and docetaxel (TXT) combination chemotherapy for unresectable non-small-cell lung cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gemcitabine; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Paclitaxel; Taxoids | 2002 |
Docetaxel as neoadjuvant therapy for radically treatable stage III non-small-cell lung cancer: a multinational randomised phase III study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Case-Control Studies; Combined Modality Therapy; Disease Progression; Docetaxel; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Postoperative Period; Safety; Survival Rate; Taxoids; Treatment Outcome | 2003 |
Weekly low-dose docetaxel in advanced non-small cell lung cancer previously treated with two chemotherapy regimens.
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Docetaxel; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Quality of Life; Salvage Therapy; Survival Rate; Taxoids; Time Factors; Treatment Outcome | 2003 |
Efficacy of modified regimen with attenuated doses of paclitaxel plus carboplatin combination chemotherapy in elderly and/or weak patients with advanced non-small cell lung cancer.
Topics: Age Factors; Aged; Carboplatin; Carcinoma, Non-Small-Cell Lung; Drug Therapy, Combination; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Survival Rate; Treatment Outcome | 2003 |
Low-dose weekly paclitaxel as second-line treatment for advanced non-small cell lung cancer: a phase II study.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Prognosis; Salvage Therapy; Survival Rate | 2002 |
Concurrent paclitaxel-cisplatin and twice-a-day irradiation in stage IIIA and IIIB NSCLC shows improvement in local control and survival with acceptable hematologic toxicity.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Radiotherapy Dosage; Survival Rate; Taxoids; Time Factors; Treatment Outcome | 2002 |
[Comparison of effects of three chemotherapy regimens for advanced non-small cell lung cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Docetaxel; Female; Humans; Ifosfamide; Lung Neoplasms; Male; Middle Aged; Mitomycin; Paclitaxel; Taxoids; Treatment Outcome | 2002 |
[Combination chemotherapy with Taxol and cisplatin for 57 patients with non-small cell lung cancer by intraartery and intravenous infusion].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Female; Humans; Infusions, Intra-Arterial; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Nausea; Paclitaxel; Survival Rate; Thrombocytopenia; Treatment Outcome | 2002 |
Gemcitabine and vinorelbine followed by docetaxel in patients with advanced non-small-cell lung cancer: a multi-institutional phase II trial of nonplatinum sequential triplet combination chemotherapy (JMTO LC00-02).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Drug Administration Schedule; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Survival Analysis; Taxoids; Vinblastine; Vinorelbine | 2003 |
Phase II study of Taxol combined With ifosfamide and carboplatin in the treatment of stage IIIb-IV non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Female; Humans; Ifosfamide; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Remission Induction; Survival Analysis | 2003 |
A phase III randomized evaluation of amifostine in stage IIIA/IIIB non-small cell lung cancer patients receiving concurrent carboplatin, paclitaxel, and radiation therapy followed by gemcitabine and cisplatin intensification: preliminary findings.
Topics: Adult; Aged; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Cytoprotection; Deoxycytidine; Esophagitis; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Prospective Studies; Radiation Injuries; Radiation-Protective Agents | 2002 |
A phase I study of carboplatin and docetaxel for advanced non-small cell lung cancer using the continual reassessment method.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; Infusions, Intravenous; Lung Neoplasms; Maximum Tolerated Dose; Middle Aged; Neutropenia; Paclitaxel; Taxoids; Thrombocytopenia | 2002 |
Bcl-2 and bax expression in advanced non-small cell lung cancer: lack of correlation with chemotherapy response or survival in patients treated with docetaxel plus vinorelbine.
Topics: Antineoplastic Combined Chemotherapy Protocols; bcl-2-Associated X Protein; Biomarkers, Tumor; Biopsy; Carcinoma, Non-Small-Cell Lung; Cohort Studies; Docetaxel; Female; Humans; Lung Neoplasms; Male; Neoplasm Staging; Paclitaxel; Prognosis; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Survival Rate; Taxoids; Vinblastine; Vinorelbine | 2003 |
Concomitant weekly docetaxel, cisplatin and radiation therapy in locally advanced non-small cell lung cancer: a dose finding study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Paclitaxel; Prospective Studies; Survival Rate; Taxoids; Treatment Outcome | 2003 |
A phase II study of bryostatin-1 and paclitaxel in patients with advanced non-small cell lung cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Bryostatins; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Drug Administration Schedule; Female; Glucocorticoids; Humans; Interleukin-6; Lactones; Lung Neoplasms; Macrolides; Male; Middle Aged; Paclitaxel; Premedication; Survival Rate; T-Lymphocytes; Tumor Necrosis Factor-alpha | 2003 |
Phase II study of docetaxel and ifosfamide combination chemotherapy in non-small-cell lung cancer patients failing previous chemotherapy with or without paclitaxel.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Docetaxel; Female; Humans; Ifosfamide; Lung Diseases, Interstitial; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Salvage Therapy; Survival Rate; Taxoids; Treatment Failure | 2003 |
Preliminary results of radiotherapy with or without weekly paclitaxel in locally advanced non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Radiotherapy, Adjuvant; Survival Analysis; Treatment Outcome | 2003 |
Alpha-1-acid glycoprotein as an independent predictor for treatment effects and a prognostic factor of survival in patients with non-small cell lung cancer treated with docetaxel.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Area Under Curve; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Docetaxel; Female; Humans; Lung Neoplasms; Male; Middle Aged; Odds Ratio; Orosomucoid; Paclitaxel; Prognosis; Proportional Hazards Models; Taxoids; Time Factors; Treatment Outcome | 2003 |
[Efficacy of docetaxel (TXT) combined with cisplatin (CDDP) in non-small cell lung cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Docetaxel; Drug Administration Schedule; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Survival Rate; Taxoids | 2003 |
Docetaxel as second-line chemotherapy for advanced non-small cell lung cancer.
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Palliative Care; Survival Analysis; Taxoids; Treatment Outcome | 2002 |
Early change in patient-reported health during lung cancer chemotherapy predicts clinical outcomes beyond those predicted by baseline report: results from Eastern Cooperative Oncology Group Study 5592.
Topics: Adult; Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Etoposide; Female; Health Status; Humans; Logistic Models; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Predictive Value of Tests; Proportional Hazards Models; Time Factors; Treatment Outcome; United States | 2003 |
Phase I/II investigation of paclitaxel, ifosfamide and carboplatin for advanced non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Confidence Intervals; Female; Humans; Ifosfamide; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Survival Rate | 2003 |
Combination second-line chemotherapy with gemcitabine and docetaxel for recurrent non-small-cell lung cancer after platinum-containing chemotherapy: a phase I/II trial.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Salvage Therapy; Survival Analysis; Taxoids | 2003 |
Weekly paclitaxel and gemcitabine chemotherapy for metastatic non-small cell lung carcinoma (NSCLC): a dose-optimizing phase II trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Gemcitabine; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Prognosis; Survival Rate | 2003 |
Neoadjuvant radiotherapy concurrent with weekly paclitaxel and carboplatin and followed by surgery in locally advanced non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Pneumonectomy; Radiotherapy Dosage; Remission Induction; Survival Analysis | 2003 |
Mediastinal lymph node clearance after docetaxel-cisplatin neoadjuvant chemotherapy is prognostic of survival in patients with stage IIIA pN2 non-small-cell lung cancer: a multicenter phase II trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Docetaxel; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Prognosis; Survival; Taxoids; Treatment Outcome | 2003 |
Randomized double-blind trial of combined modality treatment with or without amifostine in unresectable stage III non-small-cell lung cancer.
Topics: Adult; Aged; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Double-Blind Method; Esophagitis; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Placebos; Radiation Injuries; Radiation-Protective Agents; Treatment Outcome | 2003 |
Gemcitabine pharmacokinetics and interaction with paclitaxel in patients with advanced non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Drug Interactions; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Metabolic Clearance Rate; Middle Aged; Neoplasm Staging; Paclitaxel | 2003 |
Weekly, high-dose paclitaxel in advanced lung carcinoma: a phase II study with pharmacokinetics by the Cancer and Leukemia Group B.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Survival Analysis; Treatment Outcome | 2003 |
Consolidation docetaxel after concurrent chemoradiotherapy in stage IIIB non-small-cell lung cancer: phase II Southwest Oncology Group Study S9504.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Disease-Free Survival; Docetaxel; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Survival Analysis; Taxoids; Treatment Outcome; United States | 2003 |
Phase I and pharmacokinetic study of carboplatin and paclitaxel with a biweekly schedule in patients with advanced non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Carcinoma, Non-Small-Cell Lung; Drug Administration Schedule; Female; Half-Life; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel | 2003 |
Pilot trial of the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib plus carboplatin and paclitaxel in patients with stage IIIB or IV non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; Epidermal Growth Factor; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Pilot Projects; Protein-Tyrosine Kinases; Quinazolines; Survival Rate; United States | 2003 |
Transcripts in pretreatment biopsies from a three-arm randomized trial in metastatic non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Biopsy; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Cyclooxygenase 2; Deoxycytidine; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Glutathione S-Transferase pi; Glutathione Transferase; Humans; Isoenzymes; Lung Neoplasms; Male; Membrane Proteins; Microtubule Proteins; Middle Aged; Paclitaxel; Phosphoproteins; Predictive Value of Tests; Prostaglandin-Endoperoxide Synthases; Randomized Controlled Trials as Topic; Ribonucleoside Diphosphate Reductase; RNA, Messenger; Stathmin; Survival Rate; Transcription, Genetic; Tubulin; Tumor Suppressor Proteins; Vinblastine; Vinorelbine | 2003 |
[Multi-center prospective randomized trial on paclitaxel liposome and traditional taxol in the treatment of breast cancer and non-small-cell lung cancer].
Topics: Adult; Aged; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Female; Humans; Liposomes; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Prospective Studies | 2003 |
Induction chemotherapy with carboplatin/paclitaxel followed by surgery or standard radiotherapy and concurrent daily low-dose cisplatin for locally advanced non-small cell lung cancer (NSCLC).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Cisplatin; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Remission Induction; Survival Analysis | 2003 |
Carboplatin and paclitaxol (Taxol) as an induction regimen for patients with biopsy-proven stage IIIA N2 non-small cell lung cancer. an EORTC phase II study (EORTC 08958).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Survival Analysis | 2003 |
New insights in beta-tubulin sequence analysis in non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents, Phytogenic; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; DNA, Neoplasm; Drug Resistance, Neoplasm; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasms, Squamous Cell; Paclitaxel; Tubulin | 2003 |
Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Docetaxel; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Quality of Life; Taxoids; Treatment Outcome | 2003 |
A multicenter phase II study of the efficacy and safety of docetaxel plus cisplatin in Asian chemonaïve patients with metastatic or locally advanced non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Asia; Carcinoma, Non-Small-Cell Lung; Cisplatin; Docetaxel; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Survival Rate; Taxoids | 2003 |
Celecoxib, a selective cyclo-oxygenase-2 inhibitor, enhances the response to preoperative paclitaxel and carboplatin in early-stage non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Celecoxib; Chemotherapy, Adjuvant; Cyclooxygenase Inhibitors; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Synergism; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Paclitaxel; Pneumonectomy; Preoperative Care; Pyrazoles; Sulfonamides; Survival Analysis; Treatment Outcome | 2003 |
Weekly low dose paclitaxel and cisplatin as first-line chemotherapy for advanced non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Paclitaxel; Treatment Outcome | 2003 |
Value of accelerated multimodality therapy in stage IIIA and IIIB non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Feasibility Studies; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Predictive Value of Tests; Radiotherapy, Adjuvant; Survival Analysis; Thoracic Surgical Procedures; Time Factors; Treatment Outcome | 2003 |
Multicenter, randomized trial for stage IIIB or IV non-small-cell lung cancer using weekly paclitaxel and carboplatin followed by maintenance weekly paclitaxel or observation.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Carcinoma, Non-Small-Cell Lung; Drug Administration Schedule; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Survival Rate; Treatment Outcome | 2003 |
The impact of age on toxicity, response rate, quality of life, and survival in patients with advanced, Stage IIIB or IV nonsmall cell lung carcinoma treated with carboplatin and paclitaxel.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Quality of Life; Randomized Controlled Trials as Topic; Retrospective Studies; Survival Rate | 2003 |
Phase I/II study of concurrent twice-weekly paclitaxel and weekly cisplatin with radiation therapy for stage III non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Dose-Response Relationship, Drug; Drug Administration Schedule; Esophagitis; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Survival Analysis; Treatment Outcome | 2003 |
Phase I/II study of docetaxel and cisplatin with concurrent thoracic radiation therapy for locally advanced non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Docetaxel; Dose-Response Relationship, Drug; Female; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Paclitaxel; Radiation-Sensitizing Agents; Survival Rate; Taxoids | 2003 |
Effect of amifostine on toxicities associated with radiochemotherapy in patients with locally advanced non-small-cell lung cancer.
Topics: Amifostine; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Esophagitis; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mouth Mucosa; Paclitaxel; Radiation Injuries; Radiation Pneumonitis; Radiation-Protective Agents; Radiotherapy Dosage; Stomatitis; Treatment Outcome | 2003 |
Phase I study of low-dose suramin as a chemosensitizer in patients with advanced non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Agents; Area Under Curve; Carboplatin; Carcinoma, Non-Small-Cell Lung; Drug Interactions; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Paclitaxel; Suramin; Time Factors | 2003 |
Protective effect of amifostine against toxicity of paclitaxel and carboplatin in non-small cell lung cancer: a single center randomized study.
Topics: Amifostine; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cytoprotection; Female; Heart Diseases; Hematologic Diseases; Humans; Lung Neoplasms; Male; Middle Aged; Nervous System Diseases; Paclitaxel; Prospective Studies; Protective Agents | 2003 |
A phase I/IIA trial of continuous five-day infusion of squalamine lactate (MSI-1256F) plus carboplatin and paclitaxel in patients with advanced non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cholestanols; Disease-Free Survival; Female; Humans; Infusions, Intravenous; Lactates; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Patient Selection; Pleural Effusion; Survival Analysis; Time Factors | 2003 |
Weekly carboplatin and paclitaxel in elderly non-small-cell lung cancer patients (>or=65 years of age): a phase II North Central Cancer Treatment Group study.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Humans; Lung Neoplasms; Paclitaxel; Survival Analysis | 2003 |
Prospective randomised phase II study of docetaxel versus paclitaxel administered weekly in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Docetaxel; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Prospective Studies; Survival Analysis; Taxoids; Treatment Outcome | 2003 |
Three-arm randomized study of two cisplatin-based regimens and paclitaxel plus gemcitabine in advanced non-small-cell lung cancer: a phase III trial of the European Organization for Research and Treatment of Cancer Lung Cancer Group--EORTC 08975.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Europe; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Survival Analysis; Treatment Outcome | 2003 |
A phase II study of weekly docetaxel plus capecitabine for patients with advanced nonsmall cell lung carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Asthenia; Capecitabine; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Drug Administration Schedule; Female; Fluorouracil; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neutropenia; Paclitaxel; Stomatitis; Survival Analysis; Taxoids; Treatment Outcome | 2003 |
Phase II study of gemcitabine-cisplatin-paclitaxel triplet as induction chemotherapy in inoperable, locally-advanced non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Treatment Outcome | 2003 |
Phase II trial of weekly paclitaxel in previously untreated advanced non-small-cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Disease-Free Survival; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Survival Rate; Treatment Outcome | 2003 |
Taxol plus gemcitabine and vinorelbine given every other week in advanced chemo-naïve non-small cell lung cancer patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gemcitabine; Humans; Italy; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Treatment Outcome; Vinblastine; Vinorelbine | 2003 |
Amifostine reduces radiochemotherapy-induced toxicities in patients with locally advanced non-small cell lung cancer.
Topics: Aged; Amifostine; Antineoplastic Agents; Carboplatin; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Esophagitis; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Radiation Injuries; Radiation Pneumonitis; Radiation-Protective Agents; Radiation-Sensitizing Agents | 2003 |
A randomised phase II study of weekly paclitaxel or vinorelbine in combination with cisplatin against inoperable non-small-cell lung cancer previously untreated.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Vinblastine; Vinorelbine | 2004 |
Trastuzumab in the treatment of advanced non-small-cell lung cancer: is there a role? Focus on Eastern Cooperative Oncology Group study 2598.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Prognosis; Receptor, ErbB-2; Survival Rate; Trastuzumab; Treatment Outcome | 2004 |
Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 2.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gefitinib; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Multivariate Analysis; Neoplasm Staging; Paclitaxel; Predictive Value of Tests; Prognosis; Quinazolines; Reference Values; Risk Assessment; Survival Analysis; Treatment Outcome | 2004 |
Phase I study of cisplatin analogue nedaplatin (254-S) and paclitaxel in patients with unresectable squamous cell carcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Organoplatinum Compounds; Paclitaxel; Treatment Outcome | 2004 |
Phase I/II study of cisplatin combined with weekly paclitaxel in patients with advanced non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Paclitaxel | 2004 |
Bayesian pharmacokinetically guided dosing of paclitaxel in patients with non-small cell lung cancer.
Topics: Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bayes Theorem; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Dose-Response Relationship, Drug; Female; Humans; Lung Neoplasms; Male; Middle Aged; Models, Biological; Paclitaxel; Time Factors | 2004 |
Phase II study of weekly paclitaxel as second-line therapy in patients with advanced non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Cisplatin; Disease-Free Survival; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Treatment Outcome | 2004 |
Phase II study of alternating chemotherapy regimens for advanced non-small cell lung cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; Etoposide; Female; Gemcitabine; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Survival Analysis; Treatment Outcome; Vinblastine; Vinorelbine | 2004 |
Weekly administration of topotecan and paclitaxel in pretreated advanced cancer patients: a phase I/II study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Ovarian Neoplasms; Paclitaxel; Topotecan | 2004 |
Dose escalation study of paclitaxel in combination with fixed-dose irinotecan in patients with advanced non-small cell lung cancer (JCOG 9807).
Topics: Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Incidence; Irinotecan; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Pneumonia; Treatment Outcome | 2004 |
Phase II study of carboplatin and weekly paclitaxel combination chemotherapy in advanced non-small cell lung cancer: a Kansai Clinical Oncology Group study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Survival Analysis; Treatment Outcome | 2004 |
The combination of carboplatin and weekly paclitaxel: a safe and active regimen in advanced non small-cell lung cancer patients. A phase I-II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cohort Studies; Disease Progression; Female; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Paclitaxel; Time Factors; Treatment Outcome | 2004 |
A phase II study of oxaliplatin and paclitaxel in patients with advanced non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease Progression; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Survival Analysis; Treatment Outcome | 2004 |
Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; Female; Humans; Lung Neoplasms; Male; Paclitaxel; Proportional Hazards Models; Survival Analysis | 2004 |
Paclitaxel, cisplatin, and vinorelbine combination chemotherapy in metastatic non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Survival Analysis; Vinblastine; Vinorelbine | 2004 |
A phase I study and pharmacokinetics of irinotecan (CPT-11) and paclitaxel in patients with advanced non-small cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Camptothecin; Carcinoma, Non-Small-Cell Lung; Female; Humans; Infusions, Intravenous; Irinotecan; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neutropenia; Paclitaxel | 2004 |
Front-line paclitaxel-vinorelbine versus paclitaxel-carboplatin in patients with advanced non-small-cell lung cancer: a randomized phase III trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Neutropenia; Paclitaxel; Quality of Life; Survival Analysis; Treatment Outcome; Vinblastine; Vinorelbine | 2004 |
Gemcitabine and vinorelbine as second-line therapy for non-small cell lung cancer after treatment with paclitaxel plus platinum.
Topics: Adult; Aftercare; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Drug Administration Schedule; Feasibility Studies; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Nervous System Diseases; Neutropenia; Paclitaxel; Platinum; Survival Rate; Vinblastine; Vinorelbine | 2004 |
Second-line weekly paclitaxel in patients with inoperable non-small cell lung cancer who fail combination chemotherapy with cisplatin.
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Confidence Intervals; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Paclitaxel; Probability; Risk Assessment; Salvage Therapy; Survival Analysis; Terminally Ill | 2004 |
A phase I/II trial of induction chemotherapy with carboplatin and gemcitabine followed by concurrent vinorelbine and paclitaxel with chest radiation in patients with stage III non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Paclitaxel; Probability; Prognosis; Radiotherapy Dosage; Radiotherapy, Adjuvant; Remission Induction; Statistics, Nonparametric; Survival Analysis; Treatment Outcome; Vinblastine; Vinorelbine | 2004 |
Gemcitabine with either paclitaxel or vinorelbine vs paclitaxel or gemcitabine alone for elderly or unfit advanced non-small-cell lung cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Gemcitabine; Health Status; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Survival Analysis; Vinblastine; Vinorelbine | 2004 |
Randomized phase II trial of sequential chemotherapy in advanced non-small cell lung cancer (SWOG 9806): carboplatin/gemcitabine followed by paclitaxel or cisplatin/vinorelbine followed by docetaxel.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Salvage Therapy; Taxoids; Time Factors; Treatment Outcome; Vinblastine; Vinorelbine | 2004 |
Phase I trial of bi-weekly paclitaxel and gemcitabine as second-line therapy for patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Paclitaxel | 2004 |
A phase II trial of preoperative concurrent radiation therapy and weekly paclitaxel/carboplatin for patients with locally advanced non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Female; Humans; Lung Neoplasms; Lymph Nodes; Lymphatic Metastasis; Male; Mediastinum; Middle Aged; Paclitaxel; Pneumonectomy; Postoperative Complications; Survival Rate; Thoracotomy; United States | 2004 |
Phase II study of weekly paclitaxel in patients with non-small cell lung cancer who have failed previous treatments.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Survival Analysis; Treatment Failure; Treatment Outcome | 2004 |
Sequential chemotherapy with paclitaxel plus cisplatin, followed by vinorelbine, followed by gemcitabine in advanced non-small cell lung cancer: an Alpe-Adria Thoracic Oncology Multidisciplinary group study (ATOM 001).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neutropenia; Paclitaxel; Survival Analysis; Treatment Outcome; Vinblastine; Vinorelbine | 2004 |
Phase I trial of carboplatin and weekly paclitaxel in patients with advanced non-small-cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Drug Administration Schedule; Female; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Paclitaxel | 2004 |
Carboplatin/paclitaxel or carboplatin/vinorelbine followed by accelerated hyperfractionated conformal radiation therapy: report of a prospective phase I dose escalation trial from the Carolina Conformal Therapy Consortium.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Dose Fractionation, Radiation; Esophagus; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Proportional Hazards Models; Radiotherapy, Conformal; Survival Analysis; Treatment Outcome; Vinblastine; Vinorelbine | 2004 |
Induction and concurrent chemotherapy with high-dose thoracic conformal radiation therapy in unresectable stage IIIA and IIIB non-small-cell lung cancer: a dose-escalation phase I trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Radiotherapy, Conformal; Remission Induction; Survival Analysis; Treatment Outcome | 2004 |
Chemo-radiotherapy for stage III unresectable non-small cell lung cancer long-term results of a prospective study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Disease-Free Survival; Esophagitis; Female; Hematologic Diseases; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Prospective Studies; Survival Rate; Treatment Outcome | 2004 |
Randomized phase II feasibility study of combining the matrix metalloproteinase inhibitor BMS-275291 with paclitaxel plus carboplatin in advanced non-small cell lung cancer.
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Double-Blind Method; Female; Humans; Imidazoles; Infusions, Intravenous; Lung Neoplasms; Male; Matrix Metalloproteinases; Middle Aged; Organic Chemicals; Paclitaxel; Placebos | 2004 |
Analysis of further disease progression in metastatic non-small cell lung cancer: implications for locoregional treatment.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease Progression; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Pleural Effusion; Prognosis; Treatment Outcome | 2004 |
[A tolerability study of A cremophor-free albumin bound nanoparticle paclitaxel intravenously administered in patients with advanced solid tumor].
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Diplopia; Female; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Maximum Tolerated Dose; Middle Aged; Nanotechnology; Nasopharyngeal Neoplasms; Neutropenia; Paclitaxel | 2004 |
Preliminary results of a phase II study of weekly paclitaxel (PTX) and carboplatin (CBDCA) administered concurrently with thoracic radiation therapy (TRT) followed by consolidation chemotherapy with PTX/CBDCA for stage III unresectable non-small-cell lung
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Radiation-Sensitizing Agents; Radiotherapy Dosage; Remission Induction; Survival Analysis | 2004 |
Alternating weekly administration of paclitaxel and gemcitabine: a phase II study in patients with advanced non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Survival Rate | 2005 |
Phase II randomized trial of vinorelbine and gemcitabine versus carboplatin and paclitaxel in advanced non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Gemcitabine; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Quality of Life; Survival Analysis; Treatment Outcome; Vinblastine; Vinorelbine | 2005 |
Sequential versus concurrent paclitaxel and carboplatin for the treatment of advanced non-small cell lung cancer in elderly patients and patients with poor performance status: results of two Phase II, multicenter trials.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Paclitaxel; Quality of Life; Risk Factors; Survival Analysis; Treatment Outcome | 2005 |
Weekly paclitaxel and nedaplatin with concurrent radiotherapy for locally advanced non-small-cell lung cancer: a phase I/II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Drug Administration Schedule; Female; Humans; Lung; Lung Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Paclitaxel; Radiotherapy Dosage; Survival Rate | 2004 |
Single-agent versus combination chemotherapy in advanced non-small-cell lung cancer: the cancer and leukemia group B (study 9730).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Survival Rate | 2005 |
[Comparision of high dose impulsion and low dose density chemotherapeutic regimens with paclitaxel plus cisplatin in advanced NSCLC].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Carmustine; Cisplatin; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Leukopenia; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Quality of Life; Remission Induction; Survival Rate; Thrombocytopenia | 2004 |
Factors associated with the likelihood of receiving second line therapy for advanced non-small cell lung cancer.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Female; Health Status; Humans; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Odds Ratio; Paclitaxel; Quality of Life; Salvage Therapy; Sex Factors; Survival Analysis | 2005 |
Sequential chemotherapy of cisplatin and vinorelbine followed by paclitaxel and gemcitabine in advanced non-small-cell lung cancer. A single institution phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neutropenia; Paclitaxel; Survival Analysis; Treatment Outcome; Vinblastine; Vinorelbine | 2005 |
Vitamin E for prophylaxis against chemotherapy-induced neuropathy: a randomized controlled trial.
Topics: Administration, Oral; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cisplatin; Drug Administration Schedule; Female; Head and Neck Neoplasms; Humans; Lung Neoplasms; Male; Middle Aged; Ovarian Neoplasms; Paclitaxel; Peripheral Nervous System Diseases; Pilot Projects; Testicular Neoplasms; Uterine Cervical Neoplasms; Vitamin E | 2005 |
Induction chemotherapy with carboplatin-paclitaxel followed by standard radiotherapy with concurrent daily low-dose cisplatin plus weekly paclitaxel for inoperable non-small-cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Cisplatin; Dose Fractionation, Radiation; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Pilot Projects; Survival Analysis | 2005 |
A phase II trial of weekly paclitaxel and gemctiabine infused at a constant rate in patients with advanced non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Quality of Life; Survival Analysis; Treatment Outcome | 2005 |
Concurrent hyperfractionated radiotherapy and low-dose daily carboplatin and paclitaxel in patients with stage III non-small-cell lung cancer: long-term results of a phase II study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Dose Fractionation, Radiation; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Survival Rate | 2005 |
Randomized trial of amifostine in locally advanced non-small-cell lung cancer patients receiving chemotherapy and hyperfractionated radiation: radiation therapy oncology group trial 98-01.
Topics: Aged; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Deglutition Disorders; Dose Fractionation, Radiation; Esophagitis; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Quality of Life; Radiation Injuries; Radiation-Protective Agents; Survival Analysis; Treatment Outcome | 2005 |
[Correlation of histologic results with PET findings for tumor regression and survival in locally advanced non-small cell lung cancer after neoadjuvant treatment].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Neoplasm Staging; Paclitaxel; Positron-Emission Tomography; Radiopharmaceuticals; Survival Analysis; Tomography, X-Ray Computed; Treatment Outcome | 2005 |
Phase III study of the Eastern Cooperative Oncology Group (ECOG 2597): induction chemotherapy followed by either standard thoracic radiotherapy or hyperfractionated accelerated radiotherapy for patients with unresectable stage IIIA and B non-small-cell lu
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Dose Fractionation, Radiation; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Radiotherapy Dosage; Remission Induction; Survival Rate; Treatment Outcome | 2005 |
Randomized phase III study of matrix metalloproteinase inhibitor BMS-275291 in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: National Cancer Institute of Canada-Clinical Trials Group Study BR.18.
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Female; Humans; Imidazoles; Lung Neoplasms; Male; Matrix Metalloproteinases; Middle Aged; Organic Chemicals; Paclitaxel; Placebos; Treatment Outcome | 2005 |
Phase II study of carboplatin-paclitaxel combination chemotherapy in elderly patients with advanced non-small cell lung cancer.
Topics: Age Factors; Aged; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Drug Administration Schedule; Endpoint Determination; Humans; Leukopenia; Lung Neoplasms; Neoplasm Staging; Neutropenia; Paclitaxel; Prospective Studies; Survival Rate | 2005 |
Phase II study of radiotherapy with three-dimensional conformal boost concurrent with paclitaxel and cisplatin for Stage IIIB non-small-cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Dose Fractionation, Radiation; Female; Humans; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Paclitaxel; Prospective Studies; Radiotherapy, Conformal; Survival Analysis; Treatment Outcome | 2005 |
Randomized phase III trial comparing cisplatin-etoposide to carboplatin-paclitaxel in advanced or metastatic non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Paclitaxel; Quality of Life | 2005 |
Phase I trial of the matrix metalloproteinase inhibitor marimastat combined with carboplatin and paclitaxel in patients with advanced non-small cell lung cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; Drug Administration Schedule; Enzyme Inhibitors; Female; Hematologic Diseases; Humans; Hydroxamic Acids; Infusions, Intravenous; Lung Neoplasms; Male; Metabolic Clearance Rate; Metalloendopeptidases; Middle Aged; Nausea; Paclitaxel; Treatment Outcome | 2005 |
Cost-minimisation analysis comparing gemcitabine/cisplatin, paclitaxel/carboplatin and vinorelbine/cisplatin in the treatment of advanced non-small cell lung cancer in Italy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Cost Control; Deoxycytidine; Gemcitabine; Health Care Costs; Health Services; Humans; Italy; Lung Neoplasms; Paclitaxel; Retrospective Studies; Vinblastine; Vinorelbine | 2005 |
Comparison of neoadjuvant cisplatin-based chemotherapy versus radiochemotherapy followed by resection for stage III (N2) NSCLC.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Chi-Square Distribution; Cisplatin; Disease-Free Survival; Female; Humans; Lung Neoplasms; Lymph Node Excision; Male; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Radiotherapy, Adjuvant; Regression Analysis; Survival Rate | 2005 |
Phase II trial of postoperative adjuvant paclitaxel/carboplatin and thoracic radiotherapy in resected stage II and IIIA non-small-cell lung cancer: promising long-term results of the Radiation Therapy Oncology Group--RTOG 9705.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Paclitaxel; Pneumonectomy; Postoperative Care; Radiotherapy, Adjuvant; Risk Assessment; Survival Analysis; Treatment Outcome | 2005 |
Five-year results of a phase II trial of hyperfractionated radiotherapy and concurrent daily cisplatin chemotherapy for stage III non-small-cell lung cancer.
Topics: Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Dose Fractionation, Radiation; Esophagitis; Female; Follow-Up Studies; Humans; Life Tables; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Paclitaxel; Radiation Injuries; Radiation Pneumonitis; Radiation-Sensitizing Agents; Radiotherapy, High-Energy; Survival Analysis; Survival Rate; Treatment Outcome | 2005 |
Paclitaxel and gemcitabine combination in a biweekly schedule in patients with advanced non small-cell lung cancer: a phase I study.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Gemcitabine; Hematologic Diseases; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Outpatients; Paclitaxel; Survival Rate | 2005 |
Efficacy of platinum-based chemotherapy after cranial radiation in patients with brain metastasis from non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Leukopenia; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Survival Analysis; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2005 |
A phase II study of weekly paclitaxel and carboplatin in previously untreated patients with advanced non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Female; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Paclitaxel; Survival Rate; Treatment Outcome | 2005 |
Influence of the cyto-protective agent amifostine on the pharmacokinetics of low-dose Paclitaxel.
Topics: Amifostine; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; Drug Interactions; Drug Therapy, Combination; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Paclitaxel; Radiation-Protective Agents | 2005 |
Pilot study of accelerated radiotherapy with concurrent chemotherapy for stage III non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Dietary Supplements; Dose Fractionation, Radiation; Glutamine; Humans; Lung Neoplasms; Paclitaxel; Pilot Projects; Radiotherapy, Conformal | 2005 |
A phase II study of paclitaxel in advanced bronchioloalveolar carcinoma (EORTC trial 08956).
Topics: Adenocarcinoma, Bronchiolo-Alveolar; Adult; Aged; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Disease Progression; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Survival Analysis; Treatment Outcome | 2005 |
Survival outcome of inoperable non-small cell lung cancer patients receiving conventional dose epirubicin and Paclitaxel as first-line treatment.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; Epirubicin; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Survival Rate; Treatment Outcome | 2005 |
Phase II study of the farnesyltransferase inhibitor lonafarnib with paclitaxel in patients with taxane-refractory/resistant nonsmall cell lung carcinoma.
Topics: Adult; Aged; Alkyl and Aryl Transferases; Antineoplastic Agents, Phytogenic; Bridged-Ring Compounds; Carcinoma, Non-Small-Cell Lung; Drug Therapy, Combination; Enzyme Inhibitors; Farnesyltranstransferase; Female; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Paclitaxel; Piperidines; Pyridines; Remission Induction; Survival Rate; Taxoids; Treatment Outcome | 2005 |
Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; DNA Mutational Analysis; ErbB Receptors; Erlotinib Hydrochloride; Female; Genes, ras; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Placebos; Predictive Value of Tests; Prognosis; Quinazolines; Survival Analysis; Treatment Outcome | 2005 |
TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Placebos; Protein Kinase Inhibitors; Quinazolines; Survival Analysis | 2005 |
Combined chemoradiotherapy regimens of paclitaxel and carboplatin for locally advanced non-small-cell lung cancer: a randomized phase II locally advanced multi-modality protocol.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Survival Analysis | 2005 |
Bexarotene in combination with chemotherapy fails to prolong survival in patients with advanced non-small-cell lung cancer: results from the SPIRIT I and II trials.
Topics: Anticarcinogenic Agents; Antineoplastic Combined Chemotherapy Protocols; Bexarotene; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Survival Analysis; Tetrahydronaphthalenes; Treatment Outcome; Vinblastine; Vinorelbine | 2005 |
Paclitaxel poliglumex/carboplatin is similar to paclitaxel/carboplatin as first-line treatment in elderly patients with advanced non-small-cell lung cancer and a poor performance status.
Topics: Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Paclitaxel; Polyglutamic Acid; Treatment Outcome | 2005 |
Induction paclitaxel/carboplatin followed by concurrent chemoradiation therapy for unresectable stage III non-small-cell lung cancer: a limited-access study--CALGB 9534.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Survival Analysis; Treatment Outcome | 2005 |
Long term results of CHART and weekly Paclitaxel in locally advanced non-small cell lung cancer.
Topics: Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Combined Modality Therapy; Disease Progression; Dose Fractionation, Radiation; Humans; Lung Neoplasms; Paclitaxel; Radiotherapy; Time Factors; Treatment Outcome | 2005 |
Phase II multicenter study of induction chemotherapy followed by concurrent efaproxiral (RSR13) and thoracic radiotherapy for patients with locally advanced non-small-cell lung cancer.
Topics: Adult; Aged; Aniline Compounds; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Propionates; Radiation-Sensitizing Agents; Survival Analysis | 2005 |
Phase I/IIa study of cisplatin and gemcitabine as induction chemotherapy followed by concurrent chemoradiotherapy with gemcitabine and paclitaxel for locally advanced non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Confidence Intervals; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Paclitaxel; Probability; Radiotherapy, Adjuvant; Remission Induction; Survival Analysis | 2005 |
Concurrent hyperfractionated radiotherapy and low-dose daily carboplatin/paclitaxel in patients with early-stage (I/II) non-small-cell lung cancer: long-term results of a phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Disease Progression; Dose Fractionation, Radiation; Drug Administration Schedule; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Paclitaxel; Survival Analysis; Treatment Outcome | 2005 |
Phase I/II trial of paclitaxel and vinorelbine in advanced non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Female; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Paclitaxel; Treatment Outcome; Vinblastine; Vinorelbine | 2005 |
Dose-finding and phase 2 study of weekly paclitaxel (taxol) and cisplatin combination in treating Chinese patients with advanced nonsmall cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; China; Cisplatin; Drug Administration Schedule; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Taxoids | 2005 |
Randomized phase II study of weekly docetaxel plus trastuzumab versus weekly paclitaxel plus trastuzumab in patients with previously untreated advanced nonsmall cell lung carcinoma.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Docetaxel; Female; Humans; Immunohistochemistry; Lung Neoplasms; Male; Paclitaxel; Receptor, ErbB-2; Survival Analysis; Taxoids; Trastuzumab; Treatment Outcome | 2005 |
Multicenter phase I/II study of cetuximab with paclitaxel and carboplatin in untreated patients with stage IV non-small-cell lung cancer.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cetuximab; Dose-Response Relationship, Drug; ErbB Receptors; Exanthema; Fatigue; Female; Follow-Up Studies; Humans; Immunohistochemistry; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Survival Analysis; Time Factors; Treatment Outcome | 2005 |
Phase I study of 90Y-CC49 monoclonal antibody therapy in patients with advanced non-small cell lung cancer: effect of chelating agents and paclitaxel co-administration.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Neoplasm; Antigens, Neoplasm; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chelating Agents; Clinical Trials as Topic; Disease Progression; Edetic Acid; Female; Glycoproteins; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neutropenia; Paclitaxel; Pentetic Acid; Radioimmunotherapy; Radiometry; Thrombocytopenia; Treatment Outcome; Up-Regulation; Yttrium Radioisotopes | 2005 |
A randomized phase II trial comparing every 3-weeks carboplatin/paclitaxel with every 3-weeks carboplatin and weekly paclitaxel in advanced non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Prospective Studies; Quality of Life; Survival Rate | 2006 |
Front-line paclitaxel and irinotecan combination chemotherapy in advanced non-small-cell lung cancer: a phase I-II trial.
Topics: Adult; Aged; Camptothecin; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Humans; Irinotecan; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Survival Rate | 2005 |
Evaluation of irinotecan plus paclitaxel in patients with advanced non-small cell lung cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Diarrhea; Disease Progression; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Irinotecan; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Neutropenia; Paclitaxel; Survival Analysis; Time Factors | 2005 |
Induction and concurrent chemotherapy with concomitant boost radiotherapy in non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Disease-Free Survival; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Radiotherapy Dosage; Survival Analysis; Survival Rate; Treatment Outcome | 2005 |
Thoracic radiation therapy and concomitant low-dose daily paclitaxel in non-small cell lung cancer: a phase I study.
Topics: Aged; Antineoplastic Agents, Phytogenic; Area Under Curve; Carcinoma, Non-Small-Cell Lung; Chromatography, High Pressure Liquid; Combined Modality Therapy; Dose-Response Relationship, Drug; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Radiotherapy Dosage; Survival Analysis; Treatment Outcome | 2005 |
Recombinant human angiostatin (rhAngiostatin) in combination with paclitaxel and carboplatin in patients with advanced non-small-cell lung cancer: a phase II study from Indiana University.
Topics: Aged; Angiostatins; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; Feasibility Studies; Female; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Paclitaxel; Proteomics; Recombinant Proteins; Survival Rate; Time Factors | 2006 |
Paclitaxel, carboplatin and gemcitabine combination as induction chemotherapy for stage IIIA N2 bulky non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Radiotherapy, Adjuvant; Remission Induction; Survival Analysis; Treatment Outcome | 2005 |
Phase I trial of nedaplatin and paclitaxel for patients with non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Organoplatinum Compounds; Paclitaxel | 2005 |
Weekly paclitaxel and carboplatin with concurrent radiation therapy in locally advanced non-small cell lung cancer: phase I study.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cohort Studies; Combined Modality Therapy; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Hemodynamics; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Paclitaxel | 2005 |
Efficacy and safety of paclitaxel poliglumex as first-line chemotherapy in patients at high risk with advanced-stage non-small-cell lung cancer: results of a phase II study.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Disease Progression; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Survival Analysis | 2005 |
Phase III trial of paclitaxel plus carboplatin with or without tirapazamine in advanced non-small-cell lung cancer: Southwest Oncology Group Trial S0003.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cell Hypoxia; Drug Administration Schedule; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Survival Analysis; Tirapazamine; Treatment Outcome; Triazines | 2005 |
A multicenter phase II study of carboplatin and paclitaxel with a biweekly schedule in patients with advanced non-small-cell lung cancer: Kyushu thoracic oncology group trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Japan; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Treatment Outcome | 2006 |
Breath alcohol concentrations in Japanese outpatients following paclitaxel and docetaxel infusion.
Topics: Adult; Aged; Alcoholic Intoxication; Antineoplastic Agents, Phytogenic; Asian People; Breast Neoplasms; Breath Tests; Carcinoma, Non-Small-Cell Lung; Docetaxel; Ethanol; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Neoplasms; Outpatients; Ovarian Neoplasms; Paclitaxel; Taxoids | 2005 |
A phase II study of carboplatin and paclitaxel as first line chemotherapy in elderly patients with advanced non-small cell lung cancer (NSCLC).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Female; Humans; Italy; Lung Neoplasms; Male; Paclitaxel; Survival Analysis; Treatment Outcome | 2006 |
Adding gemcitabine to paclitaxel/carboplatin combination increases survival in advanced non-small-cell lung cancer: results of a phase II-III study.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Neutropenia; Paclitaxel; Prognosis; Risk Factors; Survival Rate; Thrombocytopenia; Treatment Outcome | 2006 |
A phase II study of weekly paclitaxel combined with carboplatin for elderly patients with advanced non-small cell lung cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Female; Humans; Japan; Lung Neoplasms; Male; Paclitaxel; Survival Rate; Treatment Outcome | 2006 |
Front-line paclitaxel and topotecan chemotherapy in advanced or metastatic non-small-cell lung cancer: a phase II trial.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Survival Analysis; Topotecan | 2006 |
Pharmacology of the paclitaxel-cisplatin, gemcitabine-cisplatin, and paclitaxel-gemcitabine combinations in patients with advanced non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Drug Interactions; Female; Gemcitabine; Half-Life; Humans; Lung Neoplasms; Male; Metabolic Clearance Rate; Middle Aged; Paclitaxel | 2006 |
A phase I study of the humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody EMD 72000 (matuzumab) in combination with paclitaxel in patients with EGFR-positive advanced non-small-cell lung cancer (NSCLC).
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cetuximab; Dose-Response Relationship, Drug; ErbB Receptors; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel | 2006 |
Beyond the TRIBUTE trial: integrating HER1/EGFR tyrosine kinase inhibitors with chemotherapy in advanced NSCLC.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Paclitaxel; Protein Kinase Inhibitors; Quinazolines; Smoking; Survival; Treatment Outcome; Up-Regulation | 2006 |
[Phase I clinical trail of intravenous pegylated recombinant human granulocyte colony-stimulating factor].
Topics: Adult; Aged; Antigens, CD34; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Arthralgia; Blood Cell Count; Breast Neoplasms; Carboplatin; Carcinoma, Non-Small-Cell Lung; Fatigue; Female; Granulocyte Colony-Stimulating Factor; Humans; Injections, Subcutaneous; Lung Neoplasms; Male; Middle Aged; Neutropenia; Neutrophils; Paclitaxel; Polyethylene Glycols; Recombinant Proteins | 2006 |
Multicenter randomized trial for stage IIIB/IV non-small-cell lung cancer using every-3-week versus weekly paclitaxel/carboplatin.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Prognosis; Survival Rate; Treatment Outcome | 2006 |
Results of a Phase I trial of concurrent chemotherapy and escalating doses of radiation for unresectable non-small-cell lung cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Female; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Paclitaxel; Radiation Pneumonitis; Radiotherapy Dosage; Radiotherapy Planning, Computer-Assisted | 2006 |
Abraxane, a novel Cremophor-free, albumin-bound particle form of paclitaxel for the treatment of advanced non-small-cell lung cancer.
Topics: Adult; Aged; Albumin-Bound Paclitaxel; Albumins; Carcinoma, Non-Small-Cell Lung; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Treatment Outcome | 2006 |
[Carboplatin plus gemcitabine therapy versus carboplatin plus weekly paclitaxel therapy for advanced non-small cell lung cancer].
Topics: Adult; Aged; Aged, 80 and over; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neutropenia; Paclitaxel; Survival Rate; Thrombocytopenia | 2006 |
Rational drug sequencing of paclitaxel, gemcitabine and carboplatin in patients with untreated stage IV and select stage IIIB non-small cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Pleural Effusion; Survival Analysis; Treatment Outcome | 2006 |
Phase II trial of concurrent paclitaxel, carboplatin, and external-beam radiation followed by surgical resection in locally advanced non-small-cell lung cancer, protocol 99-444.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel | 2006 |
Phase II trial of weekly paclitaxel and gemcitabine for previously untreated, stage IIIB-IV nonsmall cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Lung; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neutropenia; Paclitaxel; Salvage Therapy; Survival Rate | 2006 |
[Efficacy of once-per-cycle administration pegylated recombinant human granulocyte colony-stimulating factor in chemotherapy-induced neutropenia in a phase I trial].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Carcinoma, Non-Small-Cell Lung; Female; Granulocyte Colony-Stimulating Factor; Humans; Lung Neoplasms; Male; Middle Aged; Neutropenia; Paclitaxel; Recombinant Proteins | 2006 |
Toxicity and outcome of a phase II trial of taxane-based neoadjuvant chemotherapy and 3-dimensional, conformal, accelerated radiotherapy in locally advanced nonsmall cell lung cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Combined Modality Therapy; Deglutition Disorders; Disease-Free Survival; Female; Humans; Leukocyte Count; Lung; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Platelet Count; Radiotherapy Dosage; Radiotherapy, Conformal; Treatment Outcome | 2006 |
Weekly chemotherapy with cisplatin and paclitaxel in advanced NSClC: a phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Cohort Studies; Drug Administration Schedule; Female; Humans; Injections, Intravenous; Kaplan-Meier Estimate; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Paclitaxel; Treatment Outcome | 2006 |
Induction chemotherapy with the TIP regimen (paclitaxel/ifosfamide/cisplatin) in stage III non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Austria; Carcinoma, Non-Small-Cell Lung; Cisplatin; Disease Progression; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Ifosfamide; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Recombinant Proteins; Taxoids; Treatment Outcome | 2006 |
[A randomized comparative trial of three combined regimens containing cisplatin for treatment of advanced non-small cell lung cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Leukopenia; Lung Neoplasms; Male; Middle Aged; Nausea; Neoplasm Staging; Paclitaxel; Prospective Studies; Remission Induction; Survival Rate; Vinblastine; Vinorelbine | 2006 |
Simultaneous chemoradiotherapy compared with radiotherapy alone after induction chemotherapy in inoperable stage IIIA or IIIB non-small-cell lung cancer: study CTRT99/97 by the Bronchial Carcinoma Therapy Group.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Disease-Free Survival; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Radiotherapy, Adjuvant; Remission Induction; Survival Analysis; Treatment Outcome | 2006 |
Induction cisplatin-gemcitabine-paclitaxel plus concurrent radiotherapy and gemcitabine in the multimodality treatment of unresectable stage IIIB non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Radiotherapy, Adjuvant; Survival Analysis; Treatment Outcome | 2006 |
Phase II trial of sequential chemotherapy followed by chemoradiation, surgery, and postoperative chemotherapy for the treatment of stage IIIA/IIIB non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Agents; Carboplatin; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Female; Follow-Up Studies; Humans; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Postoperative Care; Thoracotomy | 2006 |
A phase I/randomized phase II, non-comparative, multicenter, open label trial of CP-547,632 in combination with paclitaxel and carboplatin or paclitaxel and carboplatin alone as first-line treatment for advanced non-small cell lung cancer (NSCLC).
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Carcinoma, Non-Small-Cell Lung; Diarrhea; Dose-Response Relationship, Drug; Drug Administration Schedule; Exanthema; Female; Gastrointestinal Diseases; Half-Life; Hematologic Diseases; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Prognosis; Thiazoles; Treatment Outcome; Urea | 2007 |
Randomized phase II trial of gemcitabine plus weekly versus three-weekly paclitaxel in previously untreated advanced non-small-cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Deoxycytidine; Female; Gemcitabine; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Paclitaxel; Prognosis; Survival Rate; Treatment Outcome | 2007 |
Paclitacxel and carboplatin in advanced non-small-cell lung cancer.
Topics: Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease Progression; Female; Humans; Injections, Intravenous; Lung Neoplasms; Male; Middle Aged; Nausea; Neoplasm Staging; Neutropenia; Paclitaxel; Thrombocytopenia; Tomography, X-Ray Computed; Treatment Outcome; Vomiting | 2006 |
Efficacy of the combination of cisplatin with either gemcitabine and vinorelbine or gemcitabine and paclitaxel in the treatment of locally advanced or metastatic non-small-cell lung cancer: a phase III randomised trial of the Southern Italy Cooperative On
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Deoxycytidine; Female; Gemcitabine; Humans; Italy; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Prognosis; Survival Rate; Vinblastine; Vinorelbine | 2007 |
Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small-cell lung cancer: Four-Arm Cooperative Study in Japan.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Irinotecan; Japan; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Prognosis; Quality of Life; Survival Rate; Vinblastine; Vinorelbine | 2007 |
Phase II study of weekly chemotherapy with paclitaxel and gemcitabine as second-line treatment for advanced non-small cell lung cancer after treatment with platinum-based chemotherapy.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Survival Rate | 2007 |
Phase II study of consolidation paclitaxel after concurrent chemoradiation in poor-risk stage III non-small-cell lung cancer: SWOG S9712.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Etoposide; Feasibility Studies; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Patient Selection; Prognosis; Radiotherapy, Adjuvant; Risk Factors; Survival Analysis; Treatment Outcome | 2006 |
Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer.
Topics: Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Vascular Endothelial Growth Factor A | 2006 |
Randomized study of concurrent carboplatin, paclitaxel, and radiotherapy with or without prior induction chemotherapy in patients with locally advanced non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Radiotherapy; Survival Analysis; Treatment Outcome | 2006 |
Randomized phase II trial of paclitaxel plus carboplatin or gemcitabine plus cisplatin in Eastern Cooperative Oncology Group performance status 2 non-small-cell lung cancer patients: ECOG 1599.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Survival Analysis | 2007 |
Intra-patient alternated dose escalation of paclitaxel and gemcitabine versus paclitaxel followed by fixed dose rate infusion of gemcitabine in fit elderly non-small cell lung cancer patients. A Southern Italy Cooperative Oncology Group randomised phase I
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Gemcitabine; Humans; Italy; Lung Neoplasms; Male; Paclitaxel; Survival Analysis; Survival Rate | 2007 |
A phase III study of surgical resection and paclitaxel/carboplatin chemotherapy with or without adjuvant radiation therapy for resected stage III non-small-cell lung cancer: Cancer and Leukemia Group B 9734.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel | 2007 |
A novel triplet regimen with paclitaxel, carboplatin and gemcitabine (PACCAGE) as induction chemotherapy for locally advanced unresectable non small cell lung cancer (NSCLC).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Survival Rate | 2007 |
Pemetrexed combined with paclitaxel in patients with advanced or metastatic non-small-cell lung cancer: a phase I-II trial.
Topics: Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Asthenia; Carcinoma, Non-Small-Cell Lung; Female; Follow-Up Studies; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Middle Aged; Nausea; Neoplasm Metastasis; Paclitaxel; Pemetrexed; Survival Analysis; Time Factors; Vomiting | 2007 |
A phase III randomised trial comparing sequential chemotherapy using cisplatin-based regimen and paclitaxel to cisplatin-based chemotherapy alone in advanced non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Gemcitabine; Humans; Ifosfamide; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Survival Analysis; Treatment Outcome | 2007 |
Induction chemotherapy followed by chemoradiotherapy compared with chemoradiotherapy alone for regionally advanced unresectable stage III Non-small-cell lung cancer: Cancer and Leukemia Group B.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Combined Modality Therapy; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Survival Analysis | 2007 |
A phase II study of concurrent carboplatin and paclitaxel and thoracic radiotherapy for completely resected stage II and IIIA non-small cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Dose-Response Relationship, Drug; Drug Administration Schedule; Feasibility Studies; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Paclitaxel; Pneumonectomy; Probability; Prospective Studies; Radiotherapy Dosage; Radiotherapy, Adjuvant; Statistics, Nonparametric; Survival Analysis; Treatment Outcome | 2007 |
Phase I study of Paclitaxel given by seven-week continuous infusion concurrent with radiation therapy for locally advanced non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Retrospective Studies; Time Factors; Treatment Outcome | 2006 |
Phase II trial of gemcitabine-carboplatin-paclitaxel as neoadjuvant chemotherapy for operable non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Agents; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Drug Therapy, Combination; Female; Follow-Up Studies; Gemcitabine; Humans; Immunosuppressive Agents; Lung Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Ribonucleotide Reductases; Severity of Illness Index; Survival Rate | 2006 |
A Phase II randomized study of paclitaxel plus carboplatin or cisplatin against chemo-naive inoperable non-small cell lung cancer in the elderly.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Contraindications; Disease Progression; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Neoplasm Staging; Paclitaxel; Pneumonectomy; Retrospective Studies; Risk Factors; Severity of Illness Index; Taiwan; Treatment Outcome | 2006 |
Treatment of elderly non-small cell lung cancer patients with three different schedules of weekly paclitaxel in combination with carboplatin: subanalysis of a randomized trial.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Drug Administration Schedule; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Neutropenia; Paclitaxel; Survival Rate | 2006 |
Weekly paclitaxel combined with monthly carboplatin in elderly patients with advanced non-small cell lung cancer: a multicenter phase II study.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Female; Humans; Lung Neoplasms; Male; Paclitaxel; Quality of Life | 2006 |
DHA-paclitaxel (Taxoprexin) as first-line treatment in patients with stage IIIB or IV non-small cell lung cancer: report of a phase II open-label multicenter trial.
Topics: Adult; Age Factors; Aged; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Docosahexaenoic Acids; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Combinations; Female; Follow-Up Studies; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Paclitaxel; Patient Selection; Probability; Prospective Studies; Risk Factors; Single-Blind Method; Survival Analysis | 2006 |
A phase I evaluation of oral CI-1033 in combination with paclitaxel and carboplatin as first-line chemotherapy in patients with advanced non-small cell lung cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Confidence Intervals; Dose-Response Relationship, Drug; Drug Administration Schedule; Evaluation Studies as Topic; Female; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Morpholines; Neoplasm Invasiveness; Neoplasm Staging; Neutropenia; Odds Ratio; Paclitaxel; Patient Selection; Probability; Prognosis; Risk Assessment; Single-Blind Method; Survival Analysis; Treatment Outcome; United States | 2006 |
Measurement and impact of co-morbidity in elderly patients with advanced non-small cell lung cancer treated with chemotherapy. A phase II study of weekly paclitaxel.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Comorbidity; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Heart Diseases; Humans; Lung Neoplasms; Male; Multivariate Analysis; Paclitaxel; Patient Compliance; Proportional Hazards Models; Pulmonary Disease, Chronic Obstructive; Renal Insufficiency; Severity of Illness Index; Survival Analysis; Treatment Outcome; Vascular Diseases | 2007 |
Phase I study of cisplatin analogue nedaplatin, paclitaxel, and thoracic radiotherapy for unresectable stage III non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Drug Administration Schedule; Drug Tolerance; Female; Humans; Lung Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Paclitaxel | 2007 |
Second-line paclitaxel in non-small cell lung cancer initially treated with cisplatin: a study by the European Lung Cancer Working Party.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Cisplatin; Deoxycytidine; Europe; Female; Gemcitabine; Humans; Ifosfamide; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Survival Analysis; Treatment Failure | 2007 |
Phase I/II trial of sequential chemoradiotherapy using a novel hypoxic cell radiosensitizer, doranidazole (PR-350), in patients with locally advanced non-small-cell lung Cancer (WJTOG-0002).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Female; Humans; Imidazoles; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Radiation Pneumonitis; Radiation-Sensitizing Agents; Radiotherapy Dosage; Survival Rate | 2007 |
Phase I study to determine the MTD of paclitaxel given three times per week during concurrent radiation therapy for stage III non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Drug Administration Schedule; Female; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Paclitaxel; Treatment Outcome | 2007 |
In focus: non-small cell lung cancer: E1505.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Disease Progression; Humans; Lung Neoplasms; Neoplasm Staging; Neovascularization, Pathologic; Paclitaxel; Vascular Endothelial Growth Factor A | 2007 |
Independent review of interstitial lung disease associated with death in TRIBUTE (paclitaxel and carboplatin with or without concurrent erlotinib) in advanced non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Double-Blind Method; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Prognosis; Protein Kinase Inhibitors; Quinazolines; Survival Rate | 2007 |
Phase II trial of carboplatin and paclitaxel in non-small cell lung cancer patients previously treated with chemotherapy.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Remission Induction; Salvage Therapy; Survival Analysis; Survival Rate; Treatment Outcome | 2007 |
Mature results of a phase II trial of gemcitabine/paclitaxel given every 2 weeks in patients with advanced non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Treatment Outcome | 2007 |
Phase I study of the combination of nedaplatin and weekly paclitaxel in patients with advanced non-small cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemical and Drug Induced Liver Injury; Dose-Response Relationship, Drug; Female; Fever; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neutropenia; Organoplatinum Compounds; Paclitaxel; Severity of Illness Index; Treatment Outcome | 2008 |
Gemcitabine, ifosfamide and paclitaxel in advanced/metastatic non-small cell lung cancer patients: a phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease Progression; Disease-Free Survival; Female; Gemcitabine; Humans; Ifosfamide; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Paclitaxel; Survival Rate; Treatment Outcome | 2008 |
Induction chemotherapy with paclitaxel plus carboplatin followed by paclitaxel with concurrent radiotherapy in stage IIIB non-small-cell lung cancer (NSCLC) patients: a phase II trial.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Disease Progression; Drug-Related Side Effects and Adverse Reactions; Humans; Lung Neoplasms; Middle Aged; Neoplasm Staging; Paclitaxel; Patient Compliance; Survival Analysis; Treatment Failure | 2007 |
Phase I clinical trial of concurrent paclitaxel, carboplatin, and external beam chest irradiation with glutamine in patients with locally advanced non-small cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; Dose-Response Relationship, Radiation; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Patient Selection; Radiotherapy | 2007 |
Comparison of the safety and efficacy of paclitaxel plus gemcitabine combination in young and elderly patients with locally advanced or metastatic non-small cell lung cancer. A retrospective analysis of the Southern Italy Cooperative Oncology Group trials
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease-Free Survival; Drug-Related Side Effects and Adverse Reactions; Female; Gemcitabine; Humans; Italy; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Retrospective Studies; Survival Rate | 2008 |
Phase II study of paclitaxel and irinotecan chemotherapy in patients with advanced nonsmall cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Female; Humans; Irinotecan; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Paclitaxel; Prognosis; Survival Rate; Treatment Outcome | 2007 |
Multicenter phase II trial of Genexol-PM, a novel Cremophor-free, polymeric micelle formulation of paclitaxel, with cisplatin in patients with advanced non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Female; Humans; Lung Neoplasms; Male; Micelles; Middle Aged; Paclitaxel; Polymers; Treatment Outcome | 2007 |
Phase II multicenter trial with carboplatin and gemcitabine induction chemotherapy followed by radiotherapy concomitantly with low-dose paclitaxel and gemcitabine for stage IIIA and IIIB non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Combined Modality Therapy; Deoxycytidine; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Paclitaxel; Prognosis; Prospective Studies; Radiotherapy Dosage; Remission Induction; Survival Rate; Treatment Outcome | 2007 |
Phase I study of paclitaxel, carboplatin and UFT in chemo-naive patients with advanced non-small cell lung cancer (NSCLC).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Tegafur; Treatment Outcome; Uracil | 2007 |
Phase I study of biweekly paclitaxel and carboplatin for frail patients with advanced non-small cell lung cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase II as Topic; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Frail Elderly; Humans; Leukocyte Count; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Patient Selection; Platelet Count | 2007 |
Paclitaxel/Carboplatin/gemcitabine versus gemcitabine/vinorelbine in advanced non-small-cell lung cancer: a phase II/III study of the Minnie Pearl Cancer Research Network.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Prospective Studies; Survival Rate; Vinblastine; Vinorelbine | 2007 |
Paclitaxel and gemcitabine versus carboplatin and gemcitabine in patients with advanced non-small-cell lung cancer. A phase III study of the Hellenic Cooperative Oncology Group.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemical and Drug Induced Liver Injury; Cimetidine; Deoxycytidine; Dexamethasone; Diphenhydramine; Female; Gemcitabine; Heart Diseases; Hematologic Diseases; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Ondansetron; Paclitaxel; Premedication; Proportional Hazards Models | 2008 |
Phase II study of 24-hour infusion of paclitaxel (Intaxel) with carboplatin in advanced non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Survival Rate | 2007 |
[Nadaplatin or cisplatin combined with paclitaxol in treatment for non-small cell lung cancer: a randomized controlled study].
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Neutropenia; Organoplatinum Compounds; Paclitaxel; Prospective Studies; Remission Induction; Survival Analysis; Thrombocytopenia; Treatment Outcome | 2007 |
Prophylactic G-CSF and antibiotics enable a significant dose-escalation of triplet-chemotherapy in non-small cell lung cancer.
Topics: Adult; Aged; Anti-Bacterial Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Carcinoma, Non-Small-Cell Lung; Cisplatin; Female; Granulocyte Colony-Stimulating Factor; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neutropenia; Paclitaxel; Teniposide | 2008 |
Outcome of advanced nonsmall cell lung cancer patients receiving gemcitabine and weekly paclitaxel as first-line treatment.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Gemcitabine; Humans; Lung Neoplasms; Middle Aged; Paclitaxel | 2008 |
A phase II study of biweekly paclitaxel (P) and gemcitabine (G), followed by maintenance weekly paclitaxel in elderly patients with advanced non-small cell lung cancer (NSCLC).
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Neoplasm Staging; Paclitaxel | 2008 |
Toxicity profile and pharmacokinetic study of a phase I low-dose schedule-dependent radiosensitizing paclitaxel chemoradiation regimen for inoperable non-small-cell lung cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Radiation-Sensitizing Agents | 2008 |
Age and comorbidity as independent prognostic factors in the treatment of non small-cell lung cancer: a review of National Cancer Institute of Canada Clinical Trials Group trials.
Topics: Adenocarcinoma; Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Comorbidity; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Prognosis; Prospective Studies; Survival Rate; Vinblastine; Vinorelbine | 2008 |
Outcomes for elderly, advanced-stage non small-cell lung cancer patients treated with bevacizumab in combination with carboplatin and paclitaxel: analysis of Eastern Cooperative Oncology Group Trial 4599.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Female; Humans; Lung Neoplasms; Male; Neoplasm Staging; Paclitaxel; Prognosis; Survival Rate | 2008 |
Neoadjuvant chemotherapy with gemcitabine-containing regimens in patients with early-stage non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Drug Administration Schedule; Feasibility Studies; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Survival Analysis; Time Factors; Treatment Outcome | 2008 |
Phase I study of induction chemotherapy and concomitant chemoradiotherapy with irinotecan, carboplatin, and paclitaxel for stage III non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Dose-Response Relationship, Drug; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Survival Analysis | 2008 |
Phase II trial of gemcitabine/carboplatin followed by paclitaxel in patients with performance status=2,3 or other significant co-morbidity (HIV infection or s/p organ transplantation) in advanced non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Comorbidity; Deoxycytidine; Female; Gemcitabine; HIV Infections; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Organ Transplantation; Paclitaxel | 2008 |
Randomized, phase III study of weekly paclitaxel in combination with carboplatin versus standard every-3-weeks administration of carboplatin and paclitaxel for patients with previously untreated advanced non-small-cell lung cancer.
Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Carcinoma, Non-Small-Cell Lung; Epidermal Cyst; Female; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Paclitaxel; Prognosis; Survival Rate; Treatment Outcome | 2008 |
Phase I/II trial of weekly intravenous 130-nm albumin-bound paclitaxel as initial chemotherapy in patients with stage IV non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Albumins; Anemia; Carcinoma, Non-Small-Cell Lung; Diarrhea; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Neutropenia; Paclitaxel; Peripheral Nervous System Diseases; Survival Rate | 2008 |
Randomized phase II trial of erlotinib or standard chemotherapy in patients with advanced non-small-cell lung cancer and a performance status of 2.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Erlotinib Hydrochloride; Female; Humans; Karnofsky Performance Status; Lung Neoplasms; Male; Paclitaxel; Protein Kinase Inhibitors; Quality of Life; Quinazolines; Surveys and Questionnaires | 2008 |
Feasibility trial of adjuvant chemotherapy with paclitaxel and carboplatin after surgical resection in Japanese patients with non-small cell lung cancer: report of the Lung Oncology Group in Kyushu (LOGIK) protocol 0501.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Asian People; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Drug Administration Schedule; Feasibility Studies; Female; Humans; Japan; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Pneumonectomy; Treatment Outcome | 2008 |
Cell adhesion molecules, vascular endothelial growth factor, and basic fibroblast growth factor in patients with non-small cell lung cancer treated with chemotherapy with or without bevacizumab--an Eastern Cooperative Oncology Group Study.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Disease-Free Survival; E-Selectin; Female; Fibroblast Growth Factor 2; Humans; Intercellular Adhesion Molecule-1; Lung Neoplasms; Male; Paclitaxel; Prospective Studies; Survival Rate; Vascular Endothelial Growth Factor A | 2008 |
Phase I/II study of atrasentan, an endothelin A receptor antagonist, in combination with paclitaxel and carboplatin as first-line therapy in advanced non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Atrasentan; Brain Neoplasms; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Endothelin A Receptor Antagonists; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Prognosis; Pyrrolidines; Survival Rate | 2008 |
Induction chemotherapy with carboplatin, irinotecan, and paclitaxel followed by high dose three-dimension conformal thoracic radiotherapy (74 Gy) with concurrent carboplatin, paclitaxel, and gefitinib in unresectable stage IIIA and stage IIIB non-small ce
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Contraindications; ErbB Receptors; Female; Follow-Up Studies; Gefitinib; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Pneumonectomy; Quinazolines; Radiation-Sensitizing Agents; Radiotherapy, Conformal; Retrospective Studies; Time Factors; Tomography, X-Ray Computed; Treatment Outcome | 2008 |
Complete metabolic tumour response, assessed by 18-fluorodeoxyglucose positron emission tomography (18FDG-PET), after induction chemotherapy predicts a favourable outcome in patients with locally advanced non-small cell lung cancer (NSCLC).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Deoxycytidine; Female; Fluorodeoxyglucose F18; Gemcitabine; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Positron-Emission Tomography; Prognosis; Radiopharmaceuticals; Radiotherapy; Tomography, X-Ray Computed; Treatment Outcome | 2008 |
Phase I and pharmacokinetic study of daily oral AZD2171, an inhibitor of vascular endothelial growth factor tyrosine kinases, in combination with carboplatin and paclitaxel in patients with advanced non-small-cell lung cancer: the National Cancer Institut
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; Female; Hematologic Diseases; Humans; Hypertension; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Protein-Tyrosine Kinases; Quinazolines; Vascular Endothelial Growth Factor Receptor-2 | 2008 |
Phase III trial comparing carboplatin, paclitaxel, and bexarotene with carboplatin and paclitaxel in chemotherapy-naive patients with advanced or metastatic non-small-cell lung cancer: SPIRIT II.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bexarotene; Carboplatin; Carcinoma, Non-Small-Cell Lung; Drug Administration Schedule; Humans; Hypertriglyceridemia; Lung Neoplasms; Male; Middle Aged; Neoplasm Transplantation; Paclitaxel; Survival Analysis; Tetrahydronaphthalenes | 2008 |
Phase I trial of nanoparticle albumin-bound paclitaxel in combination with gemcitabine in patients with thoracic malignancies.
Topics: Adult; Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Deoxycytidine; Esophageal Neoplasms; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Nanoparticles; Paclitaxel; Survival Rate; Treatment Outcome | 2008 |
Phase III trial comparing paclitaxel poliglumex vs docetaxel in the second-line treatment of non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Docetaxel; Drug Administration Schedule; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Patient Selection; Polyglutamic Acid; Quality of Life; Taxoids; Treatment Outcome | 2008 |
[Multi-center randomized clinical study on Shenqi-fuzheng injection combined with chemotherapy in the treatment for lung cancer].
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Drugs, Chinese Herbal; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Medicine, Chinese Traditional; Middle Aged; Paclitaxel; Phytotherapy; Quality of Life; Taxoids; Young Adult | 2007 |
Randomized phase II trial of induction chemotherapy followed by concurrent chemotherapy and dose-escalated thoracic conformal radiotherapy (74 Gy) in stage III non-small-cell lung cancer: CALGB 30105.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Combined Modality Therapy; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Paclitaxel; Placebos; Prognosis; Radiography; Radiotherapy Dosage; Radiotherapy, Conformal; Remission Induction; Survival Rate; Thoracic Neoplasms | 2008 |
A phase II study of carboplatin and paclitacel with meloxicam.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Female; Humans; Lung Neoplasms; Male; Meloxicam; Middle Aged; Paclitaxel; Quality of Life; Thiazines; Thiazoles; Time Factors; Treatment Outcome | 2009 |
Pharmacokinetics of paclitaxel and carboplatin in combination.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Creatinine; Drug Interactions; Humans; Lung Neoplasms; Paclitaxel | 1995 |
Feasibility and pharmacokinetics of paclitaxel, carboplatin, and concurrent radiotherapy for regionally advanced squamous cell carcinoma of the head and neck and for regionally advanced non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Combined Modality Therapy; Drug Administration Schedule; Feasibility Studies; Female; Head and Neck Neoplasms; Humans; Karnofsky Performance Status; Lung Neoplasms; Male; Paclitaxel; Radiotherapy Dosage | 1995 |
Paclitaxel and carboplatin in the treatment of advanced non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Agranulocytosis; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Drug Administration Schedule; Female; Granulocyte Colony-Stimulating Factor; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Thrombocytopenia | 1995 |
Paclitaxel and carboplatin in combination in the treatment of advanced non-small-cell lung cancer: a phase II toxicity, response, and survival analysis.
Topics: Adult; Aged; Aged, 80 and over; Agranulocytosis; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Female; Granulocyte Colony-Stimulating Factor; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Remission Induction; Survival Rate; Thrombocytopenia | 1995 |
Paclitaxel and ifosfamide: a multicenter phase I study in advanced non-small cell lung cancer.
Topics: Adult; Aged; Agranulocytosis; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase II as Topic; Dose-Response Relationship, Drug; Drug Tolerance; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Ifosfamide; Infusions, Intravenous; Injections, Intravenous; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Recombinant Proteins; Remission Induction | 1995 |
Paclitaxel by 24- or 1-hour infusion n combination with carboplatin in advanced non-small cell lung cancer: the Fox Chase Cancer Center experience.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Arthralgia; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Fatigue; Female; Follow-Up Studies; Granulocyte Colony-Stimulating Factor; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Muscle, Skeletal; Neutropenia; Paclitaxel; Peripheral Nervous System Diseases; Remission Induction; Survival Rate; Thrombocytopenia | 1995 |
Four-day paclitaxel infusion with cisplatin for patients with lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Dose-Response Relationship, Drug; Follow-Up Studies; Granulocyte Colony-Stimulating Factor; Humans; Infusions, Intravenous; Injections, Intravenous; Lung Neoplasms; Neoplasm Staging; Neutropenia; Paclitaxel; Remission Induction; Tumor Cells, Cultured | 1995 |
Paclitaxel and carboplatin with and without filgrastim support in patients with metastatic non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase II as Topic; Cohort Studies; Creatinine; Dose-Response Relationship, Drug; Drug Tolerance; Filgrastim; Glomerular Filtration Rate; Granulocyte Colony-Stimulating Factor; Humans; Infusions, Intravenous; Lung Neoplasms; Neutropenia; Paclitaxel; Recombinant Proteins; Remission Induction; Thrombocytopenia | 1995 |
A phase I study of ifosfamide/carboplatin/etoposide/paclitaxel in advanced lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cohort Studies; Drug Tolerance; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Humans; Ifosfamide; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Neutropenia; Paclitaxel; Remission Induction; Thrombocytopenia | 1995 |
Dose-finding and sequencing study of paclitaxel and carboplatin in non-small cell lung cancer.
Topics: Adult; Aged; Alopecia; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; Female; Humans; Infusions, Intravenous; Leukopenia; Lung Neoplasms; Male; Middle Aged; Neutropenia; Paclitaxel; Palliative Care; Vomiting | 1995 |
Phase II study with paclitaxel for the treatment of advanced inoperable non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Neutropenia; Paclitaxel | 1995 |
Concurrent paclitaxel and thoracic radiation for advanced non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Radiotherapy; Radiotherapy Dosage | 1995 |
Dose-finding study of paclitaxel (Taxol) plus cisplatin in patients with non-small cell lung cancer. European Lung Cancer Working Party.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Neutropenia; Paclitaxel | 1995 |
Docetaxel in stage III and IV non-small cell lung cancer.
Topics: Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Docetaxel; Humans; Lung Neoplasms; Middle Aged; Neoplasm Staging; Paclitaxel; Taxoids | 1995 |
Phase III trial (E5592) comparing cisplatin plus etoposide with cisplatin plus paclitaxel at two dose levels for treatment of advanced non-small-cell lung cancer. Eastern Cooperative Oncology Group.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Etoposide; Humans; Lung Neoplasms; Paclitaxel | 1995 |
Paclitaxel as a radiation sensitizer in non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Drug Administration Schedule; Esophagitis; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Radiation-Sensitizing Agents | 1995 |
Paclitaxel by 1-hour infusion: an active drug in metastatic non-small-cell lung cancer.
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Leukopenia; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Remission Induction; Thrombocytopenia | 1995 |
Phase I studies of continuous-infusion paclitaxel given with standard aggressive radiation therapy for locally advanced solid tumors.
Topics: Anemia; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cell Cycle; Combined Modality Therapy; Dose-Response Relationship, Drug; Female; Glioblastoma; Head and Neck Neoplasms; Humans; Infusions, Intravenous; Lung Neoplasms; Lymphopenia; Paclitaxel; Radiation-Sensitizing Agents; Remission Induction; Uterine Cervical Neoplasms | 1995 |
A phase I study of carboplatin and paclitaxel in non-small cell lung cancer: a University of Colorado Cancer Center study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Colorado; Dose-Response Relationship, Drug; Drug Tolerance; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Neutropenia; Paclitaxel; Remission Induction; Safety | 1995 |
Paclitaxel plus carboplatin for advanced lung cancer: preliminary results of a Vanderbilt University phase II trial--LUN-46.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cohort Studies; Disease Progression; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Remission Induction; Survival Rate; Tennessee; Thrombocytopenia | 1995 |
Concurrent paclitaxel/cisplatin with thoracic radiation in patients with stage IIIA/B non-small cell carcinoma of the lung.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Esophagitis; Feasibility Studies; Female; Humans; Infusions, Intravenous; Lung; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Neutropenia; Paclitaxel; Radiotherapy; Radiotherapy Dosage; Remission Induction; Thorax | 1995 |
Phase I study of paclitaxel as a 3-hour infusion followed by carboplatin in untreated patients with stage IV non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Dose-Response Relationship, Drug; Drug Tolerance; Feasibility Studies; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Nausea; Neoplasm Staging; Neutropenia; Paclitaxel; Thrombocytopenia; Vomiting | 1995 |
Preliminary analysis of a phase II study of weekly paclitaxel and concurrent radiation therapy for locally advanced non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Drug Administration Schedule; Drug Tolerance; Esophagitis; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Lymph Nodes; Male; Middle Aged; Neoplasm Staging; Neutropenia; Paclitaxel; Radiotherapy; Radiotherapy Dosage; Remission Induction | 1995 |
Carboplatin/etoposide/radiation plus escalating doses of paclitaxel in stage III non-small cell lung cancer: a preliminary report.
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Drug Tolerance; Etoposide; Feasibility Studies; Female; Humans; Infusions, Intravenous; Injections, Intravenous; Lung Neoplasms; Male; Neoplasm Staging; Paclitaxel; Pneumonectomy; Thorax | 1995 |
Paclitaxel by 1-hour infusion in combination chemotherapy of stage III non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Esophagitis; Etoposide; Follow-Up Studies; Humans; Infusions, Intravenous; Injections, Intravenous; Leukopenia; Lung Neoplasms; Neoplasm Staging; Neutropenia; Paclitaxel; Radiotherapy; Remission Induction | 1995 |
Paclitaxel 3-hour infusion given alone and combined with carboplatin: preliminary results of dose-escalation trials.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Arthralgia; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cohort Studies; Dose-Response Relationship, Drug; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Neutropenia; Paclitaxel; Remission Induction; Sensation Disorders; Thrombocytopenia | 1995 |
[Late phase II trial of RP56976 (Docetaxel) in patients with non-small-cell lung cancer].
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Alopecia; Anorexia; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Docetaxel; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Nausea; Paclitaxel; Taxoids; Vomiting | 1995 |
Phase II trial of a 75-mg/m2 dose of docetaxel with prednisone premedication for patients with advanced non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Docetaxel; Drug Therapy, Combination; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neutropenia; Paclitaxel; Prednisone; Premedication; Survival Rate; Taxoids | 1995 |
Phase II study of docetaxel for advanced or metastatic platinum-refractory non-small-cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents, Phytogenic; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Docetaxel; Drug Hypersensitivity; Drug Resistance; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neutropenia; Paclitaxel; Remission Induction; Survival Rate; Taxoids | 1995 |
Phase II trial of docetaxel in patients with stage III and IV non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Docetaxel; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Taxoids | 1994 |
Phase II study of docetaxel for recurrent or metastatic non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Docetaxel; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Survival Rate; Taxoids | 1994 |
Docetaxel (Taxotere) is active in non-small-cell lung cancer: a phase II trial of the EORTC Early Clinical Trials Group (ECTG)
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Docetaxel; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Taxoids | 1994 |
Paclitaxel administered by 1-hour infusion. Preliminary results of a phase I/II trial comparing two schedules.
Topics: Adult; Aged; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Cimetidine; Dexamethasone; Diphenhydramine; Drug Administration Schedule; Drug Hypersensitivity; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Neoplasms; Ovarian Neoplasms; Paclitaxel; Premedication; Prospective Studies; Remission Induction | 1994 |
[Phase I clinical trial of RP 56976 (docetaxel) a new anticancer drug].
Topics: Adolescent; Adult; Aged; Alopecia; Anorexia; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Docetaxel; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Leukopenia; Lung Neoplasms; Male; Middle Aged; Nausea; Neoplasms; Neutropenia; Paclitaxel; Taxoids | 1994 |
Preliminary results of two dose-finding studies of paclitaxel (Taxol) and carboplatin in non-small cell lung and ovarian cancers: a European Cancer Centre effort.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neutropenia; Ovarian Neoplasms; Paclitaxel | 1994 |
[Early phase II clinical study of RP56976 (docetaxel) in patients with primary pulmonary cancer. Docetaxel Cooperative Study Group for Lung Cancer].
Topics: Adult; Aged; Alopecia; Anorexia; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Docetaxel; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Taxoids; Treatment Outcome | 1994 |
[Late phase II clinical study of RP56976 (docetaxel) in patients with non-small cell lung cancer].
Topics: Adolescent; Adult; Aged; Alopecia; Antineoplastic Agents, Phytogenic; Asthenia; Carcinoma, Non-Small-Cell Lung; Docetaxel; Drug Administration Schedule; Female; Fever; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Remission Induction; Taxoids; Treatment Outcome | 1994 |
Phase I trial of outpatient weekly paclitaxel and concurrent radiation therapy for advanced non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Hypersensitivity; Esophagitis; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Neutropenia; Paclitaxel; Radiotherapy Dosage | 1994 |
Phase II study of taxol in patients with untreated advanced non-small-cell lung cancer.
Topics: Carcinoma, Non-Small-Cell Lung; Cimetidine; Dexamethasone; Diphenhydramine; Drug Administration Schedule; Humans; Lung Neoplasms; Neoplasm Staging; Paclitaxel; Premedication; Remission Induction | 1993 |
Phase II study of taxol, merbarone, and piroxantrone in stage IV non-small-cell lung cancer: The Eastern Cooperative Oncology Group Results.
Topics: Adult; Aged; Aged, 80 and over; Anthraquinones; Antineoplastic Agents; Atrial Fibrillation; Carcinoma, Non-Small-Cell Lung; Drug Administration Schedule; Female; Heart; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Pyrazoles; Remission Induction; Survival Analysis; Thiobarbiturates | 1993 |
Single-agent paclitaxel by 3-hour infusion in the treatment of non-small cell lung cancer: links between p53 and K-ras gene status and chemosensitivity.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Genes, p53; Genes, ras; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Mutation; Paclitaxel; Remission Induction | 1995 |
Paclitaxel and simultaneous radiation in the treatment of stage III A/B non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Drug Administration Schedule; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Pilot Projects; Radiotherapy Dosage; Remission Induction | 1995 |
Phase II trial of a 3-hour infusion of paclitaxel in previously untreated patients with advanced non-small-cell lung cancer.
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Confidence Intervals; Disease-Free Survival; Drug Hypersensitivity; Female; Hematologic Diseases; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Nervous System Diseases; Paclitaxel; Survival Rate; Treatment Outcome | 1996 |
Paclitaxel/cisplatin in advanced non-small-cell lung cancer (NSCLC).
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel | 1995 |
Plasma alcohol concentrations in patients following paclitaxel infusion.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Ethanol; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Neoplasms; Ovarian Neoplasms; Paclitaxel; Pharmaceutical Vehicles; Solvents | 1996 |
Single agent Taxol, 3-hour infusion, in untreated advanced non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Paclitaxel | 1995 |
Paclitaxel in combination chemotherapy with radiotherapy in patients with unresectable stage III non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Pilot Projects; Survival Analysis | 1996 |
Phase II trial of docetaxel in previously untreated advanced non-small-cell lung cancer: a Japanese cooperative study.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Docetaxel; Dose-Response Relationship, Drug; Female; Humans; Japan; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Survival Rate; Taxoids; Treatment Outcome | 1996 |
[Paclitaxel and simultaneous radiotherapy in stage-III non-small-cell bronchial carcinoma].
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Carcinoma, Bronchogenic; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Pilot Projects; Radiation-Sensitizing Agents; Radiotherapy Dosage; Radiotherapy, Adjuvant; Treatment Outcome | 1996 |
[Taxol and simultaneous radiotherapy in stage IIIA and IIIB, locally advanced, non-small-cell bronchial carcinoma. Phase-I clinical trial].
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Bronchial Neoplasms; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Radiation-Sensitizing Agents; Radiotherapy Dosage; Radiotherapy, Adjuvant; Treatment Outcome | 1996 |
Chemotherapy of advanced inoperable non-small cell lung cancer with paclitaxel: a phase II trial.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Disease Progression; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Neutropenia; Paclitaxel; Peripheral Nervous System Diseases; Premedication; Remission Induction | 1995 |
Phase I/II study of paclitaxel plus cisplatin as first-line chemotherapy for advanced non-small cell lung cancer: preliminary results.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Axons; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Dose-Response Relationship, Drug; Feasibility Studies; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Neutropenia; Paclitaxel; Peripheral Nervous System Diseases; Remission Induction | 1995 |
A phase I/II trial of combination paclitaxel and carboplatin in advanced or metastatic non-small cell lung cancer: preliminary results of an ongoing study.
Topics: Aged; Aged, 80 and over; Ambulatory Care; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Arthralgia; Carboplatin; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Remission Induction; Sensation Disorders; Thrombocytopenia | 1995 |
Combined-modality therapy for advanced non-small cell lung cancer: paclitaxel and thoracic irradiation.
Topics: Ambulatory Care; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Cohort Studies; Combined Modality Therapy; Dose-Response Relationship, Drug; Drug Hypersensitivity; Esophagitis; Follow-Up Studies; Humans; Infusions, Intravenous; Lung Neoplasms; Neutropenia; Paclitaxel; Premedication; Radiation Pneumonitis; Radiation-Sensitizing Agents; Radiotherapy Dosage; Radiotherapy, High-Energy; Remission Induction | 1995 |
Paclitaxel in lung cancer: 1-hour infusions given alone or in combination chemotherapy.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cisplatin; Combined Modality Therapy; Drug Administration Schedule; Etoposide; Female; Follow-Up Studies; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Remission Induction | 1995 |
[Early phase II study of BMS-181339 (paclitaxel) in patients with non-small cell lung cancer. BMS-181339 Non-Small Cell Lung Cancer Study Group].
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Drug Administration Schedule; Drug Hypersensitivity; Female; Humans; Infusions, Intravenous; Japan; Leukopenia; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Remission Induction; Taxoids | 1996 |
Severe lymphocytopenia and interstitial pneumonia in patients treated with paclitaxel and simultaneous radiotherapy for non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Drug Administration Schedule; Flow Cytometry; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Lymphocyte Count; Lymphopenia; Middle Aged; Opportunistic Infections; Paclitaxel; Radiotherapy, Adjuvant | 1996 |
[Definitive results of a phase I study of a chemotherapy regimen using cisplatin and paclitaxel for non-small cell bronchial cancer].
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bronchial Neoplasms; Carcinoma, Non-Small-Cell Lung; Cisplatin; Drug Administration Schedule; Female; Heart; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Remission Induction; Sensation Disorders | 1995 |
Ifosfamide-based combination chemotherapy in advanced non-small cell lung cancer: two phase I studies.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Drug Tolerance; Expectorants; Female; Granulocyte Colony-Stimulating Factor; Humans; Ifosfamide; Lung Neoplasms; Male; Mesna; Middle Aged; Neoplasm Staging; Neutropenia; Paclitaxel; Remission Induction; Survival Rate; Vinblastine; Vinorelbine | 1996 |
Paclitaxel plus carboplatin in advanced non-small-cell lung cancer: a phase II trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Survival Rate | 1996 |
Ifosfamide-based chemotherapy for non-small cell lung cancer: phase I/II studies at the University of Chicago.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Female; Humans; Ifosfamide; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Palliative Care; Vinblastine; Vinorelbine | 1996 |
Phase I study of paclitaxel (Taxol) and ifosfamide in previously untreated patients with advanced non-small-cell lung cancer. A study of the National Cancer Institute of Canada Clinical Trials Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Canada; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Hematologic Diseases; Humans; Ifosfamide; Lung Neoplasms; Male; Middle Aged; Paclitaxel | 1996 |
Ifosfamide plus paclitaxel in advanced non-small-cell lung cancer: a phase I study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Dose-Response Relationship, Drug; Drug Administration Schedule; Feasibility Studies; Humans; Ifosfamide; Infusions, Intravenous; Lung Neoplasms; Paclitaxel; Treatment Outcome | 1996 |
p53 mutations do not predict response to paclitaxel/radiation for nonsmall cell lung carcinoma.
Topics: Aged; Antineoplastic Agents, Phytogenic; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Death; Combined Modality Therapy; Exons; Female; Forecasting; Genes, p53; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Paclitaxel; Polymorphism, Single-Stranded Conformational; Radiation-Sensitizing Agents; Remission Induction; Sequence Analysis, DNA | 1996 |
Paclitaxel plus hydroxyurea as second line therapy for non-small cell lung cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; DNA, Neoplasm; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Synergism; Female; Humans; Hydroxyurea; Lung Neoplasms; Male; Middle Aged; Paclitaxel | 1996 |
Preliminary results of a phase I/II clinical trial of paclitaxel and carboplatin in non-small cell lung cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Remission Induction | 1996 |
Results of the phase II EORTC study comparing paclitaxel/cisplatin with teniposide/cisplatin in patients with non-small cell lung cancer. EORTC Lung Cancer Cooperative Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Drug Administration Schedule; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Teniposide | 1996 |
Paclitaxel and cisplatin in patients with non-small cell lung cancer: results of a phase II trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Drug Administration Schedule; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel | 1996 |
Preliminary results of a phase I study of weekly paclitaxel infusion in patients with non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Drug Administration Schedule; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel | 1996 |
Paclitaxel and carboplatin in metastatic non-small cell lung cancer: preliminary results of a phase I study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Drug Administration Schedule; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Lung Neoplasms; Paclitaxel; Recombinant Proteins | 1996 |
A phase II trial of docetaxel in advanced non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Docetaxel; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Taxoids | 1996 |
Pharmacokinetics of paclitaxel and carboplatin in a dose-escalating and dose-sequencing study in patients with non-small-cell lung cancer. The European Cancer Centre.
Topics: Adult; Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Drug Administration Schedule; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neutropenia; Paclitaxel; Survival Analysis | 1997 |
Paclitaxel and carboplatin in nonoperable non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Survival Rate | 1996 |
Simultaneous radiochemotherapy with paclitaxel in non-small cell lung cancer: a clinical phase I study.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Radiation-Sensitizing Agents; Radiotherapy Dosage | 1996 |
The North American experience with paclitaxel combined with cisplatin or carboplatin in lung cancer.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cisplatin; Etoposide; Humans; Lung Neoplasms; Neutropenia; Paclitaxel; Thrombocytopenia; Treatment Outcome | 1996 |
Combination paclitaxel (1-hour) and carboplatin (AUC 7.5) in advanced non-small cell lung cancer: a phase II study by the Fox Chase Cancer Center Network.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Drug Administration Schedule; Drug Tolerance; Female; Granulocyte Colony-Stimulating Factor; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Peripheral Nervous System Diseases | 1996 |
Paclitaxel plus carboplatin in the treatment of patients with advanced lung cancer: a Vanderbilt University Cancer Center phase II trial (LUN-46).
Topics: Adult; Aged; Agranulocytosis; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Arthralgia; Carboplatin; Carcinoma, Non-Small-Cell Lung; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Nausea; Neuralgia; Paclitaxel; Peripheral Nervous System Diseases; Survival Rate; Thrombocytopenia; Treatment Outcome; Vomiting | 1996 |
Phase II study of paclitaxel and cisplatin in patients with non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Nausea; Neutropenia; Paclitaxel; Peripheral Nervous System Diseases; Remission Induction; Thrombocytopenia; Treatment Outcome; Vomiting | 1996 |
Preliminary results of a phase I/II clinical trial of paclitaxel and carboplatin in non-small cell lung cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Drug Administration Schedule; Drug Tolerance; Female; Humans; Infusions, Parenteral; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Peripheral Nervous System Diseases | 1996 |
Phase I/II trial of weekly paclitaxel in patients with advanced lung cancer.
Topics: Alopecia; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Drug Administration Schedule; Drug Eruptions; Drug Tolerance; Humans; Lung Diseases; Lung Neoplasms; Muscular Diseases; Neoplasm Metastasis; Neutropenia; Paclitaxel; Peripheral Nervous System Diseases | 1996 |
Paclitaxel and carboplatin as neoadjuvant chemotherapy in operable (stage I and II) and locally advanced (stage IIIA-N2) non-small cell lung cancer.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Combined Modality Therapy; Drug Administration Schedule; Humans; Infusions, Parenteral; Lung Neoplasms; Paclitaxel; Quality of Life | 1996 |
Paclitaxel and carboplatin in inoperable non-small cell lung cancer.
Topics: Adult; Aged; Alopecia; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Arthralgia; Carboplatin; Carcinoma, Non-Small-Cell Lung; Drug Administration Schedule; Female; Humans; Infusions, Parenteral; Lung Neoplasms; Male; Middle Aged; Muscular Diseases; Neutropenia; Paclitaxel; Peripheral Nervous System Diseases; Survival Rate; Thrombocytopenia; Treatment Outcome | 1996 |
Paclitaxel and carboplatin: a phase I study in advanced non-small cell lung cancer.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Drug Administration Schedule; Female; Humans; Infusions, Parenteral; Lung Neoplasms; Male; Middle Aged; Neutropenia; Paclitaxel; Steroids; Treatment Outcome | 1996 |
Preliminary results of a dose-finding study of paclitaxel and carboplatin in patients with advanced non-small cell lung cancer.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Drug Administration Schedule; Drug Tolerance; Female; Humans; Infusions, Parenteral; Lung Neoplasms; Male; Middle Aged; Neutropenia; Paclitaxel; Thrombocytopenia; Treatment Outcome | 1996 |
Paclitaxel via 1-hour infusion: clinical experience.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Humans; Infusions, Parenteral; Lung Neoplasms; Neoplasms; Paclitaxel | 1996 |
Phase I dose-escalation trial of paclitaxel and ifosfamide in patients with advanced non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Arthralgia; Carcinoma, Non-Small-Cell Lung; Confusion; Dexamethasone; Diphenhydramine; Drug Tolerance; Female; Hematuria; Humans; Ifosfamide; Infusions, Parenteral; Lung Neoplasms; Male; Middle Aged; Muscular Diseases; Neutropenia; Paclitaxel; Paresthesia; Survival Rate; Treatment Outcome | 1996 |
Single-agent paclitaxel as a 3-hour infusion.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Drug Administration Schedule; Female; Humans; Infusions, Parenteral; Leukopenia; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Treatment Outcome | 1996 |
One-hour paclitaxel in the treatment of non-small cell lung cancer.
Topics: Adolescent; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Drug Tolerance; Esophagitis; Humans; Infusions, Parenteral; Lung Neoplasms; Male; Paclitaxel; Peripheral Nervous System Diseases; Survival Rate | 1996 |
Chemoradiotherapy in non-small cell lung cancer: paclitaxel/carboplatin/radiotherapy in regionally advanced disease.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Drug Administration Schedule; Esophagitis; Humans; Lung Neoplasms; Middle Aged; Mucous Membrane; Neutropenia; Paclitaxel; Radiation-Sensitizing Agents; Survival Rate | 1996 |
Paclitaxel plus carboplatin and concurrent radiation therapy for patients with locally advanced non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Drug Administration Schedule; Esophagitis; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Pneumonia; Radiation-Sensitizing Agents; Radiotherapy Dosage; Treatment Outcome | 1996 |
Paclitaxel and simultaneous radiation in locally advanced stage IIIA/B non-small cell lung cancer: a clinical phase I study.
Topics: Adult; Aged; Anti-Allergic Agents; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Clemastine; Combined Modality Therapy; Dexamethasone; Drug Administration Schedule; Drug Hypersensitivity; Drug Tolerance; Female; Histamine H2 Antagonists; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Premedication; Radiation-Sensitizing Agents; Radiotherapy Dosage; Ranitidine; Remission Induction; Treatment Outcome | 1996 |
Weekly paclitaxel with and without concurrent radiation therapy: toxicity, pharmacokinetics, and response.
Topics: Adult; Aged; Aged, 80 and over; Ambulatory Care; Antineoplastic Agents, Phytogenic; Astrocytoma; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Drug Administration Schedule; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Radiation-Sensitizing Agents; Radiotherapy Dosage; Tumor Suppressor Protein p53 | 1996 |
Phase I/II study of paclitaxel and radiotherapy in non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Drug Administration Schedule; Drug Tolerance; Esophagitis; Female; Humans; Infusions, Intravenous; Leukopenia; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Peripheral Nervous System Diseases; Radiation-Sensitizing Agents; Radiotherapy; Radiotherapy Dosage | 1996 |
Effects of polyethylene glycol-conjugated recombinant human megakaryocyte growth and development factor on platelet counts after chemotherapy for lung cancer.
Topics: Adult; Aged; Carboplatin; Carcinoma, Non-Small-Cell Lung; Double-Blind Method; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Platelet Count; Polyethylene Glycols; Recombinant Proteins; Thrombocytopenia; Thrombopoietin | 1997 |
Phase II study of patients with metastatic nonsmall cell carcinoma of the lung treated with paclitaxel by 3-hour infusion.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Quality of Life; Survival Rate | 1997 |
Phase I trial of dose-escalated paclitaxel and carboplatin in combination with ifosfamide and filgrastim: preliminary results.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Carcinoma, Non-Small-Cell Lung; Drug Administration Schedule; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Ifosfamide; Immunoblastic Lymphadenopathy; Lung Neoplasms; Male; Mesothelioma; Paclitaxel; Prostatic Neoplasms; Recombinant Proteins | 1997 |
Intensive radiation therapy concurrent with up to 7-week continuous-infusion paclitaxel for locally advanced solid tumors: phase I studies.
Topics: Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Glioblastoma; Head and Neck Neoplasms; Humans; Infusions, Intravenous; Lung Neoplasms; Paclitaxel; Radiation-Sensitizing Agents; Radiotherapy, Adjuvant; Survival Analysis | 1997 |
Clinical pharmacology of carboplatin administered in combination with paclitaxel.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Carcinoma, Non-Small-Cell Lung; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neutropenia; Ovarian Neoplasms; Paclitaxel | 1997 |
Paclitaxel by 96-hour continuous infusion in combination with cisplatin: a phase I trial in patients with advanced lung cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cisplatin; Disease-Free Survival; Female; Humans; Infusions, Intravenous; Injections, Intravenous; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Treatment Outcome | 1997 |
Phase I trial of docetaxel and cisplatin in previously untreated patients with advanced non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Docetaxel; Drug Administration Schedule; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Taxoids; Treatment Outcome | 1997 |
A phase I investigation of the sequential use of methotrexate and paclitaxel with and without G-CSF for the treatment of solid tumors.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Drug Administration Schedule; Drug Synergism; Granulocyte Colony-Stimulating Factor; Head and Neck Neoplasms; Humans; Infusions, Intravenous; Lung Neoplasms; Methotrexate; Middle Aged; Neoplasms; Paclitaxel | 1996 |
[Effectiveness and hematotoxicity of paclitaxel monotherapy in patients with advanced non-small cell bronchial carcinoma (NSCLC)].
Topics: Aged; Antineoplastic Agents, Phytogenic; Blood Cells; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Prospective Studies | 1997 |
Cisplatin/etoposide vs paclitaxel/cisplatin/G-CSF vs paclitaxel/cisplatin in non-small-cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Etoposide; Granulocyte Colony-Stimulating Factor; Humans; Lung Neoplasms; Paclitaxel | 1997 |
Cisplatin/paclitaxel vs cisplatin/teniposide for advanced non-small-cell lung cancer. The EORTC Lung Cancer Cooperative Group. The European Organization for Research and Treatment of Cancer.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Humans; Lung Neoplasms; Middle Aged; Paclitaxel; Survival; Teniposide; Treatment Outcome | 1997 |
Weekly paclitaxel and cisplatin with concurrent radiotherapy in locally advanced non-small-cell lung cancer: a phase I study.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Cisplatin; Drug Administration Schedule; Esophagitis; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neutropenia; Paclitaxel; Radiotherapy Dosage; Radiotherapy, Adjuvant; Survival Analysis; Treatment Outcome | 1997 |
Phase I studies of gemcitabine combined with carboplatin or paclitaxel.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Ovarian Neoplasms; Paclitaxel; Ribonucleotide Reductases | 1997 |
Phase I study of paclitaxel on a 3-hour schedule followed by carboplatin in untreated patients with stage IV non-small cell lung cancer.
Topics: Aged; Area Under Curve; Carboplatin; Carcinoma, Non-Small-Cell Lung; Drug Administration Schedule; Female; Filgrastim; Glomerular Filtration Rate; Granulocyte Colony-Stimulating Factor; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Recombinant Proteins | 1997 |
A feasibility study of 1-h paclitaxel infusion in patients with solid tumors.
Topics: Aged; Antineoplastic Agents, Phytogenic; Bone Marrow; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Central Nervous System; Dexamethasone; Feasibility Studies; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Ovarian Neoplasms; Paclitaxel; Premedication; Promethazine; Ranitidine; Safety | 1997 |
Phase I study of paclitaxel and oral etoposide in previously untreated non-small-cell and extensive small-cell lung cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel | 1997 |
Phase II study of a one hour paclitaxel infusion in combination with carboplatin for advanced non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Paclitaxel | 1997 |
Single-agent paclitaxel in advanced non-small cell lung cancer: single-center phase II study using a 3-hour administration schedule.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Drug Administration Schedule; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Quality of Life | 1997 |
Weekly paclitaxel in patients with advanced lung cancer: preliminary data from a phase II trial.
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Drug Administration Schedule; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel | 1997 |
Paclitaxel (1-hour infusion) plus carboplatin in the treatment of advanced non-small cell lung cancer: results of a multicenter phase II trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Survival Analysis | 1997 |
Preliminary results of a phase II study of paclitaxel and cisplatin in patients with non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Drug Administration Schedule; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel | 1997 |
Preliminary analysis of a phase II study of paclitaxel, carboplatin, and hyperfractionated radiation therapy for locally advanced inoperable non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Drug Administration Schedule; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Radiotherapy Dosage; Survival Analysis | 1997 |
Paclitaxel by either 1-hour or 24-hour infusion in combination with carboplatin in advanced non-small cell lung cancer: preliminary results comparing sequential phase II trials.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Drug Administration Schedule; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Survival Analysis | 1997 |
Paclitaxel (175 mg/m2) plus carboplatin versus paclitaxel (225 mg/m2) plus carboplatin in non-small cell lung cancer: a randomized study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Prospective Studies; Quality of Life; Survival Analysis | 1997 |
Preliminary results of neoadjuvant paclitaxel and carboplatin in the treatment of early stage non-small cell lung cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Drug Administration Schedule; Feasibility Studies; Female; Humans; Lung Neoplasms; Male; Neoplasm Staging; Paclitaxel; Pneumonectomy; Remission Induction; Survival Analysis; Thoracotomy | 1997 |
Paclitaxel (3-hour infusion) followed by carboplatin (24 hours after paclitaxel): a phase II study in advanced non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Carcinoma, Non-Small-Cell Lung; Drug Administration Schedule; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Quality of Life; Survival Analysis | 1997 |
Paclitaxel/carboplatin chemotherapy as primary treatment of brain metastases in non-small cell lung cancer: a preliminary report.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carboplatin; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Cranial Irradiation; Feasibility Studies; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Treatment Outcome | 1997 |
Second-line treatment of advanced non-small cell lung cancer with paclitaxel and gemcitabine: a preliminary report on an active regimen.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Pilot Projects; Salvage Therapy; Survival Analysis | 1997 |
A sequence-dependent paclitaxel/etoposide phase II trial in patients with non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Drug Administration Schedule; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel | 1997 |
Paclitaxel/carboplatin plus ifosfamide in non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Drug Administration Schedule; Humans; Ifosfamide; Lung Neoplasms; Paclitaxel | 1997 |
Paclitaxel, ifosfamide, and carboplatin for the treatment of stages IIIB and IV non-small cell lung cancer: preliminary results.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Drug Administration Schedule; Female; Humans; Ifosfamide; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel | 1997 |
Ifosfamide/carboplatin/etoposide/paclitaxel in advanced lung cancer: update and preliminary survival analysis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Drug Administration Schedule; Etoposide; Female; Humans; Ifosfamide; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Survival Analysis | 1997 |
Paclitaxel (1-hour) and carboplatin (area under the concentration-time curve 7.5) in advanced non-small cell lung cancer: a phase II study of the Fox Chase Cancer Center and its network.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Carcinoma, Non-Small-Cell Lung; Drug Administration Schedule; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Survival Analysis | 1997 |
Induction paclitaxel and carboplatin followed by concurrent chemoradiotherapy in patients with unresectable, locally advanced non-small cell lung carcinoma: report of Fox Chase Cancer Center study 94-001.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Drug Administration Schedule; Female; Granulocyte Colony-Stimulating Factor; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Radiotherapy Dosage; Survival Analysis | 1997 |
Seven-week continuous-infusion paclitaxel plus concurrent radiation therapy for locally advanced non-small cell lung cancer: a phase I study.
Topics: Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Drug Administration Schedule; Female; Humans; Lung Neoplasms; Male; Paclitaxel; Radiation-Sensitizing Agents; Radiotherapy, High-Energy | 1997 |
Twice-weekly paclitaxel and radiation for stage III non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Drug Administration Schedule; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Radiation-Sensitizing Agents; Radiotherapy Dosage | 1997 |
Weekly paclitaxel/cisplatin with concurrent radiotherapy in patients with locally advanced non-small cell lung cancer: a phase I study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Drug Administration Schedule; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Radiotherapy Dosage; Survival Analysis | 1997 |
Induction therapy with carboplatin/paclitaxel followed by concurrent carboplatin/paclitaxel and dose-escalating conformal radiotherapy in the treatment of locally advanced, unresectable non-small cell lung cancer: preliminary report of a phase I trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Drug Administration Schedule; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Radiotherapy Dosage; Radiotherapy Planning, Computer-Assisted | 1997 |
A phase II study evaluating the efficacy of carboplatin, etoposide, and paclitaxel with granulocyte colony-stimulating factor in patients with stage IIIB and IV non-small cell lung cancer and extensive small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Etoposide; Granulocyte Colony-Stimulating Factor; Humans; Lung Neoplasms; Neoplasm Staging; Paclitaxel; Pilot Projects | 1997 |
Docetaxel (Taxotere) and vinorelbine in the treatment of advanced non-small cell lung cancer: preliminary results of a phase I/II trial.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Docetaxel; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Taxoids; Vinblastine; Vinorelbine | 1997 |
The development of docetaxel (Taxotere) in non-small cell lung cancer--docetaxel in new combinations and new schedules: an overview of ongoing and future developments.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Docetaxel; Humans; Lung Neoplasms; Paclitaxel; Taxoids | 1997 |
Docetaxel (Taxotere) and gemcitabine in the treatment of non-small cell lung cancer: preliminary results.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Taxoids | 1997 |
Clinical studies of docetaxel (Taxotere) and concomitant chest therapy.
Topics: Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Docetaxel; Female; Humans; Lung Neoplasms; Male; Paclitaxel; Radiation Dosage; Research Design; Taxoids; Thorax | 1997 |
The role of docetaxel (Taxotere) as a single agent or in combination before local treatment of non-small cell lung cancer.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials as Topic; Combined Modality Therapy; Docetaxel; Humans; Lung Neoplasms; Paclitaxel; Taxoids | 1997 |
Neurological monitoring of neurotoxicity induced by paclitaxel/cisplatin chemotherapy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Dose-Response Relationship, Drug; Electrophysiology; Female; Humans; Longitudinal Studies; Lung Neoplasms; Male; Middle Aged; Ovarian Neoplasms; Paclitaxel; Peripheral Nervous System Diseases; Vibration | 1997 |
Dose-escalation study of weekly 1-hour paclitaxel administration in patients with refractory cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Drug Administration Schedule; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasms; Paclitaxel | 1997 |
A phase I/II study of paclitaxel (TAXOL) and concurrent radiotherapy in advanced nonsmall cell lung cancer.
Topics: Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Drug Administration Schedule; Humans; Lung Neoplasms; Lymphopenia; Paclitaxel | 1997 |
Phase I trial of weekly paclitaxel in advanced lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Drug Administration Schedule; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Nervous System Diseases; Neutropenia; Paclitaxel | 1998 |
Phase I study of docetaxel with concomitant thoracic radiation therapy.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Bone Marrow; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Docetaxel; Drug Administration Schedule; Esophageal Neoplasms; Esophagitis; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Radiotherapy Dosage; Taxoids; Treatment Outcome | 1998 |
Population pharmacokinetics/pharmacodynamics of docetaxel in phase II studies in patients with cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Area Under Curve; Bayes Theorem; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Docetaxel; Edema; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasms; Neutropenia; Paclitaxel; Prospective Studies; Taxoids | 1998 |
Phase I study of paclitaxel as a radiation sensitizer in the treatment of mesothelioma and non-small-cell lung cancer.
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Mesothelioma; Middle Aged; Paclitaxel; Pleural Neoplasms; Radiation-Sensitizing Agents; Radiotherapy Dosage | 1998 |
A phase I study of paclitaxel in combination with etoposide in patients with stage IIIB/IV non-small cell lung cancer (NSCLC).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; Drug Administration Schedule; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel | 1998 |
One-hour paclitaxel plus carboplatin for advanced non-small-cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Drug Administration Schedule; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Treatment Outcome | 1998 |
Ifosfamide-based three-drug combination regimens in non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Granulocyte Colony-Stimulating Factor; Humans; Ifosfamide; Lung Neoplasms; Paclitaxel; Vinblastine; Vinorelbine | 1998 |
Phase I study of paclitaxel and etoposide for metastatic or recurrent malignancies.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Drug Administration Schedule; Etoposide; Female; Filgrastim; Germinoma; Granulocyte Colony-Stimulating Factor; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Recombinant Proteins | 1998 |
Phase II study of docetaxel and cisplatin in advanced non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Disease Progression; Docetaxel; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Survival Rate; Taxoids | 1998 |
First-line treatment of advanced non-small-cell lung cancer with docetaxel and cisplatin: a multicenter phase II study.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Docetaxel; Female; Granulocyte Colony-Stimulating Factor; Hematologic Diseases; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Severity of Illness Index; Survival Rate; Taxoids; Treatment Outcome | 1998 |
Randomized study of paclitaxel-cisplatin versus cisplatin-teniposide in patients with advanced non-small-cell lung cancer. The European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Quality of Life; Random Allocation; Survival Rate; Teniposide; Treatment Outcome | 1998 |
Phase II study of paclitaxel (Taxol) and ifosfamide (Holoxan) in inoperable non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Female; Humans; Ifosfamide; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel | 1998 |
A phase I-II study of paclitaxel, ifosfamide, and vinorelbine with filgrastim (rhG-CSF) support in advanced non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; Female; Filgrastim; Follow-Up Studies; Granulocyte Colony-Stimulating Factor; Humans; Ifosfamide; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Recombinant Proteins; Survival Rate; Vinblastine; Vinorelbine | 1998 |
Phase II trial of intrapleural paclitaxel injection for non-small-cell lung cancer patients with malignant pleural effusions.
Topics: Aged; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Drainage; Female; Humans; Injections; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Pleural Effusion, Malignant; Treatment Outcome | 1998 |
New chemotherapy combinations with docetaxel in the treatment of patients with non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Docetaxel; Female; Granulocyte Colony-Stimulating Factor; Humans; Ifosfamide; Lenograstim; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Recombinant Proteins; Taxoids | 1998 |
Combined modality therapy in non-small cell lung and esophageal cancer: a phase I dose-escalation study of docetaxel with concurrent radiotherapy.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Docetaxel; Esophageal Neoplasms; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Taxoids | 1998 |
Paclitaxel (Taxol) and carboplatin followed by concomitant paclitaxel, cisplatin and radiotherapy for inoperable stage III NSCLC.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Confidence Intervals; Dose Fractionation, Radiation; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Survival Rate | 1998 |
One-hour paclitaxel plus carboplatin in the treatment of advanced non-small cell lung cancer: results of a multicentre, phase II trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Treatment Outcome | 1998 |
Paclitaxel, cisplatin, etoposide combination chemotherapy: a multifractionated bolus dose schedule for non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Dose Fractionation, Radiation; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neutropenia; Paclitaxel; Survival Analysis; Treatment Outcome | 1998 |
Phase II trial of weekly paclitaxel and concurrent radiation therapy for locally advanced non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Drug Administration Schedule; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Prospective Studies; Survival Analysis | 1998 |
Phase I study of paclitaxel (taxol) and granulocyte colony stimulating factor (G-CSF) in patients with unresectable malignancy.
Topics: Adult; Aged; Anemia; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Female; Granulocyte Colony-Stimulating Factor; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Melanoma; Middle Aged; Neutropenia; Paclitaxel | 1998 |
A comparison of the costs of paclitaxel and best supportive care in stage IV non-small-cell lung cancer.
Topics: Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Cost-Benefit Analysis; Health Care Costs; Humans; Lung Neoplasms; Neoplasm Staging; Paclitaxel | 1997 |
Phase I trial of a 96 h paclitaxel infusion with filgrastim support in refractory solid tumor patients.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Chromatography, High Pressure Liquid; Clinical Trials, Phase I as Topic; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Lung Neoplasms; Male; Melanoma; Middle Aged; Neoplasms; Paclitaxel; Recombinant Proteins; Skin Neoplasms; Time Factors | 1998 |
Multiinstitutional phase II trial of paclitaxel, carboplatin, and concurrent radiation therapy for locally advanced non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Disease-Free Survival; Esophagitis; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Radiation-Sensitizing Agents; Treatment Failure | 1998 |
Preliminary result of phase II study of paclitaxel and cisplatin chemotherapy for advanced non-small-cell lung cancer in Chinese patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; China; Cisplatin; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Treatment Outcome | 1998 |
Risk of severe acute hypersensitivity reactions after rapid paclitaxel infusion of less than 1-h duration.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Ovarian Neoplasms; Paclitaxel; Pilot Projects | 1998 |
Weekly docetaxel and concomitant boost radiotherapy for non-small cell lung cancer. A phase I/II dose escalation trial.
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Docetaxel; Dose-Response Relationship, Drug; Drug Hypersensitivity; Hematologic Diseases; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Radiation-Sensitizing Agents; Radiotherapy; Taxoids; Treatment Outcome | 1998 |
Paclitaxel and carboplatin in combination in the treatment of advanced non-small-cell lung cancer (NSCLC): a preliminary study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Carcinoma, Non-Small-Cell Lung; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Pilot Projects; Treatment Outcome | 1998 |
A phase I trial of paclitaxel plus carboplatin in untreated patients with advanced non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Survival Analysis | 1997 |
Optimal sampling strategies for bayesian estimation of docetaxel (Taxotere) clearance.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bayes Theorem; Carcinoma, Non-Small-Cell Lung; Cisplatin; Docetaxel; Humans; Infusions, Intravenous; Likelihood Functions; Lung Neoplasms; Metabolic Clearance Rate; Neoplasms; Paclitaxel; Prospective Studies; Sampling Studies; Specimen Handling; Taxoids | 1997 |
Phase II study of 3-hour infusion of paclitaxel in previously untreated non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Paclitaxel | 1996 |
First-line treatment of advanced nonsmall cell lung carcinoma with docetaxel and vinorelbine.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Docetaxel; Female; Granulocyte Colony-Stimulating Factor; Humans; Lung Neoplasms; Male; Middle Aged; Neutropenia; Paclitaxel; Patient Compliance; Recombinant Proteins; Survival Analysis; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 1998 |
Superiority of sequential versus concurrent administration of paclitaxel with etoposide in advanced non-small cell lung cancer: comparison of two Phase II trials.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Drug Administration Schedule; Etoposide; Female; Humans; Lung Neoplasms; Middle Aged; Paclitaxel; Treatment Outcome | 1998 |
Salvage treatment with paclitaxel and gemcitabine for patients with non-small-cell lung cancer after cisplatin- or docetaxel-based chemotherapy: a multicenter phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Salvage Therapy; Survival Analysis | 1998 |
Phase I study of docetaxel dose escalation in combination with fixed weekly gemcitabine in patients with advanced malignancies.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Taxoids; Treatment Outcome | 1998 |
Combination chemotherapy with docetaxel, vinorelbine and cisplatin as first-line treatment of advanced non-small-cell lung cancer: a multicenter phase II study of the Greek Cooperative Group for Lung Cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Docetaxel; Drug Administration Schedule; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Patient Compliance; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 1998 |
Induction combination chemotherapy with docetaxel and carboplatin in advanced non-small-cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Docetaxel; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Taxoids; Time Factors; Treatment Outcome | 1998 |
Docetaxel and granulocyte colony-stimulating factor in patients with advanced non-small-cell lung cancer previously treated with platinum-based chemotherapy: a multicenter phase II trial.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Cisplatin; Docetaxel; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Granulocyte Colony-Stimulating Factor; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Recombinant Proteins; Survival Analysis; Taxoids | 1999 |
Concurrent twice-a-week docetaxel and radiotherapy: a dose escalation trial with immunological toxicity evaluation.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Docetaxel; Dose Fractionation, Radiation; Drug Administration Schedule; Feasibility Studies; Female; Glioblastoma; Humans; Lung Neoplasms; Lymphocytes; Lymphopenia; Male; Middle Aged; Neoplasms; Neutropenia; Paclitaxel; Pelvic Neoplasms; Radiation-Sensitizing Agents; Radiotherapy; Survival Analysis; Taxoids; Treatment Outcome | 1999 |
The multifractionated, twice-weekly dose schedule for a three-drug chemotherapy regimen: a phase I-II study of paclitaxel, cisplatin, and vinorelbine.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Cohort Studies; Drug Administration Schedule; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neutropenia; Paclitaxel; Vinblastine; Vinorelbine | 1999 |
Docetaxel (Taxotere) plus cisplatin: an active and well-tolerated combination in patients with advanced non-small cell lung cancer.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Docetaxel; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neutropenia; Paclitaxel; Survival Rate; Taxoids; Treatment Outcome | 1998 |
Front-line treatment of advanced non-small-cell lung cancer with docetaxel and gemcitabine: a multicenter phase II trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Female; Gemcitabine; Hematologic Diseases; Humans; Lung Neoplasms; Male; Middle Aged; Nausea; Paclitaxel; Survival Analysis; Taxoids | 1999 |
Phase I trial, including pharmacokinetic and pharmacodynamic correlations, of combination paclitaxel and carboplatin in patients with metastatic non-small-cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; Humans; Lung Neoplasms; Neoplasm Metastasis; Paclitaxel | 1999 |
Second-line chemotherapy with 96-hour infusional paclitaxel in refractory non-small cell lung cancer: report of a phase II trial.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Disease Progression; Drug Administration Schedule; Female; Humans; Infusion Pumps; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Quality of Life; Retreatment; Survival Rate | 1999 |
A single 24-hour plasma sample does not predict the carboplatin AUC from carboplatin-paclitaxel combinations or from a high-dose carboplatin-thiotepa-cyclophosphamide regimen.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cyclophosphamide; Humans; Lung Neoplasms; Middle Aged; Paclitaxel; Retrospective Studies; Thiotepa | 1999 |
Phase I/II trial of paclitaxel by 1-hour infusion, carboplatin, and gemcitabine in the treatment of patients with advanced nonsmall cell lung carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Survival Rate | 1999 |
Single-agent paclitaxel and radiation for non-small cell lung cancer.
Topics: Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Confidence Intervals; Female; Humans; Lung Neoplasms; Male; Neoplasm Staging; Paclitaxel; Radiation-Sensitizing Agents; Survival Analysis; Treatment Outcome | 1999 |
Esophagitis in combined modality therapy for locally advanced non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Esophagitis; Female; Humans; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Paclitaxel; Prospective Studies; Radiotherapy; Survival Analysis | 1999 |
Seven-week continuous-infusion paclitaxel concurrent with radiation therapy for locally advanced non-small cell lung and head and neck cancers.
Topics: Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Combined Modality Therapy; Female; Head and Neck Neoplasms; Home Infusion Therapy; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Paclitaxel; Radiation-Sensitizing Agents | 1999 |
Paclitaxel and concurrent radiotherapy in locally advanced non-small cell lung cancer: the Canadian experience.
Topics: Canada; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Paclitaxel; Radiation-Sensitizing Agents; Survival Analysis; Treatment Outcome | 1999 |
Concurrent chemoradiation using paclitaxel and carboplatin in locally advanced non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Female; Granulocyte Colony-Stimulating Factor; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Survival Analysis | 1999 |
Concurrent twice-weekly paclitaxel and thoracic irradiation for stage III non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Radiation-Sensitizing Agents; Survival Analysis | 1999 |
A pilot clinical laboratory trial of paclitaxel and endobronchial brachytherapy in patients with non-small cell lung cancer.
Topics: Aged; Antineoplastic Agents, Phytogenic; Brachytherapy; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Female; Granulocyte Colony-Stimulating Factor; Humans; Immunohistochemistry; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Pilot Projects; Radiation-Sensitizing Agents; Survival Analysis; Treatment Outcome | 1999 |
Daily paclitaxel and thoracic radiation therapy for non-small cell lung cancer: preliminary results.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Drug Administration Schedule; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Radiation-Sensitizing Agents | 1999 |
Phase I/IIa study of concurrent paclitaxel and cisplatin with radiation therapy in locally advanced non-small cell lung cancer: analysis of early and late pulmonary morbidity.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Dose-Response Relationship, Radiation; Female; Humans; Lung Neoplasms; Lymphopenia; Male; Paclitaxel; Respiratory Function Tests; Statistics, Nonparametric; Survival Rate | 1999 |
Paclitaxel steady-state plasma concentration as a determinant of disease outcome and toxicity in lung cancer patients treated with paclitaxel and cisplatin.
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Cisplatin; Demography; Dose-Response Relationship, Drug; Female; Humans; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Paclitaxel; Treatment Outcome | 1999 |
Cisplatin-topotecan-paclitaxel weekly administration with G-CSF support for ovarian and small-cell lung cancer patients: a dose-finding study.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Granulocyte Colony-Stimulating Factor; Humans; Lung Neoplasms; Male; Middle Aged; Ovarian Neoplasms; Paclitaxel; Prognosis; Topotecan; Treatment Outcome | 1999 |
Cost-effectivenes of paclitaxel plus cisplatin in advanced non-small-cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Canada; Carcinoma, Non-Small-Cell Lung; Cisplatin; Cost-Benefit Analysis; Humans; Lung Neoplasms; Paclitaxel; Retrospective Studies; Sensitivity and Specificity; Survival Analysis | 1999 |
[Evaluation of chemotherapy with docetaxel and cisplatin in advanced non-small cell lung cancer].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Docetaxel; Drug Administration Schedule; Drug Evaluation; Granulocyte Colony-Stimulating Factor; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Taxoids | 1999 |
Docetaxel (Taxotere) in combination with vinorelbine in non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Docetaxel; Female; Granulocyte Colony-Stimulating Factor; Humans; Lung Neoplasms; Male; Paclitaxel; Survival Analysis; Taxoids; Vinblastine; Vinorelbine | 1999 |
Treatment with paclitaxel 1-h infusion and carboplatin of patients with advanced non-small-cell lung cancer: a phase II multicentre trial. Joint Lung Cancer Study Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Survival Rate; Treatment Outcome | 1999 |
The use of docetaxel (Taxotere) in patients with advanced non-small cell lung cancer previously treated with platinum-containing chemotherapy regimens.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Docetaxel; Humans; Ifosfamide; Lung Neoplasms; Paclitaxel; Platinum Compounds; Quality of Life; Sickness Impact Profile; Survival Analysis; Taxoids; Vinblastine; Vinorelbine | 1999 |
Overview of docetaxel (Taxotere)/cisplatin combination in non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Docetaxel; Drug Administration Schedule; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Survival Analysis; Taxoids | 1999 |
Phase I/II dose finding study of paclitaxel and carboplatin in advanced non-small cell lung cancer.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Neutropenia; Paclitaxel; Survival Analysis; Treatment Outcome | 1999 |
Concurrent conventionally factionated radiotherapy and weekly docetaxel in the treatment of stage IIIb non-small-cell lung carcinoma.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Asthenia; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Docetaxel; Dose Fractionation, Radiation; Esophagitis; Female; Humans; Lung Neoplasms; Lymphopenia; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Radiotherapy; Survival Analysis; Taxoids | 1999 |
Preliminary analysis of a phase II study of Paclitaxel and CHART in locally advanced non-small cell lung cancer.
Topics: Adolescent; Adult; Aged; Biopsy; Carcinoma, Non-Small-Cell Lung; Dose Fractionation, Radiation; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Radiation Injuries; Radiation-Sensitizing Agents; Radiodermatitis; Retrospective Studies | 1999 |
Is there any impact of new drugs on the outcome of advanced NSCLC? An overview of the Southern Italy Cooperative Oncology Group trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Lung Neoplasms; Paclitaxel; Survival Rate; Vinblastine; Vinorelbine | 1999 |
Gemcitabine and paclitaxel: pharmacokinetic and pharmacodynamic interactions in patients with non-small-cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cells, Cultured; Deoxycytidine; Dose-Response Relationship, Drug; Drug Interactions; Female; Gemcitabine; Humans; In Vitro Techniques; Infusions, Intravenous; Leukocytes, Mononuclear; Linear Models; Lung Neoplasms; Male; Metabolic Clearance Rate; Middle Aged; Paclitaxel; Statistics, Nonparametric | 1999 |
Cisplatin, gemcitabine, and paclitaxel in locally advanced or metastatic non-small-cell lung cancer: a phase I-II study. Southern Italy Cooperative Oncology Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gemcitabine; Humans; Italy; Lung Neoplasms; Male; Middle Aged; Neutropenia; Paclitaxel; Vomiting | 1999 |
Paclitaxel, gemcitabine, and cisplatin in non-resectable non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neutropenia; Paclitaxel; Time Factors | 1999 |
Combination chemotherapy with carboplatin, docetaxel, and gemcitabine in advanced non-small-cell lung cancer: a phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Taxoids; Treatment Outcome | 1999 |
Docetaxel (Taxotere) in the neo-adjuvant setting in non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Disease Progression; Docetaxel; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Taxoids; Treatment Outcome | 1999 |
Phase II study of paclitaxel and carboplatin for advanced non-small-cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Pilot Projects; Prospective Studies | 1999 |
Activity of docetaxel in platinum-treated non-small-cell lung cancer: results of a phase II multicenter trial.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Cisplatin; Docetaxel; Drug Resistance, Neoplasm; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Survival Analysis; Taxoids | 2000 |
Comparison of survival and quality of life in advanced non-small-cell lung cancer patients treated with two dose levels of paclitaxel combined with cisplatin versus etoposide with cisplatin: results of an Eastern Cooperative Oncology Group trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Disease-Free Survival; Drug Administration Schedule; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Quality of Life; Treatment Failure | 2000 |
Phase II trial of induction high-dose chemotherapy followed by surgical resection and radiation therapy for patients with marginally resectable non-small cell carcinoma of the lung.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Combined Modality Therapy; Disease Progression; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Thoracotomy; Treatment Outcome | 2000 |
Phase I study of cisplatin and docetaxel plus mitomycin C in patients with metastatic non-small cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Hyponatremia; Lung Neoplasms; Male; Middle Aged; Mitomycin; Neutropenia; Paclitaxel; Taxoids | 1999 |
A phase I-II study of gemcitabine and paclitaxel in advanced non-small-cell lung cancer patients.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Gemcitabine; Humans; Lung Neoplasms; Neoplasm Staging; Paclitaxel | 2000 |
Induction chemotherapy before surgery for early-stage lung cancer: A novel approach. Bimodality Lung Oncology Team.
Topics: Adult; Aged; Antineoplastic Agents; Carboplatin; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Feasibility Studies; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Postoperative Care; Preoperative Care; Prospective Studies | 2000 |
Combination chemotherapy with paclitaxel plus carboplatin versus paclitaxel plus gemcitabine in inoperable non-small cell lung cancer: a phase III randomized study. Preliminary results. Hellenic Cooperative Oncology Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Survival Analysis | 2000 |
Phase II trial evaluating triplet chemotherapy using gemcitabine, paclitaxel, and carboplatin in the treatment of patients with advanced non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Gemcitabine; Humans; Lung Neoplasms; Paclitaxel; Survival Analysis | 2000 |
A multicenter, randomized, phase III study of docetaxel plus best supportive care versus best supportive care in chemotherapy-naive patients with metastatic or non-resectable localized non-small cell lung cancer (NSCLC).
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Area Under Curve; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Docetaxel; Europe; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Mexico; Middle Aged; Paclitaxel; Palliative Care; Quality of Life; Survival Analysis; Taxoids; United States | 2000 |
Phase I trial of docetaxel and vinorelbine in patients with advanced nonsmall cell lung carcinoma.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Docetaxel; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Recombinant Proteins; Taxoids; Vinblastine; Vinorelbine | 2000 |
Paclitaxel/ifosfamide or navelbine/ifosfamide chemotherapy for advanced non-small cell lung cancer: CALGB 9532.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Female; Humans; Ifosfamide; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Survival Rate; Treatment Outcome; Vinblastine; Vinorelbine | 2000 |
Phase II study of concurrent chemoradiotherapy for inoperable (bulky) stage III (A/B) non-small cell lung cancer (NSCLC): a preliminary report.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Palliative Care; Prognosis; Radiotherapy, Adjuvant; Survival Rate | 2000 |
Phase II trial of docetaxel and vinorelbine in patients with advanced non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Docetaxel; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Proto-Oncogene Mas; Recombinant Proteins; Survival Analysis; Taxoids; Vinblastine; Vinorelbine | 2000 |
Paclitaxel by 1-h infusion in combination with carboplatin in advanced non-small cell lung carcinoma (NSCLC).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cohort Studies; Dose-Response Relationship, Drug; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Survival Rate | 2000 |
[Efficacy of docetaxel in non-small cell lung cancer patients previously treated with platinum-containing chemotherapy. French Group of Pneumo-Cancerology].
Topics: Adenocarcinoma; Adult; Aged; Anti-Inflammatory Agents; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Diosmin; Docetaxel; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neutropenia; Paclitaxel; Prednisolone; Premedication; Taxoids; Time Factors | 2000 |
Phase II study of docetaxel alternating with cisplatin in chemotherapy-naïve patients with advanced non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Docetaxel; Drug Administration Schedule; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Taxoids; Treatment Outcome | 2000 |
Docetaxel in combination with carboplatin for the treatment of advanced non-small cell lung carcinoma: a multicentre phase I study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Docetaxel; Dose-Response Relationship, Drug; Female; Hematologic Diseases; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Taxoids | 2000 |
Paclitaxel in advanced non-small cell lung cancer : an alternative high-dose weekly schedule.
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Nervous System Diseases; Neutropenia; Paclitaxel; Platelet Count; Radiation-Sensitizing Agents | 2000 |
[Phase II study of docetaxel in inoperable advanced non small cell lung cancer].
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Docetaxel; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Taxoids | 2000 |
Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chi-Square Distribution; Cisplatin; Disease Progression; Docetaxel; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Palliative Care; Proportional Hazards Models; Prospective Studies; Quality of Life; Survival Analysis; Taxoids; Treatment Outcome | 2000 |
A phase I trial of docetaxel and gemcitabine in patients with advanced cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasms; Paclitaxel; Taxoids; Treatment Outcome | 2000 |
A phase II study of docetaxel and vinorelbine combination chemotherapy in patients with advanced non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Docetaxel; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Neutropenia; Paclitaxel; Survival Rate; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2000 |
Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group.
Topics: Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; Docetaxel; Drug Resistance, Neoplasm; Female; Humans; Ifosfamide; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Survival Analysis; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2000 |
Phase II trial of docetaxel in Asian patients with inoperable stage III non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Dexamethasone; Docetaxel; Female; Fever; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Neutropenia; Paclitaxel; Taxoids; Treatment Outcome; Water-Electrolyte Balance | 2000 |
A phase II study of paclitaxel, carboplatin, and hyperfractionated radiation therapy for locally advanced inoperable non-small-cell lung cancer (a Vanderbilt Cancer Center Affiliate Network Study).
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Disease Progression; Dose Fractionation, Radiation; Drug Administration Schedule; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Prospective Studies; Radiation-Sensitizing Agents; Survival Rate | 2000 |
Randomized trial of paclitaxel plus supportive care versus supportive care for patients with advanced non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Disease Progression; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Proportional Hazards Models; Quality of Life; Survival Analysis; Treatment Outcome | 2000 |
The cost-effectiveness of paclitaxel (Taxol) + cisplatin is similar to that of teniposide + cisplatin in advanced non-small cell lung cancer: a multicountry analysis.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Belgium; Carcinoma, Non-Small-Cell Lung; Cisplatin; Cost-Benefit Analysis; Costs and Cost Analysis; France; Humans; Lung Neoplasms; Netherlands; Paclitaxel; Spain; Teniposide | 1999 |
Phase II study of paclitaxel and epirubicin as first-line treatment in patients with metastatic nonsmall cell lung carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; Epirubicin; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Treatment Outcome; Ventricular Fibrillation | 2000 |
Phase II trial of paclitaxel by 96-hour continuous infusion in combination with cisplatin for patients with advanced non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Disease-Free Survival; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Survival Rate | 2000 |
Weekly docetaxel in the treatment of elderly patients with advanced nonsmall cell lung carcinoma. A Minnie Pearl Cancer Research Network Phase II Trial.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Docetaxel; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Paclitaxel; Survival Analysis; Taxoids | 2000 |
[A phase II clinical study of China-made paclitaxel in the treatment of cancer patients].
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Female; Humans; Lung Neoplasms; Male; Middle Aged; Nasopharyngeal Neoplasms; Neutropenia; Ovarian Neoplasms; Paclitaxel | 1998 |
Treatment of patients with advanced nonsmall cell lung carcinoma using docetaxel and gemcitabine plus granulocyte-colony stimulating factor.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Female; Gemcitabine; Granulocyte Colony-Stimulating Factor; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Survival Analysis; Taxoids | 2000 |
Induction carboplatin/paclitaxel followed by concurrent carboplatin/paclitaxel and dose-escalating conformal thoracic radiation therapy in unresectable stage IIIA/B nonsmall cell lung carcinoma: a modified Phase I trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Radiotherapy Dosage; Radiotherapy, Conformal; Survival Analysis; Treatment Failure | 2000 |
Multicenter phase II trial of docetaxel and carboplatin in patients with stage IIIB and IV non-small-cell lung cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Dexamethasone; Docetaxel; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Survival Analysis; Taxoids; Treatment Outcome | 2000 |
Salvage treatment of advanced non-small-cell lung cancer previously treated with docetaxel-based front-line chemotherapy with irinotecan (CPT-11) in combination with cisplatin.
Topics: Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Docetaxel; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Salvage Therapy; Survival Analysis; Taxoids; Treatment Outcome | 2000 |
Phase I and pharmacologic study of docetaxel and irinotecan in advanced non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Camptothecin; Carcinoma, Non-Small-Cell Lung; Chi-Square Distribution; Disease-Free Survival; Docetaxel; Female; Humans; Irinotecan; Lung Neoplasms; Male; Maximum Tolerated Dose; Microtubules; Middle Aged; Neoplasm Staging; Neutropenia; Paclitaxel; Taxoids; Topoisomerase I Inhibitors; Treatment Outcome | 2000 |
A phase II study of paclitaxel-ifosfamide-cisplatin combination in advanced nonsmall cell lung carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Female; Humans; Ifosfamide; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Patient Compliance; Survival Analysis; Treatment Outcome | 2000 |
Phase I study of paclitaxel and day 1/day 8 gemcitabine in patients with solid malignancies.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Colonic Neoplasms; Deoxycytidine; Diarrhea; Esophageal Neoplasms; Exanthema; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Nausea; Neoplasm Staging; Neoplasms, Unknown Primary; Neutropenia; Paclitaxel; Pancreatic Neoplasms; Paresthesia; Urinary Bladder Neoplasms; Vomiting | 2000 |
Gemcitabine, paclitaxel, and carboplatin for advanced non-small-cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Deoxycytidine; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Leukocyte Count; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Platelet Count | 2000 |
Interim analysis of a phase III trial. Triple- vs double-agent chemotherapy for advanced non-small-cell lung cancer. Southern Italy Cooperative Oncology Group.
Topics: Actuarial Analysis; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Patient Compliance; Proportional Hazards Models; Research Design; Survival Analysis; Treatment Outcome; Vinblastine; Vinorelbine | 2000 |
Interim results of a phase III trial. Paclitaxel/carboplatin vs paclitaxel/gemcitabine in advanced non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neutropenia; Paclitaxel; Thrombocytopenia | 2000 |
Retrospective comparison of toxicity and efficacy in phase II trials of 3-h infusions of paclitaxel for patients 70 years of age or older and patients under 70 years of age.
Topics: Age Factors; Aged; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Comorbidity; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Neoplasm Staging; Paclitaxel; Retrospective Studies; Safety; Survival Rate | 2000 |
Phase I/II trial of irinotecan, carboplatin, and paclitaxel in advanced or metastatic NSCLC.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Drug Administration Schedule; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Remission Induction; Survival Analysis | 2000 |
Phase II study of docetaxel in the treatment of patients with advanced non-small cell lung cancer in routine daily practice.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Docetaxel; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Survival Analysis; Taxoids; Treatment Outcome | 2000 |
Paclitaxel (175 mg/m2) plus carboplatin (6 AUC) versus paclitaxel (225 mg/m2) plus carboplatin (6 AUC) in advanced non-small-cell lung cancer (NSCLC): a multicenter randomized trial. Hellenic Cooperative Oncology Group (HeCOG).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Leukopenia; Lung Neoplasms; Male; Middle Aged; Nervous System Diseases; Paclitaxel; Prognosis; Survival Analysis; Treatment Outcome | 2000 |
Phase I and pharmacologic study of weekly gemcitabine and paclitaxel in chemo-naïve patients with advanced non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Paclitaxel | 2000 |
A phase I/II trial of paclitaxel, carboplatin, and gemcitabine in untreated patients with advanced non-small cell lung cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neutropenia; Paclitaxel; Thrombocytopenia | 2000 |
Phase III comparative study of high-dose cisplatin versus a combination of paclitaxel and cisplatin in patients with advanced non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Quality of Life; Survival Analysis | 2000 |
Dose-finding study of paclitaxel and carboplatin in patients with advanced non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Carcinoma, Non-Small-Cell Lung; Drug Administration Schedule; Female; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neutropenia; Paclitaxel; Survival Rate | 2000 |
Effects of paclitaxel and carboplatin on quality of life and survival in patients with advanced non-small-cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Quality of Life | 2000 |
Gemcitabine and paclitaxel associated pneumonitis in non-small cell lung cancer: report of a phase I/II dose-escalating study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cohort Studies; Deoxycytidine; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Maximum Allowable Concentration; Middle Aged; Paclitaxel; Pneumonia | 2000 |
Cremophor EL pharmacokinetics in a phase I study of paclitaxel (Taxol) and carboplatin in non-small cell lung cancer patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Glycerol; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Pharmaceutical Vehicles | 2000 |
Phase II study of paclitaxel, ifosfamide, and cisplatin as second-line treatment in relapsed small-cell lung cancer.
Topics: Actuarial Analysis; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Female; Greece; Humans; Ifosfamide; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Paclitaxel; Recurrence; Survival Rate | 2001 |
Paclitaxel, cisplatin, and gemcitabine combination chemotherapy within a multidisciplinary therapeutic approach in metastatic nonsmall cell lung carcinoma.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease-Free Survival; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Nausea; Neoplasm Metastasis; Neoplasm Staging; Neutropenia; Paclitaxel; Survival Rate; Treatment Outcome; Vomiting | 2000 |
A dose-escalation study of irinotecan (CPT-11) in combination with cisplatin in patients with advanced non-small cell lung cancer previously treated with a docetaxel-based front line chemotherapy.
Topics: Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Diarrhea; Docetaxel; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Fever; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neutropenia; Paclitaxel; Salvage Therapy; Taxoids | 2000 |
Phase I-II study of gemcitabine and paclitaxel in pretreated patients with stage IIIB-IV non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neutropenia; Paclitaxel; Survival Analysis; Treatment Outcome | 2000 |
Co-administration of GF120918 significantly increases the systemic exposure to oral paclitaxel in cancer patients.
Topics: Acridines; Administration, Oral; Aged; Antineoplastic Agents, Phytogenic; Area Under Curve; Biological Availability; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Female; Humans; Infusions, Intravenous; Isoquinolines; Lung Neoplasms; Male; Middle Aged; Neoplasms, Unknown Primary; Paclitaxel; Tetrahydroisoquinolines | 2001 |
Paclitaxel and carboplatin in combination with gemcitabine: a phase I-II trial in patients with advanced non-small-cell lung cancer. Gruppo Studio Tumori Polmonari Veneto (GSTPV).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Deoxycytidine; Diarrhea; Disease-Free Survival; Female; Fever; Gemcitabine; Hematologic Diseases; Humans; Life Tables; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neutropenia; Paclitaxel; Remission Induction; Survival Analysis; Treatment Outcome | 2000 |
Phase I study of carboplatin, docetaxel and irinotecan with recombinant human granulocyte colony stimulating factor support in patients with advanced non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Docetaxel; Dose-Response Relationship, Drug; Female; Granulocyte Colony-Stimulating Factor; Humans; Irinotecan; Leukopenia; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Taxoids | 2000 |
Phase II trial of paclitaxel plus gemcitabine in patients with locally advanced or metastatic non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Karnofsky Performance Status; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Paclitaxel | 2001 |
Phase I trial of the combination of irinotecan, paclitaxel, and carboplatin in patients with advanced non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Diarrhea; Drug Administration Schedule; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neutropenia; Paclitaxel | 2001 |
Carboplatin/paclitaxel or carboplatin/vinorelbine followed by accelerated hyperfractionated conformal radiation therapy: a preliminary report of a phase I dose escalation trial from the Carolina Conformal Therapy Consortium.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Dose Fractionation, Radiation; Esophagus; Female; Humans; Lung Neoplasms; Male; Paclitaxel; Radiotherapy, Conformal; Treatment Outcome; Vinblastine; Vinorelbine | 2001 |
Induction chemotherapy followed by concomitant chemoradiotherapy for non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Survival Analysis; Treatment Outcome; Vinblastine; Vinorelbine | 2001 |
A phase II study of single-agent docetaxel chemotherapy for non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Alopecia; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Docetaxel; Female; Humans; Infusions, Intravenous; Leukopenia; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Survival Analysis; Taxoids | 2000 |
Twice-weekly paclitaxel and weekly carboplatin with concurrent thoracic radiation followed by carboplatin/paclitaxel consolidation for stage III non-small-cell lung cancer: a California Cancer Consortium phase II trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Drug Administration Schedule; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Radiation-Sensitizing Agents; Survival Analysis | 2001 |
Combination of paclitaxel and etoposide in the treatment of advanced non-small cell lung cancer: a phase I-II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel | 2001 |
Second-line chemotherapy for non-small-cell lung cancer with monthly docetaxel and weekly gemcitabine: a phase II trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease Progression; Docetaxel; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Survival Analysis; Taxoids; Treatment Outcome | 2001 |
Adenovirus-mediated wild-type p53 gene transfer in patients receiving chemotherapy for advanced non-small-cell lung cancer: results of a multicenter phase II study.
Topics: Adenoviridae; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Disease Progression; Female; Genes, p53; Genetic Therapy; Genetic Vectors; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Survival Analysis; Treatment Outcome | 2001 |
Radiation induced chemotherapy sensitization in trimodality therapy of stage III non small cell lung cancer. A preliminary report.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Disease-Free Survival; Humans; Ifosfamide; Lomustine; Lung Neoplasms; Mesna; Middle Aged; Neoplasm Staging; Paclitaxel; Survival Rate; Time Factors | 2000 |
Phase II study of paclitaxel and oral etoposide in patients with locally advanced or metastatic non-small cell lung cancer.
Topics: Administration, Oral; Adult; Aged; Carcinoma, Non-Small-Cell Lung; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Paclitaxel; Survival Analysis; Treatment Outcome | 2001 |
An evaluation of two techniques for beam intensity modulation in patients irradiated for stage III non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Dose Fractionation, Radiation; Esophagus; Follow-Up Studies; Heart; Humans; Lung Neoplasms; Lymphatic Metastasis; Mediastinum; Neoplasm Staging; Paclitaxel; Particle Accelerators; Radiation Pneumonitis; Radiotherapy Dosage; Radiotherapy, Conformal; Radiotherapy, High-Energy; Treatment Outcome | 2001 |
Sequential chemo- and radiochemotherapy with weekly paclitaxel (Taxol) and 3D-conformal radiotherapy of stage III inoperable non-small cell lung cancer. Results of a dose escalation study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Cohort Studies; Combined Modality Therapy; Disease-Free Survival; Drug Hypersensitivity; Esophagitis; Humans; Leukopenia; Life Tables; Lung Neoplasms; Maximum Tolerated Dose; Nausea; Neoplasm Staging; Paclitaxel; Prospective Studies; Radiation Injuries; Radiation Pneumonitis; Radiotherapy, Conformal; Remission Induction; Survival Analysis; Survival Rate; Treatment Outcome; Vomiting | 2001 |
Docetaxel in combination with gemcitabine plus rhG-CSF support as second-line treatment in non-small cell lung cancer. A multicenter phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease Progression; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Gemcitabine; Granulocyte Colony-Stimulating Factor; Hematologic Diseases; Humans; Life Tables; Lung Neoplasms; Male; Middle Aged; Neutropenia; Paclitaxel; Recombinant Proteins; Salvage Therapy; Survival Analysis; Survival Rate; Taxoids; Treatment Outcome | 2001 |
Gemcitabine and vinorelbine as second-line therapy in non-small-cell lung cancer after prior treatment with taxane+platinum-based regimens.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Ifosfamide; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Patient Compliance; Survival Analysis; Treatment Outcome; Vinblastine; Vinorelbine | 2001 |
Phase I studies of cisplatin and docetaxel administered by three consecutive weekly infusions for advanced non-small cell lung cancer in elderly and non-elderly patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Docetaxel; Drug Administration Schedule; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Survival Analysis; Taxoids | 2001 |
Phase I and pharmacological study of paclitaxel given over 3 h with cisplatin for advanced non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Drug Administration Schedule; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel | 2001 |
Combined paclitaxel and gemcitabine as first-line treatment in metastatic non-small cell lung cancer: a multicentre phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Gemcitabine; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Neutropenia; Paclitaxel; Peripheral Nervous System Diseases; Survival Analysis; Treatment Outcome | 2001 |
Phase III trial of cisplatin/gemcitabine with or without vinorelbine or paclitaxel in advanced non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Survival Analysis; Vinblastine; Vinorelbine | 2001 |
Platinum-based and non-platinum-based chemotherapy in advanced non-small-cell lung cancer: a randomised multicentre trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Survival Rate; Taxoids | 2001 |
A Phase II study of docetaxel and carboplatin in the treatment of non-small cell lung cancer.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; Docetaxel; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Neutropenia; Paclitaxel; Taxoids; Treatment Outcome | 2001 |
A phase I study of weekly docetaxel and cisplatin in advanced non-small cell lung cancer.
Topics: Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Docetaxel; Dose-Response Relationship, Drug; Female; Fever; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Neutropenia; Paclitaxel; Taxoids; Thrombocytopenia | 2001 |
Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non--small-cell lung cancer: a Southwest Oncology Group trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Female; Health Resources; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Quality of Life; Regression Analysis; Survival Rate; United States; Vinblastine; Vinorelbine | 2001 |
Phase III randomized trial of docetaxel in combination with cisplatin or carboplatin or vinorelbine plus cisplatin in advanced non--small cell lung cancer: interim analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials, Phase III as Topic; Docetaxel; Humans; Lung Neoplasms; Paclitaxel; Quality of Life; Randomized Controlled Trials as Topic; Survival Rate; Taxoids; Vinblastine; Vinorelbine | 2001 |
Sequential combination chemotherapy in patients with advanced nonsmall cell lung carcinoma: carboplatin and gemcitabine followed by paclitaxel.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Pilot Projects; Treatment Outcome | 2001 |
Phase I/II trial of docetaxel and vinorelbine in patients with non-small cell lung cancer previously treated with platinum-based chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Docetaxel; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neutropenia; Paclitaxel; Survival Analysis; Taxoids; Vinblastine; Vinorelbine | 2001 |
Phase I trial of weekly docetaxel combined with cisplatin in patients with non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Hyponatremia; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Neutropenia; Paclitaxel; Taxoids; Treatment Outcome | 2001 |
Dose-escalating conformal thoracic radiation therapy with induction and concurrent carboplatin/paclitaxel in unresectable stage IIIA/B nonsmall cell lung carcinoma: a modified phase I/II trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Radiotherapy, Conformal; Survival Rate; Treatment Failure | 2001 |
Schedule-dependent pulsed paclitaxel radiosensitization for thoracic malignancy.
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Drug Administration Schedule; Female; Humans; Lung Neoplasms; Male; Mesothelioma; Middle Aged; Paclitaxel; Radiation-Sensitizing Agents; Radiotherapy Dosage; Tumor Cells, Cultured | 2001 |
Paclitaxel and carboplatin adjuvant therapy alone or with radiotherapy for resected nonsmall cell lung carcinoma: a feasibility study of the Minnie Pearl Cancer Research Network.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Combined Modality Therapy; Feasibility Studies; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel | 2001 |
Phase II trial of weekly docetaxel in second-line therapy for nonsmall cell lung carcinoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Docetaxel; Drug Administration Schedule; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Survival Analysis; Taxoids | 2001 |
Feasibility of oral topotecan plus intravenous paclitaxel in advanced non-small-cell lung cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; Drug Administration Schedule; Feasibility Studies; Female; Follow-Up Studies; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Survival Rate; Topotecan; Treatment Outcome | 2001 |
Weekly paclitaxel in advanced non-small cell lung cancer.
Topics: Aged; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Drug Administration Schedule; Female; Humans; Lung Neoplasms; Male; Neoplasm Recurrence, Local; Paclitaxel; Survival Analysis | 2001 |
Interim analysis of a phase II study of induction weekly paclitaxel/carboplatin regimens followed by maintenance weekly paclitaxel for advanced and metastatic non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Drug Administration Schedule; Humans; Lung Neoplasms; Paclitaxel | 2001 |
Phase II study of high-dose paclitaxel and carboplatin in previously untreated, unresectable non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Carcinoma, Non-Small-Cell Lung; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Neutropenia; Paclitaxel; Peripheral Nervous System Diseases; Survival Analysis | 2001 |
Pilot study of sequential vinorelbine and cisplatin followed by docetaxel for selected IIIB and stage IV non-small cell lung cancer.
Topics: Acute Kidney Injury; Aged; Aged, 80 and over; Agranulocytosis; Anemia; Antineoplastic Combined Chemotherapy Protocols; Back Pain; Carcinoma, Non-Small-Cell Lung; Cisplatin; Disease Progression; Docetaxel; Drug Administration Schedule; Female; Humans; Lung Neoplasms; Male; Middle Aged; Myocardial Infarction; Paclitaxel; Survival Analysis; Taxoids; Thrombocytopenia; Treatment Outcome; Vinblastine; Vinorelbine | 2001 |
Phase I trial of outpatient weekly docetaxel, carboplatin and concurrent thoracic radiation therapy for stage III unresectable non-small-cell lung cancer: a Vanderbilt cancer center affiliate network (VCCAN) trial.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Docetaxel; Drug Administration Schedule; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Taxoids; Treatment Outcome | 2001 |
Docetaxel as neo-adjuvant therapy for radically treatable stage III non-small cell lung cancer: early results of an international phase III study.
Topics: Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Docetaxel; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Survival Analysis; Taxoids | 2001 |
Weekly docetaxel as II line therapy in non-small cell lung cancer: an interim analysis of a phase II study.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Docetaxel; Drug Administration Schedule; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Quality of Life; Taxoids | 2001 |
Comparison of docetaxel/cisplatin to docetaxel/gemcitabine as first-line treatment of advanced non-small cell lung cancer: early results of a randomized trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Remission Induction; Taxoids | 2001 |
Outcome of patients with a performance status of 2 in Eastern Cooperative Oncology Group Study E1594: a Phase II trial in patients with metastatic nonsmall cell lung carcinoma .
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease Progression; Docetaxel; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Patient Selection; Prognosis; Risk Factors; Severity of Illness Index; Survival Analysis; Taxoids | 2001 |
Weekly docetaxel with either gemcitabine or vinorelbine as second-line treatment in patients with advanced nonsmall cell lung carcinoma: Phase II trials of the Minnie Pearl Cancer Research Network.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Drug Administration Schedule; Female; Fever; Gemcitabine; Humans; Infusions, Intravenous; Leukopenia; Lung Neoplasms; Male; Middle Aged; Neutropenia; Paclitaxel; Survival Analysis; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2001 |
A phase II study of weekly paclitaxel in elderly patients with advanced non-small cell lung cancer.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Area Under Curve; Carcinoma, Non-Small-Cell Lung; Humans; Infusions, Intravenous; Lung Neoplasms; Metabolic Clearance Rate; Neoplasm Staging; Paclitaxel; Survival Rate; Time Factors | 2001 |
Gemcitabine and docetaxel as second-line chemotherapy for patients with nonsmall cell lung carcinoma who fail prior paclitaxel plus platinum-based regimens.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Patient Compliance; Platinum; Survival Analysis; Taxoids; Treatment Outcome | 2001 |
Sequential therapy in advanced non-small-cell lung cancer with weekly paclitaxel followed by cisplatin-gemcitabine-vinorelbine. A phase II study.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Neutropenia; Paclitaxel; Peripheral Nervous System Diseases; Treatment Outcome; Vinblastine | 2001 |
Phase I study of weekly docetaxel and cisplatin concurrent with thoracic radiotherapy in Stage III non-small-cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Docetaxel; Drug Administration Schedule; Feasibility Studies; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Taxoids | 2002 |
Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease-Free Survival; Docetaxel; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Survival Analysis; Taxoids | 2002 |
Phase I study of second-line chemotherapy with docetaxel and carboplatin in advanced non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Carcinoma, Non-Small-Cell Lung; Dermatitis; Diarrhea; Docetaxel; Dose-Response Relationship, Drug; Female; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neutropenia; Paclitaxel; Taxoids; Thrombocytopenia | 2001 |
A phase II study of paclitaxel plus cisplatin for advanced non-small-cell lung cancer in Japanese patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Disease Progression; Female; Humans; Hypotension; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Neutropenia; Paclitaxel; Peripheral Nervous System Diseases; Survival Analysis; Treatment Outcome | 2001 |
Phase II study of docetaxel and cisplatin administered as three consecutive weekly infusions for advanced non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Docetaxel; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Neutropenia; Paclitaxel; Survival Analysis; Taxoids; Treatment Outcome | 2002 |
Drug distribution and pharmacokinetic/pharmacodynamic relationship of paclitaxel and gemcitabine in patients with non-small-cell lung cancer.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carcinoma, Non-Small-Cell Lung; Chromatography, High Pressure Liquid; Deoxycytidine; Dose-Response Relationship, Drug; Gemcitabine; Humans; Infusions, Intravenous; Lung Neoplasms; Middle Aged; Paclitaxel | 2001 |
Cisplatin-based therapy for elderly patients with advanced non-small-cell lung cancer: implications of Eastern Cooperative Oncology Group 5592, a randomized trial.
Topics: Aged; Aged, 80 and over; Aging; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Etoposide; Female; Humans; Lung Neoplasms; Male; Paclitaxel; Quality of Life; Random Allocation; Retrospective Studies; Survival Analysis; Time Factors; Treatment Outcome | 2002 |
Is weekly paclitaxel superior to paclitaxel given every 3 weeks? Results of a phase II trial.
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Survival Rate; Time Factors | 2002 |
Economic analysis of vinorelbine plus cisplatin versus paclitaxel plus carboplatin for advanced non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Cost-Benefit Analysis; Female; Health Care Costs; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Prospective Studies; Quality of Life; Vinblastine; Vinorelbine | 2002 |
A phase I-II study of docetaxel-ifosfamide-cisplatin (DIP) combination chemotherapy regimen in advanced nonsmall cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Docetaxel; Female; Humans; Ifosfamide; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Patient Compliance; Taxoids | 2002 |
Paclitaxel plus carboplatin, compared with paclitaxel plus gemcitabine, shows similar efficacy while more cost-effective: a randomized phase II study of combination chemotherapy against inoperable non-small-cell lung cancer previously untreated.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cost-Benefit Analysis; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Survival Rate; Time Factors | 2002 |
Phase III trial comparing a defined duration of therapy versus continuous therapy followed by second-line therapy in advanced-stage IIIB/IV non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Drug Administration Schedule; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Quality of Life | 2002 |
Phase II: trial of twice weekly amifostine in patients with non-small cell lung cancer treated with chemoradiotherapy.
Topics: Acute Disease; Aged; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Drug Administration Schedule; Esophagitis; Esophagus; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Radiation Injuries; Radiation-Protective Agents; Radiation-Sensitizing Agents; Survival Rate | 2002 |
A feasibility study of paclitaxel 225 mg/m(2) and carboplatin AUC = 6 in untreated advanced non-small cell lung cancer patients in Japan.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Drug Administration Schedule; Feasibility Studies; Female; Humans; Leukopenia; Lung Neoplasms; Male; Middle Aged; Neutropenia; Paclitaxel | 2002 |
Docetaxel and carboplatin as second-line chemotherapy for metastatic non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; Docetaxel; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Pilot Projects; Survival Rate; Taxoids; Treatment Outcome | 2002 |
Phase II study of docetaxel and cisplatin combination chemotherapy in metastatic or unresectable localized non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Docetaxel; Female; Hematologic Diseases; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Survival Rate; Taxoids; Treatment Outcome | 2002 |
Quality of life in advanced non-small-cell lung cancer: results of a Southwest Oncology Group randomized trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Humans; Lung Neoplasms; Paclitaxel; Quality of Life; Surveys and Questionnaires; Survival Analysis; Vinblastine; Vinorelbine | 2002 |
Phase II neoadjuvant trial of paclitaxel by 96-hour continuous infusion (CIVI) in combination with cisplatin followed by chest radiotherapy for patients with stage III non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Drug Administration Schedule; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Radiotherapy, High-Energy; Survival Analysis | 2002 |
Weekly chemotherapy with carboplatin, docetaxel and irinotecan in advanced non-small-cell-lung cancer: a phase II study.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Dexamethasone; Docetaxel; Female; Humans; Infusions, Intravenous; Irinotecan; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Survival Analysis; Taxoids; Treatment Outcome | 2002 |
Phase I study of carboplatin, irinotecan and docetaxel on a divided schedule with recombinant human granulocyte colony stimulating factor support in patients with stage IIIB or IV non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Diarrhea; Docetaxel; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Granulocyte Colony-Stimulating Factor; Humans; Infusions, Intravenous; Irinotecan; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Paclitaxel; Recombinant Proteins; Taxoids | 2002 |
A phase II study testing paclitaxel as second-line single agent treatment for patients with advanced non-small cell lung cancer failing after a first-line chemotherapy.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Polyneuropathies; Survival; Treatment Outcome | 2002 |
Phase II randomized multicenter study evaluating a treatment regimen alternating docetaxel and cisplatin-vinorelbine with a cisplatin-vinorelbine control group in patients with stage IV non-small-cell lung cancer: GFPC 97.01 study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Evaluation Studies as Topic; Female; Follow-Up Studies; Hematologic Diseases; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Probability; Reference Values; Survival Analysis; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2002 |
Long-term follow-up of patients treated with paclitaxel/carboplatin-based chemotherapy for advanced non-small-cell lung cancer: sequential phase II trials of the Minnie Pearl Cancer Research Network.
Topics: Actuarial Analysis; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Drug Administration Schedule; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Survival Analysis; Time Factors; Treatment Outcome; Vinblastine; Vinorelbine | 2002 |
Early results of a randomized phase III trial of platinum-containing doublets versus a nonplatinum doublet in the treatment of advanced non-small cell lung cancer: European Organization for Research and Treatment of Cancer 08975.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Lung Neoplasms; Paclitaxel; Quality of Life; Survival Rate | 2002 |
[Advances in lung cancer].
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Combined Modality Therapy; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Irinotecan; Lung Neoplasms; Paclitaxel; Vinblastine; Vinorelbine | 1992 |
923 other study(ies) available for paclitaxel and Carcinoma, Non-Small Cell Lung
| Article | Year |
|---|---|
Structure-activity relationship studies of ethyl 2-amino-6-bromo-4-(1-cyano-2-ethoxy-2-oxoethyl)-4H-chromene-3-carboxylate (HA 14-1), an antagonist for antiapoptotic Bcl-2 proteins to overcome drug resistance in cancer.
Topics: Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; bcl-X Protein; Benzopyrans; Carcinoma, Non-Small-Cell Lung; Cisplatin; Drug Resistance, Neoplasm; Enzyme Inhibitors; Humans; Jurkat Cells; Lung Neoplasms; Nitriles; Proto-Oncogene Proteins c-bcl-2; Structure-Activity Relationship; Tumor Cells, Cultured | 2006 |
2-Substituted 3,7,8-trimethylnaphtho[1,2-b]furan-4,5-diones as specific L-shaped NQO1-mediated redox modulators for the treatment of non-small cell lung cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Death; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Furans; Humans; Lung Neoplasms; Models, Molecular; Molecular Structure; NAD(P)H Dehydrogenase (Quinone); Naphthalenes; Oxidation-Reduction; Reactive Oxygen Species; Structure-Activity Relationship | 2017 |
Discovery of Nonquinone Substrates for NAD(P)H: Quinone Oxidoreductase 1 (NQO1) as Effective Intracellular ROS Generators for the Treatment of Drug-Resistant Non-Small-Cell Lung Cancer.
Topics: A549 Cells; Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; Glutathione; Humans; Lung Neoplasms; Mice, Nude; Models, Molecular; NAD(P)H Dehydrogenase (Quinone); Paclitaxel; Poly (ADP-Ribose) Polymerase-1; Quinones; Reactive Oxygen Species; Structure-Activity Relationship; Xenograft Model Antitumor Assays | 2018 |
Quinazolin-2,4-dione-Based Hydroxamic Acids as Selective Histone Deacetylase-6 Inhibitors for Treatment of Non-Small Cell Lung Cancer.
Topics: Acetylation; Animals; Apoptosis; B7-H1 Antigen; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Synergism; Histone Deacetylase 6; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Lung Neoplasms; Mice; Mice, Inbred C57BL; Paclitaxel; Quinazolinones; Structure-Activity Relationship; Tissue Distribution; Transplantation, Homologous; Tubulin | 2019 |
Discovery of an Oleanolic Acid/Hederagenin-Nitric Oxide Donor Hybrid as an EGFR Tyrosine Kinase Inhibitor for Non-Small-Cell Lung Cancer.
Topics: A549 Cells; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Design; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Mutation; Nitric Oxide; Nitric Oxide Donors; Oleanolic Acid; Protein Kinase Inhibitors | 2019 |
Blocking hsa_circ_0074027 suppressed non-small cell lung cancer chemoresistance via the miR-379-5p/IGF1 axis.
Topics: A549 Cells; Animals; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; Female; Humans; Insulin-Like Growth Factor I; Lung Neoplasms; Male; Mice; Mice, Nude; MicroRNAs; Neoplasm Staging; Paclitaxel; RNA, Circular; RNA, Small Interfering; Xenograft Model Antitumor Assays | 2021 |
Targeted paclitaxel-octreotide conjugates inhibited the growth of paclitaxel-resistant human non-small cell lung cancer A549 cells in vitro.
Topics: A549 Cells; Adult; Aged; Animals; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Proliferation; Drug Resistance, Neoplasm; Female; Humans; Lung Neoplasms; Male; Mice; Mice, Nude; Middle Aged; Octreotide; Paclitaxel; Receptors, Somatostatin | 2021 |
FV-429 enhances the efficacy of paclitaxel in NSCLC by reprogramming HIF-1α-modulated FattyAcid metabolism.
Topics: A549 Cells; Active Transport, Cell Nucleus; Animals; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; beta Catenin; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Synergism; Fatty Acids; Flavonoids; G2 Phase Cell Cycle Checkpoints; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Paclitaxel; Tumor Hypoxia; Wnt Signaling Pathway; Xenograft Model Antitumor Assays | 2021 |
First-line nab-paclitaxel plus carboplatin for patients with advanced non-small cell lung cancer: Results of the NEPTUN study.
Topics: Adult; Aged; Aged, 80 and over; Albumins; Carboplatin; Carcinoma, Non-Small-Cell Lung; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Prospective Studies | 2021 |
Downregulation of LINC01296 suppresses non-small-cell lung cancer via targeting miR-143-3p/ATG2B.
Topics: Animals; Apoptosis; Autophagy-Related Proteins; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cytoplasm; Down-Regulation; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Mice, Nude; MicroRNAs; Neoplasm Metastasis; Paclitaxel; RNA, Long Noncoding; Vesicular Transport Proteins | 2021 |
CD44-targeted, indocyanine green-paclitaxel-loaded human serum albumin nanoparticles for potential image-guided drug delivery.
Topics: Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Humans; Hyaluronan Receptors; Indocyanine Green; Lung Neoplasms; Nanoparticles; Paclitaxel; Pharmaceutical Preparations; Serum Albumin, Human | 2022 |
P1-39: Paclitaxel induces growth inhibition in gefitinib-resistant PC9-MET cells by downregulating MDM2 and activating p53.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Gefitinib; Humans; Lung Neoplasms; Paclitaxel; Proto-Oncogene Proteins c-mdm2; Tumor Suppressor Protein p53 | 2021 |
Carboplatin and nab-paclitaxel chemotherapy with or without atezolizumab as front-line management for treatment-naïve metastatic nonsquamous non-small cell lung cancer with PD-L1 staining: a retrospective study.
Topics: Aged; Albumins; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; B7-H1 Antigen; Carboplatin; Carcinoma, Non-Small-Cell Lung; Humans; Lung Neoplasms; Middle Aged; Paclitaxel; Retrospective Studies; Staining and Labeling | 2022 |
Clinical insights into cisplatin-induced arrhythmia in a patient with locally advanced non-small cell lung cancer: a case report.
Topics: Antineoplastic Combined Chemotherapy Protocols; Arrhythmias, Cardiac; Carcinoma, Non-Small-Cell Lung; Cisplatin; Humans; Lung Neoplasms; Paclitaxel | 2022 |
RBL2/DREAM-mediated repression of the Aurora kinase A/B pathway determines therapy responsiveness and outcome in p53 WT NSCLC.
Topics: Aurora Kinase A; Aurora Kinase B; Carcinoma, Non-Small-Cell Lung; Cell Cycle Checkpoints; Cell Line, Tumor; Gene Expression Regulation, Neoplastic; Humans; Paclitaxel; Retinoblastoma-Like Protein p130; Tumor Suppressor Protein p53 | 2022 |
Evaluation of risk factors associated with carboplatin and nab-paclitaxel treatment suspension in patients with non-small cell lung cancer.
Topics: Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Humans; Lung Neoplasms; Paclitaxel; Retrospective Studies; Risk Factors | 2022 |
Differences in the Therapeutic Effect of Chemotherapy Regimens for Concurrent Chemoradiotherapy of Locally Advanced Non-small Cell Lung Cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Cisplatin; Female; Humans; Japan; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Retrospective Studies; Treatment Outcome; Vinorelbine | 2022 |
Inhibitors of Jumonji C domain-containing histone lysine demethylases overcome cisplatin and paclitaxel resistance in non-small cell lung cancer through APC/Cdh1-dependent degradation of CtIP and PAF15.
Topics: Antigens, CD; Cadherins; Carcinoma, Non-Small-Cell Lung; Cisplatin; Histone Demethylases; Humans; Jumonji Domain-Containing Histone Demethylases; Lung Neoplasms; Lysine; Paclitaxel | 2022 |
Sintilimab with chemotherapy as first-line treatment for locally advanced or metastatic squamous non-small-cell lung cancer: a real-world data study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Gemcitabine; Humans; Lung Neoplasms; Paclitaxel; Platinum; Prospective Studies; Retrospective Studies | 2023 |
Weekly nanoparticle albumin-bound paclitaxel and paclitaxel for relapsed small cell lung cancer: A retrospective observational study.
Topics: Albumin-Bound Paclitaxel; Albumins; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Humans; Lung Neoplasms; Nanoparticles; Neoplasm Recurrence, Local; Paclitaxel; Retrospective Studies; Small Cell Lung Carcinoma | 2022 |
Clinical study of apatinib mesylate combined with paclitaxel injection and cisplatin injection in the treatment of non-small cell lung cancer.
Topics: Carcinoma, Non-Small-Cell Lung; Cisplatin; Humans; Lung Neoplasms; Paclitaxel | 2023 |
Tumorigenic circulating tumor cells from xenograft mouse models of non-metastatic NSCLC patients reveal distinct single cell heterogeneity and drug responses.
Topics: Animals; Carboplatin; Carcinogenesis; Carcinoma, Non-Small-Cell Lung; Disease Models, Animal; Heterografts; Humans; Lung Neoplasms; Mice; Neoplastic Cells, Circulating; Paclitaxel | 2022 |
Circular RNA circ_0002360 regulates the Taxol resistance and malignant behaviors of Taxol-resistant non-small cell lung cancer cells by microRNA-585-3p-dependent modulation of G protein regulated inducer of neurite outgrowth 1.
Topics: Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; GTP-Binding Proteins; Humans; Lung Neoplasms; MicroRNAs; Neuronal Outgrowth; Paclitaxel; RNA, Circular | 2022 |
Multi-institutional feasibility study of intensity-modulated radiotherapy with chemotherapy for locally advanced non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Cisplatin; Feasibility Studies; Humans; Lung Neoplasms; Middle Aged; Paclitaxel; Radiotherapy, Intensity-Modulated; Young Adult | 2022 |
Spotlight on Camrelizumab in Advanced Squamous Lung Cancer: Another Feather in the Cap of Chinese Checkpoint Inhibitors.
Topics: Animals; Antibodies, Monoclonal, Humanized; Camelus; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; China; Feathers; Humans; Lung Neoplasms; Paclitaxel | 2022 |
Construction of Intelligent Responsive Drug Delivery System and Multi-Mode Imaging Based on Gold Nanodots.
Topics: Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Delivery Systems; Drug Liberation; Gold; Humans; Lung Neoplasms; Nanoparticles; Paclitaxel; Water | 2022 |
Circ_0011292 knockdown mitigates progression and drug resistance in PTX-resistant non-small-cell lung cancer cells by regulating miR-433-3p/CHEK1 axis.
Topics: Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Checkpoint Kinase 1; Drug Resistance, Neoplasm; Humans; Lung Neoplasms; MicroRNAs; Paclitaxel | 2022 |
Circular RNA hsa_circ_0011298 enhances Taxol resistance of non-small cell lung cancer by regulating miR-486-3p/CRABP2 axis.
Topics: Animals; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Humans; Lung Neoplasms; Mice; MicroRNAs; Paclitaxel; Receptors, Retinoic Acid; RNA, Circular | 2022 |
Pirfenidone Sensitizes NCI-H460 Non-Small Cell Lung Cancer Cells to Paclitaxel and to a Combination of Paclitaxel with Carboplatin.
Topics: Antineoplastic Agents; Apoptosis; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Humans; Lung Neoplasms; Paclitaxel; Pyridones | 2022 |
Study on the Mechanism of Action of Paclitaxel-Loaded Polylactic-co-glycolic Acid Nanoparticles in Non-Small-Cell Lung Carcinoma Cells.
Topics: Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Glycolates; Glycols; Humans; Lung Neoplasms; Nanoparticles; Paclitaxel; Polylactic Acid-Polyglycolic Acid Copolymer | 2022 |
Effect of prior immunotherapy on the efficacy of chemotherapy in advanced non-small cell lung cancer: A retrospective study.
Topics: Bevacizumab; Carcinoma, Non-Small-Cell Lung; Humans; Immunotherapy; Lung Neoplasms; Paclitaxel; Retrospective Studies | 2022 |
An EHMT2/NFYA-ALDH2 signaling axis modulates the RAF pathway to regulate paclitaxel resistance in lung cancer.
Topics: Aldehyde Dehydrogenase, Mitochondrial; Carcinoma, Non-Small-Cell Lung; CCAAT-Binding Factor; Drug Resistance, Neoplasm; Histocompatibility Antigens; Histone-Lysine N-Methyltransferase; Humans; Lung Neoplasms; Paclitaxel; Transcription Factors | 2022 |
Targeting epidermal growth factor receptor in paclitaxel-resistant human breast and lung cancer cells with upregulated glucose-6-phosphate dehydrogenase.
Topics: Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; ErbB Receptors; Glucosephosphate Dehydrogenase; Humans; Lung Neoplasms; Paclitaxel; Triple Negative Breast Neoplasms | 2022 |
EML4-ALK Variant 3 Promotes Mitotic Errors and Spindle Assembly Checkpoint Deficiency Leading to Increased Microtubule Poison Sensitivity.
Topics: Carcinoma, Non-Small-Cell Lung; Humans; Lung Neoplasms; M Phase Cell Cycle Checkpoints; Microtubules; Oncogene Proteins, Fusion; Paclitaxel; Protein Kinase Inhibitors; Receptor Protein-Tyrosine Kinases | 2022 |
Inhibition of Mtorc1/2 and DNA-PK via CC-115 Synergizes with Carboplatin and Paclitaxel in Lung Squamous Cell Carcinoma.
Topics: Animals; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cell Line, Tumor; Class I Phosphatidylinositol 3-Kinases; DNA; Humans; Lung; Lung Neoplasms; Mechanistic Target of Rapamycin Complex 1; Mice; Paclitaxel; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Pyrazines; TOR Serine-Threonine Kinases; Triazoles | 2022 |
Genetic variations in the ATP-binding cassette transporter ABCC10 are associated with neutropenia in Japanese patients with lung cancer treated with nanoparticle albumin-bound paclitaxel.
Topics: Albumin-Bound Paclitaxel; Albumins; Antineoplastic Combined Chemotherapy Protocols; ATP-Binding Cassette Transporters; Carcinoma, Non-Small-Cell Lung; Genetic Variation; HeLa Cells; Humans; Japan; Lung Neoplasms; Multidrug Resistance-Associated Proteins; Nanoparticles; Neutropenia; Paclitaxel | 2022 |
Multi-organs perioperative immune-related adverse events and postoperative bronchial anastomotic fistula in a patient receiving neoadjuvant immunotherapy with NSCLC.
Topics: Bronchial Fistula; Carboplatin; Carcinoma, Non-Small-Cell Lung; Humans; Immunotherapy; Lung Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Postoperative Complications | 2022 |
Therapy for Stage IV Non-Small-Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline.
Topics: Antineoplastic Combined Chemotherapy Protocols; B7-H1 Antigen; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Docetaxel; Humans; Immune Checkpoint Inhibitors; Ipilimumab; Lung Neoplasms; Nivolumab; Paclitaxel; Pemetrexed | 2022 |
Establishment of an acquired lorlatinib-resistant cell line of non-small cell lung cancer and its mediated resistance mechanism.
Topics: Aminopyridines; Anaplastic Lymphoma Kinase; Carcinoma, Non-Small-Cell Lung; Cell Line; Cisplatin; Crizotinib; Docetaxel; Drug Resistance, Neoplasm; Humans; Lactams; Lactams, Macrocyclic; Lung Neoplasms; Microtubule Proteins; Mutation; Paclitaxel; Protein Kinase Inhibitors; Pyrazoles; Tumor Suppressor Protein p53 | 2022 |
Early Pharmacological Profiling of Antiproliferative Compounds by Live Cell Imaging.
Topics: Antimitotic Agents; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Cell Survival; Humans; Lung Neoplasms; Microtubules; Paclitaxel; Tubulin | 2022 |
SOX2 regulates paclitaxel resistance of A549 non‑small cell lung cancer cells via promoting transcription of ClC‑3.
Topics: A549 Cells; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Humans; Lung Neoplasms; Paclitaxel; SOXB1 Transcription Factors | 2022 |
Oral sodium butyrate supplementation ameliorates paclitaxel-induced behavioral and intestinal dysfunction.
Topics: Animals; Butyric Acid; Carcinoma, Non-Small-Cell Lung; Dietary Supplements; Gastrointestinal Microbiome; Intestinal Diseases; Lung Neoplasms; Mice; Mice, Inbred C57BL; Paclitaxel | 2022 |
A novel ligand-modified nanocomposite microparticles improved efficiency of quercetin and paclitaxel delivery in the non-small cell lung cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cetuximab; Delayed-Action Preparations; ErbB Receptors; Humans; Ligands; Lung Neoplasms; Nanocomposites; Paclitaxel; Quercetin | 2022 |
Efficacy and Safety of Paclitaxel/nab-paclitaxel Chemotherapy for Patients With Relapsed Small Cell Lung Cancer.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Humans; Lung Neoplasms; Neoplasm Recurrence, Local; Paclitaxel; Serum Albumin; Small Cell Lung Carcinoma | 2022 |
Blocking circ_0010235 suppresses acquired paclitaxel resistance of non-small cell lung cancer by sponging miR-512-5p to modulate FAM83F expression.
Topics: Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Humans; Lung Neoplasms; MicroRNAs; Paclitaxel; RNA, Circular | 2022 |
A patient with advanced lung squamous cell carcinoma who failed to benefit from albumin bound paclitaxel plus pembrolizumab achieved partial response with second-line treatment of docetaxel plus pembrolizumab: a case report.
Topics: Albumin-Bound Paclitaxel; Albumins; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Docetaxel; Humans; Lung; Lung Neoplasms; Male; Middle Aged; Paclitaxel | 2022 |
Combination of Paclitaxel and PXR Antagonist SPA70 Reverses Paclitaxel-Resistant Non-Small Cell Lung Cancer.
Topics: Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; Humans; Lung Neoplasms; Paclitaxel; Pregnane X Receptor; Tubulin | 2022 |
Down-regulating Nrf2 by tangeretin reverses multiple drug resistance to both chemotherapy and EGFR tyrosine kinase inhibitors in lung cancer.
Topics: Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Multiple; Drug Resistance, Neoplasm; ErbB Receptors; Humans; Lung Neoplasms; Mutation; NF-E2-Related Factor 2; Paclitaxel; Protein Kinase Inhibitors; Quinazolines; Reactive Oxygen Species | 2022 |
PROSPECTS OF NEOADJUVANT CHEMORADIOTHERAPY IN PATIENTS WITH STAGE III A NON-SMALL CELL LUNG CANCER AS A METHOD OF IMPROVING SURVIVAL.
Topics: Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Cisplatin; Docetaxel; Humans; Lung Neoplasms; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Treatment Outcome | 2022 |
Survival Analysis and Clinical Outcomes between Paclitaxel and Carboplatin Versus Carboplatin and Gemcitabine in Patients with Advanced-stage Non-small-cell Lung Cancer: A Single-center Cohort Study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cohort Studies; Female; Gemcitabine; Humans; Lung Neoplasms; Paclitaxel; Retrospective Studies; Survival Analysis | 2022 |
Circ_0058608 contributes to the progression and taxol resistance of non-small cell lung cancer by sponging miR-1299 to upregulate GBP1.
Topics: Animals; Bandages; Carcinoma, Non-Small-Cell Lung; Cell Proliferation; GTP-Binding Proteins; Humans; Lung Neoplasms; MicroRNAs; Paclitaxel | 2023 |
CircPIM3 regulates taxol resistance in non-small cell lung cancer via miR-338-3p/TNFAIP8 axis.
Topics: Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Factor VIII; Humans; Lung Neoplasms; MicroRNAs; Paclitaxel | 2023 |
Efficacy and Safety of the PD-1 Inhibitor Combined with Albumin-Bound Paclitaxel and Nedaplatin in Preoperative Neoadjuvant Therapy of Unresectable Stage III Lung Squamous Cell Carcinoma.
Topics: Agranulocytosis; Albumin-Bound Paclitaxel; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Humans; Immune Checkpoint Inhibitors; Lung; Lung Neoplasms; Male; Neoadjuvant Therapy; Paclitaxel; Thrombocytopenia | 2022 |
Hsa_circ_0092887 targeting miR-490-5p/UBE2T promotes paclitaxel resistance in non-small cell lung cancer.
Topics: Animals; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Disease Models, Animal; Humans; Lung Neoplasms; Mice; MicroRNAs; Paclitaxel; Ubiquitin-Conjugating Enzymes | 2023 |
Multistate Pharmacometric Model to Define the Impact of Second-Line Immunotherapies on the Survival Outcome of the IMpower131 Study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease Progression; Humans; Immunotherapy; Lung Neoplasms; Paclitaxel | 2023 |
Combination carboplatin and nab-paclitaxel as a first-line treatment for advanced thymic carcinoma.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Humans; Lung Neoplasms; Middle Aged; Paclitaxel; Retrospective Studies; Thymoma; Thymus Neoplasms | 2023 |
Lower SLC7A2 expression is associated with enhanced multidrug resistance, less immune infiltrates and worse prognosis of NSCLC.
Topics: Amino Acid Transport Systems, Basic; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cisplatin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Paclitaxel | 2023 |
Paclitaxel Has a Reduced Toxicity Profile in Healthy Rats After Polymeric Micellar Nanoparticle Delivery.
Topics: Animals; Antineoplastic Agents, Phytogenic; Body Weight; Carcinoma, Non-Small-Cell Lung; Disease Models, Animal; Humans; Lung Neoplasms; Male; Mammals; Micelles; Nanoparticles; Paclitaxel; Peripheral Nervous System Diseases; Polymers; Rats; Rats, Sprague-Dawley | 2023 |
Real-world Efficacy and Safety of Atezolizumab Plus Bevacizumab, Paclitaxel and Carboplatin for First-line Treatment of Japanese Patients With Metastatic Non-squamous Non-small Cell Lung Cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; B7-H1 Antigen; Bevacizumab; Carboplatin; Carcinoma, Non-Small-Cell Lung; East Asian People; Female; Humans; Lung Neoplasms; Male; Paclitaxel; Retrospective Studies | 2023 |
Forskolin affects proliferation, migration and Paclitaxel-mediated cytotoxicity in non-small-cell lung cancer cell lines via adenylyl cyclase/cAMP axis.
Topics: Adenylyl Cyclases; Carcinoma, Non-Small-Cell Lung; Cell Line; Cell Proliferation; Colforsin; Cyclic AMP; Humans; Lung Neoplasms; Paclitaxel | 2023 |
First-line nab-paclitaxel plus carboplatin for patients with advanced non-small cell lung cancer: Final results of the NEPTUN study.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Humans; Lung Neoplasms; Paclitaxel | 2023 |
A prognostic baseline blood biomarker and tumor growth kinetics integrated model in paclitaxel/platinum treated advanced non-small cell lung cancer patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Humans; Lung Neoplasms; Paclitaxel; Platinum; Prognosis | 2023 |
Association of Immune-Related Adverse Events With Efficacy of Atezolizumab in Patients With Non-Small Cell Lung Cancer: Pooled Analyses of the Phase 3 IMpower130, IMpower132, and IMpower150 Randomized Clinical Trials.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Non-Small-Cell Lung; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Randomized Controlled Trials as Topic | 2023 |
TIPE2 sensitizes breast cancer cells to paclitaxel by suppressing drug-induced autophagy and cancer stem cell properties.
Topics: Autophagy; Bone Neoplasms; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; Female; Humans; Intracellular Signaling Peptides and Proteins; Lung Neoplasms; Neoplastic Stem Cells; Paclitaxel | 2023 |
A nomogram for the prediction of the survival of patients with advanced non-small cell lung cancer and interstitial lung disease.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Nomograms; Paclitaxel | 2023 |
Spinal Cord Stimulation Increases Chemoefficacy and Prevents Paclitaxel-Induced Pain via CX3CL1.
Topics: Animals; Carcinoma, Non-Small-Cell Lung; Chemokine CX3CL1; Ganglia, Spinal; Humans; Lung Neoplasms; Male; Neuralgia; Paclitaxel; Rats; Rats, Sprague-Dawley; Spinal Cord; Spinal Cord Stimulation | 2023 |
LY103, a pomalidomide derivative, alleviates taxol resistance in NSCLC via energy metabolism crosstalk and tumor microenvironment intervention.
Topics: Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Energy Metabolism; Humans; Lung Neoplasms; Molecular Docking Simulation; Paclitaxel; Tumor Microenvironment | 2023 |
Flashback Foreword: Bevacizumab + Carboplatin/Paclitaxel in NSCLC.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Non-Small-Cell Lung; Humans; Lung Neoplasms; Paclitaxel | 2023 |
Chemotherapy for patients with EGFR-mutated NSCLC after progression on EGFR-TKI's: Exploration of efficacy of unselected treatment in a multicenter cohort study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cohort Studies; ErbB Receptors; Humans; Lung; Lung Neoplasms; Mutation; Paclitaxel; Protein Kinase Inhibitors | 2023 |
Efficacy and safety of nanopaclitaxel formulation for cancer treatment: evidence from randomized clinical trials.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Humans; Lung Neoplasms; Paclitaxel; Randomized Controlled Trials as Topic; Treatment Outcome | 2023 |
Nuclear complement C3b promotes paclitaxel resistance by assembling the SIN3A/HDAC1/2 complex in non-small cell lung cancer.
Topics: Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Complement C3b; Drug Resistance, Neoplasm; Histone Deacetylase 1; Humans; Lung Neoplasms; Paclitaxel | 2023 |
Inhalable CAR-T cell-derived exosomes as paclitaxel carriers for treating lung cancer.
Topics: Animals; Carcinoma, Non-Small-Cell Lung; CD8-Positive T-Lymphocytes; Exosomes; Lung Neoplasms; Mice; Paclitaxel; Tumor Microenvironment | 2023 |
Whole genome sequencing across clinical trials identifies rare coding variants in GPR68 associated with chemotherapy-induced peripheral neuropathy.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Female; Humans; Lung Neoplasms; Paclitaxel; Peripheral Nervous System Diseases; Randomized Controlled Trials as Topic; Receptors, G-Protein-Coupled; Taxoids | 2023 |
Surface Immobilization of Anti-VEGF Peptide on SPIONs for Antiangiogenic and Targeted Delivery of Paclitaxel in Non-Small-Cell Lung Carcinoma.
Topics: Animals; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Endothelial Cells; Humans; Lung Neoplasms; Magnetic Iron Oxide Nanoparticles; Mice; Paclitaxel; Peptides; Vascular Endothelial Growth Factor A | 2023 |
Circular RNA circ_0000376 promotes paclitaxel resistance and tumorigenesis of non-small cell lung cancer via positively modulating KPNA4 by sponging miR-1298-5p.
Topics: alpha Karyopherins; Carcinogenesis; Carcinoma, Non-Small-Cell Lung; Cell Proliferation; Cell Transformation, Neoplastic; Humans; Lung Neoplasms; MicroRNAs; Paclitaxel; RNA, Circular | 2023 |
Acovenoside A as a novel therapeutic approach to boost taxol and carboplatin apoptotic and antiproliferative activities in NSCLC: Interplay of miR-630/miR-181a and apoptosis genes.
Topics: Apoptosis; bcl-2-Associated X Protein; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Humans; Lung Neoplasms; MicroRNAs; Paclitaxel; Proto-Oncogene Proteins c-bcl-2; Tumor Suppressor Protein p53 | 2023 |
Inhibition of non-homologous end joining mitigates paclitaxel resistance resulting from mitotic slippage in non-small cell lung cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Humans; Lung Neoplasms; Mitosis; Paclitaxel | 2023 |
Blocking the functional domain of TIP1 by antibodies sensitizes cancer to radiation therapy.
Topics: Animals; Antibodies; Carcinoma, Non-Small-Cell Lung; Disease Models, Animal; Glioblastoma; Humans; Lung Neoplasms; Mice; Paclitaxel | 2023 |
PEG2000-PLA-based nanoscale polymeric micelles reduce paclitaxel-related toxicity in beagle dogs.
Topics: Animals; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Dogs; Humans; Lung Neoplasms; Micelles; Paclitaxel; Polyesters; Polyethylene Glycols; Polymers; Rats | 2023 |
Exploring the Potential of Lapatinib, Fulvestrant, and Paclitaxel Conjugated with Glycidylated PAMAM G4 Dendrimers for Cancer and Parasite Treatment.
Topics: Animals; Caenorhabditis elegans; Carcinoma, Non-Small-Cell Lung; Dendrimers; Fulvestrant; Glioma; Humans; Lapatinib; Lung Neoplasms; Paclitaxel; Parasites | 2023 |
Efficacy of paclitaxel-carboplatin with bevacizumab as a late-line therapy for patients with advanced nonsquamous non-small cell lung cancer: A platinum rechallenge.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Non-Small-Cell Lung; Humans; Lung Neoplasms; Paclitaxel; Platinum; Retrospective Studies | 2023 |
Circulating Tumor DNA Monitoring on Chemo-immunotherapy for Risk Stratification in Advanced Non-Small Cell Lung Cancer.
Topics: Carboplatin; Carcinoma, Non-Small-Cell Lung; Circulating Tumor DNA; Humans; Immunotherapy; Lung Neoplasms; Paclitaxel; Retrospective Studies; Risk Assessment | 2023 |
Predictive and Prognostic Value of TUBB3, RRM1, APE1, and Survivin Expression in Chemotherapy-Receiving Patients with Advanced Non‑Small Cell Lung Cancer.
Topics: Biomarkers, Tumor; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; DNA-Binding Proteins; Endonucleases; Humans; Lung Neoplasms; Paclitaxel; Prognosis; Ribonucleoside Diphosphate Reductase; Survivin; Tubulin; Tumor Suppressor Proteins | 2023 |
Serum Hsa_circ_0005962 Is A Prognostic Biomarker of Paclitaxel Resistance in Nonsmall Cell Lung Cancer Treatment.
Topics: Biomarkers; Carcinoma, Non-Small-Cell Lung; Humans; Lung Neoplasms; Paclitaxel; Prognosis; RNA, Circular | 2023 |
Immunotherapy as a later-line option for
Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Docetaxel; Humans; Immune Checkpoint Inhibitors; Immunotherapy; Lung Neoplasms; Paclitaxel; Taxoids | 2023 |
Spotlight Commentary: Model-informed precision dosing must demonstrate improved patient outcomes.
Topics: Body Surface Area; Carcinoma, Non-Small-Cell Lung; Humans; Lung Neoplasms; Paclitaxel; Precision Medicine | 2019 |
Inhibiting tumour metastasis by DQA modified paclitaxel plus ligustrazine micelles in treatment of non-small-cell lung cancer.
Topics: A549 Cells; Animals; Apoptosis; Biological Transport; Carcinoma, Non-Small-Cell Lung; Cell Adhesion; Dequalinium; Down-Regulation; Drug Carriers; Drug Liberation; Extracellular Matrix; Humans; Lung Neoplasms; Mice; Micelles; Neoplasm Invasiveness; Neoplasm Metastasis; Paclitaxel; Xenograft Model Antitumor Assays | 2019 |
Chemoimmunotherapy for stage IV non-small-cell lung cancer.
Topics: Albumins; Antibodies, Monoclonal, Humanized; Carboplatin; Carcinoma, Non-Small-Cell Lung; Humans; Lung Neoplasms; Paclitaxel | 2019 |
Chemoimmunotherapy for stage IV non-small-cell lung cancer - Authors' reply.
Topics: Albumins; Antibodies, Monoclonal, Humanized; Carboplatin; Carcinoma, Non-Small-Cell Lung; Humans; Lung Neoplasms; Paclitaxel | 2019 |
A pilot study to assess oxidative and inflammatory markers as early indicator for response to chemotherapy in non-small cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cohort Studies; Female; Humans; Inflammation; Interleukin-6; Lung Neoplasms; Male; Middle Aged; Oxidative Stress; Paclitaxel; Pemetrexed; Pilot Projects; Prospective Studies; Treatment Outcome | 2020 |
Role of KEAP1/NFE2L2 Mutations in the Chemotherapeutic Response of Patients with Non-Small Cell Lung Cancer.
Topics: Aged; Animals; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Drug Resistance, Neoplasm; Etoposide; Female; Humans; Kelch-Like ECH-Associated Protein 1; Lung Neoplasms; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Mutation; Neoplasm Staging; NF-E2-Related Factor 2; Paclitaxel; Prognosis; Spheroids, Cellular; Survival Rate | 2020 |
Cost-effectiveness of Atezolizumab Combination Therapy for First-Line Treatment of Metastatic Nonsquamous Non-Small Cell Lung Cancer in the United States.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cost-Benefit Analysis; Humans; Lung Neoplasms; Models, Economic; Paclitaxel; Patient Simulation; Treatment Outcome; United States | 2019 |
Extrinsic Upregulation of PD-L1 Induced by Pembrolizumab Combination Therapy in Patients with NSCLC with Low Tumor PD-L1 Expression.
Topics: Aged; Albumins; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; B7-H1 Antigen; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Clinical Trials as Topic; Humans; Lung Neoplasms; Male; Paclitaxel; Prognosis | 2019 |
Cost-effectiveness of Osimertinib as a Second-line Treatment in Patients With EGFR-mutated Advanced Non-Small Cell Lung Cancer in China.
Topics: Acrylamides; Aniline Compounds; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; China; Cisplatin; Cost-Benefit Analysis; Deoxycytidine; Docetaxel; ErbB Receptors; Gemcitabine; Humans; Lung Neoplasms; Middle Aged; Mutation; Paclitaxel; Pemetrexed; Protein Kinase Inhibitors; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic | 2019 |
MicroRNA-421 confers paclitaxel resistance by binding to the KEAP1 3'UTR and predicts poor survival in non-small cell lung cancer.
Topics: 3' Untranslated Regions; A549 Cells; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Movement; Cell Proliferation; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; HEK293 Cells; Heterografts; Humans; Kelch-Like ECH-Associated Protein 1; Male; MicroRNAs; Middle Aged; Paclitaxel | 2019 |
PLGA Porous Microspheres Dry Powders for Codelivery of Afatinib-Loaded Solid Lipid Nanoparticles and Paclitaxel: Novel Therapy for EGFR Tyrosine Kinase Inhibitors Resistant Nonsmall Cell Lung Cancer.
Topics: Afatinib; Animals; Carcinoma, Non-Small-Cell Lung; Lung Neoplasms; Male; Microspheres; Nanoparticles; Paclitaxel; Polylactic Acid-Polyglycolic Acid Copolymer; Protein Kinase Inhibitors; Rats; Rats, Sprague-Dawley; Spectroscopy, Fourier Transform Infrared | 2019 |
5-(3,4,5-trimethoxybenzoyl)-4-methyl-2-(p-tolyl) imidazol (BZML) targets tubulin and DNA to induce anticancer activity and overcome multidrug resistance in colorectal cancer cells.
Topics: Antineoplastic Agents; Apoptosis; ATP Binding Cassette Transporter, Subfamily B, Member 1; Caco-2 Cells; Carcinoma, Non-Small-Cell Lung; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Colorectal Neoplasms; DNA; DNA Damage; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; G2 Phase Cell Cycle Checkpoints; HCT116 Cells; Humans; Imidazoles; Lung Neoplasms; Paclitaxel; Tubulin | 2020 |
Survival outcomes of adjuvant chemotherapy with modified weekly nab-paclitaxel and carboplatin for completely resected nonsmall cell lung cancer: FAST-nab.
Topics: Adult; Aged; Aged, 80 and over; Albumins; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Case-Control Studies; Chemotherapy, Adjuvant; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Prognosis; Retrospective Studies; Survival Rate | 2020 |
Overcoming Taxol-resistance in A549 cells: A comprehensive strategy of targeting P-gp transporter, AKT/ERK pathways, and cytochrome P450 enzyme CYP1B1 by 4-hydroxyemodin.
Topics: A549 Cells; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily B; Carcinoma, Non-Small-Cell Lung; Cell Line; Cell Movement; Cell Survival; Cytochrome P-450 CYP1B1; Drug Resistance, Neoplasm; Emodin; Humans; Lung Neoplasms; MAP Kinase Signaling System; Molecular Docking Simulation; Molecular Structure; Paclitaxel; Proteins; Proto-Oncogene Proteins c-akt | 2020 |
[Paclitaxel-associated Acute Pain Syndrome Similarly Occurs in the Patients with or without Previously Administered Non-steroidal Anti-inflammatory Drugs Prior to Paclitaxel Administration].
Topics: Acute Pain; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Female; Humans; Injections; Lung Neoplasms; Male; Middle Aged; Myotoxicity; Paclitaxel; Patient Education as Topic; Retrospective Studies; Severity of Illness Index; Syndrome | 2019 |
A rare case of non-small cell lung cancer choroidal metastasis responding to ALK tyrosine kinase inhibitors.
Topics: Anaplastic Lymphoma Kinase; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Non-Small-Cell Lung; Choroid Neoplasms; Female; Humans; Lung Neoplasms; Middle Aged; Paclitaxel; Protein Kinase Inhibitors | 2020 |
Acute severe radiation pneumonitis among non-small cell lung cancer (NSCLC) patients with moderate pulmonary dysfunction receiving definitive concurrent chemoradiotherapy: Impact of pre-treatment pulmonary function parameters.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Dose Fractionation, Radiation; Dose-Response Relationship, Radiation; Etoposide; Female; Humans; Logistic Models; Lung; Lung Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Paclitaxel; Predictive Value of Tests; Proportional Hazards Models; Radiation Pneumonitis; Radiotherapy, Intensity-Modulated; Respiratory Function Tests; Retrospective Studies; Risk; ROC Curve; Sensitivity and Specificity; Severity of Illness Index | 2020 |
Hsa_circ_0002483 inhibited the progression and enhanced the Taxol sensitivity of non-small cell lung cancer by targeting miR-182-5p.
Topics: A549 Cells; Animals; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Cell Proliferation; Disease Progression; Drug Resistance, Neoplasm; Female; Forkhead Box Protein O1; Forkhead Box Protein O3; Gene Expression Regulation, Neoplastic; GRB2 Adaptor Protein; Heterografts; Humans; Male; Mice; MicroRNAs; Paclitaxel; RNA, Circular | 2019 |
The miRNA-149-5p/MyD88 axis is responsible for ursolic acid-mediated attenuation of the stemness and chemoresistance of non-small cell lung cancer cells.
Topics: A549 Cells; Animals; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Mice, Inbred BALB C; Mice, Nude; MicroRNAs; Myeloid Differentiation Factor 88; Neoplastic Stem Cells; Paclitaxel; Triterpenes; Ursolic Acid; Xenograft Model Antitumor Assays | 2020 |
Nanoparticle albumin-bound paclitaxel in elder patients with advanced squamous non-small-cell lung cancer: A retrospective study.
Topics: Aged; Aged, 80 and over; Albumins; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Paclitaxel; Progression-Free Survival; Retrospective Studies | 2020 |
Cytotoxic chemotherapy in advanced non-small cell lung cancer with poor performance status: A retrospective analysis from routine clinical practice.
Topics: Adenocarcinoma of Lung; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Disease Progression; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Prognosis; Retrospective Studies; Survival Rate | 2020 |
Inability of Current Dosing to Achieve Carboplatin Therapeutic Targets in People with Advanced Non-Small Cell Lung Cancer: Impact of Systemic Inflammation on Carboplatin Exposure and Clinical Outcomes.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Humans; Inflammation; Lung Neoplasms; Paclitaxel | 2020 |
A NAG-Guided Nano-Delivery System for Redox- and pH-Triggered Intracellularly Sequential Drug Release in Cancer Cells.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cytoplasm; Deoxycytidine; Drug Carriers; Drug Delivery Systems; Drug Liberation; Gemcitabine; Humans; Hydrogen-Ion Concentration; Lung Neoplasms; Male; Mice, Inbred BALB C; Nanostructures; Oxidation-Reduction; Paclitaxel; Polymers; Xenograft Model Antitumor Assays | 2020 |
The efficacy of carboplatin plus nanoparticle albumin-bound paclitaxel after cisplatin plus pemetrexed in non-squamous non-small-cell lung cancer patients.
Topics: Adult; Aged; Albumin-Bound Paclitaxel; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Female; Humans; Lung Neoplasms; Male; Middle Aged; Nanoparticles; Paclitaxel; Pemetrexed; Retrospective Studies; Treatment Outcome | 2020 |
Prognostic Variables Associated With Improved Outcomes in Patients With Stage III NSCLC Treated With Chemoradiation Followed by Consolidation Pembrolizumab: A Subset Analysis of a Phase II Study From the Hoosier Cancer Research Network LUN 14-179.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Clinical Trials, Phase II as Topic; Consolidation Chemotherapy; Etoposide; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Paclitaxel; Pemetrexed; Prognosis; Retrospective Studies; Survival Rate | 2020 |
Association Between RET Fusions and Efficacy of Pemetrexed-based Chemotherapy for Patients With Advanced NSCLC in China: A Multicenter Retrospective Study.
Topics: Adenocarcinoma of Lung; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Gene Rearrangement; Humans; Lung Neoplasms; Male; Middle Aged; Oncogene Proteins, Fusion; Paclitaxel; Pemetrexed; Prognosis; Proto-Oncogene Mas; Proto-Oncogene Proteins c-ret; Retrospective Studies; Survival Rate | 2020 |
Retrospective analysis of the effectiveness and tolerability of nab-paclitaxel in Chinese elderly patients with advanced non-small-cell lung carcinoma.
Topics: Adenocarcinoma of Lung; Aged; Aged, 80 and over; Albumins; Asian People; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Paclitaxel; Prognosis; Retrospective Studies; Survival Rate | 2020 |
Crizotinib vs platinum-based chemotherapy as first-line treatment for advanced non-small cell lung cancer with different ROS1 fusion variants.
Topics: Adenocarcinoma of Lung; Adult; Aged; Aged, 80 and over; Antigens, Differentiation, B-Lymphocyte; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Cisplatin; Crizotinib; Deoxycytidine; Docetaxel; Female; Gemcitabine; Histocompatibility Antigens Class II; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Oncogene Fusion; Paclitaxel; Pemetrexed; Platinum Compounds; Progression-Free Survival; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Retrospective Studies; Treatment Outcome | 2020 |
A novel ROS1 G2032 K missense mutation mediates lorlatinib resistance in a patient with ROS1-rearranged lung adenocarcinoma but responds to nab-paclitaxel plus pembrolizumab.
Topics: Adenocarcinoma of Lung; Albumins; Aminopyridines; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; Gene Rearrangement; Humans; Lactams; Lactams, Macrocyclic; Lung Neoplasms; Male; Middle Aged; Mutation, Missense; Paclitaxel; Prognosis; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Pyrazoles | 2020 |
PBK attenuates paclitaxel-induced autophagic cell death by suppressing p53 in H460 non-small-cell lung cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Autophagic Cell Death; Autophagy; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Survival; Gene Expression; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Mitogen-Activated Protein Kinase Kinases; Paclitaxel; Tumor Suppressor Protein p53 | 2020 |
Long-term survival trends in patients with unresectable stage III non-small cell lung cancer receiving chemotherapy and radiation therapy: a SEER cancer registry analysis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Mortality; Neoplasm Staging; Paclitaxel; Retrospective Studies; SEER Program; Survival Rate | 2020 |
Polymorphisms in Glycolysis-Related Genes Are Associated with Clinical Outcomes of Paclitaxel-Cisplatin Chemotherapy in Non-Small Cell Lung Cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Cytokines; Female; Glucose-6-Phosphate Isomerase; Glycolysis; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Phosphofructokinase-1, Liver Type; Polymorphism, Single Nucleotide; Prognosis; Survival Rate; Treatment Outcome | 2020 |
Efficacy and safety of concurrent chemoradiotherapy in ECOG 2 patients with locally advanced non-small-cell lung cancer: a subgroup analysis of a randomized phase III trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Cisplatin; Clinical Trials, Phase III as Topic; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Multicenter Studies as Topic; Paclitaxel; Prognosis; Prospective Studies; Randomized Controlled Trials as Topic; Survival Rate | 2020 |
Shikonin suppresses NEAT1 and Akt signaling in treating paclitaxel-resistant non-small cell of lung cancer.
Topics: A549 Cells; Animals; Carcinoma, Non-Small-Cell Lung; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Humans; Lung Neoplasms; Male; Mice; Naphthoquinones; Paclitaxel; Phosphorylation; Proto-Oncogene Proteins c-akt; RNA, Long Noncoding; Signal Transduction; Xenograft Model Antitumor Assays | 2020 |
FNDC5 promotes paclitaxel sensitivity of non-small cell lung cancers via inhibiting MDR1.
Topics: ATP Binding Cassette Transporter, Subfamily B; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Down-Regulation; Drug Resistance, Neoplasm; Fibronectins; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; NF-kappa B; Paclitaxel; RNA, Messenger | 2020 |
Fabrication and in vivo evaluation of ligand appended paclitaxel and artemether loaded lipid nanoparticulate systems for the treatment of NSCLC: A nanoparticle assisted combination oncotherapy.
Topics: Administration, Oral; Animals; Antineoplastic Combined Chemotherapy Protocols; Artemether; Biological Availability; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Carriers; Drug Compounding; Drug Liberation; Drug Stability; Folic Acid; Humans; Lipids; Lung Neoplasms; Male; Mice, Inbred BALB C; Nanoparticles; Paclitaxel; Polyethylene Glycols; Rats, Sprague-Dawley; Tumor Burden; Xenograft Model Antitumor Assays | 2020 |
Durvalumab-induced Immune-related Hepatitis in a Patient with Non-small Cell Lung Cancer.
Topics: Aged; Antibodies, Monoclonal; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemical and Drug Induced Liver Injury; Female; Hepatitis; Humans; Japan; Lung Neoplasms; Male; Paclitaxel | 2020 |
Chidamide combined with paclitaxel effectively reverses the expression of histone deacetylase in lung cancer.
Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzamides; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Histone Deacetylase 6; Histone Deacetylase Inhibitors; Histone Deacetylases; Humans; Lung Neoplasms; Paclitaxel; Proto-Oncogene Proteins c-myc; Tumor Cells, Cultured | 2020 |
Variants of
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Disease Progression; Female; Humans; Lung Neoplasms; Male; Middle Aged; Organic Cation Transport Proteins; Paclitaxel; Pemetrexed; Polymorphism, Single Nucleotide; Treatment Outcome | 2020 |
Low dose HSP90 inhibition with AUY922 blunts rapid evolution of metastatic and drug resistant phenotypes induced by TGF-β and paclitaxel in A549 cells.
Topics: A549 Cells; Antigens, CD; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; Cadherins; Carcinoma, Non-Small-Cell Lung; Cell Movement; Cell Plasticity; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Gene Expression Regulation, Neoplastic; HSP90 Heat-Shock Proteins; Humans; Isoxazoles; Lung Neoplasms; Multidrug Resistance-Associated Proteins; Paclitaxel; Resorcinols; Signal Transduction; Transforming Growth Factor beta | 2020 |
Comparison of three different chemotherapy regimens for concomitant chemoradiotherapy in locally advanced non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Docetaxel; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Retrospective Studies; Survival Analysis; Treatment Outcome | 2020 |
A Division of Labor between YAP and TAZ in Non-Small Cell Lung Cancer.
Topics: Adaptor Proteins, Signal Transducing; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Line, Tumor; Cell Movement; Chromatin; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Paclitaxel; Trans-Activators; Transcription Factors; Transcriptional Coactivator with PDZ-Binding Motif Proteins; YAP-Signaling Proteins | 2020 |
Circ_0011292 Enhances Paclitaxel Resistance in Non-Small Cell Lung Cancer by Regulating miR-379-5p/TRIM65 Axis.
Topics: Carcinoma, Non-Small-Cell Lung; Cell Proliferation; Humans; Lung Neoplasms; MicroRNAs; Paclitaxel; RNA, Circular; Tripartite Motif Proteins; Ubiquitin-Protein Ligases | 2022 |
Potential monoamine oxidase A inhibitor suppressing paclitaxel-resistant non-small cell lung cancer metastasis and growth.
Topics: Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Humans; Lung Neoplasms; Monoamine Oxidase Inhibitors; Neoplasm Metastasis; Paclitaxel | 2020 |
Synergistic killing effect of paclitaxel and honokiol in non-small cell lung cancer cells through paraptosis induction.
Topics: Animals; Apoptosis; Biphenyl Compounds; Calcium; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Synergism; Endoplasmic Reticulum Stress; Humans; Lignans; Lung Neoplasms; Male; Mice, Inbred BALB C; Mice, Nude; Microtubule-Associated Proteins; Mitochondria; Paclitaxel; Proteasome Endopeptidase Complex; Ubiquitin-Activating Enzymes; Vacuoles | 2021 |
Downregulated Mucin 1 alleviates paclitaxel resistance in non‑small cell lung cancer cells.
Topics: A549 Cells; Antineoplastic Agents, Phytogenic; Apoptosis; bcl-2-Associated X Protein; Carcinoma, Non-Small-Cell Lung; Caspase 3; Cell Proliferation; Cell Survival; Down-Regulation; Drug Resistance, Neoplasm; Humans; Lung Neoplasms; Mucin-1; Paclitaxel; Proto-Oncogene Proteins c-bcl-2; RNA, Small Interfering; Signal Transduction; Transfection; Up-Regulation | 2020 |
Expanding Beyond Maximum Grade: Chemotherapy Toxicity over Time by Age and Performance Status in Advanced Non-Small Cell Lung Cancer in CALGB 9730 (Alliance A151729).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Humans; Lung Neoplasms; Paclitaxel | 2021 |
Treatment of psoriasis vulgaris with guselkumab in a patient with non-small cell lung cancer.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Dermatologic Agents; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Psoriasis | 2020 |
Diagnostic and therapeutic evaluation of folate-targeted paclitaxel and vinorelbine encapsulating theranostic liposomes for non-small cell lung cancer.
Topics: Animals; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Folic Acid; Liposomes; Lung Neoplasms; Mice; Mice, Inbred C57BL; Paclitaxel; Precision Medicine; Tissue Distribution; Vinorelbine | 2021 |
Cost-Effectiveness of the Addition of Bevacizumab to First-Line Chemotherapy With Carboplatin and Paclitaxel in Patients With Non-Small Cell Lung Cancer.
Topics: Bevacizumab; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cost-Benefit Analysis; Drug Therapy; Humans; Markov Chains; Paclitaxel | 2020 |
A heavily pre-treated adenocarcinoma patient with EGFR exon 20 insertion mutation responded to pembrolizumab plus nab-paclitaxel/bevacizumab: a case report.
Topics: Adenocarcinoma; Adult; Albumins; Antibodies, Monoclonal, Humanized; Bevacizumab; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Exons; Female; Humans; Lung Neoplasms; Mutagenesis, Insertional; Paclitaxel | 2021 |
Case Report: PD-1 Inhibitor Is Active in Lung Adenocarcinoma With B Cell Deficiency.
Topics: Adenocarcinoma of Lung; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; B-Lymphocytes; Bevacizumab; Carboplatin; Carcinoma, Non-Small-Cell Lung; Humans; Immune Checkpoint Inhibitors; Immunologic Factors; Lenalidomide; Lung Neoplasms; Lymphoma, B-Cell, Marginal Zone; Male; Paclitaxel; Programmed Cell Death 1 Receptor; Progression-Free Survival; Rituximab | 2020 |
Targeted delivery of quercetin by nanoparticles based on chitosan sensitizing paclitaxel-resistant lung cancer cells to paclitaxel.
Topics: Animals; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Chitosan; Lung Neoplasms; Nanoparticles; Paclitaxel; Prospective Studies; Quercetin | 2021 |
Treatment sequencing for the care of patients with advanced or metastatic non-small cell lung cancer in the United States.
Topics: Adolescent; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Female; Humans; Lung Neoplasms; Male; Paclitaxel; Pemetrexed; United States | 2021 |
Overexpression of hsa_circ_0002874 promotes resistance of non-small cell lung cancer to paclitaxel by modulating miR-1273f/MDM2/p53 pathway.
Topics: A549 Cells; Aged; Antineoplastic Agents, Phytogenic; Apoptosis; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Female; Humans; Lung Neoplasms; Male; MicroRNAs; Middle Aged; Paclitaxel; Proto-Oncogene Proteins c-mdm2; RNA, Circular; Signal Transduction; Tumor Suppressor Protein p53 | 2021 |
Repurposing of a monoamine oxidase A inhibitor‑heptamethine carbocyanine dye conjugate for paclitaxel‑resistant non‑small cell lung cancer.
Topics: Animals; Antineoplastic Agents; Carbocyanines; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Drug Repositioning; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Mice; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Paclitaxel; Xenograft Model Antitumor Assays | 2021 |
First-line atezolizumab plus chemotherapy in advanced non-squamous non-small cell lung cancer: a cost-effectiveness analysis from China.
Topics: Albumins; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; China; Cost-Benefit Analysis; Humans; Lung Neoplasms; Markov Chains; Paclitaxel; Quality-Adjusted Life Years | 2021 |
Chemoradiotherapy by intensity-modulated radiation therapy with simultaneous integrated boost in locally advanced or oligometastatic non-small-cell lung cancer-a two center experience.
Topics: Adult; Aged; Aged, 80 and over; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Cisplatin; Cone-Beam Computed Tomography; Female; Follow-Up Studies; Four-Dimensional Computed Tomography; Hematologic Diseases; Humans; Lung Neoplasms; Lymphatic Irradiation; Lymphatic Metastasis; Male; Middle Aged; Paclitaxel; Positron Emission Tomography Computed Tomography; Progression-Free Survival; Radiation Injuries; Radiation Pneumonitis; Radiotherapy Planning, Computer-Assisted; Radiotherapy, Image-Guided; Radiotherapy, Intensity-Modulated; Retrospective Studies; Tumor Burden; Vinorelbine | 2021 |
BET inhibitors combined with chemotherapy synergistically inhibit the growth of NSCLC cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Azepines; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Cisplatin; Drug Synergism; Epigenesis, Genetic; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Heterocyclic Compounds, 4 or More Rings; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Paclitaxel; Prognosis; Signal Transduction; Transcription Factors; Triazoles | 2021 |
MiR-221-3p-mediated downregulation of MDM2 reverses the paclitaxel resistance of non-small cell lung cancer in vitro and in vivo.
Topics: A549 Cells; Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Down-Regulation; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Male; Mice, Inbred BALB C; Mice, Nude; MicroRNAs; Paclitaxel; Proto-Oncogene Proteins c-mdm2; Signal Transduction; Tumor Suppressor Protein p53; Xenograft Model Antitumor Assays | 2021 |
Serum Proteomic Profiling Reveals Differentially Expressed IGHG3 and A1AG1 as Potential Predictors of Chemotherapeutic Response in Advanced Non-small Cell Lung Cancer.
Topics: A549 Cells; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carboplatin; Carcinoma, Non-Small-Cell Lung; Clinical Decision-Making; Drug Resistance, Neoplasm; Female; Humans; Lung Neoplasms; Male; Middle Aged; Orosomucoid; Paclitaxel; Predictive Value of Tests; Proteomics; Treatment Outcome | 2021 |
Molecular Analysis of
Topics: Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Disease-Free Survival; Docetaxel; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Humans; Kruppel-Like Transcription Factors; Lung Neoplasms; Male; Neoplasm Proteins; Paclitaxel; Protein Isoforms; Survival Rate | 2021 |
Comparison of Chemotherapeutic Regimens Frequently Used in Metastatic Non-squamous NSCLC Treatment.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Female; Humans; Immune Checkpoint Inhibitors; Male; Middle Aged; Neoplasm Metastasis; Paclitaxel; Pemetrexed; Progression-Free Survival | 2021 |
Van der Waals force-driven indomethacin-ss-paclitaxel nanodrugs for reversing multidrug resistance and enhancing NSCLC therapy.
Topics: Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Humans; Indomethacin; Lung Neoplasms; Paclitaxel; Tumor Microenvironment | 2021 |
Circ_0001821 knockdown suppresses growth, metastasis, and TAX resistance of non-small-cell lung cancer cells by regulating the miR-526b-5p/GRK5 axis.
Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line; Cell Proliferation; Drug Resistance, Neoplasm; G-Protein-Coupled Receptor Kinase 5; Humans; Lung Neoplasms; Male; Mice, Inbred BALB C; Mice, Nude; MicroRNAs; Paclitaxel; RNA, Circular | 2021 |
Preclinical tolerance evaluation of the addition of a cisplatin-based dry powder for inhalation to the conventional carboplatin-paclitaxel doublet for treatment of non-small cell lung cancer.
Topics: Administration, Inhalation; Aged; Animals; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Female; Humans; Lung Neoplasms; Male; Mice; Mice, Inbred BALB C; Paclitaxel; Powders | 2021 |
Feasibility of intensity modulated radiotherapy with involved field radiotherapy for Japanese patients with locally advanced non-small cell lung cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Combined Modality Therapy; Dose-Response Relationship, Radiation; Feasibility Studies; Female; Humans; Japan; Lung Neoplasms; Male; Middle Aged; Multimodal Imaging; Neoplasm Metastasis; Organoplatinum Compounds; Organs at Risk; Paclitaxel; Radiation Pneumonitis; Radiotherapy Planning, Computer-Assisted; Radiotherapy, Conformal; Radiotherapy, Intensity-Modulated; Retrospective Studies; User-Computer Interface | 2021 |
Drug-interaction between paclitaxel and goshajinkigan extract and its constituents.
Topics: Carcinoma, Non-Small-Cell Lung; Cytochrome P-450 CYP2C8; Cytochrome P-450 CYP3A; Drug Interactions; Drugs, Chinese Herbal; Humans; Lung Neoplasms; Microsomes, Liver; Paclitaxel | 2022 |
Development of paclitaxel loaded pegylated gelatin targeted nanoparticles for improved treatment efficacy in non-small cell lung cancer (NSCLC): an in vitro and in vivo evaluation study.
Topics: A549 Cells; Animals; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Female; Gelatin; Humans; Lung Neoplasms; Mice; Mice, Inbred BALB C; Nanoparticles; Paclitaxel; Polyethylene Glycols; Xenograft Model Antitumor Assays | 2021 |
A novel multi-functionalized multicellular nanodelivery system for non-small cell lung cancer photochemotherapy.
Topics: A549 Cells; Animals; Apoptosis; Biomimetics; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Carriers; Erythrocyte Membrane; Erythrocytes; Humans; Liposomes; Lung Neoplasms; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Nanoparticle Drug Delivery System; Nanoparticles; Neoplasms; Paclitaxel; Particle Size; Photochemotherapy; Rats, Sprague-Dawley; RAW 264.7 Cells; Reactive Oxygen Species; Xenograft Model Antitumor Assays | 2021 |
Impact of Maintenance Therapy for Patients with Non-small Cell Lung Cancer in a Real-world Setting.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Disease Progression; Female; Humans; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Organoplatinum Compounds; Paclitaxel; Pemetrexed; Prospective Studies; Research Design; Treatment Outcome | 2017 |
Akt targeting as a strategy to boost chemotherapy efficacy in non-small cell lung cancer through metabolism suppression.
Topics: Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Culture Techniques; Cell Cycle Checkpoints; Cell Line, Tumor; Disease Models, Animal; Energy Metabolism; Glycolysis; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Mice; Mitochondria; Paclitaxel; Phosphorylcholine; Proto-Oncogene Proteins c-akt; Signal Transduction; Xenograft Model Antitumor Assays | 2017 |
Hypoxia Induces Multidrug Resistance via Enhancement of Epidermal Growth Factor-Like Domain 7 Expression in Non-Small Lung Cancer Cells.
Topics: A549 Cells; ATP Binding Cassette Transporter, Subfamily B, Member 1; Calcium-Binding Proteins; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cell Hypoxia; Cell Line, Tumor; Cell Survival; Deoxycytidine; Drug Resistance, Multiple; Drug Resistance, Neoplasm; EGF Family of Proteins; Endothelial Growth Factors; Gemcitabine; Humans; Lung Neoplasms; Paclitaxel; RNA Interference; RNA, Small Interfering | 2017 |
Curcumin increases the sensitivity of Paclitaxel-resistant NSCLC cells to Paclitaxel through microRNA-30c-mediated MTA1 reduction.
Topics: Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Curcumin; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Histone Deacetylases; Humans; MicroRNAs; Paclitaxel; Repressor Proteins; Trans-Activators | 2017 |
Prognostic Index for Survival in Patients with Advanced Non-Small-Cell Lung Cancer Treated with Third-Generation Agents.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; C-Reactive Protein; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Leukocytes; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Prognosis; Proportional Hazards Models; Retrospective Studies; Survival Rate; Taxoids; Vinblastine; Vinorelbine | 2017 |
PTD modified paclitaxel anti-resistant liposomes for treatment of drug-resistant non-small cell lung cancer.
Topics: Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Carriers; Drug Liberation; Drug Resistance, Neoplasm; Humans; Liposomes; Lung Neoplasms; Male; Mice, Inbred C57BL; Oligopeptides; Paclitaxel; Particle Size; Surface Properties; Tamoxifen; Xenograft Model Antitumor Assays | 2018 |
miR-30a-5p enhances paclitaxel sensitivity in non-small cell lung cancer through targeting BCL-2 expression.
Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Male; Mice, Inbred BALB C; Mice, Nude; MicroRNAs; Paclitaxel; Proto-Oncogene Proteins c-bcl-2 | 2017 |
A Novel Indication for Panobinostat as a Senolytic Drug in NSCLC and HNSCC.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Survival; Cellular Senescence; Dose-Response Relationship, Drug; Drug Synergism; Histone Deacetylase Inhibitors; Humans; Lung Neoplasms; Paclitaxel; Panobinostat; Squamous Cell Carcinoma of Head and Neck | 2017 |
The Cdc2/Cdk1 inhibitor, purvalanol A, enhances the cytotoxic effects of taxol through Op18/stathmin in non-small cell lung cancer cells in vitro.
Topics: Carcinoma, Non-Small-Cell Lung; CDC2 Protein Kinase; Cell Line, Tumor; Humans; Lung Neoplasms; Paclitaxel; Purines; Stathmin | 2017 |
Chemotherapy for pulmonary large cell neuroendocrine carcinomas: does the regimen matter?
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Carcinoma, Large Cell; Carcinoma, Neuroendocrine; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Etoposide; Female; Gemcitabine; Humans; Male; Middle Aged; Netherlands; Paclitaxel; Pemetrexed; Registries; Small Cell Lung Carcinoma; Taxoids; Vinblastine; Vinorelbine | 2017 |
Expanding the search for significant EGFR mutations in NSCLC outside of the tyrosine kinase domain with next-generation sequencing.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Algorithms; Carboplatin; Carcinoma, Non-Small-Cell Lung; Computer Simulation; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; High-Throughput Nucleotide Sequencing; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Paclitaxel; Polymorphism, Single Nucleotide; Protein Domains; Protein Kinase Inhibitors | 2017 |
RNAi targeting STMN alleviates the resistance to taxol and collectively contributes to down regulate the malignancy of NSCLC cells in vitro and in vivo.
Topics: Animals; Apoptosis; Autocrine Communication; Carcinogenesis; Carcinoma, Non-Small-Cell Lung; Caspases; Cell Line, Tumor; Cell Movement; Cell Proliferation; Down-Regulation; Drug Resistance, Neoplasm; Enzyme Activation; Extracellular Signal-Regulated MAP Kinases; Humans; Inhibitory Concentration 50; Interleukin-10; Ki-67 Antigen; Lung Neoplasms; Mice, Inbred BALB C; Mice, Nude; NF-kappa B; Paclitaxel; Proto-Oncogene Proteins c-bcl-2; RNA Interference; Stathmin; Tumor Stem Cell Assay; Xenograft Model Antitumor Assays | 2018 |
Antitumor effectiveness of a combined therapy with a new cucurbitacin B derivative and paclitaxel on a human lung cancer xenograft model.
Topics: A549 Cells; Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cell Proliferation; Female; Humans; Ki-67 Antigen; Lung Neoplasms; Mice, Inbred BALB C; Mice, Nude; Paclitaxel; Radiopharmaceuticals; Time Factors; Toxicity Tests, Subchronic; Triterpenes; Tumor Burden; Whole Body Imaging; Xenograft Model Antitumor Assays | 2017 |
Evaluation of Natriuretic Peptide in Non-small Cell Lung Cancer Patients Treated with Bevacizumab Together with Carboplatin-Paclitaxel: A Prospective Study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; Female; Humans; Lung Neoplasms; Male; Middle Aged; Natriuretic Peptides; Paclitaxel; Plasma; Prospective Studies | 2017 |
Comparative Effectiveness and Resource Usage in Patients Receiving First-line Taxol-based Chemotherapy for Stage IV NSCLC.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Humans; Lung Neoplasms; Neoplasm Staging; Paclitaxel | 2018 |
Efficacy and Safety of Nab-Paclitaxel as Second-line Chemotherapy for Locally Advanced and Metastatic Non-small Cell Lung Cancer.
Topics: Aged; Aged, 80 and over; Albumins; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Paclitaxel; Retreatment; Risk Factors; Survival Analysis; Treatment Outcome | 2017 |
Synergistic Effect of Notch-3-Specific Inhibition and Paclitaxel in Non-Small Cell Lung Cancer (NSCLC) Cells Via Activation of The Intrinsic Apoptosis Pathway.
Topics: Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Humans; Lung Neoplasms; Paclitaxel; Receptor, Notch3; Tumor Stem Cell Assay; Up-Regulation | 2017 |
The association of genetic variations in DNA repair pathways with severe toxicities in NSCLC patients undergoing platinum-based chemotherapy.
Topics: Aged; Antineoplastic Agents; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cohort Studies; DNA Repair; Female; Genotype; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Polymorphism, Single Nucleotide | 2017 |
[Nearly Complete Response after Second-Line Therapy with Nab-Paclitaxel Monotherapy in a Patient with Recurrent Advanced Non-Small Cell Lung Cancer].
Topics: Albumins; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Female; Humans; Lung Neoplasms; Magnetic Resonance Imaging; Middle Aged; Multimodal Imaging; Paclitaxel; Recurrence; Tomography, X-Ray Computed; Treatment Outcome | 2017 |
Erythrocyte Membrane-Wrapped pH Sensitive Polymeric Nanoparticles for Non-Small Cell Lung Cancer Therapy.
Topics: Biological Transport; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Carriers; Drug Liberation; Erythrocyte Membrane; Half-Life; Hemolysis; Humans; Hydrogen-Ion Concentration; Lung Neoplasms; Nanoparticles; Paclitaxel; Particle Size; Polyglutamic Acid; Polymers | 2017 |
Nab-Paclitaxel in combination with Cisplatin Versus Docetaxel Plus Cisplatin as First-Line Therapy in Non-small Cell Lung Cancer.
Topics: Aged; Albumins; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Docetaxel; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neutropenia; Paclitaxel; Retrospective Studies; Treatment Outcome | 2017 |
Survival advantage for etoposide/cisplatin over paclitaxel/carboplatin concurrent chemoradiation in patients with inoperable stage III NSCLC: a subgroup analysis for ECOG 2 patients would be of great interest.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Etoposide; Humans; Lung Neoplasms; Neoplasm Staging; Paclitaxel | 2017 |
Comparison of carboplatin and paclitaxel with or without bevacizumab in chemotherapeutic regimens for unresectable stage III non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Non-Small-Cell Lung; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel | 2017 |
miR-339-5p downregulation contributes to Taxol resistance in small-cell lung cancer by targeting α1,2-fucosyltransferase 1.
Topics: A549 Cells; Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Base Sequence; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Survival; Drug Resistance, Neoplasm; Female; Fucosyltransferases; Galactoside 2-alpha-L-fucosyltransferase; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; MicroRNAs; Molecular Mimicry; Oligodeoxyribonucleotides; Paclitaxel; Signal Transduction; Tumor Burden; Xenograft Model Antitumor Assays | 2017 |
The safety and efficacy of carboplatin plus nanoparticle albumin-bound paclitaxel in the treatment of non-small cell lung cancer patients with interstitial lung disease.
Topics: Adult; Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Female; Humans; Kaplan-Meier Estimate; Lung Diseases, Interstitial; Lung Neoplasms; Male; Middle Aged; Nanoparticles; Paclitaxel; Retrospective Studies; Treatment Outcome | 2018 |
Nicotine Prevents and Reverses Paclitaxel-Induced Mechanical Allodynia in a Mouse Model of CIPN.
Topics: Animals; Antineoplastic Agents, Phytogenic; Bridged-Ring Compounds; Carcinoma, Non-Small-Cell Lung; Disease Models, Animal; Hyperalgesia; Lung Neoplasms; Male; Mice; Mice, Inbred C57BL; Nicotine; Paclitaxel; Peripheral Nervous System Diseases; Receptors, Cholinergic; Taxoids | 2018 |
Response to 'Survival advantage for etoposide/cisplatin over paclitaxel/carboplatin concurrent chemoradiation in patients with inoperable stage III NSCLC: a subgroup analysis for ECOG 2 patients would be of great interest'.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Etoposide; Humans; Lung Neoplasms; Neoplasm Staging; Paclitaxel; Survival Analysis | 2017 |
Tumor Progression of Non-Small Cell Lung Cancer Controlled by Albumin and Micellar Nanoparticles of Itraconazole, a Multitarget Angiogenesis Inhibitor.
Topics: Albumins; Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Disease Progression; Humans; Injections, Intravenous; Itraconazole; Lung; Lung Neoplasms; Male; Mice; Mice, Inbred NOD; Mice, SCID; Micelles; Nanoparticles; Paclitaxel; Polyethylene Glycols; Rats; Rats, Sprague-Dawley; Signal Transduction; Xenograft Model Antitumor Assays | 2017 |
[Clinical analysis of 36 cases of advanced non-small cell lung cancer (NSCLC) with performance status (PS) scores between 2 and 4].
Topics: Anti-Bacterial Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease Progression; Disease-Free Survival; Docetaxel; Female; Gemcitabine; Humans; Hypoxia; Lung Neoplasms; Male; Neoplasm Staging; Paclitaxel; Pemetrexed; Remission Induction; Response Evaluation Criteria in Solid Tumors; Severity of Illness Index; Taxoids | 2017 |
Rsf-1 Influences the Sensitivity of Non-Small Cell Lung Cancer to Paclitaxel by Regulating NF-κB Pathway and Its Downstream Proteins.
Topics: Animals; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; Female; Gene Knockout Techniques; Humans; Lung; Lung Neoplasms; Mice, Nude; NF-kappa B; Nuclear Proteins; Paclitaxel; Signal Transduction; Trans-Activators | 2017 |
Novel anti-cancer drug COTI-2 synergizes with therapeutic agents and does not induce resistance or exhibit cross-resistance in human cancer cell lines.
Topics: Aminoquinolines; Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cisplatin; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Lung Neoplasms; Mice; Paclitaxel; Thiosemicarbazones; Vinblastine; Vinorelbine; Xenograft Model Antitumor Assays | 2018 |
Sensitivity to chemotherapeutics of NSCLC cells with acquired resistance to EGFR-TKIs is mediated by T790M mutation or epithelial-mesenchymal transition.
Topics: Biomarkers, Tumor; Bridged-Ring Compounds; Carcinogenesis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Docetaxel; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; ErbB Receptors; Gefitinib; Gene Knockdown Techniques; Humans; Mutation; Neoplastic Stem Cells; Paclitaxel; Protein Kinase Inhibitors; Quinazolines; Taxoids | 2018 |
Radiation Dose to the Thoracic Vertebral Bodies Is Associated With Acute Hematologic Toxicities in Patients Receiving Concurrent Chemoradiation for Lung Cancer: Results of a Single-Center Retrospective Analysis.
Topics: Acute Disease; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Cisplatin; Etoposide; Female; Hematologic Diseases; Humans; Leukopenia; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Neutropenia; Organs at Risk; Paclitaxel; Probability; Radiation Dosage; Retrospective Studies; ROC Curve; Small Cell Lung Carcinoma; Thoracic Vertebrae | 2018 |
The Safety and Efficacy of Treatment with Nab-paclitaxel and Carboplatin for Patients with Advanced Squamous Non-small Cell Lung Cancer Concurrent with Idiopathic Interstitial Pneumonias.
Topics: Aged; Aged, 80 and over; Albumins; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Comorbidity; Female; Humans; Idiopathic Interstitial Pneumonias; Lung Neoplasms; Male; Paclitaxel; Prospective Studies; Retrospective Studies | 2018 |
Overcoming drug-resistant lung cancer by paclitaxel loaded tetrahedral DNA nanostructures.
Topics: A549 Cells; Antineoplastic Agents, Phytogenic; Apoptosis; ATP Binding Cassette Transporter, Subfamily B; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; DNA; Drug Carriers; Drug Resistance, Neoplasm; Humans; Lung Neoplasms; Micelles; Nanostructures; Paclitaxel | 2018 |
Evaluation of Anti-Metastatic Potential of the Combination of Fisetin with Paclitaxel on A549 Non-Small Cell Lung Cancer Cells.
Topics: A549 Cells; Actins; Antineoplastic Agents; Apoptosis; Biomarkers; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Drug Synergism; Flavonoids; Flavonols; Gene Expression Profiling; Humans; Lung Neoplasms; Neoplasm Metastasis; Paclitaxel; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Signal Transduction; TOR Serine-Threonine Kinases; Vimentin | 2018 |
Paclitaxel and Erlotinib-co-loaded Solid Lipid Core Nanocapsules: Assessment of Physicochemical Characteristics and Cytotoxicity in Non-small Cell Lung Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Dose-Response Relationship, Drug; Drug Compounding; Drug Liberation; Drug Screening Assays, Antitumor; Drug Synergism; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Nanocapsules; Paclitaxel | 2018 |
The clinical efficacy and safety of paclitaxel combined with avastin for NSCLC patients diagnosed with malignant pleural effusion.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Pleural Effusion, Malignant; Quality of Life; Safety; Survival Analysis; Treatment Outcome | 2018 |
Chemotherapy treatment is associated with altered PD-L1 expression in lung cancer patients.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; B7-H1 Antigen; Biopsy; Bronchoscopy; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Immunohistochemistry; Leukocytes, Mononuclear; Lung Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Programmed Cell Death 1 Receptor | 2018 |
The Tradition of the Rising Sun: When Geography Counts.
Topics: Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Geography; Humans; Lung Neoplasms; Paclitaxel; Tegafur; Uracil | 2018 |
High expression of Aurora-B is correlated with poor prognosis and drug resistance in non-small cell lung cancer.
Topics: A549 Cells; Apoptosis; Aurora Kinase B; Carcinoma, Non-Small-Cell Lung; Cell Proliferation; Cisplatin; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Humans; Male; Paclitaxel; Prognosis | 2018 |
Interleukin-22 (IL-22) Regulates Apoptosis of Paclitaxel-Resistant Non-Small Cell Lung Cancer Cells Through C-Jun N-Terminal Kinase Signaling Pathway.
Topics: A549 Cells; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Proliferation; Drug Resistance, Neoplasm; Gene Knockdown Techniques; Humans; Inhibitory Concentration 50; Interleukin-22; Interleukins; JNK Mitogen-Activated Protein Kinases; Lung Neoplasms; MAP Kinase Signaling System; Paclitaxel; Up-Regulation | 2018 |
Interpretation of Results from Under-accruing Studies.
Topics: Bevacizumab; Carboplatin; Carcinoma, Non-Small-Cell Lung; Humans; Lung Neoplasms; Metformin; Paclitaxel | 2018 |
[Salvage Surgery after Radical Chemotherapy for N3 Non-small Cell Lung Cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Paclitaxel; Salvage Therapy; Treatment Outcome | 2018 |
Do older patients with non-small cell lung cancer also benefit from first-line platinum-based doublet chemotherapy? Observations from a pooled analysis of 730 prospectively-treated patients (Alliance Study A151622).
Topics: Age Factors; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Neoplasm Staging; Paclitaxel; Pemetrexed; Prospective Studies | 2018 |
Nanoformulated paclitaxel and AZD9291 synergistically eradicate non-small-cell lung cancers in vivo.
Topics: Acrylamides; Aniline Compounds; Animals; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Drug Delivery Systems; Drug Liberation; Drug Resistance, Neoplasm; Humans; Mice; Paclitaxel; Xenograft Model Antitumor Assays | 2018 |
Quality-adjusted Outcomes Stratified by Response in Patients With Advanced Non-Small-cell Lung Cancer Receiving First-line nab-Paclitaxel/Carboplatin or Paclitaxel/Carboplatin.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Clinical Trials, Phase III as Topic; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Quality-Adjusted Life Years; Retrospective Studies; Survival Rate; Treatment Outcome | 2018 |
A novel strategy of EGFR‑TKI combined chemotherapy in the treatment of human lung cancer with EGFR‑sensitive mutation.
Topics: A549 Cells; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Drug Synergism; ErbB Receptors; Gefitinib; Gemcitabine; Humans; Lung Neoplasms; Mutation; Paclitaxel; Protein Kinase Inhibitors; Quinazolines | 2018 |
Comparing first-line treatment patterns and clinical outcomes of patients with pan-negative advanced non-squamous non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Pemetrexed; Platinum; Retrospective Studies; Survival Analysis; Treatment Outcome; Vinorelbine | 2018 |
Longitudinal Evaluation of Lung Function in Patients With Advanced Non-Small Cell Lung Cancer Treated With Concurrent Chemoradiation Therapy.
Topics: Aged; Airway Resistance; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Female; Forced Expiratory Volume; Humans; Lung; Lung Neoplasms; Male; Middle Aged; Oscillometry; Paclitaxel; Plethysmography, Whole Body; Prospective Studies; Respiratory Function Tests; Vital Capacity; Walk Test | 2018 |
Frailty assessment predicts toxicity during first cycle chemotherapy for advanced lung cancer regardless of chronologic age.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Female; Frailty; Geriatric Assessment; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Proportional Hazards Models | 2019 |
Functional paclitaxel plus honokiol micelles destroying tumour metastasis in treatment of non-small-cell lung cancer.
Topics: Animals; Antineoplastic Agents; Apoptosis; Biphenyl Compounds; Carcinoma, Non-Small-Cell Lung; Cell Adhesion; Cell Line, Tumor; Cell Survival; Dequalinium; Drug Interactions; Drug Liberation; Humans; Lignans; Lung Neoplasms; Mice; Micelles; Neoplasm Metastasis; Paclitaxel; Temperature; Xenograft Model Antitumor Assays | 2018 |
Synergistic Anticancer Activity of Combined Use of Caffeic Acid with Paclitaxel Enhances Apoptosis of Non-Small-Cell Lung Cancer H1299 Cells in Vivo and in Vitro.
Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Caffeic Acids; Carcinoma, Non-Small-Cell Lung; Caspase 3; Caspase 9; Cell Line; Drug Synergism; Female; G1 Phase Cell Cycle Checkpoints; Humans; JNK Mitogen-Activated Protein Kinases; Lung Neoplasms; Mice, Nude; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Paclitaxel; Proliferating Cell Nuclear Antigen; Proto-Oncogene Proteins c-bcl-2 | 2018 |
Knockdown of miR‑935 increases paclitaxel sensitivity via regulation of SOX7 in non‑small‑cell lung cancer.
Topics: 3' Untranslated Regions; bcl-2-Associated X Protein; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Humans; Lung Neoplasms; Male; MicroRNAs; Middle Aged; Paclitaxel; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-bcl-2; RNA Interference; SOXF Transcription Factors | 2018 |
Profiles and Bioinformatics Analysis of Differentially Expressed Circrnas in Taxol-Resistant Non-Small Cell Lung Cancer Cells.
Topics: A549 Cells; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Computational Biology; Down-Regulation; Drug Resistance, Neoplasm; Gene Regulatory Networks; Humans; Lung Neoplasms; MicroRNAs; Oligonucleotide Array Sequence Analysis; Paclitaxel; RNA; RNA, Circular; Transcriptome; Up-Regulation | 2018 |
Improvement of Mycobacterium abscessus Pulmonary Disease after Nivolumab Administration in a Patient with Advanced Non-small Cell Lung Cancer.
Topics: Aged; Albumins; Anti-Bacterial Agents; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Non-Small-Cell Lung; Humans; Lung Neoplasms; Male; Mycobacterium abscessus; Mycobacterium Infections, Nontuberculous; Nivolumab; Paclitaxel; Pneumonia, Bacterial; Sputum; Treatment Outcome | 2018 |
Paclitaxel promotes lung cancer cell apoptosis via MEG3-P53 pathway activation.
Topics: A549 Cells; Antineoplastic Agents, Phytogenic; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Proliferation; Cisplatin; Humans; Lung Neoplasms; Paclitaxel; Reactive Oxygen Species; RNA, Long Noncoding; RNA, Small Interfering; Tumor Suppressor Protein p53; Up-Regulation | 2018 |
[Induction Chemoradiotherapy Followed by Surgery in Non-small-cell Lung Cancer;a Retrospective Study].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Chemoradiotherapy; Humans; Lung Neoplasms; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Radiotherapy Dosage; Retrospective Studies | 2018 |
[Efficacy and Safety of Carboplatin/Nanoparticle Albumin-Bound Paclitaxel Combination Chemotherapy in Patients with Advanced Non-Small-Cell Lung Cancer or Recurrent Non-Small-Cell Lung Cancer Following Surgery].
Topics: Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Recurrence; Retrospective Studies | 2018 |
Selonsertib (GS-4997), an ASK1 inhibitor, antagonizes multidrug resistance in ABCB1- and ABCG2-overexpressing cancer cells.
Topics: Adenosine Triphosphatases; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily G, Member 2; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cell Line, Tumor; Colonic Neoplasms; Drug Resistance, Multiple; Drug Resistance, Neoplasm; HEK293 Cells; Humans; Lung Neoplasms; MAP Kinase Kinase Kinase 5; Mitoxantrone; Models, Molecular; Neoplasm Proteins; Neoplasms; Paclitaxel; Protein Kinase Inhibitors | 2019 |
The Novel Autophagy Inhibitor Alpha-Hederin Promoted Paclitaxel Cytotoxicity by Increasing Reactive Oxygen Species Accumulation in Non-Small Cell Lung Cancer Cells.
Topics: Apoptosis; Autophagosomes; Autophagy; Carcinoma, Non-Small-Cell Lung; Cathepsins; Cell Line, Tumor; Cell Proliferation; Humans; Hydrogen-Ion Concentration; Lung Neoplasms; Lysosomes; Oleanolic Acid; Paclitaxel; Reactive Oxygen Species; Saponins; Tubulin Modulators | 2018 |
Paclitaxel-Loaded Core-Shell Magnetic Nanoparticles and Cold Atmospheric Plasma Inhibit Non-Small Cell Lung Cancer Growth.
Topics: A549 Cells; Animals; Carcinoma, Non-Small-Cell Lung; Drug Carriers; Drug Resistance, Neoplasm; Humans; Lung Neoplasms; Nanoparticles; Paclitaxel; Plasma Gases | 2018 |
Sulforaphane metabolites reduce resistance to paclitaxel via microtubule disruption.
Topics: A549 Cells; Aged; Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Proliferation; Drug Combinations; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; HSP70 Heat-Shock Proteins; Humans; Isothiocyanates; Lung Neoplasms; Male; Microtubules; Middle Aged; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Neoplasm Grading; Paclitaxel; Proteasome Endopeptidase Complex; RNA, Small Interfering; Signal Transduction; Sulfoxides; Tubulin | 2018 |
Improving Drug Delivery of Micellar Paclitaxel against Non-Small Cell Lung Cancer by Coloading Itraconazole as a Micelle Stabilizer and a Tumor Vascular Manipulator.
Topics: Animals; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Drug Delivery Systems; Humans; Itraconazole; Micelles; Paclitaxel; Polymers | 2018 |
Should patients with stage IB non-small cell lung cancer receive adjuvant chemotherapy? A comparison of survival between the 8th and 7th editions of the AJCC TNM staging system for stage IB patients.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Cisplatin; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Paclitaxel; Retrospective Studies; Survival Rate | 2019 |
An expression quantitative trait locus variant for LKB1 gene predicts the clinical outcomes of chemotherapy in patients with non-small cell lung cancer.
Topics: Aged; AMP-Activated Protein Kinase Kinases; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Polymorphism, Single Nucleotide; Promoter Regions, Genetic; Protein Serine-Threonine Kinases; Quantitative Trait Loci; Survival Analysis; Treatment Outcome | 2018 |
[Bilateral cystoid macular edema on Paclitaxel: Case report].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Female; Fluorescein Angiography; Humans; Lung Neoplasms; Macular Edema; Middle Aged; Paclitaxel; Tomography, Optical Coherence | 2019 |
Introduction of exogenous wild‑type p53 mediates the regulation of oncoprotein 18/stathmin signaling via nuclear factor‑κB in non‑small cell lung cancer NCI‑H1299 cells.
Topics: Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; CDC2 Protein Kinase; Cell Line, Tumor; Cell Proliferation; Down-Regulation; Extracellular Signal-Regulated MAP Kinases; Gene Expression Regulation, Neoplastic; Humans; Interleukin-10; Lung Neoplasms; NF-kappa B; Paclitaxel; Phosphorylation; Signal Transduction; Stathmin; Tumor Suppressor Protein p53 | 2019 |
Daurinoline suppressed the migration and invasion of chemo-resistant human non-small cell lung cancer cells by reversing EMT and Notch-1 and sensitized the cells to Taxol.
Topics: Alkaloids; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Movement; Cell Proliferation; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Humans; Lung Neoplasms; Paclitaxel; Receptor, Notch1; Wound Healing | 2019 |
Hospitalization and Survival of Medicare Patients Treated With Carboplatin Plus Paclitaxel or Pemetrexed for Metastatic, Nonsquamous, Non-Small Cell Lung Cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carboplatin; Carcinoma, Non-Small-Cell Lung; Female; Hospitalization; Humans; Lung Neoplasms; Male; Paclitaxel; Pemetrexed; Propensity Score; Retrospective Studies | 2018 |
Calpain-2 Enhances Non-Small Cell Lung Cancer Progression and Chemoresistance to Paclitaxel via EGFR-pAKT Pathway.
Topics: Animals; Apoptosis; Calpain; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Movement; Cell Proliferation; Drug Resistance, Neoplasm; ErbB Receptors; Female; Flow Cytometry; Gene Expression Regulation, Neoplastic; Humans; Immunohistochemistry; Lung Neoplasms; Male; Mice, Nude; Paclitaxel; Tissue Array Analysis | 2019 |
[Chemoradiotherapy in combination with local hyperthermia for patients with non-small cell lung cancer].
Topics: Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Disease-Free Survival; Female; Follow-Up Studies; Humans; Hyperthermia, Induced; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Survival Rate | 2016 |
A Phase II Study of Tailored-dose S-1 Plus Carboplatin Followed by Maintenance S-1 for Advanced Squamous Cell Lung Cancer: OSAKA-LCSG 1102.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Drug Combinations; Epithelial Cells; Female; Humans; Lung Neoplasms; Male; Middle Aged; Oxonic Acid; Paclitaxel; Tegafur | 2019 |
NEAT1 mediates paclitaxel-resistance of non-small cell of lung cancer through activation of Akt/mTOR signalling pathway.
Topics: A549 Cells; Animals; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Male; Mice; Mice, Inbred BALB C; Paclitaxel; Proto-Oncogene Proteins c-akt; Respiratory Mucosa; RNA, Long Noncoding; Signal Transduction; TOR Serine-Threonine Kinases; Up-Regulation | 2019 |
Diosmetin induces apoptosis and enhances the chemotherapeutic efficacy of paclitaxel in non-small cell lung cancer cells via Nrf2 inhibition.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Proliferation; Cell Survival; Cells, Cultured; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Flavonoids; Humans; Lung Neoplasms; Molecular Structure; NF-E2-Related Factor 2; Paclitaxel; Reactive Oxygen Species; Structure-Activity Relationship | 2019 |
Combined using of paclitaxel and salinomycin active targeting nanostructured lipid carriers against non-small cell lung cancer and cancer stem cells.
Topics: Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Carriers; Drug Delivery Systems; Humans; Lipids; Lung Neoplasms; Mice; Nanostructures; Neoplastic Stem Cells; Paclitaxel; Particle Size; Peptides; Polyethylene Glycols; Pyrans | 2019 |
First-line pemetrexed/carboplatin or cisplatin/bevacizumab compared with paclitaxel/carboplatin/bevacizumab in patients with advanced non-squamous non-small cell lung cancer with wild-type driver genes: A real-world study in China.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Non-Small-Cell Lung; China; Cisplatin; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Paclitaxel; Pemetrexed; Retrospective Studies; Treatment Outcome | 2019 |
Feasibility study of metabolically supported chemotherapy with weekly carboplatin/paclitaxel combined with ketogenic diet, hyperthermia and hyperbaric oxygen therapy in metastatic non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carboplatin; Carcinoma, Non-Small-Cell Lung; Diet, Ketogenic; Feasibility Studies; Female; Fever; Humans; Hyperbaric Oxygenation; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Paclitaxel; Retrospective Studies | 2019 |
Tumor growth suppression using a combination of taxol-based therapy and GSK3 inhibition in non-small cell lung cancer.
Topics: Animals; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Chromosome Aberrations; Drug Synergism; Drug Therapy, Combination; Glycogen Synthase Kinase 3; Humans; Lung Neoplasms; Male; Mice; Mice, Nude; Paclitaxel; Pyridines; Pyrimidines; RNA Interference; RNA, Small Interfering | 2019 |
Comparison of two different carboplatin and weekly paclitaxel schedule in elderly advanced non-small cell lung cancer patients.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Drug Administration Schedule; Female; Humans; Lung Neoplasms; Male; Neoplasm Metastasis; Paclitaxel; Progression-Free Survival; Retrospective Studies; Survival Rate; Turkey | 2019 |
Efficacy of additional dexamethasone administration for the attenuation of paclitaxel-associated acute pain syndrome.
Topics: Acute Pain; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemoprevention; Dexamethasone; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Retrospective Studies; Syndrome; Treatment Outcome | 2020 |
Emodin enhances antitumor effect of paclitaxel on human non-small-cell lung cancer cells in vitro and in vivo.
Topics: A549 Cells; Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Proliferation; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Emodin; Humans; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Molecular Structure; Neoplasms, Experimental; Paclitaxel; Structure-Activity Relationship; Tumor Cells, Cultured | 2019 |
The second wave of checkpoint inhibitors with chemotherapy for advanced non-small-cell lung cancer.
Topics: Albumins; Antibodies, Monoclonal, Humanized; Carboplatin; Carcinoma, Non-Small-Cell Lung; Humans; Lung Neoplasms; Paclitaxel | 2019 |
Effectiveness of first-line treatments in metastatic squamous non-small-cell lung cancer.
Topics: Aged; Albumins; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Deoxycytidine; Female; Gemcitabine; Humans; Immunotherapy; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Survival Analysis; Treatment Outcome | 2019 |
First-line atezolizumab in addition to bevacizumab plus chemotherapy for metastatic, nonsquamous non-small cell lung cancer: A United States-based cost-effectiveness analysis.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; B7-H1 Antigen; Bevacizumab; Carboplatin; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Cost-Benefit Analysis; Gene Expression Regulation, Neoplastic; Humans; Markov Chains; Neoplasm Metastasis; Paclitaxel | 2019 |
The α7 nicotinic receptor silent agonist R-47 prevents and reverses paclitaxel-induced peripheral neuropathy in mice without tolerance or altering nicotine reward and withdrawal.
Topics: A549 Cells; alpha7 Nicotinic Acetylcholine Receptor; Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Tolerance; Humans; Lung Neoplasms; Male; Mice; Mice, Inbred C57BL; Neoplasms, Experimental; Nicotine; Nicotinic Agonists; Paclitaxel; Peripheral Nervous System Diseases; Piperazines; Reward | 2019 |
Homologous recombination and DNA repair mutations in patients treated with carboplatin and nab-paclitaxel for metastatic non-small cell lung cancer.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carboplatin; Carcinoma, Non-Small-Cell Lung; DNA Repair; Female; Homologous Recombination; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Mutation; Neoplasm Metastasis; Neoplasm Staging; Paclitaxel | 2019 |
Involvement of miR-4262 in paclitaxel resistance through the regulation of PTEN in non-small cell lung cancer.
Topics: A549 Cells; Animals; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Mice; Mice, Nude; MicroRNAs; Paclitaxel; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Signal Transduction | 2019 |
Bevacizumab and weekly paclitaxel for non-squamous non small cell lung cancer patients: a retrospective study.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Paclitaxel; Prospective Studies | 2013 |
Modulation of MDR1 and MRP3 gene expression in lung cancer cells after paclitaxel and carboplatin exposure.
Topics: Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Paclitaxel | 2012 |
Factors exacerbating peripheral neuropathy induced by paclitaxel plus carboplatin in non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Peripheral Nervous System Diseases; Proportional Hazards Models | 2012 |
A three-drug induction chemotherapy with gemcitabine, carboplatin, and paclitaxel for stage III non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease-Free Survival; Female; Follow-Up Studies; Gemcitabine; Humans; Induction Chemotherapy; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel | 2013 |
A retrospective study: platinum-based induction chemotherapy combined with gemcitabine or paclitaxel for stage IIB-IIIA central non-small-cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Induction Chemotherapy; Lung Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Prognosis; Retrospective Studies; Survival Rate | 2013 |
Vitamin D receptor genetic variants are associated with chemotherapy response and prognosis in patients with advanced non-small-cell lung cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; DNA, Neoplasm; Docetaxel; Female; Follow-Up Studies; Gemcitabine; Genotype; Haplotypes; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Polymerase Chain Reaction; Polymorphism, Single Nucleotide; Prognosis; Receptors, Calcitriol; Survival Rate; Taxoids; Vinblastine; Vinorelbine | 2013 |
Impact of PLK-1 silencing on endothelial cells and cancer cells of diverse histological origin.
Topics: Antineoplastic Agents, Phytogenic; Base Sequence; Carcinoma, Non-Small-Cell Lung; Cell Cycle Checkpoints; Cell Cycle Proteins; Cell Line, Tumor; Cell Survival; Down-Regulation; Endothelial Cells; Humans; Lung Neoplasms; Male; Molecular Sequence Data; Molecular Targeted Therapy; Paclitaxel; Polo-Like Kinase 1; Prostatic Neoplasms; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Reference Values; RNA, Small Interfering; S Phase; Tumor Cells, Cultured; Tumor Microenvironment | 2013 |
Common variations of DNA repair genes are associated with response to platinum-based chemotherapy in NSCLCs.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Confidence Intervals; Deoxycytidine; Disease-Free Survival; DNA-Binding Proteins; Docetaxel; Female; Gemcitabine; Genotype; Humans; Lung Neoplasms; Male; Middle Aged; Odds Ratio; Paclitaxel; Polymorphism, Single Nucleotide; Proportional Hazards Models; Taxoids; Vinblastine; Vinorelbine; X-ray Repair Cross Complementing Protein 1; Xeroderma Pigmentosum Group D Protein | 2013 |
KRAS mutation as the biomarker of response to chemotherapy and EGFR-TKIs in patients with advanced non-small cell lung cancer: clues for its potential use in second-line therapy decision making.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Disease-Free Survival; ErbB Receptors; Female; Genetic Markers; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Paclitaxel; Prognosis; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins; Treatment Outcome; Vinblastine; Vinorelbine | 2015 |
Rates of guideline adherence among US community oncologists treating NSCLC.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Drug Costs; Guideline Adherence; Humans; Lung Neoplasms; Medical Oncology; Paclitaxel; Retrospective Studies; United States | 2013 |
Comparative effectiveness of three platinum-doublet chemotherapy regimens in elderly patients with advanced non-small cell lung cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cohort Studies; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Neoplasm Staging; Paclitaxel; Randomized Controlled Trials as Topic; SEER Program; Survival Analysis; Taxoids; Treatment Outcome; United States | 2013 |
Acute oesophageal toxicity related to paclitaxel-based concurrent chemoradiotherapy for non-small cell lung cancer.
Topics: Acute Disease; Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Comorbidity; Deoxycytidine; Docetaxel; Esophageal Diseases; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Prognosis; Prospective Studies; Risk Factors; Survival Rate; Taxoids | 2013 |
[Analysis of drug therapy of lung cancer in Hungary].
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Chemotherapy, Adjuvant; Cisplatin; Databases, Factual; Deoxycytidine; Docetaxel; Drug Administration Schedule; Erlotinib Hydrochloride; Etoposide; Gemcitabine; Glutamates; Guanine; Humans; Hungary; Inpatients; Insurance, Health; Lung Neoplasms; Paclitaxel; Pemetrexed; Prescription Drugs; Quinazolines; Retrospective Studies; Taxoids; Topotecan | 2013 |
Feasibility of adding everolimus to carboplatin and paclitaxel, with or without bevacizumab, for treatment-naive, advanced non-small cell lung cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Non-Small-Cell Lung; Demography; Dose-Response Relationship, Drug; Drug Administration Schedule; Everolimus; Feasibility Studies; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Sirolimus; Treatment Outcome | 2014 |
Sleeve lobectomy compared with pneumonectomy after induction therapy for non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Induction Chemotherapy; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Pneumonectomy; Proportional Hazards Models; Survival Rate; Vinblastine; Vinorelbine | 2013 |
Toxicity and prognosis in overweight and obese women with lung cancer receiving carboplatin-paclitaxel doublet chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Body Mass Index; Carboplatin; Carcinoma, Non-Small-Cell Lung; Drug Overdose; Female; Humans; Lung Neoplasms; Middle Aged; Neutropenia; Obesity; Overweight; Paclitaxel; Prognosis; Retrospective Studies; Risk | 2013 |
Predictive effect of XPA and XPD polymorphisms on survival of advanced NSCLC patients treated with platinum-based chemotherapy: a three-dimensional (3-D), polyacrylamide gel-based DNA microarray method.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease-Free Survival; DNA, Neoplasm; Docetaxel; Drug Resistance, Neoplasm; Female; Gemcitabine; Genotype; Humans; Lung Neoplasms; Male; Middle Aged; Oligonucleotide Array Sequence Analysis; Paclitaxel; Polymorphism, Single Nucleotide; Predictive Value of Tests; Prognosis; Survival Rate; Taxoids; Vinblastine; Vinorelbine; Xeroderma Pigmentosum Group A Protein; Xeroderma Pigmentosum Group D Protein | 2013 |
Intracellular ATP-binding cassette transporter A3 is expressed in lung cancer cells and modulates susceptibility to cisplatin and paclitaxel.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; ATP-Binding Cassette Transporters; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Survival; Cisplatin; Female; Gene Silencing; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Vinblastine; Vinorelbine | 2013 |
Clinical Significance of ABCG2 Haplotype-tagging Single Nucleotide Polymorphisms in Patients With Unresectable Non-Small Cell Lung Cancer Treated With First-line Platinum-based Chemotherapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Bridged-Ring Compounds; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Cisplatin; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Haplotypes; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Proteins; Paclitaxel; Polymorphism, Single Nucleotide; Predictive Value of Tests; Survival Rate; Taxoids; Treatment Outcome | 2015 |
Preclinical evaluation of Genexol-PM, a nanoparticle formulation of paclitaxel, as a novel radiosensitizer for the treatment of non-small cell lung cancer.
Topics: Animals; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Chemoradiotherapy; Lung; Lung Neoplasms; Mice; Mice, Nude; Nanoparticles; Paclitaxel; Polymers; Radiation-Sensitizing Agents; Tumor Burden; Xenograft Model Antitumor Assays | 2013 |
Prognostic potential of ERCC1 protein expression and clinicopathologic factors in stage III/N2 non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Chi-Square Distribution; Cisplatin; Deoxycytidine; DNA-Binding Proteins; Female; Gemcitabine; Humans; Immunohistochemistry; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Pneumonectomy; Prognosis; Proportional Hazards Models; Retrospective Studies; Survival Rate; Treatment Outcome | 2013 |
Efficacy of platinum-based adjuvant chemotherapy in T2aN0 stage IB non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Cisplatin; Diagnostic Imaging; Female; Humans; Lung Neoplasms; Lymph Node Excision; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Pneumonectomy; Proportional Hazards Models; Retrospective Studies; Risk Factors; Survival Rate; Treatment Outcome; Vinblastine; Vinorelbine | 2013 |
Management of elderly patients with advanced non-small cell lung cancer: a single-center experience.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Protein Kinase Inhibitors; Survival Analysis; Treatment Outcome | 2013 |
Chemotherapy outcomes by histologic subtypes of non-small-cell lung cancer: analysis of the southwest oncology group database for antimicrotubule-platinum therapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Pharmacological; Carcinoma, Non-Small-Cell Lung; Databases, Factual; Disease-Free Survival; Docetaxel; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Oncology Nursing; Paclitaxel; Platinum Compounds; Randomized Controlled Trials as Topic; Southwestern United States; Taxoids; Tubulin Modulators; Vinblastine; Vinorelbine | 2013 |
Identification of a KRAS mutation in a patient with non-small cell lung cancer treated with chemoradiotherapy and panitumumab.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Base Sequence; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; DNA Mutational Analysis; Female; Humans; Lung Neoplasms; Middle Aged; Mutation, Missense; Paclitaxel; Panitumumab; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Radiography; ras Proteins; Treatment Outcome | 2013 |
DNA microarray reveals different pathways responding to paclitaxel and docetaxel in non-small cell lung cancer cell line.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Docetaxel; Drug Resistance, Neoplasm; Gene Expression; Humans; Lung Neoplasms; Oligonucleotide Array Sequence Analysis; Paclitaxel; Real-Time Polymerase Chain Reaction; Signal Transduction; Taxoids | 2013 |
A preliminary study of imaging paclitaxel-induced tumor apoptosis with (99)Tc(m)-His10-Annexin V.
Topics: Animals; Annexin A5; Antineoplastic Agents, Phytogenic; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Disease Models, Animal; Histidine; Humans; Lung Neoplasms; Mice; Organotechnetium Compounds; Paclitaxel; Radiopharmaceuticals | 2013 |
Polymorphisms in DNA repair and apoptosis-related genes and clinical outcomes of patients with non-small cell lung cancer treated with first-line paclitaxel-cisplatin chemotherapy.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cisplatin; DNA Repair; Female; Genotype; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Polymorphism, Single Nucleotide; Risk Factors; Treatment Outcome | 2013 |
miR-495 enhances the sensitivity of non-small cell lung cancer cells to platinum by modulation of copper-transporting P-type adenosine triphosphatase A (ATP7A).
Topics: 3' Untranslated Regions; Adenosine Triphosphatases; Aged; Antineoplastic Agents; Binding Sites; Biomarkers, Tumor; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cation Transport Proteins; Cell Line, Tumor; Cisplatin; Cloning, Molecular; Copper-Transporting ATPases; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Male; MicroRNAs; Middle Aged; Paclitaxel; RNA Interference; RNA, Small Interfering | 2014 |
[Comparison of platinum-containing doublet chemotherapy and liposome paclitaxel monotherapy for the treatment of elderly patients with advanced non-small cell lung cancer].
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Female; Humans; Liposomes; Lung Neoplasms; Male; Paclitaxel; Platinum; Treatment Outcome | 2013 |
Selective cytotoxicity and combined effects of camptothecin or paclitaxel with sodium-R-alpha lipoate on A549 human non-small cell lung cancer cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Epithelial Cells; Humans; Lung Neoplasms; Paclitaxel; Thioctic Acid; Tumor Cells, Cultured | 2014 |
Survival analysis in advanced non small cell lung cancer treated with platinum based chemotherapy in combination with paclitaxel, gemcitabine and etoposide.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Etoposide; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Paclitaxel; Prognosis; Retrospective Studies; Survival Rate | 2013 |
ERCC1 expression does not predict survival and treatment response in advanced stage non-small cell lung cancer cases treated with platinum based chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; DNA-Binding Proteins; Docetaxel; Endonucleases; Female; Follow-Up Studies; Glutamates; Guanine; Humans; Ifosfamide; Immunoenzyme Techniques; Lung Neoplasms; Male; Middle Aged; Mitomycin; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Pemetrexed; Prognosis; Retrospective Studies; Survival Rate; Taxoids | 2013 |
Clinical study on mannan peptide combined with TP regimen in treating patients with non-small cell lung cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Case-Control Studies; Cisplatin; Combined Modality Therapy; Female; Follow-Up Studies; Glycopeptides; Humans; Lung Neoplasms; Male; Mannans; Middle Aged; Neoplasm Staging; Paclitaxel; Prognosis; Quality of Life; Remission Induction; Retrospective Studies; Survival Rate; Taxoids | 2013 |
[Efficacy and safety of albumin-bound paclitaxel in treating recurrent advanced non-small cell lung cancer].
Topics: Adult; Aged; Albumin-Bound Paclitaxel; Albumins; Carcinoma, Non-Small-Cell Lung; Female; Humans; Indoles; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Pyrroles; Retrospective Studies; Sunitinib; Survival Rate | 2013 |
Expression of RRM1 and RRM2 as a novel prognostic marker in advanced non-small cell lung cancer receiving chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Prognosis; Proportional Hazards Models; Ribonucleoside Diphosphate Reductase; Tumor Suppressor Proteins; Vinblastine; Vinorelbine | 2014 |
FBXW7 mediates chemotherapeutic sensitivity and prognosis in NSCLCs.
Topics: Adult; Aged; Aged, 80 and over; Antigens, Neoplasm; Antineoplastic Agents; Benzamides; Carcinoma, Non-Small-Cell Lung; Cell Cycle Proteins; Cell Line, Tumor; DNA Topoisomerases, Type II; DNA-Binding Proteins; Drug Resistance, Neoplasm; F-Box Proteins; F-Box-WD Repeat-Containing Protein 7; Female; Histone Deacetylase Inhibitors; Humans; Lung Neoplasms; Male; Middle Aged; Myeloid Cell Leukemia Sequence 1 Protein; Paclitaxel; Poly-ADP-Ribose Binding Proteins; Prognosis; Pyridines; RNA Interference; RNA, Small Interfering; Smoking; Survival; Ubiquitin-Protein Ligases | 2014 |
Fhit delocalizes annexin a4 from plasma membrane to cytosol and sensitizes lung cancer cells to paclitaxel.
Topics: Acid Anhydride Hydrolases; Amino Acid Sequence; Animals; Annexin A4; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Membrane; Cytosol; Gene Expression; Humans; Immunoprecipitation; Injections, Intravenous; Lung Neoplasms; Mice; Mice, Nude; Microscopy, Confocal; Molecular Sequence Data; Neoplasm Proteins; Neoplasm Transplantation; Paclitaxel; Protein Transport | 2013 |
Differences in RRM1 protein expression between diagnostic biopsies and resection specimens, and changes during carboplatin and paclitaxel treatment, in non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Carboplatin; Carcinoma, Non-Small-Cell Lung; Female; Humans; Immunohistochemistry; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Ribonucleoside Diphosphate Reductase; Treatment Outcome; Tumor Suppressor Proteins | 2014 |
Combination of paclitaxel and bevacizumab in heavily pre-treated non-small-cell lung cancer (NSCLC) patients: a case series study on 15 patients.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Drug Administration Schedule; Endothelial Cells; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Quinazolines; Retrospective Studies; Stem Cells | 2013 |
Knockdown of CABYR-a/b increases chemosensitivity of human non-small cell lung cancer cells through inactivation of Akt.
Topics: Animals; Antineoplastic Agents; Apoptosis; Calcium-Binding Proteins; Carcinoma, Non-Small-Cell Lung; Cell Growth Processes; Cell Line, Tumor; Cisplatin; Disease Progression; Drug Resistance, Neoplasm; Female; Gene Knockdown Techniques; Humans; Lung Neoplasms; Mice, Inbred BALB C; Mice, Nude; Paclitaxel; Phosphoproteins; Protein Isoforms; Proto-Oncogene Proteins c-akt; Signal Transduction; Transfection; Xenograft Model Antitumor Assays | 2014 |
Rapid and sensitive liquid chromatography coupled with electrospray ionization tandem mass spectrometry method for the analysis of paclitaxel, docetaxel, vinblastine, and vinorelbine in human plasma.
Topics: Antineoplastic Agents; Calibration; Carcinoma, Non-Small-Cell Lung; Chromatography, High Pressure Liquid; Docetaxel; Dose-Response Relationship, Drug; Drug Monitoring; Female; Humans; Lung Neoplasms; Male; Paclitaxel; Sensitivity and Specificity; Spectrometry, Mass, Electrospray Ionization; Tandem Mass Spectrometry; Taxoids; Vinblastine; Vinorelbine | 2014 |
[Correlation between baseline plasma D-dimer levels and prognosis in patients with non-smal cell lung cancer].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Disease-Free Survival; Female; Fibrin Fibrinogen Degradation Products; Follow-Up Studies; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Pneumonectomy; Proportional Hazards Models; Retrospective Studies; Survival Rate; Taxoids; Tumor Burden; Vascular Endothelial Growth Factor A | 2013 |
Therapy-resistant cancer stem cells have differing sensitivity to photon versus proton beam radiation.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell Adhesion; Cell Movement; Cell Proliferation; Drug Resistance, Neoplasm; Flow Cytometry; Humans; Lung Neoplasms; Neoplastic Stem Cells; Paclitaxel; Photons; Protons; Reactive Oxygen Species; Tumor Cells, Cultured | 2013 |
[Locally advanced granulocyte colony-stimulating factor-producing non-small cell lung cancer successfully treated with concurrent chemoradiotherapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Granulocyte Colony-Stimulating Factor; Humans; Lung Neoplasms; Male; Neoplasm Staging; Paclitaxel | 2013 |
Comparison of toxicity and outcomes of concurrent radiotherapy with carboplatin/paclitaxel or cisplatin/etoposide in stage III non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Etoposide; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel | 2013 |
Bevacizumab plus weekly paclitaxel with or without carboplatin for previously-treated non-squamous non-small cell lung cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Prognosis; Retrospective Studies; Survival Rate | 2014 |
The selective anaplastic lymphoma receptor tyrosine kinase inhibitor ASP3026 induces tumor regression and prolongs survival in non-small cell lung cancer model mice.
Topics: 3T3 Cells; Anaplastic Lymphoma Kinase; Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Proliferation; Cell Survival; Drug Synergism; Glutamates; Guanine; Humans; Immunoblotting; Lung Neoplasms; Mice; Mice, Inbred C57BL; Mice, Inbred NOD; Mice, SCID; Mice, Transgenic; Molecular Structure; Paclitaxel; Pemetrexed; Protein Kinase Inhibitors; Receptor Protein-Tyrosine Kinases; Sulfones; Survival Analysis; Triazines; Tumor Burden; Xenograft Model Antitumor Assays | 2014 |
A retrospective comparison of adjuvant chemotherapeutic regimens for non-small cell lung cancer (NSCLC): paclitaxel plus carboplatin versus vinorelbine plus cisplatin.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Cisplatin; Female; Humans; Lung Neoplasms; Male; Medication Adherence; Middle Aged; Neoplasm Staging; Paclitaxel; Retrospective Studies; Risk Factors; Vinblastine; Vinorelbine | 2014 |
Genomic polymorphisms of SLC29A3 associated with overall survival in advanced non-small-cell lung cancer treated with gemcitabine.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Female; Gemcitabine; Genotype; Humans; Leukocytes, Mononuclear; Lung Neoplasms; Male; Middle Aged; Nucleoside Transport Proteins; Paclitaxel; Polymorphism, Single Nucleotide; Proportional Hazards Models; Prospective Studies; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2014 |
Thymidylate synthase protein expression levels remain stable during paclitaxel and carboplatin treatment in non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Case-Control Studies; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Prognosis; Randomized Controlled Trials as Topic; Survival Rate; Thymidylate Synthase | 2014 |
Synergistic antitumor effect of combining metronomic chemotherapy with adoptive cell immunotherapy in nude mice.
Topics: Administration, Metronomic; Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Adhesion; Cell Line, Tumor; Combined Modality Therapy; Cytokine-Induced Killer Cells; Endothelial Cells; Female; Human Umbilical Vein Endothelial Cells; Humans; Immunotherapy, Adoptive; Intercellular Adhesion Molecule-1; Mice; Mice, Inbred BALB C; Mice, Nude; Paclitaxel; Vascular Cell Adhesion Molecule-1; Xenograft Model Antitumor Assays | 2014 |
Comparative effectiveness of adjunctive bevacizumab for advanced lung cancer: the cancer research network experience.
Topics: Age Factors; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Registries; Survival Rate | 2014 |
Cisplatin versus carboplatin-based regimens for the treatment of patients with metastatic lung cancer. An analysis of Veterans Health Administration data.
Topics: Aged; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Docetaxel; Etoposide; Female; Gemcitabine; Glutamates; Guanine; Hospitalization; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Pemetrexed; Registries; Retrospective Studies; Survival Rate; Taxoids; United States; United States Department of Veterans Affairs; Vinblastine; Vinorelbine | 2014 |
Effect of Smac and Taxol on non-small-cell lung cancer.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis Regulatory Proteins; Base Sequence; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; DNA Primers; Humans; Intracellular Signaling Peptides and Proteins; Lung Neoplasms; Mitochondrial Proteins; Neoplasm Invasiveness; Paclitaxel; Plasmids; Reverse Transcriptase Polymerase Chain Reaction | 2014 |
Synergistic antitumor effect of a combination of paclitaxel and carboplatin with nobiletin from Citrus depressa on non-small-cell lung cancer cell lines.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Line, Tumor; Citrus; Drug Synergism; Female; Flavones; Humans; Lung Neoplasms; Mice, Inbred BALB C; Paclitaxel; Phytotherapy; Plant Extracts | 2014 |
Prognostic Significance of Standardized Uptake Value of Lymph Nodes on Survival for Stage III Non-small Cell Lung Cancer Treated With Definitive Concurrent Chemoradiotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Disease-Free Survival; Female; Fluorodeoxyglucose F18; Follow-Up Studies; Humans; Lung Neoplasms; Lymph Nodes; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Positron Emission Tomography Computed Tomography; Prognosis; Radiopharmaceuticals; Radiotherapy Planning, Computer-Assisted; Survival Rate | 2016 |
Orally active microtubule-targeting agent, MPT0B271, for the treatment of human non-small cell lung cancer, alone and in combination with erlotinib.
Topics: Administration, Oral; Animals; Antineoplastic Combined Chemotherapy Protocols; Biological Availability; Carcinoma, Non-Small-Cell Lung; Cell Cycle Checkpoints; Cell Death; Cell Proliferation; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Male; Mice, Nude; Microtubules; Mitosis; Niacinamide; Paclitaxel; Phosphorylation; Polymerization; Quinazolines; STAT3 Transcription Factor; Sulfonamides; Tubulin; Tumor Suppressor Protein p53; Vincristine | 2014 |
Correlation of (18)F-FDG avid volumes on pre-radiation therapy and post-radiation therapy FDG PET scans in recurrent lung cancer.
Topics: Aged; Aged, 80 and over; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Female; Fluorodeoxyglucose F18; Glucose; Humans; Lung Neoplasms; Male; Middle Aged; Multimodal Imaging; Neoplasm Recurrence, Local; Paclitaxel; Positron-Emission Tomography; Prospective Studies; Radiopharmaceuticals; Radiotherapy, Conformal; Sensitivity and Specificity; Small Cell Lung Carcinoma; Tomography, X-Ray Computed | 2014 |
Linsitinib (OSI-906) antagonizes ATP-binding cassette subfamily G member 2 and subfamily C member 10-mediated drug resistance.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Interactions; Drug Resistance, Multiple; HEK293 Cells; Humans; Imidazoles; Lung Neoplasms; Mitoxantrone; Models, Molecular; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Paclitaxel; Protein Kinase Inhibitors; Pyrazines | 2014 |
Association of DNA base excision repair genes (OGG1, APE1 and XRCC1) polymorphisms with outcome to platinum-based chemotherapy in advanced nonsmall-cell lung cancer patients.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Case-Control Studies; Cisplatin; Deoxycytidine; DNA Glycosylases; DNA-(Apurinic or Apyrimidinic Site) Lyase; DNA-Binding Proteins; Docetaxel; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Polymorphism, Single Nucleotide; Prognosis; Prospective Studies; Survival Rate; Taxoids; X-ray Repair Cross Complementing Protein 1 | 2014 |
Does change in health-related quality of life score predict survival? Analysis of EORTC 08975 lung cancer trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials, Phase III as Topic; Deglutition Disorders; Deoxycytidine; Gemcitabine; Humans; Interpersonal Relations; Lung Neoplasms; Multicenter Studies as Topic; Nausea; Paclitaxel; Pain; Palliative Care; Prognosis; Proportional Hazards Models; Quality of Life; Randomized Controlled Trials as Topic; Risk; Severity of Illness Index; Surveys and Questionnaires; Survival Analysis | 2014 |
Efficacy and Tolerability of Palliative Split-Course Thoracic Chemoradiotherapy for Symptomatic Non-Small Cell Lung Cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Chemoradiotherapy; Chest Pain; Cohort Studies; Cough; Dyspnea; Esophagitis; Etoposide; Female; Hemoptysis; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Palliative Care; Pemetrexed; Radiation Injuries; Radiation Pneumonitis; Retrospective Studies; Treatment Outcome | 2015 |
EGFR activating mutations and their association with response to platinum-doublet chemotherapy in Brazilian non-small cell lung cancer patients.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Brazil; Carcinoma, Non-Small-Cell Lung; Cisplatin; Cohort Studies; ErbB Receptors; Exons; Female; Gene Deletion; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Paclitaxel; Protein Kinase Inhibitors; Treatment Outcome | 2014 |
Co-delivery of doxorubicin and paclitaxel by PEG-polypeptide nanovehicle for the treatment of non-small cell lung cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Delayed-Action Preparations; Diffusion; Doxorubicin; Lung Neoplasms; Male; Mice, Inbred BALB C; Mice, Nude; Nanocapsules; Nanocomposites; Paclitaxel; Peptides; Pharmaceutical Vehicles; Polyethylene Glycols; Treatment Outcome | 2014 |
E2F inhibition synergizes with paclitaxel in lung cancer cell lines.
Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cisplatin; Deoxycytidine; Drug Synergism; E2F3 Transcription Factor; Gemcitabine; Humans; Hydroxyquinolines; Inhibitory Concentration 50; Lung Neoplasms; Paclitaxel; RNA, Small Interfering; Small Cell Lung Carcinoma | 2014 |
MO06.12 Efficacy and safety of paclitaxel and carboplatin with bevacizumab for the first-line treatment of patients with nonsquamous non-small cell lung cancer (NSCLC): analyses based on age in the phase 3 PointBreak and E4599 trials.
Topics: Age Factors; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; Disease-Free Survival; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Multicenter Studies as Topic; Paclitaxel; Proportional Hazards Models | 2014 |
Commentary: highlights in NSCLC from the 15th World Conference on Lung Cancer.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Cetuximab; Combined Modality Therapy; ErbB Receptors; Erlotinib Hydrochloride; Genes, erbB-1; Humans; Lung Neoplasms; Molecular Targeted Therapy; Mutation; Neoplasm Proteins; Paclitaxel; Quinazolines | 2014 |
Mechanisms promoting escape from mitotic stress-induced tumor cell death.
Topics: Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Cycle Checkpoints; Cell Death; Cell Line, Tumor; Disease Models, Animal; Drug Resistance, Neoplasm; Female; Heterografts; Humans; Lung Neoplasms; Mice; Microtubules; Mitosis; Paclitaxel; Protein Binding; RNA Interference; Spindle Apparatus; Stress, Physiological; Tripartite Motif Proteins; Tumor Burden; Ubiquitin-Protein Ligases | 2014 |
Adverse cardiovascular events predict survival benefit in non-small lung cancer patients treated with bevacizumab.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cardiovascular Diseases; Disease-Free Survival; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Prognosis; Retrospective Studies; Survival Analysis; Treatment Outcome | 2014 |
Constitutive androstane receptor ligands modulate the anti-tumor efficacy of paclitaxel in non-small cell lung cancer cells.
Topics: Androstenols; Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Constitutive Androstane Receptor; DNA Modification Methylases; Drug Synergism; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Mice; Oximes; Paclitaxel; Pyridines; Receptors, Cytoplasmic and Nuclear; Thiazoles; WT1 Proteins | 2014 |
Prognosis of non-small cell lung cancer patients with bone oligometastases treated concurrently with thoracic three-dimensional radiotherapy and chemotherapy.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Female; Follow-Up Studies; Humans; Imaging, Three-Dimensional; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Prognosis; Radiotherapy Dosage; Radiotherapy Planning, Computer-Assisted; Radiotherapy, Intensity-Modulated; Survival Rate; Vinblastine; Vinorelbine; Young Adult | 2014 |
Long progression-free survival with first-line paclitaxel plus platinum is associated with improved response and progression-free survival with second-line docetaxel in advanced non-small-cell lung cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Disease Progression; Disease-Free Survival; Docetaxel; Drug Screening Assays, Antitumor; ErbB Receptors; Female; Humans; Lung Neoplasms; Male; Mexico; Middle Aged; Paclitaxel; Patient Selection; Taxoids; Treatment Outcome | 2014 |
Predictive role of RRM1 and BRCA1 mRNA expression on the clinical outcome of advanced non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Pharmacological; BRCA1 Protein; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Female; Gemcitabine; Gene Expression; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Ribonucleoside Diphosphate Reductase; RNA, Messenger; Survival Analysis; Treatment Outcome; Tumor Suppressor Proteins; Vinblastine; Vinorelbine | 2014 |
Heterozygote advantage of methylenetetrahydrofolate reductase polymorphisms on clinical outcomes in advanced non-small cell lung cancer (NSCLC) patients treated with platinum-based chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Docetaxel; Female; Follow-Up Studies; Gemcitabine; Heterozygote; Humans; Lung Neoplasms; Male; Methylenetetrahydrofolate Reductase (NADPH2); Middle Aged; Neoplasm Grading; Neoplasm Staging; Paclitaxel; Polymorphism, Genetic; Prognosis; Retrospective Studies; Survival Rate; Taxoids; Vinblastine; Vinorelbine | 2014 |
Predictive value of APE1, BRCA1, ERCC1 and TUBB3 expression in patients with advanced non-small cell lung cancer (NSCLC) receiving first-line platinum-paclitaxel chemotherapy.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; BRCA1 Protein; Carcinoma, Non-Small-Cell Lung; Cisplatin; Disease-Free Survival; DNA Repair; DNA-(Apurinic or Apyrimidinic Site) Lyase; DNA-Binding Proteins; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Endonucleases; Female; Gene Expression Profiling; Humans; Immunohistochemistry; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Predictive Value of Tests; Prognosis; Treatment Outcome; Tubulin | 2014 |
2'-(2-bromohexadecanoyl)-paclitaxel conjugate nanoparticles for the treatment of non-small cell lung cancer in an orthotopic xenograft mouse model.
Topics: Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Survival; Female; Lung Neoplasms; Mice; Mice, Nude; Nanoparticles; Paclitaxel; Tissue Distribution; Tubulin; Xenograft Model Antitumor Assays | 2014 |
[Down-regulated βIII-tubulin expression can reverse paclitaxel resistance in A549/taxol cells lines].
Topics: Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Line, Tumor; Down-Regulation; Drug Resistance, Neoplasm; Humans; Lung Neoplasms; Paclitaxel; RNA Interference; RNA, Messenger; Tubulin | 2014 |
Prognostic value of cyclooxygenase-2 gene polymorphisms in advanced non-small cell lung cancer patients treated with first-line platinum-based chemotherapy.
Topics: Adult; Aged; Biomarkers, Tumor; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Cyclooxygenase 2; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Polymorphism, Single Nucleotide; Proportional Hazards Models; Treatment Outcome; Vinblastine; Vinorelbine | 2016 |
Cisplatin vs. carboplatin-based chemoradiotherapy in patients >65 years of age with stage III non-small cell lung cancer.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Cisplatin; Female; Humans; Lung Neoplasms; Male; Neoplasm Staging; Paclitaxel; Proportional Hazards Models; Randomized Controlled Trials as Topic; SEER Program; Survival Rate; United States | 2014 |
Synergistic antitumor effect of α-pinene and β-pinene with paclitaxel against non-small-cell lung carcinoma (NSCLC).
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Bicyclic Monoterpenes; Bridged Bicyclo Compounds; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Drug Therapy, Combination; Humans; Lung Neoplasms; Membrane Potential, Mitochondrial; Monoterpenes; Paclitaxel | 2015 |
Alternating electric fields (tumor-treating fields therapy) can improve chemotherapy treatment efficacy in non-small cell lung cancer both in vitro and in vivo.
Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Lewis Lung; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cell Proliferation; Cisplatin; Combined Modality Therapy; Electric Stimulation Therapy; Glutamates; Guanine; Humans; In Vitro Techniques; Lung Neoplasms; Mice; Mice, Inbred C57BL; Paclitaxel; Pemetrexed; Survival Rate; Treatment Outcome; Tumor Cells, Cultured | 2014 |
Clinical investigation of efficacy of albumin bound paclitaxel plus platinum compounds as first-line chemotherapy for stage III/IV squamous non-small cell lung cancer.
Topics: Adult; Aged; Albumins; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Cohort Studies; Disease-Free Survival; Female; Humans; Leukopenia; Lung Neoplasms; Male; Middle Aged; Nausea; Neoplasm Staging; Neurotoxicity Syndromes; Paclitaxel; Prospective Studies; Thrombocytopenia; Treatment Outcome; Vomiting | 2014 |
[Paclitaxel-bevacizumab is a possible alternative as salvage chemotherapy in advanced non-small cell bronchial carcinoma].
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Retrospective Studies; Salvage Therapy | 2014 |
The safety and efficacy of paclitaxel and carboplatin with or without bevacizumab for treating patients with advanced nonsquamous non-small cell lung cancer with interstitial lung disease.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Female; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Retrospective Studies; Survival Rate; Treatment Outcome | 2014 |
Genetic variation in platinating agent and taxane pathway genes as predictors of outcome and toxicity in advanced non-small-cell lung cancer.
Topics: Aged; Aged, 80 and over; ATP Binding Cassette Transporter, Subfamily B; Bridged-Ring Compounds; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; DNA-Binding Proteins; Female; Genetic Association Studies; Humans; Male; Middle Aged; Multidrug Resistance-Associated Proteins; NAD(P)H Dehydrogenase (Quinone); Nausea; Neoplasm Staging; Neutropenia; Paclitaxel; Polymorphism, Single Nucleotide; Taxoids; Thrombocytopenia | 2014 |
High Id1 expression, a generally negative prognostic factor, paradoxically predicts a favorable prognosis for adjuvant paclitaxel plus cisplatin therapy in surgically treated lung cancer patients.
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Chemotherapy, Adjuvant; Cisplatin; Female; Humans; Inhibitor of Differentiation Protein 1; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Prognosis; Proteasome Endopeptidase Complex; Treatment Outcome; Ubiquitin | 2014 |
Outcomes treating stage III non-small cell lung carcinoma with curative-intent radiotherapy and concurrent carboplatin-paclitaxel chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Dose Fractionation, Radiation; Drug Administration Schedule; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Retrospective Studies; Survival Analysis; Treatment Outcome | 2016 |
In vitro synergistic antitumor efficacy of sequentially combined chemotherapy/icotinib in non‑small cell lung cancer cell lines.
Topics: Antineoplastic Agents; Apoptosis; Base Sequence; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cisplatin; Crown Ethers; DNA Mutational Analysis; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; ErbB Receptors; Humans; Inhibitory Concentration 50; Lung Neoplasms; Paclitaxel; Quinazolines; Resting Phase, Cell Cycle; Signal Transduction | 2015 |
Positive expression of pro-opiomelanocortin (POMC) is a novel independent poor prognostic marker in surgically resected non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cadherins; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Disease-Free Survival; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Paclitaxel; Pro-Opiomelanocortin; Prognosis; Vimentin; Vinblastine; Vinorelbine | 2015 |
Cisplatin and etoposide versus carboplatin and paclitaxel with concurrent radiotherapy for stage III non-small-cell lung cancer: an analysis of Veterans Health Administration data.
Topics: Aged; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Cisplatin; Cohort Studies; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Randomized Controlled Trials as Topic; Survival Rate; Treatment Outcome; United States; United States Department of Veterans Affairs | 2015 |
MiR-16 targets Bcl-2 in paclitaxel-resistant lung cancer cells and overexpression of miR-16 along with miR-17 causes unprecedented sensitivity by simultaneously modulating autophagy and apoptosis.
Topics: 3' Untranslated Regions; Apoptosis; Apoptosis Regulatory Proteins; Autophagy; Base Sequence; Beclin-1; Carcinoma, Non-Small-Cell Lung; Caspase 3; Cell Line, Tumor; Down-Regulation; Drug Resistance, Neoplasm; Humans; Lung Neoplasms; Membrane Potential, Mitochondrial; Membrane Proteins; MicroRNAs; Paclitaxel; Proto-Oncogene Proteins c-bcl-2; Reactive Oxygen Species; Sequence Alignment; Signal Transduction | 2015 |
Comparison of survival and hospitalization rates between Medicare patients with advanced NSCLC treated with bevacizumab-carboplatin-paclitaxel and carboplatin-paclitaxel: a retrospective cohort study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cohort Studies; Female; Hospitalization; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Medicare; Neoplasm Staging; Paclitaxel; Proportional Hazards Models; Retrospective Studies; Treatment Outcome; United States | 2014 |
Epidermal growth factor receptor mutation is associated with longer local control after definitive chemoradiotherapy in patients with stage III nonsquamous non-small-cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Cisplatin; ErbB Receptors; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Recurrence, Local; Paclitaxel; Protein Kinase Inhibitors; Radiation Tolerance; Radiotherapy Dosage; Sex Factors; Vinblastine; Vinorelbine | 2015 |
Antitumor activity of paclitaxel is significantly enhanced by a novel proapoptotic agent in non-small cell lung cancer.
Topics: Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Caspase 3; Cell Line, Tumor; Drug Synergism; Drug Therapy, Combination; Female; Humans; Hydrazones; Lung Neoplasms; Mice; Mice, Nude; Paclitaxel; Piperazines; Random Allocation; Xenograft Model Antitumor Assays | 2015 |
Quality of life in advanced non-small cell lung cancer receiving chemotherapy of platinum combination in old versus new standard chemotherapy regimen.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cohort Studies; Deoxycytidine; Disease-Free Survival; Etoposide; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Paclitaxel; Prospective Studies; Quality of Life | 2014 |
Nedaplatin or oxaliplatin combined with paclitaxel and docetaxel as first-line treatment for patients with advanced non-small cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Docetaxel; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Retrospective Studies; Taxoids | 2014 |
Effect of platinum-based chemotherapy for non-small cell lung cancer patients with interstitial lung disease.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Disease-Free Survival; Female; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Prognosis; Retrospective Studies; Survival Rate | 2015 |
Radiosensitizing effect of carboplatin and paclitaxel to carbon-ion beam irradiation in the non-small-cell lung cancer cell line H460.
Topics: Antineoplastic Agents; Apoptosis; Carbon; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Dose-Response Relationship, Drug; Dose-Response Relationship, Radiation; Heavy Ion Radiotherapy; Humans; Paclitaxel; Radiation Tolerance; Radiation-Sensitizing Agents; Treatment Outcome | 2015 |
Ramucirumab combination improves OS and PFS in NSCLC.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carboplatin; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Docetaxel; Drug Therapy, Combination; Humans; Lung Neoplasms; Paclitaxel; Ramucirumab; Stomach Neoplasms; Survival Analysis; Taxoids | 2014 |
Treatment Patterns and Health Resource Utilization Among Patients Diagnosed With Early Stage Resected Non-Small Cell Lung Cancer at US Community Oncology Practices.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Community Health Centers; Costs and Cost Analysis; Electronic Health Records; Health Resources; Humans; Lung Neoplasms; Neoplasm Staging; Paclitaxel; Pneumonectomy; Resource Allocation; Retrospective Studies; United States | 2015 |
RB1 polymorphism contributes to the efficacy of platinum-taxanes in advanced squamous cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Cohort Studies; Docetaxel; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Polymorphism, Single Nucleotide; Prognosis; Retinoblastoma Protein; Survival Rate; Taxoids; Young Adult | 2015 |
Enhanced antiproliferative and apoptosis effect of paclitaxel-loaded polymeric micelles against non-small cell lung cancers.
Topics: Animals; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Drug Delivery Systems; Drug Resistance, Neoplasm; Humans; Mice; Micelles; Paclitaxel; Polyesters; Polyethylene Glycols; Xenograft Model Antitumor Assays | 2015 |
[Ipilimumab and metastatic lung cancer: Can we change the natural history of the disease?].
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase II as Topic; Gastrointestinal Diseases; Humans; Ipilimumab; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Remission Induction; Treatment Outcome | 2015 |
Factors associated with a poor response to gefitinib in the NEJ002 study: smoking and the L858R mutation.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; Disease-Free Survival; ErbB Receptors; Exons; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Paclitaxel; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Sequence Deletion; Smoking; Treatment Outcome | 2015 |
AKT/mTOR down-regulation by CX-4945, a CK2 inhibitor, promotes apoptosis in chemorefractory non-small cell lung cancer cells.
Topics: Apoptosis; Carcinoma, Non-Small-Cell Lung; Casein Kinase II; Cell Cycle Checkpoints; Cell Line, Tumor; Cisplatin; Down-Regulation; Humans; Lung Neoplasms; Naphthyridines; Paclitaxel; Phenazines; Proto-Oncogene Proteins c-akt; TOR Serine-Threonine Kinases | 2015 |
Re-expression of LKB1 in LKB1-mutant EKVX cells leads to resistance to paclitaxel through the up-regulation of MDR1 expression.
Topics: AMP-Activated Protein Kinase Kinases; Apoptosis; ATP Binding Cassette Transporter, Subfamily B; Carcinoma, Non-Small-Cell Lung; Cell Line; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; HEK293 Cells; Humans; Lung Neoplasms; Paclitaxel; Protein Serine-Threonine Kinases; Tubulin; Up-Regulation | 2015 |
Adjuvant Chemotherapy in Resected Stage II Non-small Cell Lung Cancer: Evaluating the Impact of Dose Intensity and Time to Treatment.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Cisplatin; Dose-Response Relationship, Drug; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Platinum Compounds; Pneumonectomy; Retrospective Studies; Survival Analysis; Time-to-Treatment; Vinblastine; Vinorelbine | 2015 |
Genome-wide association study of myelosuppression in non-small-cell lung cancer patients with platinum-based chemotherapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Asian People; Blood Platelets; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Docetaxel; Female; Gemcitabine; Genome-Wide Association Study; Hemoglobins; Humans; Leukocytes; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Polymorphism, Single Nucleotide; Taxoids; Vinblastine; Vinorelbine | 2016 |
MMP-9/ANC score as a predictive biomarker for efficacy of bevacizumab plus platinum doublet chemotherapy in patients with advanced or recurrent non-squamous non-small cell lung cancer.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Blood Cell Count; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Female; Humans; Male; Matrix Metalloproteinase 9; Middle Aged; Neoplasm Recurrence, Local; Neovascularization, Pathologic; Neutrophils; Paclitaxel; Platinum; Vascular Endothelial Growth Factor A | 2015 |
Overexpression of stathmin is resistant to paclitaxel treatment in patients with non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Humans; Male; Middle Aged; Paclitaxel; Prognosis; Stathmin; Tubulin | 2015 |
Homology modelling and molecular docking of MDR1 with chemotherapeutic agents in non-small cell lung cancer.
Topics: Amino Acid Sequence; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B; Binding Sites; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Lung Neoplasms; Mice; Molecular Docking Simulation; Molecular Sequence Data; Paclitaxel; Sequence Alignment; Structural Homology, Protein; Taxoids; Thermodynamics | 2015 |
[Nab-Paclitaxel with platinum chemotherapy as sixth-line therapy for a non-small cell lung cancer patient].
Topics: Adenocarcinoma; Albumins; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Female; Humans; Lung Neoplasms; Middle Aged; Paclitaxel | 2015 |
Class III Beta-tubulin Expression in Non-small Cell Lung Cancer: A Predictive Factor for Paclitaxel Response.
Topics: Aged; Aged, 80 and over; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Humans; Male; Middle Aged; Paclitaxel; Prognosis; Tubulin | 2015 |
Maackia amurensis agglutinin enhances paclitaxel induced cytotoxicity in cultured non-small cell lung cancer cells.
Topics: Agglutinins; Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Cycle Checkpoints; Cell Line, Tumor; Drug Synergism; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Maackia; Membrane Potential, Mitochondrial; Paclitaxel; Plant Lectins | 2015 |
Efficacy of platinum combination chemotherapy after first-line gefitinib treatment in non-small cell lung cancer patients harboring sensitive EGFR mutations.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; ErbB Receptors; Female; Follow-Up Studies; Gefitinib; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Paclitaxel; Pemetrexed; Prognosis; Quinazolines; Retrospective Studies; Survival Rate | 2015 |
Use of Adjuvant Cisplatin-Based Versus Carboplatin-Based Chemotherapy in Non-Small-Cell Lung Cancer: Findings From the Florida Initiative for Quality Cancer Care.
Topics: Academic Medical Centers; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Cisplatin; Deoxycytidine; Docetaxel; Etoposide; Female; Florida; Gemcitabine; Humans; Lung Neoplasms; Male; Medical Audit; Middle Aged; Paclitaxel; Pneumonectomy; Practice Patterns, Physicians'; Quality of Health Care; Taxoids; Time Factors; Vinblastine; Vinorelbine | 2015 |
Correlation between BRCA1 and TopBP1 protein expression and clinical outcome of non-small cell lung cancer treated with platinum-based chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; BRCA1 Protein; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carrier Proteins; Cisplatin; Deoxycytidine; Disease-Free Survival; DNA-Binding Proteins; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Nuclear Proteins; Paclitaxel; Prognosis; Survival Analysis; Treatment Outcome | 2015 |
Association of TERT Polymorphisms with Clinical Outcome of Non-Small Cell Lung Cancer Patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease Progression; Female; Gemcitabine; Gene Expression; Heterozygote; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Polymorphism, Single Nucleotide; Prognosis; Survival Analysis; Telomerase; Treatment Outcome; Vinblastine; Vinorelbine | 2015 |
Clinical outcome of cisplatin-based chemotherapy is associated with the polymorphisms of GSTP1 and XRCC1 in advanced non-small cell lung cancer patients.
Topics: Adenocarcinoma; Adenosine Triphosphatases; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cation Transport Proteins; Cisplatin; Copper-Transporting ATPases; Deoxycytidine; DNA-Binding Proteins; Docetaxel; Female; Follow-Up Studies; Gemcitabine; Glutathione S-Transferase pi; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Prognosis; Survival Rate; Taxoids; Vinblastine; Vinorelbine; X-ray Repair Cross Complementing Protein 1 | 2015 |
EGFR inhibitor and chemotherapy combinations for acquired TKI resistance in EGFR-mutant NSCLC models.
Topics: Acrylamides; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cisplatin; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Mutation; Paclitaxel; Protein Kinase Inhibitors; Pyrimidines | 2015 |
Suppression of MAPK Signaling and Reversal of mTOR-Dependent MDR1-Associated Multidrug Resistance by 21α-Methylmelianodiol in Lung Cancer Cells.
Topics: AMP-Activated Protein Kinases; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Movement; Cell Proliferation; Drug Combinations; Drug Resistance, Multiple; Drug Resistance, Neoplasm; G1 Phase Cell Cycle Checkpoints; Humans; Lung Neoplasms; MAP Kinase Signaling System; Membrane Potential, Mitochondrial; Neoplasm Invasiveness; Paclitaxel; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Reactive Oxygen Species; RNA Interference; RNA, Small Interfering; TOR Serine-Threonine Kinases; Triterpenes | 2015 |
Circulating endothelial cells for evaluation of tumor response in non-small cell lung cancer patients receiving first-line chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Case-Control Studies; Cisplatin; Deoxycytidine; Disease-Free Survival; Docetaxel; Endothelial Cells; Etoposide; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplastic Cells, Circulating; Neovascularization, Pathologic; Paclitaxel; Prospective Studies; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2015 |
Efficacy and Safety of Combined Carboplatin, Paclitaxel, and Bevacizumab for Patients with Advanced Non-squamous Non-small Cell Lung Cancer with Pre-existing Interstitial Lung Disease: A Retrospective Multi-institutional Study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Retrospective Studies | 2015 |
Retrospective analysis of second-line chemotherapy outcomes with paclitaxel or docetaxel in correlation with STMN1 polymorphism in advanced non-small cell lung cancer patients.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Disease Progression; Docetaxel; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Polymorphism, Single Nucleotide; Retrospective Studies; Stathmin; Taxoids; Treatment Outcome | 2016 |
Effects of Chemotherapy Regimen and Radiation Modality on Hematologic Toxicities in Patients Receiving Definitive Platinum-based Doublet Chemoradiation for Non-Small Cell Lung Cancer.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Cisplatin; Docetaxel; Etoposide; Female; Hemoglobins; Humans; Leukopenia; Logistic Models; Lung Neoplasms; Lymphopenia; Male; Middle Aged; Multivariate Analysis; Neoplasm Staging; Neutropenia; Paclitaxel; Proportional Hazards Models; Radiation Injuries; Radiotherapy, Conformal; Radiotherapy, Intensity-Modulated; Retrospective Studies; Severity of Illness Index; Survival Rate; Taxoids; Thrombocytopenia | 2017 |
Systemic delivery of micelles loading with paclitaxel using N-succinyl-palmitoyl-chitosan decorated with cRGDyK peptide to inhibit non-small-cell lung cancer.
Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Survival; Chitosan; Drug Delivery Systems; Female; Humans; Lung Neoplasms; Mice, Nude; Micelles; Microtubules; Paclitaxel; Peptides, Cyclic; Tumor Burden | 2015 |
Cost-effectiveness analysis of EGFR mutation testing and gefitinib as first-line therapy for non-small cell lung cancer.
Topics: Administration, Intravenous; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cost-Benefit Analysis; Decision Support Techniques; DNA Mutational Analysis; Economics, Pharmaceutical; ErbB Receptors; Gefitinib; Humans; Japan; Lung Neoplasms; Markov Chains; Mutation; Paclitaxel; Precision Medicine; Protein Kinase Inhibitors; Quinazolines; Young Adult | 2015 |
D-α-tocopherol polyethylene glycol succinate-based derivative nanoparticles as a novel carrier for paclitaxel delivery.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Line, Tumor; Drug Delivery Systems; Female; Humans; Lung Neoplasms; MCF-7 Cells; Mice; Micelles; Nanoparticles; Ovarian Neoplasms; Paclitaxel; Particle Size; Polyethylene Glycols; Rats; Rats, Sprague-Dawley; Sarcoma; Succinates; Vitamin E | 2015 |
Serum human epididymis protein 4 is associated with the treatment response of concurrent chemoradiotherapy and prognosis in patients with locally advanced non-small cell lung cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Case-Control Studies; Chemoradiotherapy; Cisplatin; Enzyme-Linked Immunosorbent Assay; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Prognosis; Proteins; Retrospective Studies; ROC Curve; Survival Rate; Vinblastine; Vinorelbine; WAP Four-Disulfide Core Domain Protein 2 | 2016 |
Cost-effectiveness analysis of EGFR mutation testing in patients with non-small cell lung cancer (NSCLC) with gefitinib or carboplatin-paclitaxel.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cost-Benefit Analysis; Disease-Free Survival; Female; Gefitinib; Genes, erbB-1; Humans; Latin America; Lung Neoplasms; Male; Mexico; Models, Econometric; Mutation; Paclitaxel; Protein Kinase Inhibitors; Quality-Adjusted Life Years; Quinazolines | 2016 |
Assessing the clinical outcome of nab-paclitaxel in Chinese patients with advanced non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Albumins; Antineoplastic Combined Chemotherapy Protocols; Asian People; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Disease-Free Survival; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Treatment Outcome; Tubulin Modulators | 2017 |
β-Lapachone and Paclitaxel Combination Micelles with Improved Drug Encapsulation and Therapeutic Synergy as Novel Nanotherapeutics for NQO1-Targeted Cancer Therapy.
Topics: Anti-Infective Agents; Antineoplastic Agents, Phytogenic; Apoptosis; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell Proliferation; Drug Carriers; Drug Delivery Systems; Drug Liberation; Drug Synergism; Drug Therapy, Combination; Humans; Lung Neoplasms; Micelles; NAD(P)H Dehydrogenase (Quinone); Nanotechnology; Naphthoquinones; Paclitaxel; Pancreatic Neoplasms; Polymers; Tumor Cells, Cultured | 2015 |
Plasma biomarker signature associated with improved survival in advanced non-small cell lung cancer patients on linifanib.
Topics: Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carboplatin; Carcinoembryonic Antigen; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Female; Humans; Indazoles; Keratin-19; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Phenylurea Compounds | 2015 |
[Complete Remission after Weekly Intravenous Nanoparticle Albumin-Bound Paclitaxel in Elderly Patients with Non-Small-Cell Lung Cancer].
Topics: Aged; Aged, 80 and over; Albumins; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Neoplasm Staging; Paclitaxel; Remission Induction | 2015 |
Survival outcome according to KRAS mutation status in newly diagnosed patients with stage IV non-small cell lung cancer treated with platinum doublet chemotherapy.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Disease Progression; Disease-Free Survival; DNA Mutational Analysis; Docetaxel; ErbB Receptors; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Paclitaxel; Philadelphia; Proportional Hazards Models; Proto-Oncogene Proteins p21(ras); Retrospective Studies; Risk Factors; Taxoids; Time Factors; Treatment Outcome | 2015 |
Greater efficacy of chemotherapy plus bevacizumab compared to chemo- and targeted therapy alone on non-small cell lung cancer patients with brain metastasis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; ErbB Receptors; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Mutation; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Staging; Paclitaxel; Pemetrexed; Prognosis; Retrospective Studies; Survival Rate | 2016 |
Anti-Proliferative Effects of Hesa-A on Human Cancer Cells with Different Metastatic Potential.
Topics: Adenocarcinoma; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Cell Survival; Female; Humans; Inhibitory Concentration 50; Lung Neoplasms; Male; Neoplasms; Ovarian Neoplasms; Paclitaxel; Plant Preparations; Prostatic Neoplasms | 2015 |
Co-delivery of cisplatin and paclitaxel by folic acid conjugated amphiphilic PEG-PLGA copolymer nanoparticles for the treatment of non-small lung cancer.
Topics: Animals; Antineoplastic Agents; Area Under Curve; Carcinoma, Non-Small-Cell Lung; Cell Line; Cell Line, Tumor; Cell Survival; Cisplatin; Drug Delivery Systems; Folic Acid; Humans; Lung Neoplasms; Male; Mice, Inbred BALB C; Mice, Nude; Microscopy, Electron, Transmission; Nanoparticles; Paclitaxel; Polyesters; Polyethylene Glycols; Tissue Distribution; Treatment Outcome; Tumor Burden; Xenograft Model Antitumor Assays | 2015 |
Encapsulated paclitaxel nanoparticles exhibit enhanced anti-tumor efficacy in A549 non-small lung cancer cells.
Topics: A549 Cells; Animals; Antineoplastic Agents; Biological Availability; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Delivery Systems; Fluorescence Resonance Energy Transfer; Humans; Inhibitory Concentration 50; Kinetics; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Micelles; Nanoparticles; Paclitaxel; Solvents; Xenograft Model Antitumor Assays | 2015 |
Feasibility and clinical impact of sharing patient-reported symptom toxicities and performance status with clinical investigators during a phase 2 cancer treatment trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase II as Topic; Drug-Related Side Effects and Adverse Reactions; Feasibility Studies; Female; Humans; Information Dissemination; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Patient Reported Outcome Measures; Pemetrexed; Research Personnel; Self Report | 2016 |
Weekly carboplatin in combination with weekly paclitaxel in the treatment of metastatic non-small cell lung cancer: a single center 10-year experience.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Palliative Care; Patient Care Planning; Retrospective Studies; Risk Factors; Treatment Outcome | 2016 |
Reversal of Chemoresistance in Human Lung Cancer Cell Line A549/Taxol by Synthetic Second Mitochondria-Derived Activator of Caspase Peptide.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Apoptosis Regulatory Proteins; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Synergism; Humans; Intracellular Signaling Peptides and Proteins; Lung Neoplasms; Mitochondrial Proteins; Paclitaxel; Tumor Stem Cell Assay | 2015 |
SET antagonist enhances the chemosensitivity of non-small cell lung cancer cells by reactivating protein phosphatase 2A.
Topics: Aged; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Disease-Free Survival; DNA-Binding Proteins; Drug Synergism; Enzyme Activation; Female; Histone Chaperones; Humans; Immunohistochemistry; Lung Neoplasms; Male; Mice, Nude; Middle Aged; Paclitaxel; Protein Phosphatase 2; Proto-Oncogene Proteins c-akt; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; Transcription Factors; Xenograft Model Antitumor Assays | 2016 |
An anthraquinone derivative from Luffa acutangula induces apoptosis in human lung cancer cell line NCI-H460 through p53-dependent pathway.
Topics: Anthraquinones; Apoptosis; Ataxia Telangiectasia Mutated Proteins; bcl-2-Associated X Protein; Carcinoma, Non-Small-Cell Lung; Caspase 3; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Cyclin-Dependent Kinase Inhibitor p21; DNA Fragmentation; Fluoresceins; Gene Expression Regulation, Neoplastic; Humans; Intracellular Space; Luffa; Lung Neoplasms; Models, Biological; Molecular Docking Simulation; Molecular Dynamics Simulation; NF-kappa B; Nuclear Proteins; Paclitaxel; Reactive Oxygen Species; RNA, Messenger; Signal Transduction; Tumor Suppressor Protein p53 | 2016 |
Predictive factors for survival and correlation to toxicity in advanced Stage III non-small cell lung cancer patients with concurrent chemoradiation.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Cisplatin; Deoxycytidine; Docetaxel; Drug Administration Schedule; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Proportional Hazards Models; Radiation Injuries; Radiotherapy, Conformal; Retrospective Studies; Taxoids; Treatment Outcome | 2016 |
Combined Delivery of Let-7b MicroRNA and Paclitaxel via Biodegradable Nanoassemblies for the Treatment of KRAS Mutant Cancer.
Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell Movement; Cell Proliferation; Drug Carriers; Drug Delivery Systems; Female; Humans; Immunoenzyme Techniques; Lung Neoplasms; Mice; Mice, Nude; Micelles; MicroRNAs; Mutation; Nanocomposites; Paclitaxel; Polyethylene Glycols; Proto-Oncogene Proteins p21(ras); Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2016 |
Pharmacogenetic analysis of advanced non-small-cell lung cancer patients treated with first-line paclitaxel and carboplatin chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B; Carboplatin; Carcinoma, Non-Small-Cell Lung; Female; Glycolysis; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Lung Neoplasms; Male; Middle Aged; Organic Anion Transporters, Sodium-Independent; Paclitaxel; Polymorphism, Single Nucleotide; Prognosis; Prospective Studies; Solute Carrier Organic Anion Transporter Family Member 1B3; Survival Analysis | 2016 |
Changes of Lymphocyte Subgroups in Non-Small Cell Lung Cancer Patients Before and During Chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; CD28 Antigens; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Cisplatin; Deoxycytidine; Female; Flow Cytometry; Gemcitabine; Humans; Lung Neoplasms; Lymphocytes; Male; Middle Aged; Paclitaxel; Time Factors | 2015 |
Hemocompatibility of folic-acid-conjugated amphiphilic PEG-PLGA copolymer nanoparticles for co-delivery of cisplatin and paclitaxel: treatment effects for non-small-cell lung cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blood; Blood Coagulation; Carcinoma, Non-Small-Cell Lung; Cell Cycle Checkpoints; Cell Line; Cisplatin; Complement Activation; Drug Carriers; Drug Compounding; Folic Acid; Hemolysis; Humans; Leukocyte Count; Lung Neoplasms; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Nanoparticles; Paclitaxel; Polyesters; Polyethylene Glycols; Rabbits; Xenograft Model Antitumor Assays | 2016 |
Thoracic Vertebral Body Irradiation Contributes to Acute Hematologic Toxicity During Chemoradiation Therapy for Non-Small Cell Lung Cancer.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy Protocols; Bone and Bones; Bone Marrow; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Female; Hematologic Diseases; Humans; Leukopenia; Lung Neoplasms; Male; Middle Aged; Neutropenia; Paclitaxel; Radiation Dosage; Radiation Tolerance; Regression Analysis; Thoracic Vertebrae; Thrombocytopenia | 2016 |
Candidates for Intensive Local Treatment in cIIIA-N2 Non-Small Cell Lung Cancer: Deciphering the Heterogeneity.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Female; Humans; Lung Neoplasms; Lymph Nodes; Lymphatic Metastasis; Male; Mediastinum; Middle Aged; Mitomycin; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Patient Selection; Radiotherapy Dosage; Vinblastine; Vinorelbine | 2016 |
Afatinib and chemotherapy in non-small-cell lung cancer.
Topics: Afatinib; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; Humans; Lung Neoplasms; Paclitaxel; Quinazolines | 2016 |
Evolution of a Lung-Sparing Strategy with Sleeve Lobectomy and Induction Therapy for Non-small Cell Lung Cancer: 20-Year Experience at a Single Institution.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Chemoradiotherapy; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Humans; Induction Chemotherapy; Lung; Lung Neoplasms; Lymph Nodes; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Organ Sparing Treatments; Oxonic Acid; Paclitaxel; Platinum Compounds; Pneumonectomy; Remission Induction; Retrospective Studies; Survival Rate; Tegafur; Tumor Burden | 2016 |
Comparison of efficacy and safety of three different chemotherapy regimens delivered with concomitant radiotherapy in inoperable stage III non-small cell lung cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Disease-Free Survival; Docetaxel; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Radiotherapy Dosage; Retrospective Studies; Taxoids | 2016 |
Targeting HDAC with a novel inhibitor effectively reverses paclitaxel resistance in non-small cell lung cancer via multiple mechanisms.
Topics: Carcinoma, Non-Small-Cell Lung; Histone Deacetylases; Humans; Lung Neoplasms; Paclitaxel | 2016 |
p38 MAPK-induced MDM2 degradation confers paclitaxel resistance through p53-mediated regulation of EGFR in human lung cancer cells.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell Adhesion; Cell Proliferation; Drug Resistance, Neoplasm; Drug Synergism; ErbB Receptors; Erlotinib Hydrochloride; Flow Cytometry; Humans; Immunoenzyme Techniques; Lung Neoplasms; p38 Mitogen-Activated Protein Kinases; Paclitaxel; Phosphorylation; Protein Kinase Inhibitors; Proteolysis; Proto-Oncogene Proteins c-mdm2; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Signal Transduction; Tumor Cells, Cultured; Tumor Suppressor Protein p53 | 2016 |
Autophagy regulates resistance of non-small cell lung cancer cells to paclitaxel.
Topics: 3' Untranslated Regions; A549 Cells; Antineoplastic Agents, Phytogenic; Autophagy; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Genes, Reporter; Humans; Intracellular Signaling Peptides and Proteins; Lung Neoplasms; MicroRNAs; Neoplasm Proteins; Oligonucleotides, Antisense; Paclitaxel | 2016 |
Regulation of Oncoprotein 18/Stathmin Signaling by ERK Concerns the Resistance to Taxol in Nonsmall Cell Lung Cancer Cells.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Autocrine Communication; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell Proliferation; Drug Resistance, Neoplasm; Extracellular Signal-Regulated MAP Kinases; Humans; Immunoenzyme Techniques; Lung Neoplasms; Paclitaxel; Phosphorylation; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Stathmin; Tumor Cells, Cultured | 2016 |
A genetic variation in microRNA target site of ETS2 is associated with clinical outcomes of paclitaxel-cisplatin chemotherapy in non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Binding Sites; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Cisplatin; Female; Gene Expression Regulation, Neoplastic; Genotype; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; MicroRNAs; Middle Aged; Paclitaxel; Polymorphism, Single Nucleotide; Proto-Oncogene Protein c-ets-2 | 2016 |
[An intra-thyroid metastasis revealing non-small cell lung cancer].
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Non-Small-Cell Lung; Dysphonia; Female; Humans; Lung Neoplasms; Middle Aged; Paclitaxel; Thyroid Neoplasms; Thyroidectomy | 2015 |
A retrospective analysis of safety and efficacy of weekly nab-paclitaxel as second-line chemotherapy in elderly patients with advanced squamous non-small-cell lung carcinoma.
Topics: Aged; Aged, 80 and over; Albumins; Carcinoma, Non-Small-Cell Lung; China; Disease-Free Survival; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Neoplasm Staging; Paclitaxel; Retrospective Studies; Treatment Outcome | 2016 |
Value: Changes in the Detection and Recognition Thresholds of Three Basic Tastes in Lung Cancer Patients Receiving Cisplatin and Paclitaxel and Its Association with Nutritional and Quality of Life Parameters.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Eating; Electric Impedance; Female; Humans; Lung Neoplasms; Male; Middle Aged; Nutritional Status; Paclitaxel; Quality of Life; Taste; Taste Threshold | 2016 |
[Results of surgical and combined treatment of non-small cell lung cancer].
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Disease-Free Survival; Female; Humans; Intraoperative Care; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Pneumonectomy; Postoperative Complications; Treatment Outcome | 2016 |
[Efficacy and prognostic factors of 178 advanced non-small lung cancer patients undergoing different second-line chemotherapeutic regimens].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chi-Square Distribution; Cisplatin; Disease Progression; Disease-Free Survival; Humans; Kaplan-Meier Estimate; Leukopenia; Lung Neoplasms; Paclitaxel; Prognosis; Regression Analysis; Retrospective Studies; Survival Rate; Taxoids | 2016 |
Investigation of combination therapy modes of bevacizumab and paclitaxel for NSCLC in vivo.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Humans; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Paclitaxel; Xenograft Model Antitumor Assays | 2016 |
Synergistic anticancer effects of andrographolide and paclitaxel against A549 NSCLC cells.
Topics: Animals; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Diterpenes; Drug Synergism; Female; Humans; Lung Neoplasms; Mice; Mice, Inbred BALB C; Paclitaxel; Reactive Oxygen Species | 2016 |
Potential Combinational Anti-Cancer Therapy in Non-Small Cell Lung Cancer with Traditional Chinese Medicine Sun-Bai-Pi Extract and Cisplatin.
Topics: A549 Cells; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Autophagy; Carcinoma, Non-Small-Cell Lung; Cell Survival; Cisplatin; Drugs, Chinese Herbal; Humans; Lung Neoplasms; Medicine, Chinese Traditional; Paclitaxel; Plant Extracts; Reproducibility of Results | 2016 |
MicroRNA-mediated epigenetic targeting of Survivin significantly enhances the antitumor activity of paclitaxel against non-small cell lung cancer.
Topics: Antineoplastic Agents; Apoptosis; Benzamides; Carcinoma, Non-Small-Cell Lung; Cell Proliferation; DNA (Cytosine-5-)-Methyltransferase 1; DNA Methylation; Drug Synergism; Epigenesis, Genetic; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Inhibitor of Apoptosis Proteins; Lung Neoplasms; MicroRNAs; Paclitaxel; Phosphatidylinositol 3-Kinases; Prognosis; Pyridines; Survivin | 2016 |
PD-L1 polymorphism can predict clinical outcomes of non-small cell lung cancer patients treated with first-line paclitaxel-cisplatin chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; B7-H1 Antigen; Carcinoma, Non-Small-Cell Lung; Cisplatin; CTLA-4 Antigen; Female; Humans; Lung Neoplasms; Male; Paclitaxel; Pharmacogenomic Variants; Polymorphism, Single Nucleotide; Programmed Cell Death 1 Receptor; Survival Analysis; Treatment Outcome | 2016 |
Vascular Endothelial Growth Factor in Plasma and Pleural Effusion Is a Biomarker for Outcome After Bevacizumab plus Carboplatin-Paclitaxel Treatment for Non-small Cell Lung Cancer with Malignant Pleural Effusion.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carboplatin; Carcinoma, Non-Small-Cell Lung; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Pleural Effusion; Pleural Effusion, Malignant; Vascular Endothelial Growth Factor A | 2016 |
Hsp90 Inhibitor Ganetespib Sensitizes Non-Small Cell Lung Cancer to Radiation but Has Variable Effects with Chemoradiation.
Topics: A549 Cells; Animals; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Chemoradiotherapy; Female; HSP90 Heat-Shock Proteins; Humans; Lung Neoplasms; Mice; Mice, Nude; Paclitaxel; Radiation-Sensitizing Agents; Triazoles; Xenograft Model Antitumor Assays | 2016 |
M30/M65 ratio predicts the outcome of paclitaxel chemotherapy for NSCLC.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Apoptosis; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Case-Control Studies; Female; Follow-Up Studies; Humans; Keratin-18; Lung Neoplasms; Male; Middle Aged; Necrosis; Neoplasm Staging; Paclitaxel; Peptide Fragments; Prognosis; Survival Rate | 2017 |
[Prolonged response with paclitaxel after immunotherapy by pembrolizumab in lung cancer].
Topics: Aged; Antibodies, Monoclonal, Humanized; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Combined Modality Therapy; Female; Humans; Immunotherapy; Lung Neoplasms; Paclitaxel; Time Factors; Treatment Outcome | 2016 |
Cytokeratin 18 knockdown decreases cell migration and increases chemosensitivity in non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Movement; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; HEK293 Cells; Humans; Keratin-18; Lung Neoplasms; Male; Middle Aged; Paclitaxel; RNA, Small Interfering | 2016 |
Transferrin functionalized chitosan-PEG nanoparticles for targeted delivery of paclitaxel to cancer cells.
Topics: Animals; Antineoplastic Agents, Phytogenic; Area Under Curve; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Survival; Chitosan; Drug Delivery Systems; Humans; Lung Neoplasms; Microscopy, Fluorescence; Nanoparticles; Paclitaxel; Particle Size; Polyethylene Glycols; Rats; Receptors, Transferrin; Spectroscopy, Fourier Transform Infrared; Tissue Distribution; Transferrin | 2016 |
Effect of Angiotensin System Inhibitors on Survival in Patients Receiving Chemotherapy for Advanced Non-Small-Cell Lung Cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Non-Small-Cell Lung; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Grading; Paclitaxel; Prognosis; Renin-Angiotensin System; Retrospective Studies; Survival Rate | 2017 |
miR-186 regulates chemo-sensitivity to paclitaxel via targeting MAPT in non-small cell lung cancer (NSCLC).
Topics: 3' Untranslated Regions; Adult; Aged; Animals; Apoptosis; Base Sequence; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Disease Models, Animal; Drug Resistance, Neoplasm; Gene Expression; Gene Expression Regulation, Neoplastic; Genes, p53; Humans; Lung Neoplasms; Mice; MicroRNAs; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Paclitaxel; Prognosis; RNA Interference; tau Proteins; Tumor Burden; Xenograft Model Antitumor Assays | 2016 |
LCL161 increases paclitaxel-induced apoptosis by degrading cIAP1 and cIAP2 in NSCLC.
Topics: Adult; Aged; Animals; Antineoplastic Combined Chemotherapy Protocols; Baculoviral IAP Repeat-Containing 3 Protein; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Synergism; Female; Gene Expression Regulation, Neoplastic; Humans; Inhibitor of Apoptosis Proteins; Lung Neoplasms; Male; Mice; Middle Aged; Paclitaxel; Prognosis; Proteolysis; Thiazoles; Treatment Outcome; Ubiquitin-Protein Ligases; Up-Regulation; Xenograft Model Antitumor Assays | 2016 |
[Outcomes and Toxicity of Concurrent Radiotherapy with Carboplatin/Paclitaxel
Administrated Every Three Weeks in Inoperable Advanced
Non-small Cell Lung Cancer:
A Retrospective Study from A Single Center].
Topics: Adult; Aged; Antineoplastic Agents; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Retrospective Studies; Treatment Outcome | 2016 |
Pregnane X receptors regulate CYP2C8 and P-glycoprotein to impact on the resistance of NSCLC cells to Taxol.
Topics: Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily B; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cytochrome P-450 CYP2C8; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Paclitaxel; Pregnane X Receptor; Receptors, Steroid | 2016 |
Combination use of paclitaxel and avastin enhances treatment effect for the NSCLC patients with malignant pleural effusion.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents, Phytogenic; Bevacizumab; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Drug Therapy, Combination; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Pleural Effusion, Malignant; Survival Rate; Treatment Outcome; Vascular Endothelial Growth Factor A | 2016 |
Designing geriatric-specific trials in advanced lung cancer: What, who and how to study?
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Deoxycytidine; Docetaxel; Drug Therapy, Combination; Gemcitabine; Geriatric Assessment; Humans; Lung Neoplasms; Paclitaxel; Vinorelbine | 2017 |
Effects of ambroxol hydrochloride on concentrations of paclitaxel and carboplatin in lung cancer patients at different administration times.
Topics: Adult; Aged; Aged, 80 and over; Ambroxol; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chromatography, High Pressure Liquid; Drug Administration Schedule; Female; Hemoglobins; Humans; Leukocyte Count; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Platelet Count; Sputum; Tandem Mass Spectrometry | 2016 |
Time-Series Modeling and Simulation for Comparative Cost-Effective Analysis in Cancer Chemotherapy: An Application to Platinum-Based Regimens for Advanced Non-small Cell Lung Cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Computer Simulation; Cost-Benefit Analysis; Deoxycytidine; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Models, Economic; Paclitaxel; Quality-Adjusted Life Years; Vinblastine; Vinorelbine | 2017 |
Metuzumab enhanced chemosensitivity and apoptosis in non-small cell lung carcinoma.
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cisplatin; Deoxycytidine; Drug Synergism; Female; Gemcitabine; Humans; Lung Neoplasms; Mice; Mice, Nude; Paclitaxel; Vinblastine; Vinorelbine; Xenograft Model Antitumor Assays | 2017 |
Aurora B expression modulates paclitaxel response in non-small cell lung cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Aurora Kinase B; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Female; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Male; Middle Aged; Organophosphates; Paclitaxel; Quinazolines; Up-Regulation | 2017 |
Comparative Effectiveness and Resource Usage in Patients Receiving First-line Taxane-based Chemotherapy for Stage IV Non-Small-cell Lung Cancer in a US Community Oncology Setting.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Carboplatin; Carcinoma, Non-Small-Cell Lung; Community Networks; Female; Humans; Lung Neoplasms; Male; Nanoparticles; Neoplasm Staging; Paclitaxel; Retrospective Studies; Survival Analysis; Taxoids; United States; Withholding Treatment | 2017 |
Treatment Patterns and Overall Survival Associated with First-Line Systemic Therapy for Patients with Advanced Non-Small Cell Lung Cancer.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Bridged-Ring Compounds; Carboplatin; Carcinoma, Non-Small-Cell Lung; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Pemetrexed; Proportional Hazards Models; Retrospective Studies; Taxoids | 2017 |
Hyaluronic acid-modified didecyldimethylammonium bromide/ d-a-tocopheryl polyethylene glycol succinate mixed micelles for delivery of baohuoside I against non-small cell lung cancer: in vitro and in vivo evaluation.
Topics: Animals; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Drug Carriers; Drug Compounding; Flavonoids; Humans; Hyaluronic Acid; Inhibitory Concentration 50; Injections, Intravenous; Lung Neoplasms; Male; Mice, Inbred BALB C; Mice, Nude; Micelles; Paclitaxel; Quaternary Ammonium Compounds; Solubility; Surface Properties; Technology, Pharmaceutical; Time Factors; Vitamin E; Xenograft Model Antitumor Assays | 2017 |
ERBB2-Mutated Metastatic Non-Small Cell Lung Cancer: Response and Resistance to Targeted Therapies.
Topics: Adenocarcinoma; Ado-Trastuzumab Emtansine; Adult; Afatinib; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Class I Phosphatidylinositol 3-Kinases; Docetaxel; Drug Resistance, Neoplasm; Female; Gene Dosage; Genes, erbB-2; Humans; Lung Neoplasms; Male; Maytansine; Middle Aged; Molecular Targeted Therapy; Paclitaxel; Quinazolines; Retrospective Studies; Taxoids; Trastuzumab; Vinblastine; Vinorelbine | 2017 |
Weekly paclitaxel after first-line failure in patients with advanced non-small-cell lung cancer: everyday clinical practice in a single centre.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Drug Administration Schedule; Feasibility Studies; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel | 2017 |
Vinblastine differs from Taxol as it inhibits the malignant phenotypes of NSCLC cells by increasing the phosphorylation of Op18/stathmin.
Topics: Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Paclitaxel; Phosphorylation; Stathmin; Vinblastine | 2017 |
Nanoparticle abraxane possesses impaired proliferation in A549 cells due to the underexpression of glucosamine 6-phosphate N-acetyltransferase 1 (GNPNAT1/GNA1).
Topics: A549 Cells; Actins; Albumin-Bound Paclitaxel; Apoptosis; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell Adhesion; Cell Proliferation; Cell Survival; Chromatography, Liquid; Glucosamine 6-Phosphate N-Acetyltransferase; Humans; Isotope Labeling; Lung Neoplasms; Models, Biological; Nanoparticles; Paclitaxel; Polymerization; Proteomics; Reproducibility of Results; Tandem Mass Spectrometry | 2017 |
Tumor-targeted polymeric nanostructured lipid carriers with precise ratiometric control over dual-drug loading for combination therapy in non-small-cell lung cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Biocompatible Materials; Carcinoma, Non-Small-Cell Lung; Cell Death; Cell Line, Tumor; Deoxycytidine; Drug Carriers; Drug Delivery Systems; Drug Stability; Endocytosis; Galactose; Gemcitabine; Humans; Inhibitory Concentration 50; Lipids; Lung Neoplasms; Mice; Nanostructures; Paclitaxel; Polymers | 2017 |
Preclinical Antitumor Efficacy of BAY 1129980-a Novel Auristatin-Based Anti-C4.4A (LYPD3) Antibody-Drug Conjugate for the Treatment of Non-Small Cell Lung Cancer.
Topics: Aminobenzoates; Animals; Antibodies, Monoclonal; Carcinoma, Non-Small-Cell Lung; Cell Adhesion Molecules; Cell Line, Tumor; Cisplatin; GPI-Linked Proteins; Humans; Immunoconjugates; Mice; Oligopeptides; Paclitaxel; Vinblastine; Vinorelbine; Xenograft Model Antitumor Assays | 2017 |
Induction concurrent chemoradiotherapy using Paclitaxel and Carboplatin combination followed by surgery in locoregionally advanced non-small cell lung cancer--Asian experience.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Pneumonectomy; Radiotherapy, Adjuvant; Retrospective Studies | 2008 |
Paclitaxel and cisplatin in the treatment of metastatic non-small-cell lung cancer during pregnancy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Female; Humans; Lung Neoplasms; Paclitaxel; Pregnancy; Pregnancy Complications; Pregnancy Outcome | 2008 |
ERCC1 expression as a prognostic marker in N2(+) nonsmall-cell lung cancer patients treated with platinum-based neoadjuvant concurrent chemoradiotherapy.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Disease-Free Survival; DNA-Binding Proteins; Docetaxel; Endonucleases; Etoposide; Female; Humans; Immunoenzyme Techniques; Lung Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Survival Rate; Taxoids; Treatment Outcome | 2008 |
Bowel perforation in non-small cell lung cancer after bevacizumab therapy.
Topics: Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Non-Small-Cell Lung; Humans; Intestinal Perforation; Lung Neoplasms; Male; Paclitaxel | 2009 |
Synergistic inhibitory activity of zoledronate and paclitaxel on bone metastasis in nude mice.
Topics: Animals; Antineoplastic Agents, Phytogenic; bcl-2-Associated X Protein; bcl-X Protein; Bone Density Conservation Agents; Bone Neoplasms; Carcinoma, Non-Small-Cell Lung; Collagen Type I; Diphosphonates; Drug Therapy, Combination; Enzyme-Linked Immunosorbent Assay; Humans; Imidazoles; Immunoenzyme Techniques; Incidence; Lung Neoplasms; Mice; Mice, Nude; Paclitaxel; Peptides; Proto-Oncogene Proteins c-bcl-2; Survival Rate; Tumor Cells, Cultured; Xenograft Model Antitumor Assays; Zoledronic Acid | 2008 |
Predictors of acute esophagitis in lung cancer patients treated with concurrent three-dimensional conformal radiotherapy and chemotherapy.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Drug Administration Schedule; Esophagitis; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Prospective Studies; Radiotherapy Dosage; Radiotherapy, Conformal; ROC Curve; Small Cell Lung Carcinoma; Tumor Burden; Vinblastine; Vinorelbine | 2009 |
Docetaxel as second line therapy in advanced non-small cell lung cancer-the dose and combination may matter!
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Lung Neoplasms; Paclitaxel; Salvage Therapy; Taxoids; Treatment Outcome | 2008 |
Differential impairment of regulatory T cells rather than effector T cells by paclitaxel-based chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Apoptosis; Carcinoma, Non-Small-Cell Lung; fas Receptor; Female; Humans; Interferon-gamma; Interleukin-2; Lung Neoplasms; Male; Middle Aged; Paclitaxel; T-Lymphocytes; T-Lymphocytes, Regulatory | 2008 |
Adjuvant chemotherapy for non-small-cell lung cancer: a fading effect?
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Disease-Free Survival; Evidence-Based Medicine; Humans; Lung Neoplasms; Neoplasm Staging; Paclitaxel; Patient Selection; Risk Assessment; Survival Analysis; Time Factors; Treatment Outcome | 2008 |
Gender differences in treatment outcomes among patients with non-small cell lung cancer given a combination of carboplatin and paclitaxel.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Sex Factors; Survival Rate; Treatment Outcome | 2008 |
The efficacy of prophylactic Shakuyaku-Kanzo-to for myalgia and arthralgia following carboplatin and paclitaxel combination chemotherapy for non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Arthralgia; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chi-Square Distribution; Drugs, Chinese Herbal; Female; Humans; Lung Neoplasms; Male; Middle Aged; Muscular Diseases; Paclitaxel; Statistics, Nonparametric | 2009 |
Establishment of patient-derived non-small cell lung cancer xenografts as models for the identification of predictive biomarkers.
Topics: Adenocarcinoma; Adult; Aged; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Biomarkers, Tumor; Carboplatin; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cetuximab; Deoxycytidine; Disease Models, Animal; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Etoposide; Female; Gemcitabine; Gene Expression Profiling; Genes, ras; Humans; Immunoblotting; Lung Neoplasms; Male; Mice; Mice, Inbred NOD; Mice, Nude; Mice, SCID; Middle Aged; Mutation; Oligonucleotide Array Sequence Analysis; Paclitaxel; Polymerase Chain Reaction; Prognosis; Protein Kinase Inhibitors; Quinazolines; Radiation-Sensitizing Agents; Small Cell Lung Carcinoma; Tumor Suppressor Protein p53; Vinblastine; Vinorelbine; Xenograft Model Antitumor Assays | 2008 |
The effect of radiation dose and chemotherapy on overall survival in 237 patients with Stage III non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Radiotherapy Dosage; Relative Biological Effectiveness; Retrospective Studies; Survival Rate; Vinblastine; Vinorelbine | 2009 |
Expression of ERCC1 and class III beta-tubulin in non-small cell lung cancer patients treated with carboplatin and paclitaxel.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; DNA-Binding Proteins; Drug Resistance, Neoplasm; Endonucleases; Female; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Predictive Value of Tests; Prognosis; Retrospective Studies; Survival Analysis; Treatment Outcome; Tubulin | 2009 |
Paclitaxel-octreotide conjugates in tumor growth inhibition of A549 human non-small cell lung cancer xenografted into nude mice.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Body Weight; Carcinoma, Non-Small-Cell Lung; Drug Delivery Systems; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Male; Mice; Mice, Nude; Octreotide; Paclitaxel; Receptors, Somatostatin; RNA, Messenger; Time Factors; Toxicity Tests; Xenograft Model Antitumor Assays | 2008 |
Cooperation of the agonistic DR5 antibody apomab with chemotherapy to inhibit orthotopic lung tumor growth and improve survival.
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Female; Humans; Immunoblotting; In Situ Nick-End Labeling; Lung Neoplasms; Mice; Mice, Nude; Paclitaxel; Receptors, TNF-Related Apoptosis-Inducing Ligand; Xenograft Model Antitumor Assays | 2008 |
Tubulin-targeted drug action: functional significance of class ii and class IVb beta-tubulin in vinca alkaloid sensitivity.
Topics: Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Division; Cell Line, Tumor; Drug Delivery Systems; G2 Phase; Humans; Lung Neoplasms; Paclitaxel; Protein Isoforms; RNA Interference; RNA, Messenger; RNA, Small Interfering; Transfection; Tubulin; Vinblastine; Vinca Alkaloids; Vincristine | 2008 |
Tumor cavitation: impact on objective response evaluation in trials of angiogenesis inhibitors in non-small-cell lung cancer.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Outcome and Process Assessment, Health Care; Paclitaxel; Radiography; Retrospective Studies; Vascular Endothelial Growth Factor A | 2009 |
[Tumor growth inhibition of paclitaxel-octreotide conjugates on human non small cell lung cancer: experiment with mice].
Topics: Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Humans; Lung Neoplasms; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Microvessels; Octreotide; Paclitaxel; Receptors, Somatostatin; RNA, Messenger; Xenograft Model Antitumor Assays | 2008 |
Use of a novel Arg-Gly-Asp radioligand, 18F-AH111585, to determine changes in tumor vascularity after antitumor therapy.
Topics: Animals; Antineoplastic Agents; Carcinoma, Lewis Lung; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; Mice; Neoplasms; Oligopeptides; Paclitaxel; Peptides; Polyethylene Glycols; Positron-Emission Tomography; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Tissue Distribution; Triazoles | 2009 |
Microtubule-damaging agents enhance RASSF1A-induced cell death in lung cancer cell lines.
Topics: Antimitotic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Death; Cell Line, Tumor; Cyclin B; Cyclin B1; Humans; Lung Neoplasms; Microtubules; Paclitaxel; RNA Interference; Tubulin Modulators; Tumor Suppressor Proteins; Vincristine | 2009 |
Circulating endothelial cells in non-small cell lung cancer patients treated with carboplatin and paclitaxel.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Endothelium, Vascular; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Neoplastic Cells, Circulating; Paclitaxel; Prognosis; Survival Rate; Treatment Outcome | 2009 |
Expansile nanoparticles: synthesis, characterization, and in vivo efficacy of an acid-responsive polymeric drug delivery system.
Topics: Animals; Carcinoma, Lewis Lung; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Delivery Systems; Drug Screening Assays, Antitumor; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Lung Neoplasms; Mice; Nanoparticles; Paclitaxel; Polymers | 2009 |
Role of p53 in the induction of cyclooxygenase-2 by cisplatin or paclitaxel in non-small cell lung cancer cell lines.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cisplatin; Cyclooxygenase 2; Dinoprostone; Enzyme Induction; Humans; Lung Neoplasms; Mutation; Paclitaxel; RNA Interference; RNA, Messenger; RNA, Small Interfering; Time Factors; Tumor Suppressor Protein p53 | 2009 |
Local control and survival following concomitant chemoradiotherapy in inoperable stage I non-small-cell lung cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Combined Modality Therapy; Disease Progression; Docetaxel; Dose Fractionation, Radiation; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Radiotherapy, Conformal; Regression Analysis; Retrospective Studies; Survival Rate; Taxoids | 2009 |
Molecular determinants of response to matuzumab in combination with paclitaxel for patients with advanced non-small cell lung cancer.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Cohort Studies; DNA Mutational Analysis; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Genes, erbB-1; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins; Retrospective Studies | 2009 |
Prognostic factors in elderly patients with advanced non-small cell lung cancer treated with chemotherapy.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Deoxycytidine; Disease Progression; Etoposide; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Medical Records; Neoplasm Staging; Paclitaxel; Prognosis; Retrospective Studies; Survival Rate; Treatment Outcome; Vinblastine; Vinorelbine | 2009 |
CALGB 9633: an underpowered trial with a methodologically questionable conclusion.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Humans; Lung Neoplasms; Paclitaxel | 2009 |
Carboplatin and weekly paclitaxel for the treatment of advanced non-small cell lung cancer (NSCLC) during pregnancy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Female; Humans; Lung Neoplasms; Paclitaxel; Pregnancy; Pregnancy Complications, Neoplastic | 2009 |
Systemic chemotherapy using paclitaxel and carboplatin plus regional hyperthermia and hyperbaric oxygen treatment for non-small cell lung cancer with multiple pulmonary metastases: preliminary results.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Disease-Free Survival; Female; Humans; Hyperbaric Oxygenation; Hyperthermia, Induced; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Retrospective Studies; Treatment Outcome | 2009 |
A pharmacokinetic and dose escalation study of pegfilgrastim (KRN125) in lung cancer patients with chemotherapy-induced neutropenia.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Neutropenia; Paclitaxel; Polyethylene Glycols; Prognosis; Recombinant Proteins; Small Cell Lung Carcinoma; Survival Rate; Treatment Outcome; Young Adult | 2009 |
Final overall results of a study with a novel triplet induction chemotherapy regimen (PACCAGE) followed by consolidation radiotherapy in locally advanced inoperable non-small cell lung cancer (NSCLC).
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Combined Modality Therapy; Deoxycytidine; Dose Fractionation, Radiation; Feasibility Studies; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Prognosis; Remission Induction; Salvage Therapy; Survival Rate; Treatment Outcome | 2009 |
XPA A23G polymorphism is associated with the elevated response to platinum-based chemotherapy in advanced non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; DNA-Binding Proteins; Docetaxel; Endonucleases; Female; Gemcitabine; Gene Frequency; Genotype; Humans; Logistic Models; Lung Neoplasms; Male; Middle Aged; Nuclear Proteins; Paclitaxel; Polymorphism, Single Nucleotide; Taxoids; Transcription Factors; Treatment Outcome; Vinblastine; Vinorelbine; Xeroderma Pigmentosum Group A Protein | 2009 |
Japanese-US common-arm analysis of paclitaxel plus carboplatin in advanced non-small-cell lung cancer: a model for assessing population-related pharmacogenomics.
Topics: Anemia; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Disease-Free Survival; Humans; Japan; Lung Neoplasms; Neoplasm Staging; Neutropenia; Paclitaxel; Pharmacogenetics; Pneumonectomy; Proportional Hazards Models; Prospective Studies; Quality of Life; Survival; United States | 2009 |
Single-agent versus combination chemotherapy in patients with advanced non-small cell lung cancer and a performance status of 2: prognostic factors and treatment selection based on two large randomized clinical trials.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Biomarkers; Carboplatin; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Prognosis; Proportional Hazards Models; Randomized Controlled Trials as Topic; Regression Analysis; Survival Rate; Vinblastine; Vinorelbine | 2009 |
Substrate-dependent bidirectional modulation of P-glycoprotein-mediated drug resistance by erlotinib.
Topics: ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Carcinoma, Non-Small-Cell Lung; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Humans; K562 Cells; Lung Neoplasms; Mitoxantrone; Neoplasm Proteins; Paclitaxel; Protein Kinase Inhibitors; Quinazolines; Substrate Specificity; Tumor Cells, Cultured; Vincristine | 2009 |
Paclitaxel alters the expression and specific activity of deoxycytidine kinase and cytidine deaminase in non-small cell lung cancer cell lines.
Topics: Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Proliferation; Cytidine Deaminase; Deoxycytidine; Deoxycytidine Kinase; Gemcitabine; Gene Expression Regulation, Enzymologic; Humans; Lung Neoplasms; Paclitaxel; Phosphorylation; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tumor Cells, Cultured | 2009 |
[Effect of different chemotherapy regimens for concurrent chemoradiotherapy on locally advanced non-small cell lung cancer].
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Etoposide; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Proportional Hazards Models; Radiation Pneumonitis; Radiotherapy, Conformal; Retrospective Studies; Survival Rate; Topotecan | 2009 |
Alpha-tocopheryl succinate potentiates the paclitaxel-induced apoptosis through enforced caspase 8 activation in human H460 lung cancer cells.
Topics: alpha-Tocopherol; Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Caspase 8; Cell Growth Processes; Cell Line, Tumor; Drug Synergism; Drug Therapy, Combination; Humans; Neoplastic Stem Cells; Paclitaxel | 2009 |
Cell cycle effects and increased adduct formation by temozolomide enhance the effect of cytotoxic and targeted agents in lung cancer cell lines.
Topics: Animals; Antineoplastic Agents, Alkylating; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Line, Tumor; Dacarbazine; Deoxycytidine; Deoxyguanosine; DNA Adducts; DNA Methylation; Drug Synergism; Gemcitabine; Humans; Lung Neoplasms; Mice; O(6)-Methylguanine-DNA Methyltransferase; Paclitaxel; Piperidines; Pyridines; Temozolomide | 2009 |
Nuclear factor-kappaB inhibition by parthenolide potentiates the efficacy of Taxol in non-small cell lung cancer in vitro and in vivo.
Topics: Analysis of Variance; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; bcl-X Protein; Carcinoma, Non-Small-Cell Lung; Caspases; Cell Line, Tumor; Cell Survival; Cytochromes c; Drug Synergism; Histocytochemistry; I-kappa B Kinase; Kaplan-Meier Estimate; Lung Neoplasms; Mice; Mitochondrial Membranes; NF-kappa B; Paclitaxel; Sesquiterpenes; Xenograft Model Antitumor Assays | 2009 |
Synergistic antitumor activity of oncolytic reovirus and chemotherapeutic agents in non-small cell lung cancer cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Caspases; Cell Cycle; Cell Line, Tumor; Cell Survival; Combined Modality Therapy; Deoxycytidine; Drug Synergism; Enzyme Activation; Gemcitabine; Humans; Lung Neoplasms; Mammalian orthoreovirus 3; Oncolytic Virotherapy; Paclitaxel; Poly(ADP-ribose) Polymerases; ras Proteins; Vinblastine; Virion | 2009 |
Gefitinib plus paclitaxel after failure of gefitinib in non-small cell lung cancer initially responding to gefitinib.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Quinazolines; Survival Analysis | 2009 |
Vorinostat increases carboplatin and paclitaxel activity in non-small-cell lung cancer cells.
Topics: Acetylation; Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cell Line, Tumor; Clinical Trials, Phase I as Topic; DNA Damage; DNA, Neoplasm; Drug Synergism; Histone Deacetylase Inhibitors; Histones; Humans; Hydroxamic Acids; Lung Neoplasms; Neoplasm Proteins; Paclitaxel; Protein Processing, Post-Translational; Tubulin; Tumor Stem Cell Assay; Vorinostat | 2010 |
The relationship between response to previous systemic treatment and the efficacy of subsequent pemetrexed therapy in advanced non-small cell lung cancer.
Topics: Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease Progression; Docetaxel; Drug Therapy, Combination; ErbB Receptors; Erlotinib Hydrochloride; Female; Gemcitabine; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Neoplasm Staging; Paclitaxel; Pemetrexed; Prognosis; Quinazolines; Retrospective Studies; Survival Analysis; Taxoids; Treatment Outcome | 2010 |
Preclinical efficacy studies of a novel nanoparticle-based formulation of paclitaxel that out-performs Abraxane.
Topics: Albumin-Bound Paclitaxel; Albumins; Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Female; Humans; Lung Neoplasms; Melanoma, Experimental; Mice; Nanoparticles; Ovarian Neoplasms; Paclitaxel; Proteins; Transplantation, Heterologous; Treatment Outcome | 2010 |
Changes in pulmonary function tests after neoadjuvant therapy predict postoperative complications.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Child; Combined Modality Therapy; Disease-Free Survival; Female; Humans; Infant; Lung; Lung Neoplasms; Lung Volume Measurements; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Pneumonectomy; Postoperative Complications; Prognosis; Pulmonary Alveoli; Pulmonary Diffusing Capacity; Radiation Injuries; Radiotherapy Dosage; Risk Assessment | 2009 |
The incidence of perioperative anastomotic complications after sleeve lobectomy is not increased after neoadjuvant chemoradiotherapy.
Topics: Aged; Anastomosis, Surgical; Antineoplastic Combined Chemotherapy Protocols; Bronchoscopy; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Disease-Free Survival; Etoposide; Female; Fluorouracil; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Pneumonectomy; Postoperative Complications; Pulmonary Diffusing Capacity; Radiotherapy Dosage; Retrospective Studies | 2009 |
Amplification of the ABCB1 region accompanied by a short sequence of 200bp from chromosome 2 in lung cancer cells.
Topics: Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Base Sequence; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Chromosome Breakage; Chromosomes, Human, Pair 2; Chromosomes, Human, Pair 7; Comparative Genomic Hybridization; DNA, Neoplasm; Dose-Response Relationship, Drug; Gene Amplification; Gene Dosage; Humans; In Situ Hybridization, Fluorescence; Lung Neoplasms; Molecular Sequence Data; Paclitaxel; Polymerase Chain Reaction; Time Factors; Translocation, Genetic | 2009 |
A multicenter retrospective analysis of survival outcome following postoperative chemoradiotherapy in non-small-cell lung cancer patients with N2 nodal disease.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Cisplatin; Deoxycytidine; Disease-Free Survival; Etoposide; Female; Gemcitabine; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Multivariate Analysis; Paclitaxel; Postoperative Care; Radiotherapy Dosage; Radiotherapy, Adjuvant; Retrospective Studies; Survival Rate; Treatment Outcome | 2010 |
Pemetrexed-induced pneumonitis: a case report.
Topics: Adrenal Cortex Hormones; Aged; Anti-Infective Agents; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Ciprofloxacin; Cisplatin; Drug Hypersensitivity; Drug Therapy, Combination; Dyspnea; Erythema; Glutamates; Guanine; Humans; Lung; Lung Neoplasms; Male; Neoplasm Recurrence, Local; Paclitaxel; Pemetrexed; Pneumonia; Pulmonary Fibrosis; Recovery of Function; Solitary Pulmonary Nodule | 2009 |
[Clinical investigation of weekly Carboplatin and Paclitaxel with concurrent radiation therapy for locally advanced non-small cell lung cancer].
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Disease Progression; Dose-Response Relationship, Drug; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Retrospective Studies; Survival Rate | 2009 |
Chemotherapy-associated toxicity in a large cohort of elderly patients with non-small cell lung cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Cohort Studies; Deoxycytidine; Drug-Related Side Effects and Adverse Reactions; Female; Follow-Up Studies; Gemcitabine; Humans; Incidence; Lung Neoplasms; Male; Neoplasm Staging; Paclitaxel; Prognosis; SEER Program; Survival Rate; Treatment Outcome; Vinblastine; Vinorelbine | 2010 |
[A case of pseudomenbranous colitis after paclitaxel and carboplatin chemotherapy].
Topics: Aged; Anti-Infective Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Diagnosis, Differential; Enterocolitis, Pseudomembranous; Humans; Lung Neoplasms; Male; Metronidazole; Paclitaxel; Sigmoidoscopy; Tomography, X-Ray Computed | 2009 |
Putative chemopreventive molecules can increase Nrf2-regulated cell defense in some human cancer cell lines, resulting in resistance to common cytotoxic therapies.
Topics: Antineoplastic Agents; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cullin Proteins; Doxorubicin; Drug Resistance, Neoplasm; Female; Humans; Intracellular Signaling Peptides and Proteins; Kelch-Like ECH-Associated Protein 1; Lung Neoplasms; NF-E2-Related Factor 2; Paclitaxel | 2010 |
Targeting heat shock protein 90 with CUDC-305 overcomes erlotinib resistance in non-small cell lung cancer.
Topics: Animals; Apoptosis; Benzodioxoles; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Synergism; Erlotinib Hydrochloride; Female; HSP90 Heat-Shock Proteins; Humans; Imidazoles; Lung Neoplasms; Mice; Mice, Nude; Mitogen-Activated Protein Kinases; Paclitaxel; Phosphatidylinositol 3-Kinases; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Signal Transduction; Survival Analysis; Tumor Burden; Xenograft Model Antitumor Assays | 2009 |
Prevention of local tumor recurrence following surgery using low-dose chemotherapeutic polymer films.
Topics: Animals; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Drug Delivery Systems; Female; Humans; Lung Neoplasms; Mice; Mice, Inbred C57BL; Neoplasm Recurrence, Local; Paclitaxel; Polymers; Tumor Cells, Cultured; Wound Healing | 2010 |
[Successful gefitinib every other day administration in an advanced lung cancer patient with brain metastasis after gamma knife radiotherapy and chemotherapy].
Topics: Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carboplatin; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Drug Administration Schedule; Female; Gefitinib; Humans; Lung Neoplasms; Paclitaxel; Quinazolines; Radiosurgery | 2009 |
Expression of ERCC1 and class IIIbeta tubulin for predicting effect of carboplatin/paclitaxel in patients with advanced inoperable non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; DNA-Binding Proteins; Drug Resistance, Neoplasm; Endonucleases; Female; Humans; Immunohistochemistry; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Prognosis; Tubulin | 2009 |
[Estimation of preoperative induction chemoradiotherapy effectiveness for non small-cell lung cancer].
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Docetaxel; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Taxoids; Treatment Outcome | 2009 |
Second and third line treatment in advanced non-small cell lung cancer.
Topics: Antineoplastic Agents; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Docetaxel; Drug Therapy, Combination; Gemcitabine; Glutamates; Guanine; Humans; Lung Neoplasms; Paclitaxel; Pemetrexed; Taxoids | 2009 |
Radiation pneumonitis following twice-daily radiotherapy with concurrent carboplatin and paclitaxel in patients with stage III non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Dose Fractionation, Radiation; Dose-Response Relationship, Radiation; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Pneumonia; Radiotherapy Planning, Computer-Assisted; Radiotherapy, Conformal; Retrospective Studies | 2010 |
Histology matters: individualizing treatment in non-small cell lung cancer.
Topics: Adenocarcinoma, Bronchiolo-Alveolar; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cetuximab; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Glutamates; Guanine; Humans; Lung Neoplasms; Mutation; Paclitaxel; Pemetrexed; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; SEER Program | 2010 |
[Comparative safety evaluation of first- and second-line therapy with carboplatin + paclitaxel for advanced non-small cell lung cancer].
Topics: Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Thrombocytopenia | 2010 |
Association of nutritional status and serum albumin levels with development of toxicity in patients with advanced non-small cell lung cancer treated with paclitaxel-cisplatin chemotherapy: a prospective study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Female; Humans; Lung Neoplasms; Lymphocytes; Male; Malnutrition; Middle Aged; Nutritional Status; Paclitaxel; Prospective Studies; Serum Albumin | 2010 |
Weekly paclitaxel/ docetaxel combined with a platinum in the treatment of advanced non-small cell lung cancer: a study on efficacy, safety and pre-medication.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Docetaxel; Female; Humans; Lung Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Premedication; Taxoids; Treatment Outcome | 2009 |
[Comparison of outcomes of Taxol + Cisplatin and Taxol + Nedaplatin chemotherapy regimens for advanced non-small cell lung cancer].
Topics: Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carcinoma, Non-Small-Cell Lung; Cisplatin; Humans; Leukopenia; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Paclitaxel; Remission Induction; Survival Rate; Taxoids; Young Adult | 2010 |
New treatment strategy enhances outcome for lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase II as Topic; Disease Progression; Disease-Free Survival; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Lung Neoplasms; Medical Oncology; Paclitaxel; Placebos; Randomized Controlled Trials as Topic; Time Factors; Treatment Outcome; Vorinostat | 2009 |
Anti-angiogenesis drugs in lung cancer.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cost-Benefit Analysis; Humans; Lung Neoplasms; Paclitaxel; Treatment Outcome; Vascular Endothelial Growth Factor A | 2010 |
A retrospective analysis of outcomes by age in a three-arm phase III trial of gemcitabine in combination with carboplatin or paclitaxel vs. paclitaxel plus carboplatin for advanced non-small cell lung cancer.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Retrospective Studies; Survival Analysis; Treatment Outcome | 2011 |
Enhanced antitumor efficacy by paclitaxel-loaded pluronic P123/F127 mixed micelles against non-small cell lung cancer based on passive tumor targeting and modulation of drug resistance.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Carcinoma, Non-Small-Cell Lung; Drug Delivery Systems; Drug Resistance, Neoplasm; Humans; Lung Neoplasms; Micelles; Paclitaxel; Poloxalene | 2010 |
In vitro sequence-dependent synergism between paclitaxel and gefitinib in human lung cancer cell lines.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Line, Tumor; Drug Administration Schedule; Drug Synergism; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Paclitaxel; Phosphorylation; Quinazolines; Signal Transduction | 2011 |
Factors affecting bone marrow toxicity following administration of carboplatin and paclitaxel in patients with non-small cell lung cancer.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Blood Cell Count; Bone Marrow Cells; Bone Marrow Diseases; Carboplatin; Carcinoma, Non-Small-Cell Lung; Humans; Lung Neoplasms; Middle Aged; Paclitaxel; Retrospective Studies; Young Adult | 2010 |
Paclitaxel efficacy is increased by parthenolide via nuclear factor-kappaB pathways in in vitro and in vivo human non-small cell lung cancer models.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Nucleus; Cell Survival; Drug Synergism; Humans; I-kappa B Proteins; Lung Neoplasms; Mice; Mice, Nude; NF-kappa B; Paclitaxel; Phosphorylation; Protein Transport; Random Allocation; Sesquiterpenes; Survival Analysis; Xenograft Model Antitumor Assays | 2010 |
Additive effects of C(2)-ceramide on paclitaxel-induced premature senescence of human lung cancer cells.
Topics: Apoptosis; Baculoviral IAP Repeat-Containing 3 Protein; beta-Galactosidase; Carcinoma, Non-Small-Cell Lung; Caspase 3; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cellular Senescence; Cyclin-Dependent Kinase Inhibitor p21; DNA Fragmentation; Extracellular Signal-Regulated MAP Kinases; G2 Phase; Gene Expression; GTP-Binding Proteins; Humans; Inhibitor of Apoptosis Proteins; JNK Mitogen-Activated Protein Kinases; Microfilament Proteins; Muscle Proteins; Osteonectin; p38 Mitogen-Activated Protein Kinases; Paclitaxel; Phosphorylation; Plasminogen Activator Inhibitor 1; Protein Glutamine gamma Glutamyltransferase 2; Proto-Oncogene Proteins c-bcl-2; Sphingosine; Transglutaminases; Ubiquitin-Protein Ligases | 2010 |
Comparison of cisplatin- and carboplatin-based third-generation chemotherapy in 1,014 Chinese patients with advanced non-small-cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Asian People; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Proportional Hazards Models; Retrospective Studies; Taxoids; Vinblastine; Vinorelbine | 2011 |
Association between pulmonary uptake of fluorodeoxyglucose detected by positron emission tomography scanning after radiation therapy for non-small-cell lung cancer and radiation pneumonitis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Fluorodeoxyglucose F18; Fluorouracil; Humans; Lung; Lung Neoplasms; Lymphatic Irradiation; Paclitaxel; Positron-Emission Tomography; Prospective Studies; Pulmonary Disease, Chronic Obstructive; Radiation Pneumonitis; Radiopharmaceuticals; Radiotherapy Dosage; Time Factors | 2011 |
Societal cost savings through bevacizumab-based treatment in non-small cell lung cancer (NSCLC).
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Cisplatin; Cost of Illness; Deoxycytidine; European Union; Gemcitabine; Humans; Lung Neoplasms; Middle Aged; Paclitaxel | 2010 |
Failure rates and patterns of recurrence in patients with resected N1 non-small-cell lung cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Female; Follow-Up Studies; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Mediastinal Neoplasms; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Pneumonectomy; Proportional Hazards Models; Retrospective Studies; SEER Program; Treatment Failure; Vinblastine; Vinorelbine | 2011 |
Symplekin specifies mitotic fidelity by supporting microtubule dynamics.
Topics: Animals; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Humans; Lung Neoplasms; Mice; Microtubule-Associated Proteins; Microtubules; Mitosis; Neoplasm Transplantation; Nuclear Proteins; Paclitaxel; Phenotype; RNA, Messenger; RNA, Neoplasm; RNA, Small Interfering; Spindle Apparatus; Transplantation, Heterologous | 2010 |
Clinical perspectives on dose escalation for non-small-cell lung cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cetuximab; Clinical Trials as Topic; Combined Modality Therapy; Humans; Lung Neoplasms; Paclitaxel; Radiotherapy Dosage; Radiotherapy, Conformal; Survival Rate | 2010 |
[A retrospective study of carboplatin and weekly paclitaxel combination chemotherapy for elderly patients with advanced non-small cell lung cancer].
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Female; Humans; Lung Neoplasms; Male; Neoplasm Staging; Paclitaxel; Retrospective Studies | 2010 |
Clinical pharmacokinetics of paclitaxel liposome with a new route of administration in human based on the analysis with ultra performance liquid chromatography.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Area Under Curve; Carcinoma, Non-Small-Cell Lung; Chromatography, High Pressure Liquid; Drug Administration Routes; Humans; Linear Models; Liposomes; Middle Aged; Paclitaxel; Pleural Cavity; Pleural Effusion, Malignant; Sensitivity and Specificity | 2010 |
Alternative efficacy-predicting markers for paclitaxel instead of CHFR in non-small-cell lung cancer.
Topics: Antineoplastic Agents, Phytogenic; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Cell Cycle Proteins; Cell Line, Tumor; DNA Methylation; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Genes, erbB-1; Humans; Lung Neoplasms; Mutation; Neoplasm Proteins; Paclitaxel; Poly-ADP-Ribose Binding Proteins; Polymerase Chain Reaction; Promoter Regions, Genetic; Sequence Analysis, DNA; Smoking; Succinate Dehydrogenase; Ubiquitin-Protein Ligases | 2010 |
Increasing p53 protein sensitizes non-small cell lung cancer to paclitaxel and cisplatin in vitro.
Topics: Antineoplastic Agents; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Survival; Cisplatin; Drug Resistance, Neoplasm; Enzyme-Linked Immunosorbent Assay; Humans; Lung Neoplasms; Paclitaxel; Transfection; Tumor Suppressor Protein p53 | 2010 |
A retrospective analysis of non-platinum-based first- and second-line chemotherapy in patients with advanced non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Etoposide; Female; Gemcitabine; Glutamates; Guanine; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Pemetrexed; Piperidines; Quinazolines; Retrospective Studies; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2010 |
Carboplatin plus weekly paclitaxel treatment in non-small cell lung cancer patients with interstitial lung disease.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cohort Studies; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Patient Compliance; Retrospective Studies | 2010 |
Connections between CHFR, the cell cycle, and chemosensitivity: Are they critical in cancer?
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Cycle Proteins; Cell Line, Tumor; DNA Methylation; Drug Resistance, Neoplasm; Humans; Lung Neoplasms; Neoplasm Proteins; Paclitaxel; Poly-ADP-Ribose Binding Proteins; Smoking; Ubiquitin-Protein Ligases | 2010 |
Genome-wide association study on overall survival of advanced non-small cell lung cancer patients treated with carboplatin and paclitaxel.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; DNA, Neoplasm; Female; Genome-Wide Association Study; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Pharmacogenetics; Polymerase Chain Reaction; Polymorphism, Single Nucleotide; Prognosis; Risk Factors; Survival Rate; Tissue Distribution | 2011 |
[Cost-effectiveness analysis comparing carboplatin and weekly paclitaxel with cisplatin and docetaxel in the treatment of advanced non-small cell lung carcinoma].
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Cost-Benefit Analysis; Docetaxel; Humans; Lung Neoplasms; Paclitaxel; Taxoids | 2010 |
Prognostic and predictive values of pERK1/2 and pAkt-1 expression in non-small cell lung cancer patients treated with adjuvant chemotherapy.
Topics: Adult; Aged; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; China; Deoxycytidine; Docetaxel; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Paclitaxel; Pharmacogenetics; Predictive Value of Tests; Prognosis; Proto-Oncogene Proteins c-akt; Retrospective Studies; Taxoids; Vinblastine; Vinorelbine | 2011 |
Nanotechnology takes a new look at old drugs.
Topics: Albumins; Animals; Antineoplastic Agents; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Drug Carriers; Female; Humans; Lung Neoplasms; Nanoparticles; Nanotechnology; Paclitaxel; Tumor Necrosis Factor-alpha | 2010 |
Pre-treatment levels of circulating free IGF-1 identify NSCLC patients who derive clinical benefit from figitumumab.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cadherins; Carboplatin; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase II as Topic; Enzyme-Linked Immunosorbent Assay; Female; Follow-Up Studies; Humans; Immunoglobulins, Intravenous; Insulin; Insulin-Like Growth Factor Binding Protein 1; Insulin-Like Growth Factor I; Lung Neoplasms; Male; Middle Aged; Multicenter Studies as Topic; Neoplasm Staging; Paclitaxel; Randomized Controlled Trials as Topic; Survival Rate; Treatment Outcome | 2011 |
Thymidylate synthase and dihydropyrimidine dehydrogenase expression levels are associated with response to S-1 plus carboplatin in advanced non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carboplatin; Carcinoma, Non-Small-Cell Lung; Dihydrouracil Dehydrogenase (NADP); Disease-Free Survival; Drug Combinations; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Orotate Phosphoribosyltransferase; Oxonic Acid; Paclitaxel; ROC Curve; Tegafur; Thymidylate Synthase; Treatment Outcome | 2011 |
Genetic polymorphisms in the endothelial nitric oxide synthase gene correlate with overall survival in advanced non-small-cell lung cancer patients treated with platinum-based doublet chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Introns; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Minisatellite Repeats; Neoplasm Staging; Nitric Oxide Synthase Type III; Paclitaxel; Polymorphism, Single Nucleotide; Survival Rate; Treatment Outcome | 2010 |
[Prognostic value of (18)F-fluorodeoxyglucose uptake in patients with non-small cell lung cancer treated by concurrent chemoradiotherapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Positron-Emission Tomography; Prognosis; Radiopharmaceuticals; Radiotherapy, Conformal; Tomography, X-Ray Computed; Vinblastine; Vinorelbine | 2010 |
Targeted therapy for non-small-cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Asia; Carboplatin; Carcinoma, Non-Small-Cell Lung; Gefitinib; Humans; Lung Neoplasms; Multicenter Studies as Topic; Paclitaxel; Quinazolines; Randomized Controlled Trials as Topic; Survival Rate; Treatment Outcome | 2010 |
Italian Survey on adjuvant treatment of non-small cell lung cancer (ISA).
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Cisplatin; Deoxycytidine; Gemcitabine; Health Care Surveys; Humans; Lung Neoplasms; Neoplasm Staging; Paclitaxel; Radiotherapy, Adjuvant; Vinblastine; Vinorelbine | 2011 |
Targeting the insulin-like growth factor I receptor inhibits proliferation and VEGF production of non-small cell lung cancer cells and enhances paclitaxel-mediated anti-tumor effect.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Movement; Cell Proliferation; Culture Media, Conditioned; Drug Interactions; Endothelial Cells; Humans; Insulin-Like Growth Factor I; Lung Neoplasms; Mitogen-Activated Protein Kinases; Paclitaxel; Phosphorylation; Receptor, IGF Type 1; Vascular Endothelial Growth Factor A | 2011 |
Navitoclax enhances the efficacy of taxanes in non-small cell lung cancer models.
Topics: Aniline Compounds; Animals; Antineoplastic Agents; bcl-X Protein; Carcinoma, Non-Small-Cell Lung; Cell Culture Techniques; Cell Cycle; Cell Lineage; Cell Survival; Gene Expression Regulation, Neoplastic; Green Fluorescent Proteins; Humans; Image Processing, Computer-Assisted; Lung Neoplasms; Mice; Mitosis; Neoplasm Transplantation; Paclitaxel; Sulfonamides; Taxoids; Time Factors | 2011 |
Molecular mechanism of the schedule-dependent synergistic interaction in EGFR-mutant non-small cell lung cancer cell lines treated with paclitaxel and gefitinib.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Drug Synergism; ErbB Receptors; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Paclitaxel; Quinazolines; Signal Transduction; Transforming Growth Factor alpha | 2011 |
Preoperative bevacizumab in combination with paclitaxel and carboplatin in surgically resectable non-small cell lung cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Drug Administration Schedule; Humans; Lung Neoplasms; Neoplasm Staging; Paclitaxel; Premedication | 2011 |
Antagonism between gefitinib and cisplatin in non-small cell lung cancer cells: why randomized trials failed?
Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Clinical Trials, Phase III as Topic; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Genes, ras; Humans; Lung Neoplasms; Mutation; Paclitaxel; Quinazolines; Randomized Controlled Trials as Topic; Treatment Failure; Tumor Cells, Cultured | 2011 |
Early findings on toxicity of proton beam therapy with concurrent chemotherapy for nonsmall cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Esophagitis; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Pneumonia; Proton Therapy; Protons; Radiotherapy Dosage; Radiotherapy, Conformal | 2011 |
Cure- or care-oriented regimen for stage III non-small-cell lung cancer?
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Humans; Lung Neoplasms; Neoplasm Staging; Paclitaxel; Radiotherapy, Adjuvant | 2011 |
Paclitaxel-loaded expansile nanoparticles delay local recurrence in a heterotopic murine non-small cell lung cancer model.
Topics: Animals; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Drug Delivery Systems; Female; Lung Neoplasms; Mice; Mice, Inbred C57BL; Nanoparticles; Neoplasm Recurrence, Local; Paclitaxel; Time Factors | 2011 |
Roles of BCL-2 and MDR1 expression in the efficacy of paclitaxel-based lung cancer chemoradiation.
Topics: Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Docetaxel; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Immunoenzyme Techniques; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Prospective Studies; Proto-Oncogene Proteins c-bcl-2; Radiotherapy Dosage; Survival Rate; Taxoids; Treatment Outcome | 2011 |
Split-course chemoradiotherapy for locally advanced non-small cell lung cancer: a single-institution experience of 144 patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Dose Fractionation, Radiation; Etoposide; Humans; Lung Neoplasms; Middle Aged; Neoplasm Staging; Paclitaxel; Retrospective Studies; Risk Assessment; Survival Analysis; Treatment Outcome | 2011 |
Improved response to nab-paclitaxel compared with cremophor-solubilized paclitaxel is independent of secreted protein acidic and rich in cysteine expression in non-small cell lung cancer.
Topics: Albumin-Bound Paclitaxel; Albumins; Animals; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Humans; Lung Neoplasms; Mice; Mice, SCID; Neoplasm Proteins; Osteonectin; Paclitaxel; Polyethylene Glycols; RNA, Messenger; Treatment Outcome; Xenograft Model Antitumor Assays | 2011 |
miR-135a contributes to paclitaxel resistance in tumor cells both in vitro and in vivo.
Topics: Animals; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Genes, APC; Humans; Lung Neoplasms; Mice; Mice, Nude; MicroRNAs; Neoplasm Transplantation; Paclitaxel; Up-Regulation | 2011 |
Molecular mode of action and role of TP53 in the sensitivity to the novel epothilone sagopilone (ZK-EPO) in A549 non-small cell lung cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Benzothiazoles; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Cyclin-Dependent Kinase Inhibitor p21; Cytoskeleton; DNA Damage; Epothilones; Humans; In Vitro Techniques; Lung Neoplasms; Oligonucleotide Array Sequence Analysis; Paclitaxel; Phenotype; Tumor Suppressor Protein p53; Up-Regulation | 2011 |
[Relationship between the protein expression of ERCC1, BRCA, β-tubulin and K-ras and the efficacy and prognosis in advanced non-small cell lung cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; BRCA1 Protein; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease-Free Survival; DNA-Binding Proteins; Endonucleases; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Proportional Hazards Models; ras Proteins; Remission Induction; Survival Rate; Taxoids; Tubulin; Vinblastine; Vinorelbine | 2011 |
Neuroendocrine differentiation as an indicator of chemosensitivity and prognosis in nonsmall cell lung cancer.
Topics: Adult; Aged; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Cell Differentiation; Chromogranin A; Cisplatin; Drug Resistance, Neoplasm; Female; Humans; Male; Middle Aged; Neuroendocrine Cells; Neuroendocrine Tumors; Paclitaxel; Phosphopyruvate Hydratase; Prognosis; Synaptophysin; Treatment Outcome | 2011 |
SRSF1 regulates the alternative splicing of caspase 9 via a novel intronic splicing enhancer affecting the chemotherapeutic sensitivity of non-small cell lung cancer cells.
Topics: Alternative Splicing; Carcinoma, Non-Small-Cell Lung; Caspase 9; Cell Line, Tumor; Cisplatin; Daunorubicin; Drug Resistance, Neoplasm; Drug Synergism; Enhancer Elements, Genetic; Erlotinib Hydrochloride; HeLa Cells; Humans; Introns; Lung Diseases; Nuclear Proteins; Paclitaxel; Quinazolines; RNA Precursors; RNA Splice Sites; RNA-Binding Proteins; RNA, Antisense; RNA, Small Interfering; Serine-Arginine Splicing Factors | 2011 |
Lack of any relationship between chemotherapy toxicity in non-small cell lung cancer cases and polymorphisms in XRCC1 codon 399 or XPD codon 751.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Codon; Deoxycytidine; DNA-Binding Proteins; DNA, Neoplasm; Docetaxel; Female; Follow-Up Studies; Gemcitabine; Genotype; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Polymerase Chain Reaction; Polymorphism, Restriction Fragment Length; Polymorphism, Single Nucleotide; Survival Rate; Taxoids; Treatment Outcome; X-ray Repair Cross Complementing Protein 1; Xeroderma Pigmentosum Group D Protein | 2011 |
Molecular selection trumps clinical selection.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Gefitinib; Gene Dosage; Humans; Immunohistochemistry; In Situ Hybridization, Fluorescence; Lung Neoplasms; Mutation; Paclitaxel; Precision Medicine; Predictive Value of Tests; Protein Kinase Inhibitors; Quinazolines; Risk Assessment; Risk Factors; Survival Rate; Time Factors; Treatment Outcome | 2011 |
Expression of CD147 in advanced non-small cell lung cancer correlated with cisplatin-based chemotherapy resistance.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Basigin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Membrane; Cell Proliferation; Cisplatin; Deoxycytidine; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Immunoenzyme Techniques; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Survival Rate; Treatment Outcome; Vinblastine; Vinorelbine | 2011 |
Combination chemotherapy for older adults with advanced non-small-cell lung cancer.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Paclitaxel; Vinblastine; Vinorelbine | 2011 |
Ethnic difference in hematological toxicity in patients with non-small cell lung cancer treated with chemotherapy: a pooled analysis on Asian versus non-Asian in phase II and III clinical trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Asian People; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Deoxycytidine; Ethnicity; Gemcitabine; Hematologic Diseases; Humans; Lung Neoplasms; Paclitaxel; Prognosis; Randomized Controlled Trials as Topic; Review Literature as Topic | 2011 |
Synthesis and biological evaluation of a peptide-paclitaxel conjugate which targets the integrin αvβ₆.
Topics: Animals; Antigens, Neoplasm; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Death; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Female; Flow Cytometry; Humans; Integrins; Lung Neoplasms; Mice; Mice, Inbred NOD; Mice, SCID; Molecular Conformation; Paclitaxel; Peptides; Stereoisomerism; Structure-Activity Relationship | 2011 |
ATP-binding cassette B1 gene polymorphisms, mRNA expression and chemosensitivity to paclitaxel in non-small cell lung cancer cells.
Topics: Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter 1; ATP-Binding Cassette Transporters; Carcinoma, Non-Small-Cell Lung; DNA, Neoplasm; Drug Resistance, Neoplasm; Gene Frequency; Humans; Lung Neoplasms; Paclitaxel; Polymorphism, Genetic; Real-Time Polymerase Chain Reaction | 2011 |
Implications of delayed initiation of radiotherapy: accelerated repopulation after induction chemotherapy for stage III non-small cell lung cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Deoxycytidine; Etoposide; Female; Gemcitabine; Humans; Induction Chemotherapy; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Prognosis; Retrospective Studies; Time Factors; Tomography, X-Ray Computed | 2011 |
New anti-cancer characteristics of jatrophane diterpenes from Euphorbia dendroides.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Line, Tumor; Diterpenes; Drug Resistance, Multiple; Drug Synergism; Euphorbia; Gene Expression Regulation, Neoplastic; Humans; Leukocytes, Mononuclear; Neoplasms; Paclitaxel; Plant Extracts; RNA, Messenger; Vascular Endothelial Growth Factors | 2011 |
Predictive value of intratumoral microvascular density in patients with advanced non-small cell lung cancer receiving chemotherapy plus bevacizumab.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Non-Small-Cell Lung; Female; Humans; Lung Neoplasms; Male; Microvessels; Middle Aged; Neovascularization, Pathologic; Paclitaxel; Platelet Endothelial Cell Adhesion Molecule-1; Predictive Value of Tests; Prognosis; Tomography, X-Ray Computed; Treatment Outcome | 2012 |
Angiographically silent cystoid macular oedema secondary to paclitaxel therapy.
Topics: Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Fluorescein Angiography; Humans; Lung Neoplasms; Macular Edema; Male; Middle Aged; Paclitaxel; Tomography, Optical Coherence | 2012 |
Syndrome of inappropriate secretion of antidiuretic hormone (SIADH) following carboplatin-paclitaxel administration in a patient with lung cancer.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Female; Humans; Hyponatremia; Inappropriate ADH Syndrome; Lung; Lung Neoplasms; Lymphatic Metastasis; Middle Aged; Paclitaxel; Vasopressins | 2011 |
Porous quaternized chitosan nanoparticles containing paclitaxel nanocrystals improved therapeutic efficacy in non-small-cell lung cancer after oral administration.
Topics: Administration, Oral; Animals; Antineoplastic Agents, Phytogenic; Biocompatible Materials; Carcinoma, Non-Small-Cell Lung; Cell Line; Chitosan; Drug Carriers; Humans; Lung Neoplasms; Male; Mice; Mice, Inbred C57BL; Nanoparticles; Paclitaxel; Quaternary Ammonium Compounds; Xenograft Model Antitumor Assays | 2011 |
SMAC mimetic (JP1201) sensitizes non-small cell lung cancers to multiple chemotherapy agents in an IAP-dependent but TNF-α-independent manner.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Apoptosis Regulatory Proteins; Carboplatin; Carcinoma, Non-Small-Cell Lung; Caspase 3; Caspase 9; Cell Line, Tumor; Deoxycytidine; Drug Synergism; Gemcitabine; Humans; Inhibitor of Apoptosis Proteins; Intracellular Signaling Peptides and Proteins; Lung Neoplasms; Mice; Mice, Inbred NOD; Mice, SCID; Mitochondrial Proteins; Molecular Mimicry; Paclitaxel; RNA Interference; Tumor Burden; Tumor Necrosis Factor-alpha; Vinblastine; Vinorelbine; Xenograft Model Antitumor Assays | 2011 |
Hydrogels as intracellular depots for drug delivery.
Topics: Biological Transport; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Survival; Chemical Phenomena; Drug Carriers; Drug Compounding; Humans; Hydrogels; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Lung Neoplasms; Microscopy, Electron, Scanning; Microscopy, Fluorescence; Nanoparticles; Osmolar Concentration; Paclitaxel; Particle Size; Polymethacrylic Acids | 2012 |
A C118T polymorphism of ERCC1 and response to cisplatin chemotherapy in patients with late-stage non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Cohort Studies; Disease-Free Survival; DNA-Binding Proteins; Endonucleases; Female; Gene Frequency; Genotype; Humans; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Neoplasm Staging; Paclitaxel; Polymorphism, Single Nucleotide; Regression Analysis; Treatment Outcome; Vinblastine; Vinorelbine | 2012 |
Silencing of X-linked inhibitor of apoptosis decreases resistance to cisplatin and paclitaxel but not gemcitabine in non-small cell lung cancer.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Caspase 3; Caspase 9; Cell Line, Tumor; Cell Proliferation; Cisplatin; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Gene Knockdown Techniques; Humans; Lung Neoplasms; Paclitaxel; RNA Interference; X-Linked Inhibitor of Apoptosis Protein | 2011 |
Long-term survival in patients with non-small cell lung cancer and synchronous brain metastasis treated with whole-brain radiotherapy and thoracic chemoradiation.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Cisplatin; Cranial Irradiation; Disease-Free Survival; Female; Humans; Induction Chemotherapy; Kaplan-Meier Estimate; Lung; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Retrospective Studies | 2011 |
Drug resistance to paclitaxel is not only associated with ABCB1 mRNA expression but also with drug accumulation in intracellular compartments in human lung cancer cell lines.
Topics: Acetylation; Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Binding Sites; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; Humans; Lung Neoplasms; Microscopy, Confocal; Paclitaxel; Point Mutation; RNA, Messenger; Tubulin | 2012 |
The role of expression and polymorphism of the BAG-1 gene in response to platinum-based chemotherapeutics in NSCLC.
Topics: Antineoplastic Combined Chemotherapy Protocols; Base Sequence; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Case-Control Studies; Chi-Square Distribution; China; Cisplatin; Disease-Free Survival; DNA-Binding Proteins; Drug Resistance, Neoplasm; Female; Genotype; Humans; Immunohistochemistry; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Molecular Sequence Data; Odds Ratio; Paclitaxel; Phenotype; Polymorphism, Genetic; Proportional Hazards Models; Reverse Transcriptase Polymerase Chain Reaction; Risk Assessment; Risk Factors; Time Factors; Transcription Factors; Treatment Outcome; Up-Regulation; Vinblastine; Vinorelbine | 2012 |
Video-assisted thoracoscopic surgery is more favorable than thoracotomy for administration of adjuvant chemotherapy after lobectomy for non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Cisplatin; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Patient Compliance; Pneumonectomy; Postoperative Complications; Psychosurgery; Retrospective Studies; Thoracic Surgery, Video-Assisted; Thoracotomy; Treatment Outcome | 2011 |
Synergistic activity of the Hsp90 inhibitor ganetespib with taxanes in non-small cell lung cancer models.
Topics: Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Survival; Docetaxel; Drug Combinations; Female; HSP90 Heat-Shock Proteins; Humans; Mice; Mice, SCID; Paclitaxel; Taxoids; Triazoles; Tumor Burden; Xenograft Model Antitumor Assays | 2012 |
Combined MEK and VEGFR inhibition in orthotopic human lung cancer models results in enhanced inhibition of tumor angiogenesis, growth, and metastasis.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Disease Progression; Humans; Lung Neoplasms; Male; Mice; Mice, Nude; Mitogen-Activated Protein Kinases; Molecular Targeted Therapy; Neovascularization, Pathologic; Paclitaxel; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Receptors, Vascular Endothelial Growth Factor; Xenograft Model Antitumor Assays | 2012 |
Mixed micelles of PEG(2000)-DSPE and vitamin-E TPGS for concurrent delivery of paclitaxel and parthenolide: enhanced chemosenstization and antitumor efficacy against non-small cell lung cancer (NSCLC) cell lines.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Survival; Drug Carriers; Humans; Inhibitory Concentration 50; Lung Neoplasms; Magnetic Resonance Spectroscopy; Micelles; Paclitaxel; Particle Size; Phosphatidylethanolamines; Polyethylene Glycols; Sesquiterpenes; Vitamin E | 2012 |
Risk associated with bilobectomy after neoadjuvant concurrent chemoradiotherapy for stage IIIA-N2 non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Cisplatin; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Pneumonectomy; Retrospective Studies; Risk; Survival Analysis; Treatment Outcome | 2012 |
Synergistic antitumor efficacy of sequentially combined paclitaxel with sorafenib in vitro and in vivo NSCLC models harboring KRAS or BRAF mutations.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzenesulfonates; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Female; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Mutation; Myeloid Cell Leukemia Sequence 1 Protein; Niacinamide; Paclitaxel; Phenylurea Compounds; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-bcl-2; Pyridines; ras Proteins; Retinoblastoma Protein; Signal Transduction; Sorafenib; Tumor Suppressor Protein p53; Xenograft Model Antitumor Assays | 2012 |
Antitumor activity of lobaplatin alone or in combination with antitubulin agents in non-small-cell lung cancer.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cyclobutanes; Docetaxel; Drug Synergism; Female; Humans; Lung Neoplasms; Mice; Mice, Nude; Organoplatinum Compounds; Paclitaxel; Taxoids; Tubulin Modulators; Tumor Burden; Vinblastine; Vinorelbine; Xenograft Model Antitumor Assays | 2012 |
HADHA is a potential predictor of response to platinum-based chemotherapy for lung cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Electrophoresis, Gel, Two-Dimensional; Etoposide; Follow-Up Studies; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Mitochondrial Trifunctional Protein; Mitochondrial Trifunctional Protein, alpha Subunit; Multienzyme Complexes; Neoplasm Recurrence, Local; Paclitaxel; Prognosis; Small Cell Lung Carcinoma; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Tumor Cells, Cultured | 2011 |
Histopathologic response criteria predict survival of patients with resected lung cancer after neoadjuvant chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Cross-Sectional Studies; Deoxycytidine; Etoposide; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Prognosis; Survival Rate | 2012 |
Individual dose and scheduling determine the efficacy of combining cytotoxic anticancer agents with a kinase inhibitor in non-small-cell lung cancer.
Topics: Antineoplastic Agents; Apoptosis; bcl-2 Homologous Antagonist-Killer Protein; bcl-2-Associated X Protein; bcl-X Protein; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Survival; Dactinomycin; Dose-Response Relationship, Drug; Doxorubicin; Drug Antagonism; Drug Synergism; Etoposide; Humans; Immunoblotting; Lung Neoplasms; Paclitaxel; Protein Kinase C; Signal Transduction; Staurosporine; Time Factors | 2012 |
Radiation/paclitaxel treatment of p53-abnormal non-small cell lung cancer xenograft tumor and associated mechanism.
Topics: Animals; Antineoplastic Agents, Phytogenic; bcl-2-Associated X Protein; Carcinoma, Non-Small-Cell Lung; Caspase 3; Chemoradiotherapy; Humans; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mutation; Neoplasm Transplantation; Oncogene Protein v-akt; Paclitaxel; Phosphatidylinositol 3-Kinase; Phosphorylation; PTEN Phosphohydrolase; Signal Transduction; Tumor Suppressor Protein p53 | 2012 |
Carboplatin and paclitaxel with vs without bevacizumab in older patients with advanced non-small cell lung cancer.
Topics: Age Factors; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cohort Studies; Female; Humans; Lung Neoplasms; Male; Medicare; Neoplasm Staging; Paclitaxel; Propensity Score; Retrospective Studies; SEER Program; Survival Analysis; United States | 2012 |
Effect of molecular weight of PGG-paclitaxel conjugates on in vitro and in vivo efficacy.
Topics: Animals; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Survival; Female; Humans; Lung; Lung Neoplasms; Mice; Mice, Nude; Molecular Weight; Neoplasms; Paclitaxel; Prodrugs; Proteins | 2012 |
Isolation, identification, semi-synthesis of aziditaxel derivatives and their biological evaluation.
Topics: Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Docetaxel; Drug Screening Assays, Antitumor; Humans; Lung Neoplasms; Molecular Structure; Nuclear Magnetic Resonance, Biomolecular; Paclitaxel; Taxoids | 2012 |
Method to our madness or madness in our methods? Pitfalls in trial methodology.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Albumins; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Humans; Ipilimumab; Lung Neoplasms; Male; Melanoma; Paclitaxel; Quinazolines; Smoking; Solvents | 2012 |
Five-year tumor-free survival after aggressive trimodality therapy for T3N0M1b non-small cell lung cancer with synchronous solitary brain metastasis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biopsy; Brain Neoplasms; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Disease-Free Survival; Humans; Lung Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Pneumonectomy; Radiosurgery; Time Factors; Tomography, X-Ray Computed; Treatment Outcome | 2012 |
Gefitinib enhances cytotoxicities of antimicrotubule agents in non-small-cell lung cancer cells exhibiting no sensitizing epidermal growth factor receptor mutation.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Drug Synergism; ErbB Receptors; Gefitinib; Genes, MDR; Humans; Lung Neoplasms; Microtubules; Mutation; Paclitaxel; Quinazolines; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tubulin Modulators | 2012 |
miR-337-3p and its targets STAT3 and RAP1A modulate taxane sensitivity in non-small cell lung cancers.
Topics: Antineoplastic Agents; Base Sequence; Bridged-Ring Compounds; Carcinoma, Non-Small-Cell Lung; Cell Cycle Checkpoints; Cell Line, Tumor; Drug Resistance, Neoplasm; Gene Expression; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; MicroRNAs; Paclitaxel; rap1 GTP-Binding Proteins; RNA Interference; RNA, Messenger; STAT3 Transcription Factor; Taxoids | 2012 |
Successful treatment of solitary bone metastasis of non-small cell lung cancer with bevacizumab and hyperthermia.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Bone Neoplasms; Carboplatin; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Diphosphonates; Humans; Hyperthermia, Induced; Imidazoles; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Zoledronic Acid | 2013 |
Protective effect of caffeic acid on paclitaxel induced anti-proliferation and apoptosis of lung cancer cells involves NF-κB pathway.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Caffeic Acids; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Humans; Inhibitor of Apoptosis Proteins; Lung Neoplasms; NF-kappa B; Paclitaxel; Signal Transduction; Survivin; Up-Regulation | 2012 |
UbcH10 expression provides a useful tool for the prognosis and treatment of non-small cell lung cancer.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Line; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Immunohistochemistry; Kaplan-Meier Estimate; Lung; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Prognosis; Proportional Hazards Models; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; Ubiquitin-Conjugating Enzymes | 2012 |
Polymeric nanoparticles containing taxanes enhance chemoradiotherapeutic efficacy in non-small cell lung cancer.
Topics: Animals; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Chemoradiotherapy; Docetaxel; Drug Synergism; Endocytosis; Feasibility Studies; Humans; Lung Neoplasms; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Microscopy, Electron, Scanning; Nanoconjugates; Paclitaxel; Polymers; Radiation-Sensitizing Agents; Random Allocation; Taxoids; Xenograft Model Antitumor Assays | 2012 |
Efficacy of carboplatin and paclitaxel with bevacizumab as salvage chemotherapy for non-small cell lung cancer after failure of platinum-doublet chemotherapy.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Non-Small-Cell Lung; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Retrospective Studies; Salvage Therapy | 2012 |
Multiple cancer testis antigens function to support tumor cell mitotic fidelity.
Topics: Antigens, Neoplasm; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Carrier Proteins; Cell Line, Tumor; Centrosome; Chromosome Segregation; Humans; Lung Neoplasms; Male; Membrane Transport Proteins; Microtubule-Associated Proteins; Microtubules; Mitosis; Neoplasm Proteins; Paclitaxel; Seminal Plasma Proteins; Spindle Apparatus | 2012 |
Triplet platinum-based combination sequential chemotherapy improves survival outcome and quality of life of advanced non-small cell lung cancer patients.
Topics: Adenocarcinoma; Adolescent; Adrenal Gland Neoplasms; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Prognosis; Prospective Studies; Quality of Life; Survival Rate; Vinblastine; Vinorelbine; Young Adult | 2012 |
Genetic variants in the PI3K/PTEN/AKT/mTOR pathway predict platinum-based chemotherapy response of advanced non-small cell lung cancers in a Chinese population.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Docetaxel; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Phosphatidylinositol 3-Kinases; Polymorphism, Single Nucleotide; Prognosis; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Stomach Neoplasms; Survival Rate; Taxoids; TOR Serine-Threonine Kinases; Vinblastine; Vinorelbine | 2012 |
In vitro and in vivo therapeutic efficacy of CXCR4 antagonist BKT140 against human non-small cell lung cancer.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Chemokine CXCL2; Chemoradiotherapy; Cisplatin; Dose-Response Relationship, Drug; Humans; Lung Neoplasms; Mice; Mice, Nude; Oligopeptides; Paclitaxel; Receptors, CXCR4; Time Factors; Tumor Burden; Xenograft Model Antitumor Assays | 2012 |
Analysis of the risk factors for myelosuppression after concurrent chemoradiotherapy for patients with advanced non-small cell lung cancer.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Body Surface Area; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Creatinine; Female; Hematologic Diseases; Humans; Logistic Models; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Paclitaxel; Retrospective Studies; Risk Factors; Sex Factors | 2013 |
Quantitative determination of paclitaxel and its metabolites, 6α-hydroxypaclitaxel and p-3'-hydroxypaclitaxel, in human plasma using column-switching liquid chromatography/tandem mass spectrometry.
Topics: Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Chromatography, High Pressure Liquid; Drug Monitoring; Equipment Design; Humans; Limit of Detection; Lung Neoplasms; Paclitaxel; Tandem Mass Spectrometry; Taxoids | 2013 |
[A case of complete resection of non-squamous non-small-cell lung cancer after induction chemotherapy using carboplatin, paclitaxel, and bevacizumab].
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Female; Humans; Induction Chemotherapy; Lung Neoplasms; Neoplasm Staging; Paclitaxel; Tomography, X-Ray Computed | 2012 |
Abnormal expression of the pre-mRNA splicing regulators SRSF1, SRSF2, SRPK1 and SRPK2 in non small cell lung carcinoma.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cell Line, Tumor; Drug Resistance, Neoplasm; Female; Gene Expression; Gene Expression Regulation, Neoplastic; Humans; Lung; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Nuclear Proteins; Paclitaxel; Phenotype; Phosphoproteins; Protein Serine-Threonine Kinases; Ribonucleoproteins; RNA-Binding Proteins; Serine-Arginine Splicing Factors; Signal Transduction | 2012 |
Bevacizumab-containing chemotherapy for non-small cell lung cancer patients: a population-based observational study by the Ibaraki thoracic integrative (POSITIVE) research group.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Non-Small-Cell Lung; Female; Glutamates; Guanine; Humans; Japan; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Pemetrexed; Retrospective Studies; Treatment Outcome | 2012 |
Phosphoinositide 3-kinase (PI3K) pathway alterations are associated with histologic subtypes and are predictive of sensitivity to PI3K inhibitors in lung cancer preclinical models.
Topics: Animals; Antineoplastic Agents; Biomarkers, Tumor; Bridged Bicyclo Compounds, Heterocyclic; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Class I Phosphatidylinositol 3-Kinases; Comparative Genomic Hybridization; DNA Copy Number Variations; DNA Mutational Analysis; Drug Synergism; Erlotinib Hydrochloride; Female; Gene Amplification; Humans; Indazoles; Inhibitory Concentration 50; Lung Neoplasms; Mice; Mice, Nude; Molecular Targeted Therapy; Paclitaxel; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; PTEN Phosphohydrolase; Pyrimidines; Quinazolines; Signal Transduction; Sulfonamides; Transcriptome; Xenograft Model Antitumor Assays | 2012 |
Clinical and molecular features in patients with advanced non-small-cell lung carcinoma refractory to first-line platinum-based chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Anaplastic Lymphoma Kinase; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease Progression; Docetaxel; Drug Resistance, Neoplasm; ErbB Receptors; Exons; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Mutation; Paclitaxel; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins; Receptor Protein-Tyrosine Kinases; Retrospective Studies; Taxoids | 2013 |
Prognostic significance of GSTP1, XRCC1 and XRCC3 polymorphisms in non-small cell lung cancer patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chi-Square Distribution; Cisplatin; Deoxycytidine; DNA-Binding Proteins; Docetaxel; Female; Gemcitabine; Genotype; Glutathione S-Transferase pi; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Polymorphism, Single Nucleotide; Prognosis; Proportional Hazards Models; Prospective Studies; Taxoids; Vinblastine; Vinorelbine; X-ray Repair Cross Complementing Protein 1 | 2012 |
Ascorbic acid alleviates toxicity of paclitaxel without interfering with the anticancer efficacy in mice.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Ascorbic Acid; Blood Cell Count; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Female; Gene Expression; Hemoglobins; Humans; Mice; Mice, Inbred BALB C; Paclitaxel; Sarcoma 180; Vitamins | 2012 |
Bevacizumab as first-line therapy in advanced non-small-cell lung cancer: a brazilian center experience.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brazil; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Prognosis; Retrospective Studies; Treatment Outcome | 2012 |
Paclitaxel plus platinum or gemcitabine plus platinum in first-line treatment of advanced non-small-cell lung cancer: results from 6 randomized controlled trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Drug-Related Side Effects and Adverse Reactions; Gemcitabine; Humans; Neoplasm Staging; Paclitaxel; Platinum; Randomized Controlled Trials as Topic; Treatment Outcome | 2013 |
Metformin-mediated downregulation of p38 mitogen-activated protein kinase-dependent excision repair cross-complementing 1 decreases DNA repair capacity and sensitizes human lung cancer cells to paclitaxel.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Survival; DNA Repair; DNA-Binding Proteins; Dose-Response Relationship, Drug; Down-Regulation; Endonucleases; Humans; Hypoglycemic Agents; Lung Neoplasms; Metformin; p38 Mitogen-Activated Protein Kinases; Paclitaxel; RNA, Messenger; Up-Regulation | 2013 |
[Efficacy of chemotherapy with carboplatin-paclitaxel plus bevacizumab for previously treated patients with advanced non-small cell carcinoma].
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Bevacizumab; Carboplatin; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Retrospective Studies; Salvage Therapy | 2012 |
Lung cancer and pregnancy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Bronchoscopy; Carboplatin; Carcinoma, Non-Small-Cell Lung; Female; Humans; Lung Neoplasms; Mutation; Neoplasm Staging; Oncogene Proteins, Fusion; Paclitaxel; Pregnancy; Pregnancy Complications, Neoplastic; Premature Birth; Treatment Outcome | 2013 |
Suppressive oligodeoxynucleotides synergistically enhance antiproliferative effects of anticancer drugs in A549 human lung cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Drug Synergism; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Oligodeoxyribonucleotides; Paclitaxel; Proto-Oncogene Proteins c-akt; Repetitive Sequences, Nucleic Acid | 2013 |
A retrospective study of the novel combination of paclitaxel and S1 for pretreated advanced non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Drug Administration Schedule; Drug Combinations; ErbB Receptors; Female; Humans; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Mutation; Oxonic Acid; Paclitaxel; Proportional Hazards Models; Retrospective Studies; Survival Rate; Tegafur; Time Factors; Treatment Outcome | 2012 |
The current status of docetaxel in solid tumors. An M. D. Anderson Cancer Center Review.
Topics: Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Clinical Trials as Topic; Docetaxel; Female; Head and Neck Neoplasms; Humans; Lung Neoplasms; Male; Neoadjuvant Therapy; Neoplasms; Paclitaxel; Taxoids | 2002 |
Phase II clinical trial of XYOTAX in non-small cell lung cancer to continue.
Topics: Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase II as Topic; Drug Tolerance; Humans; Lung Neoplasms; Paclitaxel; Polyglutamic Acid; Taxoids | 2002 |
Paclitaxel and carboplatin plus megestrol acetate in the treatment of advanced non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Female; Humans; Lung Neoplasms; Male; Megestrol Acetate; Middle Aged; Paclitaxel; Survival Analysis | 2002 |
Gastrointestinal toxicity associated with weekly docetaxel treatment.
Topics: Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Digestive System; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug-Related Side Effects and Adverse Reactions; Enterocolitis; Fatal Outcome; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Multiple Organ Failure; Neoplasm Staging; Paclitaxel; Risk Assessment; Taxoids | 2002 |
Postoperative complications of lung resection after induction chemotherapy using Paclitaxel (and radiotherapy) for advanced non-small lung cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Female; Humans; Intraoperative Care; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Pneumonectomy; Postoperative Complications; Vinblastine; Vinorelbine | 2002 |
Combination chemotherapy should be standard of care for lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; Humans; Lung Neoplasms; Paclitaxel; Prognosis; Quality of Life; Research Design; Survival; Treatment Outcome | 2002 |
Re: Economic analysis of vinorelbine plus cisplatin versus paclitaxel plus carboplatin for advanced non-small-cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Health Care Costs; Lung Neoplasms; Paclitaxel; Vinblastine; Vinorelbine | 2002 |
Sequential combination chemotherapy in patients with advanced nonsmall cell lung carcinoma. Carboplatin and gemcitabine followed by paclitaxel.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Drug Administration Schedule; Gemcitabine; Humans; Lung Neoplasms; Paclitaxel | 2002 |
Repeated arthralgia associated with granulocyte colony stimulating factor administration.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Arthralgia; Carcinoma, Non-Small-Cell Lung; Granulocyte Colony-Stimulating Factor; Humans; Lung Neoplasms; Male; Organoplatinum Compounds; Paclitaxel | 2002 |
Sensitivity to ionizing radiation and chemotherapeutic agents in gemcitabine-resistant human tumor cell lines.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Deoxycytidine Kinase; Drug Resistance, Neoplasm; Gemcitabine; Humans; Lung Neoplasms; Paclitaxel; Radiation Tolerance; Tumor Cells, Cultured | 2002 |
Treatment of advanced non-small-cell lung cancer with two-drug combinations.
Topics: Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Lung Neoplasms; Paclitaxel; Patient Selection | 2002 |
Declining hemoglobin during chemoradiotherapy for locally advanced non-small cell lung cancer is significant.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Female; Hemoglobins; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Prognosis; Radiotherapy; Retrospective Studies; Survival Rate | 2002 |
Predicting chemotherapy response to paclitaxel-based therapy in advanced non-small-cell lung cancer (stage IIIb or IV) with a higher T stage (> T2). Technetium-99m methoxyisobutylisonitrile chest single photon emission computed tomography and P-glycoprote
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B, Member 1; Carcinoma, Non-Small-Cell Lung; Female; Humans; Immunohistochemistry; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Phytotherapy; Predictive Value of Tests; Technetium Tc 99m Sestamibi; Tomography, Emission-Computed, Single-Photon; Treatment Outcome | 2002 |
Is cisplatin still the best platinum compound in non-small-cell lung cancer?
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Disease-Free Survival; Humans; Lung Neoplasms; Paclitaxel; Quality of Life; Randomized Controlled Trials as Topic; Treatment Outcome | 2002 |
Cytotoxicity of combinations of IFN-beta and chemotherapeutic drugs.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Death; Cell Division; Cisplatin; Deoxycytidine; Drug Synergism; Female; Fluorouracil; Gemcitabine; Humans; Interferon-beta; Lung Neoplasms; Paclitaxel; Tumor Cells, Cultured; Uterine Cervical Neoplasms | 2002 |
Early detection and successful treatment of drug-induced pneumonitis with corticosteroids.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Gemcitabine; Glucocorticoids; Humans; Lung Neoplasms; Male; Paclitaxel; Pneumonia; Prednisone; Radiography, Thoracic; Tomography, X-Ray Computed; Topotecan; Treatment Outcome; Vinblastine; Vinorelbine | 2002 |
Front-line paclitaxel/cisplatin-based chemotherapy in brain metastases from non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease-Free Survival; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Retrospective Studies; Survival Rate; Treatment Outcome; Vinblastine; Vinorelbine | 2003 |
Conservation of the class I beta-tubulin gene in human populations and lack of mutations in lung cancers and paclitaxel-resistant ovarian cancers.
Topics: Animals; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Case-Control Studies; Conserved Sequence; DNA Mutational Analysis; DNA Primers; DNA, Neoplasm; Drug Resistance, Neoplasm; Female; Genetic Variation; Haplotypes; Heterozygote; Humans; Lung Neoplasms; Mice; Mutation; Ovarian Neoplasms; Paclitaxel; Polymerase Chain Reaction; Polymorphism, Single-Stranded Conformational; Tubulin; Tumor Cells, Cultured | 2002 |
Combined platinum containing treatment in NSCLC.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Drug Synergism; Gemcitabine; Humans; Lung Neoplasms; Paclitaxel; Prognosis | 2002 |
The anthelmintic drug mebendazole induces mitotic arrest and apoptosis by depolymerizing tubulin in non-small cell lung cancer cells.
Topics: Administration, Oral; Animals; Antinematodal Agents; Antineoplastic Agents, Phytogenic; Apoptosis; Biomarkers, Tumor; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Caspases; Cell Cycle; Cytochrome c Group; Flow Cytometry; Humans; In Situ Nick-End Labeling; Lung Neoplasms; Mebendazole; Mice; Mice, Nude; Microscopy, Fluorescence; Mitochondria; Paclitaxel; Spindle Apparatus; Tubulin; Tumor Cells, Cultured | 2002 |
A retrospective analysis of the outcome of patients who have received two prior chemotherapy regimens including platinum and docetaxel for recurrent non-small-cell lung cancer.
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Disease Progression; Docetaxel; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Platinum; Retrospective Studies; Survival Rate; Taxoids; Time Factors; Treatment Outcome | 2003 |
Comparison of antiangiogenic activities using paclitaxel (taxol) and docetaxel (taxotere).
Topics: Angiogenesis Inhibitors; Animals; Aorta; Apoptosis; Capillaries; Carcinoma, Non-Small-Cell Lung; Cell Differentiation; Cell Division; Cells, Cultured; Chemotaxis; Docetaxel; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Endothelium, Vascular; Fibrosarcoma; Glioblastoma; Humans; Lung Neoplasms; Male; Melanoma; Mice; Mice, Nude; Neoplasm Transplantation; Paclitaxel; Rats; Taxoids; Tumor Cells, Cultured; Umbilical Veins; Xenograft Model Antitumor Assays | 2003 |
[New data presented at ASCO 2002 concerning non-small cell bronchial cancers].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Cisplatin; Deoxycytidine; Gastrointestinal Diseases; Gemcitabine; Hematologic Diseases; Humans; Lung Neoplasms; Paclitaxel; Survival Analysis; Treatment Outcome; Vinblastine; Vinorelbine | 2002 |
[Therapeutic strategies in advanced non-small cell bronchial cancers: combinations without platin drugs].
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Docetaxel; Humans; Lung Neoplasms; Paclitaxel; Patient Selection; Survival Analysis; Taxoids; Treatment Outcome | 2002 |
[Therapeutic strategies in advanced non-small cell bronchial cancers: platin-based combinations].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Lung Neoplasms; Neoplasm Staging; Paclitaxel; Patient Selection; Survival Analysis; Treatment Outcome; Vinblastine; Vinorelbine | 2002 |
Timing is everything, or could be.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Lung Neoplasms; Paclitaxel | 2003 |
[Histoculture drug response assay (HDRA) guided induction concurrent chemoradiotherapy for mediastinal node-positive non-small cell lung cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Docetaxel; Drug Screening Assays, Antitumor; Etoposide; Female; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Paclitaxel; Pneumonectomy; Taxoids; Tumor Cells, Cultured | 2003 |
In regard to hyperfractionation for non-small-cell lung cancer: fire, ready, aim!
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials as Topic; Combined Modality Therapy; Dose Fractionation, Radiation; Etoposide; Humans; Lung Neoplasms; Multicenter Studies as Topic; Paclitaxel; Prospective Studies; Randomized Controlled Trials as Topic | 2003 |
Dramatic effect of ZD1839 ('Iressa') in a patient with advanced non-small-cell lung cancer and poor performance status.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Docetaxel; Enzyme Inhibitors; Epidermal Growth Factor; Female; Gefitinib; Humans; Irinotecan; Lung Neoplasms; Middle Aged; Neoplasm Staging; Paclitaxel; Protein-Tyrosine Kinases; Quinazolines; Salvage Therapy; Taxoids; Treatment Outcome | 2003 |
Concurrent two-dimensional radiotherapy and weekly docetaxel in the treatment of stage III non-small cell lung cancer: a good local response but no good survival due to radiation pneumonitis.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Combined Modality Therapy; Docetaxel; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Radiation Pneumonitis; Radiotherapy; Survival Rate; Taxoids | 2003 |
[Cost-effectiveness of weekly paclitaxel for patients with advanced non-small cell lung cancer].
Topics: Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Cost-Benefit Analysis; Drug Administration Schedule; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Vinblastine; Vinorelbine | 2003 |
Acute myocardial infarction and cardiac arrest in a patient receiving paclitaxel.
Topics: Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Coronary Angiography; Electrocardiography; Heart Arrest; Heart Conduction System; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Myocardial Infarction; Paclitaxel | 2003 |
Sensitivity of non-small-cell lung cancer cell lines established from patients treated with prolonged infusions of Paclitaxel.
Topics: Adult; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Docetaxel; Enzyme-Linked Immunosorbent Assay; Female; Gene Expression Regulation, Neoplastic; Genes, MDR; Humans; Immunohistochemistry; Inhibitory Concentration 50; Lung Neoplasms; Male; Middle Aged; Multidrug Resistance-Associated Proteins; Paclitaxel; Phenotype; Polymerase Chain Reaction; Receptor, ErbB-2; Taxoids; Tumor Cells, Cultured | 2003 |
[Aeroportia and necrotizing enteritis after chemotherapy with paclitaxel for lung carcinoma].
Topics: Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Embolism, Air; Enteritis; Female; Humans; Lung Neoplasms; Middle Aged; Necrosis; Paclitaxel; Portal Vein | 2003 |
Absence of beta-tubulin gene mutation in gastric carcinoma.
Topics: Aged; Antineoplastic Agents, Phytogenic; Base Sequence; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Cell Division; Codon; Drug Resistance, Neoplasm; Exons; Female; Genetic Predisposition to Disease; Humans; Introns; Japan; Lung Neoplasms; Male; Microtubules; Middle Aged; Mutation; Paclitaxel; Polymerase Chain Reaction; Predictive Value of Tests; Sequence Analysis, DNA; Stomach Neoplasms; Taxoids; Tubulin | 2003 |
Inhibition of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase enhances chemotherapeutic effects on H460 human non-small cell lung cancer cells through activation of apoptosis.
Topics: Antineoplastic Agents; Apoptosis; bcl-X Protein; Butadienes; Carcinoma, Non-Small-Cell Lung; Caspases; Doxorubicin; Drug Synergism; Drug Therapy, Combination; Enzyme Activation; Enzyme Inhibitors; Humans; JNK Mitogen-Activated Protein Kinases; Lung Neoplasms; MAP Kinase Kinase 4; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Mitogen-Activated Protein Kinase Kinases; Mitogen-Activated Protein Kinases; Nitriles; Paclitaxel; Phosphorylation; Poly(ADP-ribose) Polymerases; Protein Kinase C; Proteins; Proto-Oncogene Proteins c-bcl-2; Signal Transduction; Staurosporine; Tumor Cells, Cultured; X-Linked Inhibitor of Apoptosis Protein | 2003 |
Measuring the side effects of taxane therapy in oncology: the functional assesment of cancer therapy-taxane (FACT-taxane).
Topics: Antineoplastic Agents, Phytogenic; Attitude to Health; Bridged-Ring Compounds; Carboplatin; Carcinoma, Non-Small-Cell Lung; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Quality of Life; Randomized Controlled Trials as Topic; Surveys and Questionnaires; Taxoids | 2003 |
Weekly paclitaxel for advanced non-small cell lung cancer patients not suitable for platinum-based therapy.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Prognosis; Salvage Therapy; Survival Rate; Time Factors | 2003 |
Using technetium-99m tetrofosmin chest imaging to predict taxol-based chemotherapy response in non-small cell lung cancer but not related to lung resistance protein expression.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily B, Member 1; Carcinoma, Non-Small-Cell Lung; Cisplatin; Drug Resistance, Multiple; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Proteins; Organophosphorus Compounds; Organotechnetium Compounds; Paclitaxel; Radionuclide Imaging; Radiopharmaceuticals; Vault Ribonucleoprotein Particles | 2003 |
Usefulness of chest single photon emission computed tomography with technetium-99m methoxyisobutylisonitrile to predict taxol based chemotherapy response in advanced non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents, Phytogenic; Biological Transport; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Humans; Lung Neoplasms; Middle Aged; Neoplasm Staging; Paclitaxel; Radiopharmaceuticals; Retrospective Studies; Technetium Tc 99m Sestamibi; Tomography, Emission-Computed, Single-Photon | 2003 |
A little to a lot or a lot to a little? An analysis of pneumonitis risk from dose-volume histogram parameters of the lung in patients with lung cancer treated with 3-D conformal radiotherapy.
Topics: Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Dose-Response Relationship, Radiation; Female; Follow-Up Studies; Humans; Imaging, Three-Dimensional; Logistic Models; Lung; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Radiation Pneumonitis; Radiography, Thoracic; Radiotherapy Dosage; Radiotherapy Planning, Computer-Assisted; Radiotherapy, Conformal; Risk Assessment; Time Factors; Tomography, X-Ray Computed | 2003 |
Epiphora induced by intermittent docetaxel (taxotere) in patients with non-small cell lung cancer.
Topics: Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Docetaxel; Humans; Lacrimal Apparatus Diseases; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Taxoids | 2003 |
Gemcitabine, paclitaxel, and cisplatin as induction chemotherapy for patients with biopsy-proven Stage IIIA(N2) nonsmall cell lung carcinoma: a Phase II multicenter study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel | 2003 |
Combination chemotherapy with topotecan for non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Lung Neoplasms; Paclitaxel; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors; Topotecan; Vinblastine; Vinorelbine | 2003 |
Bombesin/gastrin-releasing peptide receptor: a potential target for antibody-mediated therapy of small cell lung cancer.
Topics: Animals; Antibodies, Monoclonal; Blotting, Western; Body Weight; Bombesin; Carcinoma, Non-Small-Cell Lung; CD56 Antigen; Cell Division; Cell Line, Tumor; Cisplatin; Dose-Response Relationship, Drug; Etoposide; Flow Cytometry; Humans; Immunotherapy; Interferon-gamma; Lung Neoplasms; Mice; Mice, SCID; Models, Chemical; Monocytes; Neoplasm Transplantation; Paclitaxel; Protein Binding; Receptors, Bombesin; Thymidine | 2003 |
Proteomic profiling drug-induced apoptosis in non-small cell lung carcinoma: identification of RS/DJ-1 and RhoGDIalpha.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Butadienes; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Enzyme Inhibitors; Guanine Nucleotide Dissociation Inhibitors; Humans; Intracellular Signaling Peptides and Proteins; Lung Neoplasms; MAP Kinase Kinase Kinase 1; Nitriles; Oncogene Proteins; Paclitaxel; Protein Deglycase DJ-1; Protein Serine-Threonine Kinases; Proteomics; Reverse Transcriptase Polymerase Chain Reaction; rho-Specific Guanine Nucleotide Dissociation Inhibitors | 2003 |
Gene expression and mitotic exit induced by microtubule-stabilizing drugs.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Epothilones; Gene Expression; Gene Expression Profiling; Humans; Lung Neoplasms; Microtubules; Mitosis; Oligonucleotide Array Sequence Analysis; Paclitaxel; Polyploidy; RNA, Messenger | 2003 |
[Non-platinum induction chemotherapy for stage III non-small cell lung cancer].
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel | 2003 |
Development of an orthotopic model to study the biology and therapy of primary human lung cancer in nude mice.
Topics: Animals; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Carcinoma, Squamous Cell; Cell Line, Tumor; Fibroblast Growth Factor 2; Humans; Interleukin-8; Lung Neoplasms; Lymphatic Metastasis; Mice; Mice, Nude; Models, Biological; Neoplasm Metastasis; Neovascularization, Pathologic; Paclitaxel; Vascular Endothelial Growth Factor A | 2003 |
Paclitaxel and Cisplatin-induced neurotoxicity: a protective role of acetyl-L-carnitine.
Topics: Acetylcarnitine; Animals; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Survival; Cisplatin; Colonic Neoplasms; Female; Ganglia, Spinal; HeLa Cells; Humans; Lung Neoplasms; Male; Models, Animal; Neurotoxins; Ovarian Neoplasms; Paclitaxel; Prostatic Neoplasms; Rats; Rats, Wistar | 2003 |
Highlights from the 10th World Conference on Lung Cancer. Vancouver, British Columbia, Canada, August 10-14, 2003.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials as Topic; Deoxycytidine; Docetaxel; ErbB Receptors; Gefitinib; Gemcitabine; Humans; Lung Neoplasms; Paclitaxel; Quinazolines; Taxoids | 2003 |
Comparing the relationship of Taxol-based chemotherapy response with P-glycoprotein and lung resistance-related protein expression in non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily B, Member 1; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Female; Humans; Immunohistochemistry; Lung Neoplasms; Male; Middle Aged; Neoplasm Proteins; Paclitaxel; Prognosis; Vault Ribonucleoprotein Particles | 2003 |
CT-2103 extends median survival of high-risk lung cancer patients.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Humans; Lung Neoplasms; Paclitaxel; Polyglutamic Acid; Risk Factors; Survival Rate; Taxoids | 2003 |
Cathepsin B mediates caspase-independent cell death induced by microtubule stabilizing agents in non-small cell lung cancer cells.
Topics: Alkanes; Antineoplastic Agents; Apoptosis; Base Sequence; Carbamates; Carcinoma, Non-Small-Cell Lung; Caspases; Cathepsin B; Cell Death; DNA Primers; Epothilones; Humans; Lactones; Lung Neoplasms; Lysosomes; Microscopy, Fluorescence; Microtubules; Paclitaxel; Pyrones; Transfection; Tumor Cells, Cultured | 2004 |
2-deoxy-D-glucose increases the efficacy of adriamycin and paclitaxel in human osteosarcoma and non-small cell lung cancers in vivo.
Topics: Animals; Bone Neoplasms; Carcinoma, Non-Small-Cell Lung; Deoxyglucose; Doxorubicin; Drug Synergism; Humans; Lung Neoplasms; Mice; Mice, Nude; Osteosarcoma; Paclitaxel; Transplantation, Heterologous; Tumor Cells, Cultured | 2004 |
Potentiation of paclitaxel cytotoxicity in lung and esophageal cancer cells by pharmacologic inhibition of the phosphoinositide 3-kinase/protein kinase B (Akt)-mediated signaling pathway.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Survival; Chromones; Dose-Response Relationship, Drug; Down-Regulation; Drug Therapy, Combination; Enzyme Activation; Enzyme Inhibitors; Esophageal Neoplasms; Humans; Lung Neoplasms; Morpholines; NF-kappa B; Paclitaxel; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Phosphorylation; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Signal Transduction; Statistics as Topic; Time Factors; Treatment Failure; Tumor Cells, Cultured | 2004 |
Study of paclitaxel and dose escalation of cisplatin in patients with advanced non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Dose-Response Relationship, Drug; Drug Administration Schedule; Feasibility Studies; Female; Humans; Leukopenia; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neutropenia; Paclitaxel; Peripheral Nervous System Diseases | 2003 |
Fatal outcome of a hypersensitivity reaction to paclitaxel: a critical review of premedication regimens.
Topics: Anti-Inflammatory Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clemastine; Dexamethasone; Drug Hypersensitivity; Fatal Outcome; Histamine H1 Antagonists; Histamine H2 Antagonists; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Ranitidine; Risk Factors | 2004 |
Effect of paclitaxel administration on P wave duration and dispersion.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Electrocardiography; Female; Heart; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasms; Ovarian Neoplasms; Paclitaxel | 2004 |
Cellular immune profile in patients with non-small cell lung cancer after weekly paclitaxel therapy.
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Immunity, Cellular; Infusions, Intravenous; Killer Cells, Natural; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Prospective Studies; Risk Assessment; Sampling Studies; Treatment Outcome | 2004 |
[Outpatient chemotherapy and clinical pathway for non-small cell lung cancer].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Critical Pathways; Female; Humans; Length of Stay; Lung Neoplasms; Male; Middle Aged; Outpatients; Paclitaxel; Retrospective Studies; Treatment Outcome | 2004 |
Investigating the relationship between serum thrombopoietin kinetics and the platelet-sparing effect: A clinical pharmacological evaluation of combined paclitaxel and carboplatin in patients with non-small cell lung cancer.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Blood Platelets; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Chromatography, High Pressure Liquid; Enzyme-Linked Immunosorbent Assay; Female; Humans; Kinetics; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Spectrophotometry, Atomic; Thrombopoietin | 2004 |
Synergistic suppression of microtubule dynamics by discodermolide and paclitaxel in non-small cell lung carcinoma cells.
Topics: Alkanes; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Binding Sites; Carbamates; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Synergism; G2 Phase; Humans; Inhibitory Concentration 50; Lactones; Lung Neoplasms; Microtubules; Mitosis; Paclitaxel; Pyrones | 2004 |
[Single nucleotide polymorphisms in XRCC1 and clinical response to platin-based chemotherapy in advanced non-small cell lung cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; DNA-Binding Proteins; Docetaxel; Drug Screening Assays, Antitumor; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Phenotype; Polymorphism, Single Nucleotide; Taxoids; Vinblastine; Vinorelbine; X-ray Repair Cross Complementing Protein 1 | 2004 |
[Efficacy of combined paclitaxel and oxaliplatin therapy in patients with pretreated advanced non-small cell lung cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carcinoma, Non-Small-Cell Lung; Female; Humans; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Treatment Outcome | 2004 |
A less intensive combination of paclitaxel and carboplatin in advanced non-small cell lung cancer patients who have aged 60 years or more and has a poor performance status.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Sickness Impact Profile; Survival Analysis; Treatment Outcome | 2004 |
Synthesis of taxoids with improved cytotoxicity and solubility for use in tumor-specific delivery.
Topics: Antineoplastic Agents; Biochemistry; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Disulfides; Drug Carriers; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Female; Humans; Lung Neoplasms; Paclitaxel; Polyethylene Glycols; Solubility; Structure-Activity Relationship; Taxoids; Tumor Cells, Cultured | 2004 |
Development of a chemoresistant orthotopic human nonsmall cell lung carcinoma model in nude mice: analyses of tumor heterogenity in relation to the immunohistochemical levels of expression of cyclooxygenase-2, ornithine decarboxylase, lung-related resista
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Brain Neoplasms; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cyclooxygenase 2; Disease Models, Animal; Drug Resistance, Neoplasm; Female; Glutathione S-Transferase pi; Glutathione Transferase; Humans; Intramolecular Oxidoreductases; Irinotecan; Isoenzymes; Liver Neoplasms; Lung Neoplasms; Membrane Proteins; Mice; Mice, Nude; Neoplasm Proteins; Organoplatinum Compounds; Ornithine Decarboxylase; Oxaliplatin; Paclitaxel; Prostaglandin-E Synthases; Prostaglandin-Endoperoxide Synthases; Survival Rate; Transplantation, Heterologous; Vault Ribonucleoprotein Particles | 2004 |
[Advanced non-small cell lung cancer responded to both vinorelbine and carboplatin over long-term outpatient treatment].
Topics: Aged; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Drug Administration Schedule; Humans; Lung Neoplasms; Male; Paclitaxel; Quality of Life; Vinblastine; Vinorelbine | 2004 |
Treatment of advanced non-small-cell lung cancer in special populations.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Humans; Lung Neoplasms; Multicenter Studies as Topic; Neoplasm Staging; Neutropenia; Paclitaxel; Prospective Studies; Randomized Controlled Trials as Topic; Retrospective Studies; Survival Analysis; Treatment Outcome; Vinblastine; Vinorelbine | 2004 |
Antitumor activity of hydrophilic Paclitaxel copolymer prodrug using locoregional delivery in human orthotopic non-small cell lung cancer xenograft models.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Humans; Immunohistochemistry; Lung Neoplasms; Male; Mice; Mice, Inbred ICR; Mice, Nude; Neoplasm Transplantation; Paclitaxel; Polyglutamic Acid; Polymers; Prodrugs; Time Factors | 2004 |
[Paclitaxel and cisplatin combined with etoposide chemotherapy in non-small cell lung cancer with brain metastases].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Cisplatin; Etoposide; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Survival Rate | 2004 |
[A case of non-small cell lung carcinoma successfully treated with carboplatin and weekly paclitaxel under renal dysfunction].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chronic Disease; Drug Administration Schedule; Humans; Lung Neoplasms; Male; Nephritis; Paclitaxel; Pleural Effusion, Malignant; Renal Insufficiency | 2004 |
In regard to Bogart et al.: 70 Gy thoracic radiotherapy is feasible concurrent with chemotherapy for limited-stage non-small-cell lung cancer: Analysis of cancer and leukemia group B study 39808 (Int J Radiat Oncol Biol Phys 2004;59:460-468).
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase II as Topic; Combined Modality Therapy; Granulocyte Colony-Stimulating Factor; Humans; Lung Neoplasms; Paclitaxel; Radiotherapy Dosage; Recurrence; Topotecan | 2004 |
Epidermal growth factor receptor tyrosine kinase inhibitor does not improve paclitaxel effect in an orthotopic mouse model of lung cancer.
Topics: Adenocarcinoma, Bronchiolo-Alveolar; Animals; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Drug Therapy, Combination; Enzyme Activation; Enzyme Inhibitors; ErbB Receptors; Fibroblast Growth Factor 2; Humans; Lung Neoplasms; Male; Mice; Mice, Nude; Mitogen-Activated Protein Kinases; Models, Animal; Paclitaxel; Phosphorylation; Pyrimidines; Pyrroles; Survival Rate | 2004 |
A selective retinoid X receptor agonist bexarotene (Targretin) prevents and overcomes acquired paclitaxel (Taxol) resistance in human non-small cell lung cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B, Member 1; Bexarotene; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; Humans; Lung Neoplasms; Male; Mice; Mice, Nude; Mutation; Paclitaxel; Retinoid X Receptors; Survival Rate; Tetrahydronaphthalenes; Transplantation, Heterologous; Tumor Cells, Cultured | 2004 |
[Pilot study-previously treated advanced non-small cell lung cancer].
Topics: Aged; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Drug Administration Schedule; Drug Evaluation; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Pilot Projects | 2004 |
Emerging advances in the management of lung cancer.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Humans; Lung Neoplasms; Paclitaxel; Polyglutamic Acid; Protease Inhibitors; Pyrazines; Taxoids | 2004 |
Results of paclitaxel (day 1 and 8) and carboplatin given on every three weeks in advanced (stage III-IV) non-small cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Drug Administration Schedule; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Retrospective Studies; Survival Analysis; Treatment Outcome | 2005 |
Paclitaxel/Platinum-based perioperative chemotherapy and surgery in stage IIIA non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Disease Progression; Drug Administration Schedule; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Perioperative Care; Platinum; Pneumonectomy; Survival Rate; Treatment Outcome | 2005 |
Apoptosis of non-small-cell lung cancer cell lines after paclitaxel treatment involves the BH3-only proapoptotic protein Bim.
Topics: Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Bcl-2-Like Protein 11; Carcinoma, Non-Small-Cell Lung; Carrier Proteins; Caspase Inhibitors; Caspases; Cell Division; Cell Line, Tumor; Enzyme Activation; Female; G2 Phase; Humans; Lung Neoplasms; Male; Membrane Proteins; Microtubules; Mitochondria; Paclitaxel; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; RNA, Small Interfering; Signal Transduction; Tumor Suppressor Protein p53 | 2005 |
Docetaxel: new indication. First-line treatment of non small-cell lung cancer: no advance.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Drug Approval; Drug Combinations; France; Humans; Infusions, Intravenous; Lung Neoplasms; Paclitaxel; Randomized Controlled Trials as Topic; Survival Rate; Taxoids; Treatment Outcome; Vinblastine; Vindesine | 2005 |
Escape from therapy-induced accelerated cellular senescence in p53-null lung cancer cells and in human lung cancers.
Topics: Antineoplastic Combined Chemotherapy Protocols; Caffeine; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; CDC2 Protein Kinase; Cell Division; Cell Line, Tumor; Cellular Senescence; G2 Phase; Humans; Lung Neoplasms; Neoadjuvant Therapy; Paclitaxel; Randomized Controlled Trials as Topic; Research Support as Topic; RNA, Small Interfering; Transcription, Genetic; Tumor Suppressor Protein p53 | 2005 |
Enhancement of the therapeutic efficacy of taxol by the mitogen-activated protein kinase kinase inhibitor CI-1040 in nude mice bearing human heterotransplants.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Synergism; Extracellular Signal-Regulated MAP Kinases; Fibroblast Growth Factors; Humans; Immunoblotting; Lung Neoplasms; Mice; Mice, Nude; Mitogen-Activated Protein Kinase Kinases; Neovascularization, Pathologic; Paclitaxel; Xenograft Model Antitumor Assays | 2005 |
Bevacizumab extends survival for patients with nonsquamous non-small-cell lung cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Carboplatin; Carcinoma, Non-Small-Cell Lung; Humans; Lung Neoplasms; Paclitaxel; Randomized Controlled Trials as Topic; Survival Analysis | 2005 |
Bevacizumab, when added to paclitaxel/carboplatin, prolongs survival in previously untreated patients with advanced non-small-cell lung cancer: preliminary results from the ECOG 4599 trial.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Carboplatin; Carcinoma, Non-Small-Cell Lung; Humans; Lung Neoplasms; Neoplasm Staging; Paclitaxel; Randomized Controlled Trials as Topic; Receptors, Vascular Endothelial Growth Factor; Survival Analysis | 2005 |
PWT-458, a novel pegylated-17-hydroxywortmannin, inhibits phosphatidylinositol 3-kinase signaling and suppresses growth of solid tumors.
Topics: Androstadienes; Animals; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Cell Line, Tumor; Dose-Response Relationship, Drug; Drug Synergism; Drug Therapy, Combination; Female; Glioma; Humans; Interferon-alpha; Kidney Neoplasms; Lung Neoplasms; Mice; Mice, Nude; Molecular Structure; Molecular Weight; Neoplasm Transplantation; Neoplasms; Paclitaxel; Phosphoinositide-3 Kinase Inhibitors; Phosphorylation; Proto-Oncogene Proteins c-akt; Signal Transduction; Sirolimus; Transplantation, Heterologous; Xenograft Model Antitumor Assays | 2005 |
[Dose response curve of paclitaxel measured by histoculture drug response assay].
Topics: Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Humans; Lung Neoplasms; Nonlinear Dynamics; Paclitaxel; Tumor Cells, Cultured | 2005 |
The synergistic combination of the farnesyl transferase inhibitor lonafarnib and paclitaxel enhances tubulin acetylation and requires a functional tubulin deacetylase.
Topics: Acetylation; Alkyl and Aryl Transferases; Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Cell Death; Cell Line, Tumor; Drug Synergism; Farnesyltranstransferase; Histone Deacetylase 6; Histone Deacetylase Inhibitors; Histone Deacetylases; Humans; Lung Neoplasms; Mice; Microtubules; Mitosis; NIH 3T3 Cells; Paclitaxel; Piperidines; Pyridines; Tubulin | 2005 |
Lung cancer - Second Annual Winter Conference.
Topics: Adenocarcinoma, Bronchiolo-Alveolar; Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Chemotherapy, Adjuvant; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Molecular Structure; Paclitaxel; Pyrazines; Quinazolines | 2005 |
Response to combined modality therapy correlates with survival in locally advanced non-small-cell lung cancer.
Topics: Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase II as Topic; Combined Modality Therapy; Disease-Free Survival; Female; Humans; Lung Neoplasms; Male; Multicenter Studies as Topic; Paclitaxel; Proportional Hazards Models; Retrospective Studies; Survival Rate | 2005 |
Front-line doublets in advanced non-small cell lung cancer: The golden age for second line chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Disease Progression; Docetaxel; Etoposide; Female; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Paclitaxel; Pemetrexed; Survival Rate; Taxoids | 2005 |
The role of thymidylate synthase and dihydropyrimidine dehydrogenase in resistance to 5-fluorouracil in human lung cancer cells.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Survival; Cisplatin; Deoxycytidine; Dihydrouracil Dehydrogenase (NADP); Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Fluorouracil; Gemcitabine; Humans; Inhibitory Concentration 50; Irinotecan; Lung Neoplasms; Paclitaxel; Pyridines; Reverse Transcriptase Polymerase Chain Reaction; Thymidylate Synthase | 2005 |
The retinoid X receptor agonist bexarotene (Targretin) synergistically enhances the growth inhibitory activity of cytotoxic drugs in non-small cell lung cancer cells.
Topics: Animals; Anticarcinogenic Agents; Antineoplastic Agents, Phytogenic; Bexarotene; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Drug Interactions; Humans; Lung Neoplasms; Male; Mice; Mice, Nude; Paclitaxel; Tetrahydronaphthalenes; Transplantation, Heterologous; Vinblastine; Vinorelbine | 2005 |
Chemotherapy for non-small cell lung cancer in elderly patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Retrospective Studies; Survival Analysis; Treatment Outcome; Vinblastine; Vinorelbine | 2005 |
Nontoxic suramin treatments enhance docetaxel activity in chemotherapy-pretreated non-small cell lung xenograft tumors.
Topics: Animals; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bromodeoxyuridine; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Docetaxel; Drug Synergism; Humans; Lung Neoplasms; Male; Mice; Mice, Nude; Paclitaxel; Suramin; Taxoids; Tumor Burden; Xenograft Model Antitumor Assays | 2005 |
Long term follow up and analysis of long term survivors in patients treated with paclitaxel-based concurrent chemo/radiation therapy for locally advanced non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Databases, Factual; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Retrospective Studies; Survival Analysis; Weight Loss | 2005 |
[Cut-off level of docetaxel, paclitaxel and gemcitabine in histoculture drug response assay for non-small cell lung cancer].
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Drug Screening Assays, Antitumor; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Taxoids; Tumor Cells, Cultured | 2005 |
Multivariate analysis of survival, local control, and time to distant metastases in patients with unresectable non-small-cell lung carcinoma treated with 3-dimensional conformal radiation therapy with or without concurrent chemotherapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Esophageal Diseases; Follow-Up Studies; Humans; Lung Diseases; Lung Neoplasms; Middle Aged; Multivariate Analysis; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Radiotherapy, Adjuvant; Radiotherapy, Conformal; Retrospective Studies; Survival Analysis | 2005 |
FHIT protein enhances paclitaxel-induced apoptosis in lung cancer cells.
Topics: Acid Anhydride Hydrolases; Antineoplastic Agents, Phytogenic; Apoptosis; Carcinoma, Non-Small-Cell Lung; Caspase 3; Caspase 7; Caspase 8; Caspases; Humans; Lung Neoplasms; Neoplasm Proteins; Paclitaxel; Plasmids; Proto-Oncogene Proteins c-bcl-2; RNA, Small Interfering; Signal Transduction; Transfection; Tumor Cells, Cultured | 2006 |
[The effect of multimodality induction therapy for locally advanced non-small cell lung cancer].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Drug Administration Schedule; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mitomycins; Paclitaxel; Pneumonectomy; Prognosis; Survival Rate; Vinblastine | 2005 |
[Surgical treatment for locally advanced lung cancer; therapeutic response of induction chemotherapy and postoperative chemotherapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Cisplatin; Drug Administration Schedule; Etoposide; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Pneumonectomy; Postoperative Period; Survival Rate | 2005 |
Role of gross tumor volume on outcome and of dose parameters on toxicity of patients undergoing chemoradiotherapy for locally advanced non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Deoxycytidine; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Paclitaxel; Prognosis; Radiotherapy Dosage; Radiotherapy, Conformal; Retrospective Studies; Survival Analysis; Survival Rate | 2005 |
Economic evaluation of three two-drug chemotherapy regimens in advanced non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Cost of Illness; Deoxycytidine; Gemcitabine; Hospitalization; Humans; Lung Neoplasms; Middle Aged; Paclitaxel; Prospective Studies | 2005 |
A real-time RT-PCR assay for the quantitative determination of adenoviral gene expression in tumor cells.
Topics: Adenoviridae; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; DNA, Viral; Gene Expression; Humans; Lung Neoplasms; Nucleic Acid Amplification Techniques; Paclitaxel; Reverse Transcriptase Polymerase Chain Reaction; Serotyping; Time Factors | 2006 |
Class III beta-tubulin expression in tumor cells predicts response and outcome in patients with non-small cell lung cancer receiving paclitaxel.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Female; Humans; Immunohistochemistry; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Paclitaxel; Survival Analysis; Treatment Outcome; Tubulin | 2005 |
Korean translation and validation of the functional assessment of cancer therapy-lung (FACT-L) version 4.
Topics: Activities of Daily Living; Affect; Aged; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Cisplatin; Female; Humans; Korea; Male; Middle Aged; Outcome Assessment, Health Care; Paclitaxel; Psychometrics; Quality of Life; Sickness Impact Profile; Surveys and Questionnaires; Translations | 2006 |
A slow disengagement from platinum-based chemotherapy for patients with advanced non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Diarrhea; Drug Administration Schedule; Humans; Irinotecan; Lung Neoplasms; Maximum Tolerated Dose; Neutropenia; Paclitaxel; Platinum; Survival Rate; Time Factors | 2005 |
Induced resistance in the human non small cell lung carcinoma (NCI-H460) cell line in vitro by anticancer drugs.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Curcumin; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Etoposide; Glutathione Transferase; Humans; Lung Neoplasms; Multidrug Resistance-Associated Proteins; Paclitaxel; Rhodamines; RNA, Messenger; RNA, Neoplasm; Tumor Cells, Cultured; Verapamil; Vinblastine | 2006 |
Nicotine inhibits apoptosis induced by chemotherapeutic drugs by up-regulating XIAP and survivin.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Chromatin Immunoprecipitation; Cisplatin; Deoxycytidine; Dihydro-beta-Erythroidine; Drug Resistance, Neoplasm; Gemcitabine; Humans; Inhibitor of Apoptosis Proteins; Lung Neoplasms; Microtubule-Associated Proteins; Neoplasm Proteins; Nicotine; Paclitaxel; Promoter Regions, Genetic; Receptors, Nicotinic; Retinoblastoma Protein; Survivin; Up-Regulation; X-Linked Inhibitor of Apoptosis Protein | 2006 |
[Combination chemotherapy with carboplatin and weekly Paclitaxel in patients with advanced non-small cell lung cancer].
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Drug Administration Schedule; Female; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Male; Middle Aged; Neutropenia; Paclitaxel; Remission Induction; Retrospective Studies; Survival Rate | 2006 |
Cost-minimization analysis for Portugal of five doublet chemotherapy regimens from two phase III trials in the treatment of advanced non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials, Phase III as Topic; Costs and Cost Analysis; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Lung Neoplasms; Male; National Health Programs; Paclitaxel; Portugal; Taxoids | 2006 |
Taxanes in the treatment of non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Humans; Lung Neoplasms; Paclitaxel; Taxoids | 2006 |
Nontoxic suramin as a chemosensitizer in patients: dosing nomogram development.
Topics: Algorithms; Antineoplastic Agents; Blood Proteins; Carboplatin; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Drug Administration Schedule; Drug Interactions; Drug Therapy, Combination; Female; Humans; Lung Neoplasms; Male; Models, Biological; Nomograms; Paclitaxel; Protein Binding; Reproducibility of Results; Suramin | 2006 |
[Current data concerning neoadjuvant chemotherapy].
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Cisplatin; Etoposide; Humans; Ifosfamide; Lung; Lung Neoplasms; Mitomycin; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Radiotherapy Dosage; Radiotherapy, Adjuvant; Randomized Controlled Trials as Topic; Risk; Time Factors | 2006 |
[Maintenance chemotherapy in advanced NSCLC].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials, Phase III as Topic; Deoxycytidine; Gemcitabine; Humans; Karnofsky Performance Status; Lung; Lung Neoplasms; Neoplasm Staging; Paclitaxel; Randomized Controlled Trials as Topic; Time Factors; Vinblastine; Vinorelbine | 2006 |
[Promising targeted molecular therapies for the future years in non-small-cell lung cancer].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Boronic Acids; Bortezomib; Carboplatin; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase II as Topic; Docetaxel; Forecasting; Humans; Lung Neoplasms; Multicenter Studies as Topic; Paclitaxel; Prognosis; Protease Inhibitors; Proteasome Endopeptidase Complex; Pyrazines; Randomized Controlled Trials as Topic; Research; Signal Transduction; Taxoids; Vascular Endothelial Growth Factor A | 2006 |
Chemotherapy-induced epidermal growth factor receptor activation determines response to combined gefitinib/chemotherapy treatment in non-small cell lung cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Line, Tumor; Cisplatin; Dose-Response Relationship, Drug; Enzyme Activation; ErbB Receptors; Gefitinib; Genes, erbB-2; Humans; Lung Neoplasms; Mitogen-Activated Protein Kinase 3; Paclitaxel; Phosphorylation; Proto-Oncogene Proteins c-akt; Quinazolines; Signal Transduction | 2006 |
[Association of the responsiveness of advanced non-small cell lung cancer to platinum-based chemotherapy with p53 and p73 polymorphisms].
Topics: Adult; Aged; Antineoplastic Agents; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; DNA-Binding Proteins; Exons; Female; Genotype; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Nuclear Proteins; Paclitaxel; Polymorphism, Genetic; Tumor Protein p73; Tumor Suppressor Protein p53; Tumor Suppressor Proteins | 2006 |
Tumor necrosis factor alpha induces spermidine/spermine N1-acetyltransferase through nuclear factor kappaB in non-small cell lung cancer cells.
Topics: Acetyltransferases; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Enzyme Induction; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Humans; Inflammation; Lung Neoplasms; NF-kappa B; Paclitaxel; Polyamines; Promoter Regions, Genetic; Recombinant Proteins; Signal Transduction; Tumor Necrosis Factor-alpha | 2006 |
Predictive value of D-dimer plasma levels in response and progressive disease in patients with lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bridged-Ring Compounds; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Deoxycytidine; Disease Progression; Docetaxel; Female; Fibrin Fibrinogen Degradation Products; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Patient Compliance; Predictive Value of Tests; Prospective Studies; Survival Analysis; Taxoids; Treatment Outcome; Vinblastine | 2006 |
HER2 mutation and response to trastuzumab therapy in non-small-cell lung cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; Female; Gene Amplification; Genes, erbB-2; Humans; Lung Neoplasms; Middle Aged; Mutation; Paclitaxel; Receptor, ErbB-2; Trastuzumab | 2006 |
[Gefitinib treatment for carcinomatous meningitis in non-small cell lung cancer].
Topics: Adenocarcinoma, Bronchiolo-Alveolar; Antineoplastic Agents; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Cranial Irradiation; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Meningitis; Middle Aged; Neoplasm Proteins; Paclitaxel; Palliative Care; Pneumonectomy; Protein Kinase Inhibitors; Quinazolines; Vinblastine; Vinorelbine | 2006 |
Pneumonectomy after high-dose radiation and concurrent chemotherapy for nonsmall cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bronchial Fistula; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Drug Administration Schedule; Etoposide; Feasibility Studies; Female; Humans; Life Tables; Lung Neoplasms; Male; Middle Aged; Myocardial Infarction; Paclitaxel; Pleural Diseases; Pneumonectomy; Pneumonia; Pneumonia, Aspiration; Postoperative Complications; Pulmonary Embolism; Radiotherapy Dosage; Radiotherapy, Conformal; Remission Induction; Respiration, Artificial; Respiratory Distress Syndrome; Respiratory Tract Fistula; Retrospective Studies; Survival Analysis; Treatment Outcome | 2006 |
PIONEER: a phase III randomized trial of paclitaxel poliglumex versus paclitaxel in chemotherapy-naive women with advanced-stage non-small-cell lung cancer and performance status of 2.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Paclitaxel; Patient Selection; Polyglutamic Acid; Randomized Controlled Trials as Topic; Research Design; Women's Health | 2006 |
Epidermal growth factor receptor mutations and response to chemotherapy in patients with non-small-cell lung cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; DNA Mutational Analysis; ErbB Receptors; Gefitinib; Gemcitabine; Genes, erbB-1; Genes, ras; Humans; Immunohistochemistry; Lung Neoplasms; Mutation; Paclitaxel; Proto-Oncogene Proteins c-akt; Quinazolines; Retrospective Studies | 2006 |
Paclitaxel and vincristine potentiate adenoviral oncolysis that is associated with cell cycle and apoptosis modulation, whereas they differentially affect the viral life cycle in non-small-cell lung cancer cells.
Topics: Adenoviridae; Adenovirus E3 Proteins; Antineoplastic Agents, Phytogenic; Apoptosis; Capsid Proteins; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Gene Expression Regulation; Genetic Vectors; Humans; Lung Neoplasms; Microtubules; Paclitaxel; Tumor Cells, Cultured; Vincristine | 2006 |
Targeting ADAM-mediated ligand cleavage to inhibit HER3 and EGFR pathways in non-small cell lung cancer.
Topics: ADAM Proteins; ADAM17 Protein; Animals; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; ErbB Receptors; Female; Gefitinib; Gene Expression; Humans; Ligands; Mice; Mice, Inbred BALB C; Mice, Nude; Models, Biological; Paclitaxel; Piperidines; Protease Inhibitors; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-3; Signal Transduction; Spiro Compounds; Xenograft Model Antitumor Assays | 2006 |
Is trimodality approach better then bimodality in stage IIIA, N2 positive non-small cell lung cancer?
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Combined Modality Therapy; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Platinum; Radiotherapy; Treatment Outcome | 2006 |
[XRCC1 and XPD genetic polymorphisms predict clinical responses to platinum-based chemotherapy in advanced non-small cell lung cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; DNA Repair; DNA-Binding Proteins; Female; Genotype; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Polymorphism, Genetic; Remission Induction; Vinblastine; Vinorelbine; X-ray Repair Cross Complementing Protein 1; Xeroderma Pigmentosum Group D Protein | 2006 |
[Lung cancer with bone metastasis].
Topics: Analgesics; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cisplatin; Combined Modality Therapy; Diphosphonates; Docetaxel; Drug Administration Schedule; Etoposide; Fractures, Bone; Gefitinib; Humans; Irinotecan; Lung Neoplasms; Paclitaxel; Pain, Intractable; Prognosis; Quinazolines; Radiotherapy Dosage; Taxoids | 2006 |
Advanced non-small-cell lung cancer: 'triplets' better than 'doublets'?
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease-Free Survival; Gemcitabine; Humans; Lung Neoplasms; Paclitaxel | 2006 |
A proper schedule of weekly paclitaxel and gemcitabine combination is highly active and very well tolerated in NSCLC patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Treatment Failure; Treatment Outcome | 2006 |
[Initial outcome of induction chemotherapy with weekly paclitaxel followed by three-dimensional conformal radiotherapy and concurrent weekly paclitaxel for stage III non-small cell lung cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Drug Administration Schedule; Esophagitis; Female; Follow-Up Studies; Humans; Lung Neoplasms; Lymphopenia; Male; Middle Aged; Paclitaxel; Radiotherapy, Conformal; Remission Induction; Survival Rate | 2006 |
Chemoradiotherapy has edge over radiotherapy alone.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Humans; Lung Neoplasms; Paclitaxel; Randomized Controlled Trials as Topic; Treatment Outcome | 2006 |
Repeat 18F-FDG PET for monitoring neoadjuvant chemotherapy in patients with stage III non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Agents; Area Under Curve; Carboplatin; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Radionuclide Imaging; Radiopharmaceuticals; Survival Analysis | 2007 |
Dexamethasone inhibits paclitaxel-induced cytotoxic activity through retinoblastoma protein dephosphorylation in non-small cell lung cancer cells.
Topics: Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Division; Cell Line, Tumor; Cell Survival; Chromones; Dexamethasone; DNA, Neoplasm; Enzyme Inhibitors; Humans; Kinetics; Lung Neoplasms; Morpholines; Paclitaxel; Retinoblastoma Protein | 2007 |
Genome-wide cDNA microarray screening of genes related to the benefits of paclitaxel and irinotecan chemotherapy in patients with advanced non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma, Non-Small-Cell Lung; Female; Gene Expression Regulation, Neoplastic; Genome; Humans; Interleukin-1alpha; Irinotecan; Lung Neoplasms; Male; Middle Aged; Oligonucleotide Array Sequence Analysis; Paclitaxel; Receptors, Thyrotropin-Releasing Hormone | 2006 |
[Correlation between the expression of PCDGF in serum and the chemotherapeutic sensitivity in NSCLC].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cisplatin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Enzyme-Linked Immunosorbent Assay; Female; Humans; Intercellular Signaling Peptides and Proteins; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Progranulins; Remission Induction; Vinblastine; Vinorelbine | 2006 |
[Lung cancer in patients with chronic renal failure].
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cisplatin; Combined Modality Therapy; Drug Administration Schedule; Female; Humans; Kidney Failure, Chronic; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Pneumonectomy; Renal Dialysis | 2007 |
In vitro and in vivo synergy of MCP compounds with mitogen-activated protein kinase pathway- and microtubule-targeting inhibitors.
Topics: 3T3 Cells; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Proliferation; Cell Transformation, Neoplastic; Colonic Neoplasms; Docetaxel; Drug Synergism; Enzyme Inhibitors; Humans; In Vitro Techniques; Lung Neoplasms; Male; Mice; Mice, Nude; Mice, SCID; Microtubules; Mitogen-Activated Protein Kinases; Paclitaxel; Proto-Oncogene Proteins c-raf; Proto-Oncogene Proteins p21(ras); Signal Transduction; Taxoids; Transcriptional Activation; Tumor Cells, Cultured; Vincristine; Xenograft Model Antitumor Assays | 2007 |
[Expression of serum breast drug-resistance protein in predicting chemosensitivity of NSCLC].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cisplatin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Enzyme-Linked Immunosorbent Assay; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Proteins; Neoplasm Staging; Paclitaxel; Remission Induction; Vinblastine; Vinorelbine | 2006 |
Bevacizumab for non-small-cell lung cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Non-Small-Cell Lung; Humans; Lung Neoplasms; Paclitaxel; Survival Analysis | 2007 |
Bevacizumab for non-small-cell lung cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Non-Small-Cell Lung; Hemoptysis; Hemorrhage; Humans; Lung Diseases; Lung Neoplasms; Paclitaxel; Risk Factors; Survival Analysis | 2007 |
Bevacizumab for non-small-cell lung cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cardiovascular Diseases; Humans; Lung Neoplasms; Paclitaxel | 2007 |
Bevacizumab for non-small-cell lung cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Humans; Lung Neoplasms; Paclitaxel | 2007 |
Salvage therapy for Chinese non-small cell lung cancer patients who failed previous chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gefitinib; Gemcitabine; Humans; Ifosfamide; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Probability; Prognosis; Quinazolines; Retrospective Studies; Risk Factors; Salvage Therapy; Statistics, Nonparametric; Survival Analysis; Taiwan; Taxoids; Treatment Outcome | 2006 |
Systemic therapy of bronchioloalveolar carcinoma: results of the first IASLC/ASCO consensus conference on bronchioloalveolar carcinoma.
Topics: Adenocarcinoma, Bronchiolo-Alveolar; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; Drug Administration Schedule; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Neoplasm Staging; Paclitaxel; Prognosis; Quinazolines; Randomized Controlled Trials as Topic; Survival Analysis; Treatment Outcome | 2006 |
Synthetic lethal screen identification of chemosensitizer loci in cancer cells.
Topics: Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Survival; DNA Mutational Analysis; Dose-Response Relationship, Drug; Genes, Lethal; Humans; Lung; Lung Neoplasms; Microtubules; Mitosis; Paclitaxel; RNA, Small Interfering; Spindle Apparatus | 2007 |
[Outpatient chemotherapy for lung cancer].
Topics: Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cisplatin; Combined Modality Therapy; Deoxycytidine; Docetaxel; Drug Administration Schedule; Etoposide; Gefitinib; Gemcitabine; Humans; Informed Consent; Irinotecan; Lung Neoplasms; Neutropenia; Paclitaxel; Quality of Life; Quinazolines; Taxoids; Vinblastine; Vinorelbine | 2007 |
EGFR and HER2 gene copy number and response to first-line chemotherapy in patients with advanced non-small cell lung cancer (NSCLC).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chi-Square Distribution; Cisplatin; Deoxycytidine; Disease Progression; Docetaxel; ErbB Receptors; Female; Gemcitabine; Humans; In Situ Hybridization, Fluorescence; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Proto-Oncogene Proteins c-akt; Receptor, ErbB-2; Survival Rate; Taxoids; Vinblastine; Vinorelbine | 2007 |
Inhibition of Stat3 activation and tumor growth suppression of non-small cell lung cancer by G-quartet oligonucleotides.
Topics: Animals; Apoptosis; bcl-X Protein; Carcinoma, Non-Small-Cell Lung; Cell Proliferation; Cyclin D1; Immunohistochemistry; Inhibitor of Apoptosis Proteins; Lung Neoplasms; Mice; Mice, Nude; Microtubule-Associated Proteins; Myeloid Cell Leukemia Sequence 1 Protein; Neoplasm Proteins; Neovascularization, Pathologic; Oligodeoxyribonucleotides; Paclitaxel; Phosphorylation; Protein Conformation; Proto-Oncogene Proteins c-bcl-2; Proto-Oncogene Proteins c-myc; STAT3 Transcription Factor; Survivin; Vascular Endothelial Growth Factor A | 2007 |
[Medical treatment for stage III non-small-cell lung cancer (NSCLC)].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Drug Administration Schedule; Gefitinib; Humans; Lung Neoplasms; Lymph Nodes; Lymphatic Metastasis; Mitomycin; Neoplasm Staging; Paclitaxel; Pneumonectomy; Quinazolines; Radiotherapy Dosage; Radiotherapy, Adjuvant; Survival Rate | 2007 |
FDA drug approval summary: bevacizumab (Avastin) plus Carboplatin and Paclitaxel as first-line treatment of advanced/metastatic recurrent nonsquamous non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Non-Small-Cell Lung; Drug Approval; Headache; Humans; Lung Neoplasms; Middle Aged; Multicenter Studies as Topic; Neoplasm Metastasis; Neoplasm Staging; Paclitaxel; Pain; Randomized Controlled Trials as Topic; Treatment Outcome; United States; United States Food and Drug Administration; Vomiting | 2007 |
Rational design of cancer-drug combinations.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Survival; Dose-Response Relationship, Drug; Drug Design; Genes, Lethal; Humans; Lung Neoplasms; Paclitaxel; RNA Interference; RNA, Small Interfering | 2007 |
Targeting BCL-2 family proteins to overcome drug resistance in non-small cell lung cancer.
Topics: Antineoplastic Agents; Apoptosis; bcl-2 Homologous Antagonist-Killer Protein; Biphenyl Compounds; Butylated Hydroxytoluene; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Doxorubicin; Drug Resistance, Neoplasm; Electrophoresis; Etoposide; Flow Cytometry; Gene Expression Regulation, Neoplastic; Humans; Immunoblotting; Immunohistochemistry; Lung Neoplasms; Mitochondria; Myeloid Cell Leukemia Sequence 1 Protein; Neoplasm Proteins; Nitrophenols; Paclitaxel; Permeability; Piperazines; Proto-Oncogene Proteins c-bcl-2; Signal Transduction; Sulfonamides | 2007 |
Multiple cycles of PBPC-supported high-dose carboplatin and paclitaxel following mobilization with epirubicin and cisplatin are feasible but ineffective in treating patients with advanced non-small cell lung cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Epirubicin; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Leukapheresis; Lung Neoplasms; Middle Aged; Paclitaxel; Peripheral Blood Stem Cell Transplantation; Pilot Projects; Recombinant Proteins | 2007 |
Preliminary experience with a modified premedication protocol that included intravenous diphenhydramine and calcium bromide for the prophylaxis of paclitaxel-related hypersensitivity reactions.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Bromides; Calcium Compounds; Carcinoma, Non-Small-Cell Lung; Cohort Studies; Diphenhydramine; Drug Hypersensitivity; Female; Humans; Injections, Intravenous; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Premedication; Retrospective Studies | 2007 |
[Lung cancer treatment in elderly patients].
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Lung Neoplasms; Middle Aged; Paclitaxel; Taxoids; Vinblastine; Vinorelbine | 2007 |
Radiation-induced myonecrosis presenting as a subcutaneous mass after combined modality therapy for non-small cell lung cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Carboplatin; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Diagnosis, Differential; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Muscle, Skeletal; Necrosis; Paclitaxel; Radiation Injuries; Thorax; Tomography, Emission-Computed, Single-Photon; Tomography, X-Ray Computed | 2007 |
Treatment of non-small cell lung cancer, stage IIIB: ACCP evidence-based clinical practice guidelines (2nd edition).
Topics: Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cytotoxins; Evidence-Based Medicine; Humans; Lung Neoplasms; Neoplasm Staging; Paclitaxel; Platinum; Quality of Life; Treatment Outcome | 2007 |
[Safety evaluation of adjuvant chemotherapy by weekly paclitaxel combined with weekly carboplatin in patients with postoperative non-small cell lung cancer].
Topics: Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Drug Administration Schedule; Drug Tolerance; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Postoperative Care; Retrospective Studies | 2007 |
[Technetium-99m labeled synaptotagmin I C2A detection of paclitaxel-induced apoptosis in non-small cell lung cancer].
Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Carcinoma, Non-Small-Cell Lung; Caspase 3; Flow Cytometry; Humans; In Situ Nick-End Labeling; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Paclitaxel; Synaptotagmin I; Technetium; Xenograft Model Antitumor Assays | 2007 |
Class III beta-tubulin mediates sensitivity to chemotherapeutic drugs in non small cell lung cancer.
Topics: Carcinoma, Non-Small-Cell Lung; Cell Division; Cell Line, Tumor; Cisplatin; DNA Damage; G2 Phase; Gene Silencing; Humans; Lung Neoplasms; Paclitaxel; RNA, Messenger; RNA, Small Interfering; Transfection; Tubulin; Vincristine | 2007 |
[Non-small-cell bronchial carcinoma--induction--combined with radiochemotherapy--a more certain alternative].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials as Topic; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Radiotherapy, Adjuvant; Survival Analysis; Treatment Outcome | 2007 |
The MDR1/ABCB1 regional amplification in large inverted repeats with asymmetric sequences and microhomologies at the junction sites.
Topics: ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Base Sequence; Blotting, Southern; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Chromosomes, Human, Pair 7; Cloning, Molecular; DNA Primers; Drug Resistance, Multiple; Gene Amplification; Humans; In Situ Hybridization, Fluorescence; Lung Neoplasms; Molecular Sequence Data; Nucleic Acid Hybridization; Oligonucleotide Array Sequence Analysis; Paclitaxel; Polymerase Chain Reaction; Sequence Homology, Nucleic Acid | 2007 |
Paclitaxel-octreotide conjugates inhibit growth of human non-small cell lung cancer cells in vitro.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Line, Tumor; Cell Proliferation; DNA Primers; Dose-Response Relationship, Drug; Drug Delivery Systems; Flow Cytometry; Humans; In Vitro Techniques; Lung Neoplasms; Octreotide; Paclitaxel; Receptors, Somatostatin; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger | 2007 |
Lung cancer may be different for men and women, but researchers ponder what to do?
Topics: Antineoplastic Combined Chemotherapy Protocols; Aromatase; Biomarkers, Tumor; Carboplatin; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Estrogens; Female; Humans; Lung Neoplasms; Male; Paclitaxel; Polyglutamic Acid; Prognosis; Smoking; Survival Analysis; United States | 2007 |
[Efficacy of adjuvant chemotherapy after left pneumonectomy on non-small cell lung cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Female; Follow-Up Studies; Forced Expiratory Volume; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Pneumonectomy; Survival Rate; Vinblastine; Vinorelbine | 2007 |
The number of residual metastatic lymph nodes following neoadjuvant chemotherapy predicts survival in patients with stage III NSCLC.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Docetaxel; Female; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Neutropenia; Paclitaxel; Predictive Value of Tests; Prognosis; Retrospective Studies; Survival Analysis; Taxoids; Vinblastine; Vinorelbine | 2008 |
Progression-free survival as primary end point in advanced non-small-cell lung cancer: does the size matter?
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Disease-Free Survival; Female; Humans; Lung Neoplasms; Male; Neoplasm Staging; Paclitaxel; Palliative Care; Pneumonectomy; Randomized Controlled Trials as Topic; Risk Assessment; Survival Analysis; Tumor Burden | 2008 |
Bevacizumab: optimal dose, schedule, and duration of therapy.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Drug Administration Schedule; Gemcitabine; Humans; Lung Neoplasms; Neoplasm Staging; Paclitaxel; Randomized Controlled Trials as Topic; Vascular Endothelial Growth Factor A | 2007 |
Inhibition of Hsp90 down-regulates mutant epidermal growth factor receptor (EGFR) expression and sensitizes EGFR mutant tumors to paclitaxel.
Topics: Animals; Antineoplastic Agents, Phytogenic; Benzoquinones; Carcinoma, Non-Small-Cell Lung; Down-Regulation; Drug Resistance, Neoplasm; Drug Synergism; Female; Gene Expression Regulation, Neoplastic; Genes, erbB-1; HSP90 Heat-Shock Proteins; Humans; Lactams, Macrocyclic; Lung Neoplasms; Mice; Mice, Nude; Mutant Proteins; NIH 3T3 Cells; Paclitaxel; Protein Kinase Inhibitors; Tumor Burden; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2008 |
[Non-small cell lung neoplasms--weekly taxane combinations are possible].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Treatment Failure; Treatment Outcome | 2007 |
Pulmonary resection in patients with nonsmall-cell lung cancer treated with gamma-knife radiosurgery for synchronous brain metastases.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Case-Control Studies; Chemotherapy, Adjuvant; Cisplatin; Cohort Studies; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Pneumonectomy; Radiosurgery; Retrospective Studies; Survival Rate | 2008 |
Imaging paclitaxel (chemotherapy)-induced tumor apoptosis with 99mTc C2A, a domain of synaptotagmin I: a preliminary study.
Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Carcinoma, Non-Small-Cell Lung; Caspase 3; Cell Line, Tumor; Disease Models, Animal; DNA Fragmentation; Female; Humans; Injections, Intravenous; Lung Neoplasms; Male; Mice; Paclitaxel; Protein Structure, Tertiary; Radioligand Assay; Radionuclide Imaging; Radiopharmaceuticals; Synaptotagmin I; Technetium; Tissue Distribution | 2008 |
Utility of positron emission tomography compared with mediastinoscopy for delineating involved lymph nodes in stage III lung cancer: insights for radiotherapy planning from a surgical cohort.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Humans; Lung Neoplasms; Lymphatic Metastasis; Mediastinoscopy; Neoplasm Staging; Paclitaxel; Positron-Emission Tomography; Radiography; Sensitivity and Specificity | 2008 |
Influence of previous chemotherapy on the efficacy of subsequent docetaxel therapy in advanced non-small cell lung cancer patients.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Disease-Free Survival; Docetaxel; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Salvage Therapy; Survival Rate; Taxoids | 2008 |
Measuring clinically significant chemotherapy-related toxicities using Medicare claims from Cancer and Leukemia Group B (CALGB) trial participants.
Topics: Aged; Aging; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Cohort Studies; Doxorubicin; Female; Humans; Insurance Claim Review; Male; Medicare; Paclitaxel; Randomized Controlled Trials as Topic; Reproducibility of Results; Retrospective Studies; ROC Curve; United States | 2008 |
[Prognosis of locally advanced non small cell lung cancer treated with three dimentional conformal radiotherapy].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Brain Neoplasms; Carboplatin; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Female; Follow-Up Studies; Humans; Karnofsky Performance Status; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Particle Accelerators; Proportional Hazards Models; Radiotherapy Dosage; Radiotherapy Planning, Computer-Assisted; Radiotherapy, Conformal; Remission Induction; Survival Rate | 2007 |
[Weekly paclitaxel and carboplatin with concurrent three dimensional conformal radiotherapy for locally advanced non small cell lung cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Leukopenia; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Prospective Studies; Radiotherapy, Conformal; Remission Induction; Survival Rate | 2007 |
Mechanistic insight into taxol-induced cell death.
Topics: Antineoplastic Agents, Phytogenic; Calpain; Carcinoma, Non-Small-Cell Lung; Caspase Inhibitors; Caspases; Cell Death; Cell Line, Tumor; Humans; Neoplasm Proteins; Paclitaxel; Proteomics | 2008 |
Improved survival with addition of bevacizumab to paclitaxel and carboplatin in elderly patients with non-small-cell lung cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Non-Small-Cell Lung; Humans; Lung Neoplasms; Paclitaxel; Survival Rate | 2008 |
Reporting of subset analysis: where do we draw the line?
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Non-Small-Cell Lung; Data Interpretation, Statistical; Humans; Lung Neoplasms; Multivariate Analysis; Paclitaxel | 2008 |
MRP7/ABCC10 expression is a predictive biomarker for the resistance to paclitaxel in non-small cell lung cancer.
Topics: Antineoplastic Agents, Phytogenic; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; Gene Expression; Humans; Lung Neoplasms; Multidrug Resistance-Associated Proteins; Paclitaxel; RNA, Small Interfering; Sulfinpyrazone; Tumor Cells, Cultured | 2008 |
Differential impact of fibroblasts on the efficient cell death of lung cancer cells induced by paclitaxel and cisplatin.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Death; Cell Line; Cell Line, Tumor; Cisplatin; Culture Media, Conditioned; Fibroblasts; Humans; Lung Neoplasms; Paclitaxel | 2008 |
Single agent gemcitabine in the second-line treatment of advanced non-small cell lung cancer after treatment with taxane + platinum regimens.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Lung Neoplasms; Paclitaxel; Retrospective Studies; Taxoids | 2008 |
Restrictive eligibility limits access to newer therapies in non-small-cell lung cancer: the implications of Eastern Cooperative Oncology Group 4599.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; Eligibility Determination; Humans; Lung Neoplasms; Multicenter Studies as Topic; Paclitaxel; Retrospective Studies | 2008 |
Clinically meaningful differences in patient-reported outcomes with amifostine in combination with chemoradiation for locally advanced non-small-cell lung cancer: an analysis of RTOG 9801.
Topics: Amifostine; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Deglutition; Female; Humans; Lung Neoplasms; Male; Neoplasm Staging; Paclitaxel; Quality of Life; Radiation-Protective Agents; Sexual Behavior; Socioeconomic Factors; Treatment Outcome; Weight Loss | 2008 |
Potential evaluation of the incremental cost-effectiveness of paclitaxel in advanced non-small-cell lung cancer (Eastern Cooperative Oncology Group 5592).
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; Cost-Benefit Analysis; Humans; Lung Neoplasms; Paclitaxel | 1995 |
Paclitaxel plus carboplatin: an effective combination chemotherapy for advanced non-small-cell lung cancer or just another Elvis sighting?
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Humans; Lung Neoplasms; Paclitaxel; Remission Induction | 1995 |
Paclitaxel-induced cutaneous toxicity.
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Cellulitis; Drug Eruptions; Erythema; Extravasation of Diagnostic and Therapeutic Materials; Humans; Lung Neoplasms; Lymphangitis; Male; Paclitaxel; Skin | 1995 |
[Taxol in small-cell and non-small-cell bronchial carcinoma].
Topics: Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Clinical Trials as Topic; Humans; Lung Neoplasms; Neoplasm Staging; Paclitaxel; Survival Rate | 1993 |
From the Food and Drug Administration.
Topics: Antineoplastic Agents; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Drugs, Investigational; Food Labeling; Humans; Lung Neoplasms; Paclitaxel; Paraplegia; Prostheses and Implants; United States; United States Food and Drug Administration; Vinblastine; Vinorelbine | 1994 |
Taxol in the treatment of lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel | 1993 |
Taxol in advanced non-small-cell lung cancer: plus Ca change?
Topics: Anthraquinones; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase II as Topic; Humans; Lung Neoplasms; Paclitaxel; Pyrazoles; Thiobarbiturates | 1993 |
Docetaxel: current status and future prospects.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Docetaxel; Forecasting; Humans; Lung Neoplasms; Neoplasms; Paclitaxel; Taxoids | 1995 |
Paclitaxel-induced severe hypersensitivity reaction occurring as a late toxicity.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Drug Hypersensitivity; Humans; Lung Neoplasms; Male; Paclitaxel | 1995 |
Pilot study of vinorelbine (navelbine) and paclitaxel in patients with refractory non-small cell lung cancer.
Topics: Adult; Aged; Anemia; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cause of Death; Female; Granulocyte Colony-Stimulating Factor; Humans; Injections, Intravenous; Leukocyte Count; Lung Neoplasms; Male; Middle Aged; Nausea; Neutropenia; Neutrophils; Paclitaxel; Peripheral Nervous System Diseases; Pilot Projects; Remission Induction; Survival Rate; Vinblastine; Vinorelbine; Vomiting | 1996 |
Antitumor efficacy of taxane liposomes on a human ovarian tumor xenograft in nude athymic mice.
Topics: Animals; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Bridged-Ring Compounds; Carcinoma; Carcinoma, Non-Small-Cell Lung; Colonic Neoplasms; Docetaxel; Drug Carriers; Female; Humans; Liposomes; Lung Neoplasms; Mice; Mice, Nude; Neoplasm Transplantation; Ovarian Neoplasms; Paclitaxel; Taxoids | 1995 |
Reversal of P-glycoprotein-mediated multidrug resistance by a potent cyclopropyldibenzosuberane modulator, LY335979.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Binding Sites; Carcinoma, Non-Small-Cell Lung; Cell Line; Cell Membrane; Cell Survival; Dibenzocycloheptenes; Drug Resistance, Multiple; Etoposide; Humans; Kinetics; Leukemia P388; Lung Neoplasms; Mice; Mice, Nude; Paclitaxel; Protein Binding; Quinolines; Transplantation, Heterologous; Tumor Cells, Cultured; Vinblastine | 1996 |
Eighty-seventh annual meeting of the American Association for Cancer Research. Washington, D,C., 20-24 April 1996.
Topics: Aged; Antineoplastic Agents; Breast; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Female; Genes, p53; Genes, Tumor Suppressor; Humans; Hyperplasia; Leukemia; Lung Neoplasms; Lymphoma, Non-Hodgkin; Neoplasms; Neovascularization, Pathologic; Paclitaxel; Pancreatic Neoplasms; Research; Survival Rate | 1996 |
Etoposide and doxorubicin antagonize the in vitro activity of paclitaxel in human non-small cell lung cancer cell lines.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Dose-Response Relationship, Drug; Doxorubicin; Drug Administration Schedule; Drug Interactions; Drug Screening Assays, Antitumor; Etoposide; Humans; Lung Neoplasms; Paclitaxel; Tumor Cells, Cultured; Vinblastine | 1996 |
Paclitaxel and radiotherapy in the treatment of advanced non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Drug Administration Schedule; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Pilot Projects; Radiation-Sensitizing Agents; Radiotherapy Dosage | 1996 |
Escalating paclitaxel doses combined with carboplatin/etoposide and thoracic radiotherapy as preoperative or definitive treatment for stage III non-small cell lung cancer.
Topics: Agranulocytosis; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Female; Humans; Lung Neoplasms; Male; Paclitaxel; Pneumonia; Remission Induction; Treatment Outcome | 1996 |
Paclitaxel and simultaneous radiation in the treatment of stage IIIA/B non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Drug Administration Schedule; Drug Tolerance; Esophagitis; Female; Humans; Leukopenia; Lung Diseases; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Pneumocystis Infections; Radiotherapy Dosage; Treatment Outcome | 1996 |
Future directions in therapeutic approaches for small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Forecasting; Humans; Irinotecan; Lung Neoplasms; Paclitaxel; Topoisomerase I Inhibitors | 1996 |
Recent advances in managing non-small-cell lung cancer: 4. Chemotherapy of metastatic cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Lung Neoplasms; Paclitaxel; Palliative Care; Taxoids; Topoisomerase I Inhibitors | 1997 |
Cytotoxic synergy between flavopiridol (NSC 649890, L86-8275) and various antineoplastic agents: the importance of sequence of administration.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carmustine; Cisplatin; Cyclin-Dependent Kinases; Cytarabine; Doxorubicin; Drug Administration Schedule; Drug Synergism; Etoposide; Flavonoids; Fluorouracil; Humans; Lung Neoplasms; Paclitaxel; Piperidines; Tumor Stem Cell Assay | 1997 |
High-dose carboplatin plus paclitaxel with granulocyte colony-stimulating factor and peripheral blood stem-cell support in non-small-cell lung cancer.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Lung Neoplasms; Paclitaxel; Survival Analysis; Treatment Outcome | 1997 |
Paclitaxel and carboplatin in inoperable non-small-cell lung cancer: a phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel | 1997 |
Induction paclitaxel/carboplatin in early stage non-small cell lung cancer. Bimodality Lung Oncology Team.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Drug Administration Schedule; Feasibility Studies; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Pneumonectomy; Thoracotomy | 1997 |
The development of docetaxel (Taxotere) in non-small cell lung cancer.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Docetaxel; Humans; Lung Neoplasms; Paclitaxel; Taxoids | 1997 |
Combination treatment with docetaxel (Taxotere) and platinum compounds for non-small cell lung cancer.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials as Topic; Docetaxel; Humans; Lung Neoplasms; Paclitaxel; Taxoids; Vinblastine; Vinorelbine | 1997 |
Docetaxel (Taxotere) and vinorelbine in the treatment of non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials as Topic; Docetaxel; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Taxoids; Vinblastine; Vinorelbine | 1997 |
Amifostine protects normal tissues from paclitaxel toxicity while cytotoxicity against tumour cells is maintained.
Topics: Amifostine; Animals; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Cell Culture Techniques; Cell Death; Cytoprotection; Female; Fibroblasts; Hematopoietic Stem Cells; Humans; Lung Neoplasms; Mice; Mice, SCID; Ovarian Neoplasms; Paclitaxel; Radiation-Sensitizing Agents; Tumor Cells, Cultured | 1997 |
Lung fibrosis induced by paclitaxel.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Pulmonary Fibrosis; Radiation-Sensitizing Agents; Tomography, X-Ray Computed | 1998 |
[Acute diffuse interstitial pneumopathy following docetaxel (Taxotère). Apropos of 2 cases].
Topics: Aged; Alveolitis, Extrinsic Allergic; Anti-Inflammatory Agents; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Docetaxel; Drug Hypersensitivity; Glucocorticoids; Humans; Lung; Lung Diseases, Interstitial; Lung Neoplasms; Male; Paclitaxel; Prednisolone; Pulmonary Edema; Taxoids | 1998 |
Carboplatin and paclitaxel for previously treated patients with non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Survival Analysis; Treatment Outcome | 1998 |
[New cytostatics in the therapy of non-small cell bronchial carcinoma].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Bronchial Neoplasms; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Gemcitabine; Humans; Lung Neoplasms; Paclitaxel; Taxoids; Vinblastine; Vinorelbine | 1998 |
Capillary protein leak syndrome appears to explain fluid retention in cancer patients who receive docetaxel treatment.
Topics: Adult; Antineoplastic Agents, Phytogenic; Body Weight; Capillary Leak Syndrome; Capillary Permeability; Carcinoma, Non-Small-Cell Lung; Docetaxel; Edema; Female; Hemodynamics; Humans; Lung Neoplasms; Male; Paclitaxel; Prospective Studies; Taxoids | 1998 |
Efficacy of MGI 114 (6-hydroxymethylacylfulvene, HMAF) against the mdr1/gp170 metastatic MV522 lung carcinoma xenograft.
Topics: Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; Female; Humans; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mitomycin; Neoplasm Transplantation; Paclitaxel; Sesquiterpenes; Transplantation, Heterologous; Tumor Cells, Cultured | 1998 |
Adenovirus-mediated delivery of p16 to p16-deficient human bladder cancer cells confers chemoresistance to cisplatin and paclitaxel.
Topics: Adenoviridae; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Survival; Cisplatin; Cyclin-Dependent Kinase Inhibitor p16; Drug Resistance, Neoplasm; G1 Phase; Genes, p16; Genes, Retinoblastoma; Genetic Therapy; Genetic Vectors; Humans; Lung Neoplasms; Mesothelioma; Paclitaxel; Recombinant Proteins; Retinoblastoma Protein; Transfection; Tumor Cells, Cultured; Urinary Bladder Neoplasms | 1997 |
Paclitaxel cytotoxicity against human lung cancer cell lines increases with prolonged exposure durations.
Topics: Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cell Cycle; Cell Survival; G2 Phase; Humans; Lung Neoplasms; Mitosis; Paclitaxel; Time Factors; Tumor Cells, Cultured | 1997 |
Synthesis and evaluation of [14C]-labelled and fluorescent-tagged paclitaxel derivatives as new biological probes.
Topics: Acetylation; Antineoplastic Agents; Biological Transport; Carbon Radioisotopes; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Survival; Fluorescein-5-isothiocyanate; Fluorescent Dyes; Humans; Indicators and Reagents; Isotope Labeling; Lung Neoplasms; Models, Molecular; Molecular Conformation; Molecular Structure; Paclitaxel; Rhodamines; Structure-Activity Relationship; Tumor Cells, Cultured | 1998 |
Short-course induction chemoradiotherapy with paclitaxel for stage III non-small-cell lung cancer.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Dose Fractionation, Radiation; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Preoperative Care; Survival Analysis; Time Factors | 1998 |
Best supportive care.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Attitude of Health Personnel; Carcinoma, Non-Small-Cell Lung; Critical Illness; Humans; Lung Neoplasms; Neoplasms; Paclitaxel; Pain; Pain Management; Palliative Care; Terminology as Topic | 1998 |
Antisense oligonucleotides to class III beta-tubulin sensitize drug-resistant cells to Taxol.
Topics: Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Fluorescent Antibody Technique; Humans; Lung Neoplasms; Oligonucleotides, Antisense; Paclitaxel; Protein Isoforms; RNA, Messenger; Tubulin; Tubulin Modulators; Tumor Cells, Cultured | 1999 |
Marked antiangiogenic and antitumor efficacy of AG3340 in chemoresistant human non-small cell lung cancer tumors: single agent and combination chemotherapy studies.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease Models, Animal; Drug Interactions; Drug Resistance, Neoplasm; Drug Therapy, Combination; Female; Humans; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; Neovascularization, Pathologic; Organic Chemicals; Paclitaxel; Transplantation, Heterologous; Treatment Outcome; Tumor Cells, Cultured | 1999 |
Docetaxel (Taxotere) in the treatment of non-small cell lung cancer.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Docetaxel; Humans; Lung Neoplasms; Paclitaxel; Taxoids | 1999 |
Docetaxel (Taxotere) in the treatment of non-small cell lung cancer: recent results and future developments.
Topics: Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Docetaxel; Humans; Lung Neoplasms; Paclitaxel; Taxoids | 1999 |
Pre-clinical evaluation of new antineoplastic agents in NSCLC cell lines: evidence of histological subtype-dependent cytotoxicity.
Topics: Adenocarcinoma; Antineoplastic Agents; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cell Division; Cell Survival; Cisplatin; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Gemcitabine; Humans; Inhibitory Concentration 50; Irinotecan; Lung Neoplasms; Paclitaxel; Sensitivity and Specificity; Taxoids; Topoisomerase I Inhibitors; Topotecan; Tumor Cells, Cultured | 1999 |
Schedule-dependent interactions between paclitaxel and etoposide in human carcinoma cell lines in vitro.
Topics: Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Cell Division; Colonic Neoplasms; Dose-Response Relationship, Drug; Drug Interactions; Drug Screening Assays, Antitumor; Etoposide; Female; Humans; Lung Neoplasms; Ovarian Neoplasms; Paclitaxel; Time Factors; Tumor Cells, Cultured | 1999 |
Sequence-dependent enhancement of paclitaxel toxicity in non-small cell lung cancer by 17-allylamino 17-demethoxygeldanamycin.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Apoptosis; Benzoquinones; Carcinoma, Non-Small-Cell Lung; Cell Line; Enzyme Inhibitors; Humans; Lactams, Macrocyclic; Lung Neoplasms; Paclitaxel; Protein Serine-Threonine Kinases; Receptor, ErbB-2; Rifabutin; Tumor Cells, Cultured | 1999 |
A limited-sampling model for the pharmacokinetics of carboplatin administered in combination with paclitaxel.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Carcinoma, Non-Small-Cell Lung; Female; Humans; Lung Neoplasms; Models, Biological; Ovarian Neoplasms; Paclitaxel; Time Factors | 1999 |
Paclitaxel resistance in non-small-cell lung cancer associated with beta-tubulin gene mutations.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; DNA Mutational Analysis; Drug Resistance, Neoplasm; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Paclitaxel; Polymerase Chain Reaction; Predictive Value of Tests; Survival Rate; Tubulin | 1999 |
Docetaxel and gemcitabine activity in NSCLC cell lines and in primary cultures from human lung cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Survival; Deoxycytidine; Docetaxel; Drug Synergism; Gemcitabine; Humans; Lung Neoplasms; Paclitaxel; Taxoids; Tumor Cells, Cultured | 1999 |
A brief historical review of the development of chemotherapy for the treatment of advanced non-small cell lung cancer: why we should look beyond platinum.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Drug Therapy; Gemcitabine; History, 20th Century; Humans; Irinotecan; Lung Neoplasms; Medical Oncology; Paclitaxel; Vinblastine; Vinorelbine | 1999 |
Clinical presentation of stage IIIA (N2) non-small cell lung cancer: role of multimodality therapy.
Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Humans; Lung Neoplasms; Lymph Node Excision; Lymphatic Metastasis; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Pneumonectomy; Radiotherapy, Adjuvant; Time Factors | 1999 |
Enhanced efficacy of a novel controlled release paclitaxel formulation (PACLIMER delivery system) for local-regional therapy of lung cancer tumor nodules in mice.
Topics: Animals; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Delayed-Action Preparations; Drug Delivery Systems; Growth Inhibitors; Humans; Injections, Intralesional; Injections, Intraperitoneal; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Microspheres; Neoplasm Transplantation; Paclitaxel; Transplantation, Heterologous; Tumor Cells, Cultured | 1999 |
Enhancement of radiation effects by combined docetaxel and carboplatin treatment in vitro.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Survival; Docetaxel; Dose-Response Relationship, Drug; Dose-Response Relationship, Radiation; Drug Administration Schedule; Drug Interactions; Flow Cytometry; Humans; Lung Neoplasms; Paclitaxel; Radiation Dosage; Radiation-Sensitizing Agents; Radiotherapy, Adjuvant; Taxoids; Tumor Cells, Cultured | 1999 |
Drug-induced apoptosis in lung cnacer cells is not mediated by the Fas/FasL (CD95/APO1) signaling pathway.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Caspase 8; Caspase 9; Caspases; Cisplatin; Deoxycytidine; Fas Ligand Protein; fas Receptor; Flow Cytometry; Gemcitabine; Genes, p53; Humans; Lung Neoplasms; Membrane Glycoproteins; Paclitaxel; Recombinant Proteins; Signal Transduction; Topotecan; Transfection; Tumor Cells, Cultured | 2000 |
Histology and sensitivity to anticancer drugs of two human non-small cell lung carcinomas implanted in the pleural cavity of nude mice.
Topics: Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Doxorubicin; Ellipticines; Etoposide; Female; Gemcitabine; Humans; Lung Neoplasms; Lymphatic Metastasis; Mice; Mice, Nude; Neoplasm Metastasis; Paclitaxel; Pleural Neoplasms; Topotecan; Transplantation, Heterologous; Tumor Cells, Cultured; Vinblastine; Vinorelbine | 2000 |
Patterns of practice survey for nonsmall cell lung carcinoma in the U.S.
Topics: Analysis of Variance; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Chi-Square Distribution; Cisplatin; Clinical Protocols; Decision Making; Diagnostic Imaging; Etoposide; Humans; Lung Neoplasms; Medical Oncology; Neoplasm Staging; Paclitaxel; Practice Patterns, Physicians'; Radiation Oncology; Radiotherapy, Adjuvant; United States | 2000 |
Paclitaxel-induced apoptosis in non-small cell lung cancer cell lines is associated with increased caspase-3 activity.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Carcinoma, Non-Small-Cell Lung; Caspase 3; Caspase Inhibitors; Caspases; DNA Fragmentation; fas Receptor; Humans; In Situ Nick-End Labeling; Lung Neoplasms; Oligopeptides; Paclitaxel; Tumor Cells, Cultured | 2000 |
Quickly predicting chemotherapy response to paclitaxel-based therapy in non-small cell lung cancer by early technetium-99m methoxyisobutylisonitrile chest single-photon-emission computed tomography.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily B, Member 1; Carcinoma, Non-Small-Cell Lung; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Predictive Value of Tests; Prognosis; Retrospective Studies; Technetium Tc 99m Sestamibi; Tomography, Emission-Computed, Single-Photon; Treatment Outcome | 2000 |
Treatment regimens including the multitargeted antifolate LY231514 in human tumor xenografts.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cell Division; Cisplatin; Cyclophosphamide; Docetaxel; Female; Fluorouracil; Folic Acid Antagonists; Glutamates; Guanine; Humans; Injections, Intraperitoneal; Lung Neoplasms; Male; Mice; Mice, Nude; Neoplasm Transplantation; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Pemetrexed; Taxoids; Transplantation, Heterologous; Tumor Cells, Cultured; Vinblastine; Vinorelbine; Weight Loss | 2000 |
Paclitaxel up-regulates interleukin-8 synthesis in human lung carcinoma through an NF-kappaB- and AP-1-dependent mechanism.
Topics: Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Humans; Interleukin-8; Lung Neoplasms; Mitogen-Activated Protein Kinase 8; Mitogen-Activated Protein Kinases; NF-kappa B; Paclitaxel; Transcription Factor AP-1; Tumor Cells, Cultured; Up-Regulation | 2000 |
Correlation between docetaxel clearance and estimated cytochrome P450 activity by urinary metabolite of exogenous cortisol.
Topics: Adult; Aged; Anti-Inflammatory Agents; Antineoplastic Agents, Phytogenic; Area Under Curve; Carcinoma, Non-Small-Cell Lung; Chromatography, High Pressure Liquid; Cytochrome P-450 Enzyme System; Docetaxel; Female; Humans; Hydrocortisone; Least-Squares Analysis; Linear Models; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Taxoids | 2000 |
p53 mutations do not predict response to paclitaxel in metastatic nonsmall cell lung carcinoma.
Topics: Antineoplastic Agents, Phytogenic; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Paclitaxel; Polymorphism, Single-Stranded Conformational; Prognosis; Treatment Outcome; Tumor Suppressor Protein p53 | 2000 |
Sequence dependent effect of paclitaxel on gemcitabine metabolism in relation to cell cycle and cytotoxicity in non-small-cell lung cancer cell lines.
Topics: Animals; Antimetabolites, Antineoplastic; Biotransformation; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Division; Cell Survival; Deoxycytidine; DNA, Neoplasm; Gemcitabine; Humans; Kinetics; Lung Neoplasms; Mice; Paclitaxel; RNA, Neoplasm; Tumor Cells, Cultured | 2000 |
Docetaxel in the management of breast and non-small-cell lung cancers. ASCO 2000, 22nd annual San Antonio Breast Cancer Symposium, and ECCO 10. Abstracts.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Docetaxel; Humans; Lung Neoplasms; Paclitaxel; Taxoids | 2000 |
Docetaxel (taxotere) extravasation: a report of five cases with treatment recommendations.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Docetaxel; Edema; Erythema; Extravasation of Diagnostic and Therapeutic Materials; Hand; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Prostatic Neoplasms; Taxoids | 2000 |
Docetaxel as second-line chemotherapy for non-small-cell lung cancer.
Topics: Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Docetaxel; Humans; Lung Neoplasms; Multicenter Studies as Topic; Paclitaxel; Randomized Controlled Trials as Topic; Taxoids | 2000 |
Roles of NF-kappaB and 26 S proteasome in apoptotic cell death induced by topoisomerase I and II poisons in human nonsmall cell lung carcinoma.
Topics: Apoptosis; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cisplatin; DNA; DNA Damage; DNA-Binding Proteins; Enzyme Inhibitors; Etoposide; Humans; I-kappa B Proteins; Irinotecan; Leupeptins; Lung Neoplasms; NF-kappa B; NF-KappaB Inhibitor alpha; Paclitaxel; Peptide Hydrolases; Proteasome Endopeptidase Complex; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors | 2001 |
Induction chemotherapy for locoregional lung cancer using paclitaxel combination. A preliminary report.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Female; Humans; Ifosfamide; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Treatment Outcome | 2000 |
Response and determinants of sensitivity to paclitaxel in human non-small cell lung cancer tumors heterotransplanted in nude mice.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents, Phytogenic; ATP-Binding Cassette Transporters; bcl-2-Associated X Protein; Blotting, Western; Bronchial Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cell Division; ErbB Receptors; Genes, p53; Humans; Lung Neoplasms; Mice; Mice, Nude; Mitosis; Multidrug Resistance-Associated Proteins; Mutation; Neoplasm Transplantation; Paclitaxel; Polymerase Chain Reaction; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Receptor, ErbB-2; Time Factors; Tumor Cells, Cultured | 2000 |
Effectiveness of water soluble poly(L-glutamic acid)-camptothecin conjugate against resistant human lung cancer xenografted in nude mice.
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma, Non-Small-Cell Lung; Drug Combinations; Female; Humans; Lung Neoplasms; Mice; Mice, Nude; Paclitaxel; Polyglutamic Acid; Solubility; Taxoids; Xenograft Model Antitumor Assays | 2001 |
Clinical trial simulation of docetaxel in patients with cancer as a tool for dosage optimization.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Computer Simulation; Docetaxel; Dose-Response Relationship, Drug; Female; Humans; Lung Neoplasms; Male; Middle Aged; Models, Biological; Multicenter Studies as Topic; Orosomucoid; Paclitaxel; Prognosis; Proportional Hazards Models; Regression Analysis; Reproducibility of Results; Survival Analysis; Taxoids | 2000 |
Paclitaxel-Based chemotherapy for non-small cell lung cancer: predicting the response with 99mTc-tetrofosmin chest imaging.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B, Member 1; Carcinoma, Non-Small-Cell Lung; Cisplatin; Drug Resistance, Multiple; Female; Humans; Lung Neoplasms; Male; Middle Aged; Organophosphorus Compounds; Organotechnetium Compounds; Paclitaxel; Predictive Value of Tests; Radionuclide Imaging; Radiopharmaceuticals; Retrospective Studies; Thorax | 2001 |
Combined effect of docetaxel and cisplatin for non-small cell lung cancer cell lines in vitro.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cell Cycle; Cell Division; Cisplatin; Docetaxel; Drug Interactions; Humans; Lung Neoplasms; Paclitaxel; Taxoids; Tumor Cells, Cultured | 2000 |
Docetaxel (Taxotere) in the treatment of non-small cell lung cancer: an international update.
Topics: Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Docetaxel; Humans; Lung Neoplasms; Paclitaxel; Radiation-Sensitizing Agents; Taxoids | 2001 |
Topoisomerase IIalpha and other drug resistance markers in advanced non-small cell lung cancer.
Topics: Amino Acid Substitution; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; ATP-Binding Cassette Transporters; Biomarkers; Carcinoma, Non-Small-Cell Lung; Cisplatin; Cyclophosphamide; DNA Mutational Analysis; DNA Topoisomerases, Type II; DNA-Binding Proteins; DNA, Neoplasm; Doxorubicin; Drug Resistance, Neoplasm; Etoposide; Female; Humans; Ifosfamide; Isoenzymes; Ki-67 Antigen; Life Tables; Lung Neoplasms; Male; Middle Aged; Multidrug Resistance-Associated Proteins; Mutation, Missense; Neoplasm Proteins; Paclitaxel; Point Mutation; Prognosis; Reverse Transcriptase Polymerase Chain Reaction; Survival Analysis; Teniposide; Topotecan; Treatment Outcome; Vault Ribonucleoprotein Particles | 2001 |
Tolerability of the cytoprotective agent amifostine in elderly patients receiving chemotherapy: a comparative study.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Amifostine; Antihypertensive Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Cyclophosphamide; Deoxycytidine; Doxorubicin; Epirubicin; Esophageal Neoplasms; Female; Fluorouracil; Gemcitabine; Humans; Hypertension; Hypocalcemia; Hypotension; Infusions, Intravenous; Lung Neoplasms; Lymphoma, Non-Hodgkin; Male; Middle Aged; Nausea; Paclitaxel; Pancreatic Neoplasms; Platinum; Prednisone; Premedication; Retrospective Studies; Vincristine | 2001 |
Use of paclitaxel in patients with pre-existing cardiomyopathy: a review of our experience.
Topics: Aged; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Cardiomyopathies; Doxorubicin; Female; Humans; Hypertension; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Retrospective Studies; Ventricular Function, Left | 2001 |
Neoadjuvant chemotherapy with docetaxel in non--small cell lung cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials as Topic; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Lung Neoplasms; Male; Neoadjuvant Therapy; Paclitaxel; Survival Rate; Taxoids | 2001 |
[Combination chemotherapy of carboplatin and docetaxel for advanced non-small cell lung cancer (NSCLC)].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Docetaxel; Drug Administration Schedule; Female; Granulocyte Colony-Stimulating Factor; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Survival Rate; Taxoids | 2001 |
Sequence-dependent cytotoxicity of combination chemotherapy using paclitaxel, carboplatin and bleomycin in human lung and ovarian cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Body Weight; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cystadenocarcinoma; Drug Synergism; Female; Flow Cytometry; Humans; Lung Neoplasms; Male; Mice; Mice, SCID; Ovarian Neoplasms; Paclitaxel; Tumor Cells, Cultured | 2001 |
Enhancement of paclitaxel-mediated cytotoxicity in lung cancer cells by 17-allylamino geldanamycin: in vitro and in vivo analysis.
Topics: Allylamine; Animals; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzoquinones; Benzothiazoles; Carcinoma, Non-Small-Cell Lung; Cell Survival; Drug Synergism; Drug Therapy, Combination; Endothelial Growth Factors; Humans; Lactams, Macrocyclic; Lung Neoplasms; Lymphokines; Mice; Mice, Nude; Neoplasm Transplantation; Neovascularization, Pathologic; Paclitaxel; Quinones; Tumor Cells, Cultured; Tyrphostins; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors | 2001 |
[Concomitant radiochemotherapy for non-small-cell lung cancer: towards an ideal strategy].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Deoxycytidine; Gemcitabine; Humans; Ifosfamide; Immunologic Factors; Lung Neoplasms; Mitomycin; Neoplasm Metastasis; Paclitaxel; Radiation-Sensitizing Agents; Randomized Controlled Trials as Topic; Vinblastine; Vinorelbine | 2001 |
Interactions of gemcitabine, carboplatin and paclitaxel in molecularly defined non-small-cell lung cancer cell lines.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Drug Screening Assays, Antitumor; Drug Synergism; Gemcitabine; Genes, p53; Genes, Retinoblastoma; Humans; Lung Neoplasms; Paclitaxel; Tumor Cells, Cultured | 2001 |
Resistance to Taxol in lung cancer cells associated with increased microtubule dynamics.
Topics: Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Drug Resistance; Humans; Interphase; Lung Neoplasms; Microscopy, Video; Microtubules; Mitosis; Paclitaxel; Spindle Apparatus; Tumor Cells, Cultured | 2001 |
Induction chemotherapy increases perioperative complications in patients undergoing resection for non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Case-Control Studies; Chemotherapy, Adjuvant; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Pneumonectomy; Postoperative Complications | 2001 |
Dosimetric predictors of radiation esophagitis in patients treated for non-small-cell lung cancer with carboplatin/paclitaxel/radiotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Drug Administration Schedule; Esophagitis; Esophagoscopy; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Radiation Injuries; Radiotherapy Dosage; Radiotherapy, Conformal | 2001 |
[A case of advanced non-small-cell lung cancer responding remarkably to weekly chemotherapy with paclitaxel].
Topics: Adenocarcinoma; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Drug Administration Schedule; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Radiography | 2001 |
Expression of Her-2/neu in human lung cancer cell lines by immunohistochemistry and fluorescence in situ hybridization and its relationship to in vitro cytotoxicity by trastuzumab and chemotherapeutic agents.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Division; Cisplatin; Deoxycytidine; Dose-Response Relationship, Drug; Drug Synergism; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Immunohistochemistry; In Situ Hybridization, Fluorescence; Lung Neoplasms; Paclitaxel; Receptor, ErbB-2; Trastuzumab; Tumor Cells, Cultured; Vinblastine; Vinorelbine | 2001 |
Chemotherapy for non-small-cell lung cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Lung Neoplasms; Paclitaxel; Prognosis; Taxoids | 2001 |
A dose escalation study of paclitaxel and carboplatin in untreated Japanese patients with advanced non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Neutropenia; Paclitaxel | 2001 |
Docetaxel and non small-cell lung cancer: new indication. One of several non curative chemotherapies.
Topics: Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Clinical Trials as Topic; France; Humans; Ifosfamide; Lung Neoplasms; Paclitaxel; Palliative Care; Treatment Outcome; Vinblastine | 2001 |
Life-threatening hypersensitivity pneumonitis induced by docetaxel (taxotere).
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Cross Infection; Docetaxel; Female; Humans; Hydrocortisone; Immunosuppressive Agents; Lung Neoplasms; Male; Methylprednisolone; Paclitaxel; Pneumonia; Pneumothorax; Respiration, Artificial; Taxoids | 2001 |
Cost-minimisation analysis of three regimens of chemotherapy (docetaxel-cisplatin, paclitaxel-cisplatin, paclitaxel-carboplatin) for advanced non-small-cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Cost-Benefit Analysis; Docetaxel; Drug Costs; Economics, Pharmaceutical; Humans; Infusions, Intravenous; Lung Neoplasms; Neoplasm Staging; Paclitaxel; Sensitivity and Specificity; Survival Rate; Taxoids | 2002 |
Genetic analysis of the beta-tubulin gene, TUBB, in non-small-cell lung cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Codon; DNA Mutational Analysis; DNA Primers; Exons; Genetic Variation; Humans; Introns; Lung Neoplasms; Mutation; Mutation, Missense; Paclitaxel; Polymorphism, Genetic; Tubulin; Tumor Cells, Cultured | 2001 |
Japanese experience with second-line chemotherapy with low-dose (60 mg/M2) docetaxel in patients with advanced non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Docetaxel; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Survival Rate; Taxoids | 2001 |
[Clinical observation of taxotere in the treatment of advanced non-small-cell lung cancer and breast cancer].
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Docetaxel; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Taxoids; Treatment Outcome | 2000 |
Vinorelbine-associated myelopathy in a patient who previously received paclitaxel: a case report.
Topics: Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Female; Humans; Lung Neoplasms; Magnetic Resonance Imaging; Middle Aged; Paclitaxel; Spinal Cord; Spinal Cord Diseases; Vinblastine; Vinorelbine | 2001 |
Docetaxel combination produces 2-year survival advantage in NSCLC patients.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Docetaxel; Humans; Lung Neoplasms; Paclitaxel; Randomized Controlled Trials as Topic; Survival Rate; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2001 |
TRAIL, FasL and a blocking anti-DR5 antibody augment paclitaxel-induced apoptosis in human non-small-cell lung cancer.
Topics: Antibodies, Monoclonal; Antineoplastic Agents, Phytogenic; Apoptosis; Apoptosis Regulatory Proteins; Carcinoma, Non-Small-Cell Lung; Caspase 3; Caspases; Enzyme Induction; Fas Ligand Protein; fas Receptor; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Membrane Glycoproteins; Paclitaxel; Receptors, TNF-Related Apoptosis-Inducing Ligand; Receptors, Tumor Necrosis Factor; RNA, Messenger; RNA, Neoplasm; TNF-Related Apoptosis-Inducing Ligand; Tumor Cells, Cultured; Tumor Necrosis Factor-alpha | 2002 |
Paclitaxel triggers cell death primarily via caspase-independent routes in the non-small cell lung cancer cell line NCI-H460.
Topics: Amino Acid Chloromethyl Ketones; Annexin A5; Antineoplastic Agents, Phytogenic; Apoptosis; Arabidopsis Proteins; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Caspase 8; Caspase 9; Caspases; Cell Death; Cell Line; Cell Survival; Cytochrome c Group; Cytosol; DNA Damage; Electrophoresis, Polyacrylamide Gel; Enzyme Activation; Enzyme Inhibitors; Fatty Acid Desaturases; Genes, Dominant; Humans; Lung Neoplasms; Mitochondria; Models, Biological; Paclitaxel; Poly(ADP-ribose) Polymerases; Propidium; Protein Structure, Tertiary; Receptors, TNF-Related Apoptosis-Inducing Ligand; Receptors, Tumor Necrosis Factor; Spectrometry, Fluorescence; Time Factors; Transfection; Tumor Cells, Cultured | 2002 |
Coexistence of non-Hodgkin's lymphoma and non-small cell lung carcinoma: diagnosis and treatment.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bronchoscopy; Carboplatin; Carcinoma, Non-Small-Cell Lung; Humans; Lung Neoplasms; Lymphoma, Non-Hodgkin; Male; Neoplasms, Second Primary; Paclitaxel; Radiography | 2002 |
Economic analysis of the TAX 317 trial: docetaxel versus best supportive care as second-line therapy of advanced non-small-cell lung cancer.
Topics: Antineoplastic Agents, Phytogenic; Canada; Carcinoma, Non-Small-Cell Lung; Cost-Benefit Analysis; Costs and Cost Analysis; Docetaxel; Hospitalization; Humans; Lung Neoplasms; Paclitaxel; Palliative Care; Radiotherapy; Retrospective Studies; Sensitivity and Specificity; Taxoids | 2002 |
Technetium-99m tetrofosmin chest imaging related to p-glycoprotein expression for predicting the response with paclitaxel-based chemotherapy for non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily B, Member 1; Carcinoma, Non-Small-Cell Lung; Humans; Immunohistochemistry; Lung; Lung Neoplasms; Middle Aged; Organophosphorus Compounds; Organotechnetium Compounds; Paclitaxel; Radionuclide Imaging; Radiopharmaceuticals | 2001 |
Exisulind in combination with docetaxel inhibits growth and metastasis of human lung cancer and prolongs survival in athymic nude rats with orthotopic lung tumors.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Division; Docetaxel; Drug Administration Schedule; Female; Humans; In Situ Nick-End Labeling; Lung Neoplasms; Mediastinal Neoplasms; Neoplasms, Experimental; Paclitaxel; Rats; Rats, Nude; Sulindac; Survival Rate; Taxoids; Tetrazolium Salts; Thiazoles | 2002 |
Quantitative analysis of angiogenesis using confocal laser scanning microscopy.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents, Phytogenic; Capillaries; Carcinoma, Non-Small-Cell Lung; Humans; Image Processing, Computer-Assisted; Lung Neoplasms; Mice; Microscopy, Confocal; Microscopy, Fluorescence; Muscle, Skeletal; Neoplasm Transplantation; Neovascularization, Pathologic; Neovascularization, Physiologic; Paclitaxel; Platelet Endothelial Cell Adhesion Molecule-1; Xenograft Model Antitumor Assays | 2001 |
[Phase III clinical trials concerning non-small-cell lung carcinoma (NSCLC) presented at the ASCO 2001].
Topics: Age Factors; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials, Phase III as Topic; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Multicenter Studies as Topic; Neoplasm Metastasis; Paclitaxel; Taxoids; Time Factors; Vinblastine; Vinorelbine | 2001 |
Differential mitotic responses to microtubule-stabilizing and -destabilizing drugs.
Topics: Alkanes; Aneuploidy; Antineoplastic Agents; Carbamates; Carcinoma, Non-Small-Cell Lung; Epothilones; Humans; Lactones; Lung Neoplasms; Macrolides; Microtubules; Mitosis; Paclitaxel; Pyrones; Spindle Apparatus; Tumor Cells, Cultured | 2002 |
Accelerated hyperfractionated radiation, concurrent paclitaxel/cisplatin chemotherapy and surgery for stage III non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Dose Fractionation, Radiation; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Prognosis; Survival Rate; Thoracotomy; Treatment Outcome | 2002 |
Docetaxel (taxotere) in the treatment of non-small cell lung cancer.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase II as Topic; Combined Modality Therapy; Docetaxel; Humans; Lung Neoplasms; Paclitaxel; Survival Analysis; Taxoids | 2002 |
Bradykinin antagonist dimer, CU201, inhibits the growth of human lung cancer cell lines in vitro and in vivo and produces synergistic growth inhibition in combination with other antitumor agents.
Topics: Animals; Antineoplastic Agents; Area Under Curve; Bradykinin; Bradykinin Receptor Antagonists; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cell Division; Cisplatin; Dimerization; Doxorubicin; Drug Synergism; Drug Therapy, Combination; Etoposide; Gefitinib; Humans; Infusion Pumps; Injections, Intralesional; Injections, Intraperitoneal; Injections, Subcutaneous; Lung Neoplasms; Mice; Mice, Nude; Neoplasm Transplantation; Oligopeptides; Paclitaxel; Quinazolines; Time Factors; Tumor Cells, Cultured; Vinblastine; Vinorelbine; Xenograft Model Antitumor Assays | 2002 |
Second-line chemotherapy for non-small cell lung cancer: is more better or just simply more?
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Docetaxel; Humans; Lung Neoplasms; Paclitaxel; Taxoids | 2002 |
Salvage chemotherapy with the gemcitabine/docetaxel combination in non-small cell lung cancer: an overview of recent phase II studies.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase II as Topic; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Salvage Therapy; Taxoids | 2002 |
Comparison of unidimensional and bidimensional measurements in metastatic non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Lung Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Outcome Assessment, Health Care; Paclitaxel; Practice Guidelines as Topic; Retrospective Studies; Tomography, X-Ray Computed; Treatment Outcome; Vinblastine; Vinorelbine; World Health Organization | 2002 |
Clinical trials referral resource. Clinical trials with taxol.
Topics: Alkaloids; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Clinical Trials as Topic; Female; Gastrointestinal Neoplasms; Head and Neck Neoplasms; Humans; Lung Neoplasms; Ovarian Neoplasms; Paclitaxel | 1992 |
Taxol improves outlook for lung, breast, and ovarian cancer.
Topics: Alkaloids; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Doxorubicin; Female; Humans; Lung Neoplasms; Ovarian Neoplasms; Paclitaxel | 1992 |
Aqueous extract of Taxus chinensis var. mairei targeting CD47 enhanced antitumor effects in non-small cell lung cancer.
Topics: Animals; Carcinoma, Non-Small-Cell Lung; CD47 Antigen; CD8-Positive T-Lymphocytes; Heterografts; Humans; Lung Neoplasms; Mice; Taxus | 2022 |
Integrated bioinformatics and network pharmacology to explore the therapeutic target and molecular mechanisms of Taxus chinensis against non-small cell lung cancer.
Topics: Carcinoma, Non-Small-Cell Lung; Computational Biology; Drugs, Chinese Herbal; Humans; Lung Neoplasms; Mitogen-Activated Protein Kinase 1; Molecular Docking Simulation; Network Pharmacology; Phosphatidylinositol 3-Kinase; Phosphatidylinositol 3-Kinases; Phosphatidylinositols; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-akt; Taxus | 2023 |
Aqueous extract of Taxus chinensis var. mairei regulates the Hippo-YAP pathway and promotes apoptosis of non-small cell lung cancer via ATF3 in vivo and in vitro.
Topics: A549 Cells; Activating Transcription Factor 3; Adaptor Proteins, Signal Transducing; Animals; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; Drugs, Chinese Herbal; Female; Hippo Signaling Pathway; Humans; Lung Neoplasms; Mice; Mice, Inbred BALB C; Protein Serine-Threonine Kinases; Signal Transduction; Taxus; Water; Xenograft Model Antitumor Assays; YAP-Signaling Proteins | 2021 |
Reversal of cisplatin resistance in non-small cell lung cancer stem cells by Taxus chinensis var.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cisplatin; Drug Combinations; Drug Resistance, Neoplasm; Drugs, Chinese Herbal; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Multidrug Resistance-Associated Proteins; Neoplastic Stem Cells; Plant Extracts; Rhodamine 123; Signal Transduction; Taxus; Vault Ribonucleoprotein Particles | 2016 |